FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Maddox, BL Wright, SS Namadingo, H AF Maddox, Brandy L. Wright, Shaunte S. Namadingo, Hazel TI Overcoming the Tide of Language Barriers: Using Focus Group Activities With Universal Elements to Aid in Qualitative Data Collection and Analysis SO INTERNATIONAL JOURNAL OF QUALITATIVE METHODS LA English DT Meeting Abstract C1 [Maddox, Brandy L.; Wright, Shaunte S.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Namadingo, Hazel] Malawi Epidemiol Intervent Res Unit, Blantyre, Malawi. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1609-4069 J9 INT J QUAL METH JI Int. J. Qual. Meth. PD DEC PY 2017 VL 16 IS 1 PG 1 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA EL7CA UT WOS:000394777500069 ER PT J AU Robertson, LD Beltran-Aguilar, E Dasanayake, A Phipps, KR Warren, JJ Hennessy, TW AF Robertson, Lawrence D. Beltran-Aguilar, Eugenio Dasanayake, Ananda Phipps, Kathy R. Warren, John J. Hennessy, Thomas W. TI A novel staging system for caries severity in the primary dentition SO JOURNAL OF PUBLIC HEALTH DENTISTRY LA English DT Article DE dental caries; disease staging; child; AI/AN; morbidity; metrics; Indians; North American ID AMERICAN-INDIAN CHILDREN; EARLY-CHILDHOOD CARIES; DENTAL-CARIES; TEETH AB Objectives: Caries in the primary dentition (CIPD) has a high prevalence in U.S. children compared to other diseases, with substantial disparities among different population groups. Few reports correlate CIPD prevalence with clinical impairment of children's quality of life, such as tooth pain, speech delay or trauma to the child from operative restorations, which we collectively term morbidity. Likewise, current case definitions (ECC, S-ECC) and disease metrics (mean dmfs/dmft) are not helpful in assessing morbidity for individual or groups of children. We describe a construct to stage caries severity for children ages 0 -5, called CIPD Levels. This metric is based on small interval age-group dmft scores, and has a direct link to current and predicted morbidity for the child. It is modeled after staging systems for medical diseases in which the various stages or levels are correlated with the probability of morbidity or mortality. Methods: We created a matrix in which CIPD Levels 0-4 are assigned for dmft scores 0-7 depending on a child's age. CIPD Level-4 is the highest level, and frequently results in clinical adverse outcomes, including pain and extensive restorations. We next tested this matrix with data from a high-risk population. Results: Among children with any cavitated caries at age <24 months, 82.8% reached the adverse outcomes threshold (CIPD Level-4) at age 36 months. For children with dmft = 0 at 24 months, 71.4% did not reach CIPD Level-4 at age 36 months. Conclusion: Our new metric is useful for quantifying disease burden from caries for high-risk children. C1 [Robertson, Lawrence D.] QUEST, 278 Sanborn Rd, White Salmon, WA 98672 USA. [Dasanayake, Ananda] NYU, Coll Dent, Grad Program Clin Res, New York, NY USA. [Warren, John J.] Univ Iowa, Dept Prevent & Community Dent, Iowa City, IA USA. [Hennessy, Thomas W.] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Anchorage, AK USA. RP Robertson, LD (reprint author), QUEST, 278 Sanborn Rd, White Salmon, WA 98672 USA. EM drobertson@gorge.net NR 19 TC 0 Z9 0 U1 8 U2 8 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4006 EI 1752-7325 J9 J PUBLIC HEALTH DENT JI J. Public Health Dent. PD WIN PY 2017 VL 77 IS 1 BP 6 EP 12 DI 10.1111/jphd.12164 PG 7 WC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health SC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health GA EN1JV UT WOS:000395767200002 PM 27307188 ER PT J AU Naavaal, S Barker, LK Griffin, SO AF Naavaal, Shillpa Barker, Laurie K. Griffin, Susan O. TI The effect of health and dental insurance on US children's dental care utilization for urgent and non-urgent dental problems-2008 SO JOURNAL OF PUBLIC HEALTH DENTISTRY LA English DT Article DE dental problem; utilization; dental care for children; health insurance; dental insurance; dental health services; Medicaid/SCHIP ID ORAL-HEALTH; MEDICAL-CARE; ACCESS; SERVICES; PERCEPTIONS; DISPARITIES; ADOLESCENTS; DEMAND; NEEDS AB Objective: We examined the association between utilization of care for a dental problem (utilization-DP) and parent-reported dental problem (DP) urgency among children with DP by type of health care insurance coverage. Methods: We used weighted 2008 National Health Interview Survey data from 2,834 children, aged 2-17 years with at least one DP within the 6 months preceding survey. Explanatory variables were selected based on Andersen's model of healthcare utilization. Need was considered urgent if DP included toothache, bleeding gums, broken or missing teeth, broken or missing filling, or decayed teeth and otherwise as non-urgent. The primary enabling variable, insurance, had four categories: none, private health no dental coverage (PHND), private health and dental (PHD), or Medicaid/State Children's Health Insurance Program (SCHIP). Predisposing variables included sociodemographic characteristics. We used bivariate and multivariate analyses to identify explanatory variables' association with utilization-DP. Using logistic regression, we obtained adjusted estimates of utilization-DP by urgency for each insurance category. Results: In bivariate analyses, utilization-DP was associated with both insurance and urgency. In multivariate analyses, the difference in percent utilizing care for an urgent versus non-urgent DP among children covered by Medicaid/SCHIP was 32 percentage points; PHD, 25 percentage points; PHND, 12 percentage points; and no insurance, 14 percentage points. The difference in utilization by DP urgency was higher for children with Medicaid/SCHIP compared with either PHND or uninsured children. Conclusion: Expansion of Medicaid/SCHIP may permit children to receive care for urgent DPs who otherwise may not, due to lack of dental insurance. C1 [Naavaal, Shillpa; Barker, Laurie K.; Griffin, Susan O.] Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Naavaal, S (reprint author), Virginia Commonwealth Univ, Sch Dent, Dept Pediat Dent, Oral Hlth Serv Res Core, 521 North 11th St, Richmond, VA 23298 USA. EM naavaals@vcu.edu NR 24 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4006 EI 1752-7325 J9 J PUBLIC HEALTH DENT JI J. Public Health Dent. PD WIN PY 2017 VL 77 IS 1 BP 54 EP 62 DI 10.1111/jphd.12171 PG 9 WC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health SC Dentistry, Oral Surgery & Medicine; Public, Environmental & Occupational Health GA EN1JV UT WOS:000395767200008 PM 27613222 ER PT J AU Aholou, TM Sutton, MY Brown, E AF Aholou, Tiffiany M. Sutton, Madeline Y. Brown, Emma (E. J. ) TI Careful Conversations and Careful Sex: HIV Posttesting Experiences Among African American Men in Rural Florida SO JOURNAL OF RURAL HEALTH LA English DT Article DE African American men; disclosure; health disparities; HIV testing; qualitative research ID UNITED-STATES; HETEROSEXUAL MEN; SOUTHERN STATES; BLACK-MEN; PREVENTION; INTERVENTIONS; STRATEGIES; DIAGNOSES; SERVICES; OUTCOMES AB PurposeIn the United States, black/African American (black) men bear the greatest burden of human immunodeficiency virus (HIV), accounting for 42% of new HIV infections in 2012 despite being 6% of the population. In Florida, heterosexual HIV transmission has increased among black men. Few studies have examined HIV testing experiences for black heterosexual men (BHM) in the rural South. This study describes the post-HIV-testing trial experiences of BHM in rural Florida. MethodsWe conducted 12 focus groups (4-7 participants per group) in 3 rural Florida counties with BHM who participated in a larger randomized HIV testing trial. Interviews were professionally transcribed and data were analyzed using NVivo 10. The qualitative analysis was informed by the strengths perspective (ie, emphasis on abilities rather than risks) and used a thematic analytical approach. ResultsSixty-seven men participated (median age 41.5 years); 39 (58%) earned a monthly income of less than $500, 38 (57%) attained education through high school or higher, 37 (55%) were unmarried, and 40 (60%) reported practicing monogamy; all who tested for HIV were negative for HIV. We identified 3 main themes based on self-reported actions: (1) risk reduction (eg, more consistent condom use, fewer sex partners), (2) sexual health communications with sex partners (eg, negotiating HIV testing with sex partners, getting to know partners better), and (3) health communications with peers and family (eg, disclosing test results, encouraging others to get tested). ConclusionsAmong BHM, being in this HIV testing study facilitated increased protective behaviors and communications for HIV prevention. Interventions for BHM in rural areas warrant incorporating these strategies to encourage routine HIV testing. C1 [Aholou, Tiffiany M.; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mailstop E 45, Atlanta, GA 30329 USA. [Brown, Emma (E. J. )] CHARM Inc, Lake City, FL USA. EM msutton@cdc.gov FU CDC's Minority HIV/AIDS Research Initiative [U01PS000677] FX This study was supported with the CDC's Minority HIV/AIDS Research Initiative, award # U01PS000677. The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. NR 42 TC 0 Z9 0 U1 65 U2 65 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X EI 1748-0361 J9 J RURAL HEALTH JI J. Rural Health PD WIN PY 2017 VL 33 IS 1 BP 62 EP 70 DI 10.1111/jrh.12171 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EI4BW UT WOS:000392438900008 PM 26768992 ER PT J AU Soeters, HM Whaley, M Alexander-Scott, N Kanadanian, KV MacNeil, JR Martin, SW McNamara, LA Sicard, K Vanner, C Vuong, J Wang, X Bandy, U Patel, M AF Soeters, Heidi M. Whaley, Melissa Alexander-Scott, Nicole Kanadanian, Koren V. MacNeil, Jessica R. Martin, Stacey W. McNamara, Lucy A. Sicard, Kenneth Vanner, Cynthia Jeni Vuong Wang, Xin Bandy, Utpala Patel, Manisha CA Rhode Isl Meningococcal Carriage TI Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE meningococcal disease; serogroup B; vaccines; nasopharyngeal carriage; outbreak ID NEISSERIA-MENINGITIDIS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; UNITED-STATES; UNIVERSITY OUTBREAK; RECOMMENDATIONS; ADOLESCENTS; SMOKING; POPULATION; PREVALENCE AB Background. Serogroup B meningococcal disease caused 7 US university outbreaks during 2013-2016. Neisseria meningitidis can be transmitted via asymptomatic nasopharyngeal carriage. MenB-FHbp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to control a college outbreak. We investigated MenB-FHbp impact on meningococcal carriage. Methods. Four cross-sectional surveys were conducted in conjunction with MenB-FHbp vaccination campaigns. Questionnaires and oropharyngeal swabs were collected from students. Specimens were evaluated using culture, slide agglutination, real-time polymerase chain reaction (rt-PCR), and whole genome sequencing. Adjusted prevalence ratios (aPRs) were calculated using generalized estimating equations. Results. During each survey, 20%-24% of participants carried any meningococcal bacteria and 4% carried serogroup B by rt-PCR. The outbreak strain (ST-9069) was not detected during the initial survey; 1 student carried ST-9069 in the second and third surveys. No carriage reduction was observed over time or with more MenB-FHbp doses. In total, 615 students participated in multiple surveys: 71% remained noncarriers, 8% cleared carriage, 15% remained carriers, and 7% acquired carriage. Ten students acquired serogroup B carriage: 3 after 1 MenB-FHbp dose, 4 after 2 doses, and 3 after 3 doses. Smoking (aPR, 1.3; 95% confidence interval [CI], 1.1-1.5) and male sex (aPR, 1.3; 95% CI, 1.1-1.5) were associated with increased meningococcal carriage. Conclusions. Carriage prevalence on campus remained stable, suggesting MenB-FHbp does not rapidly reduce meningococcal carriage or prevent serogroup B carriage acquisition. This reinforces the need for high vaccination coverage to protect vaccinated individuals and chemoprophylaxis for close contacts during outbreaks. C1 [Soeters, Heidi M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Soeters, Heidi M.; Whaley, Melissa; MacNeil, Jessica R.; Martin, Stacey W.; McNamara, Lucy A.; Jeni Vuong; Wang, Xin; Patel, Manisha] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Alexander-Scott, Nicole; Vanner, Cynthia; Bandy, Utpala] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Kanadanian, Koren V.; Sicard, Kenneth] Providence Coll, Providence, RI 02918 USA. RP Soeters, HM (reprint author), Ctr Dis Control & Prevent, MS C-25,1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM hzx8@cdc.gov FU CDC FX This work was supported by the CDC. NR 32 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2017 VL 64 IS 8 BP 1115 EP 1122 DI 10.1093/cid/cix091 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EQ1DO UT WOS:000397809800018 ER PT J AU Conderino, S Fung, L Sedlar, S Norton, JM AF Conderino, Sarah Fung, Lawrence Sedlar, Slavenka Norton, Jennifer M. TI Linkage of traffic crash and hospitalization records with limited identifiers for enhanced public health surveillance SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE Probabilistic; Linkage; Hospital; Crash; Traffic ID INJURIES; COSTS AB Background: Motor vehicle traffic (MVT) crashes kill or seriously injure approximately 4250 people in New York City (NYC) each year. Traditionally, NYC surveillance practices use hospitalization and crash data separately to monitor trends in MVT-related injuries, but key information linking crash circumstances to health outcomes is lost when analyzing these data sources in isolation. Our objective was to match crash reports to hospitalization records to create a traffic injury surveillance dataset that can be used to describe crash circumstances and related injury outcomes. The linkage of the two systems presents a unique challenge since the system tracking crashes and the system tracking hospitalizations and emergency department (ED) visits lack key identifying data such as names and dates of birth. Methods: NYC Department of Transportation provided electronic records based on reports of motor vehicle crashes submitted to the New York State Department of Motor Vehicles for all crashes occurring in NYC from 2009 to 2013. New York Statewide Planning and Research Cooperative System (SPARCS) ED and hospitalization administrative data from NYC hospitals were used to identify unintentional MVT-related injuries using external cause of injury codes. Since the two systems do not share unique individual identifiers, probabilistic record linkage was conducted using LinkSolv9.0. Sensitivity/specificity calculations and chi-square analyses of linkage rates were conducted to assess linkage results. Results: From 2009-2013, there were 1,054,344 individuals involved in MVT crashes in NYC and 280,340 ED visits and hospitalizations from MVT-related injuries. There were 145,003 linked pairs, giving a linkage rate of 52% of the total MVT-related hospital records. This linkage had a sensitivity of 74% and a specificity of 93%. Linkage rates were comparable by age, sex, crash role, collision type, hospital county, injury location, hospital type, and hospital status, indicating no apparent biases in the match by these variables. Conclusions: Performing a probabilistic linkage between MVT crash reports and hospitalization records is possible with a limited set of identifying variables. These linked data will inform traffic safety policies by providing new information on how crash circumstances translate to health outcomes. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Conderino, Sarah; Fung, Lawrence; Sedlar, Slavenka; Norton, Jennifer M.] New York City Dept Hlth & Mental Hyg, 125 Worth St Room 620, New York, NY 10013 USA. [Conderino, Sarah] Ctr Dis Control & Prevent, Council State & Terr Epidemiologists Appl Epidemi, Atlanta, GA USA. RP Fung, L (reprint author), 125 Worth St Room 620, New York, NY 10013 USA. EM sconderino1@health.nyc.gov; lfung1@health.nyc.gov FU Centers for Disease Control and Prevention (CDC) [1U38OT000143-02] FX This study was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number 1U38OT000143-02. NR 30 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 EI 1879-2057 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD APR PY 2017 VL 101 BP 117 EP 123 DI 10.1016/j.aap.2017.02.011 PG 7 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA EO8XR UT WOS:000396974300013 PM 28226252 ER PT J AU Tran, V Tindula, G Huen, K Bradman, A Harley, K Kogut, K Calafat, AM Nguyen, B Parra, K Ye, X Eskenazi, B Holland, N AF Tran, V. Tindula, G. Huen, K. Bradman, A. Harley, K. Kogut, K. Calafat, A. M. Nguyen, B. Parra, K. Ye, X. Eskenazi, B. Holland, N. TI Prenatal phthalate exposure and 8-isoprostane among Mexican-American children with high prevalence of obesity SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE LA English DT Article DE 8-isoprostane; obesity; oxidative stress; phthalates; pregnancy ID BODY-MASS INDEX; OXIDATIVE STRESS; UNITED-STATES; URINARY F-2-ISOPROSTANES; ENERGY-EXPENDITURE; NATIONAL-HEALTH; PREGNANT-WOMEN; FAT OXIDATION; PRETERM BIRTH; CHILDHOOD AB Oxidative stress has been linked to many obesity-related conditions among children including cardiovascular disease, diabetes mellitus and hypertension. Exposure to environmental chemicals such as phthalates, ubiquitously found in humans, may also generate reactive oxygen species and subsequent oxidative stress. We examined longitudinal changes of 8-isoprostane urinary concentrations, a validated biomarker of oxidative stress, and associations with maternal prenatal urinary concentrations of phthalate metabolites for 258 children at 5, 9 and 14 years of age participating in a birth cohort residing in an agricultural area in California. Phthalates are endocrine disruptors, and in utero exposure has been also linked to altered lipid metabolism, as well as adverse birth and neurodevelopmental outcomes. We found that median creatinine-corrected 8-isoprostane concentrations remained constant across all age groups and did not differ by sex. Total cholesterol, systolic and diastolic blood pressure were positively associated with 8-isoprostane in 14-year-old children. No associations were observed between 8-isoprostane and body mass index (BMI), BMI Z-score or waist circumference at any age. Concentrations of three metabolites of high molecular weight phthalates measured at 13 weeks of gestation (monobenzyl, monocarboxyoctyl and monocarboxynonyl phthalates) were negatively associated with 8-isoprostane concentrations among 9-year olds. However, at 14 years of age, isoprostane concentrations were positively associated with two other metabolites (mono(2-ethylhexyl) and mono(2-ethyl-5-carboxypentyl) phthalates) measured in early pregnancy. Longitudinal data on 8-isoprostane in this pediatric population with a high prevalence of obesity provides new insight on certain potential cardiometabolic risks of prenatal exposure to phthalates. C1 [Tran, V.; Tindula, G.; Huen, K.; Bradman, A.; Harley, K.; Kogut, K.; Nguyen, B.; Parra, K.; Eskenazi, B.; Holland, N.] Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA. [Calafat, A. M.; Ye, X.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Holland, N (reprint author), Univ Calif Berkeley, Sch Publ Hlth, 733 Univ Hall, Berkeley, CA 94720 USA. EM ninah@berkeley.edu FU U.S. Environmental Protection Agency (EPA) [R826886, R82670901]; National Institute of Environmental Health Sciences (NIEHS) [PO1 ES009605, R01ES021369] FX This publication was made possible by grants R826886 and R82670901 from the U.S. Environmental Protection Agency (EPA) and PO1 ES009605 and R01ES021369 from the National Institute of Environmental Health Sciences (NIEHS). The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention (CDC), NIEHS and the EPA. Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the U.S. Department of Health and Human Services. NR 69 TC 0 Z9 0 U1 3 U2 3 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2040-1744 EI 2040-1752 J9 J DEV ORIG HLTH DIS JI J. Dev. Orig. Health Dis. PD APR PY 2017 VL 8 IS 2 BP 196 EP 205 DI 10.1017/S2040174416000763 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EM7QY UT WOS:000395508600008 PM 28031075 ER PT J AU Yang, SX Hemarajata, P Hindler, J Li, F Adisetiyo, H Aldrovandi, G Sebra, R Kasarskis, A MacCannell, D Didelot, X Russell, D Rubin, Z Humphries, R AF Yang, Shangxin Hemarajata, Peera Hindler, Janet Li, Fan Adisetiyo, Helty Aldrovandi, Grace Sebra, Robert Kasarskis, Andrew MacCannell, Duncan Didelot, Xavier Russell, Dana Rubin, Zachary Humphries, Romney TI Evolution and Transmission of Carbapenem-Resistant Klebsiella pneumoniae Expressing the bla(OXA-232) Gene During an Institutional Outbreak Associated With Endoscopic Retrograde Cholangiopancreatography SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE CRE outbreak; whole-genome sequencing; ERCP; OXA-232; carbapenem-resistant Klebsiella pneumoniae ID MOLECULAR EPIDEMIOLOGY; ENTEROBACTERIACEAE; SURVEILLANCE; OXA-232; RMTF AB Background. Whole-genome sequencing (WGS) is an emerging and powerful technique by which to perform epidemiological studies in outbreak situations. Methods. WGS was used to identify and evaluate an outbreak of OXA-232-expressing carbapenem-resistant Klebsiella pneumoniae (CRKP) transmitted to 16 patients over the course of 40 weeks via endoscopic retrograde cholangiopancreatography procedures at a single institution. WGS was performed on 32 OXA-232 CRKP isolates (1-7 per patient) and single-nucleotide variants (SNVs) were analyzed, with reference to the index patient's isolate. Results. Interhost genetic diversity of isolates was between 0 and 15 SNVs during the outbreak; molecular clock calculations estimated 12.31 substitutions per genome per year (95% credibility interval, 7.81-17.05). Both intra-and interpatient diversification at the plasmid and transposon level was observed, significantly impacting the antibiogram of outbreak isolates. The majority of isolates evaluated (n = 27) harbored a bla(CTX-M-15) gene, but some (n = 5) lacked the transposon carrying this gene, which resulted in susceptibility to aztreonam and third-and fourth-generation cephalosporins. Similarly, an isolate from a colonized patient lacked the transposon carrying rmtF and aac(6') lb genes, resulting in susceptibility to aminoglycosides. Conclusions. This study broadens the understanding of how bacteria diversify at the genomic level over the course of a defined outbreak and provides reference for future outbreak investigations. C1 [Yang, Shangxin; Hemarajata, Peera; Hindler, Janet; Humphries, Romney] Univ Calif Los Angeles, David Geffen Sch Med, Pathol & Lab Med, Los Angeles, CA 90095 USA. [Li, Fan; Adisetiyo, Helty; Aldrovandi, Grace] Childrens Hosp Los Angeles, Mi Next Generat Sci Core Lab, Los Angeles, CA USA. [Sebra, Robert; Kasarskis, Andrew] Icahn Sch Med Mt Sinai, New York, NY USA. [MacCannell, Duncan] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA USA. [Didelot, Xavier] Imperial Coll London, Dept Infect Dis, London, England. [Russell, Dana; Rubin, Zachary] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90024 USA. RP Humphries, R (reprint author), UCLA, Pathol & Lab Med, 11633 San Vicente Bvld, Los Angeles, CA 90049 USA. EM rhumphries@mednet.ucla.edu NR 21 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2017 VL 64 IS 7 BP 894 EP 901 DI 10.1093/cid/ciw876 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP5SS UT WOS:000397439600014 PM 28362935 ER PT J AU Crist, MB Perz, JF AF Crist, Matthew B. Perz, Joseph F. TI Modern Healthcare Versus Nontuberculous Mycobacteria: Who Will Have the Upper Hand? SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE nontuberculous mycobacteria; water microbiology; disease outbreaks; medical devices; infection control ID INFECTIONS; OUTBREAK; SURGERY C1 [Crist, Matthew B.; Perz, Joseph F.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA. RP Perz, JF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-31, Atlanta, GA 1600 USA. EM bzp4@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2017 VL 64 IS 7 BP 912 EP 913 DI 10.1093/cid/ciw881 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP5SS UT WOS:000397439600016 PM 28082270 ER PT J AU Shah, AS Maahs, DM Stafford, JM Dolan, LM Lang, W Imperatore, G Bell, RA Liese, AD Reynolds, K Pihoker, C Marcovina, S D'Agostino, RB Dabelea, D AF Shah, Amy S. Maahs, David M. Stafford, Jeanette M. Dolan, Lawrence M. Lang, Wei Imperatore, Giuseppina Bell, Ronny A. Liese, Angela D. Reynolds, Kristi Pihoker, Catherine Marcovina, Santica D'Agostino, Ralph B., Jr. Dabelea, Dana TI Predictors of Dyslipidemia Over Time in Youth With Type 1 Diabetes: For the SEARCH for Diabetes in Youth Study SO DIABETES CARE LA English DT Article ID NON-HDL-CHOLESTEROL; TO-HEIGHT RATIO; CARDIOVASCULAR RISK; INTENSIVE THERAPY; SERUM-LIPIDS; YOUNG-ADULTS; ADOLESCENTS; POPULATION; LIPOPROTEIN; CHILDREN AB OBJECTIVE Understanding the risk factors associated with progression and regression of dyslipidemia in youth with type 1 diabetes may guide treatments. RESEARCH DESIGN AND METHODS We studied 1,478 youth with type 1 diabetes (age 10.8 +/- 3.9 years, 50% male, 77% non-Hispanic white, not on lipid-lowering medications) at baseline and at a mean follow-up of 7.1 +/- 1.9 years in the SEARCH for Diabetes in Youth (SEARCH) study. Progression to dyslipidemia was defined as normal lipid concentrations at baseline and abnormal at follow-up (non-HDL-cholesterol [C] >130 mg/dL or HDL-C <35 mg/dL). Regression was defined as abnormal lipids at baseline and normal at follow-up. Multivariable logistic regression was used to evaluate factors associated with progression and regression compared with stable normal and stable abnormal, respectively. An area under the curve (AUC) variable was used for the time-varying covariates A1C and waist-to-height ratio (WHtR). RESULTS Non-HDL-C progressed, regressed, was stable normal, and stable abnormal in 19%, 5%, 69%, and 7% of youth with type 1 diabetes, respectively. Corresponding percentages for HDL-C were 3%, 3%, 94%, and 1%, respectively. Factors associated with non-HDL-C progression were higher A1C AUC and higher WHtR AUC in males. Non-HDL-C regression was associated with lower WHtR AUC, and HDL-C progression was associated with male sex and higher WHtR AUC. HDL-C regression was not modeled due to small numbers. CONCLUSIONS A1C and WHtR are modifiable risk factors associated with change in dyslipidemia over time in youth with type 1 diabetes. C1 [Shah, Amy S.; Dolan, Lawrence M.] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA. [Shah, Amy S.; Dolan, Lawrence M.] Univ Cincinnati, Cincinnati, OH USA. [Maahs, David M.] Univ Colorado, Dept Pediat, Aurora, CO USA. [Stafford, Jeanette M.; Lang, Wei; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Bell, Ronny A.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA. [Liese, Angela D.] Univ South Carolina, Dept Epidemiol & Biostat, Columbia, SC USA. [Reynolds, Kristi] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Marcovina, Santica] Univ Washington, Northwest Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Dabelea, Dana] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. RP Shah, AS (reprint author), Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA.; Shah, AS (reprint author), Univ Cincinnati, Cincinnati, OH USA. EM amy.shah@cchmc.org RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395 FU National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases; Centers for Disease Control and Prevention; Kaiser Permanente Southern California [U18-DP-006133, U48/CCU919219, U01-DP-000246, U18-DP-002714]; University of Colorado Denver [U18-DP-006139, U48/CCU819241-3, U01-DP-000247, U18-DP-000247-06A1]; Cincinnati Children's Hospital Medical Center [U18-DP-006134, U48/CCU519239, U01-DP-000248, 1U18-DP-002709]; University of North Carolina at Chapel Hill [U18-DP-006138, U48/CCU419249, U01-DP-000254, U18-DP-002708]; Seattle Children's Hospital [U18-DP-006136, U58/CCU019235-4, U01-DP-000244, U18-DP-002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U18-DP-006131, U01-DP-000250, 200-2010-35171]; South Carolina Clinical & Translational Research Institute at the Medical University of South Carolina, NIH/National Center for Advancing Translational Sciences (NCATS) [UL1-TR-001450]; Seattle Children's Hospital and the University of Washington, NIH/NCATS [UL1-TR-00423]; University of Colorado Pediatric Clinical and Translational Research Center, NIH/NCATS [UL1-TR-000154]; Barbara Davis Center at the University of Colorado Denver, Diabetes Endocrinology Research Centers NIH grant [P30-DK-57516]; University of Cincinnati, NIH/NCATS [UL1-TR-001425]; Children with Medical Handicaps program FX The SEARCH for Diabetes in Youth Cohort Study (1UC4DK108173-01) is funded by the National Institutes of Health (NIH) and National Institute of Diabetes and Digestive and Kidney Diseases and supported by the Centers for Disease Control and Prevention.; Each clinical site has also received funding: Kaiser Permanente Southern California (U18-DP-006133, U48/CCU919219, U01-DP-000246, and U18-DP-002714), University of Colorado Denver (U18-DP-006139, U48/CCU819241-3, U01-DP-000247, and U18-DP-000247-06A1), Cincinnati Children's Hospital Medical Center (U18-DP-006134, U48/CCU519239, U01-DP-000248, and 1U18-DP-002709), University of North Carolina at Chapel Hill (U18-DP-006138, U48/CCU419249, U01-DP-000254, and U18-DP-002708), Seattle Children's Hospital (U18-DP-006136, U58/CCU019235-4, U01-DP-000244, and U18-DP-002710-01), and Wake Forest University School of Medicine (U18-DP-006131, U48/CCU919219, U01-DP-000250, and 200-2010-35171).; The authors acknowledge the involvement of the South Carolina Clinical & Translational Research Institute at the Medical University of South Carolina, NIH/National Center for Advancing Translational Sciences (NCATS) grant number UL1-TR-001450; Seattle Children's Hospital and the University of Washington, NIH/NCATS grant number UL1-TR-00423; University of Colorado Pediatric Clinical and Translational Research Center, NIH/NCATS grant number UL1-TR-000154; the Barbara Davis Center at the University of Colorado Denver, Diabetes Endocrinology Research Centers NIH grant number P30-DK-57516; the University of Cincinnati, NIH/NCATS grant number UL1-TR-001425; and the Children with Medical Handicaps program managed by the Department of Health. NR 34 TC 0 Z9 0 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 2017 VL 40 IS 4 BP 607 EP 613 DI 10.2337/dc16-2193 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP0UZ UT WOS:000397103500032 PM 28126715 ER PT J AU Shegog, R Rushing, SC Gorman, G Jessen, C Torres, J Lane, TL Gaston, A Revels, TK Williamson, J Peskin, MF D'Cruz, J Tortolero, S Markham, CM AF Shegog, Ross Rushing, Stephanie Craig Gorman, Gwenda Jessen, Cornelia Torres, Jennifer Lane, Travis L. Gaston, Amanda Revels, Taija Koogei Williamson, Jennifer Peskin, Melissa F. D'Cruz, Jina Tortolero, Susan Markham, Christine M. TI NATIVE-It's Your Game: Adapting a Technology-Based Sexual Health Curriculum for American Indian and Alaska Native youth SO JOURNAL OF PRIMARY PREVENTION LA English DT Article DE Teen pregnancy prevention; Cultural adaptation; Communication technology; Computer-based learning; Behavior; Adolescents; Web-based health education; Computer-based health education; Health communications; School based health ID RISK-REDUCTION INTERVENTIONS; RANDOMIZED CONTROLLED-TRIAL; NORTHERN PLAINS; CULTURAL-ADAPTATION; YOUNG ADOLESCENTS; PACIFIC-NORTHWEST; EDUCATION; PROGRAM; INTERCOURSE; INITIATION AB Sexually transmitted infection (STI) and birth rates among American Indian/Alaska Native (AI/AN) youth indicate a need for effective middle school HIV/STI and pregnancy prevention curricula to delay, or mitigate, the consequences of early sexual activity. While effective curricula exist, there is a dearth of curricula with content salient to AI/AN youth. Further, there is a lack of sexual health curricula that take advantage of the motivational appeal, reach, and fidelity of communication technology for this population, who are sophisticated technology users. We describe the adaptation process used to develop Native It's Your Game, a stand-alone 13-lesson Internet-based sexual health life-skills curriculum adapted from an existing promising sexual health curriculum, It's Your Game-Tech (IYG-Tech). The adaptation included three phases: (1) pre-adaptation needs assessment and IYG-Tech usability testing; (2) adaptation, including design document development, prototype programming, and alpha testing; and (3) post-adaption usability testing. Laboratory-and school-based tests with AI/AN middle school youth demonstrated high ratings on usability parameters. Youth rated the Native IYG lessons favorably in meeting the needs of AI/AN youth (54-86 % agreement across lessons) and in comparison to other learning channels (57-100 %) and rated the lessons as helpful in making better health choices (73-100 %). Tribal stakeholders rated Native IYG favorably, and suggested it was culturally appropriate for AI/AN youth and suitable for implementation in tribal settings. Further efficacy testing is indicated for Native IYG, as a potential strategy to deliver HIV/STI and pregnancy prevention to traditionally underserved AI/AN middle school youth. C1 [Shegog, Ross; Torres, Jennifer; Peskin, Melissa F.; Tortolero, Susan; Markham, Christine M.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, 7000 Fannin St,Suite 2668, Houston, TX 77030 USA. [Rushing, Stephanie Craig; Gaston, Amanda] Northwest Portland Area Indian Hlth Board, 2121 SW Broadway,Suite 300, Portland, OR 97201 USA. [Gorman, Gwenda; Lane, Travis L.] Inter Tribal Council Arizona Inc, 2214 North Cent Ave,Suite 100, Phoenix, AZ 85004 USA. [Jessen, Cornelia; Revels, Taija Koogei; Williamson, Jennifer] Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, 3900 Ambassador Dr, Anchorage, AK 99508 USA. [D'Cruz, Jina] CDC, OPHSS, CSELS, Atlanta, GA 30333 USA. RP Shegog, R (reprint author), Univ Texas Hlth Sci Ctr Houston, Univ Texas Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, 7000 Fannin St,Suite 2668, Houston, TX 77030 USA. EM Ross.Shegog@uth.tmc.edu; ygp4@cdc.gov FU CDC [5U48DP001949]; DHHS Agency for Children and Families Grant [HHS-2011-ACF-ACYF-AT-0157] FX This work was made possible through funding from CDC cooperative agreement (Award# 5U48DP001949) and DHHS Agency for Children and Families Grant (Award# HHS-2011-ACF-ACYF-AT-0157) and through the collaboration of tribes in Alaska, Arizona, and the Pacific Northwest, with Public Health Advisors Lori de Ravello, MPH and Scott Tulloch of the Indian Health Service, consultants Carol Kaufman, PhD. and William Lambert, PhD., and Zsolt L. Levai who facilitated manuscript development. NR 70 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0278-095X EI 1573-6547 J9 J PRIM PREV JI J. Prim. Prev. PD APR PY 2017 VL 38 IS 1-2 SI SI BP 27 EP 48 DI 10.1007/s10935-016-0440-9 PG 22 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL0ZL UT WOS:000394350200003 PM 27520459 ER PT J AU Waters, KP Zuber, A Simbini, T Bangani, Z Krishnamurthy, RS AF Waters, Keith P. Zuber, Alexandra Simbini, Tungamirirai Bangani, Zwashe Krishnamurthy, Ramesh S. TI Zimbabwe's Human Resources for health Information System (ZHRIS)-an assessment in the context of establishing a global standard SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Article DE Human resources information systems (HRIS); Human resources for health (HRH); Global public health informatics; Workforce surveillance; Data standards; Health workforce registry; Minimum data set (MDS) AB Introduction: There have been numerous global calls to action to utilize human resources information systems (HRIS) to improve the availability and quality of data for strengthening the regulation and deployment of health workers. However, with no normative guidance in existence, the development of HRIS has been inconsistent and lacking in standardization, hindering the availability and use of data for health workforce planning and decision making (Riley et al., 2012). CDC and WHO partnered with the Ministry of Health in several countries to conduct HRIS functional requirements analyses and establish a Minimum Data Set (MDS) of elements essential for a global standard HRIS. As a next step, CDC advanced a study to examine the alignment of one of the HRIS it supports (in Zimbabwe) against this MDS. Method: For this study, we created a new data collection and analysis tool to assess the extent to which Zimbabwe's CDC-supported HRIS was aligned with the WHO MDS. We performed systematic "gap analyses" in order to make prioritized recommendations for addressing the gaps, with the aim of improving the availability and quality of data on Zimbabwe's health workforce. Results: The majority of the data elements outlined in the WHO MDS were present in the ZHRIS databases, though they were found to be missing various applicable elements. The lack of certain elements could impede functions such as health worker credential verification or equitable in-service training allocation. While the HRIS MDS treats all elements equally, our assessment revealed that not all the elements have equal significance when it comes to data utilization. Further, some of the HRIS MDS elements exceeded the current needs of regulatory bodies and the Ministry of Health and Child Care (MOHCC) in Zimbabwe. The preliminary findings of this study helped inspire the development of a more recent HRH Registry MDS subset, which is a shorter list of priority data elements recommended as a global standard for HRIS. Conclusion: The field-tested assessment methodology presented here, with suggested improvements to the tool, can be used to identify absent or unaligned elements in either an HRH Registry or a full HRIS. Addressing the prioritized gaps will increase the availability of critical data in the ZHRIS and can empower the MOHCC and councils to conduct more strategic analyses, improving health workforce planning and ultimately public health outcomes in the country. Published by Elsevier Ireland Ltd. C1 [Waters, Keith P.; Zuber, Alexandra] CDC, US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Simbini, Tungamirirai] Univ Zimbabwe, Hlth Informat Training & Res Adv Ctr, Harare, Zimbabwe. [Bangani, Zwashe] CDC Zimbabwe, Harare, Zimbabwe. [Krishnamurthy, Ramesh S.] WHO, Geneva, Switzerland. RP Waters, KP (reprint author), Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, 1600 Clifton Rd,MS-E77, Atlanta, GA 30329 USA. EM kpwaters@cdc.gov FU Public Health Informatics Fellowship Program; President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) FX The authors would like to thank individuals at the following for valuable contributions to this project: WHO (Geneva); CDC Atlanta and the Public Health Informatics Fellowship Program; CDC Zimbabwe; HITRAC; and the following for permitting the databases to be assessed: MOHCC; MDPCZ and NCZ.; This study has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC). The findings and statements in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 18 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 EI 1872-8243 J9 INT J MED INFORM JI Int. J. Med. Inform. PD APR PY 2017 VL 100 BP 121 EP 128 DI 10.1016/j.ijmedinf.2017.01.011 PG 8 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA EM9XF UT WOS:000395664200013 PM 28241933 ER PT J AU Shrivastava, A Kumar, A Thomas, JD Laserson, KF Bhushan, G Carter, MD Chhabra, M Mittal, V Khare, S Sejvar, JJ Dwivedi, M Isenberg, SL Johnson, R Pirkle, JL Sharer, JD Hall, PL Yadav, R Velayudhan, A Papanna, M Singh, P Somashekar, D Pradhan, A Goel, K Pandey, R Kumar, M Kumar, S Chakrabarti, A Sivaperumal, P Kumar, AR Schier, JG Chang, A Graham, LA Mathews, TP Johnson, D Valentin, L Caldwell, KL Jarrett, JM Harden, LA Takeoka, GR Tong, SX Queen, K Paden, C Whitney, A Haberling, DL Singh, R Singh, RS Earhart, KC Dhariwal, AC Chauhan, LS Venkatesh, S Srikantiah, P AF Shrivastava, Aakash Kumar, Anil Thomas, Jerry D. Laserson, Kayla F. Bhushan, Gyan Carter, Melissa D. Chhabra, Mala Mittal, Veena Khare, Shashi Sejvar, James J. Dwivedi, Mayank Isenberg, Samantha L. Johnson, Rudolph Pirkle, James L. Sharer, Jon D. Hall, Patricia L. Yadav, Rajesh Velayudhan, Anoop Papanna, Mohan Singh, Pankaj Somashekar, D. Pradhan, Arghya Goel, Kapil Pandey, Rajesh Kumar, Mohan Kumar, Satish Chakrabarti, Amit Sivaperumal, P. Kumar, A. Ramesh Schier, Joshua G. Chang, Arthur Graham, Leigh Ann Mathews, Thomas P. Johnson, Darryl Valentin, Liza Caldwell, Kathleen L. Jarrett, Jeffery M. Harden, Leslie A. Takeoka, Gary R. Tong, Suxiang Queen, Krista Paden, Clinton Whitney, Anne Haberling, Dana L. Singh, Ram Singh, Ravi Shankar Earhart, Kenneth C. Dhariwal, A. C. Chauhan, L. S. Venkatesh, S. Srikantiah, Padmini TI Association of acute toxic encephalopathy with litchi consumption in an outbreak in Muzaffarpur, India, 2014: a case-control study SO LANCET GLOBAL HEALTH LA English DT Article ID TANDEM MASS-SPECTROMETRY; LIQUID-CHROMATOGRAPHY; ACUTE ENCEPHALITIS; ORGANIC-ACIDS; METHYLENECYCLOPROPYLGLYCINE; CHILDREN; QUANTIFICATION; URINE; FRUIT; BIHAR AB Background Outbreaks of unexplained illness frequently remain under-investigated. In India, outbreaks of an acute neurological illness with high mortality among children occur annually in Muzaffarpur, the country's largest litchi cultivation region. In 2014, we aimed to investigate the cause and risk factors for this illness. Methods In this hospital-based surveillance and nested age-matched case-control study, we did laboratory investigations to assess potential infectious and non-infectious causes of this acute neurological illness. Cases were children aged 15 years or younger who were admitted to two hospitals in Muzaffarpur with new-onset seizures or altered sensorium. Age-matched controls were residents of Muzaffarpur who were admitted to the same two hospitals for a non-neurologic illness within seven days of the date of admission of the case. Clinical specimens (blood, cerebrospinal fluid, and urine) and environmental specimens (litchis) were tested for evidence of infectious pathogens, pesticides, toxic metals, and other non-infectious causes, including presence of hypoglycin A or methylenecyclopropylglycine (MCPG), naturally-occurring fruit-based toxins that cause hypoglycaemia and metabolic derangement. Matched and unmatched (controlling for age) bivariate analyses were done and risk factors for illness were expressed as matched odds ratios and odds ratios (unmatched analyses). Findings Between May 26, and July 17, 2014, 390 patients meeting the case definition were admitted to the two referral hospitals in Muzaffarpur, of whom 122 (31%) died. On admission, 204 (62%) of 327 had blood glucose concentration of 70 mg/dL or less. 104 cases were compared with 104 age-matched hospital controls. Litchi consumption (matched odds ratio [mOR] 9.6 [95% CI 3.6 - 24]) and absence of an evening meal (2.2 [1.2-4.3]) in the 24 h preceding illness onset were associated with illness. The absence of an evening meal significantly modified the effect of eating litchis on illness (odds ratio [OR] 7.8 [95% CI 3.3-18.8], without evening meal; OR 3.6 [1.1-11.1] with an evening meal). Tests for infectious agents and pesticides were negative. Metabolites of hypoglycin A, MCPG, or both were detected in 48 [66%] of 73 urine specimens from case-patients and none from 15 controls; 72 (90%) of 80 case-patient specimens had abnormal plasma acylcarnitine profiles, consistent with severe disruption of fatty acid metabolism. In 36 litchi arils tested from Muzaffarpur, hypoglycin A concentrations ranged from 12.4 mu g/g to 152.0 mu g/g and MCPG ranged from 44.9 mu g/g to 220.0 mu g/g. Interpretation Our investigation suggests an outbreak of acute encephalopathy in Muzaffarpur associated with both hypoglycin A and MCPG toxicity. To prevent illness and reduce mortality in the region, we recommended minimising litchi consumption, ensuring receipt of an evening meal and implementing rapid glucose correction for suspected illness. A comprehensive investigative approach in Muzaffarpur led to timely public health recommendations, underscoring the importance of using systematic methods in other unexplained illness outbreaks. C1 [Shrivastava, Aakash; Kumar, Anil; Chhabra, Mala; Mittal, Veena; Khare, Shashi; Singh, Ram; Singh, Ravi Shankar; Chauhan, L. S.; Venkatesh, S.] Govt India, Natl Ctr Dis Control, Directorate Gen Hlth Serv, Minist Hlth & Family Welf, Delhi, India. [Thomas, Jerry D.; Carter, Melissa D.; Johnson, Rudolph; Pirkle, James L.; Schier, Joshua G.; Chang, Arthur; Valentin, Liza; Caldwell, Kathleen L.; Jarrett, Jeffery M.] US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Laserson, Kayla F.; Dwivedi, Mayank; Yadav, Rajesh; Velayudhan, Anoop; Papanna, Mohan; Earhart, Kenneth C.; Srikantiah, Padmini] Embassy US, Global Dis Detect Program, US Ctr Dis Control & Prevent, New Delhi, India. [Bhushan, Gyan] Sadar Hosp, Govt Bihar, Muzaffarpur Dist Hlth Dept, Muzaffarpur, Bihar, India. [Sejvar, James J.; Haberling, Dana L.] US Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Isenberg, Samantha L.; Graham, Leigh Ann; Mathews, Thomas P.; Johnson, Darryl] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sharer, Jon D.; Hall, Patricia L.] Emory Univ, Dept Human Genet, Decatur, GA USA. [Yadav, Rajesh; Velayudhan, Anoop; Papanna, Mohan; Singh, Pankaj; Somashekar, D.; Pradhan, Arghya; Goel, Kapil; Pandey, Rajesh; Kumar, Mohan; Kumar, Satish] Govt India, Minist Hlth & Family Welf, India Epidem Intelligence Serv, Natl Ctr Dis Control,Directorate Gen Hlth Serv, Delhi, India. [Chakrabarti, Amit; Sivaperumal, P.; Kumar, A. Ramesh] Govt India, Minist Hlth & Family Welf, Natl Inst Occupat Hlth, Indian Council Med Res, Ahmadabad, Gujarat, India. [Harden, Leslie A.; Takeoka, Gary R.] USDA, Western Reg Res Ctr, 800 Buchanan St, Albany, CA 94710 USA. [Tong, Suxiang; Queen, Krista; Paden, Clinton; Whitney, Anne] US Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Laserson, Kayla F.; Earhart, Kenneth C.; Srikantiah, Padmini] US Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Dhariwal, A. C.] Govt India, Minist Hlth & Family Welf, Directorate Gen Hlth Serv, Natl Vector Borne Dis Control Programme, New Delhi, India. RP Srikantiah, P (reprint author), Embassy US, Global Dis Detect Program, US Ctr Dis Control & Prevent, New Delhi, India. EM pks6@cdc.gov FU US Centers for Disease Control and Prevention FX US Centers for Disease Control and Prevention. NR 47 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2214-109X J9 LANCET GLOB HEALTH JI Lancet Glob. Health PD APR PY 2017 VL 5 IS 4 BP E458 EP E466 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN9SG UT WOS:000396339300025 PM 28153514 ER PT J AU Ge, BL Mukherjee, S Hsu, CH Davis, JA Tran, TTT Yang, Q Abbott, JW Ayers, SL Young, SR Crarey, ET Womack, NA Zhao, SH McDermott, PF AF Ge, Beilei Mukherjee, Sampa Hsu, Chih-Hao Davis, Johnnie A. Tran, Thu Thuy T. Yang, Qianru Abbott, Jason W. Ayers, Sherry L. Young, Shenia R. Crarey, Emily T. Womack, Niketta A. Zhao, Shaohua McDermott, Patrick F. TI MRSA and multidrug-resistant Staphylococcus aureus in US retail meats, 2010-2011 SO FOOD MICROBIOLOGY LA English DT Article DE MRSA; LA-MRSA; ST398; USA300; MDRSA; Retail meat ID ANTIMICROBIAL SUSCEPTIBILITY; MOLECULAR CHARACTERIZATION; ANTIBIOTIC-RESISTANCE; PREVALENCE; STRAINS; CHICKEN; ORIGIN; ST398; PORK; WORKERS AB Methicillin-resistant Staphylococcus aureus (MRSA) has been detected in retail meats, although large-scale studies are scarce. We conducted a one-year survey in 2010-2011 within the framework of the National Antimicrobial Resistance Monitoring System. Among 3520 retail meats collected from eight U.S. states, 982 (27.9%) contained S. aureus and 66 (1.9%) were positive for MRSA. Approximately 10.4% (107/1032) of S. aureus isolates, including 37.2% (29/78) of MRSA, were multidrug-resistant (MDRSA). Turkey had the highest MRSA prevalence (3.5%), followed by pork (1.9%), beef (1.7%), and chicken (0.3%). Whole-genome sequencing was performed for all 66 non-redundant MRSA. Among five multilocus sequence types identified, ST8 (72.7%) and ST5 (22.7%) were most common and livestock-associated MRSA ST398 was assigned to one pork isolate. Eleven spa types were represented, predominately t008 (43.9%) and t2031 (22.7%). All four types of meats harbored t008, whereas t2031 was recovered from turkey only. The majority of MRSA (84.8%) possessed SCCmec IV and 62.1% harbored Panton-Valentine leukocidin. Pulsed field gel electrophoresis showed that all ST8 MRSA belonged to the predominant human epidemic clone USA300, and others included USA100 and USA200. We conclude that a diverse MRSA population was present in U.S. retail meats, albeit at low prevalence. Published by Elsevier Ltd. C1 [Ge, Beilei; Mukherjee, Sampa; Hsu, Chih-Hao; Davis, Johnnie A.; Tran, Thu Thuy T.; Yang, Qianru; Abbott, Jason W.; Ayers, Sherry L.; Young, Shenia R.; Crarey, Emily T.; Womack, Niketta A.; Zhao, Shaohua; McDermott, Patrick F.] US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, 8401 Muirkirk Rd, Laurel, MD 20708 USA. [Davis, Johnnie A.] Procter & Gamble Co, Mason, OH 45040 USA. [Womack, Niketta A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Ge, BL (reprint author), US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, 8401 Muirkirk Rd, Laurel, MD 20708 USA. EM beilei.ge@fda.hhs.gov NR 44 TC 0 Z9 0 U1 68 U2 68 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0740-0020 EI 1095-9998 J9 FOOD MICROBIOL JI Food Microbiol. PD APR PY 2017 VL 62 BP 289 EP 297 DI 10.1016/j.fm.2016.10.029 PG 9 WC Biotechnology & Applied Microbiology; Food Science & Technology; Microbiology SC Biotechnology & Applied Microbiology; Food Science & Technology; Microbiology GA EF7HE UT WOS:000390499900039 PM 27889161 ER PT J AU McKnight-Eily, LR Okoro, CA Mejia, R Denny, CH Higgins-Biddle, J Hungerford, D Kanny, D Sniezek, JE AF McKnight-Eily, Lela R. Okoro, Catherine A. Mejia, Roberto Denny, Clark H. Higgins-Biddle, John Hungerford, Dan Kanny, Dafna Sniezek, Joseph E. TI Screening for Excessive Alcohol Use and Brief Counseling of Adults 17-States and the District of Columbia, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTH-CARE; METAANALYSIS AB What is already known about this topic? Although excessive or risky alcohol use is a major preventable cause of morbidity and mortality, according to 2011 CDC data, only one in six U. S. adults reports ever having a conversation with a health professional about alcohol use. It has been recommended by the U. S. Preventive Services Task Force (USPSTF) that all U.S. adults aged >= 18 years be screened for alcohol misuse and receive brief counseling if needed. What is added by this report? Findings from a 5-question module on alcohol screening and brief intervention (ASBI) using Behavioral Risk Factor Surveillance System survey data from 17 states and the District of Columbia in 2014 indicate that only one in three binge drinkers was asked about alcohol use (in person or on a form) and advised about risky drinking levels. Further, only one in six binge drinkers was asked about alcohol use (in person or on a form) and advised to reduce their drinking by a health professional. What are the implications for public health practice? Continued work at the health systems and individual practice levels is needed to implement ASBI per the USPSTF recommendation. If ASBI was provided as recommended in all appropriate medical settings, and coupled with recommended, evidencebased community interventions, preventable morbidity and mortality associated with excessive alcohol use might be reduced. C1 [McKnight-Eily, Lela R.; Mejia, Roberto; Denny, Clark H.; Higgins-Biddle, John; Hungerford, Dan; Sniezek, Joseph E.] CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Okoro, Catherine A.; Kanny, Dafna] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP McKnight-Eily, LR (reprint author), CDC, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM LMcKnightEily@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 31 PY 2017 VL 66 IS 12 BP 313 EP 319 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EQ1BH UT WOS:000397803800001 PM 28358798 ER PT J AU Faul, M Bohm, M Alexander, C AF Faul, Mark Bohm, Michele Alexander, Caleb TI Methadone Prescribing and Overdose and the Association with Medicaid Preferred Drug List Policies - United States, 2007-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material AB What is already known about this topic? It is important that prescribing methadone as a pain medication is done carefully. In 2006, the Food and Drug Administration issued a public health advisory regarding health risks associated with prescribing methadone. What is added by this report? Methadone accounted for approximately 1% of all opioids prescribed for pain but accounted for approximately 23% of all prescription opioid deaths in 2014. State drug management practices and reimbursement policies can affect methadone prescribing practices and, in turn, might reduce methadone overdose rates within a state. What are the implications for public health practice? Drug utilization management policies that reduce the use of risky opioids such as methadone might reduce opioid-related morbidity and mortality. This evidence of decreases in methadone overdoses and use of preferred drug list policies could serve as a model for future decreases in other specific opioid drug-related mortality. C1 [Faul, Mark; Bohm, Michele] CDC, Natl Ctr Injury Prevent, Atlanta, GA 30333 USA. [Alexander, Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA. [Alexander, Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Faul, M (reprint author), CDC, Natl Ctr Injury Prevent, Atlanta, GA 30333 USA. EM mfaul@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 31 PY 2017 VL 66 IS 12 BP 320 EP 323 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EQ1BH UT WOS:000397803800002 PM 28358791 ER PT J AU Quader, ZS Zhao, LX Gillespie, C Cogswell, ME Terry, AL Moshfegh, A Rhodes, D AF Quader, Zerleen S. Zhao, Lixia Gillespie, Cathleen Cogswell, Mary E. Terry, Ana L. Moshfegh, Alanna Rhodes, Donna TI Sodium Intake Among Persons Aged >= 2 Years - United States, 2013-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MORTALITY; HEALTH AB What is already known about this topic? Reducing sodium intake can reduce blood pressure; hypertension is a risk factor for cardiovascular disease. According to data from the National Health and Nutrition Examination Survey 2007-2008, average daily U. S. sodium intake was 3,266 mg, exceeding Healthy People 2020 objectives, and 44% of sodium consumed came from just 10 food types. What is added by this report? The most recent data, from 2013-2014, indicate that average daily U. S. sodium intake is 3,409 mg (excluding salt added at the table), with 44% of intake from 10 food types and 70% from 25 food types, 61% from food obtained at stores, and highest sodium density (mg/1,000 kcal) from food obtained at restaurants. Food types contributing to intake differ by racial /ethnic group, with current data indicating that non-Hispanic Asians might consume a slightly more sodium-dense diet than that of non-Hispanic whites. What are the implications for public health practice? Sodium intake remains high and comes from a variety of food types and places. Monitoring differences in types and sources of intake can help focus sodium reduction measures to reduce blood pressure and cardiovascular disease. C1 [Quader, Zerleen S.; Zhao, Lixia; Gillespie, Cathleen; Cogswell, Mary E.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Terry, Ana L.] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. [Moshfegh, Alanna; Rhodes, Donna] ARS, Food Surveys Res Grp, USDA, Beltsville, MD USA. RP Quader, ZS (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM zquader@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 31 PY 2017 VL 66 IS 12 BP 324 EP 328 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EQ1BH UT WOS:000397803800003 PM 28358799 ER PT J AU Ikejezie, J Shapiro, CN Kim, J Chiu, M Almiron, M Ugarte, C Espinal, MA Aldighieri, S AF Ikejezie, Juniorcaius Shapiro, Craig N. Kim, Jisoo Chiu, Monica Almiron, Maria Ugarte, Ciro Espinal, Marcos A. Aldighieri, Sylvain TI Zika Virus Transmission - Region of the Americas, May 15, 2015-December 15, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article AB What is already known about this topic? Zika virus, a flavivirus that is primarily transmitted by Aedes mosquitoes, has rapidly spread throughout the Region of the Americas since 2015. Zika virus infection during pregnancy is a known cause of microcephaly and other congenital abnormalities, and infection is also associated with neurologic disorders, including Guillain-Barre syndrome (GBS). What is added by this report? During May 15, 2015-December 15, 2016, autochthonous Zika virus transmission was confirmed in 48 countries and territories in the Region of the Americas. Rates of Zika virus disease peaked at different times in different subregions. During this period, the trend in reported GBS cases paralleled that of reported Zika virus disease cases. What are the implications for public health practice? Because of ongoing Zika virus transmission, the occurrence of associated complications, and the risk for recurrence of large outbreaks, countries where Aedes mosquitoes are present should continue surveillance for Zika virus disease, GBS, and congenital abnormalities; strengthen capacity for laboratory diagnosis of Zika virus and other arboviruses; and continue the implementation of vector control measures and other prevention activities. C1 [Ikejezie, Juniorcaius; Kim, Jisoo; Chiu, Monica; Almiron, Maria; Ugarte, Ciro; Espinal, Marcos A.; Aldighieri, Sylvain] Pan Amer Hlth Org, Washington, DC 20037 USA. [Shapiro, Craig N.] CDC, Div Emergency Operat, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP Ikejezie, J (reprint author), Pan Amer Hlth Org, Washington, DC 20037 USA. EM ikejezijun@paho.org NR 9 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 31 PY 2017 VL 66 IS 12 BP 329 EP 334 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EQ1BH UT WOS:000397803800004 PM 28358795 ER PT J AU Otshudiema, JO Ndakala, NG Mawanda, ETK Tshapenda, GP Kimfuta, JM Nsibu, LRN Gueye, AS Dee, J Philen, RM Giese, C Murrill, CS Arthur, RR Kebela, BI AF Otshudiema, John O. Ndakala, Nestor G. Mawanda, Elande-taty K. Tshapenda, Gaston P. Kimfuta, Jacques M. Nsibu, Loupy-Regence N. Gueye, Abdou S. Dee, Jacob Philen, Rossanne M. Giese, Coralie Murrill, Christopher S. Arthur, Ray R. Kebela, Benoit I. TI Yellow Fever Outbreak - Kongo Central Province, Democratic Republic of the Congo, August 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article AB What is already known about this topic? Border areas with high population mobility and intense trade activities can foster outbreaks such as yellow fever, particularly in settings where vaccination coverage and health screening capacity are not optimal. In December 2015, a large yellow fever outbreak began in Angola, bordering the Democratic Republic of the Congo (DRC). What is added by this report? In February 2016, a yellow fever outbreak was declared in DRC; approximately 90% of suspected cases and deaths occurred in Kongo Central Province. Thirty seven of the 393 specimens tested received laboratory confirmation of yellow fever virus; 35 of these 37 cases were imported from neighboring Angola. Most imported cases occurred in persons who crossed the DRC-Angola border at a single market city, where <= 40,000 travelers cross the border each week on market day, overwhelming the border health screening program. Insufficient laboratory supplies and delayed transport of specimens to the laboratory compromised case confirmation. What are the implications for public health practice? Reinforcement of coordination between enhanced laboratory and case-based surveillance, with health border screening and cross-border trade activities, is necessary at land crossing borders to prevent and control future yellow fever outbreaks. C1 [Otshudiema, John O.] CDC, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA. [Otshudiema, John O.] CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ndakala, Nestor G.] Field Epidemiol & Lab Training Program, Kinshasa, DEM REP CONGO. [Mawanda, Elande-taty K.; Kimfuta, Jacques M.] Minist Hlth, Div Prov Sante, Kongo Cent Prov, Kinshasa, DEM REP CONGO. [Tshapenda, Gaston P.; Kebela, Benoit I.] Minist Hlth, Direct Lutte Maladie, Kinshasa, DEM REP CONGO. [Nsibu, Loupy-Regence N.] Kongo Cent Prov, Zone Sante Nsona Mpangu, Kinshasa, DEM REP CONGO. [Gueye, Abdou S.; Philen, Rossanne M.; Giese, Coralie; Arthur, Ray R.] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Dee, Jacob] CDC, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA 30333 USA. [Murrill, Christopher S.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Otshudiema, JO (reprint author), CDC, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA.; Otshudiema, JO (reprint author), CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jotshudiema@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 31 PY 2017 VL 66 IS 12 BP 335 EP 338 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EQ1BH UT WOS:000397803800005 PM 28358796 ER PT J AU Scott, C Walusimbi, S Kirenga, B Joloba, M Winters, M Abdunoor, N Bain, R Alexander, H Shinnick, T Toney, S Odeke, R Mwangi, C Birabwa, E Dejene, S Mugabe, F YaDiul, M Cavanaugh, JS AF Scott, Colleen Walusimbi, Simon Kirenga, Bruce Joloba, Moses Winters, Muttamba Abdunoor, Nyombi Bain, Rommel Alexander, Heather Shinnick, Tom Toney, Sean Odeke, Rosemary Mwangi, Christine Birabwa, Estella Dejene, Seyoum Mugabe, Frank YaDiul, Mukadi Cavanaugh, J. Sean TI Evaluation of Automated Molecular Testing Rollout for Tuberculosis Diagnosis Using Routinely Collected Surveillance Data - Uganda, 2012-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID XPERT(R) MTB/RIF; SETTINGS; IMPACT AB What is already known about this topic? The World Health Organization recommends use of the Xpert MTB/RIF assay as the initial diagnostic test in adults and children with presumptive HIV-associated TB or multidrug-resistant TB. Currently, data on the effect of the Xpert MTB/RIF assay on case notification or TB treatment outcomes are limited. Published studies indicate the Xpert MTB/RIF assay might improve the proportion of TB diagnoses that are bacteriologically confirmed, but appears to have little effect on overall rate of diagnoses or patient care, especially in locations where clinical diagnosis and empiric TB treatment are high. What is added by this report? This early impact evaluation of the Xpert MTB/RIF rollout demonstrated no apparent increase in overall TB case notification rates after testing became available in Uganda. However, within a few selected districts the proportion of bacteriologically confirmed TB cases did increase after testing became available. These two findings validate previous reports. What are the implications for public health practice? The impact of Xpert MTB/RIF testing on TB case notification has not yet been fully realized in Uganda. Findings from this evaluation will help direct operations research, such as a review of the diagnostic algorithm for TB, as well as programmatic interventions, such as training health care workers on Xpert MTB/RIF usage and results interpretation. C1 [Scott, Colleen] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Scott, Colleen; Bain, Rommel; Alexander, Heather; Shinnick, Tom; Toney, Sean; Cavanaugh, J. Sean] CDC, Div Global HIV & TB, Atlanta, GA 30333 USA. [Walusimbi, Simon; Kirenga, Bruce; Winters, Muttamba] Makerere Univ, Coll Hlth Sci, Lung Inst, Kampala, Uganda. [Joloba, Moses; Abdunoor, Nyombi; Mugabe, Frank] Minist Hlth, TB Leprosy Control Program, Kampala, Uganda. [Odeke, Rosemary; Mwangi, Christine] CDC, Div Global HIV & TB, Kampala, Uganda. [Birabwa, Estella; Dejene, Seyoum] US Agcy Int Dev, Kampala, Uganda. [YaDiul, Mukadi] US Agcy Int Dev, Washington, DC USA. RP Scott, C (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Scott, C (reprint author), CDC, Div Global HIV & TB, Atlanta, GA 30333 USA. EM CScott2@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 31 PY 2017 VL 66 IS 12 BP 339 EP 342 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EQ1BH UT WOS:000397803800006 PM 28358797 ER PT J AU Otshudiema, JO Ndakala, NG Loko, ML Mawanda, ETK Tshapenda, GP Kimfuta, JM Gueye, AS Dee, J Philen, RM Giese, C Murrill, CS Arthur, RR Kebela, BI AF Otshudiema, John O. Ndakala, Nestor G. Loko, Maurice L. Mawanda, Elande-Taty K. Tshapenda, Gaston P. Kimfuta, Jacques M. Gueye, Abdou S. Dee, Jacob Philen, Rossanne M. Giese, Coralie Murrill, Christopher S. Arthur, Ray R. Kebela, Benoit I. TI Adverse Events Following a Mass Yellow Fever Immunization Campaign - Kongo Central Province, Democratic Republic of the Congo, September 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Otshudiema, John O.] CDC, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA. [Otshudiema, John O.] CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ndakala, Nestor G.] Field Epidemiol & Lab Training Program, Kinshasa, DEM REP CONGO. [Loko, Maurice L.] Minist Hlth, Kongo Cent Prov, Div Prov Sante, Programme Elargi Vaccinat,Expanded Program Immuni, Kinshasa, DEM REP CONGO. [Mawanda, Elande-Taty K.; Kimfuta, Jacques M.] Minist Hlth, Kongo Cent Prov, Div Provinciale Sante, Kinshasa, DEM REP CONGO. [Tshapenda, Gaston P.; Kebela, Benoit I.] Minist Hlth, Direct Lutte Maladie, Kinshasa, DEM REP CONGO. [Gueye, Abdou S.; Philen, Rossanne M.; Giese, Coralie; Arthur, Ray R.] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Dee, Jacob] CDC, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA 30333 USA. [Murrill, Christopher S.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Otshudiema, JO (reprint author), CDC, Epidem Intelligence Serv Program, Atlanta, GA 30333 USA.; Otshudiema, JO (reprint author), CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jotshudiema@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 31 PY 2017 VL 66 IS 12 BP 343 EP 344 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EQ1BH UT WOS:000397803800007 PM 28358792 ER PT J AU Lloyd-Jones, DM Huffman, MD Karmali, KN Sanghavi, DM Wright, JS Pelser, C Gulati, M Masoudi, FA Goff, DC AF Lloyd-Jones, Donald M. Huffman, Mark D. Karmali, Kunal N. Sanghavi, Darshak M. Wright, Janet S. Pelser, Colleen Gulati, Martha Masoudi, Frederick A. Goff, David C., Jr. TI Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology SO CIRCULATION LA English DT Article DE AHA Scientific Statements; cardiovascular diseases; morbidity; mortality; myocardial infarction; population; prevention; stroke ID ADULT TREATMENT PANEL; SERVICES TASK-FORCE; RANDOMIZED-TRIALS; OUTCOME INCIDENCE; NATIONAL-HEALTH; STATIN THERAPY; MULTIFACTORIAL INTERVENTION; QUITTING SMOKING; FACTOR BURDEN; EXCESS RISK AB The Million Hearts Initiative has a goal of preventing 1 million heart attacks and strokes-the leading causes of mortality-through several public health and healthcare strategies by 2017. The American Heart Association and American College of Cardiology support the program. The Cardiovascular Risk Reduction Model was developed by Million Hearts and the Center for Medicare & Medicaid Services as a strategy to assess a value-based payment approach toward reduction in 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) by implementing cardiovascular preventive strategies to manage the "ABCS" (aspirin therapy in appropriate patients, blood pressure control, cholesterol management, and smoking cessation). The purpose of this special report is to describe the development and intended use of the Million Hearts Longitudinal ASCVD Risk Assessment Tool. The Million Hearts Tool reinforces and builds on the "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk" by allowing clinicians to estimate baseline and updated 10-year ASCVD risk estimates for primary prevention patients adhering to the appropriate ABCS over time, alone or in combination. The tool provides updated risk estimates based on evidence from high-quality systematic reviews and meta-analyses of the ABCS therapies. This novel approach to personalized estimation of benefits from risk-reducing therapies in primary prevention may help target therapies to those in whom they will provide the greatest benefit, and serves as the basis for a Center for Medicare & Medicaid Services program designed to evaluate the Million Hearts Cardiovascular Risk Reduction Model. C1 [Lloyd-Jones, Donald M.] Northwestern Univ, Evanston, IL 60208 USA. [Goff, David C., Jr.] Colorado Sch Publ Hlth, Aurora, CO USA. [Gulati, Martha] Univ Arizona, Tucson, AZ 85721 USA. [Huffman, Mark D.; Karmali, Kunal N.] Northwestern Univ Prevent Med, Chicago, IL USA. [Masoudi, Frederick A.] Univ Colorado, Boulder, CO 80309 USA. [Masoudi, Frederick A.] Colorado Cardiovasc Outcomes Consortium, Denver, CO USA. [Pelser, Colleen] Mitre Corp, Mclean, VA USA. [Sanghavi, Darshak M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Wright, Janet S.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lloyd-Jones, DM (reprint author), Northwestern Univ, Evanston, IL 60208 USA. FU Center for Medicare and Medicaid Innovation; National Cancer Institute; NHLBI; National Institute of Biomedical Imaging and Bioengineering; Center for Medicare and Medicaid Innovation/The MITRE Corporation; JR Alberts Foundation (FoodSwitch USA); World Heart Federation FX Donald M. Lloyd-Jones Northwestern University Center for Medicare and Medicaid Innovation; Mark D. Huffman Northwestern University Preventive Medicine National Cancer Institute; NHLBI; National Institute of Biomedical Imaging and Bioengineering; Center for Medicare and Medicaid Innovation/The MITRE Corporation; JR Alberts Foundation (FoodSwitch USA); World Heart Federation NR 77 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD MAR 28 PY 2017 VL 135 IS 13 BP E793 EP + DI 10.1161/CIR.0000000000000467 PG 37 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EP4YY UT WOS:000397387200001 PM 27815375 ER PT J AU Levine, AD Boulet, SL Kissin, DM AF Levine, Aaron D. Boulet, Sheree L. Kissin, Dmitry M. TI Contribution of Assisted Reproductive Technology to Overall Births by Maternal Age in the United States, 2012-2014 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Levine, Aaron D.] Georgia Inst Technol, Sch Publ Policy, Atlanta, GA 30332 USA. [Boulet, Sheree L.; Kissin, Dmitry M.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Levine, AD (reprint author), Sch Publ Policy, 685 Cherry St, Atlanta, GA 30332 USA. EM aaron.levine@pubpolicy.gatech.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 28 PY 2017 VL 317 IS 12 BP 1272 EP 1273 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EP7KX UT WOS:000397557800025 PM 28350916 ER PT J AU Makarova, N Henning, T Taylor, A Dinh, C Lipscomb, J Aubert, R Hanson, D Phillips, C Papp, J Mitchell, J McNicholl, J Garcia-Lerma, GJ Heneine, W Kersh, E Dobard, C AF Makarova, Natalia Henning, Tara Taylor, Andrew Dinh, Chuong Lipscomb, Jonathan Aubert, Rachael Hanson, Debra Phillips, Christi Papp, John Mitchell, James McNicholl, Janet Garcia-Lerma, Gerardo J. Heneine, Walid Kersh, Ellen Dobard, Charles TI Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis SO AIDS LA English DT Article DE HIV/AIDS prevention; macaque model; microbicide gel; preexposure prophylaxis repeat challenge; sexually transmitted infections; simian HIV; tenofovir ID IMMUNODEFICIENCY VIRUS-INFECTION; SEXUALLY-TRANSMITTED-DISEASES; DEPOT-MEDROXYPROGESTERONE ACETATE; DISOPROXIL FUMARATE; PREEXPOSURE PROPHYLAXIS; REVERSE-TRANSCRIPTASE; PIGTAIL MACAQUES; TRANSMISSION; WOMEN; GEL AB Background: Chlamydia trachomatis and Trichomonas vaginalis, two prevalent sexually transmitted infections, are known to increase HIV risk in women and could potentially diminish preexposure prophylaxis efficacy, particularly for topical interventions that rely on local protection. We investigated in macaques whether coinfection with Chlamydia trachomatis/Trichomonas vaginalis reduces protection by vaginal tenofovir (TFV) gel. Methods: Vaginal TFV gel dosing previously shown to provide 100 or 74% protection when applied either 30 min or 3 days before simian HIV(SHIV) challenge was assessed in pigtailed macaques coinfected with Chlamydia trachomatis/Trichomonas vaginalis and challenged twice weekly with SHIV162p3 for up to 10 weeks (two menstrual cycles). Three groups of six macaques received either placebo or 1% TFV gel 30 min or 3 days before each SHIV challenge. We additionally assessed TFV and TFV diphosphate concentrations in plasma and vaginal tissues in Chlamydia trachomatis/Trichomonas vaginalis coinfected (n = 4) and uninfected (n = 4) macaques. Results: Chlamydia trachomatis/Trichomonas vaginalis coinfections were maintained during the SHIV challenge period. All macaques that received placebo gel were SHIV infected after a median of seven challenges (one menstrual cycle). In contrast, no infections were observed in macaques treated with TFV gel 30 min before SHIV challenge (P<0.001). Efficacy was reduced to 60% when TFV gel was applied 3 days before SHIV challenge (P = 0.07). Plasma TFV and TFV diphosphate concentrations in tissues and vaginal lymphocytes were significantly higher in Chlamydia trachomatis/Trichomonas vaginalis coinfected compared with Chlamydia trachomatis/Trichomonas vaginalis uninfected macaques. Conclusion: Our findings in this model suggest that Chlamydia trachomatis/Trichomonas vaginalis coinfection may have little or no impact on the efficacy of highly effective topical TFV modalities and highlight a significant modulation of TFV pharmacokinetics. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved. C1 [Makarova, Natalia; Dinh, Chuong; Lipscomb, Jonathan; Aubert, Rachael; Hanson, Debra; Mitchell, James; McNicholl, Janet; Garcia-Lerma, Gerardo J.; Heneine, Walid; Dobard, Charles] Ctr Dis Control & Prevent CDC, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA USA. [Henning, Tara; Phillips, Christi; Papp, John; Kersh, Ellen] Ctr Dis Control & Prevent CDC, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Taylor, Andrew] Total Solut Inc, Madison, AL USA. RP Dobard, C (reprint author), Ctr Dis Control & Prevent, Antiretroviral Prophylaxis & Drug Resistance Team, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. EM cdobard@cdc.gov FU Centers for Disease Control and Prevention [Y1-AI-0681-02]; National Institute of Health [Y1-AI-0681-02] FX This work was partially supported by Interagency Agreement Y1-AI-0681-02 between Centers for Disease Control and Prevention and National Institute of Health. NR 36 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD MAR 27 PY 2017 VL 31 IS 6 BP 745 EP 752 DI 10.1097/QAD.0000000000001389 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EN4UW UT WOS:000396003400002 PM 28060011 ER PT J AU Schmit, KM Wansaula, Z Pratt, R Price, SF Langer, AJ AF Schmit, Kristine M. Wansaula, Zimy Pratt, Robert Price, Sandy F. Langer, Adam J. TI Tuberculosis - United States, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Schmit, Kristine M.; Wansaula, Zimy] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Schmit, Kristine M.; Wansaula, Zimy; Pratt, Robert; Price, Sandy F.; Langer, Adam J.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Schmit, KM; Wansaula, Z (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Schmit, KM; Wansaula, Z (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM kmschmit@cdc.gov; zwansaula@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 24 PY 2017 VL 66 IS 11 BP 289 EP 294 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP3VV UT WOS:000397310700002 PM 28333908 ER PT J AU Tsang, CA Langer, AJ Navin, TR Armstrong, LR AF Tsang, Clarisse A. Langer, Adam J. Navin, Thomas R. Armstrong, Lori R. TI Tuberculosis Among Foreign- Born Persons Diagnosed >= 10 Years After Arrival in the United States, 2010-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INFECTION; ADULTS C1 [Tsang, Clarisse A.; Langer, Adam J.; Navin, Thomas R.; Armstrong, Lori R.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Tsang, CA (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM ctsang@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 24 PY 2017 VL 66 IS 11 BP 295 EP 298 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP3VV UT WOS:000397310700003 PM 28333913 ER PT J AU Hancock, WT Soeters, HM Hills, SL Link-Gelles, R Evans, ME Daley, WR Piercefield, E Anesi, MS Mataia, MA Uso, AM Sili, B Tufa, AJ Solaita, J Irvin-Barnwell, E Meaney-Delman, D Wilken, J Weidle, P Toews, KAE Walker, W Talboy, PM Gallo, WK Krishna, N Laws, RL Reynolds, MR Koneru, A Gould, CV AF Hancock, W. Thane Soeters, Heidi M. Hills, Susan L. Link-Gelles, Ruth Evans, Mary E. Daley, W. Randolph Piercefield, Emily Anesi, Magele Scott Mataia, Mary Aseta Uso, Anaise M. Sili, Benjamin Tufa, Aifili John Solaita, Jacqueline Irvin-Barnwell, Elizabeth Meaney-Delman, Dana Wilken, Jason Weidle, Paul Toews, Karrie-Ann E. Walker, William Talboy, Phillip M. Gallo, William K. Krishna, Nevin Laws, Rebecca L. Reynolds, Megan R. Koneru, Alaya Gould, Carolyn V. TI Establishing a Timeline to Discontinue Routine Testing of Asymptomatic Pregnant Women for Zika Virus Infection - American Samoa, 2016-2017 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UPDATE INTERIM GUIDANCE; UNITED-STATES; OUTBREAK C1 [Hancock, W. Thane; Daley, W. Randolph; Wilken, Jason; Toews, Karrie-Ann E.; Krishna, Nevin] CDC, Off Publ Hlth Preparedness & Response, Div State & Local Readiness, Atlanta, GA 30333 USA. [Soeters, Heidi M.] CDC, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. [Hills, Susan L.; Walker, William; Gould, Carolyn V.] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Link-Gelles, Ruth; Walker, William; Laws, Rebecca L.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Link-Gelles, Ruth; Koneru, Alaya] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Evans, Mary E.; Weidle, Paul] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Piercefield, Emily] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Anesi, Magele Scott; Mataia, Mary Aseta; Uso, Anaise M.; Sili, Benjamin; Solaita, Jacqueline] Amer Samoa Govt, Dept Hlth, Pago Pago, AS USA. [Tufa, Aifili John] Pacific Isl Hlth Officers Assoc, Honolulu, HI USA. [Irvin-Barnwell, Elizabeth] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA USA. [Meaney-Delman, Dana] CDC, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Talboy, Phillip M.] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Gallo, William K.] CDC, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. [Laws, Rebecca L.] Calif Dept Hlth, Div Environm & Occupat Dis Control, Sacramento, CA USA. [Reynolds, Megan R.] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Congenital & Dev Disorders, Atlanta, GA 30333 USA. RP Hancock, WT (reprint author), CDC, Off Publ Hlth Preparedness & Response, Div State & Local Readiness, Atlanta, GA 30333 USA. EM vie1@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 24 PY 2017 VL 66 IS 11 BP 299 EP 301 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP3VV UT WOS:000397310700004 PM 28333910 ER PT J AU Yaffee, AQ Day, DL Bastin, G Powell, M Melendez, S Allen, N Miracle, J Jones, M Brawley, R AF Yaffee, Anna Q. Day, David L. Bastin, Glenda Powell, Mary Melendez, Sandra Allen, Nancy Miracle, Julie Jones, Margaret Brawley, Robert TI Obstetric Tetanus in an Unvaccinated Woman After a Home Birth Delivery - Kentucky, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Yaffee, Anna Q.; Miracle, Julie; Jones, Margaret; Brawley, Robert] CDC, Kentucky Dept Publ Hlth, Atlanta, GA 30333 USA. [Yaffee, Anna Q.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Day, David L.; Bastin, Glenda] Lincoln Trail Dist Hlth Dept, Elizabethtown, KY USA. [Powell, Mary; Melendez, Sandra] Louisville Metro Publ Hlth & Wellness, Louisville, KY USA. [Allen, Nancy] Cent Med Associates, Elizabethtown, KY USA. RP Yaffee, AQ (reprint author), CDC, Kentucky Dept Publ Hlth, Atlanta, GA 30333 USA.; Yaffee, AQ (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ayaffee@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 24 PY 2017 VL 66 IS 11 BP 307 EP 308 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP3VV UT WOS:000397310700006 PM 28333909 ER PT J AU Shahab, L Goniewicz, ML Blount, BC Brown, J McNeill, A Alwis, KU Feng, J Wang, LQ West, R AF Shahab, Lion Goniewicz, Maciej L. Blount, Benjamin C. Brown, Jamie McNeill, Ann Alwis, K. Udeni Feng, June Wang, Lanqing West, Robert TI Nicotine, Carcinogen, and Toxin Exposure in Long-Term E-Cigarette and Nicotine Replacement Therapy Users A Cross-sectional Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID TANDEM MASS-SPECTROMETRY; ELECTRONIC CIGARETTES; CARBON-MONOXIDE; HEALTH-RISKS; CANCER-RISK; TOBACCO; SMOKERS; SMOKING; DELIVERY; METABOLITES AB Background: Given the rapid increase in the popularity of e-cigarettes and the paucity of associated longitudinal healthrelated data, the need to assess the potential risks of long-term use is essential. Objective: To compare exposure to nicotine, tobacco-related carcinogens, and toxins among smokers of combustible cigarettes only, former smokers with long-term e-cigarette use only, former smokers with long-term nicotine replacement therapy (NRT) use only, long-term dual users of both combustible cigarettes and e-cigarettes, and long-term users of both combustible cigarettes and NRT. Design: Cross-sectional study. Setting: United Kingdom. Participants: The following 5 groups were purposively recruited: combustible cigarette-only users, former smokers with longterm (= 6 months) e-cigarette-only or NRT-only use, and longterm dual combustible cigarette-e-cigarette or combustible cigarette-NRT users (n = 36 to 37 per group; total n = 181). Measurements: Sociodemographic and smoking characteristics were assessed. Participants provided urine and saliva samples and were analyzed for biomarkers of nicotine, tobaccospecific N-nitrosamines (TSNAs), and volatile organic compounds (VOCs). Results: After confounders were controlled for, no clear between-group differences in salivary or urinary biomarkers of nicotine intake were found. The e-cigarette-only and NRT-only users had significantly lower metabolite levels for TSNAs (including the carcinogenic metabolite 4-(methylnitrosamino)-1-(3pyridyl)- 1-butanol [NNAL]) and VOCs (including metabolites of the toxins acrolein; acrylamide; acrylonitrile; 1,3-butadiene; and ethylene oxide) than combustible cigarette-only, dual combustible cigarette-e-cigarette, or dual combustible cigarette-NRT users. The e-cigarette-only users had significantly lower NNAL levels than all other groups. Combustible cigarette-only, dual combustible cigarette-NRT, and dual combustible cigarette-ecigarette users had largely similar levels of TSNA and VOC metabolites. Limitation: Cross-sectional design with self-selected sample. Conclusion: Former smokers with long-term e-cigarette-only or NRT-only use may obtain roughly similar levels of nicotine compared with smokers of combustible cigarettes only, but results varied. Long-term NRT-only and e-cigarette-only use, but not dual use of NRTs or e-cigarettes with combustible cigarettes, is associated with substantially reduced levels of measured carcinogens and toxins relative to smoking only combustible cigarettes. C1 [Shahab, Lion; West, Robert] UCL, Dept Epidemiol & Publ Hlth, 1-19 Torrington St, London WC1E 7HB, England. [McNeill, Ann] Kings Coll London, Inst Psychiat Psychol & Neurosci, Addict Dept, 4 Windsor Walk, London SE5 8AF, England. [Goniewicz, Maciej L.] Roswell Pk Canc Inst, Dept Hlth Behav, Elm & Carlton St, Buffalo, NY 14263 USA. [Blount, Benjamin C.; Alwis, K. Udeni; Feng, June; Wang, Lanqing] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA. [Brown, Jamie] UCL, Dept Clin Educ & Hlth Psychol, 1-19 Torrington St, London WC1E 7HB, England. RP Shahab, L (reprint author), UCL, Dept Epidemiol & Publ Hlth, 1-19 Torrington St, London WC1E 7HB, England. EM lion.shahab@ucl.ac.uk OI Brown, Jamie/0000-0002-2797-5428 FU Cancer Research UK [C27061/A16929, C1417/A14135, C36048/A11654, C1417/A7972, C44576/A19501]; Society for the Study of Addiction; Medical Research Council; British Heart Foundation; Economic and Social Research Council; National Institute for Health Research under UK Clinical Research Collaboration [MR/K023195/1]; National Institute on Drug Abuse of the National Institutes of Health [R01DA037446, P30 CA016056]; National Cancer Institute of the National Institutes of Health [R01DA037446, P30 CA016056]; Roswell Park Alliance Foundation FX This work was supported by Cancer Research UK (grant C27061/A16929, with additional funding from grants C1417/A14135 and C36048/A11654). Dr. Brown's post is funded by a fellowship from the Society for the Study of Addiction, and Cancer Research UK also provides support (grants C1417/A7972 and C44576/A19501). Drs. McNeill and West are part of the UK Centre for Tobacco and Alcohol Studies, which is a UK Clinical Research Collaboration Public Health Research Centre of Excellence. Funding from the Medical Research Council, British Heart Foundation, Cancer Research UK, Economic and Social Research Council, and the National Institute for Health Research under the auspices of the UK Clinical Research Collaboration is gratefully acknowledged (grant MR/K023195/1). Dr. Goniewicz was supported by the National Institute on Drug Abuse and the National Cancer Institute of the National Institutes of Health (awards R01DA037446 and P30 CA016056, respectively) and by an award from Roswell Park Alliance Foundation. NR 70 TC 0 Z9 0 U1 2 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAR 21 PY 2017 VL 166 IS 6 BP 390 EP + DI 10.7326/M16-1107 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA EO9RM UT WOS:000397025800014 PM 28166548 ER PT J AU Robinson, LR Holbrook, JR Bitsko, RH Hartwig, SA Kaminski, JW Ghandour, RM Peacock, G Heggs, A Boyle, CA AF Robinson, Lara R. Holbrook, Joseph R. Bitsko, Rebecca H. Hartwig, Sophie A. Kaminski, Jennifer W. Ghandour, Reem M. Peacock, Georgina Heggs, Akilah Boyle, Coleen A. TI Differences in Health Care, Family, and Community Factors Associated with Mental, Behavioral, and Developmental Disorders Among Children Aged 2-8 Years in Rural and Urban Areas - United States, 2011-2012 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID RESIDENCE; NEEDS AB Problem/Condition: Mental, behavioral, and developmental disorders (MBDDs) begin in early childhood and often affect lifelong health and well-being. Persons who live in rural areas report more health-related disparities than those in urban areas, including poorer health, more health risk behaviors, and less access to health resources. Reporting Period: 2011-2012. Description of System: The National Survey of Children's Health (NSCH) is a cross-sectional, random-digit dial telephone survey of parents or guardians that collects information on noninstitutionalized children aged <18 years in the United States. Interviews included indicators of health and well-being, health care access, and family and community characteristics. Using data from the 2011-2012 NSCH, this report examines variations in health care, family, and community factors among children aged 2-8 years with and without MBDDs in rural and urban settings. Restricting the data to U.S. children aged 2-8 years with valid responses for child age and sex, each MBDD, and zip code resulted in an analytic sample of 34,535 children; MBDD diagnosis was determined by parent report and was not validated with health care providers or medical records. Results: A higher percentage of all children in small rural and large rural areas compared with all children in urban areas had parents who reported experiencing financial difficulties (i.e., difficulties meeting basic needs such as food and housing). Children in all rural areas more often lacked amenities and lived in a neighborhood in poor condition. However, a lower percentage of children in small rural and isolated areas had parents who reported living in an unsafe neighborhood, and children in isolated areas less often lived in a neighborhood lacking social support, less often lacked a medical home, and less often had a parent with fair or poor mental health. Across rural subtypes, approximately one in six young children had a parent-reported MBDD diagnosis. A higher prevalence was found among children in small rural areas (18.6%) than in urban areas (15.2%). In urban and the majority of rural subtypes, children with an MBDD more often lacked a medical home, had a parent with poor mental health, lived in families with financial difficulties, and lived in a neighborhood lacking physical and social resources than children without an MBDD within each of those community types. Only in urban areas did a higher percentage of children with MBDDs lack health insurance than children without MBDDs. After adjusting for race/ethnicity and poverty among children with MBDDs, those in rural areas more often had a parent with poor mental health and lived in resource-low neighborhoods than those in urban areas. Interpretation: Certain health care, family, and community disparities were more often reported among children with MBDDS than among children without MBDDs in rural and urban areas. Public Health Action: Collaboration involving health care, family, and community services and systems can be used to address fragmented services and supports for children with MBDDs, regardless ofwhether they live in urban or rural areas. However, addressing differences in health care, family, and community factors and leveraging community strengths among children who live in rural areas present opportunities to promote health among children in rural communities. C1 [Robinson, Lara R.; Holbrook, Joseph R.; Bitsko, Rebecca H.; Hartwig, Sophie A.; Kaminski, Jennifer W.; Peacock, Georgina; Heggs, Akilah] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Hartwig, Sophie A.; Heggs, Akilah] CDC, Oak Ridge Inst Sci & Educ, Res Participat Programs, Oak Ridge, TN USA. [Ghandour, Reem M.] Hlth Resources & Serv Adm, Off Epidemiol & Res, Maternal & Child Hlth Bur, Rockville, MD USA. [Boyle, Coleen A.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Robinson, LR (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM lpr0@cdc.gov NR 19 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD MAR 17 PY 2017 VL 66 IS 8 BP 3 EP 13 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP0KE UT WOS:000397075400001 ER PT J AU Kegler, SR Stone, DM Holland, KM AF Kegler, Scott R. Stone, Deborah M. Holland, Kristin M. TI Trends in Suicide by Level of Urbanization - United States, 1999-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MORTALITY C1 [Kegler, Scott R.] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Stone, Deborah M.; Holland, Kristin M.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Kegler, SR (reprint author), CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM skegler@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 17 PY 2017 VL 66 IS 10 BP 270 EP 273 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP0KC UT WOS:000397075200002 PM 28301448 ER PT J AU Kuramoto-Crawford, SJ McGee, S Li, K Hennenfent, AK Dassie, K Carney, JT Gibson, A Cooper, I Blaylock, M Blackwell, R Fields, A Davies-Cole, J AF Kuramoto-Crawford, S. Janet McGee, Sasha Li, Keith Hennenfent, Andrew K. Dassie, Kossia Carney, Jhetari T. Gibson, Arian Cooper, Ivory Blaylock, Morris Blackwell, Reginald Fields, Angela Davies-Cole, John TI Investigation of Salmonella Enteritidis Outbreak Associated with Truffle Oil - District of Columbia, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ENTERICA; SURVIVAL C1 [Kuramoto-Crawford, S. Janet] CDC, Epidem Intelligence Serv, Washington, DC USA. [Kuramoto-Crawford, S. Janet; McGee, Sasha; Li, Keith; Hennenfent, Andrew K.; Dassie, Kossia; Carney, Jhetari T.; Davies-Cole, John] Dist Columbia Dept Hlth, Ctr Policy Planning & Evaluat, Washington, DC 20002 USA. [Hennenfent, Andrew K.] CDC, Council State & Terr Epidemiologists, Dist Columbia Dept Hlth, Washington, DC USA. [Carney, Jhetari T.] CDC, Div State & Local Readiness, Off Publ Hlth Preparedness & Response, Washington, DC USA. [Gibson, Arian; Cooper, Ivory] Dist Columbia Dept Hlth, Hlth Regulat & Licensing Adm, Washington, DC USA. [Blaylock, Morris; Blackwell, Reginald] Dist Columbia Dept Forens Sci, Publ Hlth Lab Div, Washington, DC USA. [Fields, Angela] CORE Network Food & Drug Adm, College Pk, MD USA. RP McGee, S (reprint author), Dist Columbia Dept Hlth, Ctr Policy Planning & Evaluat, Washington, DC 20002 USA. EM sasha.mcgee@dc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 17 PY 2017 VL 66 IS 10 BP 278 EP 281 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP0KC UT WOS:000397075200004 PM 28301453 ER PT J AU Boyd, AT Dombaxe, D Moreira, R Oliveira, MS Manuel, E Colorado, CN Lanzieri, TM AF Boyd, Andrew T. Dombaxe, Diambi Moreira, Rosa Oliveira, M. S. Manuel, Eusebio Colorado, Carlos Navarro Lanzieri, Tatiana M. TI Investigation of Patients Testing Positive for Yellow Fever Viral RNA After Vaccination During a Mass Yellow Fever Vaccination Campaign - Angola, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Boyd, Andrew T.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Boyd, Andrew T.; Colorado, Carlos Navarro] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Dombaxe, Diambi; Moreira, Rosa] Minist Hlth, Angola Field Epidemiol & Lab Training Program, Luanda, Angola. [Oliveira, M. S.; Manuel, Eusebio] Minist Hlth, Luanda, Angola. [Lanzieri, Tatiana M.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Boyd, AT (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Boyd, AT (reprint author), CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. EM atboyd@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 17 PY 2017 VL 66 IS 10 BP 282 EP 283 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP0KC UT WOS:000397075200005 PM 28301446 ER PT J AU Duque, J Gaga, S Clark, D Muller, M Kuwane, B Cohen, C Walaza, S Tempia, S Ramatoboe, P Furumele, T Widdowson, MA McMorrow, ML Cohen, AL AF Duque, Jazmin Gaga, Sisanda Clark, David Muller, Madeleine Kuwane, Bulenani Cohen, Cheryl Walaza, Sibongile Tempia, Stefano Ramatoboe, Puleng Furumele, Tsakani Widdowson, Marc-Alain McMorrow, Meredith L. Cohen, Adam L. TI Knowledge, attitudes and practices of South African healthcare workers regarding the prevention and treatment of influenza among HIV-infected individuals SO PLOS ONE LA English DT Article ID UNITED-STATES AB Background The South African Department of Health (DOH) publishes annual guidelines identifying priority groups, including immunosuppressed individuals and healthcare workers (HCW), for influenza vaccination and treatment. How these guidelines have impacted HCW and their patients, particularly those infected with HIV, remains unknown. Methods We aimed to describe the knowledge, attitudes and practices regarding influenza and the vaccine among South African HCW. Surveys were distributed by two local non-governmental organizations in public health clinics and hospitals in 21 districts/municipalities (5 of 9 provinces). Results There were 1164 respondents; median age 41 years; 978/1126 (87%) female; 801/1122 (71%) nurses. One-third (34%) of HCW reported getting influenza vaccine 2013/2014 and most (94%) recommended influenza vaccine to patients infected with HIV. Ability to get vaccine free of charge (aOR 1.69; 95% CI 1.21 +/- 2.37) and having received influenza government training (aOR 1.50; 95% CI 1.04 +/- 2.15) were significantly associated with self-reported vaccination in 2013/2014. Self-reported 2013/2014 vaccination (aOR 3.76; 95% CI 1.28 +/- 11.03) and availability of influenza vaccine during the healthcare visit (aOR 2.56; 95% CI 1.18-5.57) were significantly associated with recommending influenza vaccine to patients infected with HIV/AIDS. Conclusion Only one-third of participants were vaccinated in 2013-2014 but those who were vaccinated were more likely to recommend vaccination to their patients. Free and close access to influenza vaccine were associated with a higher likelihood of getting vaccinated in 2013/2014. HCW who reported getting the influenza vaccine themselves, had vaccine to offer during the patient consult and were familiar with DOH guidelines/trainings were more likely to recommend vaccine to HIV-infected patients. C1 [Duque, Jazmin; Tempia, Stefano; Widdowson, Marc-Alain; McMorrow, Meredith L.; Cohen, Adam L.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Duque, Jazmin] Battelle Atlanta, Atlanta, GA 30329 USA. [Gaga, Sisanda; Muller, Madeleine] Beyond Zero, Port Elizabeth, South Africa. [Clark, David; Kuwane, Bulenani] Aurum Inst, Johannesburg, South Africa. [Cohen, Cheryl; Walaza, Sibongile; Tempia, Stefano] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Cohen, Cheryl; Walaza, Sibongile] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa. [Tempia, Stefano; Ramatoboe, Puleng; McMorrow, Meredith L.; Cohen, Adam L.] US Ctr Dis Control & Prevent South Africa, Pretoria, South Africa. [Furumele, Tsakani] Natl Dept Hlth, Pretoria, South Africa. [McMorrow, Meredith L.; Cohen, Adam L.] US PHS, Rockville, MD USA. RP Duque, J (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.; Duque, J (reprint author), Battelle Atlanta, Atlanta, GA 30329 USA. EM JDuque@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 16 PY 2017 VL 12 IS 3 AR e0173983 DI 10.1371/journal.pone.0173983 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN9KE UT WOS:000396318300104 PM 28301593 ER PT J AU Viana, GMR Okoth, SA Silva-Flannery, L Barbosa, DRL de Oliveira, AM Goldman, IF Morton, LC Huber, C Anez, A Machado, RLD Camargo, LMA do Valle, SCN Povoa, MM Udhayakumar, V Barnwell, JW AF Rachid Viana, Giselle Maria Okoth, Sheila Akinyi Silva-Flannery, Luciana Lima Barbosa, Danielle Regina de Oliveira, Alexandre Macedo Goldman, Ira F. Morton, Lindsay C. Huber, Curtis Anez, Arletta Dantas Machado, Ricardo Luiz Aranha Camargo, Luis Marcelo Negreiros do Valle, Suiane Costa Povoa, Marinete Marins Udhayakumar, Venkatachalam Barnwell, John W. TI Histidine-rich protein 2 (pfhrp2) and pfhrp3 gene deletions in Plasmodium falciparum isolates from select sites in Brazil and Bolivia SO PLOS ONE LA English DT Article ID RAPID DIAGNOSTIC-TESTS; MALARIA; ANTIBODIES; SECRETION; PARASITES; REGION AB More than 80% of available malaria rapid diagnostic tests (RDTs) are based on the detection of histidine-rich protein-2 (PfHRP2) for diagnosis of Plasmodium falciparum malaria. Recent studies have shown the genes that code for this protein and its paralog, histidine-rich protein-3 (PfHRP3), are absent in parasites from the Peruvian Amazon Basin. Lack of PfHRP2 protein through deletion of the pfhrp2 gene leads to false-negative RDT results for P. falciparum. We have evaluated the extent of pfhrp2 and pfhrp3 gene deletions in a convenience sample of 198 isolates from six sites in three states across the Brazilian Amazon Basin (Acre, Rondonia and Para) and 25 isolates from two sites in Bolivia collected at different times between 2010 and 2012. Pfhrp2 and pfhrp3 gene and their flanking genes on chromosomes 7 and 13, respectively, were amplified from 198 blood specimens collected in Brazil. In Brazil, the isolates collected in Acre state, located in the western part of the Brazilian Amazon, had the highest percentage of deletions for pfhrp2 25 (31.2%) of 79, while among those collected in Rondonia, the prevalence of pfhrp2 gene deletion was only 3.3% (2 out of 60 patients). In isolates from Para state, all parasites were pfhrp2-positive. In contrast, we detected high proportions of isolates from all 3 states that were pfhrp3-negative ranging from 18.3% (11 out of 60 samples) to 50.9% (30 out of 59 samples). In Bolivia, only one of 25 samples (4%) tested had deleted pfhrp2 gene, while 68% (17 out of 25 samples) were pfhrp3-negative. Among the isolates tested, P. falciparum pfhrp2 gene deletions were present mainly in those from Acre State in the Brazilian Amazon. These results indicate it is important to reconsider the use of PfHRP2-based RDTs in the western region of the Brazilian Amazon and to implement appropriate surveillance systems to monitor pfhrp2 gene deletions in this and other parts of the Amazon region. C1 [Rachid Viana, Giselle Maria; Lima Barbosa, Danielle Regina; Dantas Machado, Ricardo Luiz; Povoa, Marinete Marins] Inst Evandro Chagas IEC SVS MS, Ananindeua, Para, Brazil. [Okoth, Sheila Akinyi; Silva-Flannery, Luciana; de Oliveira, Alexandre Macedo; Goldman, Ira F.; Morton, Lindsay C.; Huber, Curtis; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Okoth, Sheila Akinyi; Silva-Flannery, Luciana] Atlanta Res & Educ Fdn, Decatur, GA USA. [Anez, Arletta] Pan Amer Hlth Org, La Paz, Bolivia. [Aranha Camargo, Luis Marcelo] ICB5 USP, Porto Velho, Rondonia, Brazil. [Aranha Camargo, Luis Marcelo] Fac Sao Lucas, Porto Velho, Rondonia, Brazil. [Negreiros do Valle, Suiane Costa] Secretaria Estadual Saude Acre, Hemonucleo Cruzeiro do Sul, Cruzeiro Do Sul, Acre, Brazil. RP Udhayakumar, V (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. EM vxu0@cdc.gov FU Amazon Malaria Initiative - United States Agency for International Development (USAID); Atlanta Research and Education Foundation; CDC Emerging Infectious Disease Fellowship; Oak Ridge Institute for Science and Education (ORISE) FX This study was supported by the Amazon Malaria Initiative, which is funded by the United States Agency for International Development (USAID). SAO and LS-F were also supported by the Atlanta Research and Education Foundation. LM was supported by a CDC Emerging Infectious Disease Fellowship administered through the Association of Public Health Laboratories (APHL), and subsequently by a fellowship with the Oak Ridge Institute for Science and Education (ORISE). NR 30 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 16 PY 2017 VL 12 IS 3 AR e0171150 DI 10.1371/journal.pone.0171150 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN9KE UT WOS:000396318300010 ER PT J AU Ip, DKM Lau, LLH Leung, NHL Fang, VJ Chan, KH Chu, DKW Leung, GM Peiris, JSM Uyeki, TM Cowling, BJ AF Ip, Dennis K. M. Lau, Lincoln L. H. Leung, Nancy H. L. Fang, Vicky J. Chan, Kwok-Hung Chu, Daniel K. W. Leung, Gabriel M. Peiris, J. S. Malik Uyeki, Timothy M. Cowling, Benjamin J. TI Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza virus; viral shedding; asymptomatic; public health; epidemiology ID OSELTAMIVIR TREATMENT; HONG-KONG; HOUSEHOLDS; CHILDREN; DISEASE; CHALLENGE; ILLNESS; COHORT; CARE AB Background. Influenza virus infections are associated with a wide spectrum of disease. However, few studies have investigated in detail the epidemiological and virological characteristics of asymptomatic and mild illness with influenza virus infections. Methods. In a community-based study in Hong Kong from 2008 to 2014, we followed up initially healthy individuals who were household contacts of symptomatic persons with laboratory-confirmed influenza, to identify secondary infections. Information from daily symptom diaries was used to classify infections as symptomatic (>= 2 signs/symptoms, including fever >= 37.8 degrees C, headache, myalgia, cough, sore throat, runny nose and sputum), paucisymptomatic (1 symptom only), or asymptomatic (none of these symptoms). We compared the patterns of influenza viral shedding between these groups. Results. We identified 235 virologically confirmed secondary cases of influenza virus infection in the household setting, including 31 (13%) paucisymptomatic and 25 (11%) asymptomatic cases. The duration of viral RNA shedding was shorter and declined more rapidly in paucisymptomatic and asymptomatic than in symptomatic cases. The mean levels of influenza viral RNA shedding in asymptomatic and paucisymptomatic cases were approximately 1-2 log(10) copies lower than in symptomatic cases. Conclusions. The presence of influenza viral shedding in patients with influenza who have very few or no symptoms reflects their potential for transmitting the virus to close contacts. These findings suggest that further research is needed to investigate the contribution of persons with asymptomatic or clinically mild influenza virus infections to influenza virus transmission in household, institutional, and community settings. C1 [Ip, Dennis K. M.; Leung, Nancy H. L.; Fang, Vicky J.; Chu, Daniel K. W.; Leung, Gabriel M.; Peiris, J. S. Malik; Cowling, Benjamin J.] Univ Hong Kong, WHO Collaborating Ctr Infect Dis Epidemiol & Con, Sch Publ Hlth, Hong Hom, Hong Kong, Peoples R China. [Chan, Kwok-Hung] Univ Hong Kong, Dept Microbiol, Hong Hom, Hong Kong, Peoples R China. [Chu, Daniel K. W.; Peiris, J. S. Malik] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Influenza Res, Hong Hom, Hong Kong, Peoples R China. [Lau, Lincoln L. H.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. RP Cowling, BJ (reprint author), Univ Hong Kong, Sch Publ Hlth, Li Ka Shing Fac Med, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China. EM bcowling@hku.hk FU National Institute of Allergy and Infectious Diseases (NIAID) [HHSN266200700005C, ADB N01-AI-70005]; government of the Hong Kong Special Administrative Region (from the Health and Medical Research Fund); Harvard Center for Communicable Disease Dynamics (from the National Institute of General Medical Sciences) [LT54 GM088558]; Research Grants Council of the Hong Kong Special Administrative Region China [T11-705/14N] FX This project was supported by the National Institute of Allergy and Infectious Diseases (NIAID; contract HHSN266200700005C; ADB N01-AI-70005 [NIAID Centers for Excellence in Influenza Research and Surveillance]),the government of the Hong Kong Special Administrative Region (commissioned grant from the Health and Medical Research Fund), the Harvard Center for Communicable Disease Dynamics (grant LT54 GM088558 from the National Institute of General Medical Sciences), and the Research Grants Council of the Hong Kong Special Administrative Region China (project T11-705/14N). NR 25 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2017 VL 64 IS 6 BP 736 EP 742 DI 10.1093/cid/ciw841 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TI UT WOS:000397304200007 PM 28011603 ER PT J AU Izurieta, HS Wernecke, M Kelman, J Wong, S Forshee, R Pratt, D Lu, Y Sun, Q Jankosky, C Krause, P Worrall, C MaCurdy, T Harpaz, R AF Izurieta, Hector S. Wernecke, Michael Kelman, Jeffrey Wong, Sarah Forshee, Richard Pratt, Douglas Lu, Yun Sun, Qin Jankosky, Christopher Krause, Philip Worrall, Chris MaCurdy, Tom Harpaz, Rafael TI Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Herpes Zoster vaccine; vaccine effectiveness; post-herpetic neuralgia; opthalmic zoster; elderly ID POSTHERPETIC NEURALGIA; VARICELLA-VACCINATION; PROPENSITY SCORE; ADULTS; RISK; ASSOCIATION; EFFICACY; RATES; PAIN; BIAS AB Background. Tens of millions of seniors are at risk of herpes zoster (HZ) and its complications. Live attenuated herpes zoster vaccine (HZV) reduces that risk, although questions regarding effectiveness and durability of protection in routine clinical practice remain. We used Medicare data to investigate HZV effectiveness (VE) and its durability. Methods. This retrospective cohort study included beneficiaries ages >= 65 years during January 2007 through July 2014. Multiple adjustments to account for potential bias were made. HZV-vaccinated beneficiaries were matched to unvaccinated beneficiaries (primary analysis) and to HZV-unvaccinated beneficiaries who had received pneumococcal vaccination (secondary analysis). HZ outcomes in community and hospital settings were analyzed, including ophthalmic zoster (OZ) and postherpetic neuralgia (PHN). Results. Among eligible beneficiaries (average age 77 years), the primary analysis found VE for community HZ of 33% (95% CI: 32%-35%) and 19% (95% CI: 17%-22%), for the first 3, and subsequent 4+ years postvaccination, respectively. In the secondary analysis, VE was, respectively, 37% (95% CI: 36%-39%) and 22% (95% CI: 20%-25%). In the primary analysis, VE for PHN was 57% (95% CI: 52%-61%) and 45% (95% CI: 36%-53%) in the first 3 and subsequent 4+ years, respectively; VE for hospitalized HZ was, respectively, 74% (95% CI: 67%-79%) and 55% (95% CI: 39%-67%). Differences in VE by age group were not significant. Conclusions. In both the primary and secondary analyses, HZV provided protection against HZ across all ages, but effectiveness declined over time. VE was higher and better preserved over time for PHN and HZ-associated hospitalizations than for community HZ. C1 [Izurieta, Hector S.; Forshee, Richard; Pratt, Douglas; Lu, Yun; Jankosky, Christopher; Krause, Philip] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA. [Wernecke, Michael; Wong, Sarah; Sun, Qin; MaCurdy, Tom] Acumen LLC, Burlingame, CA USA. [Kelman, Jeffrey; Worrall, Chris] Ctr Medicare & Medicaid Serv, Washington, DC USA. [Harpaz, Rafael] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Izurieta, Hector S.] Univ Rey Juan Carlos, Madrid, Spain. RP Izurieta, HS (reprint author), 10903 New Hampshire Ave, Silver Spring, MD 20993 USA. EM Hector.izurieta@fda.hhs.gov FU Food and Drug Administration; office of the Assistant Secretary of Planning and Evaluation FX This work was funded by the Food and Drug Administration. Additional funding was provided by the office of the Assistant Secretary of Planning and Evaluation. NR 34 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2017 VL 64 IS 6 BP 785 EP 793 DI 10.1093/cid/ciw854 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TI UT WOS:000397304200014 PM 28362955 ER PT J AU Fonjungo, PN Alemnji, GA Kebede, Y Opio, A Mwangi, C Spira, TJ Beard, RS Nkengasong, JN AF Fonjungo, Peter N. Alemnji, George A. Kebede, Yenew Opio, Alex Mwangi, Christina Spira, Thomas J. Beard, R. Suzanne Nkengasong, John N. TI Combatting Global Infectious Diseases: A Network Effect of Specimen Referral Systems SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE platform strategy; specimen referral; centralized model; decentralized model; innovation ID DRIED BLOOD SPOTS; PUBLIC-PRIVATE PARTNERSHIPS; LABORATORY HEALTH SYSTEMS; VIRAL LOAD; HIV; ETHIOPIA; UGANDA; CARE; INITIATION; DIAGNOSIS AB The recent Ebola virus outbreak in West Africa clearly demonstrated the critical role of laboratory systems and networks in responding to epidemics. Because of the huge challenges in establishing functional laboratories at all tiers of health systems in developing countries, strengthening specimen referral networks is critical. In this review article, we propose a platform strategy for developing specimen referral networks based on 2 models: centralized and decentralized laboratory specimen referral networks. These models have been shown to be effective in patient management in programs in resource-limited settings. Both models lead to reduced turnaround time and retain flexibility for integrating different specimen types. In Haiti, decentralized specimen referral systems resulted in a 182% increase in patients enrolling in human immunodeficiency virus treatment programs within 6 months. In Uganda, cost savings of up to 62% were observed with a centralized model. A platform strategy will create a network effect that will benefit multiple disease programs. C1 [Fonjungo, Peter N.; Beard, R. Suzanne; Nkengasong, John N.] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Div Global HIV & TB DGHT, Int Lab Branch, Atlanta, GA USA. [Alemnji, George A.] Caribbean Reg Off, CDC, DGHT, Bridgetown, Barbados. [Kebede, Yenew] CDC, Addis Ababa, Ethiopia. [Opio, Alex] Minist Hlth, Cent Publ Hlth Lab, Kampala, Uganda. [Mwangi, Christina] CDC, Kampala, Uganda. [Spira, Thomas J.] CDC, CGH, DGHT, HIV Care & Treatment Branch, Atlanta, GA USA. RP Fonjungo, PN (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV & TB, Ctr Global Hlth, 1600 Clifton Rd NE,MS-G19, Atlanta, GA 30333 USA. EM pdf4@cdc.gov FU US President's Emergency Plan for AIDS Relief through the CDC FX This work was supported by the US President's Emergency Plan for AIDS Relief through the CDC. NR 36 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 15 PY 2017 VL 64 IS 6 BP 796 EP 803 DI 10.1093/cid/ciw817 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TI UT WOS:000397304200016 ER PT J AU Daniels, RD Bertke, SJ Richardson, DB Cardis, E Gillies, M O'Hagan, JA Haylock, R Laurier, D Leuraud, K Moissonnier, M Thierry-Chef, I Kesminiene, A Schubauer-Berigan, MK AF Daniels, Robert D. Bertke, Stephen J. Richardson, David B. Cardis, Elisabeth Gillies, Michael O'Hagan, Jacqueline A. Haylock, Richard Laurier, Dominique Leuraud, Klervi Moissonnier, Monika Thierry-Chef, Isabelle Kesminiene, Ausrele Schubauer-Berigan, Mary K. TI Examining temporal effects on cancer risk in the international nuclear workers' study SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE cancer; epidemiology; longitudinal studies; dose-response; mortality studies ID ATOMIC-BOMB SURVIVORS; EXTERNAL IONIZING-RADIATION; MULTIPLE-MYELOMA; LEUKEMIA MORTALITY; OCCUPATIONAL COHORT; UNITED-KINGDOM; EXPOSURE; LYMPHOMA; INDUSTRY; TIME AB The paper continues the series of publications from the International Nuclear Workers Study cohort that comprises 308,297 workers from France, the United Kingdom and the United States, providing 8.2 million person-years of observation from a combined follow-up period (at earliest 1944 to at latest 2005). These workers' external radiation exposures were primarily to photons, resulting in an estimated average career absorbed dose to the colon of 17.4 milligray. The association between cumulative ionizing radiation dose and cancer mortality was evaluated in general relative risk models that describe modification of the excess relative risk (ERR) per gray (Gy) by time since exposure and age at exposure. Methods analogous to a nested-case control study using conditional logistic regression of sampled risks sets were used. Outcomes included: all solid cancers, lung cancer, leukemias excluding chronic lymphocytic, acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, Hodgkin lymphoma and non-Hodgkin lymphoma. Significant risk heterogeneity was evident in chronic myeloid leukemia with time since exposure, where we observed increased ERR per Gy estimates shortly after exposure (2-10 year) and again later (20-30 years). We observed delayed effects for acute myeloid leukemia although estimates were not statistically significant. Solid cancer excess risk was restricted to exposure at age 351 years and also diminished for exposure 30 years prior to attained age. Persistent or late effects suggest additional follow-up may inform on lifetime risks. However, cautious interpretation of results is needed due to analytical limitations and a lack of confirmatory results from other studies. C1 [Daniels, Robert D.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Bertke, Stephen J.; Schubauer-Berigan, Mary K.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Richardson, David B.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Cardis, Elisabeth] Ctr Res Environm Epidemiol CREAL, ISGlobal, Radiat Programme, Barcelona, Spain. [Cardis, Elisabeth] Univ Pompeu Fabra, Barcelona, Spain. [Cardis, Elisabeth] CIBERESP, Madrid, Spain. [Gillies, Michael; O'Hagan, Jacqueline A.; Haylock, Richard] Publ Hlth England, Ctr Radiat Chem & Environm Hazards PHE CRCE, Radiat Effects Dept, Chilton, England. [Laurier, Dominique; Leuraud, Klervi] IRSN, Serv Radiobiol & Epidemiol, Fontenay Aux Roses, France. [Moissonnier, Monika; Thierry-Chef, Isabelle; Kesminiene, Ausrele] IARC, Sect Environm & Radiat, Lyon, France. RP Daniels, RD (reprint author), 1090 Tusculum Ave,Mailstop C-15, Cincinnati, OH 45226 USA. EM rtd2@cdc.gov FU National Institute for Occupational Safety and Health, The United States (U.S.) Department of Energy; U.S. Department of Health and Human Services, University of North Carolina from the National Institute for Occupational Safety and Health [R03.OH-010056]; Ministry of Health, Labour and Welfare of Japan FX Grant sponsor: National Institute for Occupational Safety and Health, The United States (U.S.) Department of Energy through an agreement with the U.S. Department of Health and Human Services, University of North Carolina from the National Institute for Occupational Safety and Health; Grant number: R03.OH-010056; Grant sponsor: Ministry of Health, Labour and Welfare of Japan NR 42 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 EI 1097-0215 J9 INT J CANCER JI Int. J. Cancer PD MAR 15 PY 2017 VL 140 IS 6 BP 1260 EP 1269 DI 10.1002/ijc.30544 PG 10 WC Oncology SC Oncology GA EK5PT UT WOS:000393979000004 PM 27914102 ER PT J AU Mirkovic, KR Lathrop, E Hulland, EN Jean-Louis, R Lauture, D D'Alexis, GD Handzel, E Grand-Pierre, R AF Mirkovic, Kelsey R. Lathrop, Eva Hulland, Erin N. Jean-Louis, Reginald Lauture, Daniel D'Alexis, Ghislaine Desinor Handzel, Endang Grand-Pierre, Reynold TI Quality and uptake of antenatal and postnatal care in Haiti ( vol 17, pg 52, 2017) SO BMC PREGNANCY AND CHILDBIRTH LA English DT Correction C1 [Mirkovic, Kelsey R.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Lathrop, Eva; Hulland, Erin N.; Handzel, Endang] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. [Jean-Louis, Reginald] Ctr Dis Control & Prevent, Div Global Hlth Protect, Grand Pierre4, Port Au Prince, Haiti. [Lauture, Daniel; D'Alexis, Ghislaine Desinor; Grand-Pierre, Reynold] Haiti Minist Publ Hlth & Populat, Port Au Prince, Haiti. RP Mirkovic, KR (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM kmirkovic@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2393 J9 BMC PREGNANCY CHILDB JI BMC Pregnancy Childbirth PD MAR 14 PY 2017 VL 17 AR 88 DI 10.1186/s12884-017-1258-z PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EN7FQ UT WOS:000396167900002 PM 28292265 ER PT J AU Klein, NP Lewis, E McDonald, J Fireman, B Naleway, A Glanz, J Jackson, LA Donahue, JG Jacobsen, SJ Weintraub, E Baxter, R AF Klein, Nicola P. Lewis, Edwin McDonald, Julia Fireman, Bruce Naleway, Allison Glanz, Jason Jackson, Lisa A. Donahue, James G. Jacobsen, Steven J. Weintraub, Eric Baxter, Roger TI Risk factors and familial clustering for fever 7-10 days after the first dose of measles vaccines SO VACCINE LA English DT Article DE Measles; Fever; Safety; Vaccine ID MUMPS-RUBELLA VACCINE; FEBRILE SEIZURES; VARICELLA VACCINE; RECEPTOR POLYMORPHISMS; IMMUNE-RESPONSES; MMRV VACCINATION; CHILDREN; SAFETY; IMMUNOGENICITY; ASSOCIATIONS AB Background: Seven to ten days after a first dose of a measles-containing vaccine (MCV; i.e., MMR or MMRV), children have elevated fever risk which can be associated with febrile seizures. This study investigated individual and familial factors associated with fever 7-10 days after MCV. Methods: Retrospective cohort study among children who were <36 months of age at receipt of MCV in six sites of the Vaccine Safety Datalink from 1/112000 to 12/31/2012. We evaluated medically-attended clinic or emergency department visits with a code for fever 7-10 days after any MCV ("MCV- associated"). We evaluated factors associated with MCV-associated fever using chi(2) and multivariable logistic regression analyses. Results: Among 946,806 children vaccinated with MCV, we identified 7480 (0.8%) MCV-associated fever visits. Compared with children without fever after MCV, children with MCV-associated fever were more likely to have received MMRV than MMR (OR 1.3 95% CI 1.2,1.5), have had medically attended fever both following previous vaccines (OR 1.3 95% CI 1.1, 1.6) and at any other previous time (OR 1.7 95% CI 1.6, 1.8), have had at least 1 prior seizure (OR 2.2 95% CI 1.7, 2.7), and have had >3 medical visits within the 6 months before MCV (OR 1.7 95% CI 1.6, 1.8). In families with multiple MCV-immunized children, after adjusting for healthcare seeking behavior care for fever, those whose siblings had MCVassociated fever were more likely to also have MCV-associated fever (OR 3.5 95% CI 2.5, 4.8). Discussion: Children who received MMRV vaccine or who had prior medically-attended fevers and seizures during the first year of life had increased risk of fever after a first dose of measles vaccine. After adjusting for familial propensity to seek care, MCV-associated fever still clustered within families, suggesting a possible genetic basis for susceptibility to developing fever due to measles vaccines. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Klein, Nicola P.; Lewis, Edwin; McDonald, Julia; Fireman, Bruce; Baxter, Roger] Kaiser Permanente Vaccine Study Ctr, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA. [Glanz, Jason] Kaiser Permanente Colorado, Denver Hlth, Denver, CO USA. [Naleway, Allison] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. [Donahue, James G.] Marshfield Clin Res Fdn, Ctr Clin Epidemiol & Populat Hlth, Marshfield, WI USA. [Jacobsen, Steven J.] Kaiser Permanente Southern Calif, Res & Evaluat, Pasadena, CA USA. [Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. RP Klein, NP (reprint author), Kaiser Permanente Vaccine Study Ctr, 1 Kaiser Plaza,16th Floor, Oakland, CA 94612 USA. EM Nicola.Klein@kp.org FU Centers for Disease Control and Prevention (CDC) FX This work was supported by the Centers for Disease Control and Prevention (CDC). NR 41 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 14 PY 2017 VL 35 IS 12 BP 1615 EP 1621 DI 10.1016/j.vaccine.2017.02.013 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EO8RU UT WOS:000396958400007 PM 28233624 ER PT J AU He, XQ Wang, LY Riedel, H Wang, K Yang, Y Dinu, CZ Rojanasakul, Y AF He, Xiaoqing Wang, Liying Riedel, Heimo Wang, Kai Yang, Yong Dinu, Cerasela Zoica Rojanasakul, Yon TI Mesothelin promotes epithelial-tomesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells SO MOLECULAR CANCER LA English DT Article DE Mesothelin; Lung cancer; Mesothelioma; Epithelial to mesenchymal transition; Cancer stem cells; Circulating tumor cells; Metastasis ID MESENCHYMAL TRANSITION; BREAST-CANCER; E-CADHERIN; ALDEHYDE DEHYDROGENASE; STEM-CELLS; EMT; OVEREXPRESSION; METASTASIS; EXPRESSION; RESISTANCE AB Background: Lung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding of the disease mechanisms. We have identified mesothelin as a potentially unique therapeutic target that as a specific advantage appears nonessential in most cell types. Mesothelin (MSLN), a plasma membrane differentiation antigen, is expressed at a high level in many human solid tumors, including 70% of lung cancer and nearly all mesotheliomas. However, the role of MSLN in the disease process and underlying mechanisms is largely unknown. Methods: ShRNA knockdown and overexpression of MSLN were performed in human cancer cell lines and corresponding normal cells, respectively. Tumorigenic and metastatic effects of MSLN were examined by tumor sphere formation, migration, and invasion assays in vitro, as well as xenograft tumor assay in vivo. EMT and CSCs were detected by qPCR array, immunoblotting and flow cytometry. Results: MSLN plays a key role in controlling epithelial-to-mesenchymal transition (EMT) and stem properties of human lung cancer and mesothelioma cells that control their tumorigenicity and metastatic potential. Firstly, MSLN was found to be highly upregulated in non-small cell lung cancer (NSCLC) patient tissues and in lung carcinoma and mesothelioma cell lines. Secondly, genetic knockdown of MSLN significantly reduced anchorage-independent cell growth, tumor sphere formation, cell adhesion, migration and invasion in vitro, as well as tumor formation and metastasis in vivo. Thirdly, ectopic overexpression of MSLN induced the malignant phenotype of non-cancerous cells, supporting its role as an oncogene. Finally, mechanistic studies revealed that knockdown of MSLN reversed EMT and attenuated stem cell properties, in addition to inhibiting tumor growth and metastasis. Conclusions: These results indicate an essential role of MSLN in controlling EMT and stem cell properties of human lung cancer and mesothelioma cells. Since EMT is an important process in tumor progression and metastasis, and MSLN is nonessential in most normal tissue, our findings on MSLN may provide new insights into the disease mechanisms and may aid in the development of novel targeted therapy for lung cancer and mesothelioma. C1 [He, Xiaoqing; Rojanasakul, Yon] West Virginia Univ, Dept Pharmaceut Sci, 1 Med Ctr Dr, Morgantown, WV 26506 USA. [Wang, Liying] CDC, NIOSH, HELD, 1095 Willowdale Rd, Morgantown, WV 26505 USA. [Riedel, Heimo] West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA. [Wang, Kai; Yang, Yong; Dinu, Cerasela Zoica] West Virginia Univ, Dept Chem & Biochem Engn, 395 Evansdale Dr, Morgantown, WV 26506 USA. [Riedel, Heimo; Rojanasakul, Yon] WVU Canc Inst, 1 Med Ctr Dr, Morgantown, WV 26506 USA. RP Rojanasakul, Y (reprint author), West Virginia Univ, Dept Pharmaceut Sci, 1 Med Ctr Dr, Morgantown, WV 26506 USA.; Rojanasakul, Y (reprint author), WVU Canc Inst, 1 Med Ctr Dr, Morgantown, WV 26506 USA. EM yrojan@hsc.wvu.edu FU National Institutes of Health [R01-ES022968, R01-EB018857, R15GM122953]; National Science Foundation [CBET-1434503]; NIH [P30 GM103488, P20 RR016440, P30 RR032138/GM103488, P20 RR016477]; West Virginia University Cancer Institute FX This work was supported by grants from the National Institutes of Health (R01-ES022968, R01-EB018857, R15GM122953) and National Science Foundation (CBET-1434503). Flow cytometric analysis was performed at the West Virginia University Flow Cytometry Core Facility, which is supported in part by NIH Grant P30 GM103488. Imaging experiments and image analysis were performed at the West Virginia University Microscope Imaging Facility, which is supported by the West Virginia University Cancer Institute and NIH grants P20 RR016440, P30 RR032138/GM103488 and P20 RR016477. NR 44 TC 0 Z9 0 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-4598 J9 MOL CANCER JI Mol. Cancer PD MAR 14 PY 2017 VL 16 AR 63 DI 10.1186/s12943-017-0633-8 PG 13 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA EQ1CL UT WOS:000397806800004 PM 28288645 ER PT J AU Katz, LS Griswold, T Williams-Newkirk, AJ Wagner, D Petkau, A Sieffert, C Van Domselaar, G Deng, XY Carleton, HA AF Katz, Lee S. Griswold, Taylor Williams-Newkirk, Amanda J. Wagner, Darlene Petkau, Aaron Sieffert, Cameron Van Domselaar, Gary Deng, Xiangyu Carleton, Heather A. TI A Comparative Analysis of the Lyve-SET Phylogenomics Pipeline for Genomic Epidemiology of Foodborne Pathogens SO FRONTIERS IN MICROBIOLOGY LA English DT Article ID SINGLE-NUCLEOTIDE POLYMORPHISMS; PHYLOGENETIC ANALYSIS; OUTBREAK; SALMONELLA; ALGORITHMS; REGRESSION; PROGRAM; CLONES; FORMAT; PERL C1 [Katz, Lee S.; Griswold, Taylor; Williams-Newkirk, Amanda J.; Wagner, Darlene; Carleton, Heather A.] Enter Dis Lab Branch, Ctr Dis Control & Prevent, Atlanta, GA USA. [Katz, Lee S.; Deng, Xiangyu] Univ Georgia, Coll Agr & Environm Sci, Ctr Food Safety, Griffin, GA USA. [Griswold, Taylor] Oak Ridge Associated Univ, Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Williams-Newkirk, Amanda J.; Wagner, Darlene] IHRC Inc, Atlanta, GA USA. [Petkau, Aaron; Sieffert, Cameron; Van Domselaar, Gary] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. RP Katz, LS (reprint author), Enter Dis Lab Branch, Ctr Dis Control & Prevent, Atlanta, GA USA.; Katz, LS (reprint author), Univ Georgia, Coll Agr & Environm Sci, Ctr Food Safety, Griffin, GA USA. EM gzu2@cdc.gov FU Advanced Molecular Detection (AMD) Initiative; Public Health Agency of Canada (PHAC); Canadian Federal Government Genomics Research and Development Initiative (GRDI); Genome BC FX This work was made possible through support from the Advanced Molecular Detection (AMD) Initiative at the Centers for Disease Control and Prevention. SNVPhyl development was funded by the Public Health Agency of Canada (PHAC), the Canadian Federal Government Genomics Research and Development Initiative (GRDI) Interdepartmental Shared Priority Project on Food and Water Safety, and Genome BC. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 0 Z9 0 U1 0 U2 0 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD MAR 13 PY 2017 VL 8 AR 375 DI 10.3389/fmicb.2017.00375 PG 13 WC Microbiology SC Microbiology GA EN4OF UT WOS:000395986100001 PM 28348549 ER PT J AU Hoxmeier, JC Fleshman, AC Broeckling, CD Prenni, JE Dolan, MC Gage, KL Eisen, L AF Hoxmeier, J. Charles Fleshman, Amy C. Broeckling, Corey D. Prenni, Jessica E. Dolan, Marc C. Gage, Kenneth L. Eisen, Lars TI Metabolomics of the tick-Borrelia interaction during the nymphal tick blood meal SO SCIENTIFIC REPORTS LA English DT Article ID LYME-DISEASE SPIROCHETE; PERFORMANCE LIQUID-CHROMATOGRAPHY; IXODES-SCAPULARIS; BACTERIAL PATHOGENS; ESCHERICHIA-COLI; UNITED-STATES; ANAPLASMA-PHAGOCYTOPHILUM; ETHANOLAMINE UTILIZATION; VECTOR COMPETENCE; ACID-METABOLISM AB The causal agents of Lyme disease in North America, Borrelia burgdorferi and Borrelia mayonii, are transmitted primarily by Ixodes scapularis ticks. Due to their limited metabolic capacity, spirochetes rely on the tick blood meal for nutrients and metabolic intermediates while residing in the tick vector, competing with the tick for nutrients in the blood meal. Metabolomics is an effective methodology to explore dynamics of spirochete survival and multiplication in tick vectors before transmission to a vertebrate host via tick saliva. Using gas chromatography coupled to mass spectrometry, we identified statistically significant differences in the metabolic profile among uninfected I. scapularis nymphal ticks, B. burgdorferi- infected nymphal ticks and B. mayonii-infected nymphal ticks by measuring metabolism every 24 hours over the course of their up to 96 hour blood meals. Specifically, differences in the abundance of purines, amino acids, carbohydrates, and fatty acids during the blood meal among the three groups of nymphal ticks suggest that B. mayonii and B. burgdorferi may have different metabolic capabilities, especially during later stages of nymphal feeding. Understanding mechanisms underlying variable metabolic requirements of different Lyme disease spirochetes within tick vectors could potentially aid development of novel methods to control spirochete transmission. C1 [Hoxmeier, J. Charles; Fleshman, Amy C.; Dolan, Marc C.; Gage, Kenneth L.; Eisen, Lars] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Broeckling, Corey D.; Prenni, Jessica E.] Colorado State Univ, Prote & Metabol Facil, Ft Collins, CO 80523 USA. RP Fleshman, AC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM muj3@cdc.gov NR 82 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAR 13 PY 2017 VL 7 AR 44394 DI 10.1038/srep44394 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN7RY UT WOS:000396201100001 PM 28287618 ER PT J AU Leichliter, JS Copen, C Dittus, PJ AF Leichliter, Jami S. Copen, Casey Dittus, Patricia J. TI Confidentiality Issues and Use of Sexually Transmitted Disease Services Among Sexually Experienced Persons Aged 15-25 Years - United States, 2013-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Leichliter, Jami S.; Dittus, Patricia J.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. [Copen, Casey] CDC, Div Vital Stat, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA. RP Leichliter, JS (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. EM jleichliter@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 10 PY 2017 VL 66 IS 9 BP 237 EP 241 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO8TQ UT WOS:000396963700001 PM 28278143 ER PT J AU Ko, JY Wolicki, S Barfield, WD Patrick, SW Broussard, CS Yonkers, KA Naimon, R Iskander, J AF Ko, Jean Y. Wolicki, Sara Barfield, Wanda D. Patrick, Stephen W. Broussard, Cheryl S. Yonkers, Kimberly A. Naimon, Rebecca Iskander, John TI CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PREGNANCY; IMPLEMENTATION; STATES C1 [Ko, Jean Y.; Barfield, Wanda D.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Wolicki, Sara] Assoc Sch & Programs Publ Hlth, Washington, DC USA. [Wolicki, Sara; Naimon, Rebecca; Iskander, John] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. [Patrick, Stephen W.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. [Patrick, Stephen W.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Div Neonatol, Nashville, TN 37212 USA. [Broussard, Cheryl S.] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Congenital & Dev Disorders, Atlanta, GA 30333 USA. [Yonkers, Kimberly A.] Yale Sch Med, Dept Psychiat, New Haven, CT USA. [Yonkers, Kimberly A.] Yale Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA. RP Ko, JY (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. EM jeanko@cdc.gov NR 17 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 10 PY 2017 VL 66 IS 9 BP 242 EP 245 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO8TQ UT WOS:000396963700002 PM 28278146 ER PT J AU Barbour, KE Helmick, CG Boring, M Brady, TJ AF Barbour, Kamil E. Helmick, Charles G. Boring, Michael Brady, Teresa J. TI Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID US ADULTS; EXERCISE; HEALTH; PAIN AB Background: In the United States, doctor-diagnosed arthritis is a common and disabling chronic condition. Arthritis can lead to severe joint pain and poor physical function, and it can negatively affect quality of life. Methods: CDC analyzed 20132015 data from the National Health Interview Survey, an annual, nationally representative, in-person interview survey of the health status and behaviors of the noninstitutionalized civilian U.S. adult population, to update previous prevalence estimates of arthritis and arthritis-attributable activity limitations. Results: On average, during 20132015, 54.4 million (22.7%) adults had doctor-diagnosed arthritis, and 23.7 million (43.5% of those with arthritis) had arthritis-attributable activity limitations (an age-adjusted increase of approximately 20% in the proportion of adults with arthritis reporting activity limitations since 2002 [p-trend <0.001]). Among adults with heart disease, diabetes, and obesity, the prevalences of doctor-diagnosed arthritis were 49.3%, 47.1%, and 30.6%, respectively; the prevalences of arthritis-attributable activity limitations among adults with these conditions and arthritis were 54.5% (heart disease), 54.0% (diabetes), and 49.0% (obesity). Conclusions and Comments: The prevalence of arthritis is high, particularly among adults with comorbid conditions, such as heart disease, diabetes, and obesity. Furthermore, the prevalence of arthritis-attributable activity limitations is high and increasing over time. Approximately half of adults with arthritis and heart disease, arthritis and diabetes, or arthritis and obesity are limited by their arthritis. Greater use of evidence-based physical activity and self-management education interventions can reduce pain and improve function and quality of life for adults with arthritis and also for adults with other chronic conditions who might be limited by their arthritis. C1 [Barbour, Kamil E.; Helmick, Charles G.; Boring, Michael; Brady, Teresa J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Arthrit Program, Atlanta, GA 30333 USA. RP Barbour, KE (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Arthrit Program, Atlanta, GA 30333 USA. EM kbarbour@cdc.gov NR 27 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 10 PY 2017 VL 66 IS 9 BP 246 EP 253 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO8TQ UT WOS:000396963700003 PM 28278145 ER PT J AU Iuliano, AD Jang, YH Jones, J Davis, CT Wentworth, DE Uyeki, TM Roguski, K Thompson, MG Gubareva, L Fry, AM Burns, E Track, S Zhou, SZ Katz, JM Jernigan, DB AF Iuliano, A. Danielle Jang, Yunho Jones, Joyce Davis, C. Todd Wentworth, David E. Uyeki, Timothy M. Roguski, Katherine Thompson, Mark G. Gubareva, Larisa Fry, Alicia M. Burns, Erin Track, Susan Zhou, Suizan Katz, Jacqueline M. Jernigan, Daniel B. TI Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic - China, October 2016-February 2017 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Iuliano, A. Danielle; Jang, Yunho; Jones, Joyce; Davis, C. Todd; Wentworth, David E.; Uyeki, Timothy M.; Roguski, Katherine; Thompson, Mark G.; Gubareva, Larisa; Fry, Alicia M.; Burns, Erin; Track, Susan; Katz, Jacqueline M.; Jernigan, Daniel B.] CDC, Atlanta, GA 30333 USA. [Zhou, Suizan] CDC, Beijing, Peoples R China. RP Iuliano, AD (reprint author), CDC, Atlanta, GA 30333 USA. EM aiuliano@cdc.gov NR 6 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 10 PY 2017 VL 66 IS 9 BP 254 EP 255 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO8TQ UT WOS:000396963700004 PM 28278147 ER PT J AU Arnold, S Melville, SK Morehead, B Vaughan, G Moorman, A Crist, MB AF Arnold, Sandi Melville, Sharon K. Morehead, Bonnie Vaughan, Gilberto Moorman, Anne Crist, Matthew B. TI Hepatitis C Transmission from Inappropriate Reuse of Saline Flush Syringes for Multiple Patients in an Acute Care General Hospital - Texas, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SETTINGS C1 [Arnold, Sandi] CDC, Dept State Hlth Serv, Atlanta, GA 30333 USA. [Melville, Sharon K.; Morehead, Bonnie] CDC, Texas Dept State Hlth Serv, Hlth Serv Reg 7, Atlanta, GA 30333 USA. [Vaughan, Gilberto; Moorman, Anne] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Crist, Matthew B.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Crist, MB (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM cwu0@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 10 PY 2017 VL 66 IS 9 BP 258 EP 260 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO8TQ UT WOS:000396963700006 PM 28278142 ER PT J AU Pathmanathan, I Dokubo, EK Shiraishi, RW Agolory, SG Auld, AF Onotu, D Odafe, S Dalhatu, I Abiri, O Debem, HC Bashorun, A Ellerbrock, T AF Pathmanathan, Ishani Dokubo, E. Kainne Shiraishi, Ray W. Agolory, Simon G. Auld, Andrew F. Onotu, Dennis Odafe, Solomon Dalhatu, Ibrahim Abiri, Oseni Debem, Henry C. Bashorun, Adebobola Ellerbrock, Tedd TI Incidence and predictors of tuberculosis among HIV-infected adults after initiation of antiretroviral therapy in Nigeria, 2004-2012 SO PLOS ONE LA English DT Article ID SOUTH-AFRICA; IMMUNE RECONSTITUTION; TREATMENT OUTCOMES; RISK-FACTORS; PREVENTION; COHORT AB Background Nigeria had the most AIDS-related deaths worldwide in 2014 (170,000), and 46% were associated with tuberculosis (TB). Although treatment of people living with HIV (PLHIV) with antiretroviral therapy (ART) reduces TB-associated morbidity and mortality, incident TB can occur while on ART. We estimated incidence and characterized factors associated with TB after ART initiation in Nigeria. Methods We analyzed retrospective cohort data from a nationally representative sample of adult patients on ART. Data were abstracted from 3,496 patient records, and analyses were weighted and controlled for a complex survey design. We performed domain analyses on patients without documented TB disease and used a Cox proportional hazard model to assess factors associated with TB incidence after ART. Results At ART initiation, 3,350 patients (95.8%) were not receiving TB treatment. TB incidence after ART initiation was 0.57 per 100 person-years, and significantly higher for patients with CD4<50/mu L (adjusted hazard ratio [AHR]: 4.2, 95% confidence interval [CI]: 1.4-12.7) compared with CD4 >= 200/mu L. Patients with suspected but untreated TB at ART initiation and those with a history of prior TB were more likely to develop incident TB (AHR: 12.2, 95% CI: 4.5-33.5 and AHR: 17.6, 95% CI: 3.5-87.9, respectively). Conclusion Incidence of TB among PLHIV after ART initiation was low, and predicted by advanced HIV, prior TB, and suspected but untreated TB. Study results suggest a need for improved TB screening and diagnosis, particularly among high-risk PLHIV initiating ART, and reinforce the benefit of early ART and other TB prevention efforts. C1 [Pathmanathan, Ishani; Dokubo, E. Kainne; Shiraishi, Ray W.; Agolory, Simon G.; Auld, Andrew F.; Ellerbrock, Tedd] US Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA 30333 USA. [Pathmanathan, Ishani] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Onotu, Dennis; Odafe, Solomon; Dalhatu, Ibrahim; Debem, Henry C.] US Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA USA. [Abiri, Oseni] Univ S Alabama, Dept Nursing, Mobile, AL USA. [Bashorun, Adebobola] Fed Minist Hlth, Div HIV AIDS, Abuja, Nigeria. RP Pathmanathan, I (reprint author), US Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA 30333 USA.; Pathmanathan, I (reprint author), US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ydi6@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC) FX The study and writing of this report has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC). NR 33 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 10 PY 2017 VL 12 IS 3 AR e0173309 DI 10.1371/journal.pone.0173309 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN6CJ UT WOS:000396091800028 PM 28282390 ER PT J AU Frieden, TR Ethier, K Schuchat, A AF Frieden, Thomas R. Ethier, Kathleen Schuchat, Anne TI Improving the Health of the United States With a "Winnable Battles" Initiative SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Frieden, Thomas R.; Ethier, Kathleen; Schuchat, Anne] US Ctr Dis Control & Prevent, Atlanta, GA USA. EM tfrieden@gmail.com NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 7 PY 2017 VL 317 IS 9 BP 903 EP 904 DI 10.1001/jama.2017.0436 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EM8DM UT WOS:000395541500006 PM 28152127 ER PT J AU Seib, K Pollard, AJ de Wals, P Andrews, RM Zhou, FJ Hatchett, RJ Pickering, LK Orenstein, WA AF Seib, Katherine Pollard, Andrew J. de Wals, Philippe Andrews, Ross M. Zhou, Fangjun Hatchett, Richard J. Pickering, Larry K. Orenstein, Walter A. TI Policy making for vaccine use as a driver of vaccine innovation and development in the developed world SO VACCINE LA English DT Review DE Vaccine development; Innovation; United States; Canada; United Kingdom; Australia ID IMMUNIZATION PRACTICES ACIP; COST-EFFECTIVENESS THRESHOLD; CONGENITAL-RUBELLA SYNDROME; ADVISORY-COMMITTEE; UNITED-STATES; AUSTRALIA; RECOMMENDATIONS; PREVENTION; DECISIONS; ADJUVANTS AB In the past 200 years, vaccines have had unmistakable impacts on public health including declines in morbidity and mortality, most markedly in economically-developed countries. Highly engineered vaccines including vaccines for conditions other than infectious diseases are expected to dominate future vaccine development. We examine immunization vaccine policy as a driver of vaccine innovation and development. The pathways to recommendation for use of licensed vaccines in the US, UK, Canada and Australia have been similar, including: expert review of disease epidemiology, disease burden and severity; vaccine immunogenicity, efficacy and safety; programmatic feasibility; public demand; and increasingly cost-effectiveness. Other attributes particularly important in development of future vaccines are likely to include: duration of immunity for improved vaccines such as pertussis; a greater emphasis on optimizing community protection rather than direct protection only; programmatic implementation, feasibility, improvements (as in the case of development of a universal influenza vaccine); public concerns/confidence/fears related to outbreak pathogens like Ebola and Zika virus; and major societal burden for combating hard to treat diseases like HIV and antimicrobial resistant pathogens. Driving innovation and production of future vaccines faces enormous economic hurdles as available approaches, technologies and regulatory pathways become more complex. As such, cost-mitigating strategies and focused, aligned efforts (by governments, private organizations, and private-public partnerships) will likely be needed to continue to spur major advances in vaccine technologies and development. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Seib, Katherine; Orenstein, Walter A.] Emory Univ, Sch Med, Div Infect Dis, 1599 Clifton Rd,Room 6-403, Atlanta, GA 30322 USA. [Pollard, Andrew J.] Univ Oxford, Dept Paediat, Oxford, England. [Pollard, Andrew J.] NIHR Oxford Biomed Res Ctr, Oxford, England. [de Wals, Philippe] Univ Laval, Quebec Univ Hosp, Res Ctr, Quebec City, PQ, Canada. [de Wals, Philippe] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada. [Andrews, Ross M.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia. [Andrews, Ross M.] Australian Tech Advisory Grp Immunisat, Darwin, NT, Australia. [Zhou, Fangjun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Hatchett, Richard J.] US Dept HHS, Biomed Adv Res & Dev Author, Washington, DC 20201 USA. [Pickering, Larry K.] Emory Univ, Sch Med, Pediat Infect Dis, Atlanta, GA USA. RP Seib, K (reprint author), Emory Univ, Sch Med, Div Infect Dis, 1599 Clifton Rd,Room 6-403, Atlanta, GA 30322 USA. EM kseib@emory.edu FU Glaxo-Smith-Kline; Novartis; Sanofi Pasteur; Pfizer; Quebec Ministry of Health and Social Services; Health Canada; Public Health Agency of Canada FX PdW: Received research grants, and reimbursements of travel expenses from vaccine manufacturers including Glaxo-Smith-Kline, Novartis, Sanofi Pasteur, and Pfizer, as well as from governmental agencies including the Quebec Ministry of Health and Social Services, Health Canada, and the Public Health Agency of Canada. NR 79 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 7 PY 2017 VL 35 IS 10 BP 1380 EP 1389 DI 10.1016/j.vaccine.2016.10.080 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EM9DK UT WOS:000395611300004 PM 28253995 ER PT J AU Geiss, LS Kirtland, K Lin, J Shrestha, S Thompson, T Albright, A Gregg, EW AF Geiss, Linda S. Kirtland, Karen Lin, Ji Shrestha, Sundar Thompson, Ted Albright, Ann Gregg, Edward W. TI Changes in diagnosed diabetes, obesity, and physical inactivity prevalence in US counties, 2004-2012 SO PLOS ONE LA English DT Article ID UNITED-STATES; TRENDS; ADULTS AB Recent studies suggest that prevalence of diagnosed diabetes in the United States reached a plateau or slowed around 2008, and that this change coincided with obesity plateaus and increases in physical activity. However, national estimates can obscure important variations in geographic subgroups. We examine whether a slowing or leveling off in diagnosed diabetes, obesity, and leisure time physical inactivity prevalence is also evident across the 3143 counties of the United States. We used publicly available county estimates of the age-adjusted prevalence of diagnosed diabetes, obesity, and leisure-time physical inactivity, which were generated by the Centers for Disease Control and Prevention (CDC). Using a Bayesian multi-level regression that included random effects by county and year and applied cubic splines to smooth these estimates over time, we estimated the average annual percentage point change (APPC) from 2004 to 2008 and from 2008 to 2012 for diabetes, obesity, and physical inactivity prevalence in each county. Compared to 2004-2008, the median APPCs for diabetes, obesity, and physical inactivity were lower in 2008-2012 (diabetes APPC difference = 0.16, 95% CI 0.14, 0.18; obesity APPC difference = 0.65, 95% CI 0.59, 0.70; physical inactivity APPC difference = 0.43, 95% CI 0.37, 0.48). APPCs and APPC differences between time periods varied among counties and U.S. regions. Despite improvements, levels of these risk factors remained high with most counties merely slowing rather than reversing, which suggests that all counties would likely benefit from reductions in these risk factors. The diversity of trajectories in the prevalence of these risk factors across counties underscores the continued need to identify high risk areas and populations for preventive interventions. Awareness of how these factors are changing might assist local policy makers in targeting and tracking the impact of efforts to reduce diabetes, obesity and physical inactivity. C1 [Geiss, Linda S.; Lin, Ji; Shrestha, Sundar; Thompson, Ted; Albright, Ann; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. [Kirtland, Karen] Northrop Grumman Corp, Atlanta, GA USA. RP Geiss, LS (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. EM lsg2@cdc.gov FU Northrop Grumman Corporation FX KK is an employee of Northrop Grumman Corporation which provides scientific analysis services as directed by the Centers for Disease Control and Prevention (CDC) through a contract with CDC. Other than providing the salary of KK, Northrop Grumman Corporation did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of KK are articulated in the "author contributions" section. NR 31 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 7 PY 2017 VL 12 IS 3 AR e0173428 DI 10.1371/journal.pone.0173428 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN5QM UT WOS:000396060600032 ER PT J AU Peters, BA Dominianni, C Shapiro, JA Church, TR Wu, J Miller, G Yuen, E Freiman, H Lustbader, I Salik, J Friedlander, C Hayes, RB Ahn, J AF Peters, Brandilyn A. Dominianni, Christine Shapiro, Jean A. Church, Timothy R. Wu, Jing Miller, George Yuen, Elizabeth Freiman, Hal Lustbader, Ian Salik, James Friedlander, Charles Hayes, Richard B. Ahn, Jiyoung TI The gut microbiota in conventional and serrated precursors of colorectal cancer (vol 4, 69, 2016) SO MICROBIOME LA English DT Correction C1 [Peters, Brandilyn A.; Dominianni, Christine; Wu, Jing; Salik, James; Hayes, Richard B.; Ahn, Jiyoung] New York Univ, Sch Med, Dept Populat Hlth, New York, NY USA. [Shapiro, Jean A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Church, Timothy R.] Univ Minnesota, Sch Publ Hlth, Div Environm Hlth Sci, Minneapolis, MN USA. [Miller, George] New York Univ, Sch Med, Dept Surg, New York, NY USA. [Miller, George] New York Univ, Sch Med, Dept Cell Biol, New York, NY USA. [Miller, George; Hayes, Richard B.; Ahn, Jiyoung] New York Univ, NYU Perlmutter Canc Ctr, Sch Med, New York, NY USA. [Yuen, Elizabeth; Freiman, Hal; Salik, James] Kips Bay Endoscopy Ctr, New York, NY USA. RP Ahn, J (reprint author), New York Univ, Sch Med, Dept Populat Hlth, New York, NY USA.; Ahn, J (reprint author), New York Univ, NYU Perlmutter Canc Ctr, Sch Med, New York, NY USA. EM Jiyoung.Ahn@nyumc.org NR 1 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2049-2618 J9 MICROBIOME JI Microbiome PD MAR 6 PY 2017 VL 5 AR 29 DI 10.1186/s40168-017-0238-x PG 1 WC Microbiology SC Microbiology GA EP3UX UT WOS:000397308300001 PM 28264712 ER PT J AU Keddy, KH Takuva, S Musekiwa, A Puren, AJ Sooka, A Karstaedt, A Klugman, KP Angulo, FJ AF Keddy, Karen H. Takuva, Simbarashe Musekiwa, Alfred Puren, Adrian J. Sooka, Arvinda Karstaedt, Alan Klugman, Keith P. Angulo, Frederick J. TI An association between decreasing incidence of invasive non-typhoidal salmonellosis and increased use of antiretroviral therapy, Gauteng Province, South Africa, 2003-2013 SO PLOS ONE LA English DT Article ID GLOBAL BURDEN; DISEASE; TYPHIMURIUM; HIV; TUBERCULOSIS; HEALTH; KENYA AB Background HIV-infected persons are at increased risk of opportunistic infections, including invasive nontyphoidal Salmonella (iNTS) infections; antiretroviral therapy (ART) reduces this risk. We explored changing iNTS incidence associated with increasing ART availability in South Africa. Methods Laboratory-based surveillance for iNTS was conducted in Gauteng Province, South Africa, with verification using the National Health Laboratory Service's Central Data Warehouse (CDW), between 2003 and 2013. Isolates were serotyped at the Centre for Enteric Diseases. CDW data on patient numbers obtaining HIV viral load measurements provided estimates of numbers of HIV-infected patients receiving ART. A Poisson regression model was used to measure the changing incidence of iNTS infection from 2003 to 2013. The correlation between the incidence of iNTS and ART use from 2004 to 2013 was determined using Pearson's correlation coefficient. Results From 2003-2013, the incidence of iNTS per 100,000 population per year decreased from 5.0 to 2.2 (p < .001). From 2004 to 2013, the incidence per 100,000 population of HIV viral load testing increased from 75.2 to 3,620.3 (p < .001). The most common serotypes causing invasive disease were Salmonella enterica serovar Typhimurium (Salmonella Typhimurium), and Salmonella Enteritidis: 2,469 (55.4%) and 1,156 (25.9%) of 4,459 isolates serotyped, respectively. A strong negative correlation was observed between decreasing iNTS incidence and increasing ART use from 2004 to 2013 (r = -0.94, p < .001). Similarly, decreasing incidence of invasive Salmonella Typhimurium infection correlated with increasing ART use (r = -0.93, p <.001). Incidence of invasive Salmonella Enteritidis infection increased, however (r = 0.95, p <.001). Between 2003 and 2004, fewer adult men than women presented with iNTS (male-to- female rate ratio 0.73 and 0.89, respectively). This was reversed from 2005 through 2013 (ranging from 1.07 in 2005 to 1.44 in 2013). Adult men accessed ART less (male-to-female rate ratio ranging from 0.61 [2004] to 0.67 [2013]). Conclusions The incidence of iNTS infections including Salmonella Typhimurium decreased significantly in Gauteng Province in association with increased ART utilization. Adult men accessed ART programs less than women, translating into increasing iNTS incidence in this group. Monitoring iNTS incidence may assist in monitoring the ART program. Increasing incidence of invasive Salmonella Enteritidis infections needs further elucidation. C1 [Keddy, Karen H.] Natl Inst Communicable Dis, Ctr Enter Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. [Keddy, Karen H.; Puren, Adrian J.; Karstaedt, Alan] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Takuva, Simbarashe] CARTA Africa, Nairobi, Kenya. [Takuva, Simbarashe; Puren, Adrian J.] Natl Inst Communicable Dis, Ctr HIV, Natl Hlth Lab Serv, Johannesburg, South Africa. [Musekiwa, Alfred] South Africa Global Dis Detect Ctr, Int Emerging Infect Program, Ctr Dis Control & Prevent, Pretoria, South Africa. [Karstaedt, Alan] Chris Hani Baragwanath Hosp, Dept Med, Johannesburg, South Africa. [Klugman, Keith P.] Bill & Melinda Gates Fdn, Seattle, WA USA. [Angulo, Frederick J.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Keddy, KH (reprint author), Natl Inst Communicable Dis, Ctr Enter Dis, Natl Hlth Lab Serv, Johannesburg, South Africa.; Keddy, KH (reprint author), Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. EM karenk@nicd.ac.za FU National Institute for Communicable Diseases/National Health Laboratory Service (South Africa); Presidents Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) [5U2GPS001328]; United States Agency for International Developments Antimicrobial Resistance Initiative; Centers for Disease Control and Prevention (CDC), Atlanta, Georgia [U60/CCU022088]; HHS Centers for Disease Control and Prevention (CDC); National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); Global AIDS Program (GAP) [U62/PSO022901] FX This research has been supported by National Institute for Communicable Diseases/National Health Laboratory Service (South Africa) (www.nicd.ac.za) and the Presidents Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of [5U2GPS001328] and, in part, for 2003-2006 by funds from the United States Agency for International Developments Antimicrobial Resistance Initiative, transferred via a cooperative agreement [number U60/CCU022088] from the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. For 20072009, it was supported by the HHS Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Global AIDS Program (GAP) Cooperative Agreement [U62/PSO022901](www.cdc.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 27 TC 1 Z9 1 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 6 PY 2017 VL 12 IS 3 AR e0173091 DI 10.1371/journal.pone.0173091 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN5OE UT WOS:000396054300037 ER PT J AU Puttkammer, N Domercant, JW Adler, M Yuhas, K Myrtil, M Young, P Francois, K Grand'Pierre, R Lowrance, D AF Puttkammer, Nancy Domercant, Jean Wysler Adler, Michelle Yuhas, Krista Myrtil, Martine Young, Paul Francois, Kesner Grand'Pierre, Reynold Lowrance, David TI ART attrition and risk factors among Option B plus patients in Haiti: A retrospective cohort study SO PLOS ONE LA English DT Article ID POISSON REGRESSION APPROACH; CLUSTER RANDOMIZED-TRIAL; TO-CHILD-TRANSMISSION; ANTIRETROVIRAL THERAPY; MALAWI; CARE; HIV; RETENTION; IMPACT; PROGRAM AB Objectives In October 2012, the Haitian Ministry of Health endorsed the "Option B+" strategy to eliminate mother-to-child transmission of HIV and achieve HIV epidemic control. The objective of this paper is to assess and identify risk factors for attrition from the national ART program among Option B+ patients in the 12 months after ART initiation. Design This retrospective cohort study included patients newly initiating ART from October 2012-August 2013 at 68 ART sites covering 45% of all newly enrolled ART patients in all regions of Haiti. Methods With data from electronic medical records, we carried out descriptive analysis of sociodemographic, clinical, and pregnancy-related correlates of ART attrition, and used a modified Poisson regression approach to estimate relative risks in a multivariable model. Results There were 2,166 Option B+ patients who initiated ART, of whom 1,023 were not retained by 12 months (47.2%). One quarter (25.3%) dropped out within 3 months of ART initiation. Protective factors included older age, more advanced HIV disease progression, and any adherence counseling prior to ART initiation, while risk factors included starting ART late in gestation, starting ART within 7 days of HIV testing, and using an atypical ART regimen. Discussion Our study demonstrates early ART attrition among Option B+ patients and contributes evidence on the characteristics of women who are most at risk of attrition in Haiti. Our findings highlight the importance of targeted strategies to support retention among Option B+ patients. C1 [Puttkammer, Nancy] Univ Washington, Dept Global Hlth, Int Training & Educ Ctr Hlth I TECH, Seattle, WA 98195 USA. [Domercant, Jean Wysler; Lowrance, David] US Ctr Dis Control & Prevent, Port Au Prince, Haiti. [Adler, Michelle] US Ctr Dis Control & Prevent, Kampala, Uganda. [Yuhas, Krista] Univ Washington, Ctr AIDS Res, Seattle, WA 98195 USA. [Myrtil, Martine] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Young, Paul] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Francois, Kesner; Grand'Pierre, Reynold] Govt Haiti, Minist Publ Hlth & Populat, Port Au Prince, Haiti. RP Puttkammer, N (reprint author), Univ Washington, Dept Global Hlth, Int Training & Educ Ctr Hlth I TECH, Seattle, WA 98195 USA. EM nputt@uw.edu FU Presidents Emergency Plan for AIDS Relief (PEPFAR) through the Health Resources and Services Administration [U91HA0680]; US Centers for Disease Control and Prevention [NU2GGH001130-04-00]; International Training and Education Center for Health (I-TECH) at the University of Washington; NIAID of the National Institute of Health; NCI of the National Institute of Health; NIMH of the National Institute of Health; NIDA of the National Institute of Health; NICHD of the National Institute of Health; NHLBI of the National Institute of Health; NIA of the National Institute of Health; NIGMS of the National Institute of Health; NIDDK of the National Institute of Health [AI027757] FX This research has been supported by the Presidents Emergency Plan for AIDS Relief (PEPFAR) through the Health Resources and Services Administration, under award number U91HA0680, and the US Centers for Disease Control and Prevention (https://www.cdc.gov/), under award number NU2GGH001130-04-00, to the International Training and Education Center for Health (I-TECH) at the University of Washington. Research reported in this publication was also supported by NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK of the National Institutes of Health (https://www.nih.gov/) under award number AI027757 to the University of Washington Center for AIDS Research (CFAR). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the National Institutes of Health, or the Health Resources and Services Administration. NR 42 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 6 PY 2017 VL 12 IS 3 AR e0173123 DI 10.1371/journal.pone.0173123 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN5OE UT WOS:000396054300039 ER PT J AU Lo, MK Jordan, R Arvey, A Sudhamsu, J Shrivastava-Ranjan, P Hotard, AL Flint, M McMullan, LK Siegel, D Clarke, MO Mackman, RL Hui, HC Perron, M Ray, AS Cihlar, T Nichol, ST Spiropoulou, CF AF Lo, Michael K. Jordan, Robert Arvey, Aaron Sudhamsu, Jawahar Shrivastava-Ranjan, Punya Hotard, Anne L. Flint, Mike McMullan, Laura K. Siegel, Dustin Clarke, Michael O. Mackman, Richard L. Hui, Hon C. Perron, Michel Ray, Adrian S. Cihlar, Tomas Nichol, Stuart T. Spiropoulou, Christina F. TI GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses SO SCIENTIFIC REPORTS LA English DT Article ID GREEN FLUORESCENT PROTEIN; REVERSE GENETICS SYSTEM; FEVER VIRUS LACKING; HIGH-THROUGHPUT; ANTIVIRAL ACTIVITY; EBOLA-VIRUS; IN-VITRO; NIPAH VIRUSES; MODEL; PATHOGENESIS AB GS-5734 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a non-human primate model of Ebola virus infection. It has been administered under compassionate use to two Ebola patients, both of whom survived, and is currently in Phase 2 clinical development for treatment of Ebola virus disease. Here we report the antiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, providing evidence to support new indications for this compound against human viruses of significant public health concern. C1 [Lo, Michael K.; Shrivastava-Ranjan, Punya; Hotard, Anne L.; Flint, Mike; McMullan, Laura K.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Jordan, Robert; Arvey, Aaron; Sudhamsu, Jawahar; Siegel, Dustin; Clarke, Michael O.; Mackman, Richard L.; Hui, Hon C.; Perron, Michel; Ray, Adrian S.; Cihlar, Tomas] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. RP Lo, MK; Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM mko2@cdc.gov; ccs8@cdc.gov FU American Society for Microbiology Postdoctoral Fellowship; CDC FX We would like to thank Linda J. Rennick and W. Paul Duprex for the rMVEZGFP(3), Paul A. Rota for the MV-EZ, Donald R. Latner for the MuV, Eric Bergeron for the recombinant CCHFV, and Mark E. Peeples and Peter L. Collins for the rgRSV224. Anne L. Hotard is supported by an American Society for Microbiology Postdoctoral Fellowship. This work was funded by CDC core funding. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. NR 32 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAR 6 PY 2017 VL 7 AR 43395 DI 10.1038/srep43395 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EM6IL UT WOS:000395416000001 PM 28262699 ER PT J AU White, A Thom, TD White, MC Geiger, AM AF White, Arica Thom, Trevor D. White, Mary C. Geiger, Ann M. TI Cancer Screening Test Use - United States, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID ALASKA NATIVE WOMEN; BREAST C1 [White, Arica; Thom, Trevor D.; White, Mary C.] CDC, Div Canc Prevent & Control, Bethesda, MD 20889 USA. [Geiger, Ann M.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. RP White, A (reprint author), CDC, Div Canc Prevent & Control, Bethesda, MD 20889 USA. EM awhite5@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 3 PY 2017 VL 66 IS 8 BP 1 EP 6 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4GL UT WOS:000395965900001 ER PT J AU Shockey, TM Wheaton, AG AF Shockey, Taylor M. Wheaton, Anne G. TI Short Sleep Duration by Occupation Group-29 States, 2013-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTH INTERVIEW SURVEY; UNITED-STATES; PREVALENCE; WORKERS C1 [Shockey, Taylor M.] CDC, Natl Inst Occupat Safety & Hlth, Div Surveillance, Hazard Evaluat & Field Studies, Atlanta, GA 30333 USA. [Wheaton, Anne G.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. RP Shockey, TM (reprint author), CDC, Natl Inst Occupat Safety & Hlth, Div Surveillance, Hazard Evaluat & Field Studies, Atlanta, GA 30333 USA. EM tshockey@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 3 PY 2017 VL 66 IS 8 BP 7 EP 13 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4GL UT WOS:000395965900002 ER PT J AU Mazurek, JM Syamlal, G Wood, JM Hendricks, SA Weston, A AF Mazurek, Jacek M. Syamlal, Girija Wood, John M. Hendricks, Scott A. Weston, Ainsley TI Malignant Mesothelioma Mortality - United States, 1999-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ASBESTOS EXPOSURES C1 [Mazurek, Jacek M.; Syamlal, Girija; Wood, John M.; Weston, Ainsley] CDC, Natl Inst Occupat Safety & Hlth, Respiratory Hlth Div, Atlanta, GA 30333 USA. [Hendricks, Scott A.] CDC, Natl Inst Occupat Safety & Hlth, Div Safety Res, Atlanta, GA 30333 USA. RP Mazurek, JM (reprint author), CDC, Natl Inst Occupat Safety & Hlth, Respiratory Hlth Div, Atlanta, GA 30333 USA. EM jmazurek1@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 3 PY 2017 VL 66 IS 8 BP 14 EP 18 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4GL UT WOS:000395965900003 ER PT J AU Cragan, JD Mai, CT Petersen, EE Liberman, RF Forestieri, NE Stevens, AC Delaney, A Dawson, AL Ellington, SR Shapiro-Mendoza, CK Dunn, JE Higgins, CA Meyer, RE Williams, T Polen, KND Newsome, K Reynolds, M Isenburg, J Gilboa, SM Meaney-Delman, DM Moore, CA Boyle, CA Honein, MA AF Cragan, Janet D. Mai, Cara T. Petersen, Emily E. Liberman, Rebecca F. Forestieri, Nina E. Stevens, Alissa C. Delaney, Augustina Dawson, April L. Ellington, Sascha R. Shapiro-Mendoza, Carrie K. Dunn, Julie E. Higgins, Cathleen A. Meyer, Robert E. Williams, Tonya Polen, Kara N. D. Newsome, Kim Reynolds, Megan Isenburg, Jennifer Gilboa, Suzanne M. Meaney-Delman, Dana M. Moore, Cynthia A. Boyle, Coleen A. Honein, Margaret A. TI Baseline Prevalence of Birth Defects Associated with Congenital Zika Virus Infection - Massachusetts, North Carolina, and Atlanta, Georgia, 2013-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Cragan, Janet D.; Mai, Cara T.; Delaney, Augustina; Dawson, April L.; Polen, Kara N. D.; Newsome, Kim; Reynolds, Megan; Isenburg, Jennifer; Gilboa, Suzanne M.; Moore, Cynthia A.; Honein, Margaret A.] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Congenital & Dev Disorders, Atlanta, GA 30333 USA. [Petersen, Emily E.; Ellington, Sascha R.; Shapiro-Mendoza, Carrie K.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Liberman, Rebecca F.; Dunn, Julie E.; Higgins, Cathleen A.] Ctr Birth Defects Res & Prevent, Massachusetts Dept Publ Hlth, Boston, MA USA. [Forestieri, Nina E.] North Carolina Dept Hlth & Human Serv, Birth Defects Monitoring Program, Raleigh, NC USA. [Stevens, Alissa C.; Williams, Tonya] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Meaney-Delman, Dana M.] CDC, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA. [Boyle, Coleen A.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Cragan, JD (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, Div Congenital & Dev Disorders, Atlanta, GA 30333 USA. EM eocbirthdef@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 3 PY 2017 VL 66 IS 8 BP 19 EP 22 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4GL UT WOS:000395965900004 ER PT J AU Santos, C Kieszak, S Wang, A Law, R Schier, J Wolkin, A AF Santos, Cynthia Kieszak, Stephanie Wang, Alice Law, Royal Schier, Joshua Wolkin, Amy TI Reported Adverse Health Effects in Children from Ingestion of Alcohol-Based Hand Sanitizers - United States, 2011-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PEDIATRIC INGESTIONS; ETHANOL C1 [Santos, Cynthia; Kieszak, Stephanie; Wang, Alice; Law, Royal; Schier, Joshua] CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA. [Santos, Cynthia; Schier, Joshua] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [Wolkin, Amy] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP Santos, C (reprint author), CDC, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30333 USA.; Santos, C (reprint author), Emory Univ, Sch Med, Atlanta, GA 30322 USA. EM krx8@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 3 PY 2017 VL 66 IS 8 BP 23 EP 26 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4GL UT WOS:000395965900005 ER PT J AU Mbaeyi, C Ryan, MJ Smith, P Mahamud, A Farag, N Haithami, S Sharaf, M Jorba, JC Ehrhardt, D AF Mbaeyi, Chukwuma Ryan, Michael J. Smith, Philip Mahamud, Abdirahman Farag, Noha Haithami, Salah Sharaf, Magdi Jorba, Jaume C. Ehrhardt, Derek TI Response to a Large Polio Outbreak in a Setting of Conflict - Middle East, 2013-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ERADICATION; SYRIA; WORLDWIDE; PROGRESS C1 [Mbaeyi, Chukwuma; Farag, Noha; Ehrhardt, Derek] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. [Ryan, Michael J.; Smith, Philip; Mahamud, Abdirahman; Haithami, Salah; Sharaf, Magdi] World Hlth Org, Polio Eradicat Dept, Geneva, Switzerland. [Jorba, Jaume C.] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Mbaeyi, C (reprint author), CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. EM cmbaeyi@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAR 3 PY 2017 VL 66 IS 8 BP 27 EP 31 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4GL UT WOS:000395965900006 ER PT J AU Peters, T Bertrand, S Bjorkman, JT Brandal, LT Brown, DJ Erdosi, T Heck, M Ibrahem, S Johansson, K Kornschober, C Kotila, SM Le Hello, S Lienemann, T Mattheus, W Nielsen, EM Ragimbeau, C Rumore, J Sabol, A Torpdahl, M Trees, E Tuohy, A de Pinna, E AF Peters, T. Bertrand, S. Bjorkman, J. T. Brandal, L. T. Brown, D. J. Erdosi, T. Heck, M. Ibrahem, S. Johansson, K. Kornschober, C. Kotila, S. M. Le Hello, S. Lienemann, T. Mattheus, W. Nielsen, E. M. Ragimbeau, C. Rumore, J. Sabol, A. Torpdahl, M. Trees, E. Tuohy, A. de Pinna, E. TI Multi-laboratory validation study of multilocus variablenumber tandem repeat analysis (MLVA) for Salmonella enterica serovar Enteritidis, 2015 SO EUROSURVEILLANCE LA English DT Article ID SEROTYPE ENTERITIDIS; VNTR LOCI; TYPHIMURIUM; OUTBREAK; ELECTROPHORESIS; DENMARK AB Multilocus variable-number tandem repeat analysis (MLVA) is a rapid and reproducible typing method that is an important tool for investigation, as well as detection, of national and multinational outbreaks of a range of food-borne pathogens. Salmonella enterica serovar Enteritidis is the most common Salmonella serovar associated with human salmonellosis in the European Union/European Economic Area and North America. Fourteen laboratories from 13 countries in Europe and North America participated in a validation study for MLVA of S. Enteritidis targeting five loci. Following normalisation of fragment sizes using a set of reference strains, a blinded set of 24 strains with known allele sizes was analysed by each participant. The S. Enteritidis 5-loci MLVA protocol was shown to produce internationally comparable results as more than 90% of the participants reported less than 5% discrepant MLVA profiles. All 14 participating laboratories performed well, even those where experience with this typing method was limited. The raw fragment length data were consistent throughout, and the interlaboratory validation helped to standardise the conversion of raw data to repeat numbers with at least two countries updating their internal procedures. However, differences in assigned MLVA profiles remain between well-established protocols and should be taken into account when exchanging data. C1 [Peters, T.; de Pinna, E.] Publ Hlth England, London, England. [Bertrand, S.; Mattheus, W.] Sci Inst Publ Hlth, Brussels, Belgium. [Bjorkman, J. T.; Nielsen, E. M.; Torpdahl, M.] Statens Serum Inst, Copenhagen, Denmark. [Brandal, L. T.] Norwegian Inst Publ Hlth, Oslo, Norway. [Brown, D. J.] Scottish Microbiol Reference Labs, Glasgow, Lanark, Scotland. [Erdosi, T.] Natl Ctr Epidemiol, Budapest, Hungary. [Heck, M.] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands. [Ibrahem, S.; Lienemann, T.] Natl Inst Hlth & Welf, Helsinki, Finland. [Johansson, K.; Kotila, S. M.] European Ctr Dis Prevent & Control ECDC, Solna, Sweden. [Kornschober, C.] Austrian Agcy Hlth & Food Safety, Graz, Austria. [Le Hello, S.] Inst Pasteur, Paris, France. [Ragimbeau, C.] Lab Natl Sante, Dudelange, Luxembourg. [Rumore, J.] Publ Hlth Agcy Canada, Winnipeg, MB, Canada. [Sabol, A.; Trees, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tuohy, A.] Univ Hosp Galway, Galway, Ireland. RP Kotila, SM (reprint author), European Ctr Dis Prevent & Control ECDC, Solna, Sweden. EM saara.kotila@ecdc.europa.eu FU European Centre for Disease Prevention and Control FX The shipment of the S. Enteritidis strains to the participating laboratories and the coordination of the study were funded by the European Centre for Disease Prevention and Control. The cost for performing the MLVA analyses was covered by each participating laboratory for their part. NR 27 TC 0 Z9 0 U1 0 U2 0 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD MAR 2 PY 2017 VL 22 IS 9 BP 13 EP 20 DI 10.2807/1560-7917.ES.2017.22.9.30477 PG 8 WC Infectious Diseases SC Infectious Diseases GA EN2CD UT WOS:000395816100002 ER PT J AU Rebeiro, PF Abraham, AG Horberg, MA Althoff, KN Yehia, BR Buchacz, K Lau, BM Sterling, TR Gange, SJ AF Rebeiro, Peter F. Abraham, Alison G. Horberg, Michael A. Althoff, Keri N. Yehia, Baligh R. Buchacz, Kate Lau, Bryan M. Sterling, Timothy R. Gange, Stephen J. CA North Amer AIDS Cohort TI Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada SO AIDS PATIENT CARE AND STDS LA English DT Article DE discontinuity; injection drug use; NA-ACCORD; racial; retention; sex; disparity ID INVERSE PROBABILITY WEIGHTS; MARGINAL STRUCTURAL MODELS; DEPARTMENT-OF-HEALTH; INFECTED PERSONS; CLINICAL COHORT; MISSED VISITS; AIDS RESEARCH; FOLLOW-UP; RETENTION; US AB Disruption of continuous retention in care (discontinuity) is associated with HIV disease progression. We examined sex, race, and HIV risk disparities in discontinuity after antiretroviral therapy (ART) initiation among patients in North America. Adults (>= 18 years of age) initiating ART from 2000 to 2010 were included. Discontinuity was defined as first disruption of continuous retention (>= 2 visits separated by > 90 days in the calendar year). Relative hazard ratio (HR) and times from ART initiation until discontinuity by race, sex, and HIV risk were assessed by modeling of the cumulative incidence function (CIF) in the presence of the competing risk of death. Models were adjusted for cohort site, baseline age, and CD4(+) cell count within 1 year before ART initiation; nadir CD4(+) cell count after ART, but before a study event, was assessed as a mediator. Among 17,171 adults initiating ART, median follow-up time was 3.97 years, and 49% were observed to have >= 1 discontinuity of care. In adjusted regression models, the hazard of discontinuity for patients was lower for females versus males [HR: 0.84; 95% confidence interval (CI): 0.79-0.89] and higher for blacks versus non-blacks (HR: 1.17; 95% CI: 1.12-1.23) and persons with injection drug use (IDU) versus non-IDU risk (HR: 1.33; 95% CI: 1.25-1.41). Sex, racial, and HIV risk differences in clinical retention exist, even accounting for access to care and known competing risks for discontinuity. These results point to vulnerable populations at greatest risk for discontinuity in need of improved outreach to prevent disruptions of HIV care. C1 [Rebeiro, Peter F.; Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, 1161 21st Ave South,A-2200 Med Ctr North, Nashville, TN 37212 USA. [Abraham, Alison G.; Althoff, Keri N.; Lau, Bryan M.; Gange, Stephen J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Horberg, Michael A.] Kaiser Permanente Midatlantic States, Midatlantic Permanente Res Inst, Rockville, MD USA. [Yehia, Baligh R.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Buchacz, Kate] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Rebeiro, PF (reprint author), Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, 1161 21st Ave South,A-2200 Med Ctr North, Nashville, TN 37212 USA. EM p.rebeiro@vanderbilt.edu FU National Institutes of Health [U01AI069918, F31DA037788, G12MD007583, K01A1093197, K23EY013707, K24AI065 298, K24AI118591, K24DA000432, KL2TR000421, M01RR 000052]; Centers for Disease Control and Prevention, United States [CDC-200-2006-18797, CDC-200-2015-63931]; Agency for Healthcare Research and Quality, United States [90047713]; Health Resources and Services Administration, United States [90051652]; Canadian Institutes of Health Research, Canada [CBR-86906, CBR-94036, HCP-97105, TGF-96118]; Ontario Ministry of Health and Long-Term Care; Government of Alberta, Canada; National Cancer Institute; National Institute for Mental Health; National Institute on Drug Abuse FX The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was supported by National Institutes of Health grants U01AI069918, F31DA037788, G12MD007583, K01A1093197, K23EY013707, K24AI065 298, K24AI118591, K24DA000432, KL2TR000421, M01RR 000052, N01CP01004, NO2CP055504, NO2CP91027, P30AI0 27757, P30AI027763, P30AI027767, P30AI036219, P30AI05 0410, P30AI094189, P30AI110527, P30MH62246, R01AA01 6893, R01CA165937, RO1DA011602, R01DA012568, R24AI 067039, U01AA013566, U01AA020790, U01 AI031834, U01 AI034989, U01AI034993, U01AI034994, U01 AI035004, U01 AI035039, U01A1035040, U01A1035041, U01 AI035042, U01AI037613, U01AI037984, U01AI038855, U01AI038858, U01AI042590, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01AI103390, U01AI103397, U01AI103401, U01 AI103408, U01DA03629, U01DA036935, U01HD03 2632, U10EY008057, U10EY008052, U10EY008067, U24A A020794, U54MD007587, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR000454, UM1AI035043, Z01CP0102 14, and Z01CP010176; contracts CDC-200-2006-18797 and CDC-200-2015-63931 from the Centers for Disease Control and Prevention, United States; contract 90047713 from the Agency for Healthcare Research and Quality, United States; contract 90051652 from the Health Resources and Services Administration, United States; grants CBR-86906, CBR-94036, HCP-97105, and TGF-96118 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long-Term Care; and the Government of Alberta, Canada. Additional support was provided by the National Cancer Institute, National Institute for Mental Health, and National Institute on Drug Abuse. The authors would like to thank all collaborators, staff, and participants of the NA-ACCORD, particularly those cohorts contributing data to these analyses: NR 46 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 EI 1557-7449 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD MAR PY 2017 VL 31 IS 3 BP 129 EP 144 DI 10.1089/apc.2016.0178 PG 16 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EN4PB UT WOS:000395988300004 PM 28282246 ER PT J AU Diallo, K Modi, S Hurlston, M Beard, RS Nkengasong, JN AF Diallo, Karidia Modi, Surbhi Hurlston, Mackenzie Beard, R. Suzanne Nkengasong, John N. TI A Proposed Framework for the Implementation of Early Infant Diagnosis Point-of-Care SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article DE HIV; point-of-care; early infant diagnosis; near point-of-care ID DRIED BLOOD SPOTS; TO-CHILD TRANSMISSION; RESOURCE-LIMITED SETTINGS; HIV-INFECTED CHILDREN; HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; MIDDLE-INCOME COUNTRIES; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; CONTROLLED-TRIAL AB Early diagnosis of HIV infection in infants and children remains a challenge in resource-limited settings, with approximately half of all HIV-exposed infants receiving virological testing for HIV by the recommended age of 2 months in 2015. To reduce morbidity and mortality among HIV-infected children and close the treatment gap for HIV-infected children, there is an urgent need to evaluate existing programmatic and laboratory practices for early infant diagnosis and introduce strategies to improve identification of HIV-exposed infants and ensure access to systematic, early HIV testing, with early linkage to treatment for HIV-infected infants. This article describes progress made in follow-up of HIV-exposed infants since 2006, including remaining unmet laboratory and programmatic needs, and recommends strategies for improvement, especially those related to the implementation of point-of-care technology for early infant diagnosis. C1 [Diallo, Karidia; Hurlston, Mackenzie; Beard, R. Suzanne; Nkengasong, John N.] Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV & TB, Mail Stop G-45,1600 Clifton Rd NE, Atlanta, GA 30333 USA. [Modi, Surbhi] Ctr Dis Control & Prevent, Maternal & Child Hlth Branch, Div Global HIV & TB, Atlanta, GA, Rep of Georgia. RP Diallo, K (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global HIV & TB, Mail Stop G-45,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM edu9@cdc.gov FU PEPFAR through the Centers for Disease Control and Prevention (CDC) FX This report has been supported by the PEPFAR through the Centers for Disease Control and Prevention (CDC). NR 55 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 EI 1931-8405 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD MAR PY 2017 VL 33 IS 3 BP 203 EP 210 DI 10.1089/aid.2016.0021 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA EM8HX UT WOS:000395553200001 PM 27758117 ER PT J AU Vaidya, N Thota, AB Proia, KK Jamieson, S Mercer, SL Elder, RW Yoon, P Kaufmann, R Zaza, S AF Vaidya, Namita Thota, Anilkrishna B. Proia, Krista K. Jamieson, Sara Mercer, Shawna L. Elder, Randy W. Yoon, Paula Kaufmann, Rachel Zaza, Stephanie TI Practice-Based Evidence in Community Guide Systematic Reviews SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID PUBLIC-HEALTH; PSYCHOLOGICAL THERAPIES; PREVENTIVE-SERVICES; DECISION-MAKING; CLINICAL-TRIALS; TRANSLATION; INTERVENTIONS; PSYCHOTHERAPY; PROMOTION; FRAMEWORK AB Objectives. To assess the relative contributions and quality of practice-based evidence (PBE) and research-based evidence (RBE) in The Guide to Community Preventive Services (The Community Guide). Methods. We developed operational definitions for PBE and RBE in which the main distinguishing feature was whether allocation of participants to intervention and comparison conditions was under the control of researchers (RBE) or not (PBE). We conceptualized a continuum between RBE and PBE. Wethen categorized 3656 studies in 202 reviews completed since The Community Guide began in 1996. Results. Fifty-four percent of studies were PBE and 46% RBE. Community-based and policy reviews had more PBE. Health care system and programmatic reviews had more RBE. The majority of both PBE and RBE studies were of high quality according to Community Guide scoring methods. Conclusions. The inclusion of substantial PBE in Community Guide reviews suggests that evidence of adequate rigor to inform practice is being produced. This should increase stakeholders' confidence that The Community Guide provides recommendations with real-world relevance. Limitations in some PBE studies suggest a need for strengthening practice-relevant designs and external validity reporting standards. C1 [Vaidya, Namita; Thota, Anilkrishna B.; Proia, Krista K.; Mercer, Shawna L.; Elder, Randy W.] CSELS, Community Guide Branch, Div Publ Hlth Informat Disseminat, Atlanta, GA USA. [Jamieson, Sara] Ctr Dis Control & Prevent CDC, Off Planning Evaluat & Legislat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Yoon, Paula] CSELS, Div Hlth Informat & Surveillance, Atlanta, GA USA. [Kaufmann, Rachel] CSELS, Atlanta, GA USA. [Zaza, Stephanie] CDC, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Mercer, SL (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Publ Hlth Informat Disseminat, Ctr Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd NE,Mailstop E-69, Atlanta, GA 30333 USA. EM smercer@cdc.gov FU Oak Ridge Institute for Science and Education FX The work of K. K. Proia and N. Vaidya was supported with funds from the Oak Ridge Institute for Science and Education. NR 37 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2017 VL 107 IS 3 BP 413 EP 420 DI 10.2105/AJPH.2016.303583 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO9YV UT WOS:000397044900025 PM 28103066 ER PT J AU Jones, CM Baldwin, GT Compton, WM AF Jones, Christopher McCall Baldwin, Grant T. Compton, Wilson M. TI Recent Increases in Cocaine-Related Overdose Deaths and the Role of Opioids SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; BRITISH-COLUMBIA; CANADA AB Objectives. To assess trends in cocaine overdose deaths and examine the role opioids play in these deaths. Methods. We used data on drug overdose deaths in the United States from 2000 to 2015 collected in the National Vital Statistics System to calculate annual rates and numbers of cocaine-related overdose deaths overall and deaths both involving and not involving opioids. We assessed statistically significant changes in trends with joinpoint regression. Results. Rates of cocaine-related overdose deaths increased significantly from 1.26 to 2.50 per 100 000 population from 2000 to 2006, declined to 1.35 in 2010, and increased to 2.13 in 2015. Cocaine-related overdose deaths involving opioids increased from 0.37 to 0.91 from 2000 to 2006, declined to 0.57 in 2010, and then increased to 1.36 in 2015. Cocaine-related overdose deaths not involving opioids increased from 0.89 to 1.59 from 2000 to 2006 and then declined to 0.78 in 2015. Conclusions. Opioids, primarily heroin and synthetic opioids, have been driving the recent increase in cocaine-related overdose deaths. This corresponds to the growing supply and use of heroin and illicitly manufactured fentanyl in the United States. C1 [Jones, Christopher McCall] US Dept HHS, Div Sci Policy, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA. [Baldwin, Grant T.] Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA. [Compton, Wilson M.] NIDA, NIH, Rockville, MD USA. RP Jones, CM (reprint author), 200 Independence Ave SW, Washington, DC 20201 USA. EM christopher.jones@hhs.gov NR 13 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAR PY 2017 VL 107 IS 3 BP 430 EP 432 DI 10.2105/AJPH.2016.303627 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO9YV UT WOS:000397044900028 ER PT J AU Murphy, LB Cisternas, MG Greenlund, KJ Giles, W Hannan, C Helmick, CG AF Murphy, Louise B. Cisternas, Miriam G. Greenlund, Kurt J. Giles, Wayne Hannan, Casey Helmick, Charles G. TI Defining Arthritis for Public Health Surveillance: Methods and Estimates in Four US Population Health Surveys SO ARTHRITIS CARE & RESEARCH LA English DT Article ID MEDICAL-CARE EXPENDITURES; RHEUMATIC CONDITIONS; UNITED-STATES; EARNINGS LOSSES; PREVALENCE; DISEASES; IMPACT AB Objective: To determine the variability of arthritis prevalence in 4 US population health surveys. Methods: We estimated annualized arthritis prevalence in 2011-2012, among adults age 20 years, using 2 definition methods, both based on self-report: 1) doctor-/health care provider-diagnosed arthritis in the Behavioral Risk Factor Surveillance Survey (BRFSS), National Health and Nutrition Examination Survey (NHANES), National Health Interview Survey (NHIS), and Medical Expenditure Panel Survey (MEPS); and 2) three arthritis definitions based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) criteria in MEPS (National Arthritis Data Workgroup on Arthritis and Other Rheumatic Conditions [NADW-AORC], Clinical Classifications Software [CCS], and Centers for Disease Control and Prevention [CDC]). Results: Diagnosed arthritis prevalence percentages using the surveys were within 3 points of one another (BRFSS 26.2% [99% confidence interval (99% CI) 26.0-26.4], MEPS 26.1% [99% CI 25.0-27.2], NHIS 23.5% [99% CI 22.9-24.1], NHANES 23.0% [99% CI 19.2-26.8]), and those using ICD-9-CM were within 5 percentage points of one another (CCS 25.8% [99% CI 24.6-27.1]; CDC 28.3% [99% CI 27.0-29.6]; and NADW-AORC 30.7% [99% CI 29.4-32.1]). The variation in the estimated number (in millions) affected with diagnosed arthritis was 7.8 (BRFSS 58.5 [99% CI 58.1-59.1], MEPS 59.3 [99% CI 55.6-63.1], NHANES 51.5 [99% CI 37.2-65.5], and NHIS 52.6 [99% CI 50.9-54.4]), and using ICD-9-CM definitions it was 11.1 (CCS 58.7 [99% CI 54.5-62.9], CDC 64.3 [99% CI 59.9-68.6], and NADW 69.9 [99% CI 65.2-74.5]). Most (57-70%) reporting diagnosed arthritis also reported ICD-9-CM arthritis; respondents reporting diagnosed arthritis were older than those meeting ICD-9-CM definitions. Proxy response status affected arthritis prevalence differently across surveys. Conclusion: Public health practitioners and decision makers are frequently charged with choosing a single number to represent arthritis prevalence in the US population. We encourage them to consider the surveys' purpose, design, measurement methods, and statistical precision when choosing an estimate. C1 [Murphy, Louise B.; Greenlund, Kurt J.; Giles, Wayne; Hannan, Casey; Helmick, Charles G.] Ctr Dis Control & Prevent, 4770 Buford Highway NorthEast,Mailstop F-48, Atlanta, GA 30341 USA. [Cisternas, Miriam G.] MGC Data Serv, Carlsbad, CA USA. RP Murphy, LB (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NorthEast,Mailstop F-48, Atlanta, GA 30341 USA. EM alx2@cdc.gov NR 43 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAR PY 2017 VL 69 IS 3 BP 356 EP 367 DI 10.1002/acr.22943 PG 12 WC Rheumatology SC Rheumatology GA EM0DK UT WOS:000394988800006 PM 27214851 ER PT J AU Barbour, KE Helmick, CG Boring, M Qin, J Pan, LP Hootman, JM AF Barbour, Kamil E. Helmick, Charles G. Boring, Michael Qin, Jin Pan, Liping Hootman, Jennifer M. TI Obesity Trends Among US Adults With Doctor-Diagnosed Arthritis 2009-2014 SO ARTHRITIS CARE & RESEARCH LA English DT Article ID KNEE OSTEOARTHRITIS; OLDER-ADULTS; WEIGHT-LOSS; UNITED-STATES; PREVALENCE; EXERCISE; HEALTH; METAANALYSIS; POPULATION; OVERWEIGHT AB Objective: Arthritis and obesity are common co-occurring conditions that can increase disability and the risk of adverse outcomes (e.g., total knee replacement). Methods: We estimated recent obesity trends among adults with arthritis from 2009 to 2014, overall and by various sociodemographic and health characteristics using data from National Health Interview Survey, an ongoing, nationally representative, in-person household self-reported survey of the noninstitutionalized civilian US. A secondary aim was to examine the distribution of body mass index categories among adults with and without arthritis. Results: Obesity prevalence did not change significantly over time among middle-aged and younger adults with doctor-diagnosed arthritis either overall (P=0.925 for both groups) or by demographic and health characteristics. Among older adults with doctor-diagnosed arthritis, the unadjusted obesity prevalence was 29.4% in 2009 and 34.3% in 2014; after adjusting for all demographic and health characteristics, there was a significant relative increase in obesity prevalence (15% [95% confidence interval 6-25]) and over time (P=0.001). The age-standardized prevalence of obesity and the obesity subclasses I, II, and III among adults with doctor-diagnosed arthritis (compared with adults without doctor-diagnosed arthritis) was 40.3% versus 26.3%, 20.1% versus 16.4%, 10.4% versus 6.2%, and 9.8% versus 3.6%, respectively (P < 0.001 for all 4 comparisons). Conclusion: Obesity increased significantly over time among older adults with arthritis and remains high when compared with adults without arthritis. A greater dissemination of interventions focused on physical activity and diet are needed in order to reduce adverse outcomes associated with obesity and arthritis. C1 [Barbour, Kamil E.; Helmick, Charles G.; Boring, Michael; Qin, Jin; Pan, Liping; Hootman, Jennifer M.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Barbour, KE (reprint author), 4770 Buford Highway, Atlanta, GA 30341 USA. EM iyk1@cdc.gov NR 35 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAR PY 2017 VL 69 IS 3 BP 376 EP 383 DI 10.1002/acr.22958 PG 8 WC Rheumatology SC Rheumatology GA EM0DK UT WOS:000394988800008 PM 27332971 ER PT J AU Jain, S AF Jain, Seema TI Epidemiology of Viral Pneumonia SO CLINICS IN CHEST MEDICINE LA English DT Article DE Respiratory viruses; Pneumonia; Epidemiology ID COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; SYNCYTIAL VIRUS-INFECTION; INFLUENZA-A H1N1; REQUIRING HOSPITALIZATION; RESPIRATORY VIRUSES; YOUNG-CHILDREN; HONG-KONG; ADULTS; ETIOLOGY AB The burden of pneumonia, including that due to respiratory viruses, is markedly higher in the very young (<5 years) and older adults (>= 50 years). Respiratory viruses substantially contribute to pneumonia in both adults and children, and when systematically tested for, are more commonly detected than bacteria in both adults and children. It is difficult to distinguish between viruses by clinical presentation, and the exact clinical implication of viral detections among patients with pneumonia depends on the pathogen detected; however, there is increasing evidence of their importance in pneumonia. C1 [Jain, Seema] Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA. RP Jain, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM bwc8@cdc.gov NR 52 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-5231 EI 1557-8216 J9 CLIN CHEST MED JI Clin. Chest Med. PD MAR PY 2017 VL 38 IS 1 BP 1 EP + DI 10.1016/j.ccm.2016.11.012 PG 10 WC Respiratory System SC Respiratory System GA EO0KQ UT WOS:000396387100002 PM 28159152 ER PT J AU Ewing, AC Kottke, MJ Kraft, JM Sales, JM Brown, JL Goedken, P Wiener, J Kourtis, AP AF Ewing, Alexander C. Kottke, Melissa J. Kraft, Joan Marie Sales, Jessica M. Brown, Jennifer L. Goedken, Peggy Wiener, Jeffrey Kourtis, Athena P. TI 2GETHER-The Dual Protection Project: Design and rationale of a randomized controlled trial to increase dual protection strategy selection and adherence among African American adolescent females SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Contraception; Reproductive health; Unintended pregnancy; Sexually transmitted infections; Adolescents; Dual protection ID REVERSIBLE CONTRACEPTIVE METHODS; SEXUALLY-TRANSMITTED INFECTIONS; UNITED-STATES; CHLAMYDIA-TRACHOMATIS; RISK-FACTORS; FOLLOW-UP; WOMEN; CONDOMS; PREVALENCE; PREGNANCY AB Background: African American adolescent females are at elevated risk for unintended pregnancy and sexually transmitted infections (STIs). Dual protection (DP) is defined as concurrent prevention of pregnancy and STIs. This can be achieved by abstinence, consistent condom use, or the dual methods of condoms plus an effective non-barrier contraceptive. Previous clinic-based interventions showed short-term effects on increasing dual method use, but evidence of sustained effects on dual method use and decreased incident pregnancies and STIs are lacking. Methods/design: This manuscript describes the 2GETHER Project. 2GETHER is a randomized controlled trial of a multi-component intervention to increase dual protection use among sexually active African American females aged 14-19 years not desiring pregnancy at a Title X clinic in Atlanta, GA. The intervention is clinic-based and includes a culturally tailored interactive multimedia component and counseling sessions, both to assist in selection of a DP method and to reinforce use of the DP method. The participants are randomized to the study intervention or the standard of care, and followed for 12 months to evaluate how the intervention influences DP method selection and adherence, pregnancy and STI incidence, and participants' DP knowledge, intentions, and self-efficacy. Discussion: The 2GETHER Project is a novel trial to reduce unintended pregnancies and STIs among African American adolescents. The intervention is unique in the comprehensive and complementary nature of its components and its individual tailoring of provider-patient interaction. If the trial interventions are shown to be effective, then it will be reasonable to assess their scalability and applicability in other populations. C1 [Ewing, Alexander C.; Kraft, Joan Marie; Wiener, Jeffrey; Kourtis, Athena P.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, MS-F74, Atlanta, GA 30341 USA. [Kottke, Melissa J.; Goedken, Peggy] Emory Univ, Sch Med, Dept Gynecol & Obstet, Jane Fonda Ctr, Atlanta, GA USA. [Sales, Jessica M.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA USA. [Brown, Jennifer L.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Addict Sci Div, Cincinnati, OH USA. RP Ewing, AC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, MS-F74, Atlanta, GA 30341 USA. EM yhy4@cdc.gov NR 56 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2017 VL 54 BP 1 EP 7 DI 10.1016/j.cct.2016.12.014 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EL3YV UT WOS:000394557500001 PM 28007634 ER PT J AU Ford, N Meintjes, G Vitoria, M Greene, G Chiller, T AF Ford, Nathan Meintjes, Graeme Vitoria, Marco Greene, Greg Chiller, Tom TI The evolving role of CD4 cell counts in HIV care SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE advanced HIV disease; antiretroviral therapy; CD4 cell count; treatment monitoring; viral load ID SUB-SAHARAN AFRICA; COMBINATION ANTIRETROVIRAL THERAPY; COST-EFFECTIVENESS; VIRAL LOAD; TREATMENT INTERRUPTION; INCOME COUNTRIES; SOUTH-AFRICA; SCALE-UP; METAANALYSIS; ADULTS AB Purpose of reviewThe role of the CD4 cell count in the management of people living with HIV is once again changing, most notably with a shift away from using CD4 assays to decide when to start antiretroviral therapy (ART). This article reflects on the past, current and future role of CD4 cell count testing in HIV programmes, and the implications for clinicians, programme managers and diagnostics manufacturers.Recent findingsFollowing the results of recent randomized trials demonstrating the clinical and public health benefits of starting ART as soon as possible after HIV diagnosis is confirmed, CD4 cell count is no longer recommended as a way to decide when to initiate ART. For patients stable on ART, CD4 cell counts are no longer needed to monitor the response to treatment where HIV viral load testing is available. Nevertheless CD4 remains the best measurement of a patient's immune and clinical status, the risk of opportunistic infections, and supports diagnostic decision-making, particularly for patients with advanced HIV disease.SummaryAs countries revise guidelines to provide ART to all people living with HIV and continue to scale up access to viral load, strategic choices will need to be made regarding future investments in CD4 cell count and the appropriate use for clinical disease management. C1 [Ford, Nathan; Vitoria, Marco] WHO, Dept HIV & Global Hepatitis Programme, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. [Meintjes, Graeme] Univ Cape Town, Dept Med, Div Infect Dis & HIV Med, Cape Town, South Africa. [Meintjes, Graeme] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, Cape Town, South Africa. [Greene, Greg; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Ford, N (reprint author), WHO, Dept HIV & Global Hepatitis Programme, 20 Ave Appia, CH-1211 Geneva 27, Switzerland. EM fordn@who.int NR 45 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD MAR PY 2017 VL 12 IS 2 BP 123 EP 128 DI 10.1097/COH.0000000000000348 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EM7WB UT WOS:000395521900005 PM 28059957 ER PT J AU Greene, G Sriruttan, C Le, T Chiller, T Govender, NP AF Greene, Greg Sriruttan, Charlotte Le, Thuy Chiller, Tom Govender, Nelesh P. TI Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE advanced HIV; cryptococcal antigen screening; cryptococcal meningitis; invasive fungal infections; rapid diagnostic tests ID LATERAL FLOW ASSAY; ANTIRETROVIRAL THERAPY; CEREBROSPINAL-FLUID; COST-EFFECTIVENESS; INFECTED PATIENTS; SOUTH-AFRICA; ANTIGEN; SERUM; MENINGITIS; PREVALENCE AB Purpose of reviewAs HIV treatment programmes scale up to meet the UNAIDS 90-90-90 goals, care must be taken to start antiretroviral treatment safely in patients with advanced disease (CD4 counts <200cells/l) who are simultaneously at risk for opportunistic infections and immune reconstitution inflammatory syndrome. Invasive fungal diseases pose a great threat at this critical time point, though the development of inexpensive and highly accurate rapid diagnostic tests has changed the approach HIV programmes are taking to reduce the high mortality associated with these opportunistic infections. This article summarizes recent advances and findings in fungal opportunistic infection diagnostics with a focus on screening to prevent cryptococcal meningitis.Recent findingsCryptococcal antigen (CrAg) screening using a lateral flow assay platform is cost-effective and feasible to implement as either a laboratory reflex or point-of-care test. Recent CrAg screening pilots have elucidated the varying prevalence of cryptococcal antigenemia across geographic regions, which may aid programme planning. Evidence from recently completed clinical trials provides a strong motivation for the use of CrAg titer to refine treatment options for patients with subclinical cryptococcal disease.SummaryAlthough several operational barriers to programme effectiveness still need to be addressed, the utility of CrAg screening using inexpensive and accurate antigen assays has been demonstrated in real-world HIV programmes, paving the way for development and testing of other fungal opportunistic infection screening strategies and for an integrated advanced HIV disease testing package to reduce AIDS mortality and ensure safe antiretroviral treatment initiation. C1 [Greene, Greg; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd NE,Mailstop C-09, Atlanta, GA 30329 USA. [Sriruttan, Charlotte; Govender, Nelesh P.] Univ Witwatersrand, Ctr Opportunist Trop & Hosp Infect, Natl Inst Communicable Dis, Johannesburg, South Africa. [Sriruttan, Charlotte; Govender, Nelesh P.] Univ Witwatersrand, Fac Hlth Sci, Clin Microbiol & Infect Dis Dept, Johannesburg, South Africa. [Le, Thuy] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam. [Le, Thuy] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England. [Le, Thuy] Univ Hawaii Manoa, Hawaii Ctr AIDS, Honolulu, HI 96822 USA. [Govender, Nelesh P.] Univ Cape Town, Fac Hlth Sci, Div Med Microbiol, Cape Town, South Africa. RP Greene, G (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, 1600 Clifton Rd NE,Mailstop C-09, Atlanta, GA 30329 USA. EM yio6@cdc.gov FU Medical Research Council [G1100682] NR 67 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD MAR PY 2017 VL 12 IS 2 BP 139 EP 147 DI 10.1097/COH.0000000000000347 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EM7WB UT WOS:000395521900007 PM 28134711 ER PT J AU Alemnji, G Onyebujoh, P Nkengasong, JN AF Alemnji, George Onyebujoh, Philip Nkengasong, John N. TI Improving laboratory efficiencies to scale-up HIV viral load testing SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE laboratory efficiency; viral load scale-up; viral suppression ID SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; QUALITY; DIAGNOSIS; ASSAY AB Purpose of reviewViral load measurement is a key indicator that determines patients' response to treatment and risk for disease progression. Efforts are ongoing in different countries to scale-up access to viral load testing to meet the Joint United Nations Programme on HIV and AIDS target of achieving 90% viral suppression among HIV-infected patients receiving antiretroviral therapy. However, the impact of these initiatives may be challenged by increased inefficiencies along the viral load testing spectrum. This will translate to increased costs and ineffectiveness of scale-up approaches. This review describes different parameters that could be addressed across the viral load testing spectrum aimed at improving efficiencies and utilizing test results for patient management.Recent findingsThough progress is being made in some countries to scale-up viral load, many others still face numerous challenges that may affect scale-up efficiencies: weak demand creation, ineffective supply chain management systems; poor specimen referral systems; inadequate data and quality management systems; and weak laboratory-clinical interface leading to diminished uptake of test results.SummaryIn scaling up access to viral load testing, there should be a renewed focus to address efficiencies across the entire spectrum, including factors related to access, uptake, and impact of test results. C1 [Alemnji, George; Nkengasong, John N.] Ctr Dis Control & Prevent CDC, Div Global HIV & TB, Atlanta, GA USA. [Alemnji, George] Global AIDS Coordinator & Hlth Diplomacy S GAC, State Dept Off, 1800 G St NW,Room 10300, Washington, DC 20006 USA. [Onyebujoh, Philip] WHO, Reg Off Africa Intercountry Support Team East & S, Harare, Zimbabwe. RP Alemnji, G (reprint author), Global AIDS Coordinator & Hlth Diplomacy S GAC, State Dept Off, 1800 G St NW,Room 10300, Washington, DC 20006 USA. EM ikv3@cdc.gov FU United States President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) FX Financial support been by the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC). NR 27 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD MAR PY 2017 VL 12 IS 2 BP 165 EP 170 DI 10.1097/COH.0000000000000346 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EM7WB UT WOS:000395521900010 PM 28059956 ER PT J AU Boeras, DI Nkengasong, JN Peeling, RW AF Boeras, Debrah I. Nkengasong, John N. Peeling, Rosanna W. TI Implementation science: the laboratory as a command centre SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE command centre; implementation science; laboratory ID HIV; PROGRAMS; QUALITY AB Purpose of reviewRecent advances in point-of-care technologies to ensure universal access to affordable quality-assured diagnostics have the potential to transform patient management, surveillance programmes, and control of infectious diseases. Decentralization of testing can put tremendous stresses on fragile health systems if the laboratory is not involved in the planning, introduction, and scale-up strategies.Recent findingsThe impact of investments in novel technologies can only be realized if these tests are evaluated, adopted, and scaled up within the healthcare system with appropriate planning and understanding of the local contexts in which these technologies will be used.SummaryIn this digital age, the laboratory needs to take on the role of the Command Centre for technology introduction and implementation. Implementation science is needed to understand the political, cultural, economic, and behavioural context for technology introduction. The new paradigm should include: building a comprehensive system of laboratories and point-of-care testing sites to provide quality-assured diagnostic services with good laboratory-clinic interface to build trust in test results and linkage to care; building and coordinating a comprehensive national surveillance and communication system for disease control and global health emergencies; conducting research to monitor the impact of new tools and interventions on improving patient care. C1 [Boeras, Debrah I.; Peeling, Rosanna W.] London Sch Hyg & Trop Med, Keppel St, London, England. [Nkengasong, John N.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Boeras, DI (reprint author), London Sch Hyg & Trop Med, Keppel St, London, England. EM rosanna.peeling@lshtm.ac.uk NR 20 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD MAR PY 2017 VL 12 IS 2 BP 171 EP 174 DI 10.1097/COH.0000000000000349 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EM7WB UT WOS:000395521900011 PM 28079592 ER PT J AU Herini, ES Gunadi Triono, A Mulyadi, AWE Mardin, N Rusipah Soenarto, Y Reef, SE AF Herini, Elisabeth Siti Gunadi Triono, Agung Mulyadi, Asal Wahyuni Erlin Mardin, Niprida Rusipah Soenarto, Yati Reef, Susan E. TI Hospital-based surveillance of congenital rubella syndrome in Indonesia SO EUROPEAN JOURNAL OF PEDIATRICS LA English DT Article DE Congenital rubella syndrome; Hospital-based surveillance; Vaccine; Immunization; Indonesia ID INFECTIONS; WOMEN AB Congenital rubella syndrome (CRS) has serious consequences, such as miscarriage, stillbirth, and severe birth defects in infants, resulting from rubella virus infection during pregnancy. However, rubella vaccine has not yet been implemented in Indonesia. This study aimed (1) to estimate the incidence of CRS in Indonesia, (2) describe the clinical features of CRS at our referral hospital, and (3) pilot a CRS surveillance system to be extended to other hospitals. We conducted a 4-month prospective surveillance study of infants aged < 1 year with suspected CRS in 2013 at an Indonesian hospital. Infants with suspected CRS were examined for rubella-specific IgM antibody or rubella IgG antibody levels. Of 47 suspected cases of CRS, 11/47 (23.4%), 9/47 (19.1%), and 27/47 (57.5%) were diagnosed as laboratory-confirmed, clinically compatible, and discarded CRS, respectively. The most common defects among laboratory-confirmed CRS cases were hearing impairment (100%), congenital cataracts (72.7%), microcephaly (72.7%), and congenital heart defects (45.5%). Conclusion: The number of laboratory-confirmed CRS cases among Indonesian infants is high. Furthermore, hearing impairment is the most common clinical feature of CRS in infants. Our findings indicate the importance of implementation of rubella vaccine in Indonesia. Conducting hospital-based surveillance of CRS in other hospitals in Indonesia may be appropriate. C1 [Herini, Elisabeth Siti; Triono, Agung; Soenarto, Yati] Univ Gadjah Mada, Dept Child Hlth, Fac Med, Dr Sardjito Hosp, Jl Kesehatan 1, Yogyakarta 55281, Indonesia. [Gunadi] Univ Gadjah Mada, Div Pediat Surg, Dr Sardjito Hosp, Dept Surg,Fac Med, Yogyakarta, Indonesia. [Mulyadi, Asal Wahyuni Erlin] Univ Gadjah Mada, Div Pediat Surg, Pediat Res Off, Fac Med,Dept Child Hlth, Yogyakarta, Indonesia. [Mardin, Niprida; Rusipah] WHO, Jakarta, Indonesia. [Reef, Susan E.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. RP Herini, ES (reprint author), Univ Gadjah Mada, Dept Child Hlth, Fac Med, Dr Sardjito Hosp, Jl Kesehatan 1, Yogyakarta 55281, Indonesia. EM herini_es@ugm.ac.id; drgunadi@ugm.ac.id; agungtrionodr@yahoo.com; asal_wahyuni@yahoo.com; mardinn@who.int; rusipah@who.int; yatisoenarto@yahoo.com; sreef@cdc.gov FU World Health Organization (WHO) FX The work was supported in part by a grant from the World Health Organization (WHO). NR 22 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6199 EI 1432-1076 J9 EUR J PEDIATR JI Eur. J. Pediatr. PD MAR PY 2017 VL 176 IS 3 BP 387 EP 393 DI 10.1007/s00431-017-2853-8 PG 7 WC Pediatrics SC Pediatrics GA EL9ZM UT WOS:000394978600012 PM 28091778 ER PT J AU Mujahid, MS Moore, LV Petito, LC Kershaw, KN Watson, K Roux, AVD AF Mujahid, Mahasin S. Moore, Latetia V. Petito, Lucia C. Kershaw, Kiarri N. Watson, Karol Roux, Ana V. Diez TI Neighborhoods and racial/ethnic differences in ideal cardiovascular health (the Multi-Ethnic Study of Atherosclerosis) SO HEALTH & PLACE LA English DT Article DE Racial/ethnic health disparities; Neighborhood environments; Cardiovascular health ID CORONARY-HEART-DISEASE; BODY-MASS INDEX; PHYSICAL-ACTIVITY; UNITED-STATES; HYPERTENSION PREVALENCE; MULTILEVEL ANALYSIS; DISPARITIES; ENVIRONMENTS; RISK; ASSOCIATION AB Using data from the Multi-Ethnic Study of Atherosclerosis baseline sample from 2000 to 2002 (N=5263; mean age=62) we examined cross-sectional racial/ethnic differences in ideal CVII, defined by the American Heart Association 2020 Impact Goals as a summary measure of ideal levels of blood pressure, fasting glucose, cholesterol, body mass index, diet, physical activity, and smoking. Using three different analytical approaches, we examined differences before and after adjustment for neighborhood socioeconomic, physical, and social environments. Significant racial/ethnic differences were present for all indicators of ideal CVII (excluding physical activity). Additional adjustments for neighborhood factors produced modest reductions in racial/ethnic differences. Future research is necessary to better understand the impact of neighborhood context on health disparities using longitudinal study designs. C1 [Mujahid, Mahasin S.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, 101 Haviland Hall, Berkeley, CA 94720 USA. [Moore, Latetia V.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, 4770 Buford Highway NE,Mailstop F77, Atlanta, GA 30341 USA. [Petito, Lucia C.] Univ Calif Berkley, Sch Publ Hlth, Div Biostat, 101 Haviland Hall, Berkeley, CA 94720 USA. [Kershaw, Kiarri N.] Northwestern Univ, Feinberg Sch Med, Div Prevent Med Epidemiol, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. [Watson, Karol] Univ Calif Los Angeles, David Geffen Sch Med, Dept Cardiol, 200 UCLA Med Plaza,C365, Los Angeles, CA 90095 USA. [Roux, Ana V. Diez] Drexel Univ, Sch Publ Hlth, Deans Off, 3215 Market St, Philadelphia, PA 19104 USA. RP Mujahid, MS (reprint author), 101 Haviland Hall, Berkeley, CA 94720 USA. EM mmujahid@berkeley.edu; ggi9@cdc.gov; lucia.petito@berkeley.edu; k-kershaw@northwestern.edu; KWatson@mednet.ucla.edu; avd37@drexel.edu FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169]; NCRR [UL1-RR-024156, UL1-RR-025005]; National Heart, Lung, and Blood Institute at the National Institutes of Health [R01 HL071759]; National Heart, Lung, and Blood Institute of the National Institutes of Health [5K01HL115494] FX This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-RR-024156 and UL1-RR-025005 from NCRR and R01 HL071759 from National Heart, Lung, and Blood Institute at the National Institutes of Health. Dr. Mujahid is funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health, grant 5K01HL115494. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 51 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8292 EI 1873-2054 J9 HEALTH PLACE JI Health Place PD MAR PY 2017 VL 44 BP 61 EP 69 DI 10.1016/j.healthplace.2017.01.005 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO8QV UT WOS:000396955900007 PM 28167269 ER PT J AU Corathers, SD Kichler, JC Fino, NF Lang, W Lawrence, JM Raymond, JK Yi-Frazier, JP Dabelea, D Liese, AD Saydah, SH Seid, M Dolan, LM AF Corathers, Sarah D. Kichler, Jessica C. Fino, Nora F. Lang, Wei Lawrence, Jean M. Raymond, Jennifer K. Yi-Frazier, Joyce P. Dabelea, Dana Liese, Angela D. Saydah, Sharon H. Seid, Michael Dolan, Lawrence M. TI High Health Satisfaction Among Emerging Adults With Diabetes: Factors Predicting Resilience SO HEALTH PSYCHOLOGY LA English DT Article DE Type 1 diabetes mellitus; transition to adult care; resilience; adolescent ID QUALITY-OF-LIFE; YOUNG-ADULTS; GLYCEMIC CONTROL; SELF-MANAGEMENT; TYPE-1; CARE; TRANSITION; ADOLESCENTS; CHILDREN; YOUTH AB Objective: This study was conducted to identify factors contributing to health satisfaction outcomes among emerging adults (ages 18-25) with diabetes. Method: SEARCH for Diabetes in Youth study participants whose diabetes was prevalent in 2001 and were >= 18 years of age when they completed a 2008-2009 follow-up survey (n = 340) were included. We developed a health resilience model (HRM) to identify potentially modifiable factors (anticipatory guidance, social support, physical activity, quality of life) associated with health outcomes (satisfaction with health care, overall personal health, self-report of hemoglobinA1c [HbA1c]). Proportional odds logistic regression models were used to examine relationships between modifiable factors and health outcomes while adjusting for predetermined characteristics; linear regression models were used for reported HbA1c. Comparison of participants who reported HbA1c versus nonreporters was conducted. Results: A majority (70%) of participants rated satisfaction with health care = 7 out of 10, and most (71%) rated overall health as good, very good, or excellent. Satisfaction with health care was independent of change in provider between the ages of 17 and 24. After controlling for predetermined characteristics, we found that the odds of increased satisfaction with health care and overall personal health were 1.3 and 1.2 greater, respectively, when participants discussed additional diabetes-related anticipatory guidance topics with a provider and 1.3 and 2.1, respectively, for each 10-unit change in quality of life score. Relationship between HbA1c level and modifiable factors was not significant; however, participants reporting HbA1c had higher ratings of health care and overall health versus nonreporters. Conclusions: HRM describes relationships between modifiable factors and patient-reported outcomes of satisfaction with health care and overall personal health among a cohort of ethnically and racially diverse emerging adults with longstanding diabetes, over half of whom experienced a change in provider. HRM may discern candidate areas for intervention, such as effective anticipatory guidance that can impact satisfaction with health care and overall health, to promote positive health outcomes. C1 [Corathers, Sarah D.; Dolan, Lawrence M.] Childrens Hosp Med Ctr, Div Endocrinol, 3333 Burnet Ave MLC 7012, Cincinnati, OH 45229 USA. [Kichler, Jessica C.] Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Cincinnati, OH USA. [Fino, Nora F.; Lang, Wei] Kaiser Permanente Southern Calif, Wake Forest Sch Med, Dept Biostat Sci, Pasadena, CA USA. [Lawrence, Jean M.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA. [Raymond, Jennifer K.] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Boulder, CO 80309 USA. [Yi-Frazier, Joyce P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA. [Dabelea, Dana] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Liese, Angela D.] Univ South Carolina, Dept Epidemiol & Biostat, Columbia, SC USA. [Liese, Angela D.] Univ South Carolina, Ctr Res Nutr & Hlth Dispar, Columbia, SC USA. [Saydah, Sharon H.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Seid, Michael] Childrens Hosp Med Ctr, Div Pulm Med, Cincinnati, OH USA. [Seid, Michael] Childrens Hosp Med Ctr, Anderson Ctr Hlth Syst Excellence, Cincinnati, OH USA. RP Corathers, SD (reprint author), Childrens Hosp Med Ctr, Div Endocrinol, 3333 Burnet Ave MLC 7012, Cincinnati, OH 45229 USA. EM sarah.corathers@cchmc.org FU Centers for Disease Control and Prevention [PA 00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; General Clinical Research Center at the South Carolina Clinical & Translational Research Institute at the Medical University of South Carolina (NIH/NCRR Grant) [UL1RR029882]; Seattle Children's Hospital (NIH CTSA Grant) [UL1 TR00423]; University of Colorado Pediatric Clinical and Translational Research Center [UL1 TR000154]; Barbara Davis Center at the University of Colorado at Denver (DERC NIH) [P30 DK57516]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health [8 UL1 TR000077]; Children with Medical Handicaps program FX This study was conducted for the SEARCH for Diabetes in Youth Study group, which is indebted to the many youth and their families, as well as their health care providers, whose participation made this study possible. SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site Contract Numbers: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), and Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171).; The authors wish to acknowledge the involvement of General Clinical Research Center at the South Carolina Clinical & Translational Research Institute at the Medical University of South Carolina (NIH/NCRR Grant UL1RR029882); Seattle Children's Hospital (NIH CTSA Grant UL1 TR00423 of the University of Washington); University of Colorado Pediatric Clinical and Translational Research Center (Grant UL1 TR000154) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 8 UL1 TR000077; and the Children with Medical Handicaps program managed by the Ohio Department of Health. NR 41 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD MAR PY 2017 VL 36 IS 3 BP 206 EP 214 DI 10.1037/hea0000419 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA EN4UN UT WOS:000396002500003 PM 27736152 ER PT J AU Singleton, R Salkoski, AJ Bulkow, L Fish, C Dobson, J Albertson, L Skarada, J Kovesi, T McDonald, C Hennessy, TW Ritter, T AF Singleton, R. Salkoski, A. J. Bulkow, L. Fish, C. Dobson, J. Albertson, L. Skarada, J. Kovesi, T. McDonald, C. Hennessy, T. W. Ritter, T. TI Housing characteristics and indoor air quality in households of Alaska Native children with chronic lung conditions SO INDOOR AIR LA English DT Article; Proceedings Paper CT Indoor Air Conference CY 2016 CL Ghent, BELGIUM DE Alaska Native; children; indoor air quality; respiratory; volatile organic compounds; woodstoves AB Alaska Native children experience high rates of respiratory infections and conditions. Household crowding, indoor smoke, lack of piped water, and poverty have been associated with respiratory infections. We describe the baseline household characteristics of children with severe or chronic lung disease participating in a 2012-2015 indoor air study. We monitored indoor PM2.5, CO2, relative humidity %, temperature, and VOCs and interviewed caregivers about children's respiratory symptoms. We evaluated the association between reported children's respiratory symptoms and indoor air quality indicators using multiple logistic regression analysis. Compared with general US households, study households were more likely overcrowded 73% (62%-82%) vs 3.2% (3.1%-3.3%); had higher woodstove use as primary heat source 16% (9%-25%) vs 2.1% (2.0%-2.2%); and higher proportion of children in a household with a smoker 49% (38%-60%) vs 26.2% (25.5%-26.8%). Median PM2.5 was 33 mu g/ m(3). Median CO2 was 1401 ppm. VOCs were detectable in all homes. VOCs, smoker, primary wood heat, and PM2.5 > 25 mu g/ m(3) were associated with higher risk for cough between colds; VOCs were associated with higher risk for wheeze between colds and asthma diagnosis. High indoor air pollutant levels were associated with respiratory symptoms in household children, likely related to overcrowding, poor ventilation, woodstove use, and tobacco smoke. C1 [Singleton, R.] ANTHC, Div Community Hlth Serv, Anchorage, AK USA. [Singleton, R.; Bulkow, L.; Hennessy, T. W.] Ctr Dis Control & Prevent CDC, Arctic Invest Program, NCEZID, Anchorage, AK USA. [Salkoski, A. J.; McDonald, C.] ANTHC, Community Environm & Hlth, Anchorage, AK USA. [Fish, C.; Ritter, T.] ANTHC, Div Environm Hlth & Engn, Anchorage, AK USA. [Dobson, J.] Yukon Kuskokwim Hlth Corp, Off Environm Hlth, Bethel, AK USA. [Albertson, L.] Univ Alaska, Sch Nat Resources & Extens, Fairbanks, AK 99701 USA. [Skarada, J.] Bristol Bay Area Hlth Corp, Dillingham, AK USA. [Kovesi, T.] Univ Ottawa, Dept Pediat, Ottawa, ON, Canada. [Ritter, T.] CDC, ONDIEh, NCEH, Environm Hlth Serv Branch, Atlanta, GA 30333 USA. RP Singleton, R (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. EM ris2@cdc.gov FU North American Commission for Environmental Cooperation; Environmental Protection Agency [1.6.2.1.1.1]; US Department of Housing and Urban Development [AKHU0009-13] FX Funding for this study "Improving the Respiratory Health of Alaska Native People through Home-Based Interventions" was provided by the North American Commission for Environmental Cooperation, Environmental Protection Agency Project # 1.6.2.1.1.1 and the US Department of Housing and Urban Development, Grant # AKHU0009-13. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0905-6947 EI 1600-0668 J9 INDOOR AIR JI Indoor Air PD MAR PY 2017 VL 27 IS 2 BP 478 EP 486 DI 10.1111/ina.12315 PG 9 WC Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health SC Construction & Building Technology; Engineering; Public, Environmental & Occupational Health GA EL9PC UT WOS:000394951500025 PM 27317363 ER PT J AU Van Handel, MM Brooks, JT AF Van Handel, Michelle M. Brooks, John T. TI Rural Health More Than Just "Big Data" Reply SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter C1 [Van Handel, Michelle M.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Van Handel, MM (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2017 VL 74 IS 3 BP E84 EP E85 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EN4WE UT WOS:000396006800006 PM 28187087 ER PT J AU Barton, AW Hurt, TR Futris, TG Sheats, KF McElroy, SE Landor, AM AF Barton, Allen W. Hurt, Tera R. Futris, Ted G. Sheats, Kameron F. McElroy, Stacey E. Landor, Antoinette M. TI Being Committed: Conceptualizations of Romantic Relationship Commitment Among Low-Income African American Adolescents SO JOURNAL OF BLACK PSYCHOLOGY LA English DT Article DE commitment; adolescence; African American; qualitative; romantic relationships ID SEXUAL PARTNERSHIPS; PROTOTYPE ANALYSIS; MARRIAGE; COUPLES; WOMEN; YOUNG; INVOLVEMENT; ATTACHMENT; BEHAVIOR; SCHEMAS AB Few studies have examined adolescents' understanding of romantic relationship commitment, particularly among African American youth. Using three waves of semistructured interviews, the present descriptive study addresses this topic by exploring the ways in which 20 African American adolescents (age range 13-19 years) from low-income backgrounds conceptualize and describe commitment in romantic relationships. Qualitative analyses revealed three main themes related to defining commitment, indicating that which commitment provides, and describing the nature of commitment in different relationship contexts. Findings inform psychological research and practice relating to commitment and romantic relationships among African American adolescents. C1 [Barton, Allen W.; Futris, Ted G.] Univ Georgia, Athens, GA 30602 USA. [Hurt, Tera R.] Iowa State Univ, Ames, IA USA. [Sheats, Kameron F.] Ctr Dis Control & Prevent, Atlanta, GA USA. [McElroy, Stacey E.] Georgia State Univ, Atlanta, GA 30303 USA. [Landor, Antoinette M.] Univ Missouri, Columbia, MO USA. RP Barton, AW (reprint author), Univ Georgia, Ctr Family Res, 1095 Coll Stn Rd, Athens, GA 30602 USA. EM awbarton@uga.edu FU University of Georgia's Office of the Vice President for Public Service and Outreach FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by a grant awarded to the second and third authors from the University of Georgia's Office of the Vice President for Public Service and Outreach under the Poverty and the Economy Faculty Research Grants Program. NR 54 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0095-7984 EI 1552-4558 J9 J BLACK PSYCHOL JI J. Black Psychol. PD MAR PY 2017 VL 43 IS 2 BP 111 EP 134 DI 10.1177/0095798415621665 PG 24 WC Psychology, Multidisciplinary SC Psychology GA EL5IB UT WOS:000394653700001 ER PT J AU Abril, EP Szczypka, G Emery, SL AF Abril, Eulalia P. Szczypka, Glen Emery, Sherry L. TI LMFAO! Humor as a Response to Fear: Decomposing Fear Control within the Extended Parallel Process Model SO JOURNAL OF BROADCASTING & ELECTRONIC MEDIA LA English DT Article ID APPEALS; CAMPAIGN; SMOKING; MESSAGES; TOBACCO; DANGER; YOUTH; RISK AB This study seeks to analyze fear control responses to the 2012 Tips from Former Smokers campaign using the Extended Parallel Process Model (EPPM). The goal is to examine the occurrence of ancillary fear control responses, like humor. In order to explore individuals' responses in an organic setting, we use Twitter datatweetscollected via the Firehose. Content analysis of relevant fear control tweets (N = 14,281) validated the existence of boomerang responses within the EPPM: denial, defensive avoidance, and reactance. More importantly, results showed that humor tweets were not only a significant occurrence but constituted the majority of fear control responses. C1 [Abril, Eulalia P.] Univ Illinois, Commun, Chicago, IL 60607 USA. [Szczypka, Glen; Emery, Sherry L.] Univ Chicago, Hlth Media Collaboratory, Chicago, IL 60637 USA. [Szczypka, Glen; Emery, Sherry L.] Univ Chicago, NORC, Chicago, IL 60637 USA. [Szczypka, Glen] CDC, Off Smoking & Hlth, Atlanta, GA 30333 USA. RP Abril, EP (reprint author), Univ Illinois, Commun, Chicago, IL 60607 USA. FU Centers for Disease Control and Prevention; National Cancer Institute of the National Institutes of Health [U01CA154254] FX Research reported in this publication was supported by the Centers for Disease Control and Prevention and National Cancer Institute of the National Institutes of Health under Award Number U01CA154254. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 49 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0883-8151 EI 1550-6878 J9 J BROADCAST ELECTRON JI J. Broadcast. Electron. Media PD MAR PY 2017 VL 61 IS 1 BP 126 EP 143 DI 10.1080/08838151.2016.1273921 PG 18 WC Communication; Film, Radio, Television SC Communication; Film, Radio & Television GA EN0JQ UT WOS:000395696500009 ER PT J AU Rajeevan, MS Li, TG Unger, ER AF Rajeevan, Mangalathu S. Li, Tengguo Unger, Elizabeth R. TI Precision Medicine Requires Precision Laboratories SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Editorial Material ID VALIDATION; STANDARDS; TRIAL; ASSAY C1 [Rajeevan, Mangalathu S.; Li, Tengguo; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Unger, ER (reprint author), 1600 Clifton Rd,MS G41, Atlanta, GA 30329 USA. EM eunger@cdc.gov NR 12 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD MAR PY 2017 VL 19 IS 2 BP 226 EP 229 DI 10.1016/j.jmoldx.2017.01.001 PG 4 WC Pathology SC Pathology GA EL9DS UT WOS:000394920200003 PM 28130021 ER PT J AU Nguyen, DT Jang, YH Nguyen, TD Jones, J Shepard, SS Yang, H Gerloff, N Fabrizio, T Nguyen, LV Inui, K Yang, GY Creanga, A Wang, L Mai, DT Thor, S Stevens, J To, TL Wentworth, DE Nguyen, T Pham, DV Bryant, JE Davis, CT AF Nguyen, Diep T. Jang, Yunho Nguyen, Tho D. Jones, Joyce Shepard, Samuel S. Yang, Hua Gerloff, Nancy Fabrizio, Thomas Nguyen, Long V. Inui, Ken Yang, Genyan Creanga, Adrian Wang, Li Mai, Duong T. Thor, Sharmi Stevens, James To, Thanh L. Wentworth, David E. Tung Nguyen Pham, Dong V. Bryant, Juliet E. Davis, C. Todd TI Shifting Clade Distribution, Reassortment, and Emergence of New Subtypes of Highly Pathogenic Avian Influenza A(H5) Viruses Collected from Vietnamese Poultry from 2012 to 2015 SO JOURNAL OF VIROLOGY LA English DT Article DE highly pathogenic avian influenza; Vietnam; antigenicity; evolution; reassortment; vaccine selection ID H5N1 VIRUS; CHICKENS; MARKETS; ENTRY; JAPAN; PORTS; BIRDS AB Whole-genome sequences of representative highly pathogenic avian influenza A(H5) viruses from Vietnam were generated, comprising samples from poultry outbreaks and active market surveillance collected from January 2012 to August 2015. Six hemagglutinin gene clades were characterized. Clade 1.1.2 was predominant in southern Mekong provinces throughout 2012 and 2013 but gradually disappeared and was not detected after April 2014. Clade 2.3.2.1c viruses spread rapidly during 2012 and were detected in the south and center of the country. A number of clade 1.1.2 and 2.3.2.1c interclade reassortant viruses were detected with different combinations of internal genes derived from 2.3.2.1a and 2.3.2.1b viruses, indicating extensive cocirculation. Although reassortment generated genetic diversity at the genotype level, there was relatively little genetic drift within the individual gene segments, suggesting genetic stasis over recent years. Antigenically, clade 1.1.2, 2.3.2.1a, 2.3.2.1b, and 2.3.2.1c viruses remained related to earlier viruses and WHOrecommended prepandemic vaccine strains representing these clades. Clade 7.2 viruses, although detected in only low numbers, were the exception, as indicated by introduction of a genetically and antigenically diverse strain in 2013. Clade 2.3.4.4 viruses (H5N1 and H5N6) were likely introduced in April 2014 and appeared to gain dominance across northern and central regions. Antigenic analyses of clade 2.3.4.4 viruses compared to existing clade 2.3.4 candidate vaccine viruses (CVV) indicated the need for an updated vaccine virus. A/Sichuan/26221/2014 (H5N6) virus was developed, and ferret antisera generated against this virus were demonstrated to inhibit some but not all clade 2.3.4.4 viruses, suggesting consideration of alternative clade 2.3.4.4 CVVs. IMPORTANCE Highly pathogenic avian influenza (HPAI) A(H5) viruses have circulated continuously in Vietnam since 2003, resulting in hundreds of poultry outbreaks and sporadic human infections. Despite a significant reduction in the number of human infections in recent years, poultry outbreaks continue to occur and the virus continues to diversify. Vaccination of poultry has been used as a means to control the spread and impact of the virus, but due to the diversity and changing distribution of antigenically distinct viruses, the utility of vaccines in the face of mismatched circulating strains remains questionable. This study assessed the putative amino acid changes in viruses leading to antigenic variability, underscoring the complexity of vaccine selection for both veterinary and public health purposes. Given the overlapping geographic distributions of multiple, antigenically distinct clades of HPAI A(H5) viruses in Vietnam, the vaccine efficacy of bivalent poultry vaccine formulations should be tested in the future. C1 [Nguyen, Diep T.; Nguyen, Tho D.; Mai, Duong T.; To, Thanh L.] Natl Ctr Vet Diagnost, Dept Anim Hlth, Hanoi, Vietnam. [Nguyen, Diep T.; Nguyen, Long V.; Tung Nguyen; Pham, Dong V.] Minist Agr & Rural Dev Vietnam, Dept Anim Hlth, Hanoi, Vietnam. [Nguyen, Diep T.; Bryant, Juliet E.] Univ Oxford, Clin Res Unit, Hanoi, Vietnam. [Nguyen, Diep T.; Bryant, Juliet E.] Wellcome Trust Major Overseas Programme, Hanoi, Vietnam. [Nguyen, Diep T.; Bryant, Juliet E.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England. [Jang, Yunho; Jones, Joyce; Shepard, Samuel S.; Yang, Hua; Gerloff, Nancy; Yang, Genyan; Creanga, Adrian; Wang, Li; Thor, Sharmi; Stevens, James; Wentworth, David E.; Davis, C. Todd] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Fabrizio, Thomas] St Judes Ctr Excellence Influenza Res & Surveilla, Memphis, TN USA. [Inui, Ken] UN, FAO, Hanoi, Vietnam. RP Nguyen, DT (reprint author), Natl Ctr Vet Diagnost, Dept Anim Hlth, Hanoi, Vietnam.; Nguyen, DT (reprint author), Minist Agr & Rural Dev Vietnam, Dept Anim Hlth, Hanoi, Vietnam.; Nguyen, DT (reprint author), Univ Oxford, Clin Res Unit, Hanoi, Vietnam.; Nguyen, DT (reprint author), Wellcome Trust Major Overseas Programme, Hanoi, Vietnam.; Nguyen, DT (reprint author), Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England.; Davis, CT (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. EM diep.dahvn@gmail.com; ctdavis@cdc.gov FU United States Department of Health and Human Services, Centers for Disease Control and Prevention; Vietnamese Department of Animal Health; Food and Agriculture Organization of the United Nations; Wellcome Trust; Oxford University, UK FX This work was funded, in part, by the United States Department of Health and Human Services, Centers for Disease Control and Prevention. Contributions of D.T.N. were supported by the Wellcome Trust and Oxford University, UK.; We are grateful to the Vietnamese Department of Animal Health and the Food and Agriculture Organization of the United Nations for support and implementation of national poultry surveillance systems. We thank staff of DAH, NCVD, RAHOs, and SDAHs of Vietnam and field veterinary staff for their support in collecting and testing samples. We thank Rogier van Doorn for critical reviews of early drafts of the manuscript. NR 35 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAR PY 2017 VL 91 IS 5 AR UNSP e01708 DI 10.1128/JVI.01708-16 PG 18 WC Virology SC Virology GA EL1BV UT WOS:000394356400005 ER PT J AU Tao, Y Shi, M Chommanard, C Queen, K Zhang, J Markotter, W Kuzmin, IV Holmes, EC Tong, SX AF Tao, Ying Shi, Mang Chommanard, Christina Queen, Krista Zhang, Jing Markotter, Wanda Kuzmin, Ivan V. Holmes, Edward C. Tong, Suxiang TI Surveillance of Bat Coronaviruses in Kenya Identifies Relatives of Human Coronaviruses NL63 and 229E and Their Recombination History SO JOURNAL OF VIROLOGY LA English DT Article DE Africa; bats; coronavirus; HCoV-229E; HCoV-NL63; recombination; zoonoses ID RESPIRATORY SYNDROME CORONAVIRUS; CHINESE HORSESHOE BATS; RNA RECOMBINATION; SARS-LIKE; GENOMIC CHARACTERIZATION; MURINE CORONAVIRUS; ZOONOTIC VIRUSES; EVOLUTION; SEQUENCE; ORIGIN AB Bats harbor a large diversity of coronaviruses (CoVs), several of which are related to zoonotic pathogens that cause severe disease in humans. Our screening of bat samples collected in Kenya from 2007 to 2010 not only detected RNA from several novel CoVs but, more significantly, identified sequences that were closely related to human CoVs NL63 and 229E, suggesting that these two human viruses originate from bats. We also demonstrated that human CoV NL63 is a recombinant between NL63-like viruses circulating in Triaenops bats and 229E-like viruses circulating in Hipposideros bats, with the breakpoint located near 5' and 3' ends of the spike (S) protein gene. In addition, two further interspecies recombination events involving the S gene were identified, suggesting that this region may represent a recombination "hot spot" in CoV genomes. Finally, using a combination of phylogenetic and distance-based approaches, we showed that the genetic diversity of bat CoVs is primarily structured by host species and subsequently by geographic distances. IMPORTANCE Understanding the driving forces of cross-species virus transmission is central to understanding the nature of disease emergence. Previous studies have demonstrated that bats are the ultimate reservoir hosts for a number of coronaviruses (CoVs), including ancestors of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and human CoV 229E (HCoV-229E). However, the evolutionary pathways of bat CoVs remain elusive. We provide evidence for natural recombination between distantly related African bat coronaviruses associated with Triaenops afer and Hipposideros sp. bats that resulted in a NL63-like virus, an ancestor of the human pathogen HCoV-NL63. These results suggest that interspecies recombination may play an important role in CoV evolution and the emergence of novel CoVs with zoonotic potential. C1 [Tao, Ying; Chommanard, Christina; Queen, Krista; Zhang, Jing; Tong, Suxiang] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Shi, Mang; Holmes, Edward C.] Univ Sydney, Sch Life & Environm Sci, Charles Perkins Ctr, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia. [Shi, Mang; Holmes, Edward C.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia. [Markotter, Wanda] Univ Pretoria, Dept Med Virol, Fac Hlth Sci, Ctr Viral Zoonoses, Pretoria, South Africa. [Kuzmin, Ivan V.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Kuzmin, Ivan V.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA. RP Tong, SX (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM sot1@cdc.gov NR 52 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD MAR PY 2017 VL 91 IS 5 AR UNSP e01953 DI 10.1128/JVI.01953-16 PG 16 WC Virology SC Virology GA EL1BV UT WOS:000394356400013 ER PT J AU Thwing, J Ba, F Diaby, A Diedhiou, Y Sylla, A Sall, G Diouf, MB Gueye, AB Gaye, S Ndiop, M Cisse, M Ndiaye, D Ba, M AF Thwing, Julie Ba, Fatou Diaby, Alou Diedhiou, Younouss Sylla, Assane Sall, Guelaye Diouf, Mame Birame Gueye, Alioune Badara Gaye, Seynabou Ndiop, Medoune Cisse, Moustapha Ndiaye, Daouda Ba, Mady TI Assessment of the utility of a symptom-based algorithm for identifying febrile patients for malaria diagnostic testing in Senegal SO MALARIA JOURNAL LA English DT Article DE Malaria; Diagnosis; Treatment; Algorithm; Fever; Case management; Rapid diagnostic test ID ATTRIBUTABLE FRACTION; CASE-DEFINITION; FEVER; TRANSMISSION; CHILDREN; SEASON; AREA AB Background: Malaria rapid diagnostic tests (RDTs) enable point-of-care testing to be nearly as sensitive and specific as reference microscopy. The Senegal National Malaria Control Programme introduced RDTs in 2007, along with a case management algorithm for uncomplicated febrile illness, in which the first step stipulates that if a febrile patient of any age has symptoms indicative of febrile illness other than malaria (e. g., cough or rash), they would not be tested for malaria, but treated for the apparent illness and receive an RDT for malaria only if they returned in 48 h without improvement. Methods: A year-long study in 16 health posts was conducted to determine the algorithm's capacity to identify patients with Plasmodium falciparum infection identifiable by RDT. Health post personnel enrolled patients of all ages with fever (>= 37.5 degrees C) or history of fever in the previous 2 days. After clinical assessment, a nurse staffing the health post determined whether a patient should receive an RDT according to the diagnostic algorithm, but performed an RDT for all enrolled patients. Results: Over 1 year, 6039 patients were enrolled and 58% (3483) were determined to require an RDT according to the algorithm. Overall, 23% (1373/6039) had a positive RDT, 34% (1130/3376) during rainy season and 9% (243/2661) during dry season. The first step of the algorithm identified only 78% of patients with a positive RDT, varying by transmission season (rainy 80%, dry 70%), malaria transmission zone (high 75%, low 95%), and age group (under 5 years 68%, 5 years and older 84%). Conclusions: In all but the lowest malaria transmission zone, use of the algorithm excludes an unacceptably large proportion of patients with malaria from receiving an RDT at their first visit, denying them timely diagnosis and treatment. While the algorithm was adopted within a context of malaria control and scarce resources, with the goal of treating patients with symptomatic malaria, Senegal has now adopted a policy of universal diagnosis of patients with fever or history of fever. In addition, in the current context of malaria elimination, the paradigm of case management needs to shift towards the identification and treatment of all patients with malaria infection. C1 [Thwing, Julie] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Thwing, Julie] US Presidents Malaria Initiat, Atlanta, GA 30329 USA. [Ba, Fatou; Gueye, Alioune Badara; Gaye, Seynabou; Ndiop, Medoune; Cisse, Moustapha; Ba, Mady] Senegal Natl Malaria Control Programme, Dakar, Senegal. [Diaby, Alou; Sylla, Assane; Sall, Guelaye] Hop Dantec, Serv Pediat, Dakar, Senegal. [Diedhiou, Younouss] Hop Dantec, Parasitol Serv, Dakar, Senegal. [Diouf, Mame Birame] US Agcy Int Dev, Dakar, Senegal. [Ndiaye, Daouda] Univ Cheikh Anta Diop, Dakar, Senegal. [Ba, Mady] WHO, Dakar, Senegal. RP Thwing, J (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.; Thwing, J (reprint author), US Presidents Malaria Initiat, Atlanta, GA 30329 USA. EM fez3@cdc.gov FU President's Malaria Initiative (PMI); US Agency for International Development; Centers for Disease Control and Prevention (CDC) FX This work was made possible through support provided by the President's Malaria Initiative (PMI), and the US Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC). A representative of PMI participated in design, implementation, analysis, and interpretation of results. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the US Agency for International Development or CDC. NR 21 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAR 1 PY 2017 VL 16 AR 95 DI 10.1186/s12936-017-1750-y PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EN9CT UT WOS:000396299000001 PM 28249580 ER PT J AU Folster, JP Grass, JE Bicknese, A Taylor, J Friedman, CR Whichard, JM AF Folster, Jason P. Grass, Julian E. Bicknese, Amelia Taylor, Julia Friedman, Cindy R. Whichard, Jean M. TI Characterization of Resistance Genes and Plasmids from Outbreaks and Illness Clusters Caused by Salmonella Resistant to Ceftriaxone in the United States, 2011-2012 SO MICROBIAL DRUG RESISTANCE LA English DT Article DE Salmonella; antimicrobial; resistance; plasmid ID ESCHERICHIA-COLI; FOOD ANIMALS; HUMANS; TYPHIMURIUM; NEWPORT AB Salmonella is an important cause of foodborne illness; however, quickly identifying the source of these infections can be difficult, and source identification is a crucial step in preventing additional illnesses. Although most infections are self-limited, invasive salmonellosis may require antimicrobial treatment. Ceftriaxone, an extended-spectrum cephalosporin, is commonly used for treatment of salmonellosis. Previous studies have identified a correlation between the food animal/retail meat source of ceftriaxone-resistant Salmonella and the type of resistance gene and plasmid it carries. In this study, we examined seven outbreaks of ceftriaxone-resistant Salmonella infections, caused by serotypes Typhimurium, Newport, Heidelberg, and Infantis. All isolates were positive for a plasmid-encoded bla(CMY) gene. Plasmid incompatibility typing identified five IncI1 and two IncA/C plasmids. Both outbreaks containing bla(CMY)-IncA/C plasmids were linked to consumption of cattle products. Three of five outbreaks with bla(CMY)-IncI1 (ST12) plasmids were linked to a poultry source. The remaining IncI1 outbreaks were associated with ground beef (ST20) and tomatoes (ST12). In addition, we examined isolates from five unsolved clusters of ceftriaxone-resistant Salmonella infections and used our plasmid-encoded gene findings to predict the source. Overall, we identified a likely association between the source of ceftriaxone-resistant Salmonella outbreaks and the type of resistance gene/plasmid it carries. C1 [Folster, Jason P.; Whichard, Jean M.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Grass, Julian E.; Friedman, Cindy R.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Bicknese, Amelia; Taylor, Julia] IHRC Inc, Atlanta, GA USA. RP Folster, JP (reprint author), Ctr Dis Control & Prevent, Enter Dis Lab Branch, OID NCEZID DFWED EDLB, Atlanta, GA 30329 USA. EM gux8@cdc.gov FU CDC; USDA; FDA Center for Veterinary Medicine FX We thank the NARMS participating public health laboratories for submitting the isolates and PulseNet for identifying outbreaks. We also thank Matt Wise and Kelly Walsh for their assistance in providing the outbreak data. This work was partially supported by an interagency agreement between CDC, USDA, and the FDA Center for Veterinary Medicine. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 22 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1076-6294 EI 1931-8448 J9 MICROB DRUG RESIST JI Microb. Drug Resist. PD MAR PY 2017 VL 23 IS 2 BP 188 EP 193 DI 10.1089/mdr.2016.0080 PG 6 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA EN1IA UT WOS:000395762500008 PM 27828730 ER PT J AU Boghani, S Mei, ZG Perry, GS Brittenham, GM Cogswell, ME AF Boghani, Safia Mei, Zuguo Perry, Geraldine S. Brittenham, Gary M. Cogswell, Mary E. TI Accuracy of Capillary Hemoglobin Measurements for the Detection of Anemia among US Low-Income Toddlers and Pregnant Women SO NUTRIENTS LA English DT Article DE anemia; hemoglobin; iron deficiency; children; pregnant women ID DIFFERENT QUANTITATIVE METHODS; HEMOCUE SYSTEM; BLOOD-DONORS; VENOUS-BLOOD; RELIABILITY; PARAMETERS; CHILDREN; SAMPLES; COUNTS; ADULTS AB The aim of this study is to evaluate the accuracy of capillary hemoglobin (Hb) measurements in detecting anemia among low-income toddlers (aged 12-35 months) and pregnant women. In analyses of data among toddlers from Kansas City (n = 402) and St. Louis, Missouri (n = 236), and pregnant women at < 20 weeks gestation from Cleveland, Ohio (n = 397), we compared subjects' anemia status based on capillary Hb concentrations in finger puncture samples as measured by the HemoCue system with their anemia status based on venous Hb concentrations as measured by the HemoCue and Coulter Counter. The sensitivity of capillary blood analyses in identifying cases of anemia was 32.8% (95% Confidence Intervals (CI): 21.0%-46.3%), among Kansas City toddlers, 59.7% (95% CI: 45.8%-72.4%) among St. Louis toddlers, and 66.7% (95% CI: 46.0%-83.5%) among pregnant women in Cleveland; the corresponding specificities were 97.7%, 86.6%, and 96.7%, respectively. The correlation between HemoCue and Coulter Counter measurements of venous Hb (0.9) was higher than that between HemoCue measurements of capillary and venous blood (0.8). The results show that Hb measurements of capillary blood with HemoCue were not optimal for determining the anemia status of toddlers and pregnant women. C1 [Boghani, Safia; Mei, Zuguo] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Perry, Geraldine S.] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent CDC, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Brittenham, Gary M.] Columbia Univ Coll Phys & Surg, Div Pediat Hematol, Dept Pediat, New York, NY 10032 USA. [Cogswell, Mary E.] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Mei, ZG (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. EM safia.b@gmail.com; zam0@cdc.gov; gperry3943@bellsouth.net; gmb31@columbia.edu; mec0@cdc.gov NR 35 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 2072-6643 J9 NUTRIENTS JI Nutrients PD MAR PY 2017 VL 9 IS 3 AR 253 DI 10.3390/nu9030253 PG 11 WC Nutrition & Dietetics SC Nutrition & Dietetics GA EO9QQ UT WOS:000397023600072 ER PT J AU Akinbami, LJ Kit, BK Carroll, MD Fakhouri, THI Ogden, CL AF Akinbami, Lara J. Kit, Brian K. Carroll, Margaret D. Fakhouri, Tala H. I. Ogden, Cynthia L. TI Trends in Anthropometric Measures Among US Children 6 to 23 Months, 1976-2014 SO PEDIATRICS LA English DT Article ID EARLY-CHILDHOOD; UNITED-STATES; WEIGHT-GAIN; BODY-COMPOSITION; BIRTH-WEIGHT; YOUNG-ADULTS; CATCH-UP; OBESITY; INFANCY; OVERWEIGHT AB BACKGROUND AND OBJECTIVES: The surveillance of children's growth reflects a population's abstract nutritional status and risk for adverse outcomes. This study aimed to describe trends in length-for-age, weight-for-age, weight-for-length, and early childhood weight gain among US children aged 6 to 23 months. METHODS: We analyzed NHANES data from 1976-1980, 1988-1994, 1999-2002, 2003-2006, 2007-2010, and 2011-2014. We estimated z scores < -2 (low) and >=+2 (high) in comparison with World Health Organization growth standards for each indicator. Weight gain (relative to sex-age-specific medians) from birth until survey participation was estimated. Trends were assessed by low birth weight status and race/Hispanic origin. Race/Hispanic origin trends were assessed from 1988-1994 to 2011-2014. RESULTS: In 2011-2014, the prevalence of low and high length-for-age was 3.3% (SE, 0.8) and 3.7% (SE, 0.8); weight-for-age was 0.6% (SE, 0.3) and 7.0% (SE, 1.1); and weight-for-length was 1.0% (SE, 0.4) and 7.7% (SE, 1.2). The only significant trend was a decrease in high length-for-age (5.5% in 1976-1980 vs 3.7% in 2011-2014; P =.04). Relative weight gain between birth and survey participation did not differ over time, although trends differed by race/Hispanic origin. Non-Hispanic black children gained more weight between birth and survey participation in 2011-2014 versus 1988-1994, versus no change among other groups. CONCLUSIONS: Between 1976-1980 and 2011-2014, there were no significant trends in low or high weight-for-age and weight-for-length among 6- to 23-month-old children whereas the percent with high length-for-age decreased. A significant trend in relative weight gain between birth and survey participation was observed among non-Hispanic black children. C1 [Akinbami, Lara J.; Kit, Brian K.; Carroll, Margaret D.; Fakhouri, Tala H. I.; Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Akinbami, Lara J.; Kit, Brian K.] US PHS, Rockville, MD USA. RP Akinbami, LJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 3418, Hyattsville, MD 20782 USA. EM lea8@cdc.gov NR 47 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2017 VL 139 IS 3 AR e20163374 DI 10.1542/peds.2016-3374 PG 10 WC Pediatrics SC Pediatrics GA EM0IY UT WOS:000395003200052 ER PT J AU Burns, KM Bienemann, L Camperlengo, L Cottengim, C Covington, TM Dykstra, H Faulkner, M Kobau, R Lambert, ABE MacLeod, H Parks, SE Rosenberg, E Russell, MW Shapiro-Mendoza, CK Shaw, E Tian, N Whittemore, V Kaltman, JR AF Burns, Kristin M. Bienemann, Lauren Camperlengo, Lena Cottengim, Carri Covington, Theresa M. Dykstra, Heather Faulkner, Meghan Kobau, Rosemarie Lambert, Alexa B. Erck MacLeod, Heather Parks, Sharyn E. Rosenberg, Ellen Russell, Mark W. Shapiro-Mendoza, Carrie K. Shaw, Esther Tian, Niu Whittemore, Vicky Kaltman, Jonathan R. TI The Sudden Death in the Young Case Registry: Collaborating to Understand and Reduce Mortality SO PEDIATRICS LA English DT Article ID CARDIAC DEATH; UNEXPECTED DEATH; ADOLESCENTS; CHILDREN; HEART; AGE AB Knowledge gaps persist about the incidence of and risk factors for sudden death in the young (SDY). The SDY Case Registry is a collaborative effort between the National Institutes of Health, the Centers for Disease Control and Prevention, and the Michigan Public Health Institute. Its goals are to: (1) describe the incidence of SDY in the United States by using populationbased surveillance; (2) compile data from SDY cases to create a resource of information and DNA samples for research; (3) encourage standardized approaches to investigation, autopsy, and categorization of SDY cases; (4) develop partnerships between local, state, and federal stakeholders toward a common goal of understanding and preventing SDY; and (5) support families who have lost loved ones to SDY by providing resources on bereavement and medical evaluation of surviving family members. Built on existing Child Death Review programs and as an expansion of the Sudden Unexpected Infant Death Case Registry, the SDY Case Registry achieves its goals by identifying SDY cases, providing guidance to medical examiners/coroners in conducting comprehensive autopsies, evaluating cases through child death review and an advanced review by clinical specialists, and classifying cases according to a standardized algorithm. The SDY Case Registry also includes a process to obtain informed consent from next-of-kin to save DNA for research, banking, and, in some cases, diagnostic genetic testing. The SDY Case Registry will provide valuable incidence data and will enhance understanding of the characteristics of SDY cases to inform the development of targeted prevention efforts. C1 [Burns, Kristin M.; Rosenberg, Ellen; Kaltman, Jonathan R.] NHLBI, Div Cardiovasc Sci, Bethesda, MD USA. [Bienemann, Lauren; Russell, Mark W.] Univ Michigan, Sch Med, Div Pediat Cardiol, Ann Arbor, MI USA. [Camperlengo, Lena; Cottengim, Carri; Kobau, Rosemarie; Parks, Sharyn E.; Shapiro-Mendoza, Carrie K.; Tian, Niu] Ctr Dis Control & Prevent, Atlanta, GA USA. [Covington, Theresa M.; Dykstra, Heather; Faulkner, Meghan; MacLeod, Heather; Shaw, Esther] Michigan Publ Hlth Inst, Natl Ctr Fatal Review & Prevent, Okemos, MI USA. [Lambert, Alexa B. Erck] DB Consulting Grp Inc, Silver Spring, MD USA. [Whittemore, Vicky] Natl Inst Neurol Disorders & Stroke, Natl Inst Hlth, Bethesda, MD USA. RP Burns, KM (reprint author), NHLBI, Div Cardiovasc Sci, Natl Inst Hlth, 6701 Rockledge Dr,Room 8220, Bethesda, MD 20892 USA. EM kristin.burns@nih.gov FU National Institutes of Health (National Heart, Lung, and Blood Institute and the National Institute of Neurologic Disorders and Stroke); Centers for Disease Control and Prevention; National Institutes of Health (NIH) FX The Sudden Death in the Young Case Registry is supported by funds from the National Institutes of Health (National Heart, Lung, and Blood Institute and the National Institute of Neurologic Disorders and Stroke) as well as the Centers for Disease Control and Prevention. Funded by the National Institutes of Health (NIH). NR 25 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2017 VL 139 IS 3 AR e20162757 DI 10.1542/peds.2016-2757 PG 9 WC Pediatrics SC Pediatrics GA EM0IY UT WOS:000395003200036 ER PT J AU Lanzieri, TM Chung, W Flores, M Blum, P Caviness, AC Bialek, SR Grosse, SD Miller, JA Demmler-Harrison, G AF Lanzieri, Tatiana M. Chung, Winnie Flores, Marily Blum, Peggy Caviness, A. Chantal Bialek, Stephanie R. Grosse, Scott D. Miller, Jerry A. Demmler-Harrison, Gail TI Hearing Loss in Children With Asymptomatic Congenital Cytomegalovirus Infection SO PEDIATRICS LA English DT Article ID VIRUS INFECTION; CMV INFECTION; LONG-TERM; INFANTS; NEWBORNS; THRESHOLDS; PREVALENCE; DISEASE; SWEDEN; NOISE AB OBJECTIVES: To assess the prevalence, characteristics, and risk of sensorineural hearing loss (SNHL) in children with congenital cytomegalovirus infection identified through hospitalbased newborn screening who were asymptomatic at birth compared with uninfected children. METHODS: We included 92 case-patients and 51 controls assessed by using auditory brainstem response and behavioral audiometry. We used Kaplan-Meier survival analysis to estimate the prevalence of SNHL, defined as >= 25 dB hearing level at any frequency and Cox proportional hazards regression analyses to compare SNHL risk between groups. RESULTS: At age 18 years, SNHL prevalence was 25% (95% confidence interval [CI]: 17%-36%) among case-patients and 8% (95% CI: 3%-22%) in controls (hazard ratio [HR]: 4.0; 95% CI: 1.2-14.5; P =.02). Among children without SNHL by age 5 years, the risk of delayedonset SNHL was not significantly greater for case-patients than for controls (HR: 1.6; 95% CI: 0.4-6.1; P =.5). Among case-patients, the risk of delayed-onset SNHL was significantly greater among those with unilateral congenital/early-onset hearing loss than those without (HR: 6.9; 95% CI: 2.5-19.1; P <.01). The prevalence of severe to profound bilateral SNHL among case-patients was 2% (95% CI: 1%-9%). CONCLUSIONS: Delayed-onset and progression of SNHL among children with asymptomatic congenital cytomegalovirus infection continued to occur throughout adolescence. However, the risk of developing SNHL after age 5 years among case-patients was not different than in uninfected children. Overall, 2% of case-patients developed SNHL that was severe enough for them to be candidates for cochlear implantation. C1 [Lanzieri, Tatiana M.; Chung, Winnie; Flores, Marily; Blum, Peggy; Caviness, A. Chantal; Bialek, Stephanie R.; Grosse, Scott D.; Miller, Jerry A.; Demmler-Harrison, Gail] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop A 34, Atlanta, GA 30333 USA. RP Lanzieri, TM (reprint author), Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop A 34, Atlanta, GA 30333 USA. EM tmlanzieri@cdc.gov FU CMV Research Fund Donors at Baylor College of Medicine; Woman's Hospital of Texas Research Foundation; Office of Research Resources at Texas Children's Hospital and Baylor College of Medicine [NIH 5M0I RR00188-33]; General Clinical Research Center for Children at Texas Children's Hospital and Baylor College of Medicine [NIH 5M0I RR00188-33]; Mental Retardation Research Center at Baylor College of Medicine [NIH-CHHD 5 P30 HD24064P]; Research to Prevent Blindness, Inc (New York, NY); Deafness Foundation (Houston, TX); Vale Ashe Foundation (Houston, TX); Maddie's Mission Foundation (Katy, TX); Naymola Foundation (Beaumont, TX); American Pediatric Society-Society for Pediatric Research Summer Student Research Program (NIH-CHHD); Centers for Disease Control and Prevention [FOA IP 10-006]; National Institutes of Health (NIH) FX This study was supported in part by the CMV Research Fund Donors at Baylor College of Medicine; the Woman's Hospital of Texas Research Foundation; the Office of Research Resources and the General Clinical Research Center for Children at Texas Children's Hospital and Baylor College of Medicine (NIH 5M0I RR00188-33); the Mental Retardation Research Center at Baylor College of Medicine (NIH-CHHD 5 P30 HD24064P); the Research to Prevent Blindness, Inc (New York, NY); the Deafness Foundation (Houston, TX); the Vale Ashe Foundation (Houston, TX); the Maddie's Mission Foundation (Katy, TX); the Naymola Foundation (Beaumont, TX); the American Pediatric Society-Society for Pediatric Research Summer Student Research Program (NIH-CHHD); and the Centers for Disease Control and Prevention (cooperative agreement FOA IP 10-006). Funded by the National Institutes of Health (NIH). NR 29 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2017 VL 139 IS 3 AR e20162610 DI 10.1542/peds.2016-2610 PG 8 WC Pediatrics SC Pediatrics GA EM0IY UT WOS:000395003200034 ER PT J AU Su, JR Leroy, Z Lewis, PW Haber, P Marin, M Leung, J Woo, EJ Shimabukuro, TT AF Su, John R. Leroy, Zanie Lewis, Paige W. Haber, Penina Marin, Mona Leung, Jessica Woo, Emily Jane Shimabukuro, Tom T. TI Safety of Second-Dose Single-Antigen Varicella Vaccine SO PEDIATRICS LA English DT Article ID EVENT REPORTING SYSTEM; UNITED-STATES; HEALTHY-CHILDREN; SURVEILLANCE; MEASLES; IMMUNOGENICITY; EPIDEMIOLOGY; IMMUNIZATION; PREVENTION; MORTALITY AB BACKGROUND AND OBJECTIVE: In 2006, routine 2-dose varicella vaccination for children was recommended to improve control of varicella. We assessed the safety of second-dose varicella vaccination. METHODS: We identified second-dose single-antigen varicella vaccine reports in the Vaccine Adverse Event Reporting System during 2006 to 2014 among children aged 4 to 18 years. We analyzed reports by age group (4-6 and 7-18 years), sex, serious or nonserious status, most common adverse events (AEs), and whether other vaccines were administered concomitantly with varicella vaccine. We reviewed serious reports of selected AEs and conducted empirical Bayesian data mining to detect disproportional reporting of AEs. RESULTS: We identified 14 641 Vaccine Adverse Event Reporting System reports after second-dose varicella vaccination, with 494 (3%) classified as serious. Among nonserious reports, injection site reactions were most common (48% of children aged 4-6 years, 38% of children aged 7-18 years). The most common AEs among serious reports were pyrexia (31%) for children aged 4 to 6 years and headache (28%) and vomiting (27%) for children aged 7 to 18 years. Serious reports of selected AEs included anaphylaxis (83), meningitis (5), encephalitis (16), cellulitis (52), varicella (6), herpes zoster (6), and deaths (7). One immunosuppressed adolescent was reported with vaccine-strain herpes zoster. Only previously known AEs were reported more frequently after second-dose varicella vaccination compared with other vaccines. CONCLUSIONS: We identified no new or unexpected safety concerns for second-dose varicella vaccination. Robust safety monitoring remains an important component of the national varicella vaccination program. C1 [Su, John R.; Lewis, Paige W.; Haber, Penina; Shimabukuro, Tom T.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Leroy, Zanie] Ctr Dis Control & Prevent, Sch Hlth Branch, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Marin, Mona; Leung, Jessica] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Epidemiol Branch, Atlanta, GA USA. [Woo, Emily Jane] US FDA, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Silver Spring, MD USA. RP Su, JR (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd,MS D-26, Atlanta, GA 30333 USA. EM ezu2@cdc.gov NR 37 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD MAR PY 2017 VL 139 IS 3 AR e20162536 DI 10.1542/peds.2016-2536 PG 8 WC Pediatrics SC Pediatrics GA EM0IY UT WOS:000395003200029 ER PT J AU Pohl, HR Citra, M Abadin, HA Szadkowska-Stanczyk, I Kozajda, A Ingerman, L Nguyen, A Murray, HE AF Pohl, H. R. Citra, M. Abadin, H. A. Szadkowska-Stanczyk, I. Kozajda, A. Ingerman, L. Nguyen, A. Murray, H. E. TI Modeling emissions from CAFO poultry farms in Poland and evaluating potential risk to surrounding populations SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Animal feeding operations; Air pollution; Emissions modeling; Mixtures evaluation ID BIOAEROSOLS; EXPOSURE; MIXTURES; HOUSES AB The world-wide use of concentrated animal feeding operations (CAFOs) for livestock production demands the need to evaluate the potential impact to public health. We estimated the exposure of various airborne pollutants for populations residing in close proximity to 10 poultry CAFOs located in Central Poland. Ammonia (NH3), carbon dioxide (CO2), carbon monoxide (CO), hydrogen sulfide (H2S), methane (CH4), nitrogen dioxide (NO2), nitrous oxide (N2O), sulfur dioxide (SO2), and organic dust were the pollutants of interest for this study. Because no monitoring data were available, we used the steady-state Gaussian dispersion model AERMOD to estimate pollutant concentrations for the exposed population in order to calculate the hazard index (HI) for a combined mixture of chemicals. Our results indicate that while the levels of certain pollutants are expected to exceed background levels commonly found in the environment they did not result in calculated hazard indexes which exceeded unity suggesting low potential for adverse health effects for the surrounding community for the mixture of chemicals. The study was conducted through a cooperation between the Agency for Toxic Substances and Disease Registry (ATSDR) in the USA and the Nofer Institute of Occupational Medicine (NIOM) in Poland. (C) 2016 Published by Elsevier Inc. C1 [Pohl, H. R.; Abadin, H. A.; Murray, H. E.] US Dept HHS, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Citra, M.; Ingerman, L.; Nguyen, A.] SRC Inc, North Syracuse, NY USA. [Szadkowska-Stanczyk, I.; Kozajda, A.] Nofer Inst Occupat Med, Lodz, Poland. RP Pohl, HR (reprint author), ATSDR, Pohl HR, 1600 Clifton Rd,MS-F57, Atlanta, GA 30333 USA. EM hpohl@cdc.gov NR 33 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 EI 1096-0295 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD MAR PY 2017 VL 84 BP 18 EP 25 DI 10.1016/j.yrtph.2016.11.005 PG 8 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA EL9FC UT WOS:000394924300003 PM 27986593 ER PT J AU Hsu, CH Brown, CM Murphy, JM Haskell, MG Williams, C Feldman, K Mitchell, K Blanton, JD Petersen, BW Wallace, RM AF Hsu, C. H. Brown, C. M. Murphy, J. M. Haskell, M. G. Williams, C. Feldman, K. Mitchell, K. Blanton, J. D. Petersen, B. W. Wallace, R. M. TI Perceptions and Practices of Mass Bat Exposure Events in the Setting of Rabies Among US Public Health Agencies SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Bats; rabies; prophylaxis; human; exposures; guidelines ID UNITED-STATES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RECOMMENDATIONS; SURVEILLANCE; PROPHYLAXIS; HUMANS AB Current guidelines in the setting of exposures to potentially rabid bats established by the Advisory Committee on Immunization Practices (ACIP) address post-exposure prophylaxis (PEP) administration insituations where a person may not be aware that a bite or direct contact has occurred and the bat is not available for diagnostic testing. These include instances when a bat is discovered in a room where a person awakens from sleep, is a child without an adult witness, has a mental disability or is intoxicated. The current ACIP guidelines, however, do not address PEP in the setting of multiple persons exposed to a bat or a bat colony, otherwise known as mass bat exposure (MBE) events. Due to a dearth of recommendations for response to these events, the reported reactions by public health agencies have varied widely. To address this perceived limitation, a survey of 45 state public health agencies was conducted to characterize prior experiences with MBE and practices to mitigate the public health risks. In general, most states (69% of the respondents) felt current ACIP guidelines were unclear in MBE scenarios. Thirty-three of the 45 states reported prior experience with MBE, receiving an average of 16.9 MBE calls per year and an investment of 106.7 person-hours annually on MBE investigations. PEP criteria, investigation methods and the experts recruited in MBE investigations varied between states. These dissimilarities could reflect differences in experience, scenario and resources. The lack of consistency in state responses to potential mass exposures to a highly fatal disease along with the large contingent of states dissatisfied with current ACIP guidance warrants the development of national guidelines in MBE settings. C1 [Hsu, C. H.; Blanton, J. D.; Petersen, B. W.; Wallace, R. M.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Hsu, C. H.] Epidem Intelligence Serv, Atlanta, GA USA. [Brown, C. M.] Massachusetts Dept Publ Hlth, State Lab Inst, Jamaica Plain, NY USA. [Murphy, J. M.] Virginia Dept Hlth, Off Epidemiol, Richmond, VA USA. [Haskell, M. G.; Williams, C.] North Carolina Dept Hlth & Human Serv, Communicable Dis Branch, Div Publ Hlth, Raleigh, NC USA. [Feldman, K.; Mitchell, K.] Maryland Dept Hlth & Mental Hyg, Ctr Zoonot & Vector Borne Dis, Baltimore, MD USA. RP Hsu, CH (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM chsu@cdc.gov NR 19 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD MAR PY 2017 VL 64 IS 2 BP 127 EP 136 DI 10.1111/zph.12289 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA EL8YB UT WOS:000394905200007 PM 27389926 ER PT J AU McLellan, DL Williams, JA Katz, JN Pronk, NP Wagner, GR Caban-Martinez, AJ Nelson, CC Sorensen, G AF McLellan, Deborah L. Williams, Jessica A. Katz, Jeffrey N. Pronk, Nicolaas P. Wagner, Gregory R. Caban-Martinez, Alberto J. Nelson, Candace C. Sorensen, Glorian TI Key Organizational Characteristics for Integrated Approaches to Protect and Promote Worker Health in Smaller Enterprises SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID SMALL BUSINESS; BEHAVIOR-CHANGE; UNITED-STATES; WORKPLACE; EMPLOYERS; SAFETY; IMPLEMENTATION; INTERVENTION; WELLWORKS-2; PERFORMANCE AB Objective: The aim of this study was to investigate relationships between worksite organizational characteristics (size, industrial sector, leadership commitment, and organizational supports) and integrated approaches to protecting and promoting worker health implemented in smaller enterprises. Methods: We analyzed web-based survey data of Human Resource Managers at 114 smaller enterprises (<750 employees) to identify organizational factors associated with levels of integrated approaches among their work sites. Results: The companies' mean integration score was 13.6 (SD = 9.6) of a possible 44. In multivariate analyses, having a safety committee (P = 0.035) and top leadership support for health promotion (HP) (P = 0.004) were positively associated with higher integration scores. Conclusions: Smaller enterprises in one U.S. region have relatively low levels of implementing integrated safety and promotion approaches. Having a safety committee and leadership support for HP may be important contributors to implementing integrated approaches in smaller enterprises. C1 [McLellan, Deborah L.; Williams, Jessica A.; Sorensen, Glorian] Dana Farber Canc Inst, Boston, MA 02115 USA. [McLellan, Deborah L.; Katz, Jeffrey N.; Pronk, Nicolaas P.; Wagner, Gregory R.; Caban-Martinez, Alberto J.; Sorensen, Glorian] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Williams, Jessica A.] Univ Kansas, Sch Med, Kansas City, KS USA. [Katz, Jeffrey N.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Pronk, Nicolaas P.] HealthPartners Inc, Minneapolis, MN USA. [Wagner, Gregory R.] NIOSH, CDC, Washington, DC USA. [Caban-Martinez, Alberto J.] Univ Miami, Miller Sch Med, Sch Med, Miami, FL 33136 USA. [Nelson, Candace C.] Massachusetts Dept Publ Hlth, Boston, MA USA. RP McLellan, DL (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave,LW715, Boston, MA 02215 USA. EM deborah_mclellan@dfci.harvard.edu FU National Institute for Occupational Safety and Health [U19 OH008861] FX This work was supported by a grant from the National Institute for Occupational Safety and Health (U19 OH008861) for the Harvard School of Public Health Center for Work, Health and Well-being. NR 40 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD MAR PY 2017 VL 59 IS 3 BP 289 EP 294 DI 10.1097/JOM.0000000000000949 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN3JM UT WOS:000395904800010 PM 28267100 ER PT J AU Nishijima, DK Gaona, S Waechter, T Maloney, R Bair, T Blitz, A Elms, AR Farrales, RD Howard, C Montoya, J Bell, JM Coronado, VC Sugerman, DE Ballard, DW Mackey, KE Vinson, DR Holmes, JF AF Nishijima, Daniel K. Gaona, Samuel Waechter, Trent Maloney, Ric Bair, Troy Blitz, Adam Elms, Andrew R. Farrales, Roel D. Howard, Calvin Montoya, James Bell, Jeneita M. Coronado, Victor C. Sugerman, David E. Ballard, Dustin W. Mackey, Kevin E. Vinson, David R. Holmes, James F. TI Do EMS Providers Accurately Ascertain Anticoagulant and Antiplatelet Use in Older Adults with Head Trauma? SO PREHOSPITAL EMERGENCY CARE LA English DT Article DE Emergency Medical Services; anticoagulants; platelet aggregation inhibitors; medication reconciliation; head injuries; closed ID INTRACRANIAL HEMORRHAGE; BRAIN-INJURY; INTEROBSERVER AGREEMENT; EMERGENCY-MEDICINE; CLOPIDOGREL USE; WARFARIN; PATIENT; RISK; MANAGEMENT; MORTALITY AB Objective: Prehospital provider assessment of the use of anticoagulant or antiplatelet medications in older adults with head trauma is important. These patients are at increased risk for traumatic intracranial hemorrhage and therefore field triage guidelines recommend transporting these patients to centers capable of rapid evaluation and treatment. Our objective was to evaluate EMS ascertainment of anticoagulant and antiplatelet medication use in older adults with head trauma. Methods: A retrospective study of older adults with head trauma was conducted throughout Sacramento County. All 5 transporting EMS agencies and all 11 hospitals in the county were included in the study, which ran from January 2012 to December 2012. Patients 55years who were transported to a hospital by EMS after head trauma were included. We excluded patients transferred between two facilities, patients with penetrating head trauma, prisoners, and patients with unmatched hospital data. Anticoagulant and antiplatelet use were categorized as: warfarin, direct oral anticoagulants (DOAC; dabigatran, rivaroxaban, and apixaban), aspirin, and other antiplatelet agents (e.g., clopidogrel and ticagrelor). We calculated the percent agreement and kappa statistic for binary variables between EMS and emergency department (ED)/hospital providers. A kappa statistic 0.60 was considered acceptable agreement. Results: After excluding 174 (7.6%) patients, 2,110 patients were included for analysis; median age was 73years (interquartile range 62-85years) and 1,259 (60%) were male. Per ED/hospital providers, the use of any anticoagulant or antiplatelet agent was identified in 595 (28.2%) patients. Kappa statistics between EMS and ED/hospital providers for the specific agents were: 0.76 (95% CI 0.71-0.82) for warfarin, 0.45 (95% CI 0.19-0.71) for DOAC agents, 0.33 (95% CI 0.28-0.39) for aspirin, and 0.51 (95% CI 0.42-0.60) for other antiplatelet agents. Conclusions: The use of antiplatelet or anticoagulant medications in older adults who are transported by EMS for head trauma is common. EMS and ED/hospital providers have acceptable agreement with preinjury warfarin use but not with DOAC, aspirin, and other antiplatelet use. C1 [Nishijima, Daniel K.; Gaona, Samuel; Holmes, James F.] Univ Calif Davis, Sch Med, Dept Emergency Med, 4150 V St,PSSB 2100, Sacramento, CA 95817 USA. [Waechter, Trent] City Sacramento Fire Dept, Sacramento, CA USA. [Maloney, Ric] Sacramento Metropolitan Fire Dept, Sacramento, CA USA. [Bair, Troy] Cosumnes Community Serv Dist Fire Dept, Elk Grove, CA USA. [Blitz, Adam] Amer Med Response, Sacramento, CA USA. [Elms, Andrew R.; Mackey, Kevin E.] Kaiser Permanente South Sacramento, Med Ctr, Sacramento, CA USA. [Farrales, Roel D.] Mercy Gen Hosp, Sacramento, CA USA. [Howard, Calvin] City Folsom Fire Dept, Folsom, CA USA. [Montoya, James] Sutter Community Hosp, Sacramento, CA USA. [Bell, Jeneita M.; Coronado, Victor C.; Sugerman, David E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ballard, Dustin W.] Kaiser Permanente San Rafael Med Ctr, San Rafael, CA USA. [Vinson, David R.] Kaiser Permanente Sacramento Med Ctr, Sacramento, CA USA. RP Nishijima, DK (reprint author), Univ Calif Davis, Sch Med, Dept Emergency Med, 4150 V St,PSSB 2100, Sacramento, CA 95817 USA. EM dnishijima@ucdavis.edu FU Centers for Disease Control and Prevention (CDC) [U01CE002177]; Mentored Clinical Research Training Program Award from the National Center for Advancing Translational Sciences (NCATS) [UL1TR000002, KL2TR000134]; NIH Roadmap for Medical Research FX This work was funded by the Centers for Disease Control and Prevention (CDC), grant number U01CE002177. Dr. Nishijima was supported through Mentored Clinical Research Training Program Award (Grant Number UL1TR000002 and linked award KL2TR000134) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 39 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1090-3127 EI 1545-0066 J9 PREHOSP EMERG CARE JI Prehosp. Emerg. Care PD MAR-APR PY 2017 VL 21 IS 2 BP 209 EP 215 DI 10.1080/10903127.2016.1218985 PG 7 WC Emergency Medicine; Public, Environmental & Occupational Health SC Emergency Medicine; Public, Environmental & Occupational Health GA EN1CM UT WOS:000395748100009 PM 27636529 ER PT J AU Purdy, MA Sue, A AF Purdy, Michael A. Sue, Amanda TI The effect of phylogenetic signal reduction on genotyping of hepatitis E viruses of the species Orthohepevirus A SO ARCHIVES OF VIROLOGY LA English DT Article ID PARTIAL GENOMIC REGIONS; FULL-LENGTH GENOME; BOOTSTRAP; CLASSIFICATION; VARIABILITY; HEPEVIRIDAE; INFECTION; FAMILY; TREES AB Commonly, hepatitis E virus (HEV) sequences are genotyped phylogenetically using subgenomic sequences. This paper examines this practice with sequences from members of the species Orthohepevirus A. As the length of sequences becomes progressively shorter, the number of identical sequences in an alignment tends to increase; however, these sequences retain their genotypic identity down to 100 nucleotides in length. The best substitution models tend to become less parameterized, bootstrap support decreases, and trees created from short subgenomic fragments are less likely to be isomorphic with trees from longer subgenomic fragments or complete genome sequences. However, it is still possible to correctly genotype sequences using fragments as small as 200 nucleotides. While it is possible to correctly genotype sequences with short subgenomic sequences, the estimates of evolutionary relationships between genotypes degrade to such an extent that sequences below 1600 nucleotides long cannot be used reliably to study these relationships, and comparisons of trees from different subgenomic regions with little or no sequence overlap can be problematic. Subtyping may be done, but it requires a careful examination of the region to be used to ensure that it correctly resolves the subtypes. C1 [Purdy, Michael A.; Sue, Amanda] Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. RP Purdy, MA (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM mup3@cdc.gov NR 25 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD MAR PY 2017 VL 162 IS 3 BP 645 EP 656 DI 10.1007/s00705-016-3135-x PG 12 WC Virology SC Virology GA EM2ZW UT WOS:000395185300006 PM 27817109 ER PT J AU Paudel, KP Hampton, LM Gurung, S Bohara, R Rai, IK Anaokar, S Swift, RD Cochi, S AF Paudel, Krishna P. Hampton, Lee M. Gurung, Santosh Bohara, Rajendra Rai, Indra K. Anaokar, Sameer Swift, Rachel D. Cochi, Stephen TI Adapting Nepal's polio eradication programme SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID ELIMINATION; VACCINE AB Problem Many countries have weak disease surveillance and immunization systems. The elimination of polio creates an opportunity to use staff and assets from the polio eradication programme to control other vaccine-preventable diseases and improve disease surveillance and immunization systems. Approach In 2003, the active surveillance system of Nepal's polio eradication programme began to report on measles and neonatal tetanus cases. Japanese encephalitis and rubella cases were added to the surveillance system in 2004. Staff from the programme aided the development and implementation of government immunization policies, helped launch vaccination campaigns, and trained government staff in reporting practices and vaccine management. Local setting Nepal eliminated indigenous polio in 2000, and controlled outbreaks caused by polio importations between 2005 and 2010. Relevant changes In 2014, the surveillance activities had expanded to 299 sites, with active surveillance for measles, rubella and neonatal tetanus, including weekly visits from 15 surveillance medical officers. Sentinel surveillance for Japanese encephalitis consisted of 132 sites. Since 2002, staff from the eradication programme have helped to introduce six new vaccines and helped to secure funding from Gavi, the Vaccine Alliance. Staff have also assisted in responding to other health events in the country. Lesson learnt By expanding the activities,of its polio eradication programme, Nepal has improved its surveillance and immunization systems and increased vaccination coverage of other vaccine-preventable diseases. Continued donor support, a close collaboration with the Expanded Programme on Immunization, and the retention of the polio eradication programme's skilled workforce were important for this expansion. C1 [Paudel, Krishna P.] Govt Nepal, Minist Hlth & Populat, Kathmandu, Nepal. [Hampton, Lee M.; Cochi, Stephen] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gurung, Santosh; Bohara, Rajendra; Rai, Indra K.] World Hlth Org, Reg Off Western Pacific, Expanded Programme Immunizat, POB 2932, Manila 1000, Philippines. [Anaokar, Sameer; Swift, Rachel D.] Boston Consulting Grp Inc, Boston, MA USA. RP Gurung, S (reprint author), World Hlth Org, Reg Off Western Pacific, Expanded Programme Immunizat, POB 2932, Manila 1000, Philippines. EM gurungs@who.int NR 16 TC 0 Z9 0 U1 0 U2 0 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 EI 1564-0604 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD MAR PY 2017 VL 95 IS 3 BP 227 EP 232 DI 10.2471/BLT.16.173674 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4IX UT WOS:000395972300012 PM 28250536 ER PT J AU Kirk, MD Angulo, FJ Havelaar, AH Black, RE AF Kirk, Martyn D. Angulo, Frederick J. Havelaar, Arie H. Black, Robert E. TI Diarrhoeal disease in children due to contaminated food SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Editorial Material ID BANGLADESH; HYGIENE; EDUCATION C1 [Kirk, Martyn D.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia. [Angulo, Frederick J.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. [Havelaar, Arie H.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA. [Black, Robert E.] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Int Programs, Baltimore, MD USA. RP Kirk, MD (reprint author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia. EM martyn.kirk@anu.edu.au NR 12 TC 0 Z9 0 U1 0 U2 0 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 EI 1564-0604 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD MAR PY 2017 VL 95 IS 3 BP 233 EP 234 DI 10.2471/BLT.16.173229 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN4IX UT WOS:000395972300013 PM 28250537 ER PT J AU Jeffries, C Lobue, P Chorba, T Metchock, B Kashef, I AF Jeffries, Carla Lobue, Phil Chorba, Terence Metchock, Beverly Kashef, Ijaz TI Role of the Health Department in Tuberculosis Prevention and Control-Legal and Public Health Considerations SO MICROBIOLOGY SPECTRUM LA English DT Article ID US-BOUND IMMIGRANTS; NEW-YORK-CITY; UNITED-STATES; INFECTION; POPULATION; UPDATE; COUNTY; RIFAPENTINE; DETENTION; PROGRAMS AB Because tuberculosis is caused by an infectious organism that is spread from person to person through the air, public health measures are essential to control the disease. There are three priority strategies for tuberculosis prevention and control in the United States: (i) identifying and treating persons who have tuberculosis disease; (ii) finding persons exposed to infectious tuberculosis patients, evaluating them for Mycobacterium tuberculosis infection and disease, and providing subsequent treatment, if appropriate; and (iii) testing populations at high risk for latent tuberculosis infection (LTBI) and treating those persons who are infected to prevent progression to disease. These strategies for prevention and control of tuberculosis are discussed in a framework containing the following important topics: historical and epidemiological context of tuberculosis control, organization of public health tuberculosis control programs, legal basis for public health authority, conducting overall planning and development of policy, identifying persons who have clinically active tuberculosis, evaluation of immigrants, managing persons who have or who are suspected of having disease, medical consultation, interjurisdictional referrals, identifying and managing persons infected with Mycobacterium tuberculosis, providing laboratory and diagnostic services, collecting and analyzing data, and providing training and education. This chapter describes the role of the health department in the context of these components. This discussion is primarily applicable to tuberculosis prevention and control programs in the United States. C1 [Jeffries, Carla; Lobue, Phil; Chorba, Terence; Metchock, Beverly] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Kashef, Ijaz] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA 30333 USA. RP Jeffries, C (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM hhx3@cdc.gov NR 55 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA EI 2165-0497 J9 MICROBIOL SPECTR JI Microbiol. Spectr. PD MAR PY 2017 VL 5 IS 2 AR UNSP TNMI7-0034-2016 DI 10.1128/microbiolspec.TNMI7-0034-2016 PG 22 WC Microbiology SC Microbiology GA EP3IE UT WOS:000397275200005 ER PT J AU Gaskins, AJ Chavarro, JE Rich-Edwards, JW Missmer, SA Laden, F Henn, SA Lawson, CC AF Gaskins, Audrey J. Chavarro, Jorge E. Rich-Edwards, Janet W. Missmer, Stacey A. Laden, Francine Henn, Scott A. Lawson, Christina C. TI Occupational use of high-level disinfectants and fecundity among nurses SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Article DE exposure; healthcare; Nurses' Health Study 3; occupational exposure; occupational health; pregnancy; protective equipment; sterilant; time to pregnancy ID CURRENT-DURATION APPROACH; HEALTH-CARE WORKERS; ETHYLENE-OXIDE; UNITED-STATES; MICE; PREGNANCY; EXPOSURE; RATS; GLUTARALDEHYDE; TERATOGENICITY AB Objective This study aimed to examine the relationship between occupational use of high-level disinfectants (HLD) and fecundity among female nurses. Methods Women currently employed outside the home and trying to get pregnant (N=1739) in the Nurses' Health Study 3 cohort (2010-2014) were included in this analysis. Occupational exposure to HLD used to disinfect medical instruments and use of protective equipment (PE) was self-reported on the baseline questionnaire. Every six months thereafter women reported the duration of their ongoing pregnancy attempt. Multivariable accelerated failure time models were used to estimate time ratios (TR) and 95% confidence intervals (95% CI). Results Nurses exposed to HLD prior to and at baseline had a 26% (95% CI 8-47%) and 12% (95% CI -2-28%) longer median duration of pregnancy attempt compared to nurses who were never exposed. Among nurses exposed at baseline to HLD, use of PE attenuated associations with fecundity impairments. Specifically, women using 0,1, and >= 2 types of PE had 18% (95% CI-7-49%), 16% (95%-3-39%), and 0% (95%-22-28%) longer median durations of pregnancy attempt compared to women who were never exposed. While the use of PE varied greatly by type (9% for respiratory protection to 69% for protective gloves), use of each PE appeared to attenuate the associations of HLD exposure with reduced fecundity. Conclusion Occupational use of HLD is associated with reduced fecundity among nurses, but use of PE appears to attenuate this risk. C1 [Gaskins, Audrey J.; Chavarro, Jorge E.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Gaskins, Audrey J.; Chavarro, Jorge E.; Rich-Edwards, Janet W.; Missmer, Stacey A.; Laden, Francine] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Chavarro, Jorge E.; Rich-Edwards, Janet W.; Missmer, Stacey A.; Laden, Francine; Henn, Scott A.; Lawson, Christina C.] Harvard Med Sch, Boston, MA USA. [Chavarro, Jorge E.; Rich-Edwards, Janet W.; Missmer, Stacey A.; Laden, Francine] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Rich-Edwards, Janet W.] Brigham & Womens Hosp, Dept Med, Connors Ctr Womens Hlth & Gender Biol, 75 Francis St, Boston, MA 02115 USA. [Missmer, Stacey A.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, 75 Francis St, Boston, MA 02115 USA. [Laden, Francine] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Henn, Scott A.; Lawson, Christina C.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Gaskins, AJ (reprint author), Harvard TH Chan Sch Publ Hlth, Bldg 2,3rd Floor,655 Huntington Ave, Boston, MA 02115 USA. EM ajg219@mail.harvard.edu FU CDC/NIOSH [200-2013-M-54978]; Breast Cancer Research Foundation; NICHD [L50-HD085359] FX The authors were supported by contract 200-2013-M-54978 from CDC/NIOSH, a grant from the Breast Cancer Research Foundation, and L50-HD085359 from NICHD. The funding sources had no influence on the study design, data analysis, writing of the report, or the decision to submit the findings of the present study for publication. NR 42 TC 0 Z9 0 U1 0 U2 0 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 EI 1795-990X J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PD MAR PY 2017 VL 43 IS 2 BP 171 EP 180 DI 10.5271/sjweh.3623 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN2OG UT WOS:000395849200010 PM 28125764 ER PT J AU Talundzic, E Ndiaye, YD Deme, AB Olsen, C Patel, DS Biliya, S Daniels, R Vannberg, FO Volkman, SK Udhayakumar, V Ndiaye, D AF Talundzic, Eldin Ndiaye, Yaye D. Deme, Awa B. Olsen, Christian Patel, Dhruviben S. Biliya, Shweta Daniels, Rachel Vannberg, Fredrik O. Volkman, Sarah K. Udhayakumar, Venkatachalam Ndiaye, Daouda TI Molecular Epidemiology of Plasmodium falciparum kelch13 Mutations in Senegal Determined by Using Targeted Amplicon Deep Sequencing SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article DE Plasmodium falciparum; artemisinin resistance; kelch13; molecular epidemiology ID ANTIMALARIAL-DRUG RESISTANCE; REAL-TIME PCR; ARTEMISININ RESISTANCE; MALARIA; POLYMORPHISMS; POPULATIONS; CAMBODIA; SPREAD; GENES AB The emergence of Plasmodium falciparum resistance to artemisinin in Southeast Asia threatens malaria control and elimination activities worldwide. Multiple polymorphisms in the P. falciparum kelch gene found in chromosome 13 (Pfk13) have been associated with artemisinin resistance. Surveillance of potential drug resistance loci within a population that may emerge under increasing drug pressure is an important public health activity. In this context, P. falciparum infections from an observational surveillance study in Senegal were genotyped using targeted amplicon deep sequencing (TADS) for Pfk13 polymorphisms. The results were compared to previously reported Pfk13 polymorphisms from around the world. A total of 22 Pfk13 propeller domain polymorphisms were identified in this study, of which 12 have previously not been reported. Interestingly, of the 10 polymorphisms identified in the present study that were also previously reported, all had a different amino acid substitution at these codon positions. Most of the polymorphisms were present at low frequencies and were confined to single isolates, suggesting they are likely transient polymorphisms that are part of naturally evolving parasite populations. The results of this study underscore the need to identify potential drug resistance loci existing within a population, which may emerge under increasing drug pressure. C1 [Talundzic, Eldin; Patel, Dhruviben S.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA. [Talundzic, Eldin] Atlanta Res & Educ Fdn, VAMC, Atlanta, GA USA. [Ndiaye, Yaye D.; Deme, Awa B.; Ndiaye, Daouda] Univ Cheikh Anta Diop, Aristide Dantec Hosp, Lab Parasitol Mycol, Dakar, Senegal. [Olsen, Christian] Torq Informat, Mebane, NC USA. [Biliya, Shweta; Vannberg, Fredrik O.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Daniels, Rachel; Volkman, Sarah K.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA. [Daniels, Rachel; Volkman, Sarah K.] Broad Inst MIT & Harvard, Infect Dis Initiat, Cambridge, MA USA. [Volkman, Sarah K.] Simmons Coll, Sch Nursing & Hlth Sci, Boston, MA 02115 USA. RP Talundzic, E (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA.; Talundzic, E (reprint author), Atlanta Res & Educ Fdn, VAMC, Atlanta, GA USA. EM etalundzic@cdc.gov FU Advanced Molecular Detection (AMD) initiative at the CDC; Atlanta Research and Education Foundation (AREF) FX This work was made possible through support from the Advanced Molecular Detection (AMD) initiative at the CDC. E. T. is supported by the Atlanta Research and Education Foundation (AREF). The field work was supported by the NIH/ICEMR (International Centers of Excellence for Malaria Research, West Africa U19AI089696). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC. NR 32 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2017 VL 61 IS 3 AR UNSP e02116-16 DI 10.1128/AAC.02116-16 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA EL4QM UT WOS:000394605900058 ER PT J AU Li, J Hall, IJ Zhao, GX AF Li, Jun Hall, Ingrid J. Zhao, Guixiang TI Prostate cancer screening decision-making in three states: 2013 behavioral risk factor surveillance system analysis SO CANCER CAUSES & CONTROL LA English DT Article DE Shared decision-making; Prostate cancer screening; Prostate-specific antigen test ID NATIONAL-SURVEY; DISCUSSIONS; GUIDELINES; AIDS; CARE AB Given the discordant prostate cancer screening recommendations in the United States, shared decision-making (SDM) has become increasingly important. The objectives of this study were to determine who made the final decision to obtain prostate-specific antigen (PSA)-based screening and identify factors associated with the screening decision made by both patients and their health care providers. Using the 2013 Behavioral Risk Factor Surveillance System data from Delaware, Hawaii, and Massachusetts, we calculated weighted percentages of SDM. Associations between the SDM and sociodemographic, lifestyle, access to care, and PSA testing-related factors were assessed using multivariate logistic regression. There were 2,248 men aged 40 years or older who ever had a PSA-based screening in these three states. Only 36% of them made their prostate cancer screening decision jointly with their health care provider. Multivariate analyses showed that men who were married/living together or had a college degree and above were more likely to report having SDM than men who were never married or had less than high school education (P = 0.02 and 0.002). Moreover, men whose most recent PSA test occurred within the past year were more likely to report SDM than men who had the test done more than 2 years ago (P = 0.02). The majority of screening decisions were made by the patient or health care provider alone in these three states, not jointly, as recommended. Our study points to the need to promote SDM among patients and their health care providers before PSA testing. C1 [Li, Jun; Hall, Ingrid J.] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mail Stop F-76, Atlanta, GA 30341 USA. [Zhao, Guixiang] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Li, J (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mail Stop F-76, Atlanta, GA 30341 USA. EM ffa2@cdc.gov NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAR PY 2017 VL 28 IS 3 BP 235 EP 240 DI 10.1007/s10552-017-0860-8 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA EM0CI UT WOS:000394986000006 PM 28210882 ER PT J AU Van Epps, P Tumpey, T Pearce, MB Golding, H Higgins, P Hornick, T Burant, C Wilson, BM Banks, R Gravenstein, S Canaday, DH AF Van Epps, Puja Tumpey, Terrence Pearce, Melissa B. Golding, Hana Higgins, Patricia Hornick, Thomas Burant, Christopher Wilson, Brigid M. Banks, Richard Gravenstein, Stefan Canaday, David H. TI Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article DE Frailty; influenza vaccines ID HEMAGGLUTINATION INHIBITION ASSAY; HEALTH-CARE PERSONNEL; ANTIBODY-RESPONSE; UNITED-STATES; VACCINE EFFICACY; VIRUS; HOSPITALIZATIONS; PROTECTION; INFECTION; COMMUNITY AB Both preexisting immunity to influenza and age have been shown to be correlates of influenza vaccine responses. Frailty, an indicator of functional impairment in older adults, was also shown in one study to predict lower influenza vaccine responses among nonveterans. In the current study, we aimed to determine the associations between frailty, preexisting immunity, and immune responses to influenza vaccine among older veterans. We studied 117 subjects (age range, 62 to 95 years [median age, 81 years]), divided into three cohorts based on the Fried frailty test, i.e., nonfrail (NF) (n = 23 [median age, 68 years]), prefrail (n = 50 [median age, 80 years]), and frail (n = 44 [median age, 82 years]), during the 2010-2011 and 20112012 influenza seasons. Subjects received the seasonal trivalent inactivated influenza vaccine, and baseline and postvaccination samples were obtained. Anti-influenza humoral immunity, as measured by hemagglutination inhibition (HI) and microneutralization assays, was measured for influenza B, A(H1N1) pdm09, and A(H3N2) viruses. Postvaccination titers were not different between frail and NF subjects overall in this older subset of veterans. However, preexisting HI titers were strongly correlated with postvaccination titers among all functional status groups. When microneutralization titers were compared, the association between preexisting immunity and vaccine responses varied by frailty status, with the strongest correlation being observed for the NF group. In conclusion, preexisting immunity rather than frailty appeared to predict postvaccination titers in this older veteran cohort. C1 [Van Epps, Puja; Higgins, Patricia; Hornick, Thomas; Burant, Christopher; Wilson, Brigid M.; Banks, Richard; Canaday, David H.] Louis Stokes Cleveland VA Med Ctr, Geriatr Res Educ & Clin Ctr, Cleveland, OH 44106 USA. [Van Epps, Puja; Hornick, Thomas; Canaday, David H.] Case Western Reserve Univ, Dept Internal Med, Cleveland, OH 44106 USA. [Tumpey, Terrence; Pearce, Melissa B.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Golding, Hana] US FDA, Div Viral Prod, CBER, Silver Spring, MD USA. [Higgins, Patricia; Burant, Christopher] Case Western Reserve Univ, Sch Nursing, Cleveland, OH 44106 USA. [Gravenstein, Stefan] Case Western Reserve Univ, Dept Med, Div Geriatr, Cleveland, OH 44106 USA. RP Van Epps, P (reprint author), Louis Stokes Cleveland VA Med Ctr, Geriatr Res Educ & Clin Ctr, Cleveland, OH 44106 USA.; Van Epps, P (reprint author), Case Western Reserve Univ, Dept Internal Med, Cleveland, OH 44106 USA. EM puja.vanepps@va.gov FU VA Merit Review funds; NIH [AI108972] FX The work was supported by VA Merit Review funds and NIH grant AI108972. NR 41 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD MAR PY 2017 VL 24 IS 3 AR UNSP e00498 DI 10.1128/CVI.00498-16 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EN1US UT WOS:000395796300001 ER PT J AU Smith, RM Muehlenbachs, A Schaenmann, J Baxi, S Koo, S Blau, D Chin-Hong, P Thorner, AR Kuehnert, MJ Wheeler, K Liakos, A Jackson, JW Benedict, T da Silva, AJ Ritter, JM Rollin, D Metcalfe, M Goldsmith, CS Visvesvara, GS Basavaraju, SV Zaki, S AF Smith, Rachel M. Muehlenbachs, Atis Schaenmann, Joanna Baxi, Sanjiv Koo, Sophia Blau, Dianna Chin-Hong, Peter Thorner, Anna R. Kuehnert, Matthew J. Wheeler, Kristina Liakos, Alexis Jackson, Jonathan W. Benedict, Theresa da Silva, Alexandre J. Ritter, Jana M. Rollin, Dominique Metcalfe, Maureen Goldsmith, Cynthia S. Visvesvara, Govinda S. Basavaraju, Sridhar V. Zaki, Sherif TI Three Cases of Neurologic Syndrome Caused by Donor-Derived Microsporidiosis SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SOLID-ORGAN TRANSPLANTATION; ENCEPHALITOZOON-CUNICULI MICROSPORIDIOSIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; INFECTION; TRANSMISSION; RECIPIENT; DIARRHEA; DISEASE; PATIENT; AIDS AB In April 2014, a kidney transplant recipient in the United States experienced headache, diplopia, and confusion, followed by neurologic decline and death. An investigation to evaluate the possibility of donor-derived infection determined that 3 patients had received 4 organs (kidney, liver, heart/kidney) from the same donor. The liver recipient experienced tremor and gait instability; the heart/kidney and contralateral kidney recipients were hospitalized with encephalitis. None experienced gastrointestinal symptoms. Encephalitozoon cuniculi was detected by tissue PCR in the central nervous system of the deceased kidney recipient and in renal allograft tissue from both kidney recipients. Urine PCR was positive for E. cuniculi in the 2 surviving recipients. Donor serum was positive for E. cuniculi antibodies. E. cuniculi was transmitted to 3 recipients from 1 donor. This rare presentation of disseminated disease resulted in diagnostic delays. Clinicians should 'consider donor-derived microsporidial infection in organ recipients with unexplained encephalitis, even when gastrointestinal manifestations are absent. C1 [Smith, Rachel M.; Muehlenbachs, Atis; Blau, Dianna; Kuehnert, Matthew J.; Jackson, Jonathan W.; Benedict, Theresa; da Silva, Alexandre J.; Ritter, Jana M.; Rollin, Dominique; Metcalfe, Maureen; Goldsmith, Cynthia S.; Visvesvara, Govinda S.; Basavaraju, Sridhar V.; Zaki, Sherif] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A07, Atlanta, GA 30329 USA. [Schaenmann, Joanna] Univ Calif Los Angeles, Los Angeles, CA USA. [Baxi, Sanjiv; Chin-Hong, Peter] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Koo, Sophia; Thorner, Anna R.; Liakos, Alexis] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Koo, Sophia; Thorner, Anna R.; Liakos, Alexis] Harvard Med Sch, Boston, MA USA. [Wheeler, Kristina] OneLegacy, Los Angeles, CA USA. [Smith, Rachel M.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Smith, RM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A07, Atlanta, GA 30329 USA.; Smith, RM (reprint author), CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM rmsmith@cdc.gov NR 34 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 387 EP 395 DI 10.3201/eid2303.161580 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900002 PM 28220747 ER PT J AU Whittaker, R Economopoulou, A Dias, JG Bancroft, E Ramliden, M Celentano, LP AF Whittaker, Robert Economopoulou, Assimoula Dias, Joana Gomes Bancroft, Elizabeth Ramliden, Miriam Celentano, Lucia Pastore CA European Ctr Dis Prevention Contro TI Epidemiology of Invasive Haemophilus influenzae Disease, Europe, 2007-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ROUTINE CHILDHOOD VACCINATION; CONJUGATE VACCINE; MOLECULAR EPIDEMIOLOGY; HIB VACCINATION; B VACCINATION; UNITED-STATES; ENGLAND; IMPACT; WALES; INFECTIONS AB We describe the epidemiology of invasive Haemophilus influenzae disease during 2007-2014 in 12 European countries and assess overall H. influenzae disease trends by serotype and patient age. Mean annual notification rate was 0.6 cases/100,000 population, with an increasing annual trend of 3.3% (95% Cl 2.3% to 4.3%). The notification rate was highest-for patients <1 month of age (23.4 cases/100,000 population). Nontypeable H. influenzae (NTHi) caused 78% of all cases and showed increasing trends among persons <1 month and 2:20 years of age. Serotype f cases showed an increasing trend among persons 260 years of age. Serotype b cases showed decreasing trends among persons 1-5 months, 1-4 years, and 2:40 years of age. Sustained success of routine H. influenzae serotype b vaccination is evident. Surveillance systems must adopt a broad focus for invasive H. influenzae disease. Increasing reports of NTHi, particularly among neonates, highlight the potential benefit of a vaccine against NTHi. C1 [Whittaker, Robert; Economopoulou, Assimoula; Dias, Joana Gomes; Bancroft, Elizabeth; Ramliden, Miriam; Celentano, Lucia Pastore; European Ctr Dis Prevention Contro] European Ctr Dis Prevent & Control, Granits Vag 8, S-17165 Solna, Sweden. [Economopoulou, Assimoula] Hellen Ctr Dis Control & Prevent, Athens, Greece. [Bancroft, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ramliden, Miriam] Tufts Univ, Boston, MA 02111 USA. [Whittaker, Robert] European Ctr Dis Prevent & Control, Vaccine Preventable Dis Surveillance, Solna, Sweden. [Whittaker, Robert] Univ Southampton, Southampton SO9 5NH, Hants, England. [Whittaker, Robert] WHO, Geneva, Switzerland. RP Whittaker, R (reprint author), European Ctr Dis Prevent & Control, Granits Vag 8, S-17165 Solna, Sweden.; Whittaker, R (reprint author), European Ctr Dis Prevent & Control, Vaccine Preventable Dis Surveillance, Solna, Sweden.; Whittaker, R (reprint author), WHO, Geneva, Switzerland. EM Robert.Whittaker@ecdc.europa.eu NR 43 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 396 EP 404 DI 10.3201/eid2303.161552 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900003 PM 28220749 ER PT J AU Bhatnagar, J Rabeneck, DB Martines, RB Reagan-Steiner, S Ermias, Y Estetter, LBC Suzuki, T Ritter, J Keating, MK Hale, G Gary, J Muehlenbachs, A Lambert, A Lanciotti, R Oduyebo, T Meaney-Delman, D Bolanos, F Saad, EAP Shieh, WJ Zaki, SR AF Bhatnagar, Julu Rabeneck, Demi B. Martines, Roosecelis B. Reagan-Steiner, Sarah Ermias, Yokabed Estetter, Lindsey B. C. Suzuki, Tadaki Ritter, Jana Keating, M. Kelly Hale, Gillian Gary, Joy Muehlenbachs, Atis Lambert, Amy Lanciotti, Robert Oduyebo, Titilope Meaney-Delman, Dana Bolanos, Fernando Saad, Edgar Alberto Parra Shieh, Wun-Ju Zaki, Sherif R. TI Zika Virus RNA Replication and Persistence in Brain and Placental Tissue SO EMERGING INFECTIOUS DISEASES LA English DT Article ID DENGUE VIRUS; RT-PCR; INFECTION; MACROPHAGES; PREGNANCY; ANTIBODY; DEFECTS; BRAZIL; MICE AB Zika virus is causally linked with congenital microcephaly and may be associated with pregnancy loss. However, the mechanisms of Zika virus intrauterine transmission, replication, and tropism and persistence in tissues are poorly understood. We tested tissues from 52 case-patients: 8 infants with microcephaly who died and 44 women suspected of being infected with Zika virus during pregnancy. By reverse transcription PCR, tissues from 32 (62%) case-patients (brains from 8 infants with microcephaly and placental/fetal tissues from 24 women) were positive for Zika virus. In situ hybridization localized replicative Zika virus RNA in brains of 7 infants and in placentas of 9 women who had pregnancy losses during the first or second trimester. These findings demonstrate that Zika virus replicates and persists in fetal brains and placentas, providing direct evidence of its association with microcephaly. Tissue-based reverse transcription PCR extends the time frame of Zika virus detection in congenital and pregnancy-associated infections. C1 [Bhatnagar, Julu; Rabeneck, Demi B.; Martines, Roosecelis B.; Reagan-Steiner, Sarah; Ermias, Yokabed; Estetter, Lindsey B. C.; Suzuki, Tadaki; Ritter, Jana; Keating, M. Kelly; Hale, Gillian; Gary, Joy; Muehlenbachs, Atis; Oduyebo, Titilope; Meaney-Delman, Dana; Shieh, Wun-Ju; Zaki, Sherif R.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G32, Atlanta, GA 30329 USA. [Lambert, Amy; Lanciotti, Robert] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Bolanos, Fernando] Patol Hosp Univ Neiva, Neiva, Colombia. [Saad, Edgar Alberto Parra] Inst Nacl Salud, Bogota, Colombia. [Bhatnagar, Julu] CDC, Mol Pathol, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol,Natl Ctr, Atlanta, GA 30333 USA. RP Bhatnagar, J (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G32, Atlanta, GA 30329 USA.; Bhatnagar, J (reprint author), CDC, Mol Pathol, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol,Natl Ctr, Atlanta, GA 30333 USA. EM jbhatnagar@cdc.gov NR 40 TC 1 Z9 1 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 405 EP 414 DI 10.3201/eid2303.161499 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900004 PM 27959260 ER PT J AU Scott, C Cavanaugh, JS Silk, BJ Ershova, J Mazurek, GH LoBue, PA Moonan, PK AF Scott, Colleen Cavanaugh, Joseph S. Silk, Benjamin J. Ershova, Julia Mazurek, Gerald H. LoBue, Philip A. Moonan, Patrick K. TI Comparison of Sputum-Culture Conversion for Mycobacterium bovis and M-tuberculosis SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; DISEASE; HUMANS; MODEL; BCG AB Current US guidelines recommend longer treatment for tuberculosis (TB) caused by pyrazinamide-resistant organisms (e.g., Mycobacterium bovis) than for M. tuberculosis TB. We compared treatment response times for patients with M. bovis TB and M. tuberculosis TB reported in the United States during 2006-2013. We included culture-positive, pulmonary TB patients with genotyping results who received standard 4-drug treatment at the time of diagnosis. Time to sputum-culture conversion was defined as time between treatment start date and date of first consistently culture-negative sputum. We analyzed 297 case-patients with M. bovis TB and 30,848 case-patients with M. tuberculosis TB. After 2 months of treatment, 71% of M. bovis and 65% of M. tuberculosis TB patients showed conversion of sputum cultures to negative. Likelihood of culture conversion was higher for M. bovis than for M. tuberculosis, even after controlling for treatment administration type, sex, and a composite indicator of bacillary burden. C1 [Scott, Colleen; Cavanaugh, Joseph S.; Silk, Benjamin J.; Ershova, Julia; Mazurek, Gerald H.; LoBue, Philip A.; Moonan, Patrick K.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A04, Atlanta, GA 30329 USA. [Scott, Colleen] Ctr Dis Control & Prevent, Strateg Informat & Workforce Dev Branch, Div Global Immunizat, Ctr Global Hlth, Atlanta, GA USA. RP Scott, C (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A04, Atlanta, GA 30329 USA.; Scott, C (reprint author), Ctr Dis Control & Prevent, Strateg Informat & Workforce Dev Branch, Div Global Immunizat, Ctr Global Hlth, Atlanta, GA USA. EM ibk9@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 29 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 456 EP 462 DI 10.3201/eid2303.161916 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900010 PM 28221125 ER PT J AU Surie, D Fane, O Finlay, A Ogopotse, M Tobias, JL Click, ES Modongo, C Zetola, NM Moonan, PK Oeltmann, JE AF Surie, Diya Fane, Othusitse Finlay, Alyssa Ogopotse, Matsiri Tobias, James L. Click, Eleanor S. Modongo, Chawangwa Zetola, Nicola M. Moonan, Patrick K. Oeltmann, John E. CA Kopanyo Study Grp TI Molecular, Spatial, and Field Epidemiology Suggesting TB Transmission in Community, Not Hospital, Gaborone, Botswana SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TUBERCULOSIS TRANSMISSION AB During 2012-2015, 10 of 24 patients infected with matching genotypes of Mycobacterium tuberculosis received care at the same hospital in Gaborone, Botswana. Nosocomial transmission was initially suspected, but we discovered plausible sites of community transmission for 20 (95%) of 21 interviewed patients. Active case-finding at these sites could halt ongoing transmission. C1 [Surie, Diya] Ctr Dis Control & Prevent, Div Global HIV & TB, Ctr Global Hlth, Atlanta, GA USA. [Finlay, Alyssa; Click, Eleanor S.; Moonan, Patrick K.; Oeltmann, John E.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E04, Atlanta, GA 30329 USA. [Fane, Othusitse; Ogopotse, Matsiri; Modongo, Chawangwa; Zetola, Nicola M.] Botswana UPenn Partnership, Gaborone, Botswana. [Finlay, Alyssa] Ctr Dis Control & Prevent, Gaborone, Botswana. [Tobias, James L.] Northrop Grumman, Atlanta, GA USA. RP Surie, D (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E04, Atlanta, GA 30329 USA. EM dsurie@cdc.gov FU National Institutes of Health [R01A1097045]; United States President's Emergency Plan for AIDS Relief FX This work was supported by the National Institutes of Health (grant R01A1097045; principal investigator: N.M.Z.) and the United States President's Emergency Plan for AIDS Relief. NR 12 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 487 EP 490 DI 10.3201/eid2303.161183 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900015 PM 27869604 ER PT J AU Allana, S Shashkina, E Mathema, B Bablishvili, N Tukvadze, N Shah, NS Kempker, RR Blumberg, HM Moodley, P Mlisana, K Brust, JCM Gandhi, NR AF Allana, Salim Shashkina, Elena Mathema, Barun Bablishvili, Nino Tukvadze, Nestani Shah, N. Santa Kempker, Russell R. Blumberg, Henry M. Moodley, Pravi Mlisana, Koleka Brust, James C. M. Gandhi, Neel R. TI pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS AB Although pyrazinamide is commonly used for tuberculosis treatment, drug-susceptibility testing is not routinely available. We found polynnorphisms in the pncA gene for 70% of multidrug-resistant and 96% of extensively drug resistant Mycobacterium tuberculosis isolates from South Africa and Georgia. Assessment of pyrazinamide susceptibility may be prudent before using it in regimens for drug resistant tuberculosis. C1 [Allana, Salim; Kempker, Russell R.; Blumberg, Henry M.; Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE,Claudia Nance Rollins Bldg, Atlanta, GA 30322 USA. [Allana, Salim; Kempker, Russell R.; Blumberg, Henry M.; Gandhi, Neel R.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Shashkina, Elena] Rutgers State Univ, Publ Hlth Res Inst, Newark, NJ USA. [Mathema, Barun] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Bablishvili, Nino; Tukvadze, Nestani] Natl Ctr TB & Lung Dis, Tbilisi, Rep of Georgia. [Shah, N. Santa] Ctr Dis Control & Prevent, Atlanta, GA USA. [Moodley, Pravi; Mlisana, Koleka] Univ KwaZulu Natal, Durban, South Africa. [Moodley, Pravi; Mlisana, Koleka] Natl Hlth Lab Serv, Durban, South Africa. [Brust, James C. M.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Brust, James C. M.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA. RP Gandhi, NR (reprint author), Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd NE,Claudia Nance Rollins Bldg, Atlanta, GA 30322 USA. EM neel.r.gandhi@emory.edu FU US National Institutes of Health [R01A1089349, RO1A1087465, K23AI103044, D43TW007124]; National Institutes of Health [K23A1083088, K24AI114444]; Emory Center for AIDS Research [P30A1050409]; Einstein/Montefiore Institute for Clinical and Translational Research [UL1 TR001073]; Atlanta Clinical and Translational Science Institute [UL1TR000454] FX This study was funded by grants from the US National Institutes of Health: R01A1089349 (N.R.G.), RO1A1087465 (N.R.G.), K23AI103044 (R.R.K.), and D43TW007124 (H.M.B.). The study also received support in part from the following National Institutes of Health grants: K23A1083088 (J.C.M.B.), K24AI114444 (N.R.G.), Emory Center for AIDS Research P30A1050409, Einstein/Montefiore Institute for Clinical and Translational Research UL1 TR001073, and Atlanta Clinical and Translational Science Institute UL1TR000454. NR 15 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 491 EP 495 DI 10.3201/eid2303.161034 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900016 PM 28221108 ER PT J AU Gunter, SM Murray, KO Gorchakov, R Beddard, R Rossmann, SN Montgomery, SP Rivera, H Brown, EL Aguilar, D Widman, LE Garcia, MN AF Gunter, Sarah M. Murray, Kristy O. Gorchakov, Rodion Beddard, Rachel Rossmann, Susan N. Montgomery, Susan P. Rivera, Hilda Brown, Eric L. Aguilar, David Widman, Lawrence E. Garcia, Melissa N. TI Likely Autochthonous Transmission of Trypanosoma cruzi to Humans, South Central Texas, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID FORMER BLOOD-DONORS; CHAGAS-DISEASE; UNITED-STATES; INFECTION; RISK AB Chagas disease, caused by Trypanosoma cruzi, is a major neglected tropical disease affecting the Americas. The epidemiology of this disease in the United States is incomplete. We report evidence of likely autochthonous vectorborne transmission of T cruzi and health outcomes in T cruzi-seropositive blood donors in south central Texas, USA. C1 [Gunter, Sarah M.; Murray, Kristy O.; Gorchakov, Rodion; Aguilar, David; Garcia, Melissa N.] Baylor Coll Med, 1102 Bates Ave,Ste 550-02, Houston, TX 77030 USA. [Gunter, Sarah M.; Brown, Eric L.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Beddard, Rachel] South Texas Tissue & Blood Ctr, San Antonio, TX USA. [Rossmann, Susan N.] Gulf Coast Reg Blood Ctr, Houston, TX USA. [Montgomery, Susan P.; Rivera, Hilda] Ctr Dis Control & Prevent, Atlanta, GA USA. [Widman, Lawrence E.] Cardiac Elect Consultants South Texas PA, San Antonio, TX USA. RP Garcia, MN (reprint author), Baylor Coll Med, 1102 Bates Ave,Ste 550-02, Houston, TX 77030 USA. EM mnolan@bcm.edu FU Texas Children's Hospital and Baylor College of Medicine FX This study was supported by a private donation to the Texas Children's Hospital and Baylor College of Medicine. NR 15 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 500 EP 503 DI 10.3201/eid2303.161157 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900018 PM 28221110 ER PT J AU Gould, LH Kline, J Monahan, C Vierk, K AF Gould, L. Hannah Kline, Jennifer Monahan, Caitlin Vierk, Katherine TI Outbreaks of Disease Associated with Food Imported into the United States, 1996-2014(1) SO EMERGING INFECTIOUS DISEASES LA English DT Article AB The proportion of US food that is imported is increasing; most seafood and half of fruits are imported. We identified a small but increasing number of foodborne disease out-breaks associated with imported foods, most commonly fish and produce. New outbreak investigation tools and federal regulatory authority are key to maintaining food safety. C1 [Gould, L. Hannah; Kline, Jennifer] Ctr Dis Control & Prevent, Atlanta, GA USA. [Monahan, Caitlin; Vierk, Katherine] US FDA, College Pk, MD USA. RP Gould, LH (reprint author), NYC Dept Mental Hlth & Hyg, 42-09 28th St,7th Fl, Queens, NY 11101 USA. EM hgould@health.nyc.gov NR 11 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 525 EP 528 DI 10.3201/eid2303.161462 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900025 PM 28221117 ER PT J AU Benoit, SR Gregg, EW Jonnalagadda, S Phares, CR Zhou, WG Painter, JA AF Benoit, Stephen R. Gregg, Edward W. Jonnalagadda, Sasi Phares, Christina R. Zhou, Weigong Painter, John A. TI Association of Diabetes and Tuberculosis Disease among US-Bound Adult Refugees, 2009-2014 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID UNITED-STATES; IMMIGRANTS AB Diabetes is associated with an increased risk for active tuberculosis (TB) disease. We conducted a case control study and found a significant association between diabetes and TB disease among US-bound refugees. These findings underscore the value of collaborative management of both diseases. C1 [Benoit, Stephen R.; Gregg, Edward W.; Jonnalagadda, Sasi; Phares, Christina R.; Zhou, Weigong; Painter, John A.] Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F75, Atlanta, GA 30341 USA. RP Benoit, SR (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F75, Atlanta, GA 30341 USA. EM bvy8@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 543 EP 545 DI 10.3201/eid2303.161053 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900032 PM 28221111 ER PT J AU Apangu, T Griffith, K Abaru, J Candini, G Apio, H Okoth, F Okello, R Kaggwa, J Acayo, S Ezama, G Yockey, B Sexton, C Schriefer, M Mbidde, EK Mead, P AF Apangu, Titus Griffith, Kevin Abaru, Janet Candini, Gordian Apio, Harriet Okoth, Felix Okello, Robert Kaggwa, John Acayo, Sarah Ezama, Geoffrey Yockey, Brook Sexton, Christopher Schriefer, Martin Mbidde, Edward Katongole Mead, Paul TI Successful Treatment of Human Plague with Oral Ciprofloxacin SO EMERGING INFECTIOUS DISEASES LA English DT Letter AB The US Food and Drug Administration recently approved ciprofloxacin for treatment of plague (Yersina pestis infection) based on animal studies. Published evidence of efficacy in humans is sparse. We report 5 cases of culture-confirmed human plague treated successfully with oral ciprofloxacin, including 1 case of pneumonic plague. C1 [Apangu, Titus; Abaru, Janet; Candini, Gordian; Apio, Harriet; Okoth, Felix; Okello, Robert; Kaggwa, John; Acayo, Sarah; Ezama, Geoffrey; Mbidde, Edward Katongole] Uganda Virus Res Inst, Entebbe, Uganda. [Griffith, Kevin; Yockey, Brook; Sexton, Christopher; Schriefer, Martin; Mead, Paul] Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA. [Griffith, Kevin] Ft Lewis Coll, Durango, CO 81301 USA. RP Mead, P (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM pmead@cdc.gov FU Centers for Disease Control and Prevention [CK13001] FX The work was supported by the Centers for Disease Control and Prevention (Cooperative Agreement CK13001). NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 553 EP 555 DI 10.3201/eid2303.161212 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900037 ER PT J AU Chorba, T Jereb, J AF Chorba, Terence Jereb, John TI Keeping It in the Family: the Childhood Burden of Tuberculosis SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Chorba, Terence; Jereb, John] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E10, Atlanta, GA 30329 USA. RP Chorba, T (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E10, Atlanta, GA 30329 USA. EM tlc2@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2017 VL 23 IS 3 BP 561 EP 562 DI 10.3201/eid2303.AC2303 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL7WB UT WOS:000394830900043 ER PT J AU Kulkarni, R Presley, RJ Lusher, JM Shapiro, AD Gill, JC Manco-Johnson, M Koerper, MA Abshire, TC Dimichele, D Hoots, WK Mathew, P Nugent, DJ Geraghty, S Evatt, BL Soucie, JM AF Kulkarni, R. Presley, R. J. Lusher, J. M. Shapiro, A. D. Gill, J. C. Manco-Johnson, M. Koerper, M. A. Abshire, T. C. Dimichele, D. Hoots, W. K. Mathew, P. Nugent, D. J. Geraghty, S. Evatt, B. L. Soucie, J. M. TI Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System SO HAEMOPHILIA LA English DT Article DE babies; central venous access device; haemophilia; head trauma; inhibitors; intracranial hemorrhage ID AFFECTED INFANT; OPTIMAL-MODE; BLEEDING DISORDERS; CESAREAN DELIVERY; VAGINAL DELIVERY; FACTOR-VIII; DEFINITIONS; PROPHYLAXIS; DIAGNOSIS; BOYS AB Aim: To describe the prevalence and complications in babies <= 2 years with haemophilia. Methods: We used a standardized collection tool to obtain consented data on eligible babies aged <= 2 years with haemophilia enrolled in the Centers for Disease Control and Prevention Universal Data Collection System surveillance project at US Hemophilia Treatment Centers (HTCs). Results: Of 547 babies, 82% had haemophilia A, and 70% were diagnosed within one month of birth. Diagnosis was prompted by known maternal carrier status (40%), positive family history (23%), bleeding (35%) and unknown 2%; 81% bled during the first two years. The most common events were bleeding (circumcision, soft tissue, oral bleeding) and head injury. There were 46 episodes of intracranial haemorrhage (ICH) in 37 babies (7%): 18 spontaneous, 14 delivery related, 11 traumatic, 2 procedure related and 1 unknown cause. Of the 176 central venous access devices (CVADs) in 148 (27%) babies, there were 137 ports, 22 surgically inserted central catheters and 20 peripherally inserted central catheters. Ports had the lowest complication rates. Inhibitors occurred in 109 (20%) babies who experienced higher rates of ICH (14% vs. 5%; P = 0.002), CVAD placement (61% vs. 19%; P < 0.001) and CVAD complications (44% vs. 26%; P < 0.001). The most common replacement therapy was recombinant clotting factor concentrates. Conclusion: Bleeding events in haemophilic babies <= 2 years were common; no detectable difference in the rates of ICH by the mode of delivery was noted. Neonatal factor exposure did not affect the inhibitor rates. Minor head trauma, soft tissue and oropharyngeal bleeding were the leading indications for treatment. C1 [Kulkarni, R.] Michigan State Univ, Dept Pediat & Human Dev, B216 Clin Ctr, E Lansing, MI 48824 USA. [Presley, R. J.; Evatt, B. L.; Soucie, J. M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Lusher, J. M.] Childrens Hosp Michigan, Wayne State Med Ctr, Dept Pediat Hematol, Detroit, MI 48201 USA. [Shapiro, A. D.] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA. [Gill, J. C.] Blood Ctr Wisconsin, Comprehens Ctr Bleeding Disorders, Milwaukee, WI USA. [Manco-Johnson, M.] Univ Colorado, Dept Pediat, Aurora, CO USA. [Koerper, M. A.] UCSF Med Ctr, San Francisco, CA USA. [Abshire, T. C.] Blood Ctr Wisconsin, Milwaukee, WI USA. [Dimichele, D.] Div Blood Dis & Resources, Bethesda, MD USA. [Hoots, W. K.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA. [Mathew, P.] Univ New Mexico, Dept Pediat Hematol Oncol, Albuquerque, NM 87131 USA. [Nugent, D. J.] Childrens Hosp Orange Cty, Ctr Inherited Blood Disorders, Orange, CA 92668 USA. [Geraghty, S.] Univ Colorado Denver, Aurora, CO USA. RP Kulkarni, R (reprint author), Michigan State Univ, Dept Pediat & Human Dev, B216 Clin Ctr, E Lansing, MI 48824 USA. EM roshni.kulkarni@hc.msu.edu FU CDC; United States Hemophilia Treatment Center Network (US HTCN) FX The UDC project was funded by a cooperative agreement ('Prevention of Bleeding Disorder Complications through Regional Hemophilia Treatment Centers') between the CDC and the United States Hemophilia Treatment Center Network (US HTCN), which is comprised of >130 clinical centres located throughout the United States. The authors acknowledge with gratitude the staff of the US HTCN for recruiting patients to the UDC surveillance project and collecting the data. The authors also thank the regional coordinators, regional directors, patients and their families for their participation. The authors also thank the CDC Presentation and Publication Committee for their thorough review and very helpful comments and edits. NR 28 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAR PY 2017 VL 23 IS 2 BP 207 EP 214 DI 10.1111/hae.13081 PG 8 WC Hematology SC Hematology GA EP5GC UT WOS:000397406000006 PM 27813214 ER PT J AU Guh, S Grosse, SD Ullman, M Soucie, JM AF Guh, S. Grosse, S. D. Ullman, M. Soucie, J. M. TI Accounting for differences in healthcare utilization and expenditures among US males with haemophilia by type of health insurance SO HAEMOPHILIA LA English DT Letter ID EMERGENCY-DEPARTMENT; PROPENSITY SCORE; UNITED-STATES; MODELS C1 [Guh, S.; Grosse, S. D.; Soucie, J. M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Ullman, M.] Univ Texas Hlth Sci Ctr Houston, Gulf States Hemophilia & Thrombophilia Ctr, Houston, TX 77030 USA. RP Guh, S (reprint author), Blue Cross Blue Shield Louisiana, Adv Analyt, 5525 Reitz Ave, Baton Rouge, LA 70809 USA. EM soyeonguh@gmail.com NR 11 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD MAR PY 2017 VL 23 IS 2 BP E147 EP E151 DI 10.1111/hae.13161 PG 6 WC Hematology SC Hematology GA EP5GC UT WOS:000397406000034 PM 28155244 ER PT J AU Kruger, DL Rein, DB Kil, N Jordan, C Brown, KA Yartel, A Smith, BD AF Kruger, Danielle Liffmann Rein, David B. Kil, Natalie Jordan, Cynthia Brown, Kimberly A. Yartel, Anthony Smith, Bryce D. TI Implementation of Birth-Cohort Testing for Hepatitis C Virus: Lessons Learned From Three Primary Care Sites SO HEALTH PROMOTION PRACTICE LA English DT Article DE health promotion; program planning and evaluation; process evaluation; community intervention; public health laws/policies; health research ID UNITED-STATES; COST-EFFECTIVENESS; INFECTION; DESIGN AB Hepatitis C virus infection affects approximately 2.2 to 3.2 million Americans. In 2012, the Centers for Disease Control and Prevention recommended a one-time antibody test of all persons belonging to the 1945-1965 birth cohort. Efforts to implement this recommendation in clinical settings are in their infancy; this case study report therefore seeks to share the experiences of three sites that implemented interventions to increase birth-cohort testing through participation in the Birth-cohort Evaluation to Advance Screening and Testing for Hepatitis C. At each site, project managers completed standardized questionnaires about their implementation experiences, and a qualitative analysis was conducted of the responses. The testing interventions used in-person recruitment, mail recruitment, and an electronic health record prompt. Sites reported that early efforts to obtain stakeholder buy-in were critical to effectively implement and sustain interventions and that the intervention required additional staffing resources beyond those being used for risk-based testing. In each case, administrative barriers were more extensive than anticipated. For the electronic health record-based intervention, technological support was critical in achieving study goals. Despite these barriers, interventions in all sites were successful in increasing rates of testing and case identification, although future studies will need to evaluate the relative costs and benefits of each intervention. C1 [Kruger, Danielle Liffmann] Chartis Grp, 220 West Kinzie St,Third Floor, Chicago, IL 60654 USA. [Rein, David B.] Univ Chicago, NORC, Atlanta, GA USA. [Kil, Natalie] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Jordan, Cynthia] Univ Alabama Birmingham, Birmingham, AL USA. [Brown, Kimberly A.] Henry Ford Hosp, Detroit, MI 48202 USA. [Yartel, Anthony; Smith, Bryce D.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kruger, DL (reprint author), Chartis Grp, 220 West Kinzie St,Third Floor, Chicago, IL 60654 USA. EM dkruger@chartis.com FU Abbviemedical; Janssen; Novartis; Gilead; National Foundation for the Centers for Disease Control and Prevention, Inc. MOU [527-11 SC] FX K. A. Brown serves on advisory boards for Gilead, Abbviemedical, Janssen, Merck, and BMS. Her institution receives research grants from Abbviemedical, Janssen, Novartis, and Gilead for which she serves as principal investigator. This study was supported by the National Foundation for the Centers for Disease Control and Prevention, Inc. MOU # 527-11 SC. Danielle Liffmann Kruger was at NORC at the University of Chicago when she completed this study. NR 21 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8399 EI 1552-6372 J9 HEALTH PROMOT PRACT JI Health Promot. Pract. PD MAR PY 2017 VL 18 IS 2 BP 283 EP 289 DI 10.1177/1524839916661495 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP2NH UT WOS:000397219600015 PM 27496859 ER PT J AU Gonzalez, RS Salaria, SN Bohannon, CD Huber, AR Feely, MM Shi, CJ AF Gonzalez, Raul S. Salaria, Safia N. Bohannon, Caitlin D. Huber, Aaron R. Feely, Michael M. Shi, Chanjuan TI PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis' SO HISTOPATHOLOGY LA English DT Article DE colitis; gastroenteritis; gastrointestinal tract; immunotherapy; programmed cell death protein 1 ID IMMUNE CHECKPOINT INHIBITORS; AUTOIMMUNE ENTEROPATHY; ADVANCED MELANOMA; CANCER-THERAPY; COLITIS; SAFETY; IPILIMUMAB; TOLERANCE; RESPONSES; BLOCKADE AB Aims: PD-1 inhibitors facilitate immune response against certain tumour types, including melanoma. These drugs have led to prolonged survival but can also result in autoimmune-type side effects, including gastrointestinal inflammation. The histopathological effects of this medication class have not been well studied. Methods and results: We identified 37 gastrointestinal tract biopsies from 20 patients taking a PD-1 or PD-L1 inhibitor and evaluated clinicopathological findings. Diarrhoea was the most common symptom, and endoscopic findings ranged from mild erythema to erosion/ulceration. Common histological findings included lamina propria expansion, villous blunting (if applicable), intra-epithelial neutrophils and increased crypt/gland apoptosis, although intra-epithelial lymphocytes were rarely prominent. A few cases showed crypt rupture with resultant histiocytic/granulomatous response. Most patients responded to drug cessation and/or steroids, but follow-up endoscopies were not performed. Conclusions: PD-1/PD-L1 inhibitors can cause gastritis, enteritis and colitis, similar to other immunomodulatory antibodies (such as CTLA-4 inhibitors and PI3K delta inhibitors), but the histological findings vary somewhat among drug classes. Clinical history, lack of prominent intra-epithelial lymphocytes and crypt rupture may help to distinguish PD-1 inhibitor gastroenterocolitis from mimics, which include other medication effect, inflammatory bowel disease, graft-versus-host disease, cytomegalovirus infection and autoimmune enteropathy. C1 [Gonzalez, Raul S.; Huber, Aaron R.] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA. [Salaria, Safia N.; Shi, Chanjuan] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA. [Bohannon, Caitlin D.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Feely, Michael M.] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. RP Gonzalez, RS (reprint author), Univ Rochester, Med Ctr, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA. EM raul_gonzalez@urmc.rochester.edu NR 38 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0309-0167 EI 1365-2559 J9 HISTOPATHOLOGY JI Histopathology PD MAR PY 2017 VL 70 IS 4 BP 558 EP 567 DI 10.1111/his.13118 PG 10 WC Cell Biology; Pathology SC Cell Biology; Pathology GA EM0DD UT WOS:000394988100005 PM 28000302 ER PT J AU Huai, Y Guan, XH Liu, SL Uyeki, TM Jiang, H Klena, J Huang, JG Chen, MY Peng, YX Yang, H Luo, J Zheng, JD Peng, ZB Huo, XX Xiao, L Chen, H Zhang, YZ Xing, XS Feng, LZ Hu, DJ Yu, HJ Zhan, FX Varma, JK AF Huai, Yang Guan, Xuhua Liu, Shali Uyeki, Timothy M. Jiang, Hui Klena, John Huang, Jigui Chen, Maoyi Peng, Youxing Yang, Hui Luo, Jun Zheng, Jiandong Peng, Zhibin Huo, Xixiang Xiao, Lin Chen, Hui Zhang, Yuzhi Xing, Xuesen Feng, Luzhao Hu, Dale J. Yu, Hongjie Zhan, Faxian Varma, Jay K. TI Clinical characteristics and factors associated with severe acute respiratory infection and influenza among children in Jingzhou, China SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE children; influenza; risk factors; severe acute respiratory infection ID SEASONAL INFLUENZA; TOBACCO-SMOKE; VACCINE; HOSPITALIZATIONS; PNEUMONIA; COMMUNITY; EXPOSURE; THERAPY; BURDEN AB Background: Influenza is an important cause of respiratory illness in children, but data are limited on hospitalized children with laboratory-confirmed influenza in China. Methods: We conducted active surveillance for severe acute respiratory infection (SARI; fever and at least one sign or symptom of acute respiratory illness) among hospitalized pediatric patients in Jingzhou, Hubei Province, from April 2010 to April 2012. Data were collected from enrolled SARI patients on demographics, underlying health conditions, clinical course of illness, and outcomes. Nasal swabs were collected and tested for influenza viruses by reverse transcription polymerase chain reaction. We described the clinical and epidemiological characteristics of children with influenza and analyzed the association between potential risk factors and SARI patients with influenza. Results: During the study period, 15 354 children aged <15 years with signs and symptoms of SARI were enrolled at hospital admission. severe acute respiratory infection patients aged 5-15 years with confirmed influenza (H3N2) infection were more likely than children without influenza to have radiographic diagnosis of pneumonia (11/31, 36% vs 15/105, 14%. P<.05). Only 16% (1116/7145) of enrolled patients had received seasonal trivalent influenza vaccination within 12 months of hospital admission. Non-vaccinated influenza cases were more likely than vaccinated influenza cases to have pneumonia (31/133, 23% vs 37/256, 15%, P<.05). severe acute respiratory infection cases aged 5-15 years diagnosed with influenza were also more likely to have a household member who smoked cigarettes compared with SARI cases without a smoking household member (54/208, 26% vs 158/960, 16%, P<.05). Conclusions: Influenza A (H3N2) virus infection was an important contributor to pneumonia requiring hospitalization. Our results highlight the importance of surveillance in identifying factors for influenza hospitalization, monitoring adherence to influenza prevention and treatment strategies, and evaluating the disease burden among hospitalized pediatric SARI patients. Influenza vaccination promotion should target children. C1 [Huai, Yang; Klena, John; Zhang, Yuzhi; Hu, Dale J.; Varma, Jay K.] Ctr Dis Control & Prevent, Ctr Global Hlth, China US Collaborat Program Emerging & Reemerging, Beijing, Peoples R China. [Guan, Xuhua; Huo, Xixiang; Chen, Hui; Xing, Xuesen; Zhan, Faxian] Hubei Prov Ctr Dis Control & Prevent, Wuhan, Peoples R China. [Liu, Shali; Huang, Jigui; Xiao, Lin] Jingzhou Cent Hosp, Jingzhou, Peoples R China. [Uyeki, Timothy M.] Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. [Jiang, Hui; Zheng, Jiandong; Peng, Zhibin; Feng, Luzhao; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China. [Klena, John; Hu, Dale J.; Varma, Jay K.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Chen, Maoyi] Jingzhou Ctr Dis Control & Prevent, Jingzhou, Peoples R China. [Peng, Youxing] Jingzhou First Peoples Hosp, Jingzhou, Peoples R China. [Yang, Hui] Jingzhou Second Peoples Hosp, Jingzhou, Peoples R China. [Luo, Jun] Jingzhou Maternal & Childrens Hosp, Jingzhou, Peoples R China. [Hu, Dale J.] NIAID, Vaccine Clin Res Branch, Vaccine Res Program, Div AIDS,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. RP Zhan, FX (reprint author), Hubei Prov Ctr Dis Control & Prevent, Wuhan, Peoples R China. EM zhanfx@163.com FU Centers for Disease Control and Prevention [5U2GGH000018] FX This study was supported by the Cooperative Agreement Number, 5U2GGH000018, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. NR 31 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2017 VL 11 IS 2 BP 148 EP 156 DI 10.1111/irv.12419 PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA EL9SW UT WOS:000394961400006 PM 27465959 ER PT J AU Haque, F Sturm-Ramirez, K Homaira, N Gurley, ES Hossain, MJ Hasan, SMM Chowdhury, S Sarkar, S Khan, AKM Rahman, M Rahman, M Luby, SP AF Haque, Farhana Sturm-Ramirez, Katharine Homaira, Nusrat Gurley, Emily Suzane Hossain, Md Jahangir Hasan, S. M. Murshid Chowdhury, Sukanta Sarkar, Shamim Khan, Abdul Khaleque Md Dawlat Rahman, Mustafizur Rahman, Mahmudur Luby, Stephen P. TI Influenza B virus outbreak at a religious residential school for boys in Northern Bangladesh, 2011 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Bangladesh; epidemic; influenza B virus; school dormitory ID SURVEILLANCE AB Background: National media reported a febrile illness among dormitory residents of a boys' religious school. We investigated the outbreak to identify cause. Methods: Individuals with fever (>100 degrees F) and cough or sore throat between 1 and 13 August 2011 were influenza-like-illness (ILI) case-patients. We collected histories and specimens from hospitalized case-patients and visited campus to explore environmental context. Results: All 28 case-patients were dormitory residents including 27 hospitalizations. Accommodation space per resident was <0.8 square metres. Nasal and oropharyngeal swabs from 22 case-patients were positive for influenza B virus using real-time reverse transcription polymerase chain reaction (rRT-PCR). Conclusions: Overcrowding likely facilitated transmission leading to this dormitory outbreak. C1 [Haque, Farhana; Sturm-Ramirez, Katharine; Homaira, Nusrat; Gurley, Emily Suzane; Hossain, Md Jahangir; Hasan, S. M. Murshid; Chowdhury, Sukanta; Sarkar, Shamim; Khan, Abdul Khaleque Md Dawlat; Rahman, Mustafizur; Luby, Stephen P.] Icddr B, IDD, PEI, Dhaka, Bangladesh. [Haque, Farhana; Rahman, Mahmudur] IEDCR, Dhaka, Bangladesh. [Sturm-Ramirez, Katharine; Luby, Stephen P.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Haque, F (reprint author), Ctr Communicable Icddr B, IDD, PEI, Dhaka 1212, Bangladesh. EM farhanahaque@icddrb.org RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 FU Centers for Disease Control and Prevention (CDC), Atlanta; Government of the People's Republic of Bangladesh (GoB) FX Centers for Disease Control and Prevention (CDC), Atlanta; Government of the People's Republic of Bangladesh (GoB) NR 16 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2017 VL 11 IS 2 BP 165 EP 169 DI 10.1111/irv.12430 PG 5 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA EL9SW UT WOS:000394961400008 PM 27603154 ER PT J AU Xiang, NJ Bai, T Kang, K Yuan, H Zhou, SZ Ren, RQ Li, XY Wu, JB Deng, LQ Zeng, G Wang, XJ Mao, SH Shi, J Gao, RB Chen, T Zou, SM Li, D Havers, F Widdowson, MA Greene, CM Zhang, YP Ni, DX Liu, XQ Li, Q Shu, YL AF Xiang, Nijuan Bai, Tian Kang, Kai Yuan, Hui Zhou, Suizan Ren, Ruiqi Li, Xiuying Wu, Jiabing Deng, Liquan Zeng, Ge Wang, Xianjun Mao, Shenghua Shi, Jian Gao, Rongbao Chen, Tao Zou, Sumei Li, Dan Havers, Fiona Widdowson, Marc-Alain Greene, Carolyn M. Zhang, Yanping Ni, Daxin Liu, Xiaoqing Li, Qun Shu, Yuelong TI Sero-epidemiologic study of influenza A(H7N9) infection among exposed populations, China 2013-2014 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE avian influenza; close contact; general population; H7N9 virus; poultry workers; serology ID A H7N9 VIRUS AB Background: The first human infections of novel avian influenza A(H7N9) virus were identified in China in March 2013. Sentinel surveillance systems and contact tracing may not identify mild and asymptomatic human infections of influenza A(H7N9) virus. Objectives: We assessed the seroprevalence of antibodies to influenza A(H7N9) virus in three populations during the early stages of the epidemic. Patients/Methods: From March 2013 to May 2014, we collected sera from the general population, poultry workers, and contacts of confirmed infections in nine Chinese provinces reporting human A(H7N9) infections and, for contacts, second sera 2-3 weeks later. We screened for A(H7N9) antibodies by advanced hemagglutination inhibition (HI) assay and tested sera with HI titers >= 20 by modified microneutralization (MN) assay. MN titers >= 20 or fourfold increases in paired sera were considered seropositive. Results: Among general population sera (n=1480), none were seropositive. Among poultry worker sera (n=1866), 28 had HI titers >= 20; two (0.11%, 95% CI:0.02-0.44) were positive by MN. Among 61 healthcare and 117 non-healthcare contacts' sera, five had HI titers >= 20, and all were negative by MN. There was no seroconversion among 131 paired sera. Conclusions: There was no evidence of widespread transmission of influenza A(H7N9) virus during March 2013 to May 2014, although A(H7N9) may have caused rare, previously unrecognized infections among poultry workers. Although the findings suggest that there were few undetected cases of influenza A(H7N9) early in the epidemic, it is important to continue monitoring transmission as virus and epidemic evolve. C1 [Xiang, Nijuan; Ren, Ruiqi; Li, Dan; Zhang, Yanping; Ni, Daxin; Li, Qun] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China. [Bai, Tian; Gao, Rongbao; Chen, Tao; Zou, Sumei; Shu, Yuelong] Natl Hlth & Family Planning Commiss, Collaborat Innovat Ctr Diag & Treatment Infect Di, Natl Inst Viral Dis Control & Prevent, Chinese Ctr Dis Control & Prevent,Key Lab Med Vir, Beijing, Peoples R China. [Kang, Kai] Henan Prov Ctr Dis Control & Prevent, Zhengzhou, Henan Province, Peoples R China. [Yuan, Hui; Liu, Xiaoqing] Jiangxi Prov Ctr Dis Control & Prevent, Nanchang, Jiangxi, Peoples R China. [Zhou, Suizan; Havers, Fiona; Widdowson, Marc-Alain; Greene, Carolyn M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Li, Xiuying] Xinhui Dist Ctr Dis Control & Prevent, Jiangmen, Guangdong, Peoples R China. [Wu, Jiabing] Anhui Prov Ctr Dis Control & Prevent, Hefei, Anhui, Peoples R China. [Deng, Liquan] Jilin Prov Ctr Dis Control & Prevent, Changchun, Jilin Province, Peoples R China. [Zeng, Ge] Hunan Prov Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China. [Wang, Xianjun] Shandong Prov Ctr Dis Control & Prevent, Jinan, Shandong, Peoples R China. [Mao, Shenghua] Shanghai Municipal Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Shi, Jian] Hebei Prov Ctr Dis Control & Prevent, Shijiazhuang, Hebei Province, Peoples R China. RP Li, Q (reprint author), Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China.; Shu, YL (reprint author), Natl Hlth & Family Planning Commiss, Collaborat Innovat Ctr Diag & Treatment Infect Di, Natl Inst Viral Dis Control & Prevent, Chinese Ctr Dis Control & Prevent,Key Lab Med Vir, Beijing, Peoples R China. EM liqun@chinacdc.cn; yshu@cnic.org.cn FU National Key Technology Support Program (Epidemiological characteristics of human infection with avian influenza A(H7N9) virus [KJYJ-2013-01-02] FX This work was supported by the National Key Technology Support Program (Epidemiological characteristics of human infection with avian influenza A(H7N9) virus, KJYJ-2013-01-02). NR 21 TC 0 Z9 0 U1 5 U2 5 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2017 VL 11 IS 2 BP 170 EP 176 DI 10.1111/irv.12435 PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA EL9SW UT WOS:000394961400009 PM 27762061 ER PT J AU McAnerney, JM Walaza, S Tempia, S Blumberg, L Treurnicht, FK Madhi, SA Valley-Omar, Z Cohen, C AF McAnerney, Johanna M. Walaza, Sibongile Tempia, Stefano Blumberg, Lucille Treurnicht, Florette K. Madhi, Shabir A. Valley-Omar, Ziyaad Cohen, Cheryl TI Estimating vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings in South Africa, 2015 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE effectiveness; influenza; vaccine AB Trivalent seasonal influenza vaccine effectiveness during the 2015 season in South Africa was assessed using a test-negative case control study design. Influenza A(H1N1) pdm09 was the dominant circulating strain. Overall influenza vaccine coverage was 3.2% (29/899). The vaccine effectiveness estimate, against any influenza virus infection, adjusted for age, underlying conditions and timing within season was 46.2% (95% CI: -23.5 to 76.5), and 53.6% ( 95% CI: -62.6 to 80.3) against influenza A(H1N1) pdm09. C1 [McAnerney, Johanna M.; Walaza, Sibongile; Tempia, Stefano; Blumberg, Lucille; Treurnicht, Florette K.; Madhi, Shabir A.; Valley-Omar, Ziyaad; Cohen, Cheryl] NICD, NHLS, Johannesburg, South Africa. [Tempia, Stefano] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Tempia, Stefano] US Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, MRC, Fac Hlth Sci, Johannesburg, South Africa. [Valley-Omar, Ziyaad] Univ Cape Town, Clin Sci Lab, Div Med Virol, Cape Town, South Africa. RP McAnerney, JM (reprint author), Natl Inst Communicable Dis, Johannesburg, South Africa. EM jomca@nicd.ac.za NR 14 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2017 VL 11 IS 2 BP 177 EP 181 DI 10.1111/irv.12436 PG 5 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA EL9SW UT WOS:000394961400010 PM 27865064 ER PT J AU Townsend, JS Steele, CB Hayes, N Bhatt, A Moore, AR AF Townsend, Julie S. Steele, C. Brooke Hayes, Nikki Bhatt, Achal Moore, Angela R. TI Human Papillomavirus Vaccine as an Anticancer Vaccine: Collaborative Efforts to Promote Human Papillomavirus Vaccine in the National Comprehensive Cancer Control Program SO JOURNAL OF WOMENS HEALTH LA English DT Article DE human papillomavirus vaccine; Public Health Practice; neoplasms/prevention and control; cancer control; Papillomavirus Vaccines/organization and administration ID OF-THE-LITERATURE; AGED 13-17 YEARS; UNITED-STATES; HPV VACCINATION; CERVICAL-CANCER; LIVER-CANCER; WOMEN; COVERAGE; ADOLESCENTS; US AB Widespread use of the human papillomavirus (HPV) vaccine has the potential to reduce incidence from HPV-associated cancers. However, vaccine uptake among adolescents remains well below the Healthy People 2020 targets. The Centers for Disease Control and Prevention (CDC) National Comprehensive Cancer Control Program (NCCCP) awardees are well positioned to work with immunization programs to increase vaccine uptake. The CDC chronic disease management information system was queried for objectives and activities associated with HPV vaccine that were reported by NCCCP awardees from 2013 to 2016 as part of program reporting requirements. A content analysis was conducted on the query results to categorize interventions according to strategies outlined in The Guide to Community Preventive Services and the 2014 President's Cancer Panel report. Sixty-two percent of NCCCP awardees had planned or implemented at least one activity since 2013 to address low HPV vaccination coverage in their jurisdictions. Most NCCCP awardees (86%) reported community education activities, while 65% reported activities associated with provider education. Systems-based strategies such as client reminders or provider assessment and feedback were each reported by less than 25% of NCCCP awardees. Many NCCCP awardees report planning or implementing activities to address low HPV vaccination coverage, often in conjunction with state immunization programs. NCCCP awardees can play a role in increasing HPV vaccination coverage through their cancer prevention and control expertise and access to partners in the healthcare community. C1 [Townsend, Julie S.; Steele, C. Brooke; Hayes, Nikki; Moore, Angela R.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Bhatt, Achal] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Steele, CB (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F76, Chamblee, GA 30341 USA. EM bsteele1@cdc.gov NR 33 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2017 VL 26 IS 3 BP 200 EP 206 DI 10.1089/jwh.2017.6351 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA EP7LW UT WOS:000397560300003 PM 28263672 ER PT J AU Zadrozny, S Westreich, D Hudgens, MG Chasela, C Jamieson, DJ Martinson, F Zimba, C Tegha, G Hoffman, I Miller, WC Pence, BW King, CC Kourtis, AP Msungama, W van der Horst, C AF Zadrozny, Sabrina Westreich, Daniel Hudgens, Michael G. Chasela, Charles Jamieson, Denise J. Martinson, Francis Zimba, Chifundo Tegha, Gerald Hoffman, Irving Miller, William C. Pence, Brian W. King, Caroline C. Kourtis, Athena P. Msungama, Wezi van der Horst, Charles CA BAN Study Team TI Effect of Postnatal HIV Treatment on Clinical Mastitis and Breast Inflammation in HIV-Infected Breast-feeding Women SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE Mastitis; breast-feeding; human immunodeficiency virus; prophylactic antiretroviral therapy; infant nevirapine ID IMMUNODEFICIENCY-VIRUS TYPE-1; SUBCLINICAL MASTITIS; ANTIRETROVIRAL THERAPY; PROSPECTIVE COHORT; COMPETING RISK; TRANSMISSION; MILK; SUPPLEMENTATION; LACTATION; LOAD AB Background: The relationship between mastitis and antiretroviral therapy among HIV-positive, breast-feeding women is unclear. Methods: In the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study, conducted in Lilongwe, Malawi, 2369 mother-infant pairs were randomized to a nutritional supplement group and to one of three treatment groups: maternal antiretroviral therapy (ART), infant nevirapine (NVP) or standard of care for 24weeks of exclusive breast-feeding and 4weeks of weaning. Among 1472 HIV-infected women who delivered live infants between 2004 and 2007, we estimated cumulative incidence functions and sub-distribution hazard ratios (HR) of mastitis or breast inflammation comparing women in maternal ART (n = 487) or infant nevirapine (n = 492) groups to the standard of care (n = 493). Nutritional supplement groups (743 took, 729 did not) were also compared. Results: Through 28-weeks post-partum, 102 of 1472 women experienced at least one occurrence of mastitis or breast inflammation. The 28-week risk was higher for maternal ART (risk difference (RD) 4.5, 95% confidence interval (CI) 0.9, 8.1) and infant NVP (RD 3.6, 95% CI 0.3, 6.9) compared to standard of care. The hazard of late-appearing mastitis or breast inflammation (from week 5-28) was also higher for maternal ART (HR 6.7, 95% CI 2.0, 22.6) and infant NVP (HR 5.1, 95% CI 1.5, 17. 5) compared to the standard of care. Conclusions: Mastitis or breast inflammation while breast-feeding is a possible side effect for women taking prophylactic ART and women whose infants take NVP, warranting additional research in the context of postnatal HIV transmission. C1 [Zadrozny, Sabrina] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27599 USA. [Zadrozny, Sabrina; Westreich, Daniel; Pence, Brian W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Hudgens, Michael G.] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Chasela, Charles] Univ Witwatersrand, Pretoria, South Africa. [Jamieson, Denise J.; King, Caroline C.; Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Martinson, Francis; Zimba, Chifundo; Tegha, Gerald] UNC Project, Lilongwe, Malawi. [Hoffman, Irving; van der Horst, Charles] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Miller, William C.] Ohio State Univ, Coll Publ Hlth, Div Epidemiol, Columbus, OH 43210 USA. [Msungama, Wezi] Ctr Dis Control Malawi, Hlth Serv Branch, Lilongwe, Malawi. RP Zadrozny, S (reprint author), Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27599 USA. EM sabrinaz@unc.edu FU Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP00005901, SIP 22-09 U48-DP001944-01]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; NIH Fogarty AIDS International Training and Research Program [2-D43 TW01039-06, R24 TW007988]; Fogarty Clayton-Dedonder Global Health Mentorship Program [R25TW009340-03S4]; Abbott Laboratories; GlaxoSmithKline; Boehringer Ingelheim; Roche Pharmaceuticals; Bristol-Myers Squibb; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson and Johnson; US Agency for International Development FX The BAN study was supported by grants from the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP00005901, and SIP 22-09 U48-DP001944-01); the National Institute of Allergy and Infectious Diseases; the University of North Carolina Center for AIDS Research (P30-AI50410); the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 2-D43 TW01039-06 and R24 TW007988; the American Recovery and Reinvestment Act); and the Fogarty Clayton-Dedonder Global Health Mentorship Program (R25TW009340-03S4). Antiretrovirals were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action for the Preventing Mother-to-Child Transmission programme was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson and Johnson, and the US Agency for International Development. A complete list of institutions and individuals involved in the BAN study is shown in the online supplemental material (Appendix S2). NR 33 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAR PY 2017 VL 31 IS 2 BP 134 EP 143 DI 10.1111/ppe.12337 PG 10 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA EM0KU UT WOS:000395008000006 PM 28205255 ER PT J AU Tong, VT England, LJ Rockhill, KM D'Angelo, DV AF Tong, Van T. England, Lucinda J. Rockhill, Karilynn M. D'Angelo, Denise V. TI Risks of Preterm Delivery and Small for Gestational Age Infants: Effects of Nondaily and Low-Intensity Daily Smoking During Pregnancy SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE Smoking; nondaily smoking; dose-response; pregnancy; infant outcomes; preterm delivery; small for gestational age ID ASSESSMENT MONITORING-SYSTEM; BIRTH-WEIGHT; CIGARETTE-SMOKING; UNITED-STATES; CESSATION; ASSOCIATION; REDUCTION AB Background: Few studies have examined the effects of nondaily smoking or low-intensity daily smoking and infant outcomes. We examined the associations between preterm delivery and small for gestational age (SGA) infants in relation to both nondaily and daily smoking. Methods: We used population-based data on women who delivered live singleton infants using the 2009-11 Pregnancy Risk Assessment Monitoring System. Women's smoking status in the last 3 months of pregnancy was categorised as nonsmokers, quitters, nondaily smokers (< 1 cigarette/day), and daily smokers. Controlling for maternal age, maternal race/ethnicity, education, marital status, prepregnancy body mass index (BMI), trimester of prenatal care entry, parity, and alcohol use, we estimated adjusted prevalence ratios (PR) for the outcomes of preterm delivery (< 37 weeks' gestation) and SGA. Results: Of the 88 933 women, 13.1%, 1.7%, and 9.6% of the sample were quitters, nondaily smokers, and daily smokers, respectively, in the last 3 months of pregnancy. While nondaily smoking was not associated with preterm delivery, daily smoking was. However, we found no dose-response relationship with the number of cigarettes smoked per day. Risk of delivering a SGA infant was increased for both nondaily and daily smokers (PR 1.4, 95% CI 1.1, 1.8 and PR 2.0, 95% CI 1.9, 2.2 respectively). Conclusions: Nondaily smoking in the last 3 months of pregnancy was associated with an increased risk of delivering a SGA infant. Pregnant women should be counselled that smoking, including nondaily and daily smoking, can adversely affect birth outcomes. C1 [Tong, Van T.; Rockhill, Karilynn M.; D'Angelo, Denise V.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [England, Lucinda J.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Rockhill, Karilynn M.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. EM vtong@cdc.gov NR 15 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD MAR PY 2017 VL 31 IS 2 BP 144 EP 148 DI 10.1111/ppe.12343 PG 5 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA EM0KU UT WOS:000395008000007 PM 28181676 ER PT J AU Mindra, G Wortham, JM Haddad, MB Powell, KM AF Mindra, Godwin Wortham, Jonathan M. Haddad, Maryam B. Powell, Krista M. TI Tuberculosis Outbreaks in the United States, 2009-2015 SO PUBLIC HEALTH REPORTS LA English DT Article DE tuberculosis; disease outbreaks; infection control ID HOMELESS AB Objectives: The Centers for Disease Control and Prevention provides on-site epidemiologic assistance for outbreak response when the health capacity of state, tribal, local, and territorial health departments has been exceeded. We examined recent outbreaks of tuberculosis (TB) for which health departments needed assistance. Methods: We defined a TB outbreak as detection of 3 TB cases related by transmission, as suggested by routine genotyping and epidemiologic linkages. We conducted retrospective reviews of documentation from all 21TB outbreak investigations in the United States for which the Centers for Disease Control and Prevention provided on-site assistance during 2009-2015. We abstracted data on patients' demographic characteristics and TB risk factors, as well as factors contributing to the outbreak from trip reports written by on-site investigators, and we compared these with outbreaks investigated during 2002-2008. Results: The 21TB outbreaks during 2009-2015 involved 457 outbreak patients (range, 3-99 patients per outbreak). Of the 21 outbreaks, 16 were first identified through genotype data. In sum, 118 (26%) patients were identified through contact investigations of other patients in the outbreak. Most outbreak patients (n = 363, 79%) were US born. Ninety-two (26%) patients had a mental illness, 204 (45%) had been homeless in the year before diagnosis, and 379 (83%) used alcohol excessively or used illicit substances. The proportion of patients experiencing homelessness doubled between 2002-2008 and 2009-2015; other characteristics were similar between the 2 periods. Delayed TB diagnosis contributed to unmitigated transmission in all but 1 outbreak. Conclusions: TB outbreaks challenge frontline public health resources. Genotyping and contact investigations are important strategies for detecting and controlling TB outbreaks, particularly among people experiencing homelessness or those with mental illness. C1 [Mindra, Godwin; Wortham, Jonathan M.; Haddad, Maryam B.; Powell, Krista M.] Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30329 USA. [Mindra, Godwin] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Powell, KM (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30329 USA. EM duf8@cdc.gov FU CDC FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by CDC. NR 24 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2017 VL 132 IS 2 BP 157 EP 163 DI 10.1177/0033354916688270 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP5XU UT WOS:000397453100007 PM 28147211 ER PT J AU Burrer, SL Fechter-Leggett, E Bayleyegn, T Mark-Carew, M Thomas, C Bixler, D Noe, RS Hsu, J Haddy, L Wolkin, A AF Burrer, Sherry L. Fechter-Leggett, Ethan Bayleyegn, Tesfaye Mark-Carew, Miguella Thomas, Carrie Bixler, Danae Noe, Rebecca S. Hsu, Joy Haddy, Loretta Wolkin, Amy TI Assessment of Impact and Recovery Needs in Communities Affected by the Elk River Chemical Spill, West Virginia, April 2014 SO PUBLIC HEALTH REPORTS LA English DT Article DE water; environmental health; disaster ID PERCEPTION; ODOR AB Objectives: In January 2014, 4-methylcyclohexanemethanol spilled into the Elk River near Charleston, West Virginia, contaminating the water supply for about 120000 households. The West Virginia American Water Company (WVAWC) issued a do not use water order for 9 counties. After the order was lifted (10 days after the spill), the communities' use of public water systems, information sources, alternative sources of water, and perceived impact of the spill on households were unclear to public health officials. To assist in recovery efforts, the West Virginia Bureau for Public Health and the Centers for Disease Control and Prevention conducted a Community Assessment for Public Health Emergency Response (CASPER). Methods: We used the CASPER 2-stage cluster sampling design to select a representative sample of households to interview, and we conducted interviews in 171 households in April 2014. We used a weighted cluster analysis to generate population estimates in the sampling frame. Results: Before the spill, 74.4% of households did not have a 3-day alternative water supply for each household member and pet. Although 83.6% of households obtained an alternative water source within 1day of the do not use order, 37.4% of households reportedly used WVAWC water for any purpose. Nearly 3 months after the spill, 36.1% of households believed that their WVAWC water was safe, and 33.5% reported using their household water for drinking. Conclusions: CASPER results identified the need to focus on basic public health messaging and household preparedness efforts. Recommendations included (1) encouraging households to maintain a 3-day emergency water supply, (2) identifying additional alternative sources of water for future emergencies, and (3) increasing community education to address ongoing concerns about water. C1 [Burrer, Sherry L.; Bayleyegn, Tesfaye; Noe, Rebecca S.; Wolkin, Amy] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Chamblee, GA USA. [Fechter-Leggett, Ethan; Hsu, Joy] Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, Epidem Intelligence Serv, Atlanta, GA USA. [Mark-Carew, Miguella; Thomas, Carrie; Bixler, Danae; Haddy, Loretta] West Virginia Bur Publ Hlth, Off Epidemiol & Prevent Serv, Charleston, WV USA. RP Burrer, SL (reprint author), Ctr Dis Control & Prevent, Hlth Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, MS F-60,4770 Buford Hwy NE, Chamblee, GA 30341 USA. EM sburrer@cdc.gov NR 28 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2017 VL 132 IS 2 BP 188 EP 195 DI 10.1177/0033354916689606 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP5XU UT WOS:000397453100011 PM 28182514 ER PT J AU Thomasson, ED Scharman, E Fechter-Leggett, E Bixler, D Ibrahim, S Duncan, MA Hsu, J Scott, M Wilson, S Haddy, L Pizon, A Burrer, SL Wolkin, A Lewis, L AF Thomasson, Erica D. Scharman, Elizabeth Fechter-Leggett, Ethan Bixler, Danae Ibrahim, Sheri'f Duncan, Mary Anne Hsu, Joy Scott, Melissa Wilson, Suzanne Haddy, Loretta Pizon, Anthony Burrer, Sherry L. Wolkin, Amy Lewis, Lauren TI Acute Health Effects After the Elk River Chemical Spill, West Virginia, January 2014 SO PUBLIC HEALTH REPORTS LA English DT Article DE environmental exposures; disasters; water; chemical spill ID TOXICITY AB Objectives: On January 9, 2014, approximately 10000 gallons of a mixture of 4-methylcyclohexanemethanol and propylene glycol phenyl ether spilled into West Virginia's Elk River, contaminating the potable water supply of about 300000 West Virginia residents. This study sought to describe acute health effects after the chemical spill. Methods: We conducted a descriptive analysis using 3 complementary data sources: (1) medical records of patients who visited an emergency department during January 9-23, 2014, with illness potentially related to the spill; (2) West Virginia Poison Center caller records coded as contaminated water during January 9-23, 2014; and (3) answers to household surveys about health effects from a Community Assessment for Public Health Emergency Response (CASPER) questionnaire administered 3 months after the spill. Results: In the 2 weeks after the spill, 2000 people called the poison center reporting exposure to contaminated water, and 369 people visited emergency departments in the affected area with reports of exposure and symptoms potentially related to the spill. According to CASPER weighted cluster analyses, an estimated 25623 households (21.7%; 95% confidence interval [CI], 14.4%-28.9%) had 1 person with symptoms who felt that they were related to the spill in the 3 months after it. Reported health effects across all 3 data sources included mild skin, respiratory, and gastrointestinal symptoms that resolved with no or minimal treatment. Conclusions: Medical records, poison center data, and CASPER household surveys were inexact but useful data sources to describe overall community health effects after a large-scale chemical spill. Analyzing multiple data sources could inform epidemiologic investigations of similar events. C1 [Thomasson, Erica D.; Fechter-Leggett, Ethan; Hsu, Joy] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Publ Hlth Sci Serv, Atlanta, GA USA. [Thomasson, Erica D.; Bixler, Danae; Ibrahim, Sheri'f; Scott, Melissa; Wilson, Suzanne; Haddy, Loretta] West Virginia Bur Publ Hlth, West Virginia Dept Hlth & Human Resources, Off Epidemiol Prevent Serv, Div Infect Dis, Charleston, WV USA. [Thomasson, Erica D.] West Virginia Bur Publ Hlth, West Virginia Dept Hlth & Human Resources, Off Environm Hlth Serv, Charleston, WV USA. [Thomasson, Erica D.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Div State & Local Readiness, Career Epidemiol Field Officer Program, Atlanta, GA USA. [Scharman, Elizabeth] West Virginia Univ, Sch Pharm, Dept Clin Pharm, Charleston, WV USA. [Scharman, Elizabeth; Pizon, Anthony] West Virginia Poison Ctr, Charleston, WV USA. [Fechter-Leggett, Ethan] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Environm Hlth Tracking Branch, Atlanta, GA USA. [Duncan, Mary Anne] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Environm Hlth Surveillance Branch, Atlanta, GA USA. [Hsu, Joy] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, Atlanta, GA USA. [Burrer, Sherry L.; Wolkin, Amy; Lewis, Lauren] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Hlth Studies Branch, Atlanta, GA USA. RP Thomasson, ED (reprint author), West Virginia Bur Publ Hlth, Off Environm Hlth Serv, 350 Capitol St,Room 313, Charleston, WV 25301 USA. EM ejd0@cdc.gov NR 20 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2017 VL 132 IS 2 BP 196 EP 202 DI 10.1177/0033354917691257 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP5XU UT WOS:000397453100012 PM 28182515 ER PT J AU Marcell, AV Okano, L Pilgrim, NA Jennings, JM Page, KR Sanders, R Loosier, PS Dittus, PJ AF Marcell, Arik V. Okano, Lauren Pilgrim, Nanlesta A. Jennings, Jacky M. Page, Kathleen R. Sanders, Renata Loosier, Penny S. Dittus, Patricia J. TI Prevalence of HIV Testing Provision at Community Organizations Serving Young People in a Mid-Atlantic City, 2013-2014 SO PUBLIC HEALTH REPORTS LA English DT Article DE HIV testing; community health; adolescents; young adults; prevention; health education ID UNITED-STATES; CARE SETTINGS; ADOLESCENTS; HEALTH; YOUTH; ANTIBODY; OUTREACH; ADULTS AB Objectives: Little is known about the prevalence of human immunodeficiency virus (HIV) testing at community organizations or the organizational characteristics associated with testing. The objective of this study was to describe (1) the prevalence of HIV testing at community organizations serving young people in a mid-Atlantic urban city and (2) the characteristics associated with organizations that provide such testing. Methods: We conducted telephone or in-person surveys between February 2013 and March 2014 with 51 directors and administrators of community organizations serving young people. We asked whether the organization provided HIV screening or testing, and we collected data on organizational characteristics (eg, setting, client, and staff member characteristics; services offered). We generated frequencies on measures and used Poisson regression analysis to examine the association between testing and organizational characteristics. Results: Of the 51 organizations surveyed, 21 provided HIV testing. Of the 30 organizations that did not provide HIV testing, only 7 had a relationship with programs that did provide it. Characteristics associated with the provision of HIV testing included offering general health services (relative risk [RR] = 4.57; 95% confidence interval [CI], 1.68-12.48; P = .003) and referral services for sexually transmitted infection screening (RR = 5.77; 95% CI, 1.70-19.59; P = .005) and HIV care (RR = 4.78; 95% CI, 1.61-14.21; P = .005), as well as among administrators who perceived their staff members were comfortable talking with young people about sexual health (RR = 3.29; 95% CI, 1.28-8.49; P = .01). Conclusions: The prevalence of HIV testing provision at organizations serving young people in this mid-Atlantic city was low, and few organizations offered linkages to HIV testing. Strategies are needed to increase the provision of HIV testing at community organizations serving young people, whether through direct or linked approaches. C1 [Marcell, Arik V.; Jennings, Jacky M.; Page, Kathleen R.; Sanders, Renata] Johns Hopkins Univ, Sch Med, 200N Wolfe St,Room 2062, Baltimore, MD 21287 USA. [Marcell, Arik V.; Okano, Lauren] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, 200N Wolfe St,Room 2062, Baltimore, MD 21287 USA. [Pilgrim, Nanlesta A.] Populat Council, Washington, DC USA. [Loosier, Penny S.; Dittus, Patricia J.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Marcell, AV (reprint author), Johns Hopkins Univ, Sch Med, 200N Wolfe St,Room 2062, Baltimore, MD 21287 USA.; Marcell, AV (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, 200N Wolfe St,Room 2062, Baltimore, MD 21287 USA. EM amarcell@jhu.edu FU CDC [1H25PS003796]; Secretary's Minority AIDS Initiative Fund FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors acknowledge support from CDC (1H25PS003796) and the Secretary's Minority AIDS Initiative Fund. NR 23 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2017 VL 132 IS 2 BP 203 EP 209 DI 10.1177/0033354916689616 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP5XU UT WOS:000397453100013 PM 28118800 ER PT J AU Powell, KM VanderEnde, DS Holland, DP Haddad, MB Yarn, B Yamin, AS Mohamed, O Sales, RMF DiMiceli, LE Burns-Grant, G Reaves, EJ Gardner, TJ Ray, SM AF Powell, Krista M. VanderEnde, Daniel S. Holland, David P. Haddad, Maryam B. Yarn, Benjamin Yamin, Aliya S. Mohamed, Omar Sales, Rose-Marie F. DiMiceli, Lauren E. Burns-Grant, Gail Reaves, Erik J. Gardner, Tracie J. Ray, Susan M. TI Outbreak of Drug-Resistant Mycobacterium tuberculosis Among Homeless People in Atlanta, Georgia, 2008-2015 SO PUBLIC HEALTH REPORTS LA English DT Article DE tuberculosis; disease outbreaks; homeless people; drug resistance; infection control ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; INFECTIOUS TUBERCULOSIS; ANTIRETROVIRAL THERAPY; TRANSMISSION; OUTCOMES; SHELTER; COUNTY; ADULTS AB Objectives: Our objective was to describe and determine the factors contributing to a recent drug-resistant tuberculosis (TB) outbreak in Georgia. Methods: We defined an outbreak case as TB diagnosed from March 2008 through December 2015 in a person residing in Georgia at the time of diagnosis and for whom (1) the genotype of the Mycobacterium tuberculosis isolate was consistent with the outbreak strain or (2) TB was diagnosed clinically without a genotyped isolate available and connections were established to another outbreak-associated patient. To determine factors contributing to transmission, we interviewed patients and reviewed health records, homeless facility overnight rosters, and local jail booking records. We also assessed infection control measures in the 6 homeless facilities involved in the outbreak. Results: Of 110 outbreak cases in Georgia, 86 (78%) were culture confirmed and isoniazid resistant, 41 (37%) occurred in people with human immunodeficiency virus coinfection (8 of whom were receiving antiretroviral treatment at the time of TB diagnosis), and 10 (9%) resulted in TB-related deaths. All but 8 outbreak-associated patients had stayed overnight or volunteered extensively in a homeless facility; all these facilities lacked infection control measures. At least 9 and up to 36TB cases outside Georgia could be linked to this outbreak. Conclusions: This article highlights the ongoing potential for long-lasting and far-reaching TB outbreaks, particularly among populations with untreated human immunodeficiency virus infection, mental illness, substance abuse, and homelessness. To prevent and control TB outbreaks, health departments should work with overnight homeless facilities to implement infection control measures and maintain searchable overnight rosters. C1 [Powell, Krista M.; Haddad, Maryam B.; Burns-Grant, Gail; Reaves, Erik J.; Gardner, Tracie J.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [VanderEnde, Daniel S.; Holland, David P.; Yarn, Benjamin; Yamin, Aliya S.; Mohamed, Omar] Fulton Cty Dept Hlth & Wellness, Atlanta, GA USA. [Holland, David P.; Sales, Rose-Marie F.; DiMiceli, Lauren E.; Ray, Susan M.] Georgia Dept Publ Hlth, Atlanta, GA USA. [Holland, David P.; Haddad, Maryam B.; Ray, Susan M.] Emory Univ, Atlanta, GA 30322 USA. RP Powell, KM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-31, Atlanta, GA 30329 USA. EM duf8@cdc.gov FU FCDHW; Georgia Department of Public Health; CDC FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by FCDHW, Georgia Department of Public Health, and CDC. NR 37 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2017 VL 132 IS 2 BP 231 EP 240 DI 10.1177/0033354917694008 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP5XU UT WOS:000397453100016 PM 28257261 ER PT J AU Weiss, D Boyd, C Rakeman, JL Greene, SK Fitzhenry, R McProud, T Musser, K Huang, L Kornblum, J Nazarian, EJ Fine, AD Braunstein, SL Kass, D Landman, K Lapierre, P Hughes, S Tran, A Taylor, J Baker, D Jones, L Kornstein, L Liu, BN Perez, R Lucero, DE Peterson, E Benowitz, I Lee, KF Ngai, S Stripling, M Varma, JK AF Weiss, Don Boyd, Christopher Rakeman, Jennifer L. Greene, Sharon K. Fitzhenry, Robert McProud, Trevor Musser, Kimberlee Huang, Li Kornblum, John Nazarian, Elizabeth J. Fine, Annie D. Braunstein, Sarah L. Kass, Daniel Landman, Keren Lapierre, Pascal Hughes, Scott Tran, Anthony Taylor, Jill Baker, Deborah Jones, Lucretia Kornstein, Laura Liu, Boning Perez, Rodolfo Lucero, David E. Peterson, Eric Benowitz, Isaac Lee, Kristen F. Ngai, Stephanie Stripling, Mitch Varma, Jay K. CA South Bronx Legionnaires' Dis Inve TI A Large Community Outbreak of Legionnaires' Disease Associated With a Cooling Tower in New York City, 2015 SO PUBLIC HEALTH REPORTS LA English DT Article DE Legionnaires' disease; outbreak; cooling tower ID CLUSTER DETECTION; LEGIONELLA; CATALONIA; SPAIN; USA AB Objectives: Infections caused by Legionella are the leading cause of waterborne disease outbreaks in the United States. We investigated a large outbreak of Legionnaires' disease in New York City in summer 2015 to characterize patients, risk factors for mortality, and environmental exposures. Methods: We defined cases as patients with pneumonia and laboratory evidence of Legionella infection from July 2 through August 3, 2015, and with a history of residing in or visiting 1 of several South Bronx neighborhoods of New York City. We describe the epidemiologic, environmental, and laboratory investigation that identified the source of the outbreak. Results: We identified 138 patients with outbreak-related Legionnaires' disease, 16 of whom died. The median age of patients was 55. A total of 107 patients had a chronic health condition, including 43 with diabetes, 40 with alcoholism, and 24 with HIV infection. We tested 55 cooling towers for Legionella, and 2 had a strain indistinguishable by pulsed-field gel electrophoresis from 26 patient isolates. Whole-genome sequencing and epidemiologic evidence implicated 1 cooling tower as the source of the outbreak. Conclusions: A large outbreak of Legionnaires' disease caused by a cooling tower occurred in a medically vulnerable community. The outbreak prompted enactment of a new city law on the operation and maintenance of cooling towers. Ongoing surveillance and evaluation of cooling tower process controls will determine if the new law reduces the incidence of Legionnaires' disease in New York City. C1 [Weiss, Don; Boyd, Christopher; Rakeman, Jennifer L.; Greene, Sharon K.; Fitzhenry, Robert; McProud, Trevor; Huang, Li; Kornblum, John; Fine, Annie D.; Braunstein, Sarah L.; Kass, Daniel; Landman, Keren; Hughes, Scott; Tran, Anthony; Jones, Lucretia; Kornstein, Laura; Liu, Boning; Perez, Rodolfo; Lucero, David E.; Peterson, Eric; Benowitz, Isaac; Lee, Kristen F.; Ngai, Stephanie; Stripling, Mitch; Varma, Jay K.] New York City Dept Hlth & Mental Hyg, Queens, NY USA. [Musser, Kimberlee; Nazarian, Elizabeth J.; Lapierre, Pascal; Taylor, Jill; Baker, Deborah] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Benowitz, Isaac; Varma, Jay K.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Weiss, D (reprint author), New York City Dept Hlth & Mental Hyg, Bur Communicable Dis, 42-09 28th St, Queens, NY 11101 USA. EM dweiss@health.nyc.gov NR 31 TC 1 Z9 1 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0033-3549 EI 1468-2877 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2017 VL 132 IS 2 BP 241 EP 250 DI 10.1177/0033354916689620 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP5XU UT WOS:000397453100017 PM 28141970 ER PT J AU Hambidge, SJ Ross, C Shoup, JA Wain, K Narwaney, K Breslin, K Weintraub, ES McNeil, MM AF Hambidge, Simon J. Ross, Colleen Shoup, Jo Ann Wain, Kris Narwaney, Komal Breslin, Kristin Weintraub, Eric S. McNeil, Michael M. TI Integration of data from a safety net health care system into the Vaccine Safety Datalink SO VACCINE LA English DT Article DE Vaccine safety; Safety net health system; Population surveillance ID DENVER HEALTH; MODEL AB Background: In 2013 the Institute of Medicine suggested that the Vaccine Safety DataLink (VSD) should broaden its population by including data of more patients from low income and racially and ethnically diverse backgrounds. In response, Kaiser Permanente Colorado (KPCO) partnered with Denver Health (DH), an integrated safety net health care system, to explore the integration of DH data. Methods: We compared three different methods (reference date of September 1, 2013): "Empanelment" (any patient who has had a primary care visit in the past 18 months), "Proxy-enrollment" (two health care visits in 3 years separated by 90 days), and "Enrollment" in a managed care plan. For each of these methods, we compared cohort size, vaccination rates, socio-demographic characteristics, and health care utilization. Results: The empaneled population at DH provided the best comparison to KPCO. DH's empaneled population was 111,330 (57,173 adults; 54,157 children), while KPCO had 436,290 empaneled patients (336,462 adults; 99,828 children). Vaccination rates in both health care systems for empaneled patients were comparable. Two year-old up-to-date coverage rates were 83.2% (KPCO) and 86.9% (DH); rates for adolescent Tdap and MCV4 were 85.5% (KPCO) and 90.6% (DH). There were significant differences in the two populations in age, gender, race, preferred language, and % Federal Poverty Level (FPL) (DH 70.7% < 100% FPL; KPCO 17.4%), as well as in healthcare utilization - for example pediatric emergency department utilization was twice as high at DH. Conclusions: Using a cohort of "empaneled" patients, it is possible to integrate data from a safety net health care system that does not have a uniform managed care population into the VSD, and to compare vaccination rates, socio-demographic characteristics, and health care utilization across the two systems. The KPCO-DH collaboration may serve as a model for incorporating data from a safety net healthcare system into the VSD. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Hambidge, Simon J.; Ross, Colleen; Shoup, Jo Ann; Wain, Kris; Narwaney, Komal] Kaiser Permanente Colorado, Inst Hlth Res, Colorado Springs, CO USA. [Hambidge, Simon J.; Breslin, Kristin] Denver Hlth, Ambulatory Care Serv, Denver, CO USA. [Hambidge, Simon J.] Univ Colorado, Pediat & Epidemiol, Boulder, CO 80309 USA. [Weintraub, Eric S.; McNeil, Michael M.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. RP Hambidge, SJ (reprint author), Denver Hlth, Mail Code 0278,660 Bannock St, Denver, CO 80204 USA. EM simon.hambidge@dhha.org FU Centers for Disease Control and Prevention Vaccine Safety Datalink [200-2012-53582] FX The work was funded by contract 200-2012-53582 from the Centers for Disease Control and Prevention Vaccine Safety Datalink "Increasing the Diversity with Respect to Underserved Populations" task order. NR 22 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 1 PY 2017 VL 35 IS 9 BP 1329 EP 1334 DI 10.1016/j.vaccine.2017.01.027 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EN2LD UT WOS:000395840800025 PM 28161424 ER PT J AU Narwaney, KJ Breslin, K Ross, CA Shoup, JA Wain, KF Weintraub, ES McNeil, MM Hambidge, SJ AF Narwaney, Komal J. Breslin, Kristin Ross, Colleen A. Shoup, Jo Ann Wain, Kris F. Weintraub, Eric S. McNeil, Michael M. Hambidge, Simon J. TI Vaccine adverse events in a safety net healthcare system and a managed care organization SO VACCINE LA English DT Article DE Vaccine safety; Safety net health system; Population surveillance ID UNITED-STATES; ROTAVIRUS VACCINATION; IMMUNIZATION SAFETY; CASE-DEFINITION; DATALINK; RISK; INTUSSUSCEPTION; SEIZURES; GUIDELINES; COLLECTION AB Background: The Institute of Medicine, in a 2013 report, recommended that the Vaccine Safety Datalink (VSD) expand collaborations to include more diversity in the study population. Kaiser Permanente Colorado (KPCO), an established VSD site, partnered with Denver Health (DH), an integrated safety net healthcare system, to demonstrate the feasibility of integrating DH data within the VSD. Prior to incorporating the data, we examined the identification of specific vaccine associated adverse events (VAEs) in these two distinct healthcare systems. Methods: We conducted retrospective cohort analyses within KPCO and DH to compare select VAEs between the two populations. We examined the following associations between January 1, 2004 and December 31, 2013: Measles, Mumps, and Rubella (MMR) vaccine and febrile seizures in children 2 years and younger, intussusception after rotavirus vaccine in infants 4-34 weeks, syncope after adolescent vaccines (Tetanus, Diphtheria, acellular Pertussis; Meningococcal and Human Papillomavirus) in adolescents 13-17 years and medically attended local reactions after pneumococcal polysaccharide (PPSV23) vaccine in adults 65 years and older. Both sites used similar data procurement methods and chart review processes. Results: For seizures after MMR vaccine (KPCO - 3.15 vs. DH - 2.97/10,000 doses) and syncope after all adolescent vaccines (KPCO - 3.0 vs. DH- 2.37/10,000 doses), the chart confirmed rates were comparable at the two sites. However, for medically attended local reactions after PPSV23, there were differences in chart confirmed rates between the sites (KPCO - 31.65 vs. DH - 14.90/10,000 doses). For intussusception after rotavirus vaccine, the number of cases was too low to make a valid comparison (KPCO - 0 vs. DH - 0.13/10,000 doses). Conclusion: We demonstrated that data on important targeted VAEs can be captured at DH and rates appear similar to those at KPCO. Work is ongoing on the optimal approach to assimilate DH data as a potential safety net healthcare system in the VSD. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Narwaney, Komal J.; Ross, Colleen A.; Shoup, Jo Ann; Wain, Kris F.; Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Colorado Springs, CO 80920 USA. [Breslin, Kristin; Hambidge, Simon J.] Denver Hlth, Ambulatory Care Serv, Denver, CO USA. [Weintraub, Eric S.; McNeil, Michael M.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Hambidge, Simon J.] Univ Colorado, Pediat & Epidemiol, Boulder, CO 80309 USA. RP Narwaney, KJ (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, Colorado Springs, CO 80920 USA. EM Komal.j.narwaney@kp.org FU Centers for Disease Control and Prevention Vaccine Safety Datalink [200-2012-53582] FX The work was funded by contract 200-2012-53582 from the Centers for Disease Control and Prevention Vaccine Safety Datalink "Increasing the Diversity with Respect to Underserved Populations" task order. NR 26 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 1 PY 2017 VL 35 IS 9 BP 1335 EP 1340 DI 10.1016/j.vaccine.2017.01.017 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EN2LD UT WOS:000395840800026 PM 28185740 ER PT J AU Benedict, KM Santibanez, TA Black, CL Ding, H Graitcer, SB Bridges, CB Kennedy, ED AF Benedict, Katharine M. Santibanez, Tammy A. Black, Carla L. Ding, Helen Graitcer, Samuel B. Bridges, Carolyn B. Kennedy, Erin D. TI Recommendations and offers for adult influenza vaccination, 2011-2012 season, United States SO VACCINE LA English DT Article DE Influenza; Human; Vaccination; Adult; Logistic models; Population based interventions; Practice guidelines; Preventive health services ID IMMUNIZATION PRACTICES ACIP; VACCINES RECOMMENDATIONS; ADVISORY-COMMITTEE; PREGNANT-WOMEN; COVERAGE; POPULATIONS; DISPARITIES; PREVENTION AB Background: Provider recommendations and offers for influenza vaccination improve adult influenza vaccination coverage. Analysis was performed to describe receipt of influenza vaccination recommendations and offers among adults who visited a healthcare provider (HCP) during the 2011-2012 influenza season and describe differences between those receiving and not receiving recommendations and offers for influenza vaccination. Associations between influenza vaccination and receipt of recommendations and offers were examined. Methods: Respondents to a random digit dial telephone survey who had visited a HCP since July 1, 2011 were asked if they had received a recommendation for influenza vaccination. Those receiving a recommendation were asked if they received an offer for vaccination. Participants were characterized by demographic and access to health care variables. Logistic regression was used to examine the relationships between participant characteristics and recommendation alone, between participant characteristics and recommendation and offer, and between influenza vaccination and recommendation and offer. Results: Of those who reported visiting a HCP, 43.8% reported receiving a recommendation for influenza vaccination. Of those who reported receiving a recommendation, 76.6% reported receiving an offer for influenza vaccination. Persons with high-risk conditions and persons over 65 years were more likely to receive recommendations for influenza vaccination when compared to those without high-risk conditions and 18-49 year olds, respectively. Those reporting receipt of a recommendation and offer for influenza vaccination were 1.76 times more likely and those reporting receipt of a recommendation but no offer were 1.72 times more likely to report being vaccinated for influenza controlling for all patient characteristics. Conclusions: Less than half of respondents reported receipt of recommendations and offers of influenza vaccination during the 2011-2012 influenza season and disparities exist between groups. All healthcare providers seeing adults should recommend or offer influenza vaccination for all patients at every visit during the influenza season. (C) 2016 Published by Elsevier Ltd. C1 [Benedict, Katharine M.] IHRC Inc, Atlanta, GA USA. [Santibanez, Tammy A.; Black, Carla L.; Graitcer, Samuel B.; Bridges, Carolyn B.; Kennedy, Erin D.] Ctr Dis Control & Prevent CDC, NCIRD, ISD, 1600 Clifton Rd,NE,Mailstop A-19, Atlanta, GA 30329 USA. [Ding, Helen] Eagle Med Serv LLC, San Antonio, TX USA. RP Kennedy, ED (reprint author), Ctr Dis Control & Prevent CDC, NCIRD, ISD, 1600 Clifton Rd,NE,Mailstop A-19, Atlanta, GA 30329 USA. EM wte7@cdc.gov; afz5@cdc.gov; zwc0@cdc.gov; gdq3@cdc.gov; igc6@cdc.gov; ctb1@cdc.gov; ftw3@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 1 PY 2017 VL 35 IS 9 BP 1353 EP 1361 DI 10.1016/j.vaccine.2016.04.061 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EN2LD UT WOS:000395840800029 PM 27137099 ER PT J AU Pope, R Stanley, KM Domsky, I Yip, F Nohre, L Mirabelli, MC AF Pope, Ronald Stanley, Kara M. Domsky, Ira Yip, Fuyuen Nohre, Liva Mirabelli, Maria C. TI The relationship of high PM2.5 days and subsequent asthma-related hospital encounters during the fireplace season in Phoenix, AZ, 2008-2012 SO AIR QUALITY ATMOSPHERE AND HEALTH LA English DT Article DE Air pollution; Air quality; Asthma; Biomass burning; Epidemiology; Respiratory health ID AIR-POLLUTION; PARTICULATE MATTER; TIME-SERIES; ADMISSIONS; MORTALITY; SMOKE; PREVALENCE; POLLUTANTS; COPENHAGEN; PARTICLES AB Exposure to particulate matter less than 2.5 mu m in diameter (PM2.5) exacerbates asthma and increases mortality. In Phoenix, AZ, the highest PM2.5 values frequently occur during the winter fireplace season and air quality health standards are often exceeded during the Christmas and New Year's holidays. It was clear that enhanced messaging was needed by air quality and public health authorities to discourage biomass fires (BMF) on days when unhealthful levels of pollution were likely to be caused by that activity. Demonstrating adverse health outcomes would bolster this effort. We conducted this study to evaluate associations between elevated PM2.5 exposures during the fireplace season and asthma-related hospital admissions in Phoenix; days with average PM2.5 > 35 mu g/m(3) were categorized as elevated PM2.5 exposure. We used hospital discharge data to identify patients with an asthma-related hospital encounter and who lived within an 8-km radius of a PM2.5 monitor. To estimate the risk of a hospital encounter following an elevated PM2.5 event, we used generalized estimating equations, specified with a Poisson distribution, and exposure lags of 0-3 days. Controlling for influenza, temperature, humidity, rain, and year, these analyses generated elevated estimates of emergency department visit risk among adults on lag days 2 (relative risk [RR] 1.19; 95 % CI 1.06, 1.34) and 3 (RR 1.20, 95 % CI 1.05, 1.37). Elevated PM2.5 was not associated with hospital encounters among children. Our findings suggest that adults may be at elevated risk of asthma-related hospital encounters during the fireplace season. C1 [Pope, Ronald; Domsky, Ira] Maricopa Cty Air Qual Dept, 1001 N Cent,125, Phoenix, AZ 85003 USA. [Stanley, Kara M.; Nohre, Liva] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. [Yip, Fuyuen; Mirabelli, Maria C.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Pope, R (reprint author), Maricopa Cty Air Qual Dept, 1001 N Cent,125, Phoenix, AZ 85003 USA. EM rpope@mail.maricopa.gov FU Maricopa County Air Quality Department; Maricopa County Department of Public Health; Centers for Disease Control and Prevention FX This study was funded as a joint operation between the Maricopa County Air Quality Department, the Maricopa County Department of Public Health, and the Centers for Disease Control and Prevention. No outside grant funding was received. NR 50 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1873-9318 EI 1873-9326 J9 AIR QUAL ATMOS HLTH JI Air Qual. Atmos. Health PD MAR PY 2017 VL 10 IS 2 BP 161 EP 169 DI 10.1007/s11869-016-0431-2 PG 9 WC Environmental Sciences SC Environmental Sciences & Ecology GA EL0AT UT WOS:000394285800005 ER PT J AU Morris, AS Robinson, LR Hays-Grudo, J Claussen, AH Hartwig, SA Treat, AE AF Morris, Amanda Sheffield Robinson, Lara R. Hays-Grudo, Jennifer Claussen, Angelika H. Hartwig, Sophie A. Treat, Amy E. TI Targeting Parenting in Early Childhood: A Public Health Approach to Improve Outcomes for Children Living in Poverty SO CHILD DEVELOPMENT LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; SOCIAL SUPPORT; PROBLEM BEHAVIOR; MENTAL-HEALTH; FOLLOW-UP; FAMILY; INTERVENTIONS; PREVENTION; EDUCATION; MOTHERS AB In this article, the authors posit that programs promoting nurturing parent-child relationships influence outcomes of parents and young children living in poverty through two primary mechanisms: (a) strengthening parents' social support and (b) increasing positive parent-child interactions. The authors discuss evidence for these mechanisms as catalysts for change and provide examples from selected parenting programs that support the influence of nurturing relationships on child and parenting outcomes. The article focuses on prevention programs targeted at children and families living in poverty and closes with a discussion of the potential for widespread implementation and scalability for public health impact. C1 [Morris, Amanda Sheffield; Hays-Grudo, Jennifer; Treat, Amy E.] Oklahoma State Univ, Main Hall 1117,700 North Greenwood Ave, Tulsa, OK 74106 USA. [Robinson, Lara R.; Claussen, Angelika H.; Hartwig, Sophie A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Morris, AS (reprint author), Oklahoma State Univ, Human Dev & Family Sci, Main Hall 1117,700 North Greenwood Ave, Tulsa, OK 74106 USA. EM amanda.morris@okstate.edu FU George Kaiser Family Foundation; Research Participation Program at the Centers for Disease Control and Prevention FX Work on this article was supported in part by a grant to Amanda Sheffield Morris and Jennifer Hays-Grudo from the George Kaiser Family Foundation. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 46 TC 1 Z9 1 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-3920 EI 1467-8624 J9 CHILD DEV JI Child Dev. PD MAR-APR PY 2017 VL 88 IS 2 BP 388 EP 397 DI 10.1111/cdev.12743 PG 10 WC Psychology, Educational; Psychology, Developmental SC Psychology GA EN4WQ UT WOS:000396008000006 PM 28138978 ER PT J AU Wolff, BJ Benitez, AJ Desai, HP Morrison, SS Diaz, MH Winchell, JM AF Wolff, Bernard J. Benitez, Alvaro J. Desai, Heta P. Morrison, Shatavia S. Diaz, Maureen H. Winchell, Jonas M. TI Development of a multiplex taqMan real-time PCR assay for typing of Mycoplasma pneumoniae based on type-specific indels identified through whole genome sequencing SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE M. pneumoniae; P1 typing; Real-time PCR; Next generation sequencing ID TANDEM-REPEAT ANALYSIS; P1 CYTADHESIN GENE; REQUIRING HOSPITALIZATION; MACROLIDE RESISTANCE; STRAINS; INFECTIONS; OUTBREAK; JAPAN AB We developed a multiplex real-time PCR assay for simultaneously detecting M. pneumoniae and typing into historically-defined P1 types. Typing was achieved based on the presence of short type-specific indels identified through whole genome sequencing. This assay was 100% specific compared to existing methods and may be useful during epidemiologic investigations. Published by Elsevier Inc. C1 [Wolff, Bernard J.; Benitez, Alvaro J.; Desai, Heta P.; Morrison, Shatavia S.; Diaz, Maureen H.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA. EM jwinchell@cdc.gov NR 27 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD MAR PY 2017 VL 87 IS 3 BP 203 EP 206 DI 10.1016/j.diagmicrobio.2016.11.013 PG 4 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA EL1UV UT WOS:000394407700001 PM 27923522 ER PT J AU Lamers, V Hubbard, BC AF Lamers, Vanessa Hubbard, Brian C. TI What Actions Are Health Departments Taking to Improve Safe Drinking Water Programs? SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 [Lamers, Vanessa] Publ Hlth Fdn, Washington, DC USA. [Hubbard, Brian C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hubbard, BC (reprint author), Ctr Dis Control & Prevent, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA. EM bhubbard@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2017 VL 79 IS 7 BP 38 EP 40 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA EL1XO UT WOS:000394414900007 ER PT J AU Hoffman, K Webster, TF Sjodin, A Stapleton, HM AF Hoffman, Kate Webster, Thomas F. Sjodin, Andreas Stapleton, Heather M. TI Toddler's behavior and its impacts on exposure to polybrominated diphenyl ethers SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE behavior; children; exposure; flame retardants; handwipes; house dust; polybrominated diphenyl ethers (PBDEs) ID BROMINATED FLAME RETARDANTS; HOUSE-DUST; YOUNG-CHILDREN; PBDES; LEAD; SERUM; ENVIRONMENT; HANDWIPES; TOYS; FOOD AB Children have higher polybrominated diphenyl ether (PBDE) body burdens than adults, which may be related to hand-to-mouth behavior. We investigate associations between children's behavior, including hand-to-mouth contacts, and markers of PBDE exposure. In addition, we investigate associations between characteristics of the home environment and exposure. Eighty-three children aged 12-36 months were recruited from North Carolina (2009-2010). Children provided blood and handwipes samples, which were analyzed for PBDEs. Parents completed questionnaires, providing demographic, behavioral, and environmental data. More active children had higher levels of PBDEs on their hands and in their bodies. For example, children who spent more time sleeping had lower exposures to PBDEs; each additional hour of sleep resulted in a 30% decrease in handwipe BDE-99 levels (P < 0.001) and a 15% decrease in serum (P = 0.03). After accounting for handwipe PBDE levels, children who licked their fingers while eating had higher serum PBDEs. Other behaviors were not consistently associated with serum levels. Playing with plastic toys was associated with higher handwipe levels of PBDEs, while frequent vacuuming decreased handwipe PBDE levels. Characteristics of the home environment generally were not associated with serum PBDEs. Our results suggest that certain aspects of children's behavior and their environment impact exposure to PBDEs. C1 [Hoffman, Kate; Stapleton, Heather M.] Duke Univ, Nicholas Sch Environm, A150 LSRC Box 90328, Durham, NC 27708 USA. [Webster, Thomas F.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Sjodin, Andreas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. RP Hoffman, K (reprint author), Duke Univ, Nicholas Sch Environm, A150 LSRC Box 90328, Durham, NC 27708 USA. EM kate.hoffman@duke.edu FU National Institute of Environmental Health Sciences ( NIEHS) [R01 ES016099]; TFW [R01ES015829]; Fred and Alice Stanback FX Funding for this study was provided by a research grant from the National Institute of Environmental Health Sciences (NIEHS) grant R01 ES016099. TFW was supported in part by R01ES015829. KH was supported through a donation provided by Fred and Alice Stanback. The views expressed in this document are solely those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. Additional thanks are extended to all the study participants. NR 23 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 EI 1559-064X J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2017 VL 27 IS 2 BP 193 EP 197 DI 10.1038/jes.2016.11 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EL2NM UT WOS:000394456500007 PM 26956938 ER PT J AU Naik, SL Lewin, M Young, R Dearwent, SM Lee, R AF Naik, Samantha Lampert Lewin, Michael Young, Rand Dearwent, Steve M. Lee, Robin TI Mortality from asbestos-associated disease in Libby, Montana 1979-2011 SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE asbestos; asbestosis; Libby; mesothelioma; mortality; vermiculite ID VERMICULITE; EXPOSURE; COHORT; AMPHIBOLE; COMPLEX; RISK; USA AB Research on asbestos exposure in Libby, MT, has focused on occupational exposure in vermiculite mining and processing, but less attention has been paid to asbestos-related mortality among community members without vermiculite mining occupational history. Our study reports on asbestos-related mortality in Libby over 33 years (1979-2011) while controlling for occupational exposure. We calculated sex-specific 33-year standardized mortality ratios ( SMRs) for Libby residents who died from 1979 to 2011 with an asbestos-related cause of death. Decedent address at time of death was geocoded to confirm inclusion in the Libby County Division. We controlled for past W.R. Grace employment by including and then removing them from the SMR analysis. Six hundred and ninety-four decedents were identified as having at least one asbestos-related cause of death and residing in our study area boundary. Statistically significant (P < 0.05) 33-year SMRs, both before and after controlling for W. R. Grace employment, were found for: male and female non-malignant respiratory diseases, female COPD, and asbestosis for both sexes combined. Eighty-five men and two women were matched to employment records. We observed elevated asbestos-related mortality rates among males and females. SMR results for asbestosis were high for both sexes, even after controlling for past W. R. Grace employment. These results suggest that the general population may be experiencing asbestos-related effects, not just former vermiculite workers. Additional research is needed to determine whether SMRs remain elevated after controlling for secondary exposure, such as living with vermiculite workers. C1 [Naik, Samantha Lampert; Lewin, Michael; Young, Rand; Lee, Robin] Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 4770 Buford Highway,Mailstop F-57, Atlanta, GA 30341 USA. [Dearwent, Steve M.] NIOSH, Off Extramural Programs, Atlanta, GA USA. RP Naik, SL (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, 4770 Buford Highway,Mailstop F-57, Atlanta, GA 30341 USA. EM SLNaik@CDC.gov NR 23 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 EI 1559-064X J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2017 VL 27 IS 2 BP 207 EP 213 DI 10.1038/jes.2016.18 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EL2NM UT WOS:000394456500009 PM 27025411 ER PT J AU Lee, LJ Symanski, E Lupo, PJ Tinker, SC Razzaghi, H Chan, WY Hoyt, AT Canfield, MA AF Lee, Laura J. Symanski, Elaine Lupo, Philip J. Tinker, Sarah C. Razzaghi, Hilda Chan, Wenyaw Hoyt, Adrienne T. Canfield, Mark A. CA Natl Birth Defects Prevention Stud TI Role of maternal occupational physical activity and psychosocial stressors on adverse birth outcomes SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID GESTATIONAL-AGE BIRTHS; PRETERM BIRTH; UNITED-STATES; PREVENTIVE MEASURES; DEFECTS PREVENTION; WORKING-CONDITIONS; JOB STRAIN; PREGNANCY; RISK; WEIGHT AB Objectives We examined the association of an array of estimated maternal occupational physical activities and psychosocial stressors during pregnancy with odds for preterm birth (PTB) and small-for-gestational age (SGA). Methods Data for infants born without major birth defects delivered from 1997 to 2009 whose mothers reported working at least 1 month during pregnancy were obtained from the National Birth Defects Prevention Study. We linked occupational codes to the US Department of Labor's Occupational Information Network, which provides estimates of exposure for multiple domains of physical activity and psychosocial stressors by occupational categories. We conducted factor analysis using principal components extraction with 17 occupational activities and calculated factor scores. ORs for PTB and SGA across quartiles of factor scores in each trimester were computed using logistic regression. Results Factor analysis grouped occupational domains into 4 groups based on factor loadings. These groups were 'occupational physical activity', 'interpersonal stressor', 'automated work' and 'job responsibility'. High levels of occupational physical activity' were significantly associated with SGA (adjusted OR (AOR) for highest quartile compared with lowest quartile of factor score: 1.36; 95% CIs 1.02 to 1.82; p for trend=0.001) and were also positively associated with PTB (AOR: 1.24; 95% CI 0.93 to 1.64; p for trend=0.01). No clear results were observed across domains of psychosocial stressors. Conclusions Our findings expand understanding of associations between occupational physical activity and psychosocial stressors and PTB and SGA and suggest that additional research is needed to further examine these relationships. C1 [Lee, Laura J.; Symanski, Elaine] Univ Texas Hlth Sci Ctr Houston UTHlth, Sch Publ Hlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX USA. [Lee, Laura J.; Symanski, Elaine] Southwest Ctr Occupat & Environm Hlth, Houston, TX USA. [Lupo, Philip J.] Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX 77030 USA. [Tinker, Sarah C.; Razzaghi, Hilda] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Chan, Wenyaw] UTHlth Sch Publ Hlth, Dept Biostat, Houston, TX USA. [Hoyt, Adrienne T.; Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. RP Symanski, E (reprint author), Univ Texas Hlth Sci Ctr Houston UTHlth, Sch Publ Hlth, 1200 Herman Pressler Dr,RAS W1028, Houston, TX 77030 USA. EM elaine.symanski@uth.tmc.edu FU Centers for Disease Control and Prevention (CDC) National Institute for Occupational Safety and Health (NIOSH) Education and Research Center (ERC) ) through the Southwest Center for Occupational and Environmental Health [5T42OH008421]; CDC Centers for Excellence Award [U01/DD000494]; CDC [PA 96043, PA 02081, FOA DD09-001]; CDC/NIOSH [200-2000-08018] FX This work was supported by the Centers for Disease Control and Prevention (CDC) National Institute for Occupational Safety and Health (NIOSH) Education and Research Center (ERC) (grant number 5T42OH008421) through the Southwest Center for Occupational and Environmental Health. This work was also supported by the CDC Centers for Excellence Award No. U01/DD000494. For the use of the general pooled NBDPS data: this work was supported through cooperative agreements under PA 96043, PA 02081 and FOA DD09-001 from the CDC to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study. For the use of the occupational exposure assessment data: this work was supported by contract 200-2000-08018 from the CDC/NIOSH. NR 40 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD MAR PY 2017 VL 74 IS 3 BP 192 EP 199 DI 10.1136/oemed-2016-103715 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3KY UT WOS:000394519200007 PM 27919059 ER PT J AU Zhang, L Yang, P Thompson, MG Pan, Y Ma, CN Wu, SS Sun, Y Zhang, M Duan, W Wang, QY AF Zhang, Li Yang, Peng Thompson, Mark G. Pan, Yang Ma, Chunna Wu, Shuangsheng Sun, Ying Zhang, Man Duan, Wei Wang, Quanyi TI Influenza Vaccine Effectiveness in Preventing Influenza Illness Among Children During School-based Outbreaks in the 2014-2015 Season in Beijing, China SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE influenza; vaccine effectiveness; school; outbreak; China ID CONFIRMED INFLUENZA; UNITED-STATES; JANUARY 2015; VIRUS; PROTECTION; INFECTION; A(H3N2); CANADA AB Background: Little is known about vaccine effectiveness (VE) against non-medically attended A(H3N2) influenza illness during 2014-2015 when the vaccine component appeared to be a poor match with circulating strains. Methods: Forty-three eligible school influenza outbreaks in Beijing, China, from November 1, 2014, to December 31, 2014, were included in this study. The VE of 2014-2015 trivalent inactivated influenza vaccine (IIV3) was assessed in preventing laboratory-confirmed influenza among school-age children through a case-control design, using asymptomatic controls. Influenza vaccination was documented from a vaccination registry. VE was estimated adjusting for age group, sex, rural versus urban area, body mass index, chronic conditions, onset week and schools through a mixed effects logistic regression model. Results: The average coverage rate of 2014-2015 IIV3 among students across the 43 schools was 47.6%. The fully adjusted VE of 2014-2015 IIV3 against laboratory-confirmed influenza was 38% [95% confidence interval (CI): 12%-57%]. Receipt of previous season's (2013-2014) IIV3 significantly modified VE of the 2014-2015 IIV3; children who received both 2013-2014 and 2014-2015 vaccinations had VE of 29% (95% CI: -8% to 53%), whereas VE for children who received 2014-2015 IIV3 only was 54% (95% CI: 8%-77%). Conclusions: VE for 2014-2015 IIV3 against A(H3N2) illness identified in schools was modest. Children who did not receive the prior season's vaccine with a homologous A(H3N2) component may have enjoyed greater protection than repeated vaccinees. C1 [Zhang, Li; Yang, Peng; Pan, Yang; Ma, Chunna; Wu, Shuangsheng; Sun, Ying; Zhang, Man; Duan, Wei; Wang, Quanyi] Beijing Ctr Dis Prevent & Control, Inst Infect Dis & Endem Dis Control, 16 He Pingli Middle St, Beijing 100013, Peoples R China. [Zhang, Li; Yang, Peng; Pan, Yang; Ma, Chunna; Wu, Shuangsheng; Sun, Ying; Zhang, Man; Duan, Wei; Wang, Quanyi] Beijing Res Ctr Prevent Med, Beijing, Peoples R China. [Zhang, Li; Yang, Peng; Pan, Yang; Ma, Chunna; Wu, Shuangsheng; Sun, Ying; Zhang, Man; Duan, Wei; Wang, Quanyi] Capital Med Univ, Sch Publ Hlth, Beijing, Peoples R China. [Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Wang, QY (reprint author), Beijing Ctr Dis Prevent & Control, Inst Infect Dis & Endem Dis Control, 16 He Pingli Middle St, Beijing 100013, Peoples R China. EM bjcdcxm@126.com FU Beijing Health System High Level Health Technology Talent Cultivation Plan [2013-3-098]; Beijing Municipal Science and Technology Commission [D141100003114002]; Beijing Talents Fund [2014000021223ZK36]; Capital Health Research and Development of Special, expanding the use of seasonal influenza vaccines in public health programs in China [2014-1-1011, 1U51IP000819-01] FX This study was supported by Beijing Health System High Level Health Technology Talent Cultivation Plan (2013-3-098), Beijing Municipal Science and Technology Commission (D141100003114002), Beijing Talents Fund (2014000021223ZK36) and The Capital Health Research and Development of Special (2014-1-1011), expanding the use of seasonal influenza vaccines in public health programs in China (1U51IP000819-01). The authors have no conflicts of interest to disclose. NR 30 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2017 VL 36 IS 3 BP E69 EP E75 DI 10.1097/INF.0000000000001434 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EL1CE UT WOS:000394357300004 PM 27902651 ER PT J AU Ferdinands, JM Fry, AM Reynolds, S Petrie, JG Flannery, B Jackson, ML Belongia, EA AF Ferdinands, Jill M. Fry, Alicia M. Reynolds, Sue Petrie, Joshua G. Flannery, Brendan Jackson, Michael L. Belongia, Edward A. TI Intraseason Waning of Influenza Vaccine Protection: Evidence From the US Influenza Vaccine Effectiveness Network, 2011-2012 Through 2014-2015 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE case-control studies; influenza; influenza vaccine; vaccine effectiveness ID ANTIBODY-RESPONSE; IMMUNE-RESPONSE; LONG-TERM; SEASON; EFFICACY; IMMUNOGENICITY; VIRUS; HEMAGGLUTININ; HETEROGENEITY; PERSISTENCE AB Background. Recent studies suggest that influenza vaccine effectiveness (VE) may wane over the course of an influenza season, leading to suboptimal VE during late influenza seasons. Methods. We examined the association between influenza VE and time since vaccination among patients >= 9 years old with medically attended acute respiratory illness in the US Influenza Vaccine Effectiveness Network using data pooled from the 2011-2012 through 2014-2015 influenza seasons. We used multivariate logistic regression with polymerase chain reaction-confirmed influenza infection as the outcome and vaccination status defined by days between vaccination and symptom onset as the predictor. Models were adjusted for calendar time and other potential confounding factors. Results. We observed decreasing VE with increasing time since vaccination for influenza A(H3N2) (P = .004), influenza A(H1N1)pdm09 (P = .01), and influenza B viruses (P = .04). Maximum VE was observed shortly after vaccination, followed by a decline in VE of about 7% (absolute) per month for influenza A(H3N2) and influenza B and 6%-11% per month for influenza A(H1N1)pdm09 viruses. VE remained greater than zero for at least 6 months for influenza A(H1N1)pdm09 and influenza B and at least 5 months for influenza A(H3N2) viruses. Decline in VE was more pronounced among patients with prior-season influenza vaccination. A similar pattern of increasing influenza risk with increasing time since vaccination was seen in analyses limited to vaccinees. Conclusions. We observed decreasing influenza vaccine protection with increasing time since vaccination across influenza types/subtypes. This association is consistent with intraseason waning of host immunity, but bias or residual confounding could explain these findings. C1 [Ferdinands, Jill M.; Fry, Alicia M.; Reynolds, Sue; Flannery, Brendan] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Reynolds, Sue] Battelle Mem Inst, Atlanta, GA USA. [Petrie, Joshua G.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI USA. [Jackson, Michael L.] Grp Hlth Res Inst, Seattle, WA USA. [Belongia, Edward A.] Marshfield Clin Res Ctr, Marshfield, WI USA. RP Ferdinands, JM (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM jferdinands@cdc.gov FU CDC [IP11-003] FX This work was supported by the CDC (cooperative agreement IP11-003). NR 33 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2017 VL 64 IS 5 BP 544 EP 550 DI 10.1093/cid/ciw816 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TA UT WOS:000397303400002 ER PT J AU See, I Wesson, P Gualandi, N Dumyati, G Harrison, LH Lesher, L Nadle, J Petit, S Reisenauer, C Schaffner, W Tunali, A Mu, Y Ahern, J AF See, Isaac Wesson, Paul Gualandi, Nicole Dumyati, Ghinwa Harrison, Lee H. Lesher, Lindsey Nadle, Joelle Petit, Susan Reisenauer, Claire Schaffner, William Tunali, Amy Mu, Yi Ahern, Jennifer TI Socioeconomic Factors Explain Racial Disparities in Invasive Community-Associated Methicillin-Resistant Staphylococcus aureus Disease Rates SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE methicillin-resistant Staphylococcus aureus; antibiotic resistance; racial disparities; social determinants of health ID UNITED-STATES; RACIAL/ETHNIC DISPARITIES; MEDIATION ANALYSIS; INFECTIONS; RISK; EPIDEMIOLOGY; PREVALENCE AB Background. Invasive community-associated methicillin-resistant Staphylococcus aureus (MRSA) incidence in the United States is higher among black persons than white persons. We explored the extent to which socioeconomic factors might explain this racial disparity. Methods. A retrospective cohort was based on the Centers for Disease Control and Prevention's Emerging Infections Program surveillance data for invasive community-associated MRSA cases (isolated from a normally sterile site of an outpatient or on hospital admission day <= 3 in a patient without specified major healthcare exposures) from 2009 to 2011 in 33 counties of 9 states. We used generalized estimating equations to determine census tract-level factors associated with differences in MRSA incidence and inverse odds ratio-weighted mediation analysis to determine the proportion of racial disparity mediated by socioeconomic factors. Results. Annual invasive community-associated MRSA incidence was 4.59 per 100 000 among whites and 7.60 per 100 000 among blacks (rate ratio [RR], 1.66; 95% confidence interval [CI], 1.52-1.80). In the mediation analysis, after accounting for census tract-level measures of federally designated medically underserved areas, education, income, housing value, and rural status, 91% of the original racial disparity was explained; no significant association of black race with community-associated MRSA remained (RR, 1.05; 95% CI, .92-1.20). Conclusions. The racial disparity in invasive community-associated MRSA rates was largely explained by socioeconomic factors. The specific factors that underlie the association between census tract-level socioeconomic measures and MRSA incidence, which may include modifiable social (eg, poverty, crowding) and biological factors (not explored in this analysis), should be elucidated to define strategies for reducing racial disparities in community-associated MRSA rates. C1 [See, Isaac; Gualandi, Nicole; Mu, Yi] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-16, Atlanta, GA 30329 USA. [Wesson, Paul; Ahern, Jennifer] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA USA. [Dumyati, Ghinwa] Univ Rochester Med Ctr, Rochester, NY USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Lesher, Lindsey] Minnesota Dept Hlth, St Paul, MN USA. [Nadle, Joelle] Calif Emerging Infect Program, Oakland, CA USA. [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Reisenauer, Claire] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Schaffner, William] Vanderbilt Univ Sch Med, Nashville, TN USA. [Tunali, Amy] Georgia Emerging Infect Program, Atlanta, GA USA. RP See, I (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-16, Atlanta, GA 30329 USA. EM isee@cdc.gov FU CDC's Emerging Infections Program (California) [U50CK000201]; CDC's Emerging Infections Program (Colorado) [U50CK000194]; CDC's Emerging Infections Program (Connecticut) [U50CK000195]; CDC's Emerging Infections Program (Georgia) [U50CK000196]; CDC's Emerging Infections Program (Maryland) [U50CK000203]; CDC's Emerging Infections Program (Minnesota) [U50CK000204]; CDC's Emerging Infections Program (New York) [U50CK000199]; CDC's Emerging Infections Program (Oregon) [U50CK000197]; CDC's Emerging Infections Program (Tennessee) [U50CK000198] FX This work was supported by a cooperative agreement through the CDC's Emerging Infections Program (grant numbers U50CK000201 [California], U50CK000194 [Colorado], U50CK000195 [Connecticut], U50CK000196 [Georgia], U50CK000203 [Maryland], U50CK000204 [Minnesota], U50CK000199 [New York], U50CK000197 [Oregon], and U50CK000198 [Tennessee]). NR 39 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2017 VL 64 IS 5 BP 597 EP 604 DI 10.1093/cid/ciw808 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TA UT WOS:000397303400009 PM 28362911 ER PT J AU Cranston, RD Lama, JR Richardson, BA Carballo-Dieguez, A Ayudhya, RPKN Liu, K Patterson, KB Leu, CS Galaska, B Jacobson, CE Parikh, UM Marzinke, MA Hendrix, CW Johnson, S Piper, JM Grossman, C Ho, KS Lucas, J Pickett, J Bekker, LG Chariyalertsak, S Chitwarakorn, A Gonzales, P Holtz, TH Liu, AY Mayer, KH Zorrilla, C Schwartz, JL Rooney, J McGowan, I AF Cranston, Ross D. Lama, Javier R. Richardson, Barbra A. Carballo-Dieguez, Alex Ayudhya, Ratiya Pamela Kunjara Na Liu, Karen Patterson, Karen B. Leu, Cheng-Shiun Galaska, Beth Jacobson, Cindy E. Parikh, Urvi M. Marzinke, Mark A. Hendrix, Craig W. Johnson, Sherri Piper, Jeanna M. Grossman, Cynthia Ho, Ken S. Lucas, Jonathan Pickett, Jim Bekker, Linda-Gail Chariyalertsak, Suwat Chitwarakorn, Anupong Gonzales, Pedro Holtz, Timothy H. Liu, Albert Y. Mayer, Kenneth H. Zorrilla, Carmen Schwartz, Jill L. Rooney, James McGowan, Ian CA MTN-017 Protocol Team TI MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE rectal; microbicide; HIV; prevention; tenofovir ID PREEXPOSURE PROPHYLAXIS; TRANSGENDER WOMEN; MEN; HIV; SEX; MICROBICIDES; INFECTION; RISK AB Background. Human immunodeficiency virus (HIV) disproportionately affects men who have sex with men (MSM) and transgender women (TGW). Safe and acceptable topical HIV prevention methods that target the rectum are needed. Methods. MTN-017 was a phase 2, 3-period, randomized sequence, open-label, expanded safety and acceptability crossover study comparing rectally applied reduced-glycerin (RG) 1% tenofovir (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/ TDF). In each 8-week study period participants were randomized to RG-TFV rectal gel daily, or RG-TFV rectal gel before and after receptive anal intercourse (RAI; or at least twice weekly in the event of no RAI), or daily oral FTC/TDF. Results. MSM and TGW (n = 195) were enrolled from 8 sites in the United States, Thailand, Peru, and South Africa with mean age of 31.1 years (range 18-64). There were no differences in = grade 2 adverse event rates between daily gel (incidence rate ratio [IRR], 1.09; P = .59) or RAI gel (IRR, 0.90; P = .51) compared to FTC/TDF. High adherence (>= 80% of prescribed doses assessed by unused product return and Short Message System reports) was less likely in the daily gel regimen (odds ratio [OR], 0.35; P < .001), and participants reported less likelihood of future daily gel use for HIV protection compared to FTC/TDF (OR, 0.38; P < .001). Conclusions. Rectal application of RG TFV gel was safe in MSM and TGW. Adherence and product use likelihood were similar for the intermittent gel and daily oral FTC/TDF regimens, but lower for the daily gel regimen. C1 [Cranston, Ross D.; Parikh, Urvi M.; Ho, Ken S.; McGowan, Ian] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Lama, Javier R.; Gonzales, Pedro] Asociac Civil Impacta Salud Educ, Lima, Peru. [Richardson, Barbra A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Richardson, Barbra A.; Liu, Karen; Patterson, Karen B.] Fred Hutchinson Canc Res Center, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA USA. [Carballo-Dieguez, Alex; Galaska, Beth] Columbia Univ, New York State Psychiat Inst, New York, NY USA. [Ayudhya, Ratiya Pamela Kunjara Na; Galaska, Beth] Magee Womens Res Inst, Pittsburgh, PA USA. [Hendrix, Craig W.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Johnson, Sherri; Lucas, Jonathan] FHI 360, Durham, NC USA. [Piper, Jeanna M.] Nat Inst Allergy & Infect Disease, Bethesda, MD USA. [Grossman, Cynthia] Natl Inst Mental Hlth, Bethesda, MD USA. [Pickett, Jim] AIDS Fdn Chicago, Chicago, IL USA. [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa. [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai, Thailand. [Chitwarakorn, Anupong; Holtz, Timothy H.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Bangkok, Thailand. [Holtz, Timothy H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Liu, Albert Y.] Bridge HIV, San Francisco Dept Publ Hlth, San Francisco, CA USA. [Mayer, Kenneth H.] Fenway Inst, Boston, MA USA. [Zorrilla, Carmen] Univ Puerto Rico, Sch Med, Dept Obstet & Gynecol, San Juan, PR USA. [Schwartz, Jill L.] CONRAD Eastern Virginia Med Sch, Arlington, VA USA. [Rooney, James] Gilead Sci, Foster City, CA USA. RP Cranston, RD (reprint author), Hosp Univ Germans Trias Pujol, Fundacio Lluita Sida, Badalona 08916, Spain. EM rdcranston@outlook.com FU National Institute of Allergy and Infectious Diseases of the NIH [UM1AI068633, UM1AI068615, UM1AI106707]; Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH; National Institute of Mental Health of the NIH FX This work was supported by the National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707), with cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the NIH. NR 19 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2017 VL 64 IS 5 BP 614 EP 620 DI 10.1093/cid/ciw832 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TA UT WOS:000397303400011 PM 27986684 ER PT J AU Mattson, CL Bradley, H Beer, L Johnson, C Pearson, WS Shouse, RL AF Mattson, Christine L. Bradley, Heather Beer, Linda Johnson, Christopher Pearson, William S. Shouse, R. Luke CA Med Monitoring Project TI Increased Sexually Transmitted Disease Testing Among Sexually Active Persons Receiving Medical Care for Human Immunodeficiency Virus Infection in the United States, 2009-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE syphilis; chlamydia; gonorrhea; STD; HIV ID CD4 CELL COUNTS; HIV VIRAL LOAD; EPIDEMIOLOGIC SYNERGY; TREATMENT GUIDELINES; HEALTH; ASSOCIATION; SYPHILIS; AMERICA; SOCIETY; PREVENTION AB Background. Current guidelines recommend that all sexually active human immunodeficiency virus (HIV)-infected persons be tested at least annually for syphilis, chlamydia, and gonorrhea. We examined temporal trends in syphilis, chlamydia, and gonorrhea testing among sexually active HIV-infected adults receiving medical care in the United States during 2009-2013. Methods. Using medical record data from the Medical Monitoring Project, a population-based HIV surveillance system, we assessed the proportion of adults receiving HIV medical care who were tested for syphilis, chlamydia, and gonorrhea in the past 12 months by year and stratified by sex and sexual behavior, age, and race/ethnicity. Results. During 2009-2013, the proportion of sexually active HIV-infected adults receiving medical care who were tested in the past year for all 3 examined sexually transmitted diseases (STDs) increased from 20% to 36% (P-TREND < .01). Overall testing for syphilis increased from 55% to 65% (P-TREND < .01), and significant increases were noted for the following subgroups: men who have sex with men (58% to 69%), non-Hispanic whites (48% to 64%), and all age groups with the exception of persons aged 18-29 year. Overall testing for chlamydia and gonorrhea increased from 22% to 42% (P-TREND < .01), and significant increases were noted for most subgroups. Conclusions. STD testing significantly increased among sexually active HIV-infected adults receiving medical care; however, the majority of persons were not tested for all 3 STDs in 2013. While increased testing indicates progress, testing remained far below recommended guidelines. Our findings suggest enhanced efforts may be warranted to screen all sexually active HIV-infected adults for syphilis, chlamydia, and gonorrhea. C1 [Mattson, Christine L.; Bradley, Heather; Beer, Linda; Johnson, Christopher; Shouse, R. Luke] Natl Ctr HIV AIDS, Ctr Dis Control, Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA. [Pearson, William S.] Natl Ctr HIV AIDS, Ctr Dis Control, Viral Hepatitis STD & TB Prevent, Div STD Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA. RP Mattson, CL (reprint author), Natl Ctr HIV AIDS, Ctr Dis Control, Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA. EM ggi8@cdc.gov FU CDC FX This work is supported by the CDC. NR 34 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2017 VL 64 IS 5 BP 629 EP 634 DI 10.1093/cid/ciw834 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TA UT WOS:000397303400013 PM 27940947 ER PT J AU Smeesters, PR Laho, D Beall, B Steer, AC Van Beneden, CA AF Smeesters, Pierre R. Laho, Delphine Beall, Bernard Steer, Andrew C. Van Beneden, Chris A. TI Seasonal, Geographic, and Temporal Trends of emm Clusters Associated With Invasive Group A Streptococcal Infections in US Multistate Surveillance SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID VACCINE DEVELOPMENT; GENETIC DIVERSITY; TYPING SYSTEM; UNITED-STATES; EPIDEMIOLOGY C1 [Smeesters, Pierre R.; Laho, Delphine] Acad Children Hosp Queen Fabiola, Dept Pediat, Av Crocq 15, B-1020 Brussels, Belgium. [Smeesters, Pierre R.] Univ Libre Bruxelles, Mol Bacteriol Lab, Brussels, Belgium. [Smeesters, Pierre R.; Laho, Delphine; Steer, Andrew C.] Murdoch Childrens Res Inst, Grp Streptococcus Res Grp, Melbourne, Vic, Australia. [Smeesters, Pierre R.; Steer, Andrew C.] Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia. [Beall, Bernard; Van Beneden, Chris A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Steer, Andrew C.] Royal Childrens Hosp Melbourne, Dept Gen Hosp, Melbourne, Vic, Australia. RP Smeesters, PR (reprint author), Acad Children Hosp Queen Fabiola, Dept Pediat, Av Crocq 15, B-1020 Brussels, Belgium. EM pierre.smeesters@huderf.be NR 10 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2017 VL 64 IS 5 BP 694 EP 695 DI 10.1093/cid/ciw807 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TA UT WOS:000397303400026 ER PT J AU Smeesters, PR Laho, D Beall, B Steer, AC Van Beneden, CA AF Smeesters, Pierre R. Laho, Delphine Beall, Bernard Steer, Andrew C. Van Beneden, Chris A. TI Seasonal, Geographic, and Temporal Trends of emm Clusters Associated With Invasive Group A Streptococcal Infections in US Multistate Surveillance SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID VACCINE DEVELOPMENT; GENETIC DIVERSITY; TYPING SYSTEM; UNITED-STATES; EPIDEMIOLOGY C1 [Smeesters, Pierre R.; Laho, Delphine] Acad Children Hosp Queen Fabiola, Dept Pediat, Av JJ Crocq 15, B-1020 Brussels, Belgium. [Smeesters, Pierre R.] Univ Libre Bruxelles, Mol Bacteriol Lab, Brussels, Belgium. [Smeesters, Pierre R.; Laho, Delphine; Steer, Andrew C.] Murdoch Childrens Res Inst, Grp Streptococcus Res Grp, Melbourne, Vic, Australia. [Smeesters, Pierre R.; Steer, Andrew C.] Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia. [Beall, Bernard; Van Beneden, Chris A.] Centers Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Steer, Andrew C.] Royal Childrens Hosp, Dept Gen Hosp, Melbourne, Vic, Australia. RP Smeesters, PR (reprint author), Acad Children Hosp Queen Fabiola, Dept Pediat, Av JJ Crocq 15, B-1020 Brussels, Belgium. EM pierre.smeesters@huderf.be NR 10 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAR 1 PY 2017 VL 64 IS 5 BP 695 EP U175 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3TA UT WOS:000397303400027 ER PT J AU Dias, MS Rottmund, CM Cappos, KM Reed, ME Wang, M Stetter, C Shaffer, ML Hollenbeak, CS Paul, IM Christian, CW Berger, RP Klevens, J AF Dias, Mark S. Rottmund, Carroll M. Cappos, Kelly M. Reed, Marie E. Wang, Ming Stetter, Christina Shaffer, Michele L. Hollenbeak, Christopher S. Paul, Ian M. Christian, Cindy W. Berger, Rachel P. Klevens, Joanne TI Association of a Postnatal Parent Education Program for Abusive Head Trauma With Subsequent Pediatric Abusive Head Trauma Hospitalization Rates SO JAMA PEDIATRICS LA English DT Article ID SHAKEN-BABY SYNDROME; RANDOMIZED CONTROLLED-TRIAL; OPERATIONAL CASE-DEFINITION; PREVENTION PROGRAM; CHANGE KNOWLEDGE; INTERNATIONAL CLASSIFICATION; HOME VISITATION; YOUNG-CHILDREN; BRAIN-INJURY; BEHAVIOR AB IMPORTANCE Studies suggest that a postnatal parental intervention may reduce the incidence of abusive head trauma (AHT) of infants and young children. OBJECTIVE To assess the effect of statewide universal AHT education for parents on AHT hospitalization rates in Pennsylvania and on parents' self-reported knowledge gains and parenting behaviors. DESIGN, SETTING, AND PARTICIPANTS Changes in AHT hospitalization rates in Pennsylvania before and during the intervention were compared with those in 5 other states lacking universal parental AHT education during the same period. Data were collected from maternity units and birthing centers throughout Pennsylvania from the parents of 1 593 834 infants born on these units from January 1, 2003, to December 31, 2013. Parental behavior and knowledge were assessed through immediate (n = 16 111) and 7-month postintervention (n = 146) parent surveys in a per protocol analysis of evaluable parents. INTERVENTIONS Parents read a brochure, viewed an 8-minute video about infant crying and AHT, asked questions of the nurse, and signed a commitment statement affirming their participation. Educational posters were displayed on each unit. MAIN OUTCOMES AND MEASURES Changes in AHT hospitalization rates before and during the intervention in Pennsylvania and 5 other states. Secondary outcomes included self-reported knowledge gains and changes in parenting practices. RESULTS A total of 1 180 291 parents (74.1%) of children ranging in age from 0 to 23 months signed a commitment statement. Incidence rate ratios for hospitalization for AHT increased in Pennsylvania from 24.1 (95% CI, 22.1-26.3) to 26.6 (95% CI, 24.9-28.4) per 100000 children aged 0 to 23 months during the intervention period; changes in Pennsylvania were not significantly different from aggregate changes in the 5 other states, from 22.4 (95% CI, 21.2-23.6) to 22.0 (95% CI, 21.2-22.8) per 100000 children aged 0 to 23 months. A total of 16 111 parents (21.5% men, 78.5% women) completed the postnatal survey. Despite an overall 74.1% adherence with the intervention, only 20.6% of parents saw the brochure and video and only 5.7% were exposed to the entire intervention. Among the respondents answering individual questions on the postnatal surveys, 10 958 mothers (91.0%) and 2950 fathers (88.6%) reported learning a lot about understanding infant crying as normal; 11023 mothers (92.2%) and 2923 fathers (88.9%), calming their infant, 11 396 mothers (94.6%) and 3035 fathers (91.9%), calming themselves; 10 060 mothers (85.1%) and 2688 fathers (83.4%), selecting other infant caregivers; and 11 435 mothers (94.8%) and 3201 fathers (95.8%), that the information would decrease the likelihood of shaking an infant. Among the 143 respondents completing the 7-month survey, 109 (76.2%) reported remembering the information while their childwas crying. CONCLUSIONS AND RELEVANCE This intervention was not associated with a reduction in pediatric AHT hospitalization rates but was associated with self-reported gains in parental knowledge that were retained for 7 months. C1 [Dias, Mark S.; Rottmund, Carroll M.; Cappos, Kelly M.; Reed, Marie E.] Penn State Childrens Hosp, Penn State Coll Med, Dept Neurosurg, 30 Hope Dr,Mail Code 110, Hershey, PA 17033 USA. [Dias, Mark S.; Hollenbeak, Christopher S.; Paul, Ian M.] Penn State Univ, Coll Med, Penn State Childrens, Dept Pediat, Hershey, PA USA. [Wang, Ming; Stetter, Christina; Shaffer, Michele L.; Hollenbeak, Christopher S.; Paul, Ian M.] Penn State Univ, Dept Publ Hlth Sci, Coll Med, Penn State Childrens Hosp, Hershey, PA USA. [Shaffer, Michele L.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Shaffer, Michele L.] Seattle Childrens Res Inst, Childrens Core Biomed Stat, Seattle, WA USA. [Christian, Cindy W.] Univ Pennsylvania, Sch Med, Dept Pediat, Childrens Hosp Philadelphia, Philadelphia, PA USA. [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Sch Med, Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Klevens, Joanne] CDC, Div Violence Prevent, Atlanta, GA USA. RP Dias, MS (reprint author), Penn State Childrens Hosp, Penn State Coll Med, Dept Neurosurg, 30 Hope Dr,Mail Code 110, Hershey, PA 17033 USA. EM mdias@hmc.psu.edu FU CDC [5U49CE001274-04] FX This study was supported by grant 5U49CE001274-04 from the CDC. NR 28 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD MAR 1 PY 2017 VL 171 IS 3 BP 223 EP 229 DI 10.1001/jamapediatrics.2016.4218 PG 7 WC Pediatrics SC Pediatrics GA EN7SL UT WOS:000396202400012 PM 28135348 ER PT J AU Moore, CA Staples, JE Dobyns, WB Pessoa, A Ventura, CV Da Fonseca, EB Ribeiro, EM Ventura, LO Neto, NN Arena, JF Rasmussen, SA AF Moore, Cynthia A. Staples, J. Erin Dobyns, William B. Pessoa, Andre Ventura, Camila V. Da Fonseca, Eduardo Borges Ribeiro, Erlane Marques Ventura, Liana O. Nogueira Neto, Norberto Arena, J. Fernando Rasmussen, Sonja A. TI Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric Clinicians SO JAMA PEDIATRICS LA English DT Review ID FETAL-BRAIN DISRUPTION; VIRUS-INFECTION; CASE SERIES; IMAGING FINDINGS; HEARING-LOSS; SEQUENCE; INFANTS; BRAZIL; ARTHROGRYPOSIS; CALCIFICATION AB IMPORTANCE Zika virus infection can be prenatally passed from a pregnant woman to her fetus. There is sufficient evidence to conclude that intrauterine Zika virus infection is a cause of microcephaly and serious brain anomalies, but the full spectrum of anomalies has not been delineated. To inform pediatric clinicians who may be called on to evaluate and treat affected infants and children, we review the most recent evidence to better characterize congenital Zika syndrome. OBSERVATIONS We reviewed published reports of congenital anomalies occurring in fetuses or infants with presumed or laboratory-confirmed intrauterine Zika virus infection. We conducted a comprehensive search of the English literature using Medline and EMBASE for Zika from inception through September 30, 2016. Congenital anomalies were considered in the context of the presumed pathogenetic mechanism related to the neurotropic properties of the virus. We conclude that congenital Zika syndrome is a recognizable pattern of structural anomalies and functional disabilities secondary to central and, perhaps, peripheral nervous system damage. Although many of the components of this syndrome, such as cognitive, sensory, and motor disabilities, are shared by other congenital infections, there are 5 features that are rarely seen with other congenital infections or are unique to congenital Zika virus infection: (1) severe microcephaly with partially collapsed skull; (2) thin cerebral cortices with subcortical calcifications; (3) macular scarring and focal pigmentary retinal mottling; (4) congenital contractures; and (5) marked early hypertonia and symptoms of extrapyramidal involvement. CONCLUSIONS AND RELEVANCE Although the full spectrum of adverse reproductive outcomes caused by Zika virus infection is not yet determined, a distinctive phenotype-the congenital Zika syndrome- has emerged. Recognition of this phenotype by clinicians for infants and children can help ensure appropriate etiologic evaluation and comprehensive clinical investigation to define the range of anomalies in an affected infant as well as determine essential follow-up and ongoing care. C1 [Moore, Cynthia A.] Ctr Dis Control & Prevent, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Mail Stop E-86,4770 Buford Hwy NE, Atlanta, GA 30341 USA. [Staples, J. Erin] Ctr Dis Control & Prevent, Zoonot Infect Dis, Ft Collins, CO USA. [Dobyns, William B.] Univ Washington, Seattle, WA USA. [Dobyns, William B.] Seattle Childrens Res Inst, Seattle, WA USA. [Pessoa, Andre; Ribeiro, Erlane Marques] Hosp Infantil Albert Sabin, Fortaleza, Ceara, Brazil. [Ventura, Camila V.; Ventura, Liana O.] Altino Ventura Fdn, Recife, PE, Brazil. [Ventura, Camila V.; Ventura, Liana O.] HOPE Eye Hosp, Recife, PE, Brazil. [Ventura, Camila V.] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Da Fonseca, Eduardo Borges; Nogueira Neto, Norberto] NOVA Diagnost Imagem, Joao Pessoa, Paraiba, Brazil. [Da Fonseca, Eduardo Borges] Univ Fed Paraiba, Joao Pessoa, Paraiba, Brazil. [Ribeiro, Erlane Marques] Estacio Fac Med Juazeiro Norte, Juazeiro De Norte, Ceara, Brazil. [Arena, J. Fernando] Carter Consulting, Atlanta, GA USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. RP Moore, CA (reprint author), Ctr Dis Control & Prevent, Div Congenital & Dev Disorders, Natl Ctr Birth Defects & Dev Disabil, Mail Stop E-86,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM cam0@cdc.gov NR 75 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD MAR 1 PY 2017 VL 171 IS 3 BP 288 EP 295 DI 10.1001/jamapediatrics.2016.3982 PG 8 WC Pediatrics SC Pediatrics GA EN7SL UT WOS:000396202400020 PM 27812690 ER PT J AU Cooley, LA Hoots, B Wejnert, C Lewis, R Paz-Bailey, G AF Cooley, Laura A. Hoots, Brooke Wejnert, Cyprian Lewis, Rashunda Paz-Bailey, Gabriela CA NHBS Study Grp TI Policy Changes and Improvements in Health Insurance Coverage Among MSM: 20 US Cities, 2008-2014 SO AIDS AND BEHAVIOR LA English DT Article DE Health insurance; Men who have sex with men; Health disparities ID SAME-SEX; ACCESS AB Recent policy changes have improved the ability of gay, bisexual, and other men who have sex with men (MSM) to secure health insurance. We wanted to assess changes over time in self-reported health insurance status among MSM participating in CDC's National HIV Behavioral Surveillance (NHBS) in 2008, 2011, and 2014. We analyzed NHBS data from sexually active MSM interviewed at venues in 20 U.S. cities. To determine if interview year was associated with health insurance status, we used a Poisson model with robust standard errors. Among included MSM, the overall percentage of MSM with health insurance rose 16 % from 2008 (68 %) to 2014 (79 %) (p value for trend < 0.001). The change in coverage over time was greatest in key demographic segments with lower health insurance coverage all three interview years, by age, education, and income. Corresponding with recent policy changes, health insurance improved among MSM participating in NHBS, with greater improvements in historically underinsured demographic segments. Despite these increases, improved coverage is still needed. Improved access to health insurance could lead to a reduction in health disparities among MSM over time. C1 [Cooley, Laura A.; Hoots, Brooke; Wejnert, Cyprian; Lewis, Rashunda; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,MS-E46, Atlanta, GA 30329 USA. RP Cooley, LA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,MS-E46, Atlanta, GA 30329 USA. EM LCooley@cdc.gov FU CDC FX The National HIV Behavioral Surveillance (NHBS) system is funded by CDC. Data collection is conducted by funded sites in accordance with a standardized protocol developed by CDC. NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2017 VL 21 IS 3 BP 615 EP 618 DI 10.1007/s10461-016-1567-7 PG 4 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA EL0KT UT WOS:000394312000002 PM 27771817 ER PT J AU Zulliger, R Maulsby, C Solomon, L Baytop, C Orr, A Nasrullah, M Shouse, L DiNenno, E Holtgrave, D AF Zulliger, Rose Maulsby, Cathy Solomon, Liza Baytop, Chanza Orr, Alex Nasrullah, Muazzam Shouse, Luke DiNenno, Elizabeth Holtgrave, David TI Cost-utility of HIV Testing Programs Among Men Who Have Sex with Men in the United States SO AIDS AND BEHAVIOR LA English DT Article DE Men who have sex with men; HIV testing; Cost utility; Economic evaluation ID ANTIRETROVIRAL THERAPY; LIFETIME COSTS; PREVENTION; CARE; RECOMMENDATIONS; TRANSMISSION; HEALTH; RISK AB Few groups in the United States (US) are as heavily affected by HIV as men who have sex with men (MSM), yet many MSM remain unaware of their infection. HIV diagnosis is important for decreasing onward transmission and promoting effective treatment for HIV, but the cost-effectiveness of testing programs is not well-established. This study reports on the costs and cost-utility of the MSM Testing Initiative (MTI) to newly diagnose HIV among MSM and link them to medical care. Cost and testing data in 15 US cities from January 2013 to March 2014 were prospectively collected and combined to determine the cost-utility of MTI in each city in terms of the cost per Quality Adjusted Life Years (QALY) saved from payer and societal perspectives. The total venue-based HIV testing costs ranged from $18,759 to $564,284 for nine to fifteen months of MTI implementation. The cost-saving threshold for HIV testing of MSM was $20,645 per new HIV diagnosis. Overall, 27,475 men were tested through venue-based MTI, of whom 807 (3 %) were newly diagnosed with HIV. These new diagnoses were associated with approximately 47 averted HIV infections. The cost per QALY saved by implementation of MTI in each city was negative, indicating that MTI venue-based testing was cost-saving in all cities. The cost-utility of social network and couples testing strategies was, however, dependent on whether the programs newly diagnosed MSM. The cost per new HIV diagnosis varied considerably across cities and was influenced by both the local cost of MSM testing implementation and by the seropositivity rate of those reached by the HIV testing program. While the cost-saving threshold for HIV testing is highly achievable, testing programs must successfully reach undiagnosed HIV-positive individuals in order to be cost-effective. This underscores the need for HIV testing programs which target and engage populations such as MSM who are most likely to have undiagnosed HIV to maximize programmatic benefit and cost-utility. C1 [Zulliger, Rose; Maulsby, Cathy; Holtgrave, David] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 624 N Broadway, Baltimore, MD 21205 USA. [Solomon, Liza; Baytop, Chanza; Orr, Alex] Abt Associates Inc, Bethesda, MD USA. [Nasrullah, Muazzam; Shouse, Luke; DiNenno, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zulliger, R (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, 624 N Broadway, Baltimore, MD 21205 USA. EM rzulliger@cdc.gov FU Abt Associates [112476] FX This cost analysis was funded by Abt Associates grant number 112476. NR 21 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD MAR PY 2017 VL 21 IS 3 BP 619 EP 625 DI 10.1007/s10461-016-1547-y PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA EL0KT UT WOS:000394312000003 PM 27624729 ER PT J AU Deziel, NC Freeman, LEB Graubard, BI Jones, RR Hoppin, JA Thomas, K Hines, CJ Blair, A Sandler, DP Chen, HL Lubin, JH Andreotti, G Alavanja, MCR Friesen, MC AF Deziel, Nicole C. Freeman, Laura E. Beane Graubard, Barry I. Jones, Rena R. Hoppin, Jane A. Thomas, Kent Hines, Cynthia J. Blair, Aaron Sandler, Dale P. Chen, Honglei Lubin, Jay H. Andreotti, Gabriella Alavanja, Michael C. R. Friesen, Melissa C. TI Relative Contributions of Agricultural Drift, Para-Occupational, and Residential Use Exposure Pathways to House Dust Pesticide Concentrations: Meta-Regression of Published Data SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Review ID CHILDRENS EXPOSURE; CARPET DUST; HOME; CONTAMINATION; PROXIMITY; COMMUNITY; FAMILIES; FARM; IOWA; VARIABILITY AB Background: Increased pesticide concentrations in house dust in agricultural areas have been attributed to several exposure pathways, including agricultural drift, para-occupational, and residential use. Objective: To guide future exposure assessment efforts, we quantified relative contributions of these pathways using meta-regression models of published data on dust pesticide concentrations. Methods: From studies in North American agricultural areas published from 1995 to 2015, we abstracted dust pesticide concentrations reported as summary statistics [e.g., geometric means (GM)]. We analyzed these data using mixed-effects meta-regression models that weighted each summary statistic by its inverse variance. Dependent variables were either the log-transformed GM (drift) or the log-transformed ratio of GMs from two groups (para-occupational, residential use). Results: For the drift pathway, predicted GMs decreased sharply and nonlinearly, with GMs 64% lower in homes 250 m versus 23 m from fields (interquartile range of published data) based on 52 statistics from seven studies. For the para-occupational pathway, GMs were 2.3 times higher [95% confidence interval (CI): 1.5, 3.3; 15 statistics, five studies] in homes of farmers who applied pesticides more recently or frequently versus less recently or frequently. For the residential use pathway, GMs were 1.3 (95% CI: 1.1, 1.4) and 1.5 (95% CI: 1.2, 1.9) times higher in treated versus untreated homes, when the probability that a pesticide was used for the pest treatment was 1-19% and >= 20%, respectively (88 statistics, five studies). Conclusion: Our quantification of the relative contributions of pesticide exposure pathways in agricultural populations could improve exposure assessments in epidemiologic studies. The meta-regression models can be updated when additional data become available. Citation: Deziel NC, Beane Freeman LE, Graubard BI, Jones RR, Hoppin JA, Thomas K, Hines CJ, Blair A, Sandler DP, Chen H, Lubin JH, Andreotti G, Alavanja MC, Friesen MC. 2017. Relative contributions of agricultural drift, para-occupational, and residential use exposure pathways to house dust pesticide concentrations: meta-regression of published data. Environ Health Perspect 125:296-305; http://dx.doi.org/10.1289/EHP426 C1 [Deziel, Nicole C.; Freeman, Laura E. Beane; Graubard, Barry I.; Jones, Rena R.; Blair, Aaron; Lubin, Jay H.; Andreotti, Gabriella; Alavanja, Michael C. R.; Friesen, Melissa C.] NCI, Div Canc Epidemiol & Genet, NIH, US Dept HHS, Bethesda, MD 20892 USA. [Deziel, Nicole C.] Yale Univ, Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA. [Hoppin, Jane A.] North Carolina State Univ, Ctr Human Hlth & Environm, Dept Biol Sci, Raleigh, NC USA. [Thomas, Kent] US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC 27711 USA. [Hines, Cynthia J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studi, Cincinnati, OH 45226 USA. [Sandler, Dale P.; Chen, Honglei] NIEHS, Epidemiol Branch, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA. RP Deziel, NC (reprint author), Yale Sch Publ Hlth, 60 Coll St, New Haven, CT 06510 USA. EM nicole.deziel@yale.edu RI Friesen, Melissa/A-5362-2009; Beane Freeman, Laura/C-4468-2015; OI Beane Freeman, Laura/0000-0003-1294-4124; Chen, Honglei/0000-0003-3446-7779 FU Intramural Research Program of the National Institutes of Health, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics [Z01CP010119]; National Institute of Environmental Health Sciences [Z01-ES049030]; NCI [HHSN261201400231P] FX This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (Z01CP010119), and the National Institute of Environmental Health Sciences (Z01-ES049030). N.C.D. was supported, in part, through NCI (HHSN261201400231P). The U.S. Environmental Protection Agency through its Office of Research and Development collaborated in the research described here. It has been subjected to agency review and approved for publication. NR 40 TC 0 Z9 0 U1 0 U2 0 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2017 VL 125 IS 3 BP 296 EP 305 DI 10.1289/EHP426 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EN0QL UT WOS:000395714400009 PM 27458779 ER PT J AU Mora, AM Oken, E Rifas-Shiman, SL Webster, TF Gillman, MW Calafat, AM Ye, XY Sagiv, SK AF Maria Mora, Ana Oken, Emily Rifas-Shiman, Sheryl L. Webster, Thomas F. Gillman, Matthew W. Calafat, Antonia M. Ye, Xiaoyun Sagiv, Sharon K. TI Prenatal Exposure to Perfluoroalkyl Substances and Adiposity in Early and Mid-Childhood SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID GLOMERULAR-FILTRATION-RATE; PERFLUORINATED COMPOUNDS; BIRTH-WEIGHT; PROSPECTIVE COHORT; THYROID-HORMONE; EARLY-PREGNANCY; FETAL-GROWTH; FAT MASS; CHEMICALS; PERFLUOROOCTANOATE AB BACKGROUND: Few studies have examined whether prenatal exposure to perfluoroalkyl substances (PFASs) is associated with childhood adiposity. OBJECTIVE: We examined associations of prenatal exposure to PFASs with adiposity in early and mid-childhood. METHODS: We measured plasma PFAS concentrations in 1,645 pregnant women (median, 9.6 weeks gestation) enrolled in Project Viva, a prospective pre-birth cohort study in Massachusetts (USA), between 1999 and 2002. We assessed overall and central adiposity in 1,006 children in early childhood (median, 3.2 years) and 876 in mid-childhood (median, 7.7 years) using anthropometric and dual X-ray absorptiometry (DXA) measurements. We fitted multivariable linear regression models to estimate exposure-outcome associations and evaluated effect modification by child sex. RESULTS: Median (25-75th percentiles) prenatal plasma perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS), and perfluorononanoate (PFNA) concentrations in children assessed in early childhood were 5.6 (4.1-7.7), 24.8 (18.4-33.9), 2.4 (1.6-3.8), and 0.6 (0.5-0.9) ng/mL, respectively. Among girls, each interquartile range increment of prenatal PFOA concentrations was associated with 0.21 kg/m(2) (95% CI: -0.05, 0.48) higher body mass index, 0.76 mm (95% CI: -0.17, 1.70) higher sum of subscapular and triceps skinfold thickness, and 0.17 kg/m2 (95% CI: -0.02, 0.36) higher DXA total fat mass index in mid-childhood. Similar associations were observed for PFOS, PFHxS, and PFNA. We observed null associations for boys and early-childhood adiposity measures. CONCLUSIONS: In this cohort, prenatal exposure to PFASs was associated with small increases in adiposity measurements in mid-childhood, but only among girls. C1 [Maria Mora, Ana; Webster, Thomas F.; Sagiv, Sharon K.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St,Talbot Bldg,T4W, Boston, MA 02118 USA. [Maria Mora, Ana] Univ Nacl, Cent Amer Inst Studies Tox Subst, Heredia, Costa Rica. [Oken, Emily; Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Med Sch, Obes Prevent Program, Dept Populat Med, Boston, MA USA. [Oken, Emily; Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Oken, Emily; Gillman, Matthew W.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Sagiv, Sharon K.] Univ Calif Berkeley, CERCH, Sch Publ Hlth, Berkeley, CA 94720 USA. RP Mora, AM (reprint author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St,Talbot Bldg,T4W, Boston, MA 02118 USA. EM animora@bu.edu FU National Institutes of Health [R01 ES021447, K24 HD069408, P30 DK092924, R37 HD034568, PO1 ES009605]; U.S. Environmental Protection Agency [R82670901, RD83451301] FX This work was supported by National Institutes of Health (R01 ES021447, K24 HD069408, P30 DK092924, R37 HD034568, and PO1 ES009605) and U.S. Environmental Protection Agency (R82670901 and RD83451301) grants. NR 42 TC 0 Z9 0 U1 0 U2 0 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2017 VL 125 IS 3 BP 467 EP 473 DI 10.1289/EHP246 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EN0QL UT WOS:000395714400030 PM 27352404 ER PT J AU Lyall, K Croen, LA Sjodin, A Yoshida, CK Zerbo, O Kharrazi, M Windham, GC AF Lyall, Kristen Croen, Lisa. A. Sjodin, Andreas Yoshida, Cathleen K. Zerbo, Ousseny Kharrazi, Martin Windham, Gayle C. TI Polychlorinated Biphenyl and Organochlorine Pesticide Concentrations in Maternal Mid-Pregnancy Serum Samples: Association with Autism Spectrum Disorder and Intellectual Disability SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID POLYBROMINATED DIPHENYL ETHERS; IMMUNE-SYSTEM; CHILDREN; EXPOSURE; NEURODEVELOPMENT; PERSISTENT; BRAIN; BEHAVIORS; CHEMICALS; P,P'-DDE AB Background: Polychlorinated biphenyls (PCBs) and organochlorine pesticides (OCPs) are neurodevelopmental toxicants, but few studies have examined associations with autism spectrum disorder (ASD). Objectives: We aimed to determine whether prenatal exposure to PCBs and OCPs influences offspring risk of ASD and intellectual disability without autism (ID). Methods: We conducted a population-based case-control study among Southern California births, including children with ASD (n = 545) meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR) criteria and ID (n = 181), as well as general population (GP) controls (n = 418). Concentrations of 11 PCB congeners and 2 OCPs measured in banked second-trimester serum samples were compared between the diagnostic groups. Logistic regression was used to calculate crude and adjusted odds ratios (AOR) for associations with ASD, and separately for ID, compared with GP controls, by quartiles of analyte concentrations in primary analyses. Results: Geometric mean levels of several PCB congeners were higher in the ASD group than in the ID and GP groups. ASD risk was elevated for a number of PCB congeners, particularly for the highest vs. lowest quartile of PCB138/158 (AOR = 1.79; 95% CI: 1.10, 2.71) and PCB153 (AOR = 1.82; 95% CI: 1.10, 3.02), and for highest deciles of other congeners in secondary analyses. PCB138/158 was also associated with increased ID (AOR = 2.41; 95% CI: 1.18, 4.91), though no trend was suggested. OCPs were not associated with increased risk of ASD in primary analyses, whereas nonmonotonic increases in risk of ID were found with p, p' - DDE. Conclusions: Our results suggest higher levels of some organochlorine compounds during pregnancy are associated with ASD and ID. C1 [Lyall, Kristen; Kharrazi, Martin; Windham, Gayle C.] Calif Dept Publ Hlth, Environm Hlth Invest Branch, Richmond, CA USA. Kaiser Permanente, Div Res, Oakland, CA USA. [Sjodin, Andreas] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Lyall, K (reprint author), AJ Drexel Autism Inst, Suite 560,3200 Market St, Philadelphia, PA 19104 USA. EM kld98@drexel.edu FU National Institutes of Health [R01-ES016669] FX This work was funded by the National Institutes of Health (grant R01-ES016669). NR 45 TC 0 Z9 0 U1 1 U2 1 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2017 VL 125 IS 3 BP 474 EP 480 DI 10.1289/EHP277 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EN0QL UT WOS:000395714400031 PM 27548254 ER PT J AU Fleisch, AF Rifas-Shiman, SL Mora, AM Calafat, AM Ye, XY Luttmann-Gibson, H Gillman, MW Oken, E Sagiv, SK AF Fleisch, Abby F. Rifas-Shiman, Sheryl L. Mora, Ana M. Calafat, Antonia M. Ye, Xiaoyun Luttmann-Gibson, Heike Gillman, Matthew W. Oken, Emily Sagiv, Sharon K. TI Early-Life Exposure to Perfluoroalkyl Substances and Childhood Metabolic Function SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID PERFLUOROOCTANE SULFONATE PFOS; NUTRITION-EXAMINATION-SURVEY; POLYFLUOROALKYL CHEMICALS; PERFLUORINATED COMPOUNDS; NATIONAL-HEALTH; ACID PFOA; CHILDREN; ASSOCIATION; AGE; HOMEOSTASIS AB Background: Perfluoroalkyl substances (PFASs) are synthetic chemicals that may persist in the environment and in humans. There is a possible association between early-life PFAS exposure and metabolic dysfunction in later life, but data are limited. Methods: We studied 665 mother-child pairs in Project Viva, a Boston, Massachusetts-area cohort recruited 1999-2002. We quantified concentrations of PFASs [perfluorooctanoate (PFOA), perfluorooctane sulfonate (PFOS), perfluorononanoate (PFNA), perfluorohexane sulfonate (PFHxS), and perfluorodecanoate (PFDeA)] in maternal plasma collected at the first prenatal visit (median, 9.6 weeks gestation) and in child plasma from the mid-childhood research visit (median, 7.7 years). We assessed leptin, adiponectin, and homeostatic model assessment of insulin resistance (HOMA-IR) in mid-childhood. We fit covariate-adjusted linear regression models and conducted stratified analyses by child sex. Results: Children with higher PFAS concentrations had lower HOMA-IR [e.g., -10.1% (95% CI: -17.3, -2.3) per interquartile range increment in PFOA]. This inverse association between child PFAS and HOMA-IR was more pronounced in females [e.g., PFOA: -15.6% (95% CI: -25.4, -4.6) vs. -6.1% (95% CI: -16.2, 5.2) for males]. Child PFAS plasma concentrations were not associated with leptin or adiponectin. Prenatal PFAS plasma concentrations were not associated with leptin, adiponectin, or HOMA-IR in offspring. Conclusions: We found no evidence for an adverse effect of early-life PFAS exposure on metabolic function in mid-childhood. In fact, children with higher PFAS concentrations had lower insulin resistance. C1 [Fleisch, Abby F.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA. [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.; Oken, Emily] Harvard Med Sch, Dept Populat Med, Obes Prevent Program, Boston, MA USA. [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.; Oken, Emily] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Mora, Ana M.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Mora, Ana M.] Univ Nacl, Cent Amer Inst Studies Toxic Subst IRET, Heredia, Costa Rica. Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA. [Luttmann-Gibson, Heike] Harvard Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Gillman, Matthew W.; Oken, Emily] Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Sagiv, Sharon K.] Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA. RP Fleisch, AF (reprint author), Maine Med Ctr Res Inst, Ctr Outcomes Res & Evaluat, Pediat Endocrinol & Diabet Maine Med Ctr, 509 Forest Ave, Portland, ME 04101 USA. EM afleisch@mmc.org FU National Institutes of Health [R01ES021447, R37HD034568,, K12DK094721, K23ES024803, K24HD069408, P30DK092924] FX The authors have received support from the National Institutes of Health (R01ES021447, R37HD034568, K12DK094721, K23ES024803, K24HD069408, and P30DK092924). NR 42 TC 0 Z9 0 U1 1 U2 1 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD MAR PY 2017 VL 125 IS 3 BP 481 EP 487 DI 10.1289/EHP303 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA EN0QL UT WOS:000395714400032 PM 27586368 ER PT J AU Vickerman, KA Schauer, GL Malarcher, AM Zhang, L Mowery, P Nash, CM AF Vickerman, K. A. Schauer, G. L. Malarcher, A. M. Zhang, L. Mowery, P. Nash, C. M. TI Reasons for Electronic Nicotine Delivery System use and smoking abstinence at 6 months: a descriptive study of callers to employer and health plan-sponsored quitlines SO TOBACCO CONTROL LA English DT Article ID E-CIGARETTES; COST-EFFECTIVENESS; ONLINE SURVEY; QUIT SMOKING; CESSATION; SMOKERS; POPULATION; REDUCTION; PRODUCTS AB Objective Describe cigarette smoking abstinence among employer and health plan-sponsored quitline registrants who were not using Electronic Nicotine Delivery Systems (ENDS), were using ENDS to quit smoking or were using ENDS for other reasons at the time of quitline registration. Methods We examined 6029 quitline callers aged >= 18 years who smoked cigarettes at registration, and completed >= 1 counselling calls, baseline ENDS use questions and a 6-month follow-up survey (response rate: 52.4%). 30-day point prevalence smoking quit rates (PPQRs) were assessed at 6-month follow-up (ENDS-only users were considered quit). Data were weighted for non-response bias. Logistic regression analyses controlled for participant characteristics and programme engagement. Results At registration, 13.8% of respondents used ENDS (7.9% to quit smoking, 5.9% for other reasons). 30-day PPQRs were: 55.1% for callers using ENDS to quit, 43.1% for callers using ENDS for other reasons, and 50.8% for callers not using ENDS at registration. Callers using ENDS for other reasons were less likely to quit than other groups (adjusted ORs=0.65-0.77); quit rates did not significantly differ between non-ENDS users and those using ENDS to quit. Among callers using ENDS to quit at baseline, 40% used ENDS regularly at follow-up. Conclusions ENDS users not using ENDS to quit smoking were less successful at quitting at 6-month follow-up compared with callers using ENDS to quit smoking and callers who did not use ENDS at programme registration. Incorporating reasons for ENDS use may be important for future studies examining the role of ENDS in tobacco cessation. C1 [Vickerman, K. A.; Nash, C. M.] Alere Wellbeing, Evaluat, Dept Res, Training, 999 Third Ave,Suite 2000, Seattle, WA 98104 USA. [Schauer, G. L.] Battelle Mem Inst, Battelle Publ Hlth Ctr Tobacco Res, Seattle, WA USA. [Schauer, G. L.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Malarcher, A. M.; Zhang, L.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Mowery, P.] Biostatistics Inc, Sarasota, FL USA. RP Vickerman, KA (reprint author), Alere Wellbeing, Evaluat, Dept Res, Training, 999 Third Ave,Suite 2000, Seattle, WA 98104 USA. EM Katrina.Vickerman@alere.com FU Centers for Disease Control and Prevention [200-2013-M-57025] FX This secondary data analysis was funded by the Centers for Disease Control and Prevention (contract #200-2013-M-57025). NR 58 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 EI 1468-3318 J9 TOB CONTROL JI Tob. Control PD MAR PY 2017 VL 26 IS 2 DI 10.1136/tobaccocontrol-2015-052734 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3QH UT WOS:000394533400009 PM 27071731 ER PT J AU Provini, LE Corwin, MJ Geller, NL Heeren, TC Moon, RY Rybin, DV Shapiro-Mendoza, CK Colson, ER AF Provini, Lauren E. Corwin, Michael J. Geller, Nicole L. Heeren, Timothy C. Moon, Rachel Y. Rybin, Denis V. Shapiro-Mendoza, Carrie K. Colson, Eve R. TI Differences in Infant Care Practices and Smoking among Hispanic Mothers Living in the United States SO JOURNAL OF PEDIATRICS LA English DT Article ID PREGNANCY RISK-ASSESSMENT; SLEEP-POSITION; MONITORING-SYSTEM; TRENDS; DEATHS AB Objective To assess the association between maternal birth country and adherence to the American Academy of Pediatrics safe sleep recommendations in a national sample of Hispanic mothers, given that data assessing the heterogeneity of infant care practices among Hispanics are lacking. Study design We used a stratified, 2-stage, clustered design to obtain a nationally representative sample of mothers from 32 US intrapartum hospitals. A total of 907 completed follow-up surveys (administered 2-6 months postpartum) were received from mothers who self-identified as Hispanic/Latina, forming our sample, which we divided into 4 subpopulations by birth country (US, Mexico, Central/South America, and Caribbean). Prevalence estimates and aORs were determined for infant sleep position, location, breastfeeding, and maternal smoking. Results When compared with US-born mothers, we found that mothers born in the Caribbean (aOR 4.56) and Central/South America (aOR 2.68) were significantly more likely to room share without bed sharing. Caribbean-born mothers were significantly less likely to place infants to sleep supine (aOR 0.41). Mothers born in Mexico (aOR 1.67) and Central/South America (aOR 2.57) were significantly more likely to exclusively breastfeed; Caribbean-born mothers (aOR 0.13) were significantly less likely to do so. Foreign-born mothers were significantly less likely to smoke before and during pregnancy. Conclusions Among US Hispanics, adherence to American Academy of Pediatrics safe sleep recommendations varies widely by maternal birth country. These data illustrate the importance of examining behavioral heterogeneity among ethnic groups and have potential relevance for developing targeted interventions for safe infant sleep. C1 [Provini, Lauren E.; Colson, Eve R.] Yale Univ, Sch Med, Dept Pediat, POB 208064, New Haven, CT 06520 USA. [Corwin, Michael J.; Geller, Nicole L.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Heeren, Timothy C.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Moon, Rachel Y.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA. [Rybin, Denis V.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA. [Shapiro-Mendoza, Carrie K.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Colson, ER (reprint author), Yale Univ, Sch Med, Dept Pediat, POB 208064, New Haven, CT 06520 USA. EM eve.colson@yale.edu FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [U10 HD059207] FX Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (U10 HD059207). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors declare no conflicts of interest. NR 14 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD MAR PY 2017 VL 182 BP 321 EP 326 DI 10.1016/j.jpeds.2016.11.053 PG 6 WC Pediatrics SC Pediatrics GA EN8LR UT WOS:000396252400051 PM 27979582 ER PT J AU Tuanyok, A Mayo, M Scholz, H Hall, CM Allender, CJ Kaestli, M Ginther, J Spring-Pearson, S Bollig, MC Stone, JK Settles, EW Busch, JD Sidak-Loftis, L Sahl, JW Thomas, A Kreutzer, L Georgi, E Gee, JE Bowen, RA Ladner, JT Lovett, S Koroleva, G Palacios, G Wagner, DM Currie, BJ Keim, P AF Tuanyok, Apichai Mayo, Mark Scholz, Holger Hall, Carina M. Allender, Christopher J. Kaestli, Mirjam Ginther, Jennifer Spring-Pearson, Senanu Bollig, Molly C. Stone, Joshua K. Settles, Erik W. Busch, Joseph D. Sidak-Loftis, Lindsay Sahl, Jason W. Thomas, Astrid Kreutzer, Lisa Georgi, Enrico Gee, Jay E. Bowen, Richard A. Ladner, Jason T. Lovett, Sean Koroleva, Galina Palacios, Gustavo Wagner, David M. Currie, Bart J. Keim, Paul TI Burkholderia humptydooensis sp nov., a New Species Related to Burkholderia thailandensis and the Fifth Member of the Burkholderia pseudomallei Complex SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article DE Burkholderia humptydooensis sp nov.; Burkholderia pseudomallei complex; MSMB43(T) ID MELIOIDOSIS; SUSCEPTIBILITY; AGENTS; EPIDEMIOLOGY; PATHOGENESIS; PROKARYOTES; DEFINITION; MALLEI AB During routine screening for Burkholderia pseudomallei from water wells in northern Australia in areas where it is endemic, Gram-negative bacteria (strains MSMB43(T), MSMB121, and MSMB122) with a similar morphology and biochemical pattern to B. pseudomallei and B. thailandensis were coisolated with B. pseudomallei on Ashdown's selective agar. To determine the exact taxonomic position of these strains and to distinguish them from B. pseudomallei and B. thailandensis, they were subjected to a series of phenotypic and molecular analyses. Biochemical and fatty acid methyl ester analysis was unable to distinguish B. humptydooensis sp. nov. from closely related species. With matrix-assisted laser desorption ionization-time of flight analysis, all isolates grouped together in a cluster separate from other Burkholderia spp. 16S rRNA and recA sequence analyses demonstrated phylogenetic placement for B. humptydooensis sp. nov. in a novel clade within the B. pseudomallei group. Multilocus sequence typing (MLST) analysis of the three isolates in comparison with MLST data from 3,340 B. pseudomallei strains and related taxa revealed a new sequence type (ST318). Genome-to-genome distance calculations and the average nucleotide identity of all isolates to both B. thailandensis and B. pseudomallei, based on whole-genome sequences, also confirmed B. humptydooensis sp. nov. as a novel Burkholderia species within the B. pseudomallei complex. Molecular analyses clearly demonstrated that strains MSMB43(T), MSMB121, and MSMB122 belong to a novel Burkholderia species for which the name Burkholderia humptydooensis sp. nov. is proposed, with the type strain MSMB43(T) (American Type Culture Collection BAA-2767; Belgian Co-ordinated Collections of Microorganisms LMG 29471; DDBJ accession numbers CP013380 to CP013382). IMPORTANCE Burkholderia pseudomallei is a soil-dwelling bacterium and the causative agent of melioidosis. The genus Burkholderia consists of a diverse group of species, with the closest relatives of B. pseudomallei referred to as the B. pseudomallei complex. A proposed novel species, B. humptydooensis sp. nov., was isolated from a bore water sample from the Northern Territory in Australia. B. humptydooensis sp. nov. is phylogenetically distinct from B. pseudomallei and other members of the B. pseudomallei complex, making it the fifth member of this important group of bacteria. C1 [Tuanyok, Apichai; Hall, Carina M.; Allender, Christopher J.; Ginther, Jennifer; Spring-Pearson, Senanu; Bollig, Molly C.; Stone, Joshua K.; Settles, Erik W.; Busch, Joseph D.; Sidak-Loftis, Lindsay; Sahl, Jason W.; Wagner, David M.; Keim, Paul] No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA. [Tuanyok, Apichai; Hall, Carina M.; Allender, Christopher J.; Ginther, Jennifer; Spring-Pearson, Senanu; Bollig, Molly C.; Stone, Joshua K.; Settles, Erik W.; Busch, Joseph D.; Sidak-Loftis, Lindsay; Sahl, Jason W.; Wagner, David M.; Keim, Paul] No Arizona Univ, Pathogen & Microbiome Inst, Flagstaff, AZ 86011 USA. [Mayo, Mark; Currie, Bart J.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia. [Mayo, Mark; Currie, Bart J.] Royal Darwin Hosp, Northern Terr Med Program, Darwin, NT, Australia. [Scholz, Holger; Thomas, Astrid; Kreutzer, Lisa; Georgi, Enrico] Bundeswehr Inst Microbiol, Munich, Germany. [Gee, Jay E.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. [Ladner, Jason T.; Lovett, Sean; Koroleva, Galina; Palacios, Gustavo] USAMRIID, Ctr Genome Sci, Ft Detrick, MD USA. RP Keim, P (reprint author), No Arizona Univ, Dept Biol Sci, Flagstaff, AZ 86011 USA.; Keim, P (reprint author), No Arizona Univ, Pathogen & Microbiome Inst, Flagstaff, AZ 86011 USA. EM Paul.Keim@nau.edu FU U.S. Department of Homeland Security [HSHQDC-10-C-00135, HSHQDC-10-C-00149]; Defense Threat Reduction Agency [HSHQDC-10-C-00149, HDTRA1-12-C-0066]; Australian National Health and Medical Research Council; Australian Research Council FX This work was funded by the U.S. Department of Homeland Security (HSHQDC-10-C-00135 and HSHQDC-10-C-00149), the Defense Threat Reduction Agency (HDTRA1-12-C-0066 and HSHQDC-10-C-00149), the Australian National Health and Medical Research Council, and the Australian Research Council. NR 41 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD MAR PY 2017 VL 85 IS 4 AR UNSP e02802 DI 10.1128/AEM.02802-16 PG 10 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA EK5JK UT WOS:000393962500017 ER PT J AU Menas, AL Yanamala, N Farcas, MT Russo, M Friend, S Fournier, PM Star, A Iavicoli, I Shurin, GV Vogel, UB Fadeel, B Beezhold, D Kisin, ER Shvedova, AA AF Menas, Autumn L. Yanamala, Naveena Farcas, Mariana T. Russo, Maria Friend, Sherri Fournier, Philip M. Star, Alexander Iavicoli, Ivo Shurin, Galina V. Vogel, Ulla B. Fadeel, Bengt Beezhold, Donald Kisin, Elena R. Shvedova, Anna A. TI Fibrillar vs crystalline nanocellulose pulmonary epithelial cell responses: Cytotoxicity or inflammation? SO CHEMOSPHERE LA English DT Article DE Nanocellulose; Oxidative stress; Cytoxicity; Cytokine production; Lung epithelial cells ID IN-VITRO; CELLULOSE NANOCRYSTALS; LUNG; CHITIN; NANOPARTICLES; TOXICITY; NANOMATERIALS; NANOFIBERS; TOXICOLOGY; INDUCE AB Nanocellulose (NC) is emerging as a highly promising nanomaterial for a wide range of applications. Moreover, many types of NC are produced, each exhibiting a slightly different shape, size, and chemistry. The main objective of this study was to compare cytotoxic effects of cellulose nanocrystals (CNC) and nanofibrillated cellulose (NCF). The human lung epithelial cells (A549) were exposed for 24 h and 72 h to five different NC particles to determine how variations in properties contribute to cellular outcomes, including cytotoxicity, oxidative stress, and cytokine secretion. Our results showed that NCF were more toxic compared to CNC particles with respect to cytotoxicity and oxidative stress responses. However, exposure to CNC caused an inflammatory response with significantly elevated inflammatory cytokines/ chemokines compared to NCF. Interestingly, cellulose staining indicated that CNC particles, but not NCF, were taken up by the cells. Furthermore, clustering analysis of the inflammatory cytokines revealed a similarity of NCF to the carbon nanofibers response and CNC to the chitin, a known immune modulator and innate cell activator. Taken together, the present study has revealed distinct differences between fibrillar and crystalline nanocellulose and demonstrated that physicochemical properties of NC are critical in determining their toxicity. Published by Elsevier Ltd. C1 [Menas, Autumn L.; Yanamala, Naveena; Farcas, Mariana T.; Kisin, Elena R.; Shvedova, Anna A.] NIOSH, Exposure Assessment Branch, CDC, Morgantown, WV USA. [Friend, Sherri] NIOSH, Pathol & Physiol Res Branch, CDC, Morgantown, WV USA. [Russo, Maria] Univ Cattolica Sacro Cuore, Inst Publ Hlth, Sect Occupat Med, Rome, Italy. [Fournier, Philip M.; Star, Alexander] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA. [Iavicoli, Ivo] Univ Naples Federico II, Div Occupat Med, Dept Publ Hlth, Naples, Italy. [Shurin, Galina V.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. [Vogel, Ulla B.] Natl Res Ctr Working Environm, Copenhagen, Denmark. [Fadeel, Bengt] Karolinska Inst, Div Mol Toxicol, Inst Environm Med, Stockholm, Sweden. [Beezhold, Donald] NIOSH, Hlth Effects Lab Div, CDC, Morgantown, WV USA. [Shvedova, Anna A.] West Virginia Univ, Dept Physiol & Pharmacol, Morgantown, WV USA. RP Shvedova, AA (reprint author), Exposure Assessment Branch MS 2015, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ats1@cdc.gov FU NTRC [939011K]; NIH [R01ES019304]; NIOSH [OH008282]; European Commission [309329] FX This work was supported by NTRC 939011K, NIH R01ES019304, NIOSH OH008282, and the European Commission (FP7-NANOSOLUTIONS, grant agreement no. 309329). The authors also want to thank Diane Schwegler-Berry for TEMs preparation, C. Hojgaard, J.R. Winther, and M. Willemoes for providing the Biotinylated Carbohydrate Binding Module of beta-1,4-Glycanase for visualization of nanocellulose. NR 40 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 EI 1879-1298 J9 CHEMOSPHERE JI Chemosphere PD MAR PY 2017 VL 171 BP 671 EP 680 DI 10.1016/j.chemosphere.2016.12.105 PG 10 WC Environmental Sciences SC Environmental Sciences & Ecology GA EK4XL UT WOS:000393931100078 PM 28061425 ER PT J AU Luderer, U Christensen, F Johnson, WO She, JW Ip, HSS Zhou, JQ Alvaran, J Krieg, EF Kesner, JS AF Luderer, Ulrike Christensen, Fletcher Johnson, Wesley O. She, Jianwen Ip, Ho Sai Simon Zhou, Junqiang Alvaran, Josephine Krieg, Edward F., Jr. Kesner, James S. TI Associations between urinary biomarkers of polycydic aromatic hydrocarbon exposure and reproductive function during menstrual cycles in women SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Polycyclic aromatic hydrocarbon; Ovarian function; Reproduction; Luteinizing hormone; Estradiol; Menstrual cycle ID FLOUNDER PLATICHTHYS-FLESUS; CIGARETTE-SMOKING; TOBACCO-SMOKE; PROGESTERONE METABOLITES; HYDROXYLASE-ACTIVITY; NATIONAL CHILDRENS; DIETARY EXPOSURE; UNITED-STATES; LIFE-STYLE; FERTILITY AB Essentially all women are exposed to polycyclic aromatic hydrocarbons (PAHs), formed during incomplete combustion of organic materials, including fossil fuels, wood, foods, and tobacco. PAHs are ovarian toxicants in rodents, and cigarette smoking is associated with reproductive abnormalities in women. Biomonitoring of hydroxylated PAH (OH-PAH) metabolites in urine provides an integrated measure of exposure to PAHs via multiple routes and has been used to characterize exposure to PAHs in humans. We hypothesized that concentrations of OH-PAHs in urine are associated with reproductive function in women. We recruited women 18-44 years old, living in Orange County, California to conduct daily measurement of urinary luteinizing hormone (LH) and estrone 3-glucuronide (E13G) using a microelectronic fertility monitor for multiple menstrual cycles; these data were used to calculate endocrine endpoints. Participants also collected urine samples on cycle day 10 for measurement of nine OH-PAHs. Models were constructed for eight endpoints using a Bayesian mixed modeling approach with subject-specific random effects allowing each participant to act as a baseline for her set of measurements. We observed associations between individual OH-PAH concentrations and follicular phase length, follicular phase LH and E13G concentrations, preovulatory LH surge concentrations, and periovulatory 813G slope and concentration. We have demonstrated the feasibility of using urinary reproductive hormone data obtained via fertility monitors to calculate endocrine endpoints for epidemiological studies of ovarian function during multiple menstrual cycles. The results show that environmental exposure to PAHs is associated with changes in endocrine markers of ovarian function in women in a PAH-specific manner. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Luderer, Ulrike] Univ Calif Irvine, Ctr Occupat & Environm Hlth, 100 Theory,Suite 100, Irvine, CA 92617 USA. [Luderer, Ulrike] Univ Calif Irvine, Div Occupat & Environm Med, Dept Med, 100 Theory,Suite 100, Irvine, CA 92617 USA. [Christensen, Fletcher; Johnson, Wesley O.] Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA. [She, Jianwen; Ip, Ho Sai Simon; Zhou, Junqiang; Alvaran, Josephine] Calif Dept Publ Hlth, Environm Hlth Lab Branch, Richmond, CA USA. [Krieg, Edward F., Jr.; Kesner, James S.] US Dept Hlth & Human Serv, Div Appl Res & Technol, Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent,Publ Hlth Serv, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. [Luderer, Ulrike] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA. [Luderer, Ulrike] Univ Calif Irvine, Program Publ Hlth, Irvine, CA 92697 USA. RP Luderer, U (reprint author), COEH, 100 Theory Dr,Suite 100, Irvine, CA 92617 USA. EM uluderer@uci.edu; fchriste@uci.edu; wjohnson@ics.uci.edu; Jianwen.She@cdph.ca.gov; erk3@cdc.gov; jsk4@cdc.gov FU National Institutes of Health (NIH), National Institute of Environmental Health Sciences [ES016846, ES020454]; National Center for Research Resources (NCRR), a component of the NIH [UL1 RR031985]; National Center for Research Resources (NCRR), NIH Roadmap for Medical Research; California Environmental Contaminant Biomonitoring Program RFI Laboratory Pilot Study; UC Irvine Center for Occupational and Environmental Health FX The authors thank the WHE study participants and the dedicated WHE staff, Claudia Shambaugh, Opalina Valencia, and Stacey Kojaku. The authors also thank the staff of the UC Irvine Institute for Clinical and Translational Science for assistance with data and specimen collection; Scott Littlejohn of Alere, Inc., Waltham, MA and Sarah Weddell of Swiss Precision Diagnostics Spark, Bedford, UK for converting fertility monitor data and assistance with interpretation of monitor data; and Dr. Lynn Flowers for exploratory analyses performed as part of her MS thesis in Environmental Health Sciences. The study was funded by the National Institutes of Health (NIH), National Institute of Environmental Health Sciences grant numbers ES016846 and ES020454 (to UL); grant number UL1 RR031985 from the National Center for Research Resources (NCRR), a component of the NIH and the NIH Roadmap for Medical Research; a California Environmental Contaminant Biomonitoring Program RFI Laboratory Pilot Study; the UC Irvine Center for Occupational and Environmental Health. NR 69 TC 0 Z9 0 U1 6 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD MAR PY 2017 VL 100 BP 110 EP 120 DI 10.1016/j.envint.2016.12.021 PG 11 WC Environmental Sciences SC Environmental Sciences & Ecology GA EK7AE UT WOS:000394076900006 PM 28065424 ER PT J AU Harley, KG Rauch, SA Chevrier, J Kogut, K Parra, KL Trujillo, C Lustig, RH Greenspan, LC Sjodin, A Bradman, A Eskenazi, B AF Harley, Kim G. Rauch, Stephen A. Chevrier, Jonathan Kogut, Katherine Parra, Kimberly L. Trujillo, Celina Lustig, Robert H. Greenspan, Louise C. Sjodin, Andreas Bradman, Asa Eskenazi, Brenda TI Association of prenatal and childhood PBDE exposure with timing of puberty in boys and girls SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Puberty; PBDEs; Flame retardants; Endocrine disruption ID BROMINATED FLAME RETARDANTS; DIPHENYL ETHER PBDE; SECONDARY SEXUAL CHARACTERISTICS; OFFICE SETTINGS NETWORK; IN-VITRO; DEVELOPMENTAL EXPOSURE; PEDIATRIC RESEARCH; ADOLESCENT GIRLS; HORMONE-LEVELS; HUMAN-SERUM AB Background: Polybrominated diphenyl ether (PBDE) flame retardants are endocrine-disrupting chemicals that exhibit estrogenic and androgenic properties and may affect pubertal timing. Methods: Study subjects were participants between 1999 and 2013 in the Center for the Health Assessment of Mothers and Children of Salinas (CHANIACOS), a longitudinal cohort study of predominantly Mexican origin families in Northern California. We measured serum concentrations of four PBDEs (BDE-47,-99,-100,-153) in blood collected from mothers during pregnancy (N = 263) and their children at age 9 years (N = 522). We determined timing of pubertal onset in 309 boys and 314 girls using clinical Tanner staging every 9 months between 9 and 13 years of age, and timing of menarche by self-report. We used Poisson regression for relative risk (RR) of earlier puberty and parametric survival analysis for time ratios (TR) of pubertal milestones. Results: Prenatal concentrations of all 4 congeners and Sigma PBDEs were associated with later menarche in girls (RRearlier menarche = 0.5, 95% confidence interval (CI): 03, 0.9 for Sigma PBDEs) but earlier pubic hair development in boys (RRearlier pubarche = 2.0, 95% Cl: 13, 33 for Sigma PBDEs). No associations were seen between prenatal exposure and girls' breast or pubic hair development or boys' genital development. Childhood PBDE exposure was not associated with any measure of pubertal timing, except for an association of BDE-153 with later menarche. Conclusions: We found that prenatal PBDE exposure was associated with later menarche in girls but earlier pubarche in boys, suggesting opposite pubertal effects in girls and boys. (C) 2017 Elsevier Ltd. All rights reserved. C1 [Harley, Kim G.; Rauch, Stephen A.; Kogut, Katherine; Parra, Kimberly L.; Trujillo, Celina; Bradman, Asa; Eskenazi, Brenda] Univ Calif Berkeley, Sch Publ Hlth, CERCH, 1995 Univ Ave Suite 265, Berkeley, CA 94720 USA. [Chevrier, Jonathan] McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada. [Lustig, Robert H.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Greenspan, Louise C.] Kaiser Permanente, Div Res, Oakland, CA USA. [Sjodin, Andreas] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Harley, KG (reprint author), Univ Calif Berkeley, Sch Publ Hlth, CERCH, 1995 Univ Ave Suite 265, Berkeley, CA 94720 USA. EM kharley@berkeley.edu FU U.S. Environthental Protection Agency (US EPA) [RD 83171001, RD 826709]; NIEHS [P01 ES009605, R01 ES015572] FX This research was supported by the following grants: RD 83171001 and RD 826709 from the U.S. Environthental Protection Agency (US EPA) and P01 ES009605 and R01 ES015572 from NIEHS. The contents of this publication are solely the authors' responsibility and do not necessarily represent the official views of the NIEHS, NIH, EPA or the Centers for Disease Control and Prevention. NR 56 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD MAR PY 2017 VL 100 BP 132 EP 138 DI 10.1016/j.envint.2017.01.003 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA EK7AE UT WOS:000394076900008 PM 28089583 ER PT J AU Zhao, D Lam, H Peng, H Bao, S LeBlanc, DJ Nobukawa, K Pan, CS AF Zhao, Ding Lam, Henry Peng, Huei Bao, Shan LeBlanc, David J. Nobukawa, Kazutoshi Pan, Christopher S. TI Accelerated Evaluation of Automated Vehicles Safety in Lane-Change Scenarios Based on Importance Sampling Techniques SO IEEE TRANSACTIONS ON INTELLIGENT TRANSPORTATION SYSTEMS LA English DT Article DE Active safety systems; automated vehicles (AVs); autonomous emergency braking (AEB); crash avoidance; importance sampling (IS); lane change ID DRIVER MODEL; SIMULATION AB Automated vehicles (AVs) must be thoroughly evaluated before their release and deployment. A widely used evaluation approach is the Naturalistic-Field Operational Test (N-FOT), which tests prototype vehicles directly on the public roads. Due to the low exposure to safety-critical scenarios, N-FOTs are time consuming and expensive to conduct. In this paper, we propose an accelerated evaluation approach for AVs. The results can be used to generate motions of the other primary vehicles to accelerate the verification of AVs in simulations and controlled experiments. Frontal collision due to unsafe cut-ins is the target crash type of this paper. Human-controlled vehicles making unsafe lane changes are modeled as the primary disturbance to AVs based on data collected by the University of Michigan Safety Pilot Model Deployment Program. The cut-in scenarios are generated based on skewed statistics of collected human driver behaviors, which generate risky testing scenarios while preserving the statistical information so that the safety benefits of AVs in nonaccelerated cases can be accurately estimated. The cross-entropy method is used to recursively search for the optimal skewing parameters. The frequencies of the occurrences of conflicts, crashes, and injuries are estimated for a modeled AV, and the achieved accelerated rate is around 2000 to 20 000. In other words, in the accelerated simulations, driving for 1000 miles will expose the AV with challenging scenarios that will take about 2 to 20 million miles of real-world driving to encounter. This technique thus has the potential to greatly reduce the development and validation time for AVs. C1 [Zhao, Ding; Bao, Shan; LeBlanc, David J.; Nobukawa, Kazutoshi] Univ Michigan, Transportat Res Inst, Ann Arbor, MI 48109 USA. [Lam, Henry] Univ Michigan, Dept Ind & Operat Engn, Ann Arbor, MI 48109 USA. [Peng, Huei] Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA. [Pan, Christopher S.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Zhao, D (reprint author), Univ Michigan, Transportat Res Inst, Ann Arbor, MI 48109 USA. EM zhaoding@umich.edu; khlam@umich.edu; hpeng@umich.edu; shanbao@umich.edu; leblanc@umich.edu; knobukaw@umich.edu; syp4@cdc.gov FU U.S. National Institute for Occupational Safety Health [F031433] FX This work was supported by the U.S. National Institute for Occupational Safety Health under Grant F031433. The Associate Editor for this paper was L. Li. NR 58 TC 0 Z9 0 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1524-9050 EI 1558-0016 J9 IEEE T INTELL TRANSP JI IEEE Trans. Intell. Transp. Syst. PD MAR PY 2017 VL 18 IS 3 BP 595 EP 607 DI 10.1109/TITS.2016.2582208 PG 13 WC Engineering, Civil; Engineering, Electrical & Electronic; Transportation Science & Technology SC Engineering; Transportation GA EN6WD UT WOS:000396143200012 ER PT J AU Kornilova, MS Batluk, JV Yorick, RV Baughman, AL Hillis, SD Vitek, CR AF Kornilova, Marina S. Batluk, Julia V. Yorick, Roman V. Baughman, Andrew L. Hillis, Susan D. Vitek, Charles R. TI Decline in HIV seroprevalence in street youth 2006-2012, St. Petersburg, Russia: moving toward an AIDS-free generation SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Street youth; HIV; seroprevalence; drug users; Russia ID RISK; MODEL AB A 2006 survey of street youth at pre-mapped street youth locations in St. Petersburg, Russia, found extremely high HIV seroprevalence (37.4%) among 313 street youth aged 15-19 years of age, strongly associated with injection drug use, which was reported by 50.6% of participants. In response, multi-sectoral social support and prevention measures were instituted. In 2012, we conducted a follow-up survey of 15-to 19-year-old street youth using the same study procedures as in 2006. Of 311 participants, 45 (14.5%) reported injection drug use; 31 participants (10.0%, 95% confidence interval, 6.0%-16.2%) were HIV-seropositive. Predictors independently associated with HIV seropositivity included injection drug use (adjusted prevalence ratio 53.1) and transactional sex (adjusted prevalence ratio 1.3). None of the 178 participants aged 15-17 years were HIV-positive. Thirty of 31 (96.8%) HIV-seropositive individuals reported injection drug use. Street youth in St Petersburg had a 73% decrease in HIV seroprevalence from 2006 to 2012, primarily due to decreased initiation of injection drug use. This marked reduction in the HIV epidemic among street youth occurred after implementation of extensive support programs and socio-economic improvements. C1 [Kornilova, Marina S.; Vitek, Charles R.] US Ctr Dis Control & Prevent, Moscow, Russia. [Batluk, Julia V.; Yorick, Roman V.] Doctors Children, St Petersburg, Russia. [Batluk, Julia V.] St Petersburg State Univ, St Petersburg, Russia. [Baughman, Andrew L.; Hillis, Susan D.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Baughman, AL (reprint author), US Ctr Dis Control & Prevent, Private Bag 12029,Ausspannpl, Windhoek, Namibia. EM alb1@cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention [PS001426] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention under the terms of grant PS001426. NR 28 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD MAR PY 2017 VL 28 IS 4 BP 345 EP 356 DI 10.1177/0956462416649275 PG 12 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EK9PT UT WOS:000394257100003 PM 27147268 ER PT J AU McNicholl, JM Leelawiwat, W Whitehead, S Hanson, DL Evans-Strickfaden, T Cheng, CY Chonwattana, W Mueanpai, F Kittinunvorakoon, C Markowitz, L Dunne, EF AF McNicholl, Janet M. Leelawiwat, Wanna Whitehead, Sara Hanson, Debra L. Evans-Strickfaden, Tammy Cheng, Chen Y. Chonwattana, Wannee Mueanpai, Famui Kittinunvorakoon, Chonticha Markowitz, Lauri Dunne, Eileen F. TI Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE Virus; polymerase chain reaction; sampling; sexually transmitted infection; ano-genital; transmission; self-collection ID HERPES-SIMPLEX-VIRUS; RANDOMIZED CONTROLLED-TRIAL; ANTIRETROVIRAL THERAPY; MENSTRUAL-CYCLE; CHIANG-RAI; WOMEN; RNA; TYPE-2; TRANSMISSION; SECRETIONS AB HIV-1 and HSV-2 are frequent genital co-infections in women. To determine how self-collected genital swabs compare to provider-collected cervicovaginal lavage, paired self-collected genital swabs and cervicovaginal lavage from women co-infected with HIV-1 and HSV-2 were evaluated. Women were in an acyclovir clinical trial and their samples were tested for HIV-1 RNA (361 samples) and HSV-2 DNA (378 samples). Virus shedding, quantity and acyclovir effect were compared. HIV-1 and HSV-2 were more frequently detected in self-collected genital swabs: 74.5% of self-collected genital swabs and 63.6% of cervicovaginal lavage had detectable HIV-1 (p <= 0.001, Fisher's exact test) and 29.7% of self-collected genital swabs and 19.3% of cervicovaginal lavage had detectable HSV-2 (p <= 0.001) in the placebo month. Cervicovaginal lavage and self-collected genital swabs virus levels were correlated (Spearman's rho, 0.68 for HIV; 0.61 for HSV-2) and self-collected genital swabs levels were generally higher. In multivariate modeling, self-collected genital swabs and cervicovaginal lavage could equally detect the virus-suppressive effect of acyclovir: for HIV-1, proportional odds ratios were 0.42 and 0.47 and for HSV-2, they were 0.10 and 0.03 for self-collected genital swabs and cervicovaginal lavage, respectively. Self-collected genital swabs should be considered for detection and measurement of HIV-1 and HSV-2 in clinical trials and other studies as they are a sensitive method to detect virus and can be collected in the home with frequent sampling. C1 [McNicholl, Janet M.; Whitehead, Sara; Hanson, Debra L.; Evans-Strickfaden, Tammy] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [McNicholl, Janet M.; Leelawiwat, Wanna; Whitehead, Sara; Chonwattana, Wannee; Mueanpai, Famui; Kittinunvorakoon, Chonticha] US Ctr Dis Control & Prevent Collaborat, Thai Minist Publ Hlth, Nonthaburi, Thailand. [Cheng, Chen Y.; Markowitz, Lauri; Dunne, Eileen F.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP McNicholl, JM (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, MS A25, Atlanta, GA 30333 USA. EM jkm7@cdc.gov FU Centers for Disease Control and Prevention FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Centers for Disease Control and Prevention. NR 24 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0956-4624 EI 1758-1052 J9 INT J STD AIDS JI Int. J. STD AIDS PD MAR PY 2017 VL 28 IS 4 BP 372 EP 379 DI 10.1177/0956462416650123 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EK9PT UT WOS:000394257100007 PM 27179350 ER PT J AU Tejada-Strop, A Costafreda, MI Dimitrova, Z Kaplan, GG Teo, CG AF Tejada-Strop, Alexandra Costafreda, Maria Isabel Dimitrova, Zoya Kaplan, Gerardo G. Teo, Chong-Gee TI Evaluation of Potencies of Immune Globulin Products Against Hepatitis A SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Tejada-Strop, Alexandra; Dimitrova, Zoya; Teo, Chong-Gee] Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,Mailstop A33, Atlanta, GA 30329 USA. [Costafreda, Maria Isabel; Kaplan, Gerardo G.] US FDA, Off Blood Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD USA. RP Tejada-Strop, A (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd NE,Mailstop A33, Atlanta, GA 30329 USA. EM atejadastrop@cdc.gov FU US Food and Drug Administration (FDA) FX This study was supported by US Food and Drug Administration (FDA) intramural funds to Dr Kaplan; also, the appointment to the Research Participation Program at the Center for Biologics Evaluation and Research (CBER) administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy with the Centers for Disease Control and Prevention (Ms Tejada-Strop) and the FDA (Dr Costafreda). NR 6 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAR 1 PY 2017 VL 177 IS 3 BP 430 EP 432 DI 10.1001/jamainternmed.2016.9057 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA EN7RX UT WOS:000396201000032 PM 28097299 ER PT J AU Lu, XY Rowe, LA Frace, M Stevens, J Abedi, GR Elnile, O Banassir, T Al-Masri, M Watson, JT Assiri, A Erdman, DD AF Lu, Xiaoyan Rowe, Lori A. Frace, Michael Stevens, James Abedi, Glen R. Elnile, Osman Banassir, Taleb Al-Masri, Malak Watson, John T. Assiri, Abdullah Erdman, Dean D. TI Spike Gene Deletion Quasispecies in Serum of Patient With Acute MERS-CoV Infection SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE coronavirus; MERS-CoV; spike gene; genome ID EAST RESPIRATORY SYNDROME; TRANSMISSIBLE GASTROENTERITIS VIRUS; SYNDROME CORONAVIRUS; SAUDI-ARABIA; PROTEIN; REGION; EPIDEMIOLOGY; PERITONITIS; RECEPTOR; VARIANT AB The spike glycoprotein of the Middle East respiratory coronavirus (MERS-CoV) facilitates receptor binding and cell entry. During investigation of a multi-facility outbreak of MERS-CoV in Taif, Saudi Arabia, we identified a mixed population of wild-type and variant sequences with a large 530 nucleotide deletion in the spike gene from the serum of one patient. The out of frame deletion predicted loss of most of the S2 subunit of the spike protein leaving the S1 subunit with an intact receptor binding domain. This finding documents human infection with a novel genetic variant of MERS-CoV present as a quasispecies. (C) 2016 Wiley Periodicals, Inc. C1 [Lu, Xiaoyan; Rowe, Lori A.; Frace, Michael; Stevens, James; Abedi, Glen R.; Watson, John T.; Erdman, Dean D.] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G-04, Atlanta, GA 30333 USA. [Elnile, Osman; Banassir, Taleb; Al-Masri, Malak; Assiri, Abdullah] Minist Hlth, Riyadh, Saudi Arabia. RP Erdman, DD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G-04, Atlanta, GA 30333 USA. EM dde1@cdc.gov NR 21 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD MAR PY 2017 VL 89 IS 3 BP 542 EP 545 DI 10.1002/jmv.24652 PG 4 WC Virology SC Virology GA EK4JM UT WOS:000393892900024 PM 27486688 ER PT J AU Kahin, SA Wright, DS Pejavara, A Kim, SA AF Kahin, Sahra A. Wright, Demia S. Pejavara, Anu Kim, Sonia A. TI State-Level Farmers Market Activities: A Review of CDC-Funded State Public Health Actions That Support Farmers Markets SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Review DE Centers for Disease Control and Prevention; farmers markets; fruits and vegetables; state health departments; state-level ID FOOD DESERTS; FRUIT; COMMUNITIES; PROGRAM AB Context: Introducing farmers markets to underserved areas, or supporting existing farmers markets, can increase access and availability of fruits and vegetables and encourage healthy eating. Since 2003, the Centers for Disease Control and Prevention (CDC)'s Division of Nutrition, Physical Activity, and Obesity (DNPAO) has provided guidance and funding to state health departments (SHDs) to support the implementation of interventions, including activities around farmers markets, to address healthy eating, and improve the access to and availability of fruits and vegetables at state and community levels. Objective: For this project, we identified state-level farmers market activities completed with CDC's DNPAO funding from 2003 to 2013. State-level was defined as actions taken by the state health department that influence or support farmers market work across the state. Design and Participants: We completed an analysis of SHD farmers market activities of 3 DNPAO cooperative agreements from 2003 to 2013: State Nutrition and Physical Activity Programs to Prevent Obesity and Other Chronic Diseases; Nutrition, Physical Activity and Obesity Program; and Communities Putting Prevention to Work. To identify state farmers market activities, data sources for each cooperative agreement were searched using the key words "farm," "market," " produce market," and "produce stand." State data with at least one state-level farmers market action present were then coded for the presence of itemized activities. Results: Across all cooperative agreements, the most common activities identified through analysis included the following: working on existing markets and nutrition assistance benefit programs, supporting community action, and providing training and technical assistance. Common partners were nutrition assistance benefit program offices and state or regional Department of Agriculture or agricultural extension offices. Implications for Policy & Practice: Common farmers market practices and evidence-based activities, such as nutrition assistance benefits programs and land-use policies, can be adopted as methods for farmers market policy and practice work. Conclusion: The activities identified in this study can inform future planning at the state and federal levels on environment, policy, and systems approaches that improve the food environment through farmers markets. C1 [Kahin, Sahra A.; Pejavara, Anu; Kim, Sonia A.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy,NE,MS F-77, Atlanta, GA 30341 USA. [Wright, Demia S.] NIEHS, Worker Training Program, NIH, POB 12233, Res Triangle Pk, NC 27709 USA. RP Kahin, SA (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy,NE,MS F-77, Atlanta, GA 30341 USA. EM xfz9@cdc.gov FU CDC FX All authors were full-time CDC staff during the writing of this article. The CDC funds authors' salaries to do this work. NR 22 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2017 VL 23 IS 2 BP 96 EP 103 DI 10.1097/PHH.0000000000000412 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK1WM UT WOS:000393716500007 PM 27798521 ER PT J AU Kane, H Hinnant, L Day, K Council, M Tzeng, J Soler, R Chambard, M Roussel, A Heirendt, W AF Kane, Heather Hinnant, Laurie Day, Kristine Council, Mary Tzeng, Janice Soler, Robin Chambard, Megan Roussel, Amy Heirendt, Wendy TI Pathways to Program Success: A Qualitative Comparative Analysis (QCA) of Communities Putting Prevention to Work Case Study Programs SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE capacity; case study; public health; QCA ID HEALTH PROMOTION; CAPACITY; COALITIONS AB Objective: To examine the elements of capacity, a measure of organizational resources supporting program implementation that result in successful completion of public health program objectives in a public health initiative serving 50 communities. Design: We used crisp set Qualitative Comparative Analysis (QCA) to analyze case study and quantitative data collected during the evaluation of the Communities Putting Prevention to Work (CPPW) program. Setting: CPPW awardee program staff and partners implemented evidence-based public health improvements in counties, cities, and organizations (eg, worksites, schools). Participants: Data came from case studies of 22 CPPW awardee programs that implemented evidence-based, community- and organizational-level public health improvements. Intervention: Program staff implemented a range of evidence-based public health improvements related to tobacco control and obesity prevention. Main Outcome Measure: The outcome measure was completion of approximately 60% of work plan objectives. Results: Analysis of the capacity conditions revealed 2 combinations for completing most work plan objectives: (1) having experience implementing public health improvements in combination with having a history of collaboration with partners; and (2) not having experience implementing public health improvements in combination with having leadership support. Conclusion: Awardees have varying levels of capacity. The combinations identified in this analysis provide important insights into how awardees with different combinations of elements of capacity achieved most of their work plan objectives. Even when awardees lack some elements of capacity, they can build it through strategies such as hiring staff and engaging new partners with expertise. In some instances, lacking 1 or more elements of capacity did not prevent an awardee from successfully completing objectives. These findings can help funders and practitioners recognize and assemble different aspects of capacity to achieve more successful programs; awardees can draw on extant organizational strengths to compensate when other aspects of capacity are absent. C1 [Kane, Heather; Hinnant, Laurie; Council, Mary; Tzeng, Janice; Chambard, Megan; Roussel, Amy] RTI Int, Publ Hlth Res Div, Res Triangle Pk, NC USA. [Day, Kristine; Soler, Robin; Heirendt, Wendy] Ctr Dis Control & Prevent, 4770 Buford Hwy,NE,Mailstop K-45, Atlanta, GA 30333 USA. RP Day, K (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,NE,Mailstop K-45, Atlanta, GA 30333 USA. EM knd8@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The Centers for Disease Control and Prevention (CDC) provided funding for this project. The authors gratefully acknowledge all of the Communities Putting Prevention to Work awardees who participated in this evaluation. They also thank Devon McGowan and Karen Strazza, for assistance with NVivo coding, and Kyle Longest, for consultation on the Qualitative Comparative Analysis. NR 22 TC 0 Z9 0 U1 4 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2017 VL 23 IS 2 BP 104 EP 111 DI 10.1097/PHH.0000000000000449 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK1WM UT WOS:000393716500008 PM 27598714 ER PT J AU Kristoff, I Cramer, R Leichliter, JS AF Kristoff, Iris Cramer, Ryan Leichliter, Jami S. TI Health Care Communication Laws in the United States, 2013: Implications for Access to Sensitive Services for Insured Dependents SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE adolescent; confidentiality; law; policy ID ADOLESCENTS AB Young adults may not seek sensitive health services when confidentiality cannot be ensured. To better understand the policy environment for insured dependent confidentiality, we systematically assessed legal requirements for health insurance plan communications using WestlawNext to create a jurisdiction-level data set of health insurance plan communication regulations as of March 2013. Two jurisdictions require plan communications be sent to a policyholder, 22 require plan communications to be sent to an insured, and 36 give insurers discretion to send plan communications to the policyholder or insured. Six jurisdictions prohibit disclosure, and 3 allow a patient to request nondisclosure of certain patient information. Our findings suggest that in many states, health insurers are given considerable discretion in determining to whom plan communications containing sensitive health information are sent. Future research could use this framework to analyze the association between state laws concerning insured dependent confidentiality and public health outcomes and related sensitive services. C1 [Kristoff, Iris; Cramer, Ryan; Leichliter, Jami S.] Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30329 USA. RP Cramer, R (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30329 USA. EM rcramer@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2017 VL 23 IS 2 BP 148 EP 151 DI 10.1097/PHH.0000000000000418 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK1WM UT WOS:000393716500014 PM 27798524 ER PT J AU Molinari, NAM Chen, B Krishna, N Morris, T AF Molinari, Noelle Angelique M. Chen, Bei Krishna, Nevin Morris, Thomas TI Who's at Risk When the Power Goes Out? The At-home Electricity-Dependent Population in the United States, 2012 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE disaster; emergency; preparedness; vulnerable population ID HEALTH-INSURANCE; DISASTER PREPAREDNESS; OUTCOMES; BLACKOUT; VISITS; IMPACT; CARE AB Objectives: Natural and man-made disasters can result in power outages that can affect certain vulnerable populations dependent on electrically powered durable medical equipment. This study estimated the size and prevalence of that electricity-dependent population residing at home in the United States. Methods: We used the Truven Health MarketScan* 2012 database to estimate the number of employer-sponsored privately insured enrollees by geography, age group, and sex who resided at home and were dependent upon electrically powered durable medical equipment to sustain life. We estimated nationally representative prevalence and used US Census population estimates to extrapolate the national population and produce maps visualizing prevalence and distribution of electricity-dependent populations residing at home. Results: As of 2012, among the 175 million persons covered by employer-sponsored private insurance, the estimated number of electricity-dependent persons residing at home was 366 619 (95% confidence interval: 365 700-367 537), with a national prevalence of 218.2 per 100 000 covered lives (95% confidence interval: 217.7-218.8). Prevalence varied significantly by age group (chi(2) = 264 289 95, P < .0001) and region (chi(2) = 12 286 30, P < .0001), with highest prevalence in those 65 years of age or older and in the South and the West. Across all insurance types in the United States, approximately 685 000 electricity-dependent persons resided at home. Conclusions: These results may assist public health jurisdictions addressing unique needs and necessary resources for this particularly vulnerable population. Results can verify and enhance the development of functional needs registries, which are needed to help first responders target efforts to those most vulnerable during disasters affecting the power supply. C1 [Molinari, Noelle Angelique M.; Chen, Bei; Krishna, Nevin; Morris, Thomas] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, 1600 Clifton Rd,NE MS D-18, Atlanta, GA 30329 USA. RP Molinari, NAM (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, 1600 Clifton Rd,NE MS D-18, Atlanta, GA 30329 USA. EM nmolinari@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2017 VL 23 IS 2 BP 152 EP 159 DI 10.1097/PHH.0000000000000345 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK1WM UT WOS:000393716500015 PM 26360818 ER PT J AU Breysse, PN Gant, JL AF Breysse, Patrick N. Gant, Jon L. TI The Importance of Housing for Healthy Populations and Communities SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material ID ASTHMA C1 [Breysse, Patrick N.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,1600 Clifton Rd,Mailstop F61, Atlanta, GA 30333 USA. [Gant, Jon L.] US Dept Housing & Urban Dev, Off Lead Hazard Control & Hlth Homes, Washington, DC USA. RP Breysse, PN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,1600 Clifton Rd,Mailstop F61, Atlanta, GA 30333 USA. EM pjb7@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2017 VL 23 IS 2 BP 204 EP 206 DI 10.1097/PHH.0000000000000543 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK1WM UT WOS:000393716500024 PM 28121771 ER PT J AU Ashley, PJ Freemer, M Garbe, P Rowson, D AF Ashley, Peter J. Freemer, Michelle Garbe, Paul Rowson, David TI Coordinated Federal Actions Are Needed to Reduce Racial and Ethnic Disparities in Childhood Asthma SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material C1 [Ashley, Peter J.] US Dept Housing & Urban Dev, 451 7th St,SW,Room 8236, Washington, DC 20410 USA. [Freemer, Michelle] NHLBI, Bldg 10, Bethesda, MD 20892 USA. [Garbe, Paul] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rowson, David] US EPA, Washington, DC 20460 USA. RP Ashley, PJ (reprint author), US Dept Housing & Urban Dev, 451 7th St,SW,Room 8236, Washington, DC 20410 USA. EM Peter.J.Ashley@hud.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2017 VL 23 IS 2 BP 207 EP 209 DI 10.1097/PHH.0000000000000541 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK1WM UT WOS:000393716500025 PM 28121772 ER PT J AU Gleason, B West, A Avula, D Utah, O Vogt, M Cumpston, K Kelly, M Brasler, P Wyatt, S Forlano, L AF Gleason, Brigette West, Angela Avula, Danny Utah, Okey Vogt, Marshall Cumpston, Kirk Kelly, Michael Brasler, Paul Wyatt, Shane Forlano, Laurie TI Collaborative Public Health Investigation of Clenbuterol-Adulterated Heroin Outbreak-Richmond, Virginia, March-April 2015 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE adulterated; clenbuterol; collaboration; heroin; investigation AB Context: In March 2015, the Virginia Department of Health (VDH) was alerted by the Virginia Poison Center of a 6-patient cluster treated for severe clinical presentations after using heroin. Patients' symptoms were atypical for heroin use, and concern existed that patients were exposed to heroin that had been adulterated with or replaced by another substance. Objective: To understand the extent and characterization of the outbreak and implement response measures to prevent further cases. The purpose of this report is to highlight the collaborative nature of a public health investigation among a diverse group of stakeholders. Design: Active surveillance and retrospective case finding. Setting: Richmond metro area community and hospitals. Participants: Regional poison centers, the Division of Consolidated Laboratory Services, the Department of Behavioral Health and Developmental Services, community partners, local law enforcement, and multiple VDH divisions. Intervention: Outbreak investigation, communication to public health professionals, clinicians, and the community, and liaising with the local law enforcement. Main Outcome Measures: Outbreak control. Results: Laboratory confirmation of clenbuterol in clinical specimens implicated it as the heroin adulterant. Thirteen patients met clinical and epidemiologic criteria for exposure to clenbuterol-adulterated heroin. All patients were associated with a localized area within Richmond, and patient interviews elucidated heroin supplier information. VDH collaborated with local law enforcement agents who investigated and arrested the supplier, leading to cessation of the outbreak. Conclusion: This outbreak highlights the value of policies and practices that support an integrated outbreak response among public health practitioners, poison center staff, laboratorians, clinicians, law enforcement agents, community groups, and other agencies. Collaboration enabled implementation of effective control measures-including those outside the purview of the health department-and should be standard practice in future outbreaks involving illicit substances. C1 [Gleason, Brigette] Ctr Dis Control & Prevent, Richmond, VA USA. [Gleason, Brigette; West, Angela; Forlano, Laurie] Virginia Dept Hlth, 109 Governor St, Richmond, VA 23219 USA. [Avula, Danny; Utah, Okey] Richmond City Hlth Dist, Richmond, VA USA. [Vogt, Marshall] Chesterfield Hlth Dept, Chesterfield, VA USA. Virginia Commonwealth Univ, Virginia Poison Ctr, Richmond, VA USA. [Cumpston, Kirk] Virginia Commonwealth Univ, Dept Emergency Med, Sect Clin Toxicol, Richmond, VA USA. [Kelly, Michael] Richmond Cardiol Consultants, Richmond, VA USA. [Brasler, Paul] Bon Secours Hlth Syst, Richmond, VA USA. [Wyatt, Shane] Div Consolidated Lab Serv, Richmond, VA USA. RP Gleason, B (reprint author), Virginia Dept Hlth, 109 Governor St, Richmond, VA 23219 USA. EM yer7@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD MAR-APR PY 2017 VL 23 IS 2 BP E8 EP E11 DI 10.1097/PHH.0000000000000419 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EK1WM UT WOS:000393716500002 PM 28121776 ER PT J AU Cohen, C von Mollendorf, C de Gouveia, L Lengana, S Meiring, S Quan, V Nguweneza, A Moore, DP Reubenson, G Moshe, M Madhi, SA Eley, B Hallbauer, U Finlayson, H Varughese, S O'Brien, KL Zell, ER Klugman, KP Whitney, CG von Gottberg, A AF Cohen, Cheryl von Mollendorf, Claire de Gouveia, Linda Lengana, Sarona Meiring, Susan Quan, Vanessa Nguweneza, Arthermon Moore, David P. Reubenson, Gary Moshe, Mamokgethi Madhi, Shabir A. Eley, Brian Hallbauer, Ute Finlayson, Heather Varughese, Sheeba O'Brien, Katherine L. Zell, Elizabeth R. Klugman, Keith P. Whitney, Cynthia G. von Gottberg, Anne CA South African IPD Case-Control TI Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study SO LANCET GLOBAL HEALTH LA English DT Article ID EPIDEMIOLOGY; PREVENTION; MORTALITY; PROGRAM; RISK AB Background The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include disease-causing serotypes that are important in low-income and middle-income countries. Vaccine effectiveness estimates are scarce in these settings. South Africa replaced PCV7 with PCV13 in 2011 using a 2 + 1 schedule. We aimed to assess the effectiveness of two or more doses of PCV13 against invasive pneumococcal disease in children with HIV infection and in those not infected with HIV. Methods Cases of invasive pneumococcal disease in children aged 5 years or younger were identified through national laboratory-based surveillance. Isolates were serotyped with the Quellung reaction or PCR. We sought in-hospital controls for every case, matched for age, HIV status, and study site. We aimed to enrol four controls for every case not infected with HIV and six controls for every case with HIV infection (case-control sets). With conditional logistic regression, we calculated vaccine effectiveness as a percentage, with the equation 1 -[adjusted odds ratio for vaccination] x 100. We included data from an earlier investigation of PCV7 to assess vaccine effectiveness in children exposed to but not infected with HIV and in malnourished children not infected with HIV. Findings Between January, 2012, and December, 2014, we enrolled children aged 16 weeks or older to our study: 240 were cases not infected with HIV, 75 were cases with HIV infection, 1118 were controls not infected with HIV, and 283 were controls with HIV infection. The effectiveness of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95% CI 37 to 96) among 11 case-control sets of children not infected with HIV and 91% (-35 to 100) among three case-control sets of children with HIV infection. PCV13 effectiveness among 26 case-control sets of children not infected with HIV was 52% (95% CI -12 to 79) against all-serotype invasive pneumococcal disease and 94% (44 to 100) for serotype 19A. Vaccine effectiveness against PCV7-serotype invasive pneumococcal disease was 87% (95% CI 38 to 97) in children exposed to HIV but uninfected and 90% (53 to 98) in malnourished children not infected with HIV. Interpretation Our results indicate that PCV13 in a 2 + 1 schedule is effective for preventing vaccine-type pneumococcal infections in young children not infected with HIV, including those who are malnourished or who have been exposed to HIV. Although the point estimate for PCV13 vaccine effectiveness in children infected with HIV was high, it did not reach significance, possibly because of the small sample size. These findings support recommendations for widespread use of pneumococcal conjugate vaccine in low-income and middle-income countries. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license. C1 [Cohen, Cheryl; von Mollendorf, Claire; de Gouveia, Linda; Lengana, Sarona; Nguweneza, Arthermon; Madhi, Shabir A.; von Gottberg, Anne] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Meiring, Susan; Quan, Vanessa] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Div Publ Hlth Surveillance & Response, Johannesburg, South Africa. [Moore, David P.; Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Chris Hani Baragwanath Acad Hosp, Dept Paediat, Johannesburg, South Africa. [Reubenson, Gary] Univ Witwatersrand, Fac Hlth Sci, Rahima Moosa Mother & Child Hosp, Dept Paediat & Child Hlth, Johannesburg, South Africa. [Varughese, Sheeba] Univ Witwatersrand, Fac Hlth Sci, Charlotte Maxeke Johannesburg Acad Hosp, Dept Paediat, Johannesburg, South Africa. [Moshe, Mamokgethi] Medunsa Univ, Dept Paediat, Dr George Mukhari Hosp, Johannesburg, South Africa. [Madhi, Shabir A.; Klugman, Keith P.] Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, Johannesburg, South Africa. [Eley, Brian] Univ Cape Town, Red Cross War Mem Childrens Hosp, Cape Town, South Africa. [Eley, Brian] Univ Cape Town, Dept Paediat & Child Hlth, Cape Town, South Africa. [Hallbauer, Ute] Univ Free State, Dept Paediat & Child Hlth, Univ & Pelonomi Hosp, Bloemfontein, South Africa. [Finlayson, Heather] Univ Stellenbosch, Tygerberg Hosp, Cape Town, South Africa. [Finlayson, Heather] Univ Stellenbosch, Dept Paediat & Child Hlth, Cape Town, South Africa. [O'Brien, Katherine L.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Zell, Elizabeth R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [von Gottberg, Anne] Univ Witwatersrand, Sch Pathol, Johannesburg, South Africa. [von Gottberg, Anne] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [von Gottberg, Anne] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. RP Cohen, C (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, ZA-2131 Johannesburg, South Africa. EM cherylc@nicd.ac.za FU Gavi, The Vaccine Alliance FX Gavi, The Vaccine Alliance. NR 25 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2214-109X J9 LANCET GLOB HEALTH JI Lancet Glob. Health PD MAR PY 2017 VL 5 IS 3 BP E359 EP E369 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN9TE UT WOS:000396341700039 PM 28139443 ER PT J AU Marks, F von Kalckreuth, V Aaby, P Adu-Sarkodie, Y El Tayeb, MA Ali, M Aseffa, A Baker, S Biggs, HM Bjerregaard-Andersen, M Breiman, RF Campbell, JI Cosmas, L Crump, JA Espinoza, MC Deerin, JF Dekker, DM Fields, BS Gasmelseed, N Hertz, JT Hoang, NVM Jaeger, JIA Jeon, HJ Kabore, LP Keddy, KH Konings, F Krumkamp, R Ley, B Erg, SVL May, J Meyer, CG Mintz, ED Montgomery, JM Niang, AA Nichols, C Olack, B Pak, GD Panzner, U Park, JK Park, SE Rabezanahary, H Rakotozandrindrainy, R Raminosoa, TM Razafindrabe, TJL Sampo, E Schutt-Gerowitt, H Sow, AG Sarpong, N Seo, HJ Sooka, A Soura, AB Tall, A Teferi, M Thriemer, K Warren, MR Yeshitela, B Clemens, JD Wierzba, TF AF Marks, Florian von Kalckreuth, Vera Aaby, Peter Adu-Sarkodie, Yaw El Tayeb, Muna Ahmed Ali, Mohammad Aseffa, Abraham Baker, Stephen Biggs, Holly M. Bjerregaard-Andersen, Morten Breiman, Robert F. Campbell, James I. Cosmas, Leonard Crump, John A. Espinoza, Maria Cruz Deerin, Jessica Fung Dekker, Denise Myriam Fields, Barry S. Gasmelseed, Nagla Hertz, Julian T. Nguyen Van Minh Hoang Jaeger, Justin Im Anna Jeon, Hyon Jin Kabore, Leon Parfait Keddy, Karen H. Konings, Frank Krumkamp, Ralf Ley, Benedikt Erg, Sandra Valborg Lofb May, Juergen Meyer, Christian G. Mintz, Eric D. Montgomery, Joel M. Niang, Aissatou Ahmet Nichols, Chelsea Olack, Beatrice Pak, Gi Deok Panzner, Ursula Park, Jin Kyung Park, Se Eun Rabezanahary, Henintsoa Rakotozandrindrainy, Raphael Raminosoa, Tiana Mirana Razafindrabe, Tsiriniaina Jean Luco Sampo, Emmanuel Schutt-Gerowitt, Heidi Sow, Amy Gassama Sarpong, Nimako Seo, Hye Jin Sooka, Arvinda Soura, Abdramane Bassiahi Tall, Adama Teferi, Mekonnen Thriemer, Kamala Warren, Michelle R. Yeshitela, Biruk Clemens, John D. Wierzba, Thomas F. TI Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study SO LANCET GLOBAL HEALTH LA English DT Article ID ENTERICA SEROVAR TYPHI; LABORATORY DIAGNOSIS; FEVER; KENYA; COUNTRIES; CHILDREN; BURDEN; BLOOD; SENSITIVITY; INFECTIONS AB Background Available incidence data for invasive salmonella disease in sub-Saharan Africa are scarce. Standardised, multicountry data are required to better understand the nature and burden of disease in Africa. We aimed to measure the adjusted incidence estimates of typhoid fever and invasive non-typhoidal salmonella (iNTS) disease in sub-Saharan Africa, and the antimicrobial susceptibility profiles of the causative agents. Methods We established a systematic, standardised surveillance of blood culture-based febrile illness in 13 African sentinel sites with previous reports of typhoid fever: Burkina Faso (two sites), Ethiopia, Ghana, Guinea-Bissau, Kenya, Madagascar (two sites), Senegal, South Africa, Sudan, and Tanzania (two sites). We used census data and health-care records to define study catchment areas and populations. Eligible participants were either inpatients or outpatients who resided within the catchment area and presented with tympanic (>= 38.0 degrees C) or axillary temperature (>= 37.5 degrees C). Inpatients with a reported history of fever for 72 h or longer were excluded. We also implemented a health-care utilisation survey in a sample of households randomly selected from each study area to investigate health-seeking behaviour in cases of self-reported fever lasting less than 3 days. Typhoid fever and iNTS disease incidences were corrected for health-care-seeking behaviour and recruitment. Findings Between March 1, 2010, and Jan 31, 2014, 135 Salmonella enterica serotype Typhi (S Typhi) and 94 iNTS isolates were cultured from the blood of 13 431 febrile patients. Salmonella spp accounted for 33% or more of all bacterial pathogens at nine sites. The adjusted incidence rate (AIR) of S Typhi per 100 000 person-years of observation ranged from 0 (95% CI 0-0) in Sudan to 383 (274-535) at one site in Burkina Faso; the AIR of iNTS ranged from 0 in Sudan, Ethiopia, Madagascar (Isotry site), and South Africa to 237 (178-316) at the second site in Burkina Faso. The AIR of iNTS and typhoid fever in individuals younger than 15 years old was typically higher than in those aged 15 years or older. Multidrug-resistant S Typhi was isolated in Ghana, Kenya, and Tanzania (both sites combined), and multidrug-resistant iNTS was isolated in Burkina Faso (both sites combined), Ghana, Kenya, and Guinea-Bissau. Interpretation Typhoid fever and iNTS disease are major causes of invasive bacterial febrile illness in the sampled locations, most commonly affecting children in both low and high population density settings. The development of iNTS vaccines and the introduction of S Typhi conjugate vaccines should be considered for high-incidence settings, such as those identified in this study. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. C1 [Marks, Florian; von Kalckreuth, Vera; Espinoza, Maria Cruz; Deerin, Jessica Fung; Jeon, Hyon Jin; Konings, Frank; Ley, Benedikt; Nichols, Chelsea; Pak, Gi Deok; Panzner, Ursula; Park, Jin Kyung; Park, Se Eun; Schutt-Gerowitt, Heidi; Seo, Hye Jin; Thriemer, Kamala; Warren, Michelle R.; Clemens, John D.; Wierzba, Thomas F.] Int Vaccine Inst, SNU Res Pk,1 Gwanak Ro, Seoul 08826, South Korea. [Aaby, Peter; Bjerregaard-Andersen, Morten; Erg, Sandra Valborg Lofb] Bandim Hlth Project, Bissau, Guinea Bissau. [Aaby, Peter; Bjerregaard-Andersen, Morten; Erg, Sandra Valborg Lofb] Res Ctr Vitamins & Vaccines, Copenhagen, Denmark. [Adu-Sarkodie, Yaw; Sarpong, Nimako] Kwame Nkrumah Univ Sci & Technol, Kumasi Ctr Collaborat Res Trop Med, Kumasi, Ghana. [El Tayeb, Muna Ahmed; Gasmelseed, Nagla] Univ Gezira, Fac Med, Wad Madani, Sudan. [Ali, Mohammad] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Aseffa, Abraham; Teferi, Mekonnen; Yeshitela, Biruk] Armauer Hansen Res Inst, Addis Ababa, Ethiopia. [Baker, Stephen; Campbell, James I.; Nguyen Van Minh Hoang] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam. [Biggs, Holly M.; Crump, John A.; Hertz, Julian T.] Kilimanjaro Christian Med Ctr, Moshi, Tanzania. [Biggs, Holly M.; Crump, John A.; Hertz, Julian T.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA. [Breiman, Robert F.; Cosmas, Leonard; Fields, Barry S.; Montgomery, Joel M.] Ctr Dis Control & Prevent, Nairobi, Kenya. [Cosmas, Leonard] WHO Kenya Country Off, Nairobi, Kenya. [Breiman, Robert F.] Emory Univ, Global Hlth Inst, Atlanta, GA 30322 USA. [Crump, John A.] Duke Univ, Duke Global Hlth Inst, Durham, NC USA. [Crump, John A.] Univ Otago, Ctr Int Hlth, Dunedin, New Zealand. [Dekker, Denise Myriam; Jaeger, Justin Im Anna; Krumkamp, Ralf; May, Juergen] Bernhard Nocht Inst Trop Med, Hamburg, Germany. [Dekker, Denise Myriam; Krumkamp, Ralf; May, Juergen; Sarpong, Nimako] German Ctr Infect Res, Hamburg, Germany. [Gasmelseed, Nagla] Univ Hafr Al Batin, Fac Sci, Hafar al Batin, Saudi Arabia. [Kabore, Leon Parfait; Sampo, Emmanuel] Schiphra Hosp, Ouagadougou, Burkina Faso. [Keddy, Karen H.; Sooka, Arvinda] Natl Inst Communicable Dis, Johannesburg, South Africa. [Keddy, Karen H.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Ley, Benedikt; Thriemer, Kamala] Charles Darwin Univ, Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia. [Meyer, Christian G.] Eberhard Karls Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Meyer, Christian G.] Duy Tan Univ, Da Nang, Vietnam. [Mintz, Eric D.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Niang, Aissatou Ahmet; Sow, Amy Gassama; Tall, Adama] Inst Pasteur, Dakar, Senegal. [Olack, Beatrice] Kenya Govt Med Res Ctr, Clin Res Ctr, Nairobi, Kenya. [Rabezanahary, Henintsoa; Rakotozandrindrainy, Raphael; Raminosoa, Tiana Mirana; Razafindrabe, Tsiriniaina Jean Luco] Univ Antananarivo, Microbiol Lab, Antananarivo, Madagascar. [Soura, Abdramane Bassiahi] Univ Ouagadougou, Inst Super Sci Populat, Ouagadougou, Burkina Faso. [Schutt-Gerowitt, Heidi] Univ Cologne, Inst Med Microbiol, Cologne, Germany. [Sow, Amy Gassama] Univ Cheikh Anta Diop Dakar, Dakar, Senegal. [Clemens, John D.] Int Ctr Diarrheal Dis Res Bangladesh, Dhaka, Bangladesh. [Clemens, John D.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Marks, F (reprint author), Int Vaccine Inst, SNU Res Pk,1 Gwanak Ro, Seoul 08826, South Korea. EM fmarks@ivi.int RI Ali, Mohammad/E-2365-2017 OI Ali, Mohammad/0000-0003-1410-388X FU Bill & Melinda Gates Foundation FX Bill & Melinda Gates Foundation. NR 38 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2214-109X J9 LANCET GLOB HEALTH JI Lancet Glob. Health PD MAR PY 2017 VL 5 IS 3 BP E310 EP E323 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EN9TE UT WOS:000396341700035 PM 28193398 ER PT J AU Gregson, J Kaleebu, P Marconi, VC van Vuuren, C Ndembi, N Hamers, RL Kanki, P Hoffmann, CJ Lockman, S Pillay, D de Oliveira, T Clumeck, N Hunt, G Kerschberger, B Shafer, RW Yang, CF Raizes, E Kantor, R Gupta, RK AF Gregson, John Kaleebu, Pontiano Marconi, Vincent C. van Vuuren, Cloete Ndembi, Nicaise Hamers, Raph L. Kanki, Phyllis Hoffmann, Christopher J. Lockman, Shahin Pillay, Deenan de Oliveira, Tulio Clumeck, Nathan Hunt, Gillian Kerschberger, Bernhard Shafer, Robert W. Yang, Chunfu Raizes, Elliot Kantor, Rami Gupta, Ravindra K. TI Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study SO LANCET INFECTIOUS DISEASES LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; RESOURCE-LIMITED SETTINGS; FIXED-DOSE COMBINATION; SOUTH-AFRICA; VIROLOGICAL FAILURE; DISOPROXIL FUMARATE; LAMIVUDINE; STAVUDINE; 1ST; METAANALYSIS AB Background HIV-1 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub-Saharan Africa in patients with virological failure of first-line combination antiretroviral therapy (ART) containing the modem nudeoside reverse transcriptase inhibitor tenofovir. We aimed to investigate the prevalence and correlates of thymidine analogue mutations (TAM) in patients with virological failure of first-line tenofovir-containing ART. Methods We retrospectively analysed patients from 20 studies within the TenoRes collaboration who had locally defined viral failure on first-line therapy with tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa. Baseline visits in these studies occurred between 2005 and 2013. To assess between-study and within-study associations, we used meta-regression and meta-analyses to compare patients with and without TAMs for the presence of resistance to tenofovir, cytosine analogue, or NNRTIs. Findings Of 712 individuals with failure of first-line tenofovir-containing regimens, 115 (16%) had at least one TAM. In crude comparisons, patients with TAMs had lower CD4 counts at treatment initiation than did patients without TAMs (60.5 cells per mu L [IQR 21-0-128.0] in patients with TAMS vs 95.0 cells per mu L [37.0-177.0] in patients without TAMs; p=0.007) and were more likely to have tenofovir resistance (93 [81%] of 115 patients with TAMs vs 352 [59%] of 597 patients without TAMs; p<0.0001), NNRTI resistance (107 [93%] vs 462 [77%]; p<0.0001), and cytosine analogue resistance (100 [87%] vs 378 163%]; p=0-0002). We detected associations between TAMs and drug resistance mutations both between and within studies; the correlation between the study-level proportion of patients with tenofovir resistance and TAMs was 0.64 (p<0.0001), and the odds ratio for tenofovir resistance comparing patients with and without TAMs was 1.29 (1.13-1.47; p<0.0001) Interpretation TAMs are common in patients who have failure of first-line tenofovir-containing regimens in sub-Saharan Africa, and are associated with multidrug resistant HIV-1. Effective viral load monitoring and point-of-care resistance tests could help to mitigate the emergence and spread of such strains. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. C1 [Gregson, John] London Sch Hyg & Trop Med, Dept Stat, London, England. [Kaleebu, Pontiano] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda. [Kaleebu, Pontiano] Uganda Res Unit AIDS, Entebbe, Uganda. [Marconi, Vincent C.] Emory Univ, Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Marconi, Vincent C.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. [van Vuuren, Cloete] Univ Free State, Div Infect Dis, Bloemfontein, South Africa. [van Vuuren, Cloete] 3 Mil Hosp, Bloemfontein, South Africa. [Ndembi, Nicaise] Inst Human Virol Nigeria, Abuja, Nigeria. [Hamers, Raph L.] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, Amsterdam Inst Global Hlth & Dev, NL-1012 WX Amsterdam, Netherlands. [Kanki, Phyllis] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA. [Hoffmann, Christopher J.] Aurum Inst, Johannesburg, South Africa. [Hoffmann, Christopher J.] Johns Hopkins Univ, Baltimore, MD USA. [Lockman, Shahin] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Pillay, Deenan; Gupta, Ravindra K.] UCL, Dept Infect, London, England. [Pillay, Deenan; Gupta, Ravindra K.] Africa Hlth Res Inst, Kwa Zulu, South Africa. [de Oliveira, Tulio] Univ KwaZulu Natal, Coll Hlth Sci, Sch Lab Med & Med Sci, Nelson R Mandela Sch Med, Durban, South Africa. [de Oliveira, Tulio] CAPRISA, Durban, South Africa. [Clumeck, Nathan] Univ Libre Bruxelles, St Pierre Univ Hosp, Brussels, Belgium. [Hunt, Gillian] Natl Inst Communicable Dis, Johannesburg, South Africa. [Kerschberger, Bernhard] Medecins Sans Frontieres, Operat Ctr Geneva, Mbabane, Swaziland. [Shafer, Robert W.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Atlanta, GA USA. [Raizes, Elliot] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Kantor, Rami] Brown Univ, Alpert Med Sch, Div Infect Dis, Providence, RI 02912 USA. RP Gupta, RK (reprint author), UCL, London WC1E 6BT, England. EM ravindra.gupta@ucl.ac.uk FU Wellcome Trust; Research and Health Sciences IT Division [VCM UL1RR025008]; PEP EAR from HHS/CDC, Global AIDS Program [5U2GGH000925-03]; European Union [SANTE 2007 147-790]; Medical Research Council flagship grant from South Africa [MRC-RFA-UFSP-01.2013/UKZN HIVEPI] FX This work was funded by the Wellcome Trust. We thank the Uganda Virus Research Institute/Ministry of Health (UVRI/MoH) Uganda surveillance study; the Pan-African Studies to Evaluate Resistance (PASER) network; the HIV Drug Resistance Working group and participants and study teams from the treatment centres at Masaka and Mbale regional referral hospitals and Nsambya Home-Care; ACTG 5208 study team; RFVF: the Sinikithemba Clinic at McCord Hospital in Durban, South Africa, Emory University Center for AIDS Research (CFAR: VCM, P30A1050409); Research and Health Sciences IT Division grant support (VCM UL1RR025008); NIH (VCM, RO1 A1098558-01A1); Tanzanian, Kenyan, and Ugandan Ministries of Health; The Harvard/AIDS Prevention Initiative in Nigeria (APIN) prevention, treatment and care programme: participating hospitals in this study included the University College Hospital, University of Ibadan, Ibadan, Lagos University Teaching Hospital, University of Lagos, Lagos, Jos University Teaching Hospital, University of Jos, and the Nigerian Institute of Medical Research, Lagos; the President's Emergency Plan for AIDS Relief (PEPFAR) and Centers for Disease Control and Prevention (CDC): Tanzanian, Nigerian, and Kenyan Ministries of Health, Infectious Disease Institute, Uganda, and Tropical Disease Research Centre, Zambia; The Cross Sectional Survey of Acquired Drug Resistance Study at Sentinel Sites Study Team: University of Maryland, and the Kenya National HIVDR working group Tanzania/Zanzibar and the Tanzanian National HIVDR working group; CDC-Kenya; CDC-Tanzania; CDC Atlanta: ACTIONPIus Up supported by PEP EAR (cooperative agreement 5U2GGH000925-03) from HHS/CDC, Global AIDS Program; AMPATH 16 study participants. AMPATH community, Lifespan/Brown Tufts Center for AIDS Research (P30A1042853) and United States National Institutes of Health (R01 A1066922); The Africa Centre drug resistance cohort was funded European Union (SANTE 2007 147-790), the US Centre for Diseases Control via CAP RISA (project title: Health Systems Strengthening and HIV Treatment Failure [HIV-TFC]); the data curation and research in this cohort was funded through a Medical Research Council flagship grant from South Africa (MRC-RFA-UFSP-01.2013/UKZN HIVEPI). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 33 TC 1 Z9 1 U1 2 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAR PY 2017 VL 17 IS 3 BP 296 EP 304 DI 10.1016/S1473-3099(16)30469-8 PG 9 WC Infectious Diseases SC Infectious Diseases GA EL6KX UT WOS:000394732600038 PM 27914856 ER PT J AU Kraemer, MUG Faria, NR Reiner, RC Golding, N Nikolay, B Stasse, S Johansson, MA Salje, H Faye, O Wint, GRW Niedrig, M Shearer, FM Hill, SC Thompson, RN Bisanzio, D Taveira, N Nax, HH Pradelski, BSR Nsoesie, EO Murphy, NR Bogoch, II Khan, K Brownstein, JS Tatem, AJ de Oliveira, T Smith, DL Sall, AA Pybus, OG Hay, SI Cauchemez, S AF Kraemer, Moritz U. G. Faria, Nuno R. Reiner, Robert C., Jr. Golding, Nick Nikolay, Birgit Stasse, Stephanie Johansson, Michael A. Salje, Henrik Faye, Ousmane Wint, G. R. William Niedrig, Matthias Shearer, Freya M. Hill, Sarah C. Thompson, Robin N. Bisanzio, Donal Taveira, Nuno Nax, Heinrich H. Pradelski, Bary S. R. Nsoesie, Elaine O. Murphy, Nicholas R. Bogoch, Isaac I. Khan, Kamran Brownstein, John S. Tatem, Andrew J. de Oliveira, Tulin Smith, David L. Sall, Amadou A. Pybus, Oliver G. Hay, Simon I. Cauchemez, Simon TI Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study SO LANCET INFECTIOUS DISEASES LA English DT Article ID TRANSMISSION; INFECTION; DISEASE; AFRICA AB Background Since late 2015, an epidemic of yellow fever has caused more than 7334 suspected cases in Angola and the Democratic Republic of the Congo, including 393 deaths. We sought to understand the spatial spread of this outbreak to optimise the use of the limited available vaccine stock. Methods We jointly analysed datasets describing the epidemic of yellow fever, vector suitability, human demography, and mobility in central Africa to understand and predict the spread of yellow fever virus. We used a standard logistic model to infer the district-specific yellow fever virus infection risk during the course of the epidemic in the region. Findings The early spread of yellow fever virus was characterised by fast exponential growth (doubling time of 5-7 days) and fast spatial expansion (49 districts reported cases after only 3 months) from Luanda, the capital of Angola. Early invasion was positively correlated with high population density (Pearson's r 0.52,95% CI 0.34-0.66). The further away locations were from Luanda, the later the date of invasion (Pearson's r 0.60, 95% CI 0.52-0.66). In a Cox model, we noted that districts with higher population densities also had higher risks of sustained transmission (the hazard ratio for cases ceasing was 0.74, 95% CI 0 43-0 . 92 per log-unit increase in the population size of a district). A model that captured human mobility and vector suitability successfully discriminated districts with high risk of invasion from others with a lower risk (area under the curve 0.94, 95% CI 0.92-0.97). If at the start of the epidemic, sufficient vaccines had been available to target 50 out of 313 districts in the area, our model would have correctly identified 27 (84%) of the 32 districts that were eventually affected. Interpretation Our findings show the contributions of ecological and demographic factors to the ongoing spread of the yellow fever outbreak and provide estimates of the areas that could be prioritised for vaccination, although other constraints such as vaccine supply and delivery need to be accounted for before such insights can be translated into policy. Copyright (C) The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. C1 [Kraemer, Moritz U. G.; Faria, Nuno R.; Hill, Sarah C.; Thompson, Robin N.; Bisanzio, Donal; Smith, David L.; Pybus, Oliver G.] Univ Oxford, Dept Zool, Oxford OX1 3PS, England. [Reiner, Robert C., Jr.; Nsoesie, Elaine O.; Smith, David L.; Hay, Simon I.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Golding, Nick; Shearer, Freya M.; Hay, Simon I.] Oxford Big Data Inst, Li Ka Shing Ctr Hlth Informat & Discovery, Oxford, England. [Golding, Nick] Univ Melbourne, Sch Biosci, Parkville, Vic, Australia. [Nikolay, Birgit; Salje, Henrik; Cauchemez, Simon] Inst Pasteur, Math Modelling Infect Dis, Paris, France. [Nikolay, Birgit; Salje, Henrik; Cauchemez, Simon] Inst Pasteur, Ctr Bioinformat Biostat & Integrat Biol, Paris, France. [Nikolay, Birgit; Salje, Henrik; Cauchemez, Simon] CNRS, URA 3012, Paris, France. [Stasse, Stephanie] European Commiss, Hlth Programme, Int Cooperat & Dev, Delegat RDC, Kinshasa, DEM REP CONGO. [Brownstein, John S.] Ctr Dis Control & Prevent, San Juan, PR USA. [Johansson, Michael A.] Harvard Univ, Sch Med, Ctr Communicable Dis Dynam, Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Salje, Henrik] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MO USA. [Faye, Ousmane; Sall, Amadou A.] Inst Pasteur, Arbovirus & Viral Hemorrhag Fever Unit, Dakar, Senegal. [Wint, G. R. William] Environm Res Grp Oxford, Dept Zool, Oxford, England. [Niedrig, Matthias] Robert Koch Inst, Berlin, Germany. [Taveira, Nuno] Univ Lisbon, Res Inst Med iMed ULisboa, Fac Pharm, P-1699 Lisbon, Portugal. [Taveira, Nuno] Inst Super Ciencias Saude Egas Moniz, Ctr Invest Interdisciplinar Egas Moniz, Caparica, Portugal. [Nax, Heinrich H.; Pradelski, Bary S. R.] ETH, Computat Social Sci, Zurich, Switzerland. [Murphy, Nicholas R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Bogoch, Isaac I.] Univ Hlth Network, Toronto Gen Hosp, Div Gen Internal Med, Toronto, ON, Canada. [Bogoch, Isaac I.] Univ Hlth Network, Toronto Gen Hosp, Div Infect Dis, Toronto, ON, Canada. [Khan, Kamran] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada. [Tatem, Andrew J.] Univ Southampton, Dept Geog & Environm, WorldPop, Southampton, Hants, England. [Tatem, Andrew J.] Flowminder Fdn, Stockholm, Sweden. [de Oliveira, Tulin] Univ KwaZulu Natal, Sch Lab Med & Med Sci, Nelson R Mandela Sch Med, Coll Hlth Sci, Durban, South Africa. [Smith, David L.] Sanaria Inst Global Hlth & Trop Med, Rockville, MD USA. RP Kraemer, MUG (reprint author), Univ Oxford, Dept Zool, Oxford OX1 3PS, England. EM moritz.kraemer@zoo.ox.ac.uk OI Salje, Henrik/0000-0003-3626-4254 FU Wellcome Trust FX Wellcome Trust. NR 30 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD MAR PY 2017 VL 17 IS 3 BP 330 EP 338 DI 10.1016/S1473-3099(16)30513-8 PG 9 WC Infectious Diseases SC Infectious Diseases GA EL6KX UT WOS:000394732600042 PM 28017559 ER PT J AU Kahn, HS Bullard, KM AF Kahn, Henry S. Bullard, Kai McKeever TI Indicators of abdominal size relative to height associated with sex, age, socioeconomic position and ancestry among US adults SO PLOS ONE LA English DT Article ID BODY-MASS INDEX; CARDIOMETABOLIC RISK-FACTORS; AMERICAN-HEART-ASSOCIATION; VISCERAL ADIPOSE-TISSUE; WAIST CIRCUMFERENCE; ANTHROPOMETRIC MEASUREMENTS; SCIENTIFIC STATEMENT; GENERAL-POPULATION; SAGITTAL DIAMETER; FAT DISTRIBUTION AB Background/Objectives The supine sagittal abdominal diameter (SAD) and standing waist circumference (WC) describe abdominal size. The SAD/height ratio (SADHtR) or WC/height ratio (WHtR) may better identify cardiometabolic disorders than BMI (weight/height(2)), but population-based distributions of SADHtR and WHtR are not widely available. Abdominal adiposity may differ by sociodemographic characteristics. Subjects/Methods Anthropometry, including SAD by sliding-beam caliper, was performed on 9894 non-pregnant adults >= 20 years in the US National Health and Nutrition Examination Surveys of 2011-2014. Applying survey design factors and sampling weights, we estimated nationally representative SADHtR and WHtR distributions by sex, age, educational attainment, and four ancestral groups. Results The median (10th percentile, 90th percentile) for men's SADHtR was 0.130 (0.103, 0.165) and WHtR 0.569 (0.467, 0.690). For women, median SADHtR was 0.132 (0.102, 0.175) and WHtR 0.586 (0.473, 0.738). Medians for SADHtR and WHtR increased steadily through age 79. The median BMI, however, reached maximum values at ages 40-49 (men) or 60-69 (women) and then declined. Low educational attainment, adjusted for age and ancestry, was associated with elevated SADHtR more strongly than elevated BMI. While non-Hispanic Asians had substantially lower BMI compared to all other ancestral groups (adjusted for sex, age and education), their relative reductions in SADHtR and WHtR, were less marked. Conclusions These cross-sectional data are consistent with monotonically increasing abdominal adipose tissue through the years of adulthood but decreasing mass in non-abdominal regions beyond middle age. They suggest also that visceral adipose tissue, estimated by SADHtR, expands differentially in association with low socioeconomic position. Insofar as Asians have lower BMIs than other populations, employing abdominal indicators may attenuate the adiposity differences reported between ancestral groups. Documenting the distribution and sociodemographic features of SADHtR and WHtR supports the clinical and epidemiologic adoption of these adiposity indicators. C1 [Kahn, Henry S.; Bullard, Kai McKeever] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. RP Kahn, HS (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. EM hkahn@cdc.gov NR 52 TC 0 Z9 0 U1 3 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 1 PY 2017 VL 12 IS 3 AR e0172245 DI 10.1371/journal.pone.0172245 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN4NF UT WOS:000395983500033 PM 28248983 ER PT J AU Kirkcaldy, RD Schlanger, K Papp, JR Torrone, EA AF Kirkcaldy, Robert D. Schlanger, Karen Papp, John R. Torrone, Elizabeth A. TI Considerations for Strengthening Surveillance of Neisseria gonorrhoeae Antimicrobial Resistance and Interpreting Surveillance Data SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID UNITED-STATES; CEPHALOSPORINS; SUSCEPTIBILITY C1 [Kirkcaldy, Robert D.; Schlanger, Karen; Papp, John R.; Torrone, Elizabeth A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS, Viral Hepatitis STD & TB Prevent, Div STD Prevent, Atlanta, GA USA. RP Kirkcaldy, RD (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM HGL8@cdc.gov NR 12 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2017 VL 44 IS 3 BP 154 EP 156 DI 10.1097/OLQ.0000000000000584 PG 3 WC Infectious Diseases SC Infectious Diseases GA EL1CX UT WOS:000394359200005 PM 28178113 ER PT J AU Dabelea, D Stafford, JM Mayer-Davis, EJ D'Agostino, R Dolan, L Imperatore, G Linder, B Lawrence, JM Marcovina, SM Mottl, AK Black, MH Pop-Busui, R Saydah, S Hamman, RF Pihoker, C AF Dabelea, Dana Stafford, Jeanette M. Mayer-Davis, Elizabeth J. D'Agostino, Ralph Dolan, Lawrence Imperatore, Giuseppina Linder, Barbara Lawrence, Jean M. Marcovina, Santica M. Mottl, Amy K. Black, Mary Helen Pop-Busui, Rodica Saydah, Sharon Hamman, Richard F. Pihoker, Catherine CA SEARCH Diabet Youth Res Grp TI Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID PERIPHERAL NEUROPATHY; FUTURE-DIRECTIONS; ONSET TYPE-1; RISK-FACTORS; YOUTH; SEARCH; PREVALENCE; COHORT; RETINOPATHY; MORTALITY AB IMPORTANCE The burden and determinants of complications and comorbidities in contemporary youth-onset diabetes are unknown. OBJECTIVE To determine the prevalence of and risk factors for complications related to type 1 diabetes vs type 2 diabetes among teenagers and young adults who had been diagnosed with diabetes during childhood and adolescence. DESIGN, SETTING, AND PARTICIPANTS Observational study from 2002 to 2015 in 5 US locations, including 2018 participants with type 1 and type 2 diabetes diagnosed at younger than 20 years, with single outcome measures between 2011 and 2015. EXPOSURES Type 1 and type 2 diabetes and established risk factors (hemoglobin A(1c) level, body mass index, waist-height ratio, and mean arterial blood pressure). MAIN OUTCOMES AND MEASURES Diabetic kidney disease, retinopathy, peripheral neuropathy, cardiovascular autonomic neuropathy, arterial stiffness, and hypertension. RESULTS Of 2018 participants, 1746 had type 1 diabetes (mean age, 17.9 years [SD 4.1]; 1327 non-Hispanic white [76.0%]; 867 female patients [49.7%]), and 272 had type 2 (mean age, 22.1 years [SD 3.5]; 72 non-Hispanic white [26.5%]; 181 female patients [66.5%]). Mean diabetes duration was 7.9 years (both groups). Patients with type 2 diabetes vs those with type 1 had higher age-adjusted prevalence of all measured complications except cardiovascular autonomic neuropathy. After adjustment for established risk factors measured over time, participants with type 2 diabetes vs those with type 1 had significantly higher odds of diabetic kidney disease, retinopathy, and peripheral neuropathy but no significant difference in the odds of arterial stiffness and hypertension. [GRAPHICS] CONCLUSIONS AND RELEVANCE Among teenagers and young adults who had been diagnosed with diabetes during childhood or adolescence, the prevalence of complications and comorbidities was higher among those with type 2 diabetes compared with type 1, but frequent in both groups. These findings support early monitoring of youth with diabetes for development of complications. C1 [Dabelea, Dana; Hamman, Richard F.] Colorado Sch Publ Hlth, Dept Epidemiol, B-119, Aurora, CO 80045 USA. [Stafford, Jeanette M.; D'Agostino, Ralph] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA. [Dolan, Lawrence] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Imperatore, Giuseppina; Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Linder, Barbara] Natl Inst Diabet & Digest & Kidney Dis, Div Diabet Endocrinol & Metab Dis, Bethesda, MD USA. [Lawrence, Jean M.; Black, Mary Helen] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Marcovina, Santica M.] Univ Washington, Northwest Lipid Res Lab, Seattle, WA USA. [Mottl, Amy K.] Univ N Carolina, Sch Med, Div Nephrol & Hypertens, Chapel Hill, NC USA. [Pop-Busui, Rodica] Univ Michigan, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. RP Dabelea, D (reprint author), Colorado Sch Publ Hlth, Dept Epidemiol, B-119, Aurora, CO 80045 USA. EM dana.dabelea@ucdenver.edu FU National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases; Centers for Disease Control and Prevention (CDC); CDC [RFP DP15-002]; NIH, National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U18DP006133, U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado-Denver [U18DP006139, U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Cincinnati's Children's Hospital Medical Center [U18DP006134, U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U18DP006138, U48/CCU419249, U01 DP000254, U18DP002708]; Seattle Children's Hospital [U18DP006136, U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U18DP006131, U48/CC U919219, U01 DP000250, 200-2010-35171] FX The SEARCH for Diabetes in Youth Cohort Study (1UC4DK108173-01) is funded by the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases and supported by the Centers for Disease Control and Prevention (CDC). The Population Based Registry of Diabetes in Youth Study (RFP DP15-002) is funded by the CDC and supported by the NIH, National Institute of Diabetes and Digestive and Kidney Diseases. Sites: Kaiser Permanente Southern California (U18DP006133, U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado-Denver (U18DP006139, U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Cincinnati's Children's Hospital Medical Center (U18DP006134, U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U18DP006138, U48/CCU419249, U01 DP000254, and U18DP002708), Seattle Children's Hospital (U18DP006136, U58/CCU019235-4, U01 DP000244, and U18DP002710-01), and Wake Forest University School of Medicine (U18DP006131, U48/CC U919219, U01 DP000250, and 200-2010-35171). NR 39 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 28 PY 2017 VL 317 IS 8 BP 825 EP 835 DI 10.1001/jama.2017.0686 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA EM7PW UT WOS:000395505600020 PM 28245334 ER PT J AU Cubenas-Potts, C Rowley, MJ Lyu, XW Li, G Lei, EP Corces, VG AF Cubenas-Potts, Caelin Rowley, M. Jordan Lyu, Xiaowen Li, Ge Lei, Elissa P. Corces, Victor G. TI Different enhancer classes in Drosophila bind distinct architectural proteins and mediate unique chromatin interactions and 3D architecture SO NUCLEIC ACIDS RESEARCH LA English DT Article ID INTEGRATIVE GENOMICS VIEWER; LONG-RANGE INTERACTIONS; GENE-EXPRESSION; RNA-POLYMERASE; HI-C; INSULATOR FUNCTION; ACTIVE CHROMATIN; HUMAN-CELLS; PROMOTER; ORGANIZATION AB Eukaryotic gene expression is regulated by enhancer-promoter interactions but the molecular mechanisms that govern specificity have remained elusive. Genome-wide studies utilizing STARR-seq identified two enhancer classes in Drosophila that interact with different core promoters: housekeeping enhancers (hkCP) and developmental enhancers (dCP). We hypothesized that the two enhancer classes are occupied by distinct architectural proteins, affecting their enhancer-promoter contacts. By evaluating ChIP-seq occupancy of architectural proteins, typical enhancer-associated proteins, and histone modifications, we determine that both enhancer classes are enriched for RNA Polymerase II, CBP, and architectural proteins but there are also distinctions. hkCP enhancers contain H3K4me3 and exclusively bind Cap-H2, Chromator, DREF and Z4, whereas dCP enhancers contain H3K4me1 and are more enriched for Rad21 and Fs(1) h-L. Additionally, we map the interactions of each enhancer class utilizing a Hi-C dataset with <1 kb resolution. Results suggest that hkCP enhancers are more likely to form multi-TSS interaction networks and be associated with topologically associating domain (TAD) borders, while dCP enhancers are more often bound to one or two TSSs and are enriched at chromatin loop anchors. The data support a model suggesting that the unique architectural protein occupancy within en-hancers is one contributor to enhancer-promoter interaction specificity. C1 [Cubenas-Potts, Caelin; Rowley, M. Jordan; Lyu, Xiaowen; Li, Ge; Corces, Victor G.] Emory Univ, Dept Biol, 1510 Clifton Rd NE, Atlanta, GA 30322 USA. [Lei, Elissa P.] NIDDK, Nucl Org & Gene Express Sect, Lab Cellular & Dev Biol, NIH, Bethesda, MD 20892 USA. [Li, Ge] Emory Univ, Div Digest Dis, 1670 Clairmont Rd, Decatur, GA 30033 USA. [Cubenas-Potts, Caelin] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. RP Corces, VG (reprint author), Emory Univ, Dept Biol, 1510 Clifton Rd NE, Atlanta, GA 30322 USA. EM vgcorces@gmail.com FU U.S. Public Health Service Award [R01 GM035463]; National Institutes of Health; National Research Service Award [F32 GM113570] FX U.S. Public Health Service Award R01 GM035463 (to V.G.C.); Intramural Research Program of the NIDDK (to E.L.) from the National Institutes of Health and Ruth L. Kirschstein National Research Service Award F32 GM113570 (to M.J.R.). Funding for open access charge: U.S. Public Health Service Award [R01 GM035463]. Conflict of interest statement. None declared. NR 71 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD FEB 28 PY 2017 VL 45 IS 4 BP 1714 EP 1730 DI 10.1093/nar/gkw1114 PG 17 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EN5OO UT WOS:000396055400022 ER PT J AU Shah, MP Wikswo, ME Barclay, L Kambhampati, A Shioda, K Parashar, UD Vinje, J Hall, AJ AF Shah, Minesh P. Wikswo, Mary E. Barclay, Leslie Kambhampati, Anita Shioda, Kayoko Parashar, Umesh D. Vinje, Jan Hall, Aron J. TI Near Real-Time Surveillance Norovirus Sentinel Testing and August SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; GASTROENTERITIS; OUTBREAKS C1 [Shah, Minesh P.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Shah, Minesh P.; Wikswo, Mary E.; Barclay, Leslie; Kambhampati, Anita; Shioda, Kayoko; Parashar, Umesh D.; Vinje, Jan; Hall, Aron J.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Kambhampati, Anita; Shioda, Kayoko] Oak Ridge Associated Univ, Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37831 USA. RP Shah, MP (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Shah, MP (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM yxi8@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 24 PY 2017 VL 66 IS 7 BP 185 EP 189 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EM1AC UT WOS:000395048600001 PM 28231235 ER PT J AU Nnadi, C Damisa, E Esapa, L Braka, F Waziri, N Siddique, A Jorba, J Nganda, GW Ohuabunwo, C Bolu, O Wiesen, E Adamu, U AF Nnadi, Chimeremma Damisa, Eunice Esapa, Lisa Braka, Fiona Waziri, Ndadilnasiya Siddique, Anisur Jorba, Jaume Nganda, Gatei Wa Ohuabunwo, Chima Bolu, Omotayo Wiesen, Eric Adamu, Usman TI Continued Endemic Wild Poliovirus Transmission in Security-Compromised Areas-Nigeria, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POLIOMYELITIS ERADICATION; PROGRESS C1 [Nnadi, Chimeremma; Esapa, Lisa; Nganda, Gatei Wa; Ohuabunwo, Chima; Bolu, Omotayo; Wiesen, Eric] CDC, Global Immunizat Div, Atlanta, GA 30333 USA. [Damisa, Eunice; Adamu, Usman] Natl Primary Hlth Care Dev Agcy, Natl Polio Emergency Operat Ctr, Abuja, Nigeria. [Braka, Fiona] Nigeria Country Off, World Hlth Org, Expanded Program Immunizat, Abuja, Nigeria. [Waziri, Ndadilnasiya; Siddique, Anisur] Nigeria Country Off, Africa Field Epidemiol Network, Natl Stop Transmiss Polio Program, Abuja, Nigeria. [Waziri, Ndadilnasiya; Siddique, Anisur] Nigeria Country Off, United Nations Childrens Fund, Abuja, Nigeria. [Jorba, Jaume] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Nnadi, C (reprint author), CDC, Global Immunizat Div, Atlanta, GA 30333 USA. EM cnnadi@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 24 PY 2017 VL 66 IS 7 BP 190 EP 193 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EM1AC UT WOS:000395048600002 PM 28233765 ER PT J AU Alemnji, G Edghill, L Guevara, G Wallace-Sankarsingh, S Albalak, R Cognat, S Nkengasong, J Gabastou, JM AF Alemnji, George Edghill, Lisa Guevara, Giselle Wallace-Sankarsingh, Sacha Albalak, Rachel Cognat, Sebastien Nkengasong, John Gabastou, Jean-Marc TI Development and implementation of the Caribbean Laboratory Quality Management Systems Stepwise Improvement Process (LQMS-SIP) Towards Accreditation SO AFRICAN JOURNAL OF LABORATORY MEDICINE LA English DT Article ID REGION AB Background: Implementing quality management systems and accrediting laboratories in the Caribbean has been a challenge. Objectives: We report the development of a stepwise process for quality systems improvement in the Caribbean Region. Methods: The Caribbean Laboratory Stakeholders met under a joint Pan American Health Organization/US Centers for Disease Control and Prevention initiative and developed a userfriendly framework called 'Laboratory Quality Management System -Stepwise Improvement Process (LQMS-SIP) Towards Accreditation' to support countries in strengthening laboratory services through a stepwise approach toward fulfilling the ISO 15189: 2012 requirements. Results: This approach consists of a three-tiered framework. Tier 1 represents the minimum requirements corresponding to the mandatory criteria for obtaining a licence from the Ministry of Health of the participating country. The next two tiers are quality improvement milestones that are achieved through the implementation of specific quality management system requirements. Laboratories that meet the requirements of the three tiers will be encouraged to apply for accreditation. The Caribbean Regional Organisation for Standards and Quality hosts the LQMS-SIP Secretariat and will work with countries, including the Ministry of Health and stakeholders, including laboratory staff, to coordinate and implement LQMS-SIP activities. The Caribbean Public Health Agency will coordinate and advocate for the LQMS-SIP implementation. Conclusion: This article presents the Caribbean LQMS-SIP framework and describes how it will be implemented among various countries in the region to achieve quality improvement. C1 [Alemnji, George; Guevara, Giselle; Albalak, Rachel] Ctr Dis Control & Prevent CDC, Caribbean Reg Off, Bridgetown, Barbados. [Edghill, Lisa; Wallace-Sankarsingh, Sacha] Caribbean Publ Hlth Agcy CARPHA, Port Of Spain, Trinid & Tobago. [Cognat, Sebastien] WHO, Lyon, France. [Nkengasong, John] US Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Gabastou, Jean-Marc] PAHO, Lima, Peru. RP Guevara, G (reprint author), Ctr Dis Control & Prevent CDC, Caribbean Reg Off, Bridgetown, Barbados. EM vju7@cdc.gov FU President's Emergency Plan for AIDS Relief from the US Centers for Disease Control and Prevention [PS001426] FX This project was supported by the President's Emergency Plan for AIDS Relief through Cooperative Agreement number PS001426 from the US Centers for Disease Control and Prevention. We would like to acknowledge the contributions of all members of the Caribbean LQMS-SIP Technical Working Group (Claudette Brown, Jamaica National Agency for Accreditation; Eileen Burke, Caribbean Epidemiology Center; Ellison Floyd-Tobas, Trinidad & Tobago Laboratory Accreditation Service; Floris Gordon, African Field Epidemiology Network; Wendy Kitson-Piggott, Caribbean Med Labs Foundation; Vernita Maryat, Caribbean Community Regional Organisation for Standards and Quality; Mary Nagel, Laboratoire de Sante Publique en Haiti; Marsha Samaroo, Ministry of Health, Republic of Trinidad & Tobago; David Turgeon, US Centers for Disease Control and Prevention; and Valerie Wilson, Caribbean Med Labs Foundation). The WHO AFRO SLIPTA process also played an important role in the development of this framework, since the WHO AFRO SLIPTA guidance document was used as a template for conceptualising the LQMS-SIP. NR 20 TC 0 Z9 0 U1 0 U2 0 PU AOSIS PI CAPE TOWN PA POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA SN 2225-2002 EI 2225-2010 J9 AFR J LAB MED JI Afr. J. Lab. Med. PD FEB 24 PY 2017 VL 6 IS 1 AR a496 DI 10.4102/ajlm.v6i1.496 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EP0TM UT WOS:000397099600001 ER PT J AU Okoro, CA Zhao, GX Fox, JB Eke, PI Greenland, KJ Town, M AF Okoro, Catherine A. Zhao, Guixiang Fox, Jared B. Eke, Paul I. Greenland, Kurt J. Town, Machell TI Surveillance for Health Care Access and Health Services Use, Adults Aged 18-64 Years-Behavioral Risk Factor Surveillance System, United States, 2014 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID DEPENDENT COVERAGE EXPANSION; CLINICAL PREVENTIVE SERVICES; YOUNG-ADULTS; INSURANCE-COVERAGE; OREGON EXPERIMENT; MENTAL-HEALTH; ACT; MORTALITY; MEDICAID; REFORM AB Problem/Condition: As a result of the 2010 Patient Protection and Affordable Care Act, millions of U.S. adults attained health insurance coverage. However, millions of adults remain uninsured or underinsured. Compared with adults without barriers to health care, adults who lack health insurance coverage, have coverage gaps, or skip or delay care because of limited personal finances might face increased risk for poor physical and mental health and premature mortality. Period Covered: 2014. Description of System: The Behavioral Risk Factor Surveillance System (BRFSS) is an ongoing, state-based, landline- and cellular-telephone survey of noninstitutionalized adults aged 18 years residing in the United States. Data are collected from states, the District of Columbia, and participating U.S. territories on health risk behaviors, chronic health conditions, health care access, and use of clinical preventive services (CPS). An optional Health Care Access module was included in the 2014 BRFSS. This report summarizes 2014 BRFSS data from all 50 states and the District of Columbia on health care access and use of selected CPS recommended by the U.S. Preventive Services Task Force or the Advisory Committee on Immunization Practices among working-aged adults (aged 18-64 years), by state, state Medicaid expansion status, expanded geographic region, and federal poverty level (FPL). This report also provides analysis of primary type of health insurance coverage at the time of interview, continuity of health insurance coverage during the preceding 12 months, and other health care access measures (i.e., unmet health care need because of cost, unmet prescription need because of cost, medical debt [medical bills being paid off over time], number of health care visits during the preceding year, and satisfaction with received health care) from 43 states that included questions from the optional BRFSS Health Care Access module. Results: In 2014, health insurance coverage and other health care access measures varied substantially by state, state Medicaid expansion status, expanded geographic region (i.e., states categorized geographically into nine regions), and FPL category. The following proportions refer to the range of estimated prevalence for health insurance and other health care access measures by examined geographical unit (unless otherwise specified), as reported by respondents. Among adults with health insurance coverage, the range was 70.8%-94.5% for states, 78.8%-94.5% for Medicaid expansion states, 70.8%-89.1% for nonexpansion states, 73.3%-91.0% for expanded geographic regions, and 64.2%-95.8% for FPL categories. Among adults who had a usual source of health care, the range was 57.2%-86.6% for states, 57.2%-86.6% for Medicaid expansion states, 61.8%-83.9% for nonexpansion states, 64.4%-83.6% for expanded geographic regions, and 61.0%-81.6% for FPL categories. Among adults who received a routine checkup, the range was 52.1%-75.5% for states, 56.0%-75.5% for Medicaid expansion states, 52.1%-71.1% for nonexpansion states, 56.8%-70.2% for expanded geographic regions, and 59.9%-69.2% for FPL categories. Among adults who had unmet health care need because of cost, the range was 8.0%-23.1% for states, 8.0%-21.9% for Medicaid expansion states, 11.9%-23.1% for nonexpansion states, 11.6%-20.3% for expanded geographic regions, and 5.3%-32.9% for FPL categories. Estimated prevalence of cancer screenings, influenza vaccination, and having ever been tested for human immunodeficiency virus also varied by state, state Medicaid expansion status, expanded geographic region, and FPL category. The prevalence of insurance coverage varied by approximately 25 percentage points among racial/ethnic groups (range: 63.9% among Hispanics to 88.4% among non-Hispanic Asians) and by approximately 32 percentage points by FPL category (range: 64.2% among adults with household income <100% of FPL to 95.8% among adults with household income >400% of FPL). The prevalence of unmet health care need because of cost varied by nearly 14 percentage points among racial/ethnic groups (range: 11.3% among non-Hispanic Asians to 25.0% among Hispanics), by approximately 17 percentage points among adults with and without disabilities (30.8% versus 13.7%), and by approximately 28 percentage points by FPL category (range: 5.3% among adults with household income >400% of FPL to 32.9% among adults with household income <100% of FPL). Among the 43 states that included questions from the optional module, a majority of adults reported private health insurance coverage (63.4%), followed by public health plan coverage (19.4%) and no primary source of insurance (17.1%). Financial barriers to health care (unmet health care need because of cost, unmet prescribed medication need because of cost, and medical bills being paid off over time [medical debt]) were typically lower among adults in Medicaid expansion states than those in nonexpansion states regardless of source of insurance. Approximately 75.6% of adults reported being continuously insured during the preceding 12 months, 12.9% reported a gap in coverage, and 11.5% reported being uninsured during the preceding 12 months. The largest proportion of adults reported >= 3 visits to a health care professional during the preceding 12 months (47.3%), followed by 1-2 visits (37.1%), and no health care visits (15.6%). Adults in expansion and nonexpansion states reported similar levels of satisfaction with received health care by primary source of health insurance coverage and by continuity of health insurance coverage during the preceding 12 months. Interpretation: This report presents for the first time estimates of population-based health care access and use of CPS among adults aged 18-64 years. The findings in this report indicate substantial variations in health insurance coverage; other health care access measures; and use of CPS by state, state Medicaid expansion status, expanded geographic region, and FPL category. In 2014, health insurance coverage, having a usual source of care, having a routine checkup, and not experiencing unmet health care need because of cost were higher among adults living below the poverty level (i.e., household income <100% of FPL) in states that expanded Medicaid than in states that did not. Similarly, estimates of breast and cervical cancer screening and influenza vaccination were higher among adults living below the poverty level in states that expanded Medicaid than in states that did not. These disparities might be due to larger differences to begin with, decreased disparities in Medicaid expansion states versus nonexpansion states, or increased disparities in nonexpansion states. Public Health Action: BRFSS data from 2014 can be used as a baseline by which to assess and monitor changes that might occur after 2014 resulting from programs and policies designed to increase access to health care, reduce health disparities, and improve the health of the adult population. Post-2014 changes in health care access, such as source of health insurance coverage, attainment and continuity of coverage, financial barriers, preventive care services, and health outcomes, can be monitored using these baseline estimates. C1 [Okoro, Catherine A.; Zhao, Guixiang; Town, Machell] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Populat Hlth Surveillance Branch, Atlanta, GA 30333 USA. [Fox, Jared B.] CDC, Policy Res Anal & Dev Off, Atlanta, GA 30333 USA. [Eke, Paul I.; Greenland, Kurt J.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. RP Okoro, CA (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. EM cokoro@cdc.gov NR 54 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD FEB 24 PY 2017 VL 66 IS 7 BP 1 EP 41 PG 41 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP0KD UT WOS:000397075300001 PM 28231239 ER PT J AU Minchella, PA Chipungu, G Kim, AA Sarr, A Ali, H Mwenda, R Nkengasong, JN Singer, D AF Minchella, Peter A. Chipungu, Geoffrey Kim, Andrea A. Sarr, Abdoulaye Ali, Hammad Mwenda, Reuben Nkengasong, John N. Singer, Daniel TI Specimen origin, type and testing laboratory are linked to longer turnaround times for HIV viral load testing in Malawi SO PLOS ONE LA English DT Article ID RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL TREATMENT; MORTALITY; QUALITY; THERAPY; AFRICA AB Background Efforts to reach UNAIDS' treatment and viral suppression targets have increased demand for viral load (VL) testing and strained existing laboratory networks, affecting turnaround time. Longer VL turnaround times delay both initiation of formal adherence counseling and switches to second-line therapy for persons failing treatment and contribute to poorer health outcomes. Methods We utilized descriptive statistics and logistic regression to analyze VL testing data collected in Malawi between January 2013 and March 2016. The primary outcomes assessed were greater-than-median pretest phase turnaround time (days elapsed from specimen collection to receipt at the laboratory) and greater-than-median test phase turnaround time (days from receipt to testing). Results The median number of days between specimen collection and testing increased 3-fold between 2013 (8 days, interquartile range (IQR) = 6-16) and 2015 (24, IQR = 13-39) (p<0.001). Multivariable analysis indicated that the odds of longer pretest phase turnaround time were significantly higher for specimen collection districts without laboratories capable of conducting viral load tests (adjusted odds ratio (aOR) = 5.16; 95% confidence interval (CI) = 5.04-5.27) as well as for Malawi's Northern and Southern regions. Longer test phase turnaround time was significantly associated with use of dried blood spots instead of plasma (aOR = 2.30; 95% CI = 2.23-2.37) and for certain testing months and testing laboratories. Conclusion Increased turnaround time for VL testing appeared to be driven in part by categorical factors specific to the phase of turnaround time assessed. Given the implications of longer turnaround time and the global effort to scale up VL testing, addressing these factors via increasing efficiencies, improving quality management systems and generally strengthening the VL spectrum should be considered essential components of controlling the HIV epidemic. C1 [Minchella, Peter A.] Ctr Dis Control & Prevent, Lab Leadership Serv, Div Global HIV & TB, Atlanta, GA 30333 USA. [Chipungu, Geoffrey; Sarr, Abdoulaye; Singer, Daniel] Ctr Dis Control & Prevent, Div Global HIV & TB, Lilongwe, Malawi. [Kim, Andrea A.; Ali, Hammad; Nkengasong, John N.] Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA USA. [Mwenda, Reuben] Minist Hlth, Lilongwe, Malawi. RP Minchella, PA (reprint author), Ctr Dis Control & Prevent, Lab Leadership Serv, Div Global HIV & TB, Atlanta, GA 30333 USA. EM klf9@cdc.gov; remwenda@yahoo.com FU U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC), Division of Global HIV and Tuberculosis (DGHT) FX This publication was made possible by support from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC), Division of Global HIV and Tuberculosis (DGHT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 24 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 24 PY 2017 VL 12 IS 2 AR e0173009 DI 10.1371/journal.pone.0173009 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EL5VB UT WOS:000394688200185 ER PT J AU Njenga, SM Kanyi, HM Mutungi, FM Okoyo, C Matendechero, HS Pullan, RL Halliday, KE Brooker, SJ Wamae, CN Onsongo, JK Won, KY AF Njenga, Sammy M. Kanyi, Henry M. Mutungi, Faith M. Okoyo, Collins Matendechero, Hadley S. Pullan, Rachel L. Halliday, Katherine E. Brooker, Simon J. Wamae, C. Njeri Onsongo, Joyce K. Won, Kimberly Y. TI Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya SO PARASITES & VECTORS LA English DT Article DE Lymphatic filariasis; Wuchereria bancrofti; Transmission assessment; Cross-sectional study; ICT test; Circulating filarial antigen; Microfilariae; Kenya ID BANCROFTIAN FILARIASIS; WUCHERERIA-BANCROFTI; VECTOR CONTROL; CONTINUING TRANSMISSION; CULEX-QUINQUEFASCIATUS; COUNTING CHAMBER; MALARIA CONTROL; GLOBAL PROGRAM; MOSQUITO NETS; WEST-AFRICA AB Background: Lymphatic filariasis (LF) is a debilitating disease associated with extensive disfigurement and is one of a diverse group of diseases referred to as neglected tropical diseases (NTDs) which mainly occur among the poorest populations. In line with global recommendations to eliminate LF, Kenya launched its LF elimination programme in 2002 with the aim to implement annual mass drug administration (MDA) in order to interrupt LF transmission. However, the programme faced financial and administrative challenges over the years such that sustained annual MDA was not possible. Recently, there has been renewed interest to eliminate LF and the Kenyan Ministry of Health, through support from World Health Organization (WHO), restarted annual MDA in 2015. The objective of this study was to evaluate the current status of LF infection in the endemic coastal region of Kenya before MDA campaigns were restarted. Results: Ten sentinel sites in Kwale, Kilifi, Tana River, Lamu, and Taita-Taveta counties in coastal Kenya were selected for participation in a cross-sectional survey of LF infection prevalence. At least 300 individuals in each sentinel village were sampled through random house-to-house visits. During the day, the point-of-care immunochromatographic test (ICT) was used to detect the presence of Wuchereria bancrofti circulating filarial antigen in finger prick blood samples collected from residents of the selected sentinel villages. Those individuals who tested positive with the ICT test were requested to provide a night-time blood sample for microfilariae (MF) examination. The overall prevalence of filarial antigenaemia was 1.3% (95% CI: 0.9-1.8%). Ndau Island in Lamu County had the highest prevalence (6.3%; 95% CI: 4.1-9.7%), whereas sites in Kilifi and Kwale counties had prevalences < 1.7%. Mean microfilarial density was also higher in Ndau Island (234 MF/ml) compared to sentinel sites in Kwale and Kilifi counties (< 25 MF/ml). No LF infection was detected in Tana River and Taita-Taveta counties. Overall, more than 88% of the study participants reported to have used a bed net the previous night. Conclusions: Prevalence of LF infection is generally very low in coastal Kenya, but there remain areas that require further rounds of MDA if the disease is to be eliminated as a public health problem in line with the ongoing global elimination efforts. However, areas where there was no evidence of LF transmission should be considered for WHO-recommended transmission assessment surveys in view of stopping MDA. C1 [Njenga, Sammy M.; Kanyi, Henry M.; Mutungi, Faith M.; Okoyo, Collins] Kenya Govt Med Res Ctr, Eastern & Southern Africa Ctr Int Parasite Contro, Nairobi, Kenya. [Matendechero, Hadley S.] Minist Hlth, Neglected Trop Dis Unit, Nairobi, Kenya. [Pullan, Rachel L.; Halliday, Katherine E.; Brooker, Simon J.] London Sch Hyg & Trop Med, London, England. [Wamae, C. Njeri] WHO Country Off, Nairobi, Kenya. [Onsongo, Joyce K.] Mt Kenya Univ, Sch Med, Dept Microbiol, Thika, Kenya. [Won, Kimberly Y.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Njenga, SM (reprint author), Kenya Govt Med Res Ctr, Eastern & Southern Africa Ctr Int Parasite Contro, Nairobi, Kenya. EM sammynjenga@gmail.com FU WHO-AFRO office; Bill and Melinda Gates Foundation [OPP1033751]; DFID/MRC/Wellcome Trust global health trials scheme [MR/M021289/1]; Children's Investment Fund Foundation; Wellcome Trust Senior Fellowship in Basic Biomedical Science [098045]; Task Force for Global Health through NTD Support Center, USA FX This study was supported by grant provided by the WHO-AFRO office to the Kenya Medical Research Institute (KEMRI) through the WHO country office. The London School of Hygiene and Tropical Medicine through TUMIKIA Project, which is funded by the Bill and Melinda Gates Foundation (#OPP1033751), the DFID/MRC/Wellcome Trust global health trials scheme (MR/M021289/1) and the Children's Investment Fund Foundation, provided field supplies. SJB was supported by a Wellcome Trust Senior Fellowship in Basic Biomedical Science (098045), which also supports RLP and KEH. The Task Force for Global Health through NTD Support Center, USA provided funds fopr serology work linked to this study. The funders, however, had no role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. NR 40 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD FEB 22 PY 2017 VL 10 AR 99 DI 10.1186/s13071-017-2044-5 PG 9 WC Parasitology SC Parasitology GA EN9QD UT WOS:000396333800001 PM 28228160 ER PT J AU Alan, H Ian, B Nancy, C Ruben, OD Siddhivinayak, H Daniel, J Jacqueline, K John, M Fernando, M Takato, O Tam, JS Anthony, W Richard, W Thedi, Z Zhang, WQ AF Alan, Hampson Ian, Barr Nancy, Cox Ruben, Donis O. Siddhivinayak, Hirve Daniel, Jernigan Jacqueline, Katz John, McCauley Fernando, Motta Takato, Odagiri Tam, John S. Anthony, Waddell Richard, Webby Thedi, Ziegler Zhang Wenqing TI Improving the selection and development of influenza vaccine viruses Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015 SO VACCINE LA English DT Article DE Influenza vaccines; Surveillance; Antigenic drift; Pandemic influenza ID HEMAGGLUTININ-STEM; NEURAMINIDASE; ANTIBODY; PROTECTION; EVOLUTION; HUMANS AB Since 2010 the WHO has held a series of informal consultations to explore ways of improving the currently highly complex and time-pressured influenza vaccine virus selection and development process. In November 2015 experts from around the world met to review the current status of efforts in this field. Discussion topics included strengthening influenza surveillance activities to increase the availability of candidate vaccine viruses and improve the extent, timeliness and quality of surveillance data. Consideration was also given to the development and potential application of newer laboratory assays to better characterize candidate vaccine viruses, the potential importance of antibodies directed against influenza virus neuraminidase, and the role of vaccine effectiveness studies. Advances in next generation sequencing and whole genome sequencing of influenza viruses were also discussed, along with associated developments in synthetic genomics technologies, evolutionary analysis and predictive mathematical modelling. Discussions were also held on the late emergence of an antigenic variant influenza A(H3N2) virus in mid-2014 that could not be incorporated in time into the 2014-15 northern hemisphere vaccine. There was broad recognition that given the current highly constrained influenza vaccine development and production timeline it would remain impossible to incorporate any variant virus which emerged significantly long after the relevant WHO biannual influenza vaccine composition meetings. Discussions were also held on the development of pandemic and broadly protective vaccines, and on associated regulatory and manufacturing requirements and constraints. With increasing awareness of the health and economic burdens caused by seasonal influenza, the everpresent threat posed by zoonotic influenza viruses, and the significant impact of the 2014-15 northern hemisphere seasonal influenza vaccine mismatch, this consultation provided a very timely opportunity to share developments and exchange views. In all areas, a renewed and strengthened emphasis was placed on developing concrete and measurable actions and identifying the key stakeholders responsible for their implementation. (C) 2017 The Authors. Published by Elsevier Ltd. C1 [Alan, Hampson] Interflu Pty Ltd, Mitcham, Vic, Australia. [Ian, Barr] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. [Nancy, Cox; Daniel, Jernigan; Jacqueline, Katz] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ruben, Donis O.] US Dept HHS, BARDA, ASPR, Washington, DC 20201 USA. [Siddhivinayak, Hirve; Thedi, Ziegler; Zhang Wenqing] WHO, Global Influenza Programme, Ave Appia 20, CH-1211 Geneva, Switzerland. [John, McCauley] Francis Crick Inst, London, England. [Fernando, Motta] Inst Oswaldo Cruz, Rio De Janeiro, Brazil. [Takato, Odagiri] Natl Inst Infect Dis, Tokyo, Japan. [Tam, John S.] Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R China. [Richard, Webby] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA. RP Siddhivinayak, H (reprint author), WHO, Global Influenza Programme, Ave Appia 20, CH-1211 Geneva, Switzerland. EM interflu@bigpond.net.au; Ian.Barr@influenzacentre.org; njcl@cdc.gov; Ruben.Donis@hhs.gov; hirves@who.int; dbj0@cdc.gov; jmk9@cdc.gov; John.McCauley@crick.ac.uk; fcm@ioc.fiocruz.br; todagiri@nih.go.jp; johntam64@yahoo.com; waddell.t@btinternet.com; richard.webby@stjude.org; thedi.ziegler@utu.fi; zhangw@who.int NR 24 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 22 PY 2017 VL 35 IS 8 BP 1104 EP 1109 DI 10.1016/j.vaccine.2017.01.018 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EL2UP UT WOS:000394476000003 PM 28131392 ER PT J AU Vazquez-Cintron, EJ Beske, PH Tenezaca, L Tran, BQ Oyler, JM Glotfelty, EJ Angeles, CA Syngkon, A Mukherjee, J Kalb, SR Band, PA McNutt, PM Shoemaker, CB Ichtchenko, K AF Vazquez-Cintron, Edwin J. Beske, Phillip H. Tenezaca, Luis Tran, Bao Q. Oyler, Jonathan M. Glotfelty, Elliot J. Angeles, Christopher A. Syngkon, Aurelia Mukherjee, Jean Kalb, Suzanne R. Band, Philip A. McNutt, Patrick M. Shoemaker, Charles B. Ichtchenko, Konstantin TI Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery SO SCIENTIFIC REPORTS LA English DT Article ID BIOLOGICAL-ACTIVITY; GANGLIOSIDES; BINDING; PROTEIN; TOXIN; MOUSE; EXPRESSION; SURVIVAL; RECEPTOR; HYBRID AB Botulinum neurotoxin (BoNT) binds to and internalizes its light chain into presynaptic compartments with exquisite specificity. While the native toxin is extremely lethal, bioengineering of BoNT has the potential to eliminate toxicity without disrupting neuron-specific targeting, thereby creating a molecular vehicle capable of delivering therapeutic cargo into the neuronal cytosol. Building upon previous work, we have developed an atoxic derivative (ad) of BoNT/C1 through rationally designed amino acid substitutions in the metalloprotease domain of wild type (wt) BoNT/C1. To test if BoNT/C1 ad retains neuron-specific targeting without concomitant toxic host responses, we evaluated the localization, activity, and toxicity of BoNT/C1 ad in vitro and in vivo. In neuronal cultures, BoNT/C1 ad light chain is rapidly internalized into presynaptic compartments, but does not cleave SNARE proteins nor impair spontaneous neurotransmitter release. In mice, systemic administration resulted in the specific co-localization of BoNT/C1 ad with diaphragmatic motor nerve terminals. The mouse LD50 of BoNT/C1 ad is 5 mg/kg, with transient neurological symptoms emerging at sub-lethal doses. Given the low toxicity and highly specific neuron-targeting properties of BoNT/C1 ad, these data suggest that BoNT/C1 ad can be useful as a molecular vehicle for drug delivery to the neuronal cytoplasm. C1 [Vazquez-Cintron, Edwin J.; Tenezaca, Luis; Angeles, Christopher A.; Syngkon, Aurelia; Band, Philip A.; Ichtchenko, Konstantin] NYU, Dept Biochem & Mol Pharmacol, Sch Med, New York, NY 10016 USA. [Vazquez-Cintron, Edwin J.; Tenezaca, Luis; Band, Philip A.] CytoDel LLC, New York, NY 10027 USA. [Vazquez-Cintron, Edwin J.; Beske, Phillip H.; Oyler, Jonathan M.; Glotfelty, Elliot J.; McNutt, Patrick M.] US Army Med Res Inst Chem Def, Aberdeen Proving Ground, MD 21010 USA. [Tran, Bao Q.] Excet Inc, 6225 Brandon Ave,Suite 360, Springfield, VA 22150 USA. [Mukherjee, Jean; Shoemaker, Charles B.] Tufts Univ, Dept Infect Dis & Global Hlth, Clin & Translat Sci Inst, North Grafton, MA 01536 USA. [Kalb, Suzanne R.] Ctr Dis Control & Prevent, Natl Ctr Environm Health, Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. [Band, Philip A.] NYU, Dept Orthopaed Surg, Hosp Joint Dis, New York, NY 10016 USA. RP Ichtchenko, K (reprint author), NYU, Dept Biochem & Mol Pharmacol, Sch Med, New York, NY 10016 USA. EM Konstantin.Ichtchenko@nyumc.org FU NIAID [R01AI093504, R01AI093467] FX This study was supported by NIAID awards R01AI093504 to K.I. and R01AI093467 to C.B.S. We thank Dr. Eric A. Johnson (University of Wisconsin at Madison) for providing wt BoNT/C1, Drs. Jianlong Lou and James Marks (University of California at San Francisco) for providing the monoclonal antibodies against BoNT/C1 used in the laboratory of K.I. for this study. We are also grateful for the thoughts generated as a result of discussion with Dr. Cesare Montecucco (University of Padova, Italy). The authors also thank Dr. Eric Milner for reading and careful editing of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 43 TC 0 Z9 0 U1 3 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD FEB 21 PY 2017 VL 7 AR 42923 DI 10.1038/srep42923 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EL3EP UT WOS:000394502700001 PM 28220863 ER PT J AU Ko, JY Rockhill, KM AF Ko, Jean Y. Rockhill, Karilynn M. TI Trends in Postpartum Depressive Symptoms --27 States, 2004, 2008, and 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; WOMEN; AGE C1 [Ko, Jean Y.; Rockhill, Karilynn M.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. US DOE, Oak Ridge Inst Sci & Educ, Washington, DC 20585 USA. CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Ko, JY (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM JeanKo@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 17 PY 2017 VL 66 IS 6 BP 153 EP 158 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3ZZ UT WOS:000394561000001 PM 28207685 ER PT J AU Blanton, L Mustaquim, D Alabi, N Kniss, K Kramer, N Budd, A Garg, S Cummings, CN Fry, AM Bresee, J Sessions, W Garten, R Xu, X Abd Elal, AI Gubareva, L Barnes, J Wentworth, DE Burns, E Katz, J Jernigan, D Brammer, L AF Blanton, Lenee Mustaquim, Desiree Alabi, Noreen Kniss, Krista Kramer, Natalie Budd, Alicia Garg, Shilrha Cummings, Charisse N. Fry, Alicia M. Bresee, Joseph Sessions, Wendy Garten, Rebecca Xu, Xiyan Abd Elal, Anwar Isa Gubareva, Larisa Barnes, John Wentworth, David E. Burns, Erin Katz, Jacqueline Jernigan, Daniel Brammer, Lynnette TI Update: Influenza Activity - United States, October 2, 2016-February 4, 2017 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Blanton, Lenee; Mustaquim, Desiree; Alabi, Noreen; Kniss, Krista; Kramer, Natalie; Budd, Alicia; Garg, Shilrha; Cummings, Charisse N.; Fry, Alicia M.; Bresee, Joseph; Sessions, Wendy; Garten, Rebecca; Xu, Xiyan; Abd Elal, Anwar Isa; Gubareva, Larisa; Barnes, John; Wentworth, David E.; Burns, Erin; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Blanton, L (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM LBlanton@cdc.gov NR 5 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 17 PY 2017 VL 66 IS 6 BP 159 EP 166 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3ZZ UT WOS:000394561000002 PM 28207684 ER PT J AU Flannery, B Chung, JR Thaker, SN Monto, AS Martin, ET Belongia, EA McLean, HQ Gaglani, M Murthy, K Zimmerman, RK Nowalk, MP Jackson, ML Jackson, LA Foust, A Sessions, W Berman, L Spencer, S Fry, AM AF Flannery, Brendan Chung, Jessie R. Thaker, Swathi N. Monto, Arnold S. Martin, Emily T. Belongia, Edward A. McLean, Huong Q. Gaglani, Manjusha Murthy, Kempapura Zimmerman, Richard K. Nowalk, Mary Patricia Jackson, Michael L. Jackson, Lisa A. Foust, Angie Sessions, Wendy Berman, LaShondra Spencer, Sarah Fry, Alicia M. TI Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PROTECTION; VIRUSES; A(H3N2) C1 [Flannery, Brendan; Chung, Jessie R.; Thaker, Swathi N.; Foust, Angie; Sessions, Wendy; Berman, LaShondra; Spencer, Sarah; Fry, Alicia M.] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Monto, Arnold S.; Martin, Emily T.] Univ Michigan, Ann Arbor, MI 48109 USA. [Belongia, Edward A.; McLean, Huong Q.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Gaglani, Manjusha; Murthy, Kempapura] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Baylor Scott & White Hlth, Temple, TX 76508 USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia] Univ Pittsburgh, Sch Hlth Sci, Pittsburgh, PA USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Jackson, Michael L.; Jackson, Lisa A.] Grp Hlth Res Inst, Seattle, WA USA. RP Flannery, B (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM bif4@cdc.gov FU NCIRD CDC HHS [U01 IP001037] NR 10 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 17 PY 2017 VL 66 IS 6 BP 167 EP 171 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3ZZ UT WOS:000394561000003 PM 28207689 ER PT J AU Journel, I Andrecy, LL Metellus, D Pierre, JS Faublas, RM Jain, S Dismer, AM Fitter, DL Neptune, D Laraque, MJ Corvil, S Pierre, M Buteau, J Lafontant, D Patel, R Lemoine, JF Lowrance, DW Charles, M Boncy, J Adrien, P AF Journel, Ito Andrecy, Lesly L. Metellus, Dudley Pierre, Jean S. Faublas, Rose Murka Jain, Stanley Dismer, Amber M. Fitter, David L. Neptune, Daniel Laraque, Marie Jose Corvil, Salomon Pierre, Manise Buteau, Josiane Lafontant, Donald Patel, Roopal Lemoine, Jean Frantz Lowrance, David W. Charles, Macarthur Boncy, Jacques Adrien, Paul TI Transmission of Zika Virus - Haiti, October 12, 2015-September 10, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Journel, Ito; Laraque, Marie Jose; Buteau, Josiane; Lafontant, Donald; Boncy, Jacques] Natl Lab Publ Hlth, Port Au Prince, Haiti. [Andrecy, Lesly L.; Metellus, Dudley; Pierre, Jean S.; Faublas, Rose Murka; Neptune, Daniel; Laraque, Marie Jose; Corvil, Salomon; Adrien, Paul] Directorate Epidemiol Lab & Res, Port Au Prince, Haiti. [Jain, Stanley; Fitter, David L.; Pierre, Manise; Patel, Roopal; Charles, Macarthur] CDC, Port Au Prince, Haiti. [Dismer, Amber M.] CDC, Div Global Hlth Protect, Atlanta, GA 30333 USA. [Lemoine, Jean Frantz] Natl Malaria Control Program, Port Au Prince, Haiti. [Lowrance, David W.] CDC, Dar Es Salaam, Tanzania. RP Adrien, P (reprint author), Directorate Epidemiol Lab & Res, Port Au Prince, Haiti. EM padrien2004@yahoo.fr NR 8 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 17 PY 2017 VL 66 IS 6 BP 172 EP 176 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3ZZ UT WOS:000394561000004 PM 28207688 ER PT J AU Narra, R Maeda, JM Temba, H Mghamba, J Nyanga, A Greiner, AL Bakari, M Beer, KD Chae, SR Curran, KG Eidex, RB Gibson, JJ Handzel, T Kiberiti, SJ Kishimba, RS Lukupulo, H Malibiche, T Massa, K Massay, AE McCrickard, LS Mchau, GJ Mmbaga, V Mohamed, AA Mwakapeje, ER Nestory, E Newton, AE Oyugi, E Rajasingham, A Roland, ME Rusibamayila, N Sembuche, S Urio, LJ Walker, TA Wang, A Quick, RE AF Narra, Rupa Maeda, Justin M. Temba, Herilinda Mghamba, Janneth Nyanga, Ali Greiner, Ashley L. Bakari, Muhammad Beer, Karlyn D. Chae, Sae-Rom Curran, Kathryn G. Eidex, Rachel B. Gibson, James J. Handzel, Thomas Kiberiti, Stephen J. Kishimba, Rogath S. Lukupulo, Haji Malibiche, Theophil Massa, Khalid Massay, Amani E. McCrickard, Lindsey S. Mchau, Geofrey J. Mmbaga, Vida Mohamed, Ahmed A. Mwakapeje, Elibariki R. Nestory, Emmanuel Newton, Anna E. Oyugi, Elvis Rajasingham, Anu Roland, Michelle E. Rusibamayila, Neema Sembuche, Senga Urio, Loveness J. Walker, Tiffany A. Wang, Alice Quick, Robert E. TI Ongoing Cholera Epidemic - Tanzania, 2015-2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Narra, Rupa; Greiner, Ashley L.; Beer, Karlyn D.; Chae, Sae-Rom; Curran, Kathryn G.; McCrickard, Lindsey S.; Walker, Tiffany A.; Wang, Alice] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Narra, Rupa; Beer, Karlyn D.; Chae, Sae-Rom; Curran, Kathryn G.; McCrickard, Lindsey S.; Newton, Anna E.; Walker, Tiffany A.; Quick, Robert E.] CDC, Div Foodbome Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Maeda, Justin M.; Temba, Herilinda; Mghamba, Janneth; Nyanga, Ali; Bakari, Muhammad; Kiberiti, Stephen J.; Malibiche, Theophil; Massa, Khalid; Mchau, Geofrey J.; Mmbaga, Vida; Mwakapeje, Elibariki R.; Rusibamayila, Neema] Tanzanian Minist Hlth Community Dev Gender Elderl, Dar Es Salaam, Tanzania. [Greiner, Ashley L.; Handzel, Thomas; Rajasingham, Anu] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Eidex, Rachel B.; Gibson, James J.; Roland, Michelle E.] CDC Tanzania, Dar Es Salaam, Tanzania. [Kishimba, Rogath S.; Lukupulo, Haji; Massay, Amani E.; Mohamed, Ahmed A.; Nestory, Emmanuel; Sembuche, Senga; Urio, Loveness J.] Tanzania Field Epidemiol & Lab Training Program, Dar Es Salaam, Tanzania. [Oyugi, Elvis] Kenya Field Epidemiol & Lab Training Program, Nairobi, Kenya. [Wang, Alice] CDC, Off Noncommunicable Dis Injury & Environm Hlth, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Narra, R (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Narra, R (reprint author), CDC, Div Foodbome Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM rnarra@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 17 PY 2017 VL 66 IS 6 BP 177 EP 178 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3ZZ UT WOS:000394561000005 PM 28207686 ER PT J AU Requena, P Arevalo-Herrera, M Menegon, M Martinez-Espinosa, FE Padilla, N Botto-Menezes, C Malheiro, A Hans, D Castellanos, ME Robinson, L Samol, P Kochar, S Kochar, SK Kochar, DK Desai, M Sanz, S Quinto, L Mayor, A Rogerson, S Mueller, I Severini, C del Portillo, HA Bardaji, A Chitnis, CC Menendez, C Dobano, C AF Requena, Pilar Arevalo-Herrera, Myriam Menegon, Michela Martinez-Espinosa, Flor E. Padilla, Norma Botto-Menezes, Camila Malheiro, Adriana Hans, Dhiraj Eugenia Castellanos, Maria Robinson, Leanne Samol, Paula Kochar, Swati Kochar, Sanjay K. Kochar, Dhanpat K. Desai, Meghna Sanz, Sergi Quinto, Llorenc Mayor, Alfredo Rogerson, Stephen Mueller, Ivo Severini, Carlo del Portillo, Hernando A. Bardaji, Azucena Chitnis, Chetan C. Menendez, Clara Dobano, Carlota TI Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein in Pregnant Women Are Associated with Higher Birth Weight in a Multicenter Study SO FRONTIERS IN IMMUNOLOGY LA English DT Article DE malaria in pregnancy; vivax; falciparum; immunity; antibodies; T cell; cytokines; PvDBP ID FALCIPARUM-INFECTED ERYTHROCYTES; PAPUA-NEW-GUINEA; IMMUNE-RESPONSES; BLOOD-STAGE; CIRCUMSPOROZOITE PROTEIN; VARIANT ANTIGENS; MALARIA; SURFACE; VACCINE; IMMUNOGENICITY AB A vaccine to eliminate malaria would need a multi-stage and multi-species composition to achieve robust protection, but the lack of knowledge about antigen targets and mechanisms of protection precludes the development of fully efficacious malaria vaccines, especially for Plasmodium vivax (Pv). Pregnant women constitute a risk population who would greatly benefit from a vaccine preventing the adverse events of Plasmodium infection during gestation. We hypothesized that functional immune responses against putative targets of naturally acquired immunity to malaria and vaccine candidates will be associated with protection against malaria infection and/or poor outcomes during pregnancy. We measured (i) IgG responses to a large panel of Pv and Plasmodium falciparum (Pf) antigens, (ii) the capacity of anti-Pv ligand Duffy binding protein (PvDBP) antibodies to inhibit binding to Duffy antigen, and (iii) cellular immune responses to two Pv antigens, in a subset of 1,056 pregnant women from Brazil, Colombia, Guatemala, India, and Papua New Guinea (PNG). There were significant intraspecies and interspecies correlations for most antibody responses (e.g., PfMSP1(19) versus PfAMA1, Spearman's rho = 0.81). Women from PNG and Colombia had the highest levels of IgG overall. Submicroscopic infections seemed sufficient to boost antibody responses in Guatemala but not antigen-specific cellular responses in PNG. Brazil had the highest percentage of Duffy binding inhibition (p-values versus Colombia: 0.040; Guatemala: 0.047; India: 0.003, and PNG: 0.153) despite having low anti-PvDBP IgG levels. Almost all antibodies had a positive association with present infection, and coinfection with the other species increased this association. Anti-PvDBP, anti-PfMSP1, and anti-PfAMA1 IgG levels at recruitment were positively associated with infection at delivery (p-values: 0.010, 0.003, and 0.023, respectively), suggesting that they are markers of malaria exposure. Peripheral blood mononuclear cells from Pv-infected women presented fewer CD8(+)IFN-gamma(+) T cells and secreted more G-CSF and IL-4 independently of the stimulus used in vitro. Functional anti-PvDBP levels at recruitment had a positive association with birth weight (difference per doubling antibody levels: 45 g, p-value: 0.046). Thus, naturally acquired binding-inhibitory antibodies to PvDBP might confer protection against poor outcomes of Pv malaria in pregnancy. C1 [Requena, Pilar; Sanz, Sergi; Quinto, Llorenc; Mayor, Alfredo; Mueller, Ivo; del Portillo, Hernando A.; Bardaji, Azucena; Menendez, Clara; Dobano, Carlota] Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Catalonia, Spain. [Arevalo-Herrera, Myriam] Univ Valle, Caucaseco Sci Res Ctr, Cali, Colombia. [Menegon, Michela; Severini, Carlo] Ist Super Sanita, Rome, Italy. [Martinez-Espinosa, Flor E.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil. [Martinez-Espinosa, Flor E.; Botto-Menezes, Camila] Fiocruz Amazonia, ILMD, Amazonia, Brazil. [Padilla, Norma; Eugenia Castellanos, Maria] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Botto-Menezes, Camila] Univ Estado Amazonas, Manaus, Amazonas, Brazil. [Malheiro, Adriana] Univ Fed Amazonas, Inst Ciencias Biol, Manaus, Amazonas, Brazil. [Hans, Dhiraj; Chitnis, Chetan C.] Int Ctr Genet Engn & Biotechnol, Delhi, India. [Robinson, Leanne; Samol, Paula] Papua New Guinea Inst Med Res, Madang, Papua N Guinea. [Robinson, Leanne] Macfarlane Burnet Inst Med Res, Melbourne, Vic, Australia. [Robinson, Leanne; Mueller, Ivo] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia. [Kochar, Swati; Kochar, Sanjay K.; Kochar, Dhanpat K.] Med Coll Bikaner, Bikaner, Rajasthan, India. [Desai, Meghna] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Rogerson, Stephen] Univ Melbourne, Melbourne, Vic, Australia. [del Portillo, Hernando A.] ICREA, Barcelona, Spain. RP Requena, P (reprint author), Univ Barcelona, Hosp Clin, Barcelona Ctr Int Hlth Res CRESIB, ISGlobal, Barcelona, Catalonia, Spain. EM pilar.requena.mendez@gmail.com; carlota.dobano@isglobal.org RI Dobano, Carlota/N-4119-2014 OI Dobano, Carlota/0000-0002-6751-4060 FU European Union Seventh Framework Programme [201588]; Ministerio de Economia y Competitividad (National R&D Internationalisation Programme, EUROSALUD, Spain) [EUS2009-03560]; CDC Foundation; Malaria in Pregnancy Consortium (MiPc); Bill & Melinda Gates Foundation [46099]; Ministerio de Economia y Competitividad [RYC-2008-02631]; Instituto de Salud Carlos III [CES10/021-I3SNS]; National Health and Medical Research Council Senior Research Fellowship [GNT1043345] FX The PREGVAX project received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 201588, and co-funding from the Ministerio de Economia y Competitividad (National R&D Internationalisation Programme, EUROSALUD 2008, Spain) under grant agreement EUS2009-03560. The Latin American sites received co-funding from the CDC Foundation, which received a grant from the Malaria in Pregnancy Consortium (MiPc) which is partially funded through a grant from the Bill & Melinda Gates Foundation to the Liverpool School of Tropical Medicine (46099). The studies in PNG also received co-funding from the MiPc. CD was supported by a fellowship from the Ministerio de Economia y Competitividad (RYC-2008-02631), AM was supported by Instituto de Salud Carlos III (CES10/021-I3SNS), and IM was supported by a National Health and Medical Research Council Senior Research Fellowship (GNT1043345). CD and HP were affiliate and full member, respectively, of the EU FP7 Network of Excellence EviMalaR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya. NR 71 TC 0 Z9 0 U1 2 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD FEB 17 PY 2017 VL 8 AR 163 DI 10.3389/fimmu.2017.00163 PG 16 WC Immunology SC Immunology GA EK7OP UT WOS:000394115400001 PM 28261219 ER PT J AU Kahende, J Malarcher, A England, L Zhang, L Mowery, P Xu, X Sevilimedu, V Rolle, I AF Kahende, Jennifer Malarcher, Ann England, Lucinda Zhang, Lei Mowery, Paul Xu, Xin Sevilimedu, Varadan Rolle, Italia TI Utilization of smoking cessation medication benefits among medicaid fee-for-service enrollees 1999-2008 SO PLOS ONE LA English DT Article ID NICOTINE REPLACEMENT THERAPY; SMOKERS; COVERAGE; QUIT; IMPACT; AIDS AB Objective To assess state coverage and utilization of Medicaid smoking cessation medication benefits among fee-for-service enrollees who smoked cigarettes. Methods We used the linked National Health Interview Survey (survey years 1995, 1997 - 2005) and the Medicaid Analytic eXtract files (1999 - 2008) to assess utilization of smoking cessation medication benefits among 5,982 cigarette smokers aged 18 - 64 years enrolled in Medicaid fee-for-service whose state Medicaid insurance covered at least one cessation medication. We excluded visits during pregnancy, and those covered by managed care or under dual enrollment (Medicaid and Medicare). Multivariate logistic regression was used to determine correlates of cessation medication benefit utilization among Medicaid fee-for-service enrollees, including measures of drug coverage (comprehensive cessation medication coverage, number of medications in state benefit, varenicline coverage), individual-level demographics at NHIS interview, age at Medicaid enrollment, and state-level cigarette excise taxes, statewide smoke-free laws, and per-capita tobacco control funding. Results In 1999, the percent of smokers with >= 1 medication claims was 5.7% in the 30 states that covered at least one Food and Drug Administration (FDA)-approved cessation medication; this increased to 9.9% in 2008 in the 44 states that covered at least one FDA-approved medication (p < 0.01). Cessation medication utilization was greater among older individuals ( >= 25 years), females, non-Hispanic whites, and those with higher educational attainment. Comprehensive coverage, the number of smoking cessation medications covered and varenicline coverage were all positively associated with utilization; cigarette excise tax and percapita tobacco control funding were also positively associated with utilization. Conclusions Utilization of medication benefits among fee-for-service Medicaid enrollees increased from 1999 - 2008 and varied by individual and state-level characteristics. Given that the Affordable Care Act bars state Medicaid programs from excluding any FDA-approved cessation medications from coverage as of January 2014, monitoring Medicaid cessation medication claims may be beneficial for informing efforts to increase utilization and maximize smoking cessation. C1 [Kahende, Jennifer; Malarcher, Ann; England, Lucinda; Zhang, Lei; Xu, Xin; Rolle, Italia] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Mowery, Paul; Sevilimedu, Varadan] Biostatistics Inc, Sarasota, FL USA. RP Kahende, J (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM izk7@cdc.gov FU Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion [4157-026]; Biostatistics, Inc. FX The Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion provided funding for this project (contract 4157-026). Through this funding, Biostatistics, Inc. served as a contractor to CDC for this project and did not provide any funding for the project. Biostatistics, Inc. provided support in the form of salaries for authors Paul Mowery and Varadan Sevilimedu, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 16 PY 2017 VL 12 IS 2 AR e0170381 DI 10.1371/journal.pone.0170381 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EL2BG UT WOS:000394424500010 ER PT J AU Patel, LN Arciuolo, RJ Fu, J Giancotti, FR Zucker, JR Rakeman, JL Rosen, JB AF Patel, Leena N. Arciuolo, Robert J. Fu, Jie Giancotti, Francesca R. Zucker, Jane R. Rakeman, Jennifer L. Rosen, Jennifer B. TI Mumps Outbreak Among a Highly Vaccinated University Community-New York City, January-April 2014 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE mumps; outbreak; parotitis; university; vaccination ID UNITED-STATES; COLLEGE-STUDENTS; POPULATION; RUBELLA; MEASLES; TRANSMISSION; PREVENTION; RESURGENCE; INFECTION; COVERAGE AB Background. On 14 January 2014, a vaccinated student presented with parotitis. Mumps immunoglobulin M (IgM) testing was negative and reverse-transcription polymerase chain reaction (RT-PCR) testing was not performed, resulting in a missed diagnosis and the start of an outbreak at a New York City (NYC) university. Methods. Mumps case investigations included patient interviews, medical records review, and laboratory testing including mumps serology and RT-PCR. Case patients were considered linked to the outbreak if they attended or had epidemiologic linkage to the university. Epidemiologic, clinical, and laboratory data for outbreak cases residing in NYC were analyzed. Results. Fifty-six NYC residents with mumps were identified with onset between 12 January and 30 April 2014. Fifty-three cases (95%) were university students, 1 (2%) was a staff member, and 2 (4%) had epidemiologic links to the university. The median age was 20 years (range 18-37 years). All cases had parotitis. Three cases were hospitalized, including 1 of 2 cases with orchitis. Fiftyfour (96%) cases had received >= 1 mumps-containing vaccine, 1 (2%) was unvaccinated due to religious exemption, and 1 (2%) had unknown vaccination status. Two of the 44 (5%) cases tested by serology were mumps IgM positive, and 27 of the 40 (68%) tested by RT-PCR were positive. Conclusions. Mumps outbreaks can occur in highly vaccinated populations. Mumps should be considered in patients with parotitis regardless of vaccination status. RT-PCR is the preferred testing method; providers should not rely on IgM testing alone. High vaccination coverage and control measures likely limited the extent of the outbreak. C1 [Patel, Leena N.] New York City Dept Hlth & Mental Hyg, Div Epidemiol, Publ Hlth Prevent Med Residency Program, Queens, NY USA. [Arciuolo, Robert J.; Zucker, Jane R.; Rosen, Jennifer B.] New York City Dept Hlth & Mental Hyg, Bur Immunizat, 42-09 28th St,CN 21, Queens, NY 11101 USA. [Arciuolo, Robert J.] Council State & Territorial Epidemiologists Appl, Atlanta, GA USA. [Fu, Jie; Giancotti, Francesca R.; Rakeman, Jennifer L.] New York City Dept Hlth & Mental Hyg, Publ Hlth Lab, Queens, NY USA. [Zucker, Jane R.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Atlanta, GA USA. RP Rosen, JB (reprint author), New York City Dept Hlth & Mental Hyg, Bur Immunizat, 42-09 28th St,CN 21, Queens, NY 11101 USA. EM jrosen4@health.nyc.gov FU Applied Epidemiology Fellowship Program; Centers for Disease Control and Prevention [5U38HM000414-5] FX This work was supported by the Applied Epidemiology Fellowship Program, administered by the Council of State and Territorial Epidemiologists, and the Centers for Disease Control and Prevention (cooperative agreement number 5U38HM000414-5). NR 36 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2017 VL 64 IS 4 BP 408 EP 412 DI 10.1093/cid/ciw762 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3SB UT WOS:000397300900010 ER PT J AU Mazur, NI Bont, L Cohen, AL Cohen, C von Gottberg, A Groome, MJ Hellferscee, O Klipstein-Grobusch, K Mekgoe, O Naby, F Moyes, J Tempia, S Treurnicht, FK Venter, M Walaza, S Wolter, N Madhi, SA AF Mazur, Natalie I. Bont, Louis Cohen, Adam L. Cohen, Cheryl von Gottberg, Anne Groome, Michelle J. Hellferscee, Orienka Klipstein-Grobusch, Kerstin Mekgoe, Omphile Naby, Fathima Moyes, Jocelyn Tempia, Stefano Treurnicht, Florette K. Venter, Marietje Walaza, Sibongile Wolter, Nicole Madhi, Shabir A. CA South African Severe Acute Resp Il TI Severity of Respiratory Syncytial Virus Lower Respiratory Tract Infection With Viral Coinfection in HIV-Uninfected Children SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE respiratory syncytial virus; viral coinfection; lower respiratory tract infection disease severity ID HUMAN METAPNEUMOVIRUS INFECTION; ACUTE BRONCHIOLITIS; DISEASE SEVERITY; YOUNG-CHILDREN; RISK-FACTORS; SOUTH-AFRICA; INFANTS; MULTIPLE; ADENOVIRUS; INFLUENZA AB Background. Molecular diagnostics enable sensitive detection of respiratory viruses, but their clinical significance remains unclear in pediatric lower respiratory tract infection (LRTI). We aimed to determine whether viral coinfections increased life-threatening disease in a large cohort. Methods. Molecular testing was performed for respiratory viruses in nasopharyngeal aspirates collected from children aged < 5 years within 24 hours of hospital admission during sentinel surveillance for severe acute respiratory illness (SARI) hospitalization conducted in South Africa during February 2009-December 2013. The primary outcome was life-threatening disease, defined as mechanical ventilation, intensive care unit admission, or death. Results. Of 2322 HIV-uninfected children with respiratory syncytial virus (RSV)-associated LRTI, 1330 (57.3%) had RSV monoinfection, 38 (1.6%) had life-threatening disease, 575 (24.8%) had rhinovirus, 347 (14.9%) had adenovirus (ADV), and 30 (1.3%) had influenza virus. RSV and any other viral coinfection was not associated with severe disease (odds ratio [OR], 1.4; 95% confidence interval [CI], OR, 0.74; 95% CI,.39-1.4), ADV coinfection had increased odds of life-threatening disease (adjusted OR, 3.4; 95% CI, 1.6-7.2; P =.001), and influenza coinfection had increased odds of life-threatening disease and prolonged length of stay (adjusted OR, 2.1; 95% CI, 1.0-4.5; P =.05) compared with RSV monoinfection. Conclusions. RSV coinfection with any respiratory virus is not associated with more severe disease when compared to RSV alone in this study. However, increased life-threatening disease in RSV-ADV and RSV-influenza coinfection warrants further study. C1 [Mazur, Natalie I.; Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, Med Res Council, Respiratory & Meningeal Pathogens Unit, ZA-2050 Johannesburg, South Africa. [Mazur, Natalie I.; Bont, Louis] Wilhelmina Childrens Hosp, Utrecht, Netherlands. [Mazur, Natalie I.; Klipstein-Grobusch, Kerstin] Univ Med Ctr Utrecht, Julius Global Hlth Ctr Hlth Sci & Primary Care, Utrecht, Netherlands. [Bont, Louis] ReSViNET, Utrecht, Netherlands. [Cohen, Cheryl] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Respiratory Dis, Influenza Div, Atlanta, GA USA. [Cohen, Cheryl] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa. [Cohen, Cheryl; Walaza, Sibongile] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Div Epidemiol & Biostat, ZA-2050 Johannesburg, South Africa. [Cohen, Adam L.; Cohen, Cheryl; Hellferscee, Orienka; Moyes, Jocelyn; Walaza, Sibongile; Wolter, Nicole] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Ctr Respiratory Dis & Meningitis, Pretoria, South Africa. [von Gottberg, Anne; Hellferscee, Orienka; Wolter, Nicole] Univ Witwatersrand, Sch Pathol, ZA-2050 Johannesburg, South Africa. [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, ZA-2050 Johannesburg, South Africa. [Mekgoe, Omphile] Klerksdorp Hosp, Klerksdorp, South Africa. [Naby, Fathima] Pietermartizburg Metropolitan Hosp, Dept Pediat, Pietermaritzburg, South Africa. [Venter, Marietje] Global Dis Detect Ctr South Africa, Ctr Dis Control & Prevent, Div Global Hlth Protect, Pretoria, South Africa. [Venter, Marietje] Univ Pretoria, Dept Med Virol, ZA-0002 Pretoria, South Africa. RP Madhi, SA (reprint author), MRC, Respiratory & Meningeal Pathogens Res Unit, DST NRF, Vaccine Preventable Dis, New Nurses Residence,11th Floor West Wing,PO 9075, Johannesburg, ZA-2013, South Africa. EM shabirm@nicd.ac.za NR 50 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2017 VL 64 IS 4 BP 443 EP 450 DI 10.1093/cid/ciw756 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3SB UT WOS:000397300900016 ER PT J AU Wong, C Gange, SJ Buchacz, K Moore, RD Justice, AC Horberg, MA Gill, MJ Koethe, JR Rebeiro, PF Silverberg, MJ Palella, FJ Patel, P Kitahata, MM Crane, HM Abraham, AG Samji, H Napravnik, S Ahmed, T Thorne, JE Bosch, RJ Mayor, AM Althoff, KN AF Wong, Cherise Gange, Stephen J. Buchacz, Kate Moore, Richard D. Justice, Amy C. Horberg, Michael A. Gill, M. John Koethe, John R. Rebeiro, Peter F. Silverberg, Michael J. Palella, Frank J. Patel, Pragna Kitahata, Mari M. Crane, Heidi M. Abraham, Alison G. Samji, Hasina Napravnik, Sonia Ahmed, Tareq Thorne, Jennifer E. Bosch, Ronald J. Mayor, Angel M. Althoff, Keri N. CA North American AIDS Cohort Collabo TI First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension Among North American HIV-Infected Adults, 2000-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE noncommunicable disease; disparities; aging; HIV ID GLOMERULAR-FILTRATION-RATE; ANTIRETROVIRAL THERAPY; CLINICAL CARE; RISK-FACTORS; AIDS COHORT; PREVALENCE; COLLABORATION; INDIVIDUALS; DISPARITIES; POPULATION AB Background. There remains concern regarding the occurrence of noncommunicable diseases (NCDs) among individuals aging with human immunodeficiency virus (HIV), but few studies have described whether disparities between demographic subgroups are present among individuals on antiretroviral therapy (ART) with access to care. Methods. We assessed the first documented occurrence of type 2 diabetes mellitus (DM), chronic kidney disease (CKD), and treated hypertension (HTN) by age, sex, and race within the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). HIV-infected adults (>= 18 years) who initiated ART were observed for first NCD occurrence between 1 January 2000 and 31 December 2013. Cumulative incidences as of age 70 were estimated accounting for the competing risk of death; Poisson regression was used to compare rates of NCD occurrence by demographic subgroup. Results. We included > 50 000 persons with > 250 000 person-years of follow-up. Median follow-up was 4.7 (interquartile range, 2.4-8.1) years. Rates of first occurrence (per 100 person-years) were 1.2 for DM, 0.6 for CKD, and 2.6 for HTN. Relative to non-black women, the cumulative incidences were increased in black women (68% vs 51% for HTN, 52% vs 41% for DM, and 38% vs 35% for CKD; all P <.001); this disparity was also found among men (73% vs 60% for HTN, 44% vs 34% for DM, and 30% vs 25% for CKD; all P <.001). Conclusions. Racial disparities in the occurrence of DM, CKD, and HTN emphasize the need for prevention and treatment options for these HIV populations receiving care in North America. C1 [Wong, Cherise; Gange, Stephen J.; Moore, Richard D.; Althoff, Keri N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Buchacz, Kate] Ctr Dis Control & Prevent, Atlanta, GA USA. [Justice, Amy C.] Vet Affairs Connecticut HealthCare Syst, West Haven, CT USA. [Horberg, Michael A.] Kaiser Permanente Mid Atlantic States, Mid Atlantic Permanente Res Inst, Rockville, MD USA. [Gill, M. John] Univ Calgary, Calgary, AB T2N 1N4, Canada. [Koethe, John R.] Vanderbilt Univ, Nashville, TN USA. [Silverberg, Michael J.] Kaiser Permanente Northern Calif, Kaiser Permanente Div Res, Oakland, CA USA. [Palella, Frank J.] Northwestern Univ, Chicago, IL 60208 USA. [Kitahata, Mari M.; Crane, Heidi M.] Univ Washington, Seattle, WA 98195 USA. [Samji, Hasina; Ahmed, Tareq] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Napravnik, Sonia] Univ N Carolina, Chapel Hill, NC USA. [Bosch, Ronald J.] Harvard Sch Publ Hlth, Boston, MA USA. [Mayor, Angel M.] Univ Cent Caribe, Bayamon, PR USA. RP Wong, C (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Suite E7133, Baltimore, MD 21205 USA. EM cwong32@jhu.edu FU National Institutes of Health [U01AI069918, F31DA037788, G12MD007583, K01AI093197, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, M01RR000052, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01CA165937, R01DA011602, R01DA012568, R24AI067039, U01AA013566, U01AA020790, U01AI031834, U01AI034989, U01AI034993, U01AI034994, U01AI035004, U01AI035039, U01AI035040, U01AI035041, U01AI035042, U01AI037613, U01AI037984, U01AI038855, U01AI038858, U01AI042590, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01AI103390, U01AI103397, U01AI103401, U01AI103408, U01DA03629, U01DA036935, U01HD032632, U10EY008057, U10EY008052, U10EY008067, U24AA020794, U54MD007587, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR000454, UM1AI035043, T32-AG000247, Z01CP010214, Z01CP010176, R24AG044325]; Centers for Disease Control and Prevention [CDC-200-200618797, CDC-200-2015-63931]; Agency for Healthcare Research and Quality [90047713]; Health Resources and Services Administration [90051652]; Canadian Institutes of Health Research [CBR-86906, CBR-94036, HCP-97105, TGF-96118]; Ontario Ministry of Health and Long Term Care; Government of Alberta, Canada; National Cancer Institute; National Institute of Mental Health; National Institute on Drug Abuse FX This work was supported by the National Institutes of Health (grant numbers U01AI069918, F31DA037788, G12MD007583, K01AI093197, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, M01RR000052, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01CA165937, R01DA011602, R01DA012568, R24AI067039, U01AA013566, U01AA020790, U01AI031834, U01AI034989, U01AI034993, U01AI034994, U01AI035004, U01AI035039, U01AI035040, U01AI035041, U01AI035042, U01AI037613, U01AI037984, U01AI038855, U01AI038858, U01AI042590, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01AI103390, U01AI103397, U01AI103401, U01AI103408, U01DA03629, U01DA036935, U01HD032632, U10EY008057, U10EY008052, U10EY008067, U24AA020794, U54MD007587, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR000454, UM1AI035043, T32-AG000247, Z01CP010214, Z01CP010176, and pilot grant R24AG044325); the Centers for Disease Control and Prevention (contract numbers CDC-200-200618797 and CDC-200-2015-63931); the Agency for Healthcare Research and Quality (contract number 90047713); the Health Resources and Services Administration (contract number 90051652); the Canadian Institutes of Health Research (grant numbers CBR-86906, CBR-94036, HCP-97105, and TGF-96118); the Ontario Ministry of Health and Long Term Care; the Government of Alberta, Canada; the National Cancer Institute; the National Institute of Mental Health; and the National Institute on Drug Abuse. NR 35 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2017 VL 64 IS 4 BP 459 EP 467 DI 10.1093/cid/ciw804 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3SB UT WOS:000397300900018 PM 28172581 ER PT J AU Fill, MMA Compton, ML McDonald, EC Moncayo, AC Dunn, JR Schaffner, W Bhatnagar, J Zaki, SR Jones, TF Shieh, WJ AF Fill, Mary-Margaret A. Compton, Margaret L. McDonald, Edward C. Moncayo, Abelardo C. Dunn, John R. Schaffner, William Bhatnagar, Julu Zaki, Sherif R. Jones, Timothy F. Shieh, Wun-Ju TI Novel Clinical and Pathologic Findings in a Heartland Virus-Associated Death SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE emerging infections; tickborne disease; viral infections; heartland virus ID THROMBOCYTOPENIA SYNDROME; SEVERE FEVER; TRANSMISSION AB We describe an investigation into a Heartland virus (HRTV)-associated death in Tennessee with novel clinical and pathologic findings. HRTV can cause rapidly fatal, widely disseminated infection with multisystem organ failure in patients without substantial comorbidities. We identified viral antigen in multiple organ tissues where it was not detected previously. C1 [Fill, Mary-Margaret A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA. [Fill, Mary-Margaret A.; Moncayo, Abelardo C.; Dunn, John R.; Jones, Timothy F.] Tennessee Dept Hlth, Div Communicable & Environm Dis & Emergency Prepa, Nashville, TN USA. [Compton, Margaret L.; McDonald, Edward C.; Zaki, Sherif R.; Shieh, Wun-Ju] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA. [Schaffner, William] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA. [Bhatnagar, Julu] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Infect Dis Pathol Branch, Atlanta, GA USA. RP Fill, MMA (reprint author), 710 James Robertson Pkwy,Andrew Johnson Tower, Nashville, TN 37243 USA. EM mary-margaret.fill@tn.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2017 VL 64 IS 4 BP 510 EP 512 DI 10.1093/cid/ciw766 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3SB UT WOS:000397300900025 ER PT J AU Sissoko, D Keita, M Diallo, B Aliabadi, N Fitter, DL Dahl, BA Bore, JA Koundouno, FR Singethan, K Meisel, S Enkirch, T Mazzarelli, A Amburgey, V Faye, O Sall, AA Magassouba, N Carroll, MW Anglaret, X Malvy, D Formenty, P Aylward, RB Keita, S Djingarey, MH Loman, NJ Gunther, S Duraffour, S AF Sissoko, Daouda Keita, Mory Diallo, Boubacar Aliabadi, Negar Fitter, David L. Dahl, Benjamin A. Bore, Joseph Akoi Koundouno, Fara Raymond Singethan, Katrin Meisel, Sarah Enkirch, Theresa Mazzarelli, Antonio Amburgey, Victoria Faye, Ousmane Sall, Amadou Alpha Magassouba, N'Faly Carroll, Miles W. Anglaret, Xavier Malvy, Denis Formenty, Pierre Aylward, Raymond Bruce Keita, Sakoba Djingarey, Mamoudou Harouna Loman, Nicholas J. Guenther, Stephan Duraffour, Sophie TI Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Ebola virus; mother-to-child transmission; real-time sequencing; breast milk; asymptomatic carriage ID FLUIDS AB A 9-month-old infant died from Ebola virus (EBOV) disease with unknown epidemiological link. While her parents did not report previous illness, laboratory investigations revealed persisting EBOV RNA in the mother's breast milk and the father's seminal fluid. Genomic analysis strongly suggests EBOV transmission to the child through breastfeeding. C1 [Sissoko, Daouda; Anglaret, Xavier; Malvy, Denis] Bordeaux Univ, INSERM, U1219, Bordeaux, France. [Sissoko, Daouda] Bordeaux Univ Hosp, Bordeaux, France. [Keita, Mory; Djingarey, Mamoudou Harouna] WHO, Conakry, Guinea. [Aliabadi, Negar; Fitter, David L.; Dahl, Benjamin A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bore, Joseph Akoi; Koundouno, Fara Raymond; Singethan, Katrin; Meisel, Sarah; Enkirch, Theresa; Mazzarelli, Antonio; Carroll, Miles W.; Duraffour, Sophie] European Mobile Lab Consortium, Hamburg, Germany. [Bore, Joseph Akoi; Koundouno, Fara Raymond] Minist Hlth, Conakry, Guinea. [Singethan, Katrin] Tech Univ Munich, Inst Virol, Helmholtz Zentrum Munchen, Munich, Germany. [Meisel, Sarah; Guenther, Stephan; Duraffour, Sophie] Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany. [Enkirch, Theresa] Paul Ehrlich Inst, Div Vet Med, Langen, Germany. [Mazzarelli, Antonio; Aylward, Raymond Bruce] Natl Inst Infect Dis L Spallanzani, Rome, Italy. [Amburgey, Victoria] Sandia Natl Labs, POB 5800, Albuquerque, NM 87185 USA. [Amburgey, Victoria] Ratoma Ebola Diagnost Ctr, Conakry, Guinea. [Faye, Ousmane; Sall, Amadou Alpha] Inst Pasteur, Dakar, Senegal. [Magassouba, N'Faly] Univ Gamal Abdel Nasser Conakry, Lab Fievres Hemorrag Guinee, Conakry, Guinea. [Carroll, Miles W.] Publ Hlth England, Salisbury, Wilts, England. [Carroll, Miles W.] Univ Southampton, South Gen Hosp, Southampton, Hants, England. [Anglaret, Xavier] Treichville Univ Hosp, ANRS Res Site, PAC CI, Abidjan, Cote Ivoire. [Formenty, Pierre] WHO, Geneva, Switzerland. [Loman, Nicholas J.] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England. RP Duraffour, S (reprint author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany. EM sophieduraffour@yahoo.fr FU European Union [666100, 666092]; Directorate-General for International Cooperation and Development [IFS/2011/272372]; French Institute of Health and Medical Research (INSERM) [C15-101] FX This work was carried out in the context of the projects EVIDENT (Ebola virus disease: correlates of protection, determinants of outcome, and clinical management) and REACTION! that received funding from the European Union's Horizon 2020 research and innovation program (grant agreements 666100 to S. G. and 666092 to D. M., respectively), and in the context of service contract IFS/2011/272372 (to S. G.) funded by the Directorate-General for International Cooperation and Development. The study was further supported by the French Institute of Health and Medical Research (INSERM) to D. S. (grant number C15-101). NR 12 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2017 VL 64 IS 4 BP 513 EP 516 DI 10.1093/cid/ciw793 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3SB UT WOS:000397300900026 ER PT J AU Huang, W Blount, BC Watson, CH Watson, C Chambers, DM AF Huang, Wenlin Blount, Benjamin C. Watson, Clifford H. Watson, Christina Chambers, David M. TI Quantitative analysis of menthol in human urine using solid phase microextraction and stable isotope dilution gas chromatography-mass spectrometry SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES LA English DT Article DE Menthol; GC-MS; SPME; Urine; Mentholated cigarette; Tobacco ID EXPOSURE; PLASMA AB To accurately measure menthol levels in human urine, we developed a method using gas chromatography/electron ionization mass spectrometry with menthol-d(4) stable isotope internal standardization. We used solid phase microextraction (SPME) headspace sampling for collection, preconcentration and automation. Conjugated forms of menthol were released using beta-glucuronidase/sulfatase to allow for measuring total menthol. Additionally, we processed the specimens without using, beta-glucuronidase/sulfatase to quantify the levels of unconjugated (free) menthol in urine. This method was developed to verify mentholated cigarette smoking status to study the influence of menthol on smoking behaviour and exposure. This objective was accomplished with this method, which has no carryover or memory from the SPME fiber assembly, a method detection limit of 0.0017 mu g/mL, a broad linear range of 0.002-0.5 rho g/mL for free menthol and 0.01-10 1.1 mu g/mL for total menthol, a 7.6% precision and 88.5% accuracy, and an analysis runtime of 17 min. We applied this method in analysis of urine specimens collected from cigarette smokers who smoke either mentholated or non-mentholated cigarettes. Among these smokers, the average total urinary menthol levels was three-fold higher (p < 0.001) among mentholated cigarette smokers compared with non-mentholated cigarette smokers. Published by Elsevier B.V. C1 [Huang, Wenlin] Georgia Gwinnett Coll, Sch Sci & Technol, Lawrenceville, NJ 30043 USA. [Blount, Benjamin C.; Watson, Clifford H.; Watson, Christina; Chambers, David M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Chambers, DM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,Mailstop F-47, Atlanta, GA 30341 USA. EM mzz7@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-0232 EI 1873-376X J9 J CHROMATOGR B JI J. Chromatogr. B PD FEB 15 PY 2017 VL 1044 BP 200 EP 205 DI 10.1016/j.jchromb.2016.12.019 PG 6 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA EL2TF UT WOS:000394472400026 PM 28153673 ER PT J AU Batts, WN LaPatra, SE Katona, R Leis, E Ng, TFF Brieuc, MSO Breyta, RB Purcell, MK Conway, CM Waltzek, TB Delwart, E Winton, JR AF Batts, William N. LaPatra, Scott E. Katona, Ryan Leis, Eric Ng, Terry Fei Fan Brieuc, Marine S. O. Breyta, Rachel B. Purcell, Maureen K. Conway, Carla M. Waltzek, Thomas B. Delwart, Eric Winton, James R. TI Molecular characterization of a novel orthomyxovirus from rainbow and steelhead trout (Oncorhynchus mykiss) SO VIRUS RESEARCH LA English DT Article DE Orthomyxovirus; Rainbow trout; Fish virus; Oncorhynchus mykiss ID INFECTIOUS-SALMON-ANEMIA; INFLUENZA-A VIRUS; ATLANTIC SALMON; NUCLEAR EXPORT; NS1 PROTEIN; SALAR L.; DOMAINS; GENOME; CELLS; ISAV AB A novel virus, rainbow trout orthomyxovirus (RbtOV), was isolated in 1997 and again in 2000 from commercially-reared rainbow trout (Oncorhynchus mykiss) in Idaho, USA. The virus grew optimally in the CHSE-214 cell line at 15 degrees C producing a diffuse cytopathic effect; however, juvenile rainbow trout exposed to cell culture-grown virus showed no mortality or gross pathology. Electron microscopy of preparations from infected cell cultures revealed the presence of typical orthomyxovirus particles. The complete genome of RbtOV is comprised of eight linear segments of single-stranded, negative-sense RNA having highly conserved 5' and 3'-terminal nucleotide sequences. Another virus isolated in 2014 from steelhead trout (also O. mykiss) in Wisconsin, USA, and designated SttOV was found to have eight genome segments with high amino acid sequence identities (89-99%) to the corresponding genes of RbtOV, suggesting these new viruses are isolates of the same virus species and may be more widespread than currently realized. The new isolates had the same genome segment order and the closest pairwise amino acid sequence identities of 16-42% with Infectious salmon anemia virus (ISAV), the type species and currently only member of the genus Isavirus in the family Orthomyxoviridae. However, pairwise comparisons of the predicted amino acid sequences of the 10 RbtOV and SttOV proteins with orthologs from representatives of the established orthomyxoviral genera and a phylogenetic analysis using the PB1 protein showed that while RbtOV and SttOV clustered most closely with ISAV, they diverged sufficiently to merit consideration as representatives of a novel genus. A set of PCR primers was designed using conserved regions of the PB1 gene to produce amplicons that may be sequenced for identification of similar fish orthomyxoviruses in the future. Published by Elsevier B.V. C1 [Batts, William N.; Purcell, Maureen K.; Conway, Carla M.; Winton, James R.] US Geol Survey, Western Fisheries Res Ctr, 6505 NE 65th St, Seattle, WA 98115 USA. [LaPatra, Scott E.] Clear Springs Foods Inc, Div Res, Buhl, ID 83316 USA. [Katona, Ryan; Leis, Eric] US Fish & Wildlife Serv, La Crosse Fish Hlth Ctr, Onalaska, WI 54650 USA. [Ng, Terry Fei Fan] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Brieuc, Marine S. O.; Breyta, Rachel B.] Univ Washington, Sch Aquat & Fishery Sci, Seattle, WA 98105 USA. [Waltzek, Thomas B.] Univ Florida, Coll Vet Med, Gainesville, FL 32610 USA. [Delwart, Eric] Blood Syst Res Inst, San Francisco, CA 94118 USA. RP Batts, WN (reprint author), US Geol Survey, Western Fisheries Res Ctr, 6505 NE 65th St, Seattle, WA 98115 USA. EM bbatts@usgs.gov OI Ng, Terry Fei Fan/0000-0002-4815-8697 FU US Geological Survey; Blood Systems Research; USGS-USFWS Science Support Partnership FX Jerry Jones and Bill Shewmaker sampled the juvenile rainbow trout and inoculated the cell cultures at Clear Springs Foods. Susan Marcquenski, Wisconsin Department of Natural Resources, collected the steelhead trout samples. The authors would like to thank Jacob Gregg at the Marrowstone Field Station, Western Fisheries Research Center, US Geological Survey for initial efforts at analyzing the next generation sequencing data for RbtOV-1. We thank Bobbie Schneider, Manager of the Electron Microscopy Core Service Laboratory at the Fred Hutchinson Cancer Research Center for her assistance in obtaining the EM images of RbtOV. Partial funding for this research came from the US Geological Survey, Blood Systems Research, and the USGS-USFWS Science Support Partnership. Mention of trade names does not imply endorsement by the US Government, private company, or any affiliated University. NR 48 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 EI 1872-7492 J9 VIRUS RES JI Virus Res. PD FEB 15 PY 2017 VL 230 BP 38 EP 49 DI 10.1016/j.virusres.2017.01.005 PG 12 WC Virology SC Virology GA EL1QL UT WOS:000394396000006 PM 28088362 ER PT J AU Johnson, TP Tyagi, R Lee, PR Lee, MH Johnson, KR Kowalak, J Elkahloun, A Medynets, M Hategan, A Kubofcik, J Sejvar, J Ratto, J Bunga, S Makumbi, I Aceng, JR Nutman, TB Dowell, SF Nath, A AF Johnson, Tory P. Tyagi, Richa Lee, Paul R. Lee, Myoung-Hwa Johnson, Kory R. Kowalak, Jeffrey Elkahloun, Abdel Medynets, Marie Hategan, Alina Kubofcik, Joseph Sejvar, James Ratto, Jeffrey Bunga, Sudhir Makumbi, Issa Aceng, Jane R. Nutman, Thomas B. Dowell, Scott F. Nath, Avindra TI Nodding syndrome may be an autoimmune reaction to the parasitic worm Onchocerca volvulus SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID MUSCLE-CELLS; MUNDRI COUNTY; CASE SERIES; EPILEPSY; TANZANIA; UGANDA; ENCEPHALITIS; EXPRESSION; ANTIBODIES; RECEPTOR AB Nodding syndrome is an epileptic disorder of unknown etiology that occurs in children in East Africa. There is an epidemiological association with Onchocerca volvulus, the parasitic worm that causes onchocerciasis (river blindness), but there is limited evidence that the parasite itself is neuroinvasive. We hypothesized that nodding syndrome may be an autoimmune-mediated disease. Using protein chip methodology, we detected autoantibodies to leiomodin-1 more abundantly in patients with nodding syndrome compared to unaffected controls from the same village. Leiomodin-1 autoantibodies were found in both the sera and cerebrospinal fluid of patients with nodding syndrome. Leiomodin-1 was found to be expressed in mature and developing human neurons in vitro and was localized in mouse brain to the CA3 region of the hippocampus, Purkinje cells in the cerebellum, and cortical neurons, structures that also appear to be affected in patients with nodding syndrome. Antibodies targeting leiomodin-1 were neurotoxic in vitro, and leiomodin-1 antibodies purified from patients with nodding syndrome were cross-reactive with O. volvulus antigens. This study provides initial evidence supporting the hypothesis that nodding syndrome is an autoimmune epileptic disorder caused by molecular mimicry with O. volvulus antigens and suggests that patients may benefit from immunomodulatory therapies. C1 [Johnson, Tory P.; Tyagi, Richa; Lee, Paul R.; Lee, Myoung-Hwa; Hategan, Alina; Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA. [Johnson, Kory R.] NINCDS, Bioinformat Sect, NIH, Bethesda, MD 20892 USA. [Kowalak, Jeffrey] NINCDS, Clin Prote Unit, NIH, Bethesda, MD 20892 USA. [Elkahloun, Abdel] NINCDS, Microarray Core Facil, NIH, Bethesda, MD 20892 USA. [Medynets, Marie] NINCDS, Neural Differentiat Unit, NIH, Bethesda, MD 20892 USA. [Kubofcik, Joseph; Nutman, Thomas B.] NINCDS, Helminth Immunol Sect, Lab Parasit Dis, NIH, Bethesda, MD 20892 USA. [Sejvar, James] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Ratto, Jeffrey; Bunga, Sudhir] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Makumbi, Issa; Aceng, Jane R.] Minist Hlth, Kampala, Uganda. [Dowell, Scott F.] Bill & Melinda Gates Fdn, Seattle, WA 98109 USA. RP Nath, A (reprint author), NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA. EM natha@ninds.nih.gov FU NIH; CDC FX This research was supported by the Intramural Research Programs of the NIH and CDC. The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the CDC. NR 35 TC 1 Z9 1 U1 1 U2 1 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD FEB 15 PY 2017 VL 9 IS 377 AR eaaf6953 DI 10.1126/scitranslmed.aaf6953 PG 10 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA EL2LL UT WOS:000394451100002 ER PT J AU Abara, WE Collier, MG Teshale, EH AF Abara, W. E. Collier, M. G. Teshale, E. H. TI Impact of universal infant hepatitis B vaccination in the US-affiliated Pacific Islands, 1985-2015 SO VACCINE LA English DT Article DE Hepatitis B virus infection; HBV; HBsAg; Hepatitis B vaccination; Children; Pacific Islands ID VIRUS-INFECTION; IMMUNIZATION; PREVALENCE AB The US-affiliated Pacific Island countries (USAPI) is an endemic region for hepatitis B virus (HBV) infection. Universal infant hepatitis B vaccination was introduced in the USAPI in the mid-1980s to mitigate the HBV burden. We assessed the impact of universal infant vaccination on the HBV infection prevalence over time among children born in the 1980s, 1990s, and 2000s in the USAPI. Demographic and serologic data from serial sero-surveys conducted between 1985 and 2015 were obtained. Descriptive statistics and analysis of variance were performed. From data obtained from 4827 children (2-11 years), HBV prevalence decreased markedly: 8.4% in the 1980s; 2.5% in the 1990s; and 0.2% in the 2000s (P < 0.0001) as vaccination coverage increased: 76.4% in the 1980s; 87.3% in the 1990s; and 97.5% in the 2000s (P < 0.0001). These findings underscore the protective effect of universal infant hepatitis B vaccination over time on the HBV burden in an HBV endemic region. Published by Elsevier Ltd. C1 [Abara, W. E.; Collier, M. G.; Teshale, E. H.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS G37, Atlanta, GA 30333 USA. RP Abara, WE (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS G37, Atlanta, GA 30333 USA. EM wabara@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 15 PY 2017 VL 35 IS 7 BP 997 EP 1000 DI 10.1016/j.vaccine.2017.01.020 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EK6WQ UT WOS:000394067100002 PM 28117171 ER PT J AU Weinberg, M Dietz, S Potter, R Swanson, R Miller, C McFadden, J AF Weinberg, Meghan Dietz, Stephanie Potter, Rachel Swanson, Robert Miller, Corinne McFadden, Jevon TI Vaccine shot-limiting: Estimating the prevalence, indicators, and impact on vaccination status - Michigan, 2012 SO VACCINE LA English DT Article DE Vaccination; Michigan; Up-to-date vaccination; Shot-limiting; Prevalence ID SCHEDULE; CHILDREN; PARENTS; ASSOCIATION; COHORT; RISK AB Background: Concerns regarding vaccine safety and pain have prompted certain parents to limit the number of shots their child receives per visit. We estimated the prevalence of shot-limited children in Michigan, described their characteristics, assessed whether shot-limited children were up-to-date on recommended vaccinations, and investigated possible intervention points for vaccination education. Methods: We analyzed vaccination registry and birth record data of children born in Michigan during 2012 who had >= 2 vaccination visits, with >= 1 visits after age 5 months. Shot-limited was defined as receiving <= 2 shots at all visits through age 24 months. Nonlimited children received >2 shots at >= 1 visits. Up-to-date vaccination was based on receipt of a seven-vaccine series and was determined at ages 24 months and 35 months. Risk ratios (RR) were calculated using risk regression. Results: Of 101,443 children, a total of 2,967 (3%) children were shot-limited. Mothers of shot-limited children were more likely to be white (RR: 1.2; 95% confidence interval [CI]: 1.2-1.2), college graduate (RR: 1.9; 95% CI: 1.9-2.0), and married (RR: 1.5; 95% CI: 1.5-1.5). Compared with nonlimited children, shot-limited children were more likely to be born in a nonhospital setting (RR: 11.7; 95% CI: 9.4-14.6) and have a midwife attendant (RR: 1.9; 95% CI: 1.7-2.1). Shot-limited children were less likely to be up-to-date on recommended vaccinations (RR: 0.2; 95% CI: 0.2-0.3); this association was stronger for those with a midwife birth attendant (RR: 0.1; 95% CI: 0.1-0.2) rather than a medical doctor (RR: 0.3; 95% CI: 0.2-0.3). Conclusions: Shot-limited children are less likely to be up-to-date on vaccinations, possibly leading to increased risk for vaccine-preventable diseases. This association was stronger for those with a midwife birth attendant. This analysis should prompt targeted education, such as to midwives, concerning risks associated with shot-limiting behavior. Published by Elsevier Ltd. C1 [Weinberg, Meghan] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Weinberg, Meghan; Potter, Rachel; Swanson, Robert; Miller, Corinne; McFadden, Jevon] Michigan Dept Hlth & Human Serv, 333 S Grand Ave, Lansing, MI 48909 USA. [Dietz, Stephanie] Ctr Dis Control & Prevent, Div Sci Educ & Profess Dev, Epidemiol Workforce Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA. [McFadden, Jevon] Ctr Dis Control & Prevent, Career Epidemiol Field Officer Program, Div State & Local Readiness, 1600 Clifton Rd, Atlanta, GA 30329 USA. RP Weinberg, M (reprint author), 333 S Grand Ave, Lansing, MI 48909 USA. EM weinbergm1@michigan.gov NR 24 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 15 PY 2017 VL 35 IS 7 BP 1018 EP 1023 DI 10.1016/j.vaccine.2017.01.013 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EK6WQ UT WOS:000394067100005 PM 28108229 ER PT J AU Sundaram, N Chen, C Yoong, J Luvsan, ME Fox, K Sarankhuu, A La Vincente, S Jit, M AF Sundaram, Neisha Chen, Cynthia Yoong, Joanne Luvsan, Munkh-Erdene Fox, Kimberley Sarankhuu, Amarzaya La Vincente, Sophie Jit, Mark TI Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia SO VACCINE LA English DT Article DE Pneumococcal conjugate vaccine; Cost-effectiveness; Mongolia; Vaccine; Budget impact; PCV13 ID GAVI-ELIGIBLE COUNTRIES; STREPTOCOCCUS-PNEUMONIAE; DOSING SCHEDULES; CHILDREN YOUNGER; DISEASE; MORTALITY; RISK; SURVEILLANCE; POPULATION; INFECTIONS AB Objective: The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness and budget impact of introducing PCV13 compared to no PCV vaccination in Mongolia. Methods: The incremental cost-effectiveness ratio (ICER) of introducing PCV13 compared to no PCV vaccination was assessed using an age-stratified static multiple cohort model. The risk of various clinical presentations of pneumococcal disease (meningitis, pneumonia, non-meningitis non-pneumonia invasive pneumococcal disease and acute otitis media) at all ages for thirty birth cohorts was assessed. The analysis considered both health system and societal perspectives. A 3 + 0 vaccine schedule and price of US $3.30 per dose was assumed for the baseline scenario based on Gavi, the Vaccine Alliance's advance market commitment tail price. Results: The ICER of PCV13 introduction is estimated at US$52 per disability-adjusted life year (DALY) averted (health system perspective), and cost-saving (societal perspective). Although indirect effects of PCV have been well -documented, a conservative scenario that does not consider indirect effects estimated PCV13 introduction to cost US$79 per DALY averted (health system perspective), and US$19 per DALY averted (societal perspective). Vaccination with PCV13 is expected to cost around US$920,000 in 2016, and thereafter US$820,000 every year. The programme is likely to reduce direct disease-related costs to MOH by US$440,000 in the first year, increasing to US$510,000 by 2025. Conclusion: Introducing PCV13 as part of Mongolia's national programme appears to be highly cost-effective when compared to no vaccination and cost-saving from a societal perspective at vaccine purchase prices offered through Gavi. Notwithstanding uncertainties around some parameters, cost-effectiveness of PCV introduction for Mongolia remains robust over a range of conservative scenarios. Availability of high quality national data would improve future economic analyses for vaccine introduction. (C) 2017 The Authors. Published by Elsevier Ltd. C1 [Sundaram, Neisha; Chen, Cynthia; Yoong, Joanne] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2,10-01, Singapore 117549, Singapore. [Luvsan, Munkh-Erdene] Mongolian Natl Univ Med Sci, S Zorig St 3,POB 48-111, Ulaanbaatar 14210, Mongol Peo Rep. [Fox, Kimberley] WHO, Expanded Programme Immunizat, Reg Off Western Pacific, United Nations Ave,Corner Taft Ave, Manila 1000, Philippines. [Sarankhuu, Amarzaya] Minist Hlth & Sports, Govt Bldg 8,Olymp St 2, Sukhbaatar Dist 14210, Ulaanbaatar, Mongol Peo Rep. [La Vincente, Sophie] Royal Childrens Hosp, Murdoch Childrens Res Inst, Pneumococcal Grp, Flemington Rd, Parkville, Vic 3052, Australia. [La Vincente, Sophie] Royal Childrens Hosp, Murdoch Childrens Res Inst, Int Child Hlth Res Grp, Flemington Rd, Parkville, Vic 3052, Australia. [La Vincente, Sophie] Univ Melbourne, Royal Childrens Hosp, Dept Paediat, Flemington Rd, Parkville, Vic, Australia. [Jit, Mark] Publ Hlth England, Modelling & Econ Unit, 61 Colindale Ave, London NW9 5EQ, England. [Jit, Mark] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England. [Fox, Kimberley] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Global Immunizat Div, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. RP Yoong, J (reprint author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, 12 Sci Dr 2,10-01, Singapore 117549, Singapore. EM neisha_sundaram@nuhs.edu.sg; ephchc@nus.edu.sg; joanne_yoong@nuhs.edu.sg; munkherdene@mnums.edu.mn; kaf6@cdc.gov; amarzaya@moh.gov.mn; sophie.lavincente@rch.org.au; mark.jit@lshtm.ac.uk OI Sundaram, Neisha/0000-0003-4159-9518 FU Mongolia's Ministry of Health; World Health Organization; Geneva; Gavi, the Vaccine Aliance FX We thank Mongolia's Ministry of Health for their support, advice and convening of experts to guide model development. We also especially thank Dr. D. Sodbayar (World Health Organization), Dr. D. Gantulga (NCCD), Ms. Narangav (NCCD), Mr. Shinebayar (NCCD), Dr G. Surenkhand (NCCD), Dr D. Narangerel (Public Health Unit and national EPI manager).; This study was funded by the World Health Organization, Geneva and Gavi, the Vaccine Aliance. The WHO Regional Office for the Western Pacific provided travel support. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy or views of the World Health Organization. Nothing in this report should be construed as an endorsement by WHO or any other organization of any product. NR 40 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 15 PY 2017 VL 35 IS 7 BP 1055 EP 1063 DI 10.1016/j.vaccine.2016.12.070 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EK6WQ UT WOS:000394067100010 PM 28109706 ER PT J AU Duggal, NK Ritter, JM Pestorius, SE Zaki, SR Davis, BS Chang, GJJ Bowen, RA Brault, AC AF Duggal, Nisha K. Ritter, Jana M. Pestorius, Samuel E. Zaki, Sherif R. Davis, Brent S. Chang, Gwong-Jen J. Bowen, Richard A. Brault, Aaron C. TI Frequent Zika Virus Sexual Transmission and Prolonged Viral RNA Shedding in an Immunodeficient Mouse Model SO CELL REPORTS LA English DT Article ID INFECTION; SEMEN; MICE AB Circulation of Zika virus (ZIKV) was first identified in the Western hemisphere in late 2014. Primarily transmitted through mosquito bite, ZIKV can also be transmitted through sex and from mother to fetus, and maternal ZIKVinfection has been associated with fetal malformations. We assessed immunodeficient AG129 mice for their capacity to shed ZIKV in semen and to infect female mice via sexual transmission. Infectious virus was detected in semen between 7 and 21 days post-inoculation, and ZIKV RNA was detected in semen through 58 days post-inoculation. During mating, 73% of infected males transmitted ZIKV to uninfected females, and 50% of females became infected, with evidence of fetal infection in resulting pregnancies. Semen from vasectomized mice contained significantly lower levels of infectious virus, though sexual transmission still occurred. This model provides a platform for studying the kinetics of ZIKV sexual transmission and prolonged RNA shedding also observed in human semen. C1 [Duggal, Nisha K.; Davis, Brent S.; Chang, Gwong-Jen J.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Ritter, Jana M.; Pestorius, Samuel E.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM abrault@cdc.gov NR 30 TC 0 Z9 0 U1 2 U2 2 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD FEB 14 PY 2017 VL 18 IS 7 BP 1751 EP 1760 DI 10.1016/j.celrep.2017.01.056 PG 10 WC Cell Biology SC Cell Biology GA EP4BG UT WOS:000397324900016 PM 28199846 ER PT J AU Faruque, LI Zaman, RU Gurley, ES Massung, RF Alamgir, ASM Galloway, RL Powers, AM Bai, Y Kosoy, M Nicholson, WL Rahman, M Luby, SP AF Faruque, Labib Imran Zaman, Rashid Uz Gurley, Emily S. Massung, Robert F. Alamgir, A. S. M. Galloway, Renee L. Powers, Ann M. Bai, Ying Kosoy, Michael Nicholson, William L. Rahman, Mahmudur Luby, Stephen P. TI Prevalence and clinical presentation of Rickettsia, Coxiella, Leptospira, Bartonella and chikungunya virus infections among hospital-based febrile patients from December 2008 to November 2009 in Bangladesh SO BMC INFECTIOUS DISEASES LA English DT Article DE Febrile illness; Rickettsia; Coxiella; Leptospira; Bartonella; Chikungunya virus; Bangladesh ID MOUNTAIN-SPOTTED-FEVER; SCRUB TYPHUS; MURINE TYPHUS; LEPTOTROMBIDIUM-AKAMUSHI; URBAN BANGLADESH; DIAGNOSIS; SEROVARS; SEROGROUP; DISEASES; ILLNESS AB Background: We conducted a study to identify Rickettsia, Coxiella, Leptospira, Bartonella, and Chikungunya virus infections among febrile patients presenting at hospitals in Bangladesh. Methods: We collected blood samples from patients at six tertiary hospitals from December 2008 to November 2009 and performed laboratory tests at the United States Centers for Disease Control and Prevention (CDC). Results: Out of 720 enrolled patients, 263 (37%) were infected with Rickettsia; 132 patients had immunofluorescence antibody titer >64 against spotted fever, 63 patients against scrub typhus fever and 10 patients against typhus fever. Ten patients were identified with Coxiella. We isolated Leptospira from two patients and Bartonella from one patient. Ten patients had antibodies against Chikungunya virus. The proportion of patients who died was higher with rickettsial fever (5%) compared to those without a diagnosis of rickettsial infection (2%). None of the patients were initially diagnosed with rickettsial fever. Conclusions: Rickettsial infections are frequent yet under-recognized cause of febrile illness in Bangladesh. Clinical guidelines should be revised so that local clinicians can diagnose rickettsial infections and provide appropriate drug treatment. C1 [Faruque, Labib Imran; Zaman, Rashid Uz; Gurley, Emily S.; Luby, Stephen P.] Int Ctr Diarrheal Dis Res Bangladesh, Dhaka, Bangladesh. [Massung, Robert F.; Galloway, Renee L.; Powers, Ann M.; Bai, Ying; Kosoy, Michael; Nicholson, William L.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Alamgir, A. S. M.; Rahman, Mahmudur] IEDCR, Dhaka, Bangladesh. RP Faruque, LI (reprint author), Int Ctr Diarrheal Dis Res Bangladesh, Dhaka, Bangladesh. EM labibimran@yahoo.com FU Centers for Disease Control and Prevention (CDC) [5U51CI000298-05] FX This research protocol was funded by Centers for Disease Control and Prevention (CDC), grant number_5U51CI000298-05; icddr,b acknowledges with gratitude the commitment of CDC to the Centre's research efforts. icddr,b is also grateful to the Governments of Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. NR 47 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD FEB 13 PY 2017 VL 17 AR 141 DI 10.1186/s12879-017-2239-6 PG 12 WC Infectious Diseases SC Infectious Diseases GA EP4XP UT WOS:000397383500003 PM 28193163 ER PT J AU Quiner, CA Moses, C Monroe, BP Nakazawa, Y Doty, JB Hughes, CM McCollum, AM Ibata, S Malekani, J Okitolonda, E Carroll, DS Reynolds, MG AF Quiner, Claire A. Moses, Cynthia Monroe, Benjamin P. Nakazawa, Yoshinori Doty, Jeffrey B. Hughes, Christine M. McCollum, Andrea M. Ibata, Saturnin Malekani, Jean Okitolonda, Emile Carroll, Darin S. Reynolds, Mary G. TI Presumptive risk factors for monkeypox in rural communities in the Democratic Republic of the Congo SO PLOS ONE LA English DT Article ID EBOLA-VIRUS DISEASE; SMALLPOX VACCINATION; TRANSMISSION; OUTBREAK AB Monkeypox virus (MPXV), a close relative of Variola virus, is a zoonotic virus with an unknown reservoir. Interaction with infected wildlife, bites from peri-domestic animals, and bushmeat hunting are hypothesized routes of infection from wildlife to humans. Using a Risk Questionnaire, performed in monkeypox-affected areas of rural Democratic Republic of the Congo, we describe the lifestyles and demographics associated with presumptive risk factors for MPXV infection. We generated two indices to assess risk: Household Materials Index (HMI), a proxy for socioeconomic status of households and Risk Activity Index (RAI), which describes presumptive risk for animal-to-human transmission of MPXV. Based on participant self-reported activity patterns, we found that people in this population are more likely to visit the forest than a market to fulfill material needs, and that the reported occupation is limited in describing behavior of individuals may participate. Being bitten by rodents in the home was commonly reported, and this was significantly associated with a low HMI. The highest scoring RAI sub-groups were 'hunters' and males aged >= 18 years; however, several activities involving MPXV-implicated animals were distributed across all sub-groups. The current analysis may be useful in identifying at-risk groups and help to direct education, outreach and prevention efforts more efficiently. C1 [Quiner, Claire A.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol & Biostat, Berkeley, CA 94720 USA. [Quiner, Claire A.; Monroe, Benjamin P.; Nakazawa, Yoshinori; Doty, Jeffrey B.; Hughes, Christine M.; McCollum, Andrea M.; Reynolds, Mary G.] US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. [Moses, Cynthia; Ibata, Saturnin; Carroll, Darin S.] Int Conservat Educ Fund, Washington, DC USA. [Malekani, Jean] Univ Kinshasa, Dept Biol, Kinshasa, DEM REP CONGO. [Okitolonda, Emile] Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO. RP Reynolds, MG (reprint author), US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. EM cquiner@berkeley.edu; cynmoses@gmail.com; ihd2@cdc.gov; inp7@cdc.gov; uwb7@cdc.gov; bvp6@cdc.gov; zuz4@cdc.gov; sribata@gmail.com; jean.malekani@unikin.ac.cd; okitow@yahoo.fr; azv4@cdc.gov; nzr6@cdc.gov FU Centers for Disease Control and Prevention; Oakridge Institute for Science and Education, (ORISE) FX This work was financially supported by the Centers for Disease Control and Prevention, and Oakridge Institute for Science and Education, (ORISE). NR 25 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 13 PY 2017 VL 12 IS 2 AR e0168664 DI 10.1371/journal.pone.0168664 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EL2AZ UT WOS:000394423800002 ER PT J AU Rogier, E Plucinski, M Lucchi, N Mace, K Chang, M Lemoine, JF Candrinho, B Colborn, J Dimbu, R Fortes, F Udhayakumar, V Barnwell, J AF Rogier, Eric Plucinski, Mateusz Lucchi, Naomi Mace, Kimberly Chang, Michelle Lemoine, Jean Frantz Candrinho, Baltazar Colborn, James Dimbu, Rafael Fortes, Filomeno Udhayakumar, Venkatachalam Barnwell, John TI Bead-based immunoassay allows sub-picogram detection of histidine-rich protein 2 from Plasmodium falciparum and estimates reliability of malaria rapid diagnostic tests SO PLOS ONE LA English DT Article ID SEVERE FEBRILE ILLNESS; ANTIGEN-DETECTION; PREGNANT-WOMEN; PARASITE; PLASMA; HRP2; PERFORMANCE; PFHRP2; BLOOD; ELIMINATION AB Detection of histidine-rich protein 2 (HRP2) from the malaria parasite Plasmodium falciparum provides evidence for active or recent infection, and is utilized for both diagnostic and surveillance purposes, but current laboratory immunoassays for HRP2 are hindered by low sensitivities and high costs. Here we present a new HRP2 immunoassay based on antigen capture through a bead-based system capable of detecting HRP2 at sub-picogram levels. The assay is highly specific and cost-effective, allowing fast processing and screening of large numbers of samples. We utilized the assay to assess results of HRP2-based rapid diagnostic tests (RDTs) in different P. falciparum transmission settings, generating estimates for true performance in the field. Through this method of external validation, HRP2 RDTs were found to perform well in the high-endemic areas of Mozambique and Angola with 86.4% and 73.9% of persons with HRP2 in their blood testing positive by RDTs, respectively, and false-positive rates of 4.3% and 0.5%. However, in the low-endemic setting of Haiti, only 14.5% of persons found to be HRP2 positive by the bead assay were RDT positive. Additionally, 62.5% of Haitians showing a positive RDT test had no detectable HRP2 by the bead assay, likely indicating that these were false positive tests. In addition to RDT validation, HRP2 biomass was assessed for the populations in these different settings, and may provide an additional metric by which to estimate P. falciparum transmission intensity and measure the impact of interventions. C1 [Rogier, Eric; Plucinski, Mateusz; Lucchi, Naomi; Mace, Kimberly; Chang, Michelle; Udhayakumar, Venkatachalam; Barnwell, John] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30329 USA. [Lemoine, Jean Frantz] Minist Sante Publ & Populat, Programme Natl Controle Malaria, Port Au Prince, Haiti. [Candrinho, Baltazar] Natl Malaria Control Program, Maputo, Mozambique. [Colborn, James] Clinton Hlth Access Initiat, Boston, MA USA. [Dimbu, Rafael; Fortes, Filomeno] Natl Malaria Control Program, Luanda, Angola. RP Rogier, E (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30329 USA. EM erogier@cdc.gov FU Global Fund; President's Malaria Initiative; World Health Organization FX This work was supported by: The Global Fund, grant number not available, http://www.theglobalfund.org/en/; President's Malaria Initiative, grant number not available, https://www.pmi.gov/; and the World Health Organization, www.who.int, grant number not available. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 13 PY 2017 VL 12 IS 2 AR e0172139 DI 10.1371/journal.pone.0172139 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EL2AZ UT WOS:000394423800075 ER PT J AU Girond, F Randrianasolo, L Randriamampionona, L Rakotomanana, F Randrianarivelojosia, M Ratsitorahina, M Brou, TY Herbreteau, V Mangeas, M Zigiumugabe, S Hedje, J Rogier, C Piola, P AF Girond, Florian Randrianasolo, Laurence Randriamampionona, Lea Rakotomanana, Fanjasoa Randrianarivelojosia, Milijaona Ratsitorahina, Maherisoa Brou, Telesphore Yao Herbreteau, Vincent Mangeas, Morgan Zigiumugabe, Sixte Hedje, Judith Rogier, Christophe Piola, Patrice TI Analysing trends and forecasting malaria epidemics in Madagascar using a sentinel surveillance network: a web-based application SO MALARIA JOURNAL LA English DT Article ID OUTBREAK DETECTION; PREDICTION; HIGHLANDS; ETHIOPIA; MODELS; SYSTEM AB Background: The use of a malaria early warning system (MEWS) to trigger prompt public health interventions is a key step in adding value to the epidemiological data routinely collected by sentinel surveillance systems. Methods: This study describes a system using various epidemic thresholds and a forecasting component with the support of new technologies to improve the performance of a sentinel MEWS. Malaria-related data from 21 sentinel sites collected by Short Message Service are automatically analysed to detect malaria trends and malaria outbreak alerts with automated feedback reports. Results: Roll Back Malaria partners can, through a user-friendly web-based tool, visualize potential outbreaks and generate a forecasting model. The system already demonstrated its ability to detect malaria outbreaks in Madagascar in 2014. Conclusion: This approach aims to maximize the usefulness of a sentinel surveillance system to predict and detect epidemics in limited-resource environments. C1 [Girond, Florian; Randrianasolo, Laurence; Randriamampionona, Lea; Rakotomanana, Fanjasoa; Randrianarivelojosia, Milijaona; Ratsitorahina, Maherisoa; Rogier, Christophe; Piola, Patrice] Inst Pasteur Madagascar, Antananarivo, Madagascar. [Girond, Florian; Brou, Telesphore Yao; Herbreteau, Vincent; Mangeas, Morgan] Stn SEAS OI, UMR 228, ESPACE DEV, IRD,UAG,UM,UR,175 CD 26, St Pierre 97414, Lentre Deux, Reunion. [Randriamampionona, Lea; Ratsitorahina, Maherisoa] Minist Hlth, Antananarivo, Madagascar. [Brou, Telesphore Yao] Univ Reunion, St Denis, Reunion. [Zigiumugabe, Sixte; Hedje, Judith] US Presidents Malaria Initiat, Antananarivo, Madagascar. [Hedje, Judith] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rogier, Christophe] URMITE, UMR 6236, Marseille, France. [Rogier, Christophe] Inst Biomed Res French Armed Forces IRBA, Bretigny Sur Orge, France. RP Girond, F (reprint author), Stn SEAS OI, UMR 228, ESPACE DEV, IRD,UAG,UM,UR,175 CD 26, St Pierre 97414, Lentre Deux, Reunion. EM florian.girond@gmail.com FU USAID [AID-687-G-13-00003] FX This research was supported by the USAID (Grant No. AID-687-G-13-00003). NR 29 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 13 PY 2017 VL 16 AR 72 DI 10.1186/s12936-017-1728-9 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EK8QS UT WOS:000394189100001 PM 28193215 ER PT J AU Schuh, AJ Amman, BR Jones, MEB Sealy, TK Uebelhoer, LS Spengler, JR Martin, BE Coleman-McCray, JAD Nichol, ST Towner, JS AF Schuh, Amy J. Amman, Brian R. Jones, Megan E. B. Sealy, Tara K. Uebelhoer, Luke S. Spengler, Jessica R. Martin, Brock E. Coleman-McCray, Jo Ann D. Nichol, Stuart T. Towner, Jonathan S. TI Modelling filovirus maintenance in nature by experimental transmission of Marburg virus between Egyptian rousette bats SO NATURE COMMUNICATIONS LA English DT Article ID ESCHERICHIA-COLI O157; MEXICAN FREETAIL BAT; FRUIT BATS; EBOLA-VIRUS; HEMORRHAGIC-FEVER; EXPERIMENTAL INOCULATION; INSECTIVOROUS BATS; RESERVOIR HOSTS; PTEROPID BATS; INFECTION AB The Egyptian rousette bat (ERB) is a natural reservoir host for Marburg virus (MARV); however, the mechanisms by which MARV is transmitted bat-to-bat and to other animals are unclear. Here we co-house MARV-inoculated donor ERBs with naive contact ERBs. MARV shedding is detected in oral, rectal and urine specimens from inoculated bats from 5-19 days post infection. Simultaneously, MARV is detected in oral specimens from contact bats, indicating oral exposure to the virus. In the late study phase, we provide evidence that MARV can be horizontally transmitted from inoculated to contact ERBs by finding MARV RNA in blood and oral specimens from contact bats, followed by MARV IgG antibodies in these same bats. This study demonstrates that MARV can be horizontally transmitted from inoculated to contact ERBs, thereby providing a model for filovirus maintenance in its natural reservoir host and a potential mechanism for virus spillover to other animals. C1 [Schuh, Amy J.; Amman, Brian R.; Jones, Megan E. B.; Sealy, Tara K.; Uebelhoer, Luke S.; Spengler, Jessica R.; Martin, Brock E.; Coleman-McCray, Jo Ann D.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. [Jones, Megan E. B.; Towner, Jonathan S.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA. [Jones, Megan E. B.] San Diego Zoo Global, Inst Conservat Res, Wildlife Dis Lab, Escondido, CA 92027 USA. [Uebelhoer, Luke S.] Oregon Hlth & Sci Univ, Childhood Dev & Rehabil Ctr, Portland, OR 97239 USA. [Martin, Brock E.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. RP Towner, JS (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Viral Special Pathogens Branch, Atlanta, GA 30333 USA.; Towner, JS (reprint author), Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA. EM jit8@cdc.gov FU DTRA Grant [HDTRA-14-1-0016, S-1340-03] FX We thank Peter Eworonsky, Lester Slough, Eddie Jackson, Sharon Dietz and Abiola Aminu from the Centers for Disease Control and Prevention's Comparative Medicine Branch for providing care and support of the bats. This study was funded in part by DTRA Grant HDTRA-14-1-0016, Subaward S-1340-03. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 56 TC 0 Z9 0 U1 10 U2 10 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD FEB 13 PY 2017 VL 8 AR 14446 DI 10.1038/ncomms14446 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EK3FP UT WOS:000393812100001 PM 28194016 ER PT J AU Paes, JA Lorenzatto, KR de Moraes, SN Moura, H Barr, JR Ferreira, HB AF Paes, Jessica A. Lorenzatto, Karina R. de Moraes, Sofia N. Moura, Hercules Barr, John R. Ferreira, Henrique B. TI Secretomes of Mycoplasma hyopneumoniae and Mycoplasma flocculare reveal differences associated to pathogenesis SO JOURNAL OF PROTEOMICS LA English DT Article DE Mycoplasma hyopneumoniae; Mycoplasma flocculare; Secretome; Comparative analyses; LC-MS/MS ID PROTEIN FAMILIES DATABASE; PROTEOMIC ANALYSIS; MASS-SPECTROMETRY; STATISTICAL-MODEL; COG DATABASE; SWINE; STRAINS; SUIPNEUMONIAE; PATHOGENICITY; EXPRESSION AB Mycoplasma hyopneumoniae and Mycoplasma flocculare cohabit the porcine respiratory tract. However, M. hyopneumoniae causes the porcine enzootic pneumonia, while M. flocculare is a commensal bacterium. Comparative analyses demonstrated high similarity between these species, which includes the sharing of all predicted virulence factors. Nevertheless, studies related to soluble secretomes of mycoplasmas were little known, although they are important for bacterial-host interactions. The aim of this study was to perform a comparative analysis between the soluble secreted proteins repertoires of the pathogenic Mycoplasma hyopneumoniae and its closely related commensal Mycoplasma flocculare. For that, bacteria were cultured in medium with reduced serum concentration and secreted proteins were identified by a LC-MS/MS proteomics approach. Altogether, 62 and 26 proteins were identified as secreted by M. hyopneumoniae and M. flocculare, respectively, being just seven proteins shared between these bacteria. In M. hyopneumoniae secretome, 15 proteins described as virulence factors were found; while four putative virulence factors were identified in M. flocculare secretome. For the first time, clear differences related to virulence were found between these species, helping to elucidate the pathogenic nature of M. hyopneumoniae to swine hosts. Biological significance: For the first time, the secretomes of two porcine respiratory mycoplasmas, namely the pathogenic M. hyopneumoniae and the commensal M. flocculare were compared. The presented results revealed previously unknown differences between these two genetically related species, some of which are associated to the M. hyopneumoniae ability to cause porcine enzootic pneumonia. (C) 2016 Elsevier B.V. All rights reserved. C1 [Paes, Jessica A.; Lorenzatto, Karina R.; de Moraes, Sofia N.; Ferreira, Henrique B.] Univ Fed Rio Grande do Sul, Lab Genom Estrutural & Func, Ctr Biotecnol, Ave Bento Goncalves 9500, Porto Alegre, RS, Brazil. [Moura, Hercules; Barr, John R.] Ctr Dis Control & Prevent, Biol Mass Spectrometry Lab, Clin Chem Branch, Div Lab Sci,Natl Ctr Environm Hlth, Atlanta, GA USA. RP Ferreira, HB (reprint author), Univ Fed Rio Grande do Sul, Lab Genom Estrutural & Func, Ctr Biotecnol, Caixa Postal 15005, BR-91501970 Porto Alegre, RS, Brazil. EM henrique@cbiot.ufrgs.br FU Fundacao de Amparo a Pesquisa do Estado Rio Grande do Sul (FAPERGS) [19752551/13-3]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil) FX We thank to Empresa Brasileira de Pesquisa Agropecuaria-Centro Nacional de Pesquisa de Suinos e Ayes (EMBRAPA-CNPSA) for kindly donate M. flocculare ATCC 27716. This work was supported by Fundacao de Amparo a Pesquisa do Estado Rio Grande do Sul (FAPERGS, Grant 19752551/13-3). J.A.P. and K.R.L were recipients of Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil) Ph.D. and post-doctoral fellowships, respectively. NR 52 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1874-3919 EI 1876-7737 J9 J PROTEOMICS JI J. Proteomics PD FEB 10 PY 2017 VL 154 BP 69 EP 77 DI 10.1016/j.jprot.2016.12.002 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA EK8RK UT WOS:000394191200008 PM 28003119 ER PT J AU Graham, KA Fox, DJ Talati, A Pantea, C Brady, L Carter, SL Friedenberg, E Vora, NM Browne, ML Lee, CT AF Graham, Krishika A. Fox, Deborah J. Talati, Achala Pantea, Cristian Brady, Laura Carter, Sondra L. Friedenberg, Eric Vora, Neil M. Browne, Marilyn L. Lee, Christopher T. TI Prevalence and Clinical Attributes of Congenital Microcephaly - New York, 2013-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID BIRTH-DEFECTS C1 [Graham, Krishika A.; Talati, Achala] New York City Dept Hlth & Mental Hyg, Div Epidemiol, Publ Hlth Prevent Med Residency Program, Long Isl City, NY 11101 USA. [Fox, Deborah J.; Pantea, Cristian; Brady, Laura; Browne, Marilyn L.] New York State Dept Hlth, Congenital Malformat Registry, Albany, NY 12237 USA. [Carter, Sondra L.; Friedenberg, Eric; Vora, Neil M.; Lee, Christopher T.] New York City Dept Hlth & Mental Hyg, Div Dis Control, Long Isl City, NY USA. [Vora, Neil M.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Lee, Christopher T.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Graham, KA (reprint author), New York City Dept Hlth & Mental Hyg, Div Epidemiol, Publ Hlth Prevent Med Residency Program, Long Isl City, NY 11101 USA.; Fox, DJ (reprint author), New York State Dept Hlth, Congenital Malformat Registry, Albany, NY 12237 USA. EM kgraham1@health.nyc.gov; deb.fox@health.ny.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 10 PY 2017 VL 66 IS 5 BP 125 EP 129 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL1US UT WOS:000394407400001 PM 28182608 ER PT J AU Weiss, D Tomasallo, CD Meiman, JG Alarcon, W Graber, NM Bisgard, KM Anderson, HA AF Weiss, Debora Tomasallo, Carrie D. Meiman, Jon G. Alarcon, Walter Graber, Nathan M. Bisgard, Kristine M. Anderson, Henry A. TI Elevated Blood Lead Levels Associated with Retained Bullet Fragments - United States, 2003-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Weiss, Debora; Meiman, Jon G.] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA. [Weiss, Debora; Tomasallo, Carrie D.; Meiman, Jon G.; Anderson, Henry A.] Wisconsin Dept Hlth Serv, Bur Environm & Occupat Hlth, Madison, WI 53703 USA. [Alarcon, Walter] CDC, NIOSH, Atlanta, GA 30333 USA. [Graber, Nathan M.] New York State Dept Hlth, Albany, NY 12237 USA. [Bisgard, Kristine M.] CDC, Ctr Surveillance, Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Weiss, D (reprint author), CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA 30333 USA.; Weiss, D (reprint author), Wisconsin Dept Hlth Serv, Bur Environm & Occupat Hlth, Madison, WI 53703 USA. EM DWeiss2@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 10 PY 2017 VL 66 IS 5 BP 130 EP 133 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL1US UT WOS:000394407400002 PM 28182606 ER PT J AU Robinson, CL Romero, JR Kempe, A Pellegrini, C AF Robinson, Candice L. Romero, Jose R. Kempe, Allison Pellegrini, Cynthia CA Advisory Comm Immunization Practic TI Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID VACCINATION C1 [Robinson, Candice L.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Romero, Jose R.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Romero, Jose R.] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA. [Kempe, Allison] Univ Colorado, Dept Pediat, Anschutz Med Campus, Denver, CO 80202 USA. [Pellegrini, Cynthia] March Dimes, Washington, DC USA. RP Robinson, CL (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM crobinson4@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 10 PY 2017 VL 66 IS 5 BP 134 EP 135 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL1US UT WOS:000394407400003 PM 28182607 ER PT J AU Kim, DK Riley, LE Harriman, KH Hunter, P Bridges, CB AF Kim, David K. Riley, Laura E. Harriman, Kathleen H. Hunter, Paul Bridges, Carolyn B. TI Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kim, David K.; Bridges, Carolyn B.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Riley, Laura E.] Harvard Univ, Cambridge, MA 02138 USA. [Harriman, Kathleen H.] Calif Dept Publ Hlth, Sacramento, CA USA. [Hunter, Paul] Univ Wisconsin, Madison, WI 53706 USA. RP Kim, DK (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM dkim@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 10 PY 2017 VL 66 IS 5 BP 136 EP 138 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL1US UT WOS:000394407400004 PM 28182599 ER PT J AU Carroll, YI Eichwald, J Scinicariello, F Hoffman, HJ Deitchman, S Radke, MS Themann, CL Breysse, P AF Carroll, Yulia I. Eichwald, John Scinicariello, Franco Hoffman, Howard J. Deitchman, Scott Radke, Marilyn S. Themann, Christa L. Breysse, Patrick TI Vital Signs: Noise-Induced Hearing Loss Among Adults - United States 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTH AB Introduction: The 2016 National Academies of Sciences report "Hearing Health Care for Adults: Priorities for Improving Access and Affordability" included a call to action for government agencies to strengthen efforts to collect, analyze, and disseminate population-based data on hearing loss in adults. Methods: CDC analyzed the most recent available data collected both by questionnaire and audiometric tests of adult participants aged 20-69 years in the 2011-2012 National Health. and Nutrition Examination Survey (NHANES) to determine the presence of audiometric notches indicative of noise-induced hearing loss. Prevalence of both unilateral and,bilateral audiometric notches and their association with sociodemographics and self-reported exposure to loud noise were calculated. Results: Nearly one in four adults (24%) had audiometric notches, suggesting a high prevalence of noise-induced hearing loss. The prevalence of notches was higher among males. Almost one in four U.S. adults who reported excellent or good hearing had audiometric notches (5.5% bilateral and 18.0% unilateral). Among participants who reported exposure to loud noise at work, almost one third had a notch. Conclusions and Implications for Public Health Practice: Noise-induced hearing loss is a significant, often unrecognized health problem among U.S. adults. Discussions between patients and personal health care providers about hearing loss symptoms, tests, and ways to protect hearing might help with early diagnosis of hearing loss and provide opportunities to prevent harmful noise expoSures. Avoiding prolonged exposure to loud environments and using personal hearing protection devices can prevent noise-induced hearing loss. C1 [Carroll, Yulia I.; Eichwald, John] CDC, Off Sci, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Scinicariello, Franco] Agcy Toxic Subst & Dis Registry, Div Toxicol & Human Hlth Serv, Atlanta, GA USA. [Hoffman, Howard J.] NIDCD, NIH, Bethesda, MD USA. [Deitchman, Scott; Breysse, Patrick] CDC, Off Director, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Radke, Marilyn S.] CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Themann, Christa L.] CDC, NIOSH, Atlanta, GA 30333 USA. RP Carroll, YI (reprint author), CDC, Off Sci, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM YCarroll@cdc.gov NR 16 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 10 PY 2017 VL 66 IS 5 BP 139 EP 144 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL1US UT WOS:000394407400005 PM 28182600 ER PT J AU Wang, A Issa, A Bayleyegn, T Noe, RS Mullarkey, C Casani, J Nelson, CL Fleischauer, A Clement, KD Hamilton, JJ Harrison, C Edison, L Hobron, K Kurkjian, KM Choudhary, E Wolkin, A AF Wang, Alice Issa, Anindita Bayleyegn, Tesfaye Noe, Rebecca S. Mullarkey, Christine Casani, Julie Nelson, Craig L. Fleischauer, Aaron Clement, Kimberly D. Hamilton, Janet J. Harrison, Christopher Edison, Laura Hobron, Kathrin Kurkjian, Katie M. Choudhary, Ekta Wolkin, Amy CA Hurricane Matthew Incident Managem CDC Emergency Operations Ctr TI Mortality Associated with Hurricane Matthew - United States, October 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Wang, Alice; Issa, Anindita] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Wang, Alice; Issa, Anindita; Bayleyegn, Tesfaye; Noe, Rebecca S.; Choudhary, Ekta; Wolkin, Amy] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Mullarkey, Christine; Casani, Julie; Fleischauer, Aaron; Clement, Kimberly D.] North Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Nelson, Craig L.] North Carolina Off Chief Med Examiner, Raleigh, NC USA. [Fleischauer, Aaron; Edison, Laura; Kurkjian, Katie M.] CDC, Career Epidemiol Field Officer Program, Atlanta, GA 30333 USA. [Hamilton, Janet J.] Florida Dept Hlth, Tallahassee, FL USA. [Harrison, Christopher; Edison, Laura] Georgia Dept Publ Hlth, Atlanta, GA USA. [Hobron, Kathrin; Kurkjian, Katie M.] Virginia Dept Hlth, Richmond, VA USA. RP Wang, A (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Wang, A (reprint author), CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM ilm1@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 10 PY 2017 VL 66 IS 5 BP 145 EP 146 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL1US UT WOS:000394407400006 PM 28182603 ER PT J AU Frishman, N Conway, KC Andrews, J Oleson, J Mathews, K Ciafaloni, E Oleszek, J Lamb, M Matthews, D Paramsothy, P McKirgan, L Romitti, P AF Frishman, Natalia Conway, Kristin Caspers Andrews, Jennifer Oleson, Jacob Mathews, Katherine Ciafaloni, Emma Oleszek, Joyce Lamb, Molly Matthews, Dennis Paramsothy, Pangaja McKirgan, Lowell Romitti, Paul TI Perceived quality of life among caregivers of children with a childhood-onset dystrophinopathy: a double ABCX model of caregiver stressors and perceived resources SO HEALTH AND QUALITY OF LIFE OUTCOMES LA English DT Article DE Becker muscular dystrophy; Caregivers; Duchenne muscular dystrophy; Dystrophinopathy; Muscular dystrophies; Quality of life ID DUCHENNE MUSCULAR-DYSTROPHY; AUTISM SPECTRUM DISORDER; NETWORK MD STARNET; SOCIAL SUPPORT; MULTIDIMENSIONAL SCALE; SURVEILLANCE TRACKING; PARENTAL STRESS; FAMILY FUNCTION; MOTHERS; WELL AB Background: Duchenne and Becker muscular dystrophies, collectively referred to as dystrophinopathies, are recessive X-linked disorders characterized by progressive muscle weakness and ultimately cardiac and respiratory failure. Immediate family members are often primary caregivers of individuals with a dystrophinopathy. Methods: We explored the impact of this role by inviting primary caregivers (n = 209) of males diagnosed with childhood-onset dystrophinopathy who were identified by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) to complete a mailed questionnaire measuring perceived social support and stress, spirituality, and family quality of life (FQoL). Bivariate and multivariate analyses examined associations between study variables using the Double ABCX model as an analytic framework. Results: Higher stressor pile-up was associated with lower perceived social support (r = -0.29, p <.001), availability of supportive family (r = -0.30, p <.001) or non-family (r = -0.19, p <.01) relationships, and higher perceived stress (r = 0.33, p <.001); but not with spirituality (r = -0.14, p > 0.05). FQoL was positively associated with all support measures (correlations ranged from: 0.25 to 0.58, p-values 0.01-0.001) and negatively associated with perceived stress and control (r = -0.49, p <.001). The association between stressor pile-up and FQoL was completely mediated through global perceived social support, supportive family relationships, and perceived stress and control; supportive non-family relationships did not remain statistically significant after controlling for other mediators. Conclusions: Findings suggest caregiver adaptation to a dystrophinopathy diagnosis can be optimized by increased perceived control, supporting family resources, and creation of a healthy family identity. Our findings will help identify areas for family intervention and guide clinicians in identifying resources that minimize stress and maximize family adaptation. C1 [Romitti, Paul] Univ Iowa, Coll Publ Hlth, Dept Epidemiol & Biostat, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA. [Romitti, Paul] Univ Iowa, Coll Publ Hlth, Interdisciplinary Program Toxicol, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA. [Frishman, Natalia; Conway, Kristin Caspers; McKirgan, Lowell] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. [Andrews, Jennifer] Univ Arizona, Dept Pediat, Tucson, AZ USA. [Oleson, Jacob] Univ Iowa, Dept Biostat, Iowa City, IA USA. [Mathews, Katherine] Univ Iowa, Dept Pediat, Iowa City, IA USA. [Mathews, Katherine] Univ Iowa, Dept Neurol, Iowa City, IA USA. [Ciafaloni, Emma] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY USA. [Ciafaloni, Emma] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY USA. [Oleszek, Joyce; Matthews, Dennis] Univ Colorado, Dept Phys Med & Rehabil, Aurora, CO USA. [Oleszek, Joyce; Matthews, Dennis] Univ Colorado, Childrens Hosp Colorado, Aurora, CO USA. [Lamb, Molly] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Paramsothy, Pangaja] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Frishman, Natalia] Gen Dynam Informat Technol, Coralville, IA USA. RP Romitti, P (reprint author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol & Biostat, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA.; Romitti, P (reprint author), Univ Iowa, Coll Publ Hlth, Interdisciplinary Program Toxicol, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA. EM paul-romitti@uiowa.edu FU CDC [5U01DD000831, 5U01DD000187, 5U01DD000189, 5U01DD000191, 5U01DD000190] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The writing of this manuscript was funded by CDC cooperative agreement 5U01DD000831. Data collection by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) was funded by CDC cooperative agreements: 5U01DD000187, 5U01DD000189, 5U01DD000191, and 5U01DD000190. NR 65 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1477-7525 J9 HEALTH QUAL LIFE OUT JI Health Qual. Life Outcomes PD FEB 10 PY 2017 VL 15 AR 33 DI 10.1186/s12955-017-0612-1 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EL7TA UT WOS:000394822300002 PM 28187773 ER PT J AU Sunderam, S Kissin, DM Crawford, SB Folger, SG Jamieson, DJ Warner, L Barfield, WD AF Sunderam, Saswati Kissin, Dmitry M. Crawford, Sara B. Folger, Suzanne G. Jamieson, Denise J. Warner, Lee Barfield, Wanda D. TI Assisted Reproductive Technology Surveillance - United States, 2014 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID IN-VITRO FERTILIZATION; SINGLE-EMBRYO-TRANSFER; MULTIPLE-BIRTH RISK; LIVE-BIRTH; FERTILITY TREATMENTS; INSURANCE MANDATES; PERINATAL OUTCOMES; PRETERM BIRTH; PREGNANCIES; IVF AB Problem/Condition: Since the first U.S. infant conceived with assisted reproductive technology (ART) was born in 1981, both the use of ART and the number of fertility clinics providing ART services have increased steadily in the United States. ART includes fertility treatments in which eggs or embryos are handled in the laboratory (i.e., in vitro fertilization [IVF] and related procedures). Women who undergo ART procedures are more likely than women who conceive naturally to deliver multiple-birth infants. Multiple births pose substantial risks to both mothers and infants, including obstetric complications, preterm delivery, and low birthweight infants. This report provides state-specific information for the United States (including the District of Columbia and Puerto Rico) on ART procedures performed in 2014 and compares birth outcomes that occurred in 2014 (resulting from ART procedures performed in 2013 and 2014) with outcomes for all infants born in the United States in 2014. Period Covered: 2014. Description of System: In 1996, CDC began collecting data on ART procedures performed in fertility clinics in the United States as mandated by the Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA) (Public Law 102493). Data are collected through the National ART Surveillance System (NASS), a web-based data collection system developed by CDC. This report includes data from 52 reporting areas (the 50 states, the District of Columbia, and Puerto Rico). Results: In 2014, a total of 169,568 ART procedures (range: 124 in Wyoming to 21,018 in California) with the intent to transfer at least one embryo were performed in 458 U.S. fertility clinics and reported to CDC. These procedures resulted in 56,028 live-birth deliveries (range: 52 in Wyoming to 7,230 in California) and 68,782 infants born (range: 64 in Wyoming to 8,793 in California). Nationally, the total number of ART procedures performed per million women of reproductive age (1544 years), a proxy measure of the ART usage rate, was 2,647 (range: 364 in Puerto Rico to 6,726 in Massachusetts). ART use exceeded the national average in 13 reporting areas (Connecticut, Delaware, the District of Columbia, Hawaii, Illinois, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Virginia). Eight reporting areas (Connecticut, the District of Columbia, Hawaii, Illinois, Maryland, Massachusetts, New Jersey, and New York) had rates of ART use exceeding 1.5 times the national average. Nationally, among ART transfer procedures in patients using fresh embryos from their own eggs, the average number of embryos transferred increased with increasing age of the woman (1.7 among women aged <35 years, 1.9 among women aged 3537 years, and 2.3 among women aged >37 years). Among women aged <35 years, who typically are considered to be good candidates for elective single embryo transfer (eSET) procedures, the national eSET rate was 28.5% (range: 4.3% in Puerto Rico to 67.9% in Delaware). In 2014, ART contributed to 1.6% of all infants born in the United States (range: 0.4% in Puerto Rico to 4.7% in Massachusetts) and 18.3% of all multiple-birth infants (range: 5.5% in Alaska and West Virginia to 37.3% in Hawaii), including 18.0% of all twin infants (range: 5.2% in some states to 36.2% in Hawaii) and 26.4% of all triplets and higher-order infants (range: 0% in some states to 65.2% in Hawaii). Percentages of live births that were multiple-birth deliveries were higher among infants conceived with ART (39.4%; range: 11.5% in Delaware to 55.6% in Puerto Rico) than among all infants born in the total birth population (3.5%; range: 2.2% in Puerto Rico to 4.4% in New Jersey). Approximately 38.0% of ART-conceived infants were twin infants, and 2.0% were triplets and higher-order infants. ART-conceived twins accounted for approximately 95.3% of all ART-conceived infants born in multiple deliveries. Nationally, infants conceived with ART contributed to 5.5% of all low birthweight (<2,500 g) infants (range: 1.2% in West Virginia to 14.2% in Massachusetts). Among ART-conceived infants, 27.8% were low birthweight (range: 10.6% in Delaware to 44.4% in Puerto Rico), compared with 8.0% among all infants (range: 5.9% in Alaska to 11.3% in Mississippi). ART-conceived infants contributed to 4.7% of all preterm (<37 weeks) infants (range: 1.2% in Puerto Rico to 13.4% in Massachusetts). Percentages of preterm births were higher among infants conceived with ART (33.2%; range: 18.9% in the District of Columbia to 45.9% in Puerto Rico) than among all infants born in the total birth population (11.3%; range: 8.5% in California to 16.0% in Mississippi). The percentage of ART-conceived infants who were low birthweight was 8.9% (range: 3.2% in some states to 16.1% in Vermont) among singletons and 55.2% (range: 38.5% in Delaware to 77.8% in Alaska) among twins; the corresponding percentages of low birthweight infants among all infants born were 6.3% for singletons (range: 4.6% in Alaska, North Dakota, and Oregon to 9.5% in Puerto Rico) and 55.2% for twins (range: 46.1% in Alaska to 65.6% in Mississippi). The percentage of ART-conceived infants who were preterm was 13.2% (range: 7.5% in Rhode Island to 23.4% in West Virginia) among singletons and 62.2% (range: 33.3% in some states to 81.4% in Mississippi) among twins; the corresponding percentages of preterm infants among all infants were 9.7% for singletons (range: 1.7% in the District of Columbia to 14.2% in Mississippi) and 56.6% for twins (range: 47.2% in Vermont to 66.9% in Wyoming). Interpretation: The percentage of infants conceived with ART varied considerably by reporting area. Multiple births from ART contributed to a substantial proportion of all twins, triplets, and higher-order infants born. Low birthweight and preterm infant birth rates were disproportionately higher among ART-conceived infants than among the overall birth population. Although women aged <35 years are typically considered good candidates for eSET, on average two embryos were transferred per ART procedure with women in this group. Compared with ART-conceived singletons, ART-conceived twins were approximately five times more likely to be born preterm and approximately six times more likely to be born with low birthweight. Singleton infants conceived with ART had higher percentages of preterm birth and low birthweight than all singleton infants born in the United States. ART use per population unit was geographically variable, with 13 reporting areas showing ART use higher than the national rate. Of the four states (Illinois, Massachusetts, New Jersey, and Rhode Island) with comprehensive statewide-mandated health insurance coverage for ART procedures (i.e., coverage for at least four cycles of IVF), three (Illinois, Massachusetts, and New Jersey) had rates of ART use exceeding 1.5 times the national rate. This type of mandated insurance has been associated with greater use of ART and likely accounts for some of the difference in per capita ART use observed among states. Public Health Action: Reducing the number of embryos transferred and increasing use of eSET when clinically appropriate could help reduce multiple births and related adverse health consequences. Because twins account for the majority of ART-conceived multiple births, improved provider practices and patient education and counseling on the maternal and infant health risks of having twins are needed. Although ART contributes to high percentages of multiple births, other factors not investigated in this report (e.g., delayed childbearing and use of non-ART fertility treatments) also contribute to multiple births and warrant further study. C1 [Sunderam, Saswati; Kissin, Dmitry M.; Crawford, Sara B.; Folger, Suzanne G.; Jamieson, Denise J.; Warner, Lee; Barfield, Wanda D.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30329 USA. RP Sunderam, S (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30329 USA. EM msunderam@cdc.gov NR 71 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD FEB 10 PY 2017 VL 66 IS 6 BP 1 EP 24 PG 24 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL1VA UT WOS:000394408300001 PM 28182605 ER PT J AU Kim, DK Riley, LE Harriman, KH Hunter, P Bridges, CB AF Kim, David K. Riley, Laura E. Harriman, Kathleen H. Hunter, Paul Bridges, Carolyn B. CA Advisory Comm Immunization Practic TI Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017 SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID ADVISORY-COMMITTEE; VACCINATION COVERAGE; VACCINES; POPULATIONS; US C1 [Kim, David K.; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Riley, Laura E.] Harvard Univ, Cambridge, MA USA. [Harriman, Kathleen H.] Calif Dept Publ Hlth, Richmond, CA USA. [Hunter, Paul] Univ Wisconsin, Madison, WI USA. RP Kim, DK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30329 USA. EM dkim@cdc.gov FU U.S. Department of Health and Human Services FX To assure the integrity of the ACIP, the U.S. Department of Health and Human Services has taken steps to ensure technical adherence to ethics statutes and regulations regarding financial conflicts of interest. Concerns regarding the potential for the appearance of a conflict are addressed, or avoided altogether, through pre- and postappointment considerations. Individuals with particular vaccine- related interests will not be considered for appointment to the committee. Potential nominees are screened for conflicts of interest, and if any are found, they are asked to divest or forgo certain vaccine- related activities. In addition, at the beginning of each ACIP meeting, each member is asked to declare his or her conflicts. Members with conflicts are not permitted to vote if the conflict involves the vaccine or biological being voted on. Details can be found at www.cdc.gov/vaccines/acip/committee/structure-role.html. Conflict of interest disclosures of members of the ACIP are available at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-293 6. NR 11 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 7 PY 2017 VL 166 IS 3 BP 209 EP + DI 10.7326/M16-2936 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA EL7DL UT WOS:000394781200010 PM 28166560 ER PT J AU Cornick, JE Bishop, OT Yalcin, F Kiran, AM Kumwenda, B Chaguza, C Govindpershad, S Ousmane, S Senghore, M du Plessis, M Pluschke, G Ebruke, C Mcgee, L Sigauque, B Collard, JM Bentley, SD Kadioglu, A Antonio, M von Gottberg, A French, N Klugman, KP Heyderman, RS Alderson, M Everett, DB AF Cornick, Jennifer E. Bishop, Oezlem Tastan Yalcin, Feyruz Kiran, Anmol M. Kumwenda, Benjamin Chaguza, Chrispin Govindpershad, Shanil Ousmane, Sani Senghore, Madikay du Plessis, Mignon Pluschke, Gerd Ebruke, Chinelo McGee, Lesley Sigauque, Beutel Collard, Jean-Marc Bentley, Stephen D. Kadioglu, Aras Antonio, Martin von Gottberg, Anne French, Neil Klugman, Keith P. Heyderman, Robert S. Alderson, Mark Everett, Dean B. CA PAGe Consortium TI The global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1 SO VACCINE LA English DT Article DE Protein modelling; Structural diversity; Antigenic diversity; Antigenic profiling; Variant; Pneumococcal disease; Multi-valent; PCV ID PNEUMONIAE; DISEASE; PNEUMOCOCCI; MENINGITIS; PREDICTION; OUTBREAK; CHILDREN; SERVER AB Serotype 1 is one of the most common causes of pneumococcal disease worldwide. Pneumococcal protein vaccines are currently being developed as an alternate intervention strategy to pneumococcal conjugate vaccines. Pre-requisites for an efficacious pneumococcal protein vaccine are universal presence and minimal variation of the target antigen in the pneumococcal population, and the capability to induce a robust human immune response. We used in silico analysis to assess the prevalence of seven protein vaccine candidates (CbpA, PcpA, PhtD, PspA, SP0148, SP1912, SP2108) among 445 serotype 1 pneumococci from 26 different countries, across four continents. CbpA (76%), PspA (68%), PhtD (28%), PcpA (11%) were not universally encoded in the study population, and would not provide full coverage against serotype 1. PcpA was widely present in the European (82%), but not in the African (2%) population. A multi-valent vaccine incorporating CbpA, PcpA, PhtD and PspA was predicted to provide coverage against 86% of the global population. SP0148, SP1912 and SP2108 were universally encoded and we further assessed their predicted amino acid, antigenic and structural variation. Multiple allelic variants of these proteins were identified, different allelic variants dominated in different continents; the observed variation was predicted to impact the antigenicity and structure of two SP0148 variants, one SP1912 variant and four SP2108 variants, however these variants were each only present in a small fraction of the global population (<2%). The vast majority of the observed variation was predicted to have no impact on the efficaciousness of a protein vaccine incorporating a single variant of SP0148, SP1912 and/or SP2108 from S. pneumoniae TIGR4. Our findings emphasise the importance of taking geographic differences into account when designing global vaccine interventions and support the continued development of SP0148, SP1912 and SP2108 as protein vaccine candidates against this important pneumococcal serotype. (C) 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. C1 [Cornick, Jennifer E.; Kiran, Anmol M.; Kumwenda, Benjamin; Chaguza, Chrispin; Heyderman, Robert S.; Everett, Dean B.] Queen Elizabeth Cent Hosp, Malawi Liverpool Wellcome Trust Clin Res Programm, POB 30096, Blantyre 3, Malawi. [Cornick, Jennifer E.; Kiran, Anmol M.; Chaguza, Chrispin; Kadioglu, Aras; French, Neil; Everett, Dean B.] Univ Liverpool, Inst Infect & Global Hlth, Clin Infect Microbiol & Immunol, Liverpool L69 7BE, Merseyside, England. [Bishop, Oezlem Tastan; Bentley, Stephen D.] Rhodes Univ, Dept Biochem & Microbiol, Res Unit Bioinformat RUBi, Grahamstown, South Africa. [Yalcin, Feyruz] Wellcome Trust Sanger Inst, Pathogen Genom, Wellcome Trust Genome Campus, Cambridge CB10 ISA, England. [Ousmane, Sani; Collard, Jean-Marc] Ctr Rech Med & Sanit, Niamey, Niger. [Senghore, Madikay; Ebruke, Chinelo; Antonio, Martin] MRC, Banjul, Gambia. [Senghore, Madikay; Antonio, Martin] Univ Warwick, Div Translat & Syst Med, Microbiol & Infect Unit, Coventry CV4 7AL, W Midlands, England. [Govindpershad, Shanil; du Plessis, Mignon; von Gottberg, Anne] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Govindpershad, Shanil; du Plessis, Mignon; von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa. [Pluschke, Gerd] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [McGee, Lesley] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sigauque, Beutel] Ctr Invest Saude Manhica, Maputo, Mozambique. [Antonio, Martin] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England. [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Alderson, Mark] PATH, Seattle, WA USA. RP Cornick, JE (reprint author), Queen Elizabeth Cent Hosp, Malawi Liverpool Wellcome Trust Clin Res Programm, POB 30096, Blantyre 3, Malawi. EM j.cornick@liv.ac.uk OI Tastan Bishop, Ozlem/0000-0001-6861-7849 FU Bill and Melinda Gates Foundation [OPP1023440]; Wellcome Trust [084679/Z/08/Z]; National Research Foundation of South Africa [93690]; NIH Common Fund Award (H3A Bionet) [U41HG006941] FX This work supported by the Bill and Melinda Gates Foundation (Grant No. OPP1023440), Wellcome Trust (Award No. 084679/Z/08/Z), National Research Foundation of South Africa (Grant No. 93690) and the NIH Common Fund Award (H3A Bionet) (Grant No. U41HG006941). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the funders. NR 25 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 7 PY 2017 VL 35 IS 6 BP 972 EP 980 DI 10.1016/j.vaccine.2016.12.037 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EK8SX UT WOS:000394196000019 PM 28081968 ER PT J AU Mathews, TP Carter, MD Johnson, D Isenberg, SL Graham, LA Thomas, JD Johnson, RC AF Mathews, Thomas P. Carter, Melissa D. Johnson, Darryl Isenberg, Samantha L. Graham, Leigh Ann Thomas, Jerry D. Johnson, Rudolph C. TI High-Confidence Qualitative Identification of Organophosphorus Nerve Agent Adducts to Human Butyrylcholinesterase SO ANALYTICAL CHEMISTRY LA English DT Article ID TANDEM MASS-SPECTROMETRY; IMMUNOMAGNETIC-UHPLC-MS/MS; CHEMICAL WARFARE AGENTS; HUMAN-SERUM; RETROSPECTIVE DETECTION; EXPOSURE; CHOLINESTERASE; SARIN; ACETYLCHOLINESTERASE; PHOSPHONYLATION AB In this study, a data-dependent, high-resolution tandem mass spectrometry (ddHRMS/MS) method capable of detecting all organophosphorus nerve agent (OPNA) adducts to human butyrylcholinesterase (BChE) was developed. After an exposure event, immunoprecipitation from blood with a BChE-specific antibody and digestion with pepsin produces a nine amino acid peptide containing the OPNA adduct. Signature product ions of this peptic BChE nonapeptide (FGES*AGAAS) offer a route to broadly screen for OPNA exposure. Taking this approach on an HRMS instrument identifies biomarkers, including unknowns, with high mass accuracy. Using a set of pooled human sera exposed to OPNAs as quality control (QC) materials, the developed method successfully identified precursor ions with <1 ppm and tied them to signature product ions with <5 ppm deviation from their chemical formulas. This high mass accuracy data from precursor and product ions, collected over 23 independent immunoprecipitation preparations, established method operating limits. QC data and experiments with 14 synthetic reference peptides indicated that reliable qualitative identification of biomarkers was possible for analytes >15 ng/mL. The developed method was applied to a convenience set of 96 unexposed serum samples and a blinded set of 80 samples treated with OPNAs. OPNA biomarkers were not observed in convenience set samples and no false positive or negative identifications were observed in blinded samples. All biomarkers in the blinded serum set >15 ng/mL were correctly identified. For the first time, this study reports a ddHRIVIS/MS method capable of complementing existing quantitative methodologies and suitable for identifying exposure to unknown organophosphorus agents. C1 [Mathews, Thomas P.; Graham, Leigh Ann] Battelle Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Carter, Melissa D.; Isenberg, Samantha L.; Thomas, Jerry D.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Johnson, Darryl] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ, Atlanta, GA 30341 USA. RP Carter, MD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. EM melissa.carter@cdc.hhs.gov FU Defense Threat Reduction Agency, Office of Public Health Preparedness and Response at the Centers for Disease Control; Oak Ridge Institute for Science Education FX This work was supported by the Defense Threat Reduction Agency, Office of Public Health Preparedness and Response at the Centers for Disease Control, and the Oak Ridge Institute for Science Education. The authors would like to thank Ms. Chariety Sapp for dispensing individual serum for convenience set analysis and distribution of blinded samples. NR 36 TC 0 Z9 0 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD FEB 7 PY 2017 VL 89 IS 3 BP 1955 EP 1964 DI 10.1021/acs.analchem.6b04441 PG 10 WC Chemistry, Analytical SC Chemistry GA EK2DQ UT WOS:000393738300076 PM 28208252 ER PT J AU Vijayakumar, P Hoyer, A Nelson, RG Brinks, R Pavkov, ME AF Vijayakumar, Pavithra Hoyer, Annika Nelson, Robert G. Brinks, Ralph Pavkov, Meda E. TI Estimation of chronic kidney disease incidence from prevalence and mortality data in American Indians with type 2 diabetes SO PLOS ONE LA English DT Article ID PIMA-INDIANS; RISK-FACTORS; MELLITUS; ESRD; MICROALBUMINURIA; ALBUMINURIA; POPULATION; ANTIBODIES; REMISSION; EQUATION AB The objective was to estimate chronic kidney disease (CKD) incidence rates from prevalence and mortality data, and compare the estimates with observed (true) incidence rates in a well-characterized population with diabetes. Pima Indians aged 20 years and older with type 2 diabetes were followed from 1982 through 2007. CKD was defined by estimated GFR (eGFR) <60 ml/min/1.72 m(2) or albumin-to-creatinine ratio (ACR) >= 30 mg/g. True CKD incidence and mortality rates were computed for the whole study period, and prevalence for the intervals 1982-1994 and 1995-2007. Estimated age-sex stratified CKD incidence rates were computed using illness-death models of the observed prevalences, and of the whole period mortality rate ratio of CKD to non-CKD persons. Among 1201 participants, 616 incident events of CKD occurred during a median follow-up of 5.6 years. Observed CKD prevalence was 56.9% (95%X153.7-60.0) and 48.0% (95%X145.2-50.8) in women; 54.0% (95% CI 49.9-58.1) and 49.6% (95%C 46.0-53.3) in men, across the two periods. Mortality rate was 2.5 (95%CI 11.9-3.3) times as high in women with CKD and 1.6 (95%Cl 1.3-2.1) times as high in men with CKD, compared to women or men without CKD. In women, estimated CKD incidence increased linearly from 25.6 (95%CI14.2-53.0) to 128.6 (95%CI177.1-196.6) with each 5-year age group up to 69 years, and to 99.8 (95% CI 38.7-204.7) at age >= 70. In men, estimated CKD incidence increased form 28.5 (95% CI13.8-71.2) at age 20-24 years to 118.7 (95%CI123.6-336.7) at age >= 70. Age-sex-stratified estimated incidence reflected the magnitude and directional trend of the true incidence and were similar to the true incidence rates (p>0.05 for difference) except for age 20-24 in women (p = 0.008) and age 2529 in men (p = 0.002). In conclusion, the estimated and observed incidence rates of CKD agree well over 25 years of observation in this well characterized population with type 2 diabetes. C1 [Vijayakumar, Pavithra; Nelson, Robert G.] NIDDK, NIH, Phoenix, AZ USA. [Hoyer, Annika; Brinks, Ralph] German Diabet Ctr Duesseldorf, Inst Epidemiol & Biometry, Dusseldorf, Germany. [Pavkov, Meda E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. [Pavkov, Meda E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Pavkov, ME (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA.; Pavkov, ME (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM mpavkov@cdc.gov FU Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases FX This work was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The authors received no specific funding for this work. There was no additional external funding received for this study. NR 27 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 6 PY 2017 VL 12 IS 2 AR e0171027 DI 10.1371/journal.pone.0171027 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EK1QH UT WOS:000393700100020 PM 28166298 ER PT J AU Thongnoi, P Praphasiri, P Dawood, FS Lindblade, KA AF Thongnoi, Pipat Praphasiri, Prabda Dawood, Fatimah S. Lindblade, Kim A. TI Maternal death from influenza in tropical Thailand SO LANCET LA English DT Editorial Material ID WOMEN C1 [Thongnoi, Pipat] Phon Thong Hosp, Sa Nok Kaeo, Roi Et Province, Thailand. [Praphasiri, Prabda; Lindblade, Kim A.] US Ctr Dis Control & Prevent, Thailand Minist Publ Hlth, Influenza Program, Nonthaburi, Thailand. [Dawood, Fatimah S.; Lindblade, Kim A.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Praphasiri, P (reprint author), Minist Publ Hlth, Thailand MOPH US CDC Collaborat, Nonthaburi 11000, Thailand. EM hpu3@cdc.gov NR 4 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD FEB 4 PY 2017 VL 389 IS 10068 BP 571 EP 572 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EJ5UH UT WOS:000393283400039 PM 28170335 ER PT J AU Matthews, KA Croft, JB Liu, Y Lu, H Kanny, D Wheaton, AG Cunningham, TJ Khan, LK Caraballo, RS Holt, JB Eke, PI Giles, WH AF Matthews, Kevin A. Croft, Janet B. Liu, Yong Lu, Hua Kanny, Dafna Wheaton, Anne G. Cunningham, Timothy J. Khan, Laura Kettel Caraballo, Ralph S. Holt, James B. Eke, Paul I. Giles, Wayne H. TI Health-Related Behaviors by Urban-Rural County Classification - United States, 2013 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID AREAS; OBESITY AB Problem/Condition: Persons living in rural areas are recognized as a health disparity population because the prevalence of disease and rate of premature death are higher than for the overall population of the United States. Surveillance data about health-related behaviors are rarely reported by urban-rural status, which makes comparisons difficult among persons living in metropolitan and nonmetropolitan counties. Reporting Period: 2013. Description of System: The Behavioral Risk Factor Surveillance System (BRFSS) is an ongoing, state-based, random-digit dialed landline- and cellular-telephone survey of noninstitutionalized adults aged years residing in the United States. BRFSS collects data on health-risk behaviors, chronic diseases and conditions, access to health care, and use of preventive health services related to the leading causes of death and disability. BRFSS data were analyzed for 398,208 adults aged 18 years to estimate the prevalence of five self-reported health-related behaviors (sufficient sleep, current nonsmoking, nondrinking or moderate drinking, maintaining normal body weight, and meeting aerobic leisure time physical activity recommendations) by urban-rural status. For this report, rural is defined as the noncore counties described in the 2013 National Center for Health Statistics Urban-Rural Classification Scheme for Counties. Results: Approximately one third of U.S. adults practice at least four of these five behaviors. Compared with adults living in the four types of metropolitan counties (large central metropolitan, large fringe metropolitan, medium metropolitan, and small metropolitan), adults living in the two types of nonmetropolitan counties (micropolitan and noncore) did not differ in the prevalence of sufficient sleep; had higher prevalence of nondrinking or moderate drinking; and had lower prevalence of current nonsmoking, maintaining normal body weight, and meeting aerobic leisure time physical activity recommendations. The overall age-adjusted prevalence of reporting at least four of the five health-related behaviors was 30.4%. The prevalence among the estimated 13.3 million adults living in noncore counties was lower (27.0%) than among those in micropolitan counties (28.8%), small metropolitan counties (29.5%), medium metropolitan counties (30.5%), large fringe metropolitan counties (30.2%), and large metropolitan centers (31.7%). Interpretation: This is the first report of the prevalence of these five health-related behaviors for the six urban-rural categories. Nonmetropolitan counties have lower prevalence of three and clustering of at least four health-related behaviors that are associated with the leading chronic disease causes of death. Prevalence of sufficient sleep was consistently low and did not differ by urban-rural status. Public Health Action: Chronic disease prevention efforts focus on improving the communities, schools, worksites, and health systems in which persons live, learn, work, and play. Evidence-based strategies to improve health-related behaviors in the population of the United States can be used to reach the Healthy People 2020 objectives for these five self-reported health-related behaviors (sufficient sleep, current nonsmoking, nondrinking or moderate drinking, maintaining normal body weight, and meeting aerobic leisure time physical activity 'recommendations). These findings suggest an ongoing need to increase public awareness and public education, particularly in rural counties where prevalence of these health-related behaviors is lowest. C1 [Matthews, Kevin A.; Croft, Janet B.; Liu, Yong; Lu, Hua; Kanny, Dafna; Wheaton, Anne G.; Cunningham, Timothy J.; Holt, James B.; Eke, Paul I.; Giles, Wayne H.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Khan, Laura Kettel] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Caraballo, Ralph S.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Matthews, KA (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM yrp4@cdc.gov NR 21 TC 0 Z9 0 U1 5 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD FEB 3 PY 2017 VL 66 IS 5 BP 1 EP 8 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL4AB UT WOS:000394561200001 PM 28151923 ER PT J AU Dailey, AF Johnson, AS Wu, BH AF Dailey, Andre F. Johnson, Anna Satcher Wu, Baohua TI National Black HIV/AIDS Awareness Day - February 7, 2017 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CARE C1 [Dailey, Andre F.; Johnson, Anna Satcher; Wu, Baohua] CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Dailey, AF (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM ADailey@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 3 PY 2017 VL 66 IS 4 BP 1 EP 7 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EJ6RY UT WOS:000393347700002 ER PT J AU McCree, DH Sutton, M Bradley, E Harris, N AF McCree, Donna Hubbard Sutton, Madeline Bradley, Erin Harris, Norma TI Changes in the Disparity of HIV Diagnosis Rates Among Black Women - United States, 2010-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [McCree, Donna Hubbard; Sutton, Madeline; Bradley, Erin; Harris, Norma] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP McCree, DH (reprint author), CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM drriccree@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 3 PY 2017 VL 66 IS 4 BP 8 EP 10 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EJ6RY UT WOS:000393347700003 ER PT J AU Miller, G Merlo, C Demissie, Z Sliwa, S Park, S AF Miller, Gabrielle Merlo, Caitlin Demissie, Zewditu Sliwa, Sarah Park, Sohyun TI Trends in Beverage Consumption Among High School Students - United States, 2007-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID US CHILDREN; ADULTS; ADOLESCENCE; HEALTH; FRUIT C1 [Miller, Gabrielle] CDC, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Merlo, Caitlin; Sliwa, Sarah] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Demissie, Zewditu] CDC, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Demissie, Zewditu] US PHS, Commissioned Corps, Rockville, MD USA. [Park, Sohyun] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Merlo, C (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ihb7@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 3 PY 2017 VL 66 IS 4 BP 16 EP 20 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EJ6RY UT WOS:000393347700005 ER PT J AU Marlow, MA Pambasange, MACD Francisco, C Receado, ODB Soares, MJ Silva, S Navarro-Colorado, C Zielinski-Gutierrez, E AF Marlow, Mariel A. Pambasange, Maria Augusta Chitula de Feliciano Francisco, Constantino Receado, Odete Da Conceicao Bambi Soares, Maria Jose Silva, Sandra Navarro-Colorado, Carlos Zielinski-Gutierrez, Emily TI Knowledge, Attitudes, and Practices Regarding Yellow Fever Vaccination Among Men During an Outbreak - Luanda, Angola, 2016 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Marlow, Mariel A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Marlow, Mariel A.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Pambasange, Maria Augusta Chitula de Feliciano; Francisco, Constantino; Receado, Odete Da Conceicao Bambi; Soares, Maria Jose] Minist Hlth, Angola Field Epidemiol & Lab Training Program, Luanda, Angola. [Silva, Sandra] WHO, Geneva, Switzerland. [Navarro-Colorado, Carlos] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Zielinski-Gutierrez, Emily] CDC, Div Global HIV & TB Kenya, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Marlow, MA (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA.; Marlow, MA (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM mmarlow@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD FEB 3 PY 2017 VL 66 IS 4 BP 21 EP 22 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EJ6RY UT WOS:000393347700006 ER PT J AU Rader, EP Naimo, MA Ensey, J Baker, BA AF Rader, Erik P. Naimo, Marshall A. Ensey, James Baker, Brent A. TI Agonist muscle adaptation accompanied by antagonist muscle atrophy in the hindlimb of mice following stretch-shortening contraction training SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article DE Stretch-shortening contractions; Plantarflexor muscles; Dorsiflexor muscles; C57BL6 mice; Myosin heavy chain; Muscle physiology; Biomechanics; Muscle fiber type ID RAT SKELETAL-MUSCLE; FIBER HYPERPLASIA; OLD RATS; RECOVERY; EXERCISE; GROWTH; IMMOBILIZATION; PERFORMANCE; EXPOSURE; MYOGENIN AB Background: The vast majority of dynamometer-based animal models for investigation of the response to chronic muscle contraction exposure has been limited to analysis of isometric, lengthening, or shortening contractions in isolation. An exception to this has been the utilization of a rat model to study stretch-shortening contractions (SSCs), a sequence of consecutive isometric, lengthening, and shortening contractions common during daily activity and resistance-type exercise. However, the availability of diverse genetic strains of rats is limited. Therefore, the purpose of the present study was to develop a dynamometer-based SSC training protocol to induce increased muscle mass and performance in plantarflexor muscles of mice. Methods: Young (3 months old) C57BL/6 mice were subjected to 1 month of plantarflexion SSC training. Hindlimb muscles were analyzed for muscle mass, quantitative morphology, myogenesis/myopathy relevant gene expression, and fiber type distribution. Results: The main aim of the research was achieved when training induced a 2-fold increase in plantarflexion peak torque output and a 19% increase in muscle mass for the agonist plantaris (PLT) muscle. In establishing this model, several outcomes emerged which raised the value of the model past that of being a mere recapitulation of the rat model. An increase in the number of muscle fibers per transverse muscle section accounted for the PLT muscle mass gain while the antagonist tibialis anterior (TA) muscle atrophied by 30% with preferential atrophy of type IIb and IIx fibers. These alterations were accompanied by distinct gene expression profiles. Conclusions: The findings confirm the development of a stretch-shortening contraction training model for the PLT muscle of mice and demonstrate that increased cross-sectional fiber number can occur following high-intensity SSC training. Furthermore, the TA muscle atrophy provides direct evidence for the concept of muscle imbalance in phasic non-weight bearing muscles, a concept largely characterized based on clinical observation of patients. The susceptibility to this imbalance is demonstrated to be selective for the type IIb and IIx muscle fiber types. Overall, the study highlights the importance of considering muscle fiber number modulation and the effect of training on surrounding muscles in exercise comprised of SSCs. C1 [Rader, Erik P.; Naimo, Marshall A.; Ensey, James; Baker, Brent A.] Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, MS L3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. [Naimo, Marshall A.] West Virginia Univ, Sch Med, Div Exercise Physiol, Morgantown, WV 26506 USA. RP Rader, EP (reprint author), Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, MS L3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM WLZ4@cdc.gov FU internal National Institute for Occupational Safety and Health funds FX This study was supported by internal National Institute for Occupational Safety and Health funds. The funding body did not have a role in the design of the study, collection, analysis, interpretation of data, and writing of the manuscript. NR 64 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD FEB 2 PY 2017 VL 18 AR 60 DI 10.1186/s12891-017-1397-4 PG 15 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA EM3HH UT WOS:000395204600003 PM 28148306 ER PT J AU Rutledge, GG Bohme, U Sanders, M Rrid, AJ Cotton, JA Maiga-Ascofare, O Djimde, AA Apinjoh, TO Amenga-Etego, L Manske, M Barnwell, JW Renaud, F Ollomo, B Prugnolle, F Anstey, NM Auburn, S Price, RN McCarthy, JS Kwiatkowski, DP Newbold, CI Berriman, M Otto, TD AF Rutledge, Gavin G. Bohme, Ulrike Sanders, Mandy Rrid, Adam J. Cotton, James A. Maiga-Ascofare, Oumou Djimde, Abdoulaye A. Apinjoh, Tobias O. Amenga-Etego, Lucas Manske, Magnus Barnwell, John W. Renaud, Francois Ollomo, Benjamin Prugnolle, Franck Anstey, Nicholas M. Auburn, Sarah Price, Ric N. McCarthy, James S. Kwiatkowski, Dominic P. Newbold, Chris I. Berriman, Matthew Otto, Thomas D. TI Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution SO NATURE LA English DT Article ID GENE-EXPRESSION; PROTEIN FAMILIES; SEQUENCING DATA; WEB SERVER; I-TASSER; FALCIPARUM; ALGORITHM; ALIGNMENT; TRANSCRIPTS; BRASILIANUM AB Elucidation of the evolutionary history and interrelatedness of Plasmodium species that infect humans has been hampered by a lack of genetic information for three human-infective species: P. malariae and two P. ovale species (P. o. curtisi and P. o. wallikeri)(1). These species are prevalent across most regions in which malaria is endemic(2,3) and are often undetectable by light microscopy(4), rendering their study in human populations difficult(5). The exact evolutionary relationship of these species to the other human-infective species has been contested(6,7). Using a new reference genome for P. malariae and a manually curated draft P. o. curtisi genome, we are now able to accurately place these species within the Plasmodium phylogeny. Sequencing of a P. malariae relative that infects chimpanzees reveals similar signatures of selection in the P. malariae lineage to another Plasmodium lineage shown to be capable of colonization of both human and chimpanzee hosts. Molecular dating suggests that these host adaptations occurred over similar evolutionary timescales. In addition to the core genome that is conserved between species, differences in gene content can be linked to their specific biology. The genome suggests that P. malariae expresses a family of heterodimeric proteins on its surface that have structural similarities to a protein crucial for invasion of red blood cells. The data presented here provide insight into the evolution of the Plasmodium genus as a whole. C1 [Rutledge, Gavin G.; Bohme, Ulrike; Sanders, Mandy; Rrid, Adam J.; Cotton, James A.; Djimde, Abdoulaye A.; Manske, Magnus; Berriman, Matthew; Otto, Thomas D.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England. [Maiga-Ascofare, Oumou; Amenga-Etego, Lucas; Barnwell, John W.] Univ Sci Techn & Technol Bamako, Malaria Res & Training Ctr, BP E 2528, Bamako, Mali. [Sanders, Mandy; Apinjoh, Tobias O.; Auburn, Sarah] German Ctr Infect Res, D-20359 Hamburg, Germany. [Cotton, James A.; Manske, Magnus; Auburn, Sarah; Price, Ric N.] Univ Buea, Post Off Box 63, Buea, South West Regi, Cameroon. [Sanders, Mandy; Apinjoh, Tobias O.; McCarthy, James S.] Navrongo Hlth Res Ctr, Post Off Box 114, Navrongo, Upper East Regi, Ghana. [Cotton, James A.; Amenga-Etego, Lucas; Ollomo, Benjamin; Anstey, Nicholas M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Rrid, Adam J.; Barnwell, John W.; Renaud, Francois; Ollomo, Benjamin; Prugnolle, Franck; Auburn, Sarah] UM1 CNRS IRD, Lab MIVEGEC, F-34394 Montpellier, France. [Sanders, Mandy; Djimde, Abdoulaye A.; Manske, Magnus; Prugnolle, Franck; Price, Ric N.] Ctr Int Recherches Med Franceville, BP 709 Franceville, Franceville, Gabon. [Sanders, Mandy; Apinjoh, Tobias O.; Anstey, Nicholas M.] Menzies Sch Hlth Res & Charles Darwin Univ, Global & Trop Hlth Div, Darwin, NT, Australia. [Sanders, Mandy; Djimde, Abdoulaye A.; Barnwell, John W.; Prugnolle, Franck] Univ Oxford, Nuffield Dept Clin Med, Ctr Top Med & Global Hlth, Oxford OX3 7LJ, England. [Bohme, Ulrike; Berriman, Matthew] Univ Queensland, QIMR Berghofer Med Res Inst, Clin Trop Med Lab, Brisbane, Qld, Australia. [Rrid, Adam J.; Djimde, Abdoulaye A.; Barnwell, John W.; McCarthy, James S.; Kwiatkowski, Dominic P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England. [Sanders, Mandy; Renaud, Francois; McCarthy, James S.; Newbold, Chris I.] Univ Oxford, Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England. RP Berriman, M; Otto, TD (reprint author), Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England. EM mb4@sanger.ac.uk; tdo@sanger.ac.uk OI Kwiatkowski, Dominic/0000-0002-5023-0176; Manske, Magnus/0000-0001-5916-0947 FU Medical Research Council [MR/J004111/1, MR/L008661/1]; Wellcome Trust [098051, 091625, 104792/Z/14/Z]; ANR JCJC ORIGIN; LMI Zofac; CNRS; IRD; CIRMF; NHMRC [1041802, 1042072] FX This work was supported by the Medical Research Council (MR/J004111/1; MR/L008661/1) and the Wellcome Trust (098051). S.A. and R.N.P. are funded by the Wellcome Trust (091625). F.R., B.O. and F.P. are financed by the ANR JCJC 2012 ORIGIN, the LMI Zofac, as well as by CNRS, IRD, and CIRMF. C.I.N. is funded by a Wellcome Trust Investigator Award (104792/Z/14/Z). A.A.D. is funded as a Sanger International Fellow. J.S.M. and N.M.A. are supported by NHMRC Practitioner Fellowships (1041802; 1042072). The authors thank E. Willaume from the Park of La Lekedi and the people involved in the sanitary controls of the chimpanzees. The authors also thank P. Griffin and S. Sekuloski for assistance in collection of P. malariae isolate PmGN01. NR 77 TC 1 Z9 1 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD FEB 2 PY 2017 VL 542 IS 7639 BP 101 EP + DI 10.1038/nature21038 PG 20 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN6MY UT WOS:000396119300039 PM 28117441 ER PT J AU Mosites, E Sammons, M Otiang, E Eng, A Noecker, C Manor, O Hilton, S Thumbi, SM Onyango, C Garland-Lewis, G Call, DR Njenga, MK Wasserheit, JN Zambriski, JA Walson, JL Palmer, GH Montgomery, J Borenstein, E Omore, R Rabinowitz, PM AF Mosites, Emily Sammons, Matt Otiang, Elkanah Eng, Alexander Noecker, Cecilia Manor, Ohad Hilton, Sarah Thumbi, Samuel M. Onyango, Clayton Garland-Lewis, Gemina Call, Douglas R. Njenga, M. Kariuki Wasserheit, Judith N. Zambriski, Jennifer A. Walson, Judd L. Palmer, Guy H. Montgomery, Joel Borenstein, Elhanan Omore, Richard Rabinowitz, Peter M. TI Microbiome sharing between children, livestock and household surfaces in western Kenya SO PLOS ONE LA English DT Article ID GUT MICROBIOTA; DIVERSITY; COMMUNITIES; IMPACT; AGE AB The gut microbiome community structure and development are associated with several health outcomes in young children. To determine the household influences of gut microbiome structure, we assessed microbial sharing within households in western Kenya by sequencing 16S rRNA libraries of fecal samples from children and cattle, cloacal swabs from chickens, and swabs of household surfaces. Among the 156 households studied, children within the same household significantly shared their gut microbiome with each other, although we did not find significant sharing of gut microbiome across host species or household surfaces. Higher gut microbiome diversity among children was associated with lower wealth status and involvement in livestock feeding chores. Although more research is necessary to identify further drivers of microbiota development, these results suggest that the household should be considered as a unit. Livestock activities, health and microbiome perturbations among an individual child may have implications for other children in the household. C1 [Mosites, Emily; Garland-Lewis, Gemina; Rabinowitz, Peter M.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. [Mosites, Emily; Sammons, Matt; Thumbi, Samuel M.; Call, Douglas R.; Njenga, M. Kariuki; Zambriski, Jennifer A.; Palmer, Guy H.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA. [Otiang, Elkanah; Onyango, Clayton; Omore, Richard] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Eng, Alexander; Noecker, Cecilia; Manor, Ohad; Hilton, Sarah; Borenstein, Elhanan] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Wasserheit, Judith N.; Walson, Judd L.; Rabinowitz, Peter M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Wasserheit, Judith N.; Walson, Judd L.] Univ Washington, Dept Med, Seattle, WA USA. [Wasserheit, Judith N.; Walson, Judd L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Walson, Judd L.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Montgomery, Joel] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. [Borenstein, Elhanan] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA. [Borenstein, Elhanan] Santa Fe Inst, Santa Fe, NM 87501 USA. [Rabinowitz, Peter M.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA. RP Garland-Lewis, G (reprint author), Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. EM gemina@uw.edu FU Bill and Melinda Gates Foundation: Grand Challenges Explorations [OPP1098757]; NIH post-doctoral fellowship [NIH T32 AI07025]; Washington State University, College of Veterinary Medicine, Summer Research Scholars Program; UW Center for One Health Research FX This work was supported by the Bill and Melinda Gates Foundation: Grand Challenges Explorations Grant Number OPP1098757. http://gcgh.grandchallenges.org/about. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. It also received support from an NIH post-doctoral fellowship (NIH T32 AI07025) for author EM. https://researchtraining.nih.gov/programs/training-grants/T32. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Washington State University, College of Veterinary Medicine, Summer Research Scholars Program (internal) provided support for author MS. http://www.vetmed.wsu.edu/research/student-research/research-scholars. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. UW Center for One Health Research (internal, supplemental) also provided support. http.//deohs.washington.edu/cohr/. Author PR is the director of the Center for One Health Research and played a role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. Supplemental funding was provided by the Center only to complete additional data analysis. NR 44 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 2 PY 2017 VL 12 IS 2 AR e0171017 DI 10.1371/journal.pone.0171017 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN7DB UT WOS:000396161200073 ER PT J AU Plucinski, MM Dimbu, PR Macaia, AP Ferreira, CM Samutondo, C Quivinja, J Afonso, M Kiniffo, R Mbounga, E Kelley, JS Patel, DS He, Y Talundzic, E Garrett, DO Halsey, ES Udhayakumar, V Ringwald, P Fortes, F AF Plucinski, Mateusz M. Dimbu, Pedro Rafael Macaia, Aleixo Panzo Ferreira, Carolina Miguel Samutondo, Claudete Quivinja, Joltim Afonso, Marilia Kiniffo, Richard Mbounga, Eliane Kelley, Julia S. Patel, Dhruviben S. He, Yun Talundzic, Eldin Garrett, Denise O. Halsey, Eric S. Udhayakumar, Venkatachalam Ringwald, Pascal Fortes, Filomeno TI Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015 SO MALARIA JOURNAL LA English DT Article ID INDIVIDUAL PATIENT DATA; ARTEMISININ RESISTANCE; DRUG-RESISTANCE; PFMDR1; POLYMORPHISMS; ASSOCIATION; ALLELES; AFRICA AB Background: Recent anti-malarial resistance monitoring in Angola has shown efficacy of artemether-lumefantrine (AL) in certain sites approaching the key 90% lower limit of efficacy recommended for artemisinin-based combination therapy. In addition, a controversial case of malaria unresponsive to artemisinins was reported in a patient infected in Lunda Sul Province in 2013. Methods: During January-June 2015, investigators monitored the clinical and parasitological response of children with uncomplicated Plasmodium falciparum infection treated with AL, artesunate-amodiaquine (ASAQ), or dihydroartemisinin-piperaquine (DP). The study comprised two treatment arms in each of three provinces: Benguela (AL, ASAQ), Zaire (AL, DP), and Lunda Sul (ASAQ, DP). Samples from treatment failures were analysed for molecular markers of resistance for artemisinin (K13) and lumefantrine (pfmdr1). Results: A total of 467 children reached a study endpoint. Fifty-four treatment failures were observed: four early treatment failures, 40 re-infections and ten recrudescences. Excluding re-infections, the 28-day microsatellite-corrected efficacy was 96.3% (95% CI 91-100) for AL in Benguela, 99.9% (95-100) for ASAQ in Benguela, 88.1% (81-95) for AL in Zaire, and 100% for ASAQ in Lunda Sul. For DP, the 42-day corrected efficacy was 98.8% (96-100) in Zaire and 100% in Lunda Sul. All treatment failures were wild type for K13, but all AL treatment failures had pfmdr1 haplotypes associated with decreased lumefantrine susceptibility. Conclusions: No evidence was found to corroborate the specific allegation of artemisinin resistance in Lunda Sul. The efficacy below 90% of AL in Zaire matches findings from 2013 from the same site. Further monitoring, particularly including measurement of lumefantrine blood levels, is recommended. C1 [Plucinski, Mateusz M.; Kelley, Julia S.; Patel, Dhruviben S.; He, Yun; Talundzic, Eldin; Garrett, Denise O.; Halsey, Eric S.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA. [Plucinski, Mateusz M.; Garrett, Denise O.; Halsey, Eric S.] Ctr Dis Control & Prevent, Presidents Malaria Initiat, Atlanta, GA 30333 USA. [Dimbu, Pedro Rafael; Ferreira, Carolina Miguel; Afonso, Marilia; Fortes, Filomeno] Minist Hlth, Natl Malaria Control Program, Luanda, Angola. [Macaia, Aleixo Panzo] Agostinho Neto Univ, Fac Med, Luanda, Angola. [Samutondo, Claudete; Quivinja, Joltim] Minist Hlth, Field Epidemiol & Lab Training Programme, Luanda, Angola. [Kiniffo, Richard] WHO, Luanda, Angola. [Mbounga, Eliane] USAID, Presidents Malaria Initiat, Luanda, Angola. [Kelley, Julia S.; Talundzic, Eldin] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Ringwald, Pascal] WHO, Global Malaria Programme, Geneva, Switzerland. RP Plucinski, MM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, 1600 Clifton Rd, Atlanta, GA 30329 USA.; Plucinski, MM (reprint author), Ctr Dis Control & Prevent, Presidents Malaria Initiat, Atlanta, GA 30333 USA. EM mplucinski@cdc.gov FU US President's Malaria Initiative (PMI); Global Malaria Programme, WHO; PMI Artemisinin Resistance Monitoring in Africa (PARMA) Network FX The study was funded by the US President's Malaria Initiative (PMI) and the Global Malaria Programme, WHO. Molecular marker testing was funded as part of the PMI Artemisinin Resistance Monitoring in Africa (PARMA) Network. NR 29 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 2 PY 2017 VL 16 AR 62 DI 10.1186/s12936-017-1712-4 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA EK0NX UT WOS:000393624500004 PM 28153004 ER PT J AU Curtis, KM Peipert, JF AF Curtis, Kathryn M. Peipert, Jeffrey F. TI Long-Acting Reversible Contraception SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID MEDICAL ELIGIBILITY CRITERIA; PELVIC-INFLAMMATORY-DISEASE; BREAST-FEEDING WOMEN; INTRAUTERINE-DEVICE; UNINTENDED PREGNANCY; UNITED-STATES; EXTENDED USE; LEVONORGESTREL; ETONOGESTREL; INSERTION AB A 17-year-old high school student who has never been pregnant presents for advice regarding contraception. She has an unremarkable medical history and is planning to become sexually active with her boyfriend in the near future. Her primary concern is an unintended pregnancy, and she inquires about methods of contraception that are highly effective. How would you counsel her about options for contraception? C1 [Curtis, Kathryn M.] Ctr Dis Control & Prevent, MS F-17,4770 Buford Hwy NE, Atlanta, GA 30341 USA. [Peipert, Jeffrey F.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA. RP Curtis, KM (reprint author), Ctr Dis Control & Prevent, MS F-17,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM kmc6@cdc.gov FU Teva Pharmaceuticals; Perrigo Pharmaceuticals; Bayer Healthcare; Merck FX Dr. Peipert reports receiving fees for serving on advisory boards from Teva Pharmaceuticals and Perrigo Pharmaceuticals and grant support from Bayer Healthcare, Teva Pharmaceuticals, and Merck. No other potential conflict of interest relevant to this article was reported. NR 53 TC 1 Z9 1 U1 2 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 2 PY 2017 VL 376 IS 5 BP 461 EP 468 DI 10.1056/NEJMcp1608736 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EJ8WH UT WOS:000393507200009 PM 28146650 ER PT J AU Millman, AJ Greenbaum, A Walaza, S Cohen, AL Groome, MJ Reed, C McMorrow, M Tempia, S Venter, M Treurnicht, FK Madhi, SA Cohen, C Variava, E AF Millman, Alexander J. Greenbaum, Adena Walaza, Sibongile Cohen, Adam L. Groome, Michelle J. Reed, Carrie McMorrow, Meredith Tempia, Stefano Venter, Marietjie Treurnicht, Florette K. Madhi, Shabir A. Cohen, Cheryl Variava, Ebrahim TI Development of a respiratory severity score for hospitalized adults in a high HIV-prevalence setting-South Africa, 2010-2011 SO BMC PULMONARY MEDICINE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; PREDICTION RULE; VALIDATION; MODELS AB Background: Acute lower respiratory tract infections (LRTI) are a frequent cause of hospitalization and mortality in South Africa; however, existing respiratory severity scores may underestimate mortality risk in HIV-infected adults in resource limited settings. A simple predictive clinical score for low-resource settings could aid healthcare providers in the management of patients hospitalized with LRTI. Methods: We analyzed 1,356 LRTI hospitalizations in adults aged >= 18 years enrolled in Severe Acute Respiratory Illness (SARI) surveillance in three South African hospitals from January 2010 to December 2011. Using demographic and clinical data at admission, we evaluated potential risk factors for in-hospital mortality. We evaluated three existing respiratory severity scores, CURB-65, CRB-65, and Classification Tree Analysis (CTA) Score assessing for discrimination and calibration. We then developed a new respiratory severity score using a multivariable logistic regression model for in-hospital mortality and assigned points to risk factors based on the coefficients in the multivariable model. Finally we evaluated the model statistically using bootstrap resampling techniques. Results: Of the 1,356 patients hospitalized with LRTI, 101 (7.4%) died while hospitalized. The CURB-65, CRB-65, and CTA scores had poor calibration and demonstrated low discrimination with c-statistics of 0.594, 0.548, and 0.569 respectively. Significant risk factors for in-hospital mortality included age >= 45 years (A), confusion on admission (C), HIV-infection (H), and serum blood urea nitrogen >7 mmol/L (U), which were used to create the seven-point ACHU clinical predictor score. In-hospital mortality, stratified by ACHU score was: score <= 1, 2.4%, score 2, 6.4%, score 3, 11. 9%, and score >= 4, 29.3%. Final models showed good discrimination (c-statistic 0.789) and calibration (chi-square 1.6, Hosmer-Lemeshow goodness-of-fit p-value = 0.904) and discriminated well in the bootstrap sample (average optimism of 0.003). Conclusions: Existing clinical predictive scores underestimated mortality in a low resource setting with a high HIV burden. The ACHU score incorporates a simple set a risk factors that can accurately stratify patients >= 18 years of age with LRTI by in-hospital mortality risk. This score can quantify in-hospital mortality risk in an HIV-endemic, resource-limited setting with limited clinical information and if used to facilitate timely treatment may improve clinical outcomes. C1 [Millman, Alexander J.; Greenbaum, Adena; Cohen, Adam L.; Reed, Carrie; McMorrow, Meredith; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Millman, Alexander J.; Greenbaum, Adena] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Cohen, Adam L.; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa. [Walaza, Sibongile; Tempia, Stefano; Treurnicht, Florette K.; Madhi, Shabir A.; Cohen, Cheryl] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Walaza, Sibongile; Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa. [Groome, Michelle J.; Madhi, Shabir A.] Univ Witwatersrand, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Venter, Marietjie] Ctr Dis Control & Prevent, Div Global Hlth Protect, Global Dis Detect Ctr, Pretoria, South Africa. [Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonoses Res Program, Pretoria, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa. [Variava, Ebrahim] Klerksdorp Tshepong Hosp Complex, Dept Med, Klerksdorp, South Africa. [Variava, Ebrahim] Univ Witwatersrand, Dept Med, Fac Hlth Sci, Johannesburg, South Africa. [Variava, Ebrahim] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa. RP Millman, AJ (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA.; Millman, AJ (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. EM amillman@cdc.gov FU Centers for Disease Control and Prevention FX This study was funded by the Centers for Disease Control and Prevention. NR 15 TC 0 Z9 0 U1 4 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2466 J9 BMC PULM MED JI BMC Pulm. Med. PD FEB 2 PY 2017 VL 17 AR 28 DI 10.1186/s12890-017-0368-8 PG 8 WC Respiratory System SC Respiratory System GA EJ6QO UT WOS:000393344100001 PM 28148246 ER PT J AU Barrera, R Acevedo, V Felix, GE Hemme, RR Vazquez, J Munoz, JL Amador, M AF Barrera, Roberto Acevedo, Veronica Felix, Gilberto E. Hemme, Ryan R. Vazquez, Jesus Munoz, Jorge L. Amador, Manuel TI Impact of Autocidal Gravid Ovitraps on Chikungunya Virus Incidence in Aedes aegypti (Diptera: Culicidae) in Areas With and Without Traps SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE mosquito control; Aedes aegypti; arboviral transmission; invasive species; vector-borne pathogen ID DENGUE TRANSMISSION; LETHAL OVITRAP; VECTOR CONTROL; PUERTO-RICO; ZIKA VIRUS; 1ST REPORT; SURVEILLANCE; POPULATIONS; COMMUNITIES; PERFORMANCE AB Puerto Rico detected the first confirmed case of chikungunya virus (CHIKV) in May 2014 and the virus rapidly spread throughout the island. The invasion of CHIKV allowed us to observe Aedes aegypti (L.) densities, infection rates, and impact of vector control in urban areas using CDC autocidal gravid ovitraps (AGO traps) for mosquito control over several years. Because local mosquitoes can only get the virus from infectious residents, detecting the presence of virus in mosquitoes functions as a proxy for the presence of virus in people. We monitored the incidence of CHIKV in gravid females of Ae. aegypti in four neighborhoods- two with three AGO traps per home in most homes and two nearby neighborhoods without AGO mosquito control traps. Monitoring of mosquito density took place weekly using sentinel AGO traps from June to December 2014. In all, 1,334 pools of female Ae. aegypti (23,329 individuals) were processed by real- time reverse transcription PCR to identify CHIKV and DENV RNA. Density of Ae. aegypti females was 10.5 times lower (91%) in the two areas with AGO control traps during the study. Ten times (90.9%) more CHIKV- positive pools were identified in the nonintervention areas (50/55 pools) than in intervention areas (5/55). We found a significant linear relationship between the number of positive pools and both density of Ae. aegypti and vector index (average number of expected infected mosquitoes per trap per week). Temporal and spatial patterns of positive CHIKV pools suggested limited virus circulation in areas with AGO traps. C1 [Barrera, Roberto; Acevedo, Veronica; Felix, Gilberto E.; Hemme, Ryan R.; Amador, Manuel] Ctr Dis Control & Prevent, Entomol & Ecol Act, Dengue Branch, San Juan, PR 00920 USA. [Vazquez, Jesus; Munoz, Jorge L.] Ctr Dis Control & Prevent, Mol Diagnost Lab, Dengue Branch, San Juan, PR USA. RP Barrera, R (reprint author), Ctr Dis Control & Prevent, Entomol & Ecol Act, Dengue Branch, San Juan, PR 00920 USA. EM rbarrera@cdc.gov; gra3@cdc.gov; ckn5@cdc.gov; wma0@cdc.gov; jvazquez@cdc.gov; ckq2@cdc.gov; maa4@cdc.gov FU Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention FX We thank the residents and Municipalities of Salinas and Guayama and our technical personnel Orlando Gonzalez, Juan Medina, Jose Gonzalez, and Luis Rivera. Funding was provided by the Division of Vector Borne Infectious Diseases, Centers for Disease Control and Prevention. This investigation would not have been possible without the support of Dr. Harold Margolis, Chief of the CDC Dengue Branch. NR 52 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD FEB PY 2017 VL 54 IS 2 BP 387 EP 395 DI 10.1093/jme/tjw187 PG 9 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA EQ5ED UT WOS:000398103900017 ER PT J AU Dolan, MC Schulze, TL Jordan, RA Schulze, CJ Ullmann, AJ Hojgaard, A Williams, MA Piesman, J AF Dolan, Marc C. Schulze, Terry L. Jordan, Robert A. Schulze, Christopher J. Ullmann, Amy J. Hojgaard, Andrias Williams, Martin A. Piesman, Joseph TI Evaluation of Doxycycline-Laden Oral Bait and Topical Fipronil Delivered in a Single Bait Box to Control Ixodes scapularis (Acari: Ixodidae) and Reduce Borrelia burgdorferi and Anaplasma phagocytophilum Infection in Small Mammal Reservoirs and Host-Seeking Ticks SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Lyme disease; Borrelia burgdorferi; Ixodes scapularis; bait box; doxycycline ID AMBLYOMMA-AMERICANUM ACARI; HUMAN GRANULOCYTIC EHRLICHIOSIS; FOREST FLOOR ARTHROPODS; LYME-DISEASE; GRANULAR DELTAMETHRIN; RODENT RESERVOIRS; SAMPLING METHODS; MURINE MODEL; NEW-JERSEY; HYCLATE AB A field trial was conducted on residential properties in a Lyme disease endemic area of New Jersey to determine the efficacy of Maxforce Tick Management System (TMS) bait boxes modified with doxycycline hyclate-laden bait to reduce the acarological risk of Lyme disease and the utility of galvanized steel shrouds to protect the bait boxes from squirrel depredation and ability to routinely service these devices. The strategy began with a 9-wk deployment against larvae followed by a 17-wk deployment against nymphs and larvae the second year. Passive application of fipronil reduced nymphal and larval tick burdens on small mammals by 76 and 77%, respectively, and nymphal tick abundance by 81% on treated properties. In addition, the percentage of infected small mammals recovered from intervention areas following treatment was reduced by 96% for Borrelia burgdorferi and 93% for Anaplasma phagocytophilum. Infection prevalence in host-seeking nymphal ticks for both B. burgdorferi and A. phagocytophilum were reduced by 93 and 61%, respectively. Results indicate that MaxforceTMS bait boxes fitted with doxycycline-impregnated bait is an effective means of reducing ticks and infection prevalence for B. burgdorferi and A. phagocytophilum in both rodent reservoirs and questing Ixodes scapularis Say ticks. The protective shroud allows the device to be routinely serviced and protect against squirrel depredation. C1 [Dolan, Marc C.; Ullmann, Amy J.; Hojgaard, Andrias; Williams, Martin A.; Piesman, Joseph] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Enter & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. [Schulze, Terry L.; Schulze, Christopher J.] Terry L Schulze PhD Inc, 9 Evergreen Court, Perrineville, NJ 08535 USA. [Jordan, Robert A.] Monmouth Cty Mosquito Exterminat Commiss, POB 162, Eatontown, NJ 07724 USA. [Jordan, Robert A.] Monmouth Cty Mosquito Control Div, Tick Borne Dis Program, 1901 Wayside Rd, Tinton Falls, NJ 07724 USA. [Piesman, Joseph] Colorado State Univ, Coll Agr Sci, Dept Bioagr Sci & Pest Management, Ft Collins, CO USA. RP Dolan, MC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Enter & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM marc.dolan@cdc.hhs.gov; tlschulze@monmouth.com; rajordanphd@optimum.net; cjschulze1@gmail.com; aff1@cdc.gov; fth3@cdc.gov; martinrwilliam-s@hotmail.com; j.piesman@comcast.net FU Centers for Disease Control and Prevention [200-2008-M-25420] FX We thank the Millstone Township, New Jersey residents who graciously allowed us access to their properties to conduct this study. The authors thank Dr. Lars Eisen for critical review of the manuscript. The current research was supported by a contract (200-2008-M-25420) from the Centers for Disease Control and Prevention to Terry L. Schulze, Ph.D., Inc. NR 35 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD FEB PY 2017 VL 54 IS 2 BP 403 EP 410 DI 10.1093/jme/tjw194 PG 8 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA EQ5ED UT WOS:000398103900019 ER PT J AU Allerdice, MEJ Hecht, JA Karpathy, SE Paddock, CD AF Allerdice, Michelle E. J. Hecht, Joy A. Karpathy, Sandor E. Paddock, Christopher D. TI Evaluation of Gulf Coast Ticks (Acari: Ixodidae) for Ehrlichia and Anaplasma Species SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Amblyomma maculatum; Gulf Coast tick; Anaplasma; Ehrlichia ID WHITE-TAILED DEER; AMBLYOMMA-AMERICANUM ACARI; LONE STAR TICKS; REAL-TIME PCR; UNITED-STATES; RICKETTSIA-PARKERI; ODOCOILEUS-VIRGINIANUS; EWINGII INFECTION; NORTH-CAROLINA; CHAFFEENSIS RICKETTSIALES AB Amblyomma maculatum Koch (the Gulf Coast tick) is an aggressive, human-biting ixodid tick distributed throughout much of the southeastern United States and is the primary vector for Rickettsia parkeri, an emerging human pathogen. Amblyommamaculatum has diverse host preferences that include white-tailed deer, a known reservoir for Ehrlichia and Anaplasma species, including the human pathogens E. ewingii and E. chaffeensis. To examine more closely the potential role of A. maculatum in the maintenance of various pathogenic Ehrlichia and Anaplasma species, we screened DNA samples from 493 questing adult A. maculatum collected from six U. S. states using broad-range Anaplasmataceae and Ehrlichia genus-specific PCR assays. Of the samples tested, four (0.8%) were positive for DNA of Ehrlichia ewingii, one (0.2%) was positive for Anaplasma platys, and one (0.2%) was positive for a previously unreported Ehrlichia species closely related to Ehrlichia muris and an uncultivated Ehrlichia species from Haemaphysalis longicornis ticks in Japan. No ticks contained DNA of Ehrlichia chaffeensis, Ehrlichia canis, the Panola Mountain Ehrlichia, or Anaplasma phagocytophilum. This is the first identification of E. ewingii, A. platys, and the novel Ehrlichia in questing Gulf Coast ticks; nonetheless the low prevalence of these agents suggests that A. maculatum is not likely an important vector of these zoonotic pathogens. C1 [Allerdice, Michelle E. J.; Hecht, Joy A.; Karpathy, Sandor E.; Paddock, Christopher D.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. RP Allerdice, MEJ (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM mallerdice@cdc.gov; jhecht@cdc.gov; skarpathy@cdc.gov; CPaddock@cdc.gov NR 45 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD FEB PY 2017 VL 54 IS 2 BP 481 EP 484 DI 10.1093/jme/tjw176 PG 4 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA EQ5ED UT WOS:000398103900030 ER PT J AU Neumann, MS Finlayson, TJ Pitts, NL Keatley, J AF Neumann, Mary Spink Finlayson, Teresa J. Pitts, Nicole L. Keatley, JoAnne TI Comprehensive HIV Prevention for Transgender Persons SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID SEXUALLY-TRANSMITTED-DISEASES; RISK-REDUCTION INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; SAN-FRANCISCO; BEHAVIORS; WOMEN; SEX; MEN; EFFICACY; COMMUNITY AB Transgender persons are at high risk for HIV infection, but prevention efforts specifically targeting these people have been minimal. Part of the challenge of HIV prevention for transgender populations is that numerous individual, interpersonal, social, and structural factors contribute to their risk. By combining HIV prevention services with complementary medical, legal, and psychosocial services, transgender persons' HIV risk behaviors, risk determinants, and overall health can be affected simultaneously. For maximum health impact, comprehensive HIV prevention for transgender persons warrants efforts targeted to various impact levels-socioeconomic factors, decision-making contexts, long-lasting protections, clinical interventions, and counseling and education. We present current HIV prevention efforts that reach transgender persons and present others for future consideration. C1 [Neumann, Mary Spink; Finlayson, Teresa J.] Ctr Dis Control & Prevent CDC, Off Director, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Pitts, Nicole L.] ICF Int, Atlanta, GA USA. [Keatley, JoAnne] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. RP Neumann, MS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-E37, Atlanta, GA 30329 USA. EM mneumann@cdc.gov NR 44 TC 0 Z9 0 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2017 VL 107 IS 2 BP 207 EP 212 DI 10.2105/AJPH.2016.303509 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO9XG UT WOS:000397040800012 PM 27997228 ER PT J AU Shelley, G Williams, W Uhl, G Hoyte, T Eke, A Wright, C Rebchook, G Pollack, L Bell, K Wang, Y Cheng, Q Kegeles, SM AF Shelley, Gene Williams, Weston Uhl, Gary Hoyte, Tamoka Eke, Adanze Wright, Carolyn Rebchook, Gregory Pollack, Lance Bell, Kelly Wang, Yan Cheng, Qi Kegeles, Susan M. TI AN EVALUATION OF MPOWERMENT ON INDIVIDUAL-LEVEL HIV RISK BEHAVIOR, TESTING, AND PSYCHOSOCIAL FACTORS AMONG YOUNG MSM OF COLOR: THE MONITORING AND EVALUATION OF MP (MEM) PROJECT SO AIDS EDUCATION AND PREVENTION LA English DT Article ID PREVENTION INTERVENTION; AGGRESSIVE BOYS; UNITED-STATES; GAY AB Young men who have sex with men (MSM) of color are at increased risk for HIV infection. Mpowerment (MP) is an intervention designed to reduce risky sexual behavior and increase HIV testing among young MSM ages 18-29. From 2009 to 2012, three community-based organizations with support from the U.S. Centers for Disease Control and Prevention evaluated MP among N = 298 participants. Following a repeated measures design, data from 3-and 6-month follow-ups were compared to baseline. HIV testing and self-efficacy for safer sex increased at both follow-up time points; self-acceptance as an MSM was higher at follow-up 2. Condomless anal/ vaginal sex was lower at follow-up 1 only. Frequency of exchange of safer sex messages among gay/bisexual/transgender friends was lower at follow-up 1, but similar to baseline at follow-up 2. Exposure to MP was associated with improved perceived positive social norms about safer sex and safer sex messages among gay/bisexual/transgender friends. C1 [Shelley, Gene; Uhl, Gary; Wright, Carolyn; Wang, Yan] Ctr Dis Control & Prevent, Mailstop E-59,1600 Clifton Rd, Atlanta, GA 30329 USA. [Rebchook, Gregory; Pollack, Lance; Kegeles, Susan M.] Ctr AIDS Prevent Studies, San Francisco, CA USA. [Williams, Weston] Publ Hlth Analyt Consulting Serv Inc, Miami, FL USA. [Eke, Adanze; Cheng, Qi] Karna LLC, Atlanta, GA USA. RP Shelley, G (reprint author), Ctr Dis Control & Prevent, Mailstop E-59,1600 Clifton Rd, Atlanta, GA 30329 USA. EM gshelley@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA SN 0899-9546 EI 1943-2755 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD FEB PY 2017 VL 29 IS 1 BP 24 EP 37 PG 14 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA EM3QP UT WOS:000395230000003 PM 28195781 ER PT J AU Brownson, RC Samet, JM Bensyl, DM AF Brownson, Ross C. Samet, Jonathan M. Bensyl, Diana M. TI Applied epidemiology and public health: are we training the future generations appropriately? SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Education; Epidemiology; Genomics; Globalization; Medicine; Public health training; Translational research AB To extend the reach and relevance of epidemiology for public health practice, the science needs be broadened beyond etiologic research, to link more strongly with emerging technologies and to acknowledge key societal transformations. This new focus for epidemiology and its implications for epidemiologic training can be considered in the context of macro trends affecting society, including a greater focus on upstream causes of disease, shifting demographics, the Affordable Care Act and health care system reform, globalization, changing health communication environment, growing centrality of team and transdisciplinary science, emergence of translational sciences, greater focus on accountability, big data, informatics, high-throughput technologies ("omits"), privacy changes, and the evolving funding environment. This commentary describes existing approaches to and competencies for training in epidemiology, maps macro trends with competencies, highlights an example of competency-based education in the Epidemic Intelligence Service of Centers for Disease Control and Prevention, and suggests expanded and more dynamic training approaches. A reexamination of current approaches to epidemiologic training is needed. (C) 2016 Elsevier Inc. All rights reserved. C1 [Brownson, Ross C.] Washington Univ, Prevent Res Ctr, Brown Sch, One Brookings Dr,Campus Box 1196, St Louis, MO USA. [Brownson, Ross C.] Washington Univ, Sch Med, Div Publ Hlth Sci, St Louis, MO USA. [Brownson, Ross C.] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO USA. [Samet, Jonathan M.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Bensyl, Diana M.] Ctr Dis Control & Prevent, Epidemiol Workforce Branch, Atlanta, GA USA. RP Brownson, RC (reprint author), Washington Univ, Prevent Res Ctr, Brown Sch, One Brookings Dr,Campus Box 1196, St Louis, MO USA. EM rbrownson@wustl.edu FU National Cancer Institute at the National Institutes of Health [P30 CA09184] FX This project was funded in part by the National Cancer Institute at the National Institutes of Health (grant number P30 CA09184). NR 28 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD FEB PY 2017 VL 27 IS 2 BP 77 EP 82 DI 10.1016/j.annepidem.2016.12.002 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL6KF UT WOS:000394730500001 PM 28038933 ER PT J AU Cruz, MA Rubens, M Garcia, SJ Malilay, J Levin, KL Williams, OD AF Cruz, Miguel A. Rubens, Muni Garcia, Stephanie J. Malilay, Josephine Levin, Karen L. Williams, O. Dale TI Knowledge of and Preparedness for Use of Environmental Assessments in Shelters During Disasters: Results of the 2013 State and Territorial Use of Shelter Assessments Survey SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE disaster assessments; public health; disaster shelters; vulnerable populations; risk assessments AB Objective:Environmental health assessments of disaster shelters are critical for monitoring the living conditions of the occupants. However, knowledge and levels of utilization of these assessments have never been estimated in the United States or its territories. We aimed to conduct a cross-sectional survey to ascertain knowledge and Utilization of environmental health disaster shelter assessments. Methods:The State and Territorial Use of Shelter Assessments Survey (STUSA) of environmental health department directors (N=56) was carried out in 2013. Results:Survey responses were received from 55 of 56 targeted jurisdictions. Of those respondents, 92% of state jurisdictions and 100% of territories reported having knowledge about shelter assessments. However, only 40% of states and 60% of territories reported receiving formal training, and 53% of states and 50% of territories reported having operational procedures for shelter assessments. High levels of knowledge and familiarity and low levels of training and processes for operationalizing assessments were assessed. Conclusions:Because environmental health assessments may provide useful information in disaster settings, we need to understand the barriers to their implementation. The results of these assessments may also help to validate their usefulness in protecting shelter occupants during disasters. (Disaster Med Public Health Preparedness. 2017;11:11-14) C1 [Cruz, Miguel A.] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Environm & Occupat Hlth, Miami, FL 33199 USA. [Rubens, Muni] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Hlth Promot & Dis Prevent, Miami, FL 33199 USA. [Garcia, Stephanie J.; Williams, O. Dale] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Biostat, Miami, FL 33199 USA. [Cruz, Miguel A.; Malilay, Josephine] Natl Ctr Environm Hlth, Ctr Dis Control & Prevent, Atlanta, GA USA. [Levin, Karen L.] Columbia Univ, Sch Int & Publ Affairs, New York, NY USA. RP Cruz, MA (reprint author), Natl Ctr Environm Hlth, Ctr Dis Control & Prevent, Atlanta, GA USA. EM mcruz@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1935-7893 EI 1938-744X J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD FEB PY 2017 VL 11 IS 1 BP 11 EP 14 DI 10.1017/dmp.2016.72 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EM6TB UT WOS:000395444000004 PM 27511727 ER PT J AU Farcas, D Harper, M Januch, JW Jacobs, TA Sarkisian, K Stetler, LD Schwegler-Berry, D AF Farcas, Daniel Harper, Martin Januch, Jed W. Jacobs, Teri A. Sarkisian, Khachatur Stetler, Larry D. Schwegler-Berry, Diane TI Evaluation of fluidized bed asbestos segregator to determine erionite in soil SO ENVIRONMENTAL EARTH SCIENCES LA English DT Article DE Erionite; Soil analysis; South Dakota; Fluidized bed asbestos segregator; FBAS; Microscopy ID UNITED-STATES; NORTH-DAKOTA AB Three sets of soil samples were collected by the National Institute for Occupational Safety and Health and one set by South Dakota School of Mines & Technology from in and around the Slim Buttes Land Unit of the Sioux Ranger District of the Custer-Gallatin National Forest in the northwest of South Dakota. The rocks forming the Slim Buttes are sedimentary clays, sands and gravels including re-worked volcanic ash-falls in which the zeolite mineral erionite has crystallized during diagenesis in a fibrous form or morphology similar to that of asbestos. The samples were prepared using the fluidized bed asbestos segregator (FBAS) and analyzed by phase contrast microscopy (PCM) or transmission electron microscopy to detect the presence of mineral fibers. FBAS-PCM results compared to semi-quantitative polarized light microscopy (PLM) and X-ray diffraction analysis indicated a recovery of approximately 1% and a linear relationship that likely can be extrapolated to concentrations well below the 1% detection limit of PLM. There were small variations between a PCM count of 10 fibers to a count of 100 fibers (or a maximum of 200 microscopic fields of view), which indicates the possibility of rapid turnaround of results. Although the four sets of samples examined in this work were collected by slightly different techniques, some tentative conclusions can be drawn about the distribution of erionite in soils. Erionite was detected in almost every soil sample, even those taken several miles from the outcrop, but without any distribution indicating recent transportation from the current volcaniclastic sediment outcrops. Removal of more extensive volcaniclastic sediments through erosion may have resulted in remnant material in soils, including erionite crystals, but this possibility requires further study. Although we have demonstrated that erionite in soils can be detected through FBAS-PCM, we have not attempted to correlate those results with human inhalation exposure through activity-based sampling, and thus, any risk inherent in working these soils is unknown. C1 [Farcas, Daniel; Harper, Martin] NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd M-S 3030, Morgantown, WV 26505 USA. [Farcas, Daniel] West Virginia Univ, Dept Occupat & Environm Hlth Sci, Morgantown, WV 26505 USA. [Januch, Jed W.] US EPA, Off Environm Assessment, Reg 10, Port Orchard, WA 98366 USA. [Jacobs, Teri A.] NIOSH, Surveillance Branch, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Sarkisian, Khachatur] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Stetler, Larry D.] South Dakota Sch Mines & Technol, Dept Geol & Geol Engn, Rapid City, SD 57701 USA. [Schwegler-Berry, Diane] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Harper, M (reprint author), NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd M-S 3030, Morgantown, WV 26505 USA. EM zzg7@cdc.gov NR 28 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1866-6280 EI 1866-6299 J9 ENVIRON EARTH SCI JI Environ. Earth Sci. PD FEB PY 2017 VL 76 IS 3 AR 126 DI 10.1007/s12665-017-6438-7 PG 15 WC Environmental Sciences; Geosciences, Multidisciplinary; Water Resources SC Environmental Sciences & Ecology; Geology; Water Resources GA EL9VD UT WOS:000394967300006 ER PT J AU Westercamp, M Jaoko, W Mehta, S Abuor, P Siambe, P Bailey, RC AF Westercamp, Matthew Jaoko, Walter Mehta, Supriya Abuor, Pauline Siambe, Perez Bailey, Robert C. TI Changes in Male Circumcision Prevalence and Risk Compensation in the Kisumu, Kenya Population, 2008-2013 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE circumcision; male; HIV infections; Kenya; sexual behavior; health surveys; risk compensation ID RANDOMIZED CONTROLLED-TRIAL; POSTTRIAL FOLLOW-UP; SUB-SAHARAN AFRICA; HIV PREVENTION; PROSPECTIVE COHORT; NYANZA PROVINCE; YOUNG MEN; INFECTION; UGANDA; RAKAI AB Background: Three randomized controlled trials showed that voluntary medical male circumcision (VMMC) reduces the risk of female-to-male HIV transmission by approximately 60%. However, data from communities where VMMC programs have been implemented are needed to assess changes in circumcision prevalence and whether men and women compensate for perceived reductions in risk by increasing their HIV risk behaviors. Methods: Scale-up of free VMMC began in Kisumu, Kenya in 2008. Between 2009 and 2013, a sequence of 3 unlinked crosssectional surveys were conducted. All individuals 15-49 years of age residing in randomly selected households were interviewed and offered HIV testing. Male circumcision status was confirmed by examination. Design-adjusted bivariate comparisons and multivariable analyses were used for statistical inference. Results: The prevalence of male circumcision increased from 32% (95% CI: 26% to 38%) in 2009 to 60% (95% CI: 56% to 63%) in 2013. The adjusted prevalence ratio of HIV and genital ulcer disease in circumcised compared with uncircumcised men was 0.48 (95% CI: 0.36 to 0.66) and 0.51 (95% CI: 0.37 to 0.69), respectively. There was no association between circumcision status and sexual behaviors, HIV knowledge, or indicators of risk perception. Conclusions: The conditions necessary for the VMMC program to have a significant public health impact are present in Kisumu, Kenya. Between 2009 and 2013, circumcision prevalence increased from 30% to 60%; HIV prevalence in circumcised men was half that of uncircumcised men, and there was no or minimal sexual risk compensation. C1 [Westercamp, Matthew; Mehta, Supriya; Bailey, Robert C.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA. [Jaoko, Walter] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya. [Abuor, Pauline; Siambe, Perez] Nyanza Reprod Hlth Soc, Kisumu, Kenya. RP Westercamp, M (reprint author), Ctr Dis Control & Prevent CDC, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM mwestercamp@cdc.gov FU FHI360; Male Circumcision Consortium (MCC); EngenderHealth; University of Illinois at Chicago; Bill & Melinda Gates Foundation FX Support for the Circumcision Impact Study is from a contract to the University of Illinois at Chicago from FHI360 and the Male Circumcision Consortium (MCC), a partnership between FHI360, EngenderHealth, and the University of Illinois at Chicago working closely with the Nyanza Reproductive Health Society. The MCC was supported by the Bill & Melinda Gates Foundation. NR 43 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2017 VL 74 IS 2 BP E30 EP E37 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EN4SS UT WOS:000395997800001 PM 27632232 ER PT J AU Greenberg, AE Gordon, CM Purcell, DW AF Greenberg, Alan E. Gordon, Christopher M. Purcell, David W. TI Promotion of Research on the HIV Continuum of Care in the United States: The CFAR HIV Continuum of Care/ECHPP Working Group SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE Centers for AIDS Research; HIV continuum of care; academic-public health partnerships; ECHPP ID LINKAGE; PERCEPTIONS; SUPPORT; AIDS C1 [Greenberg, Alan E.] George Washington Univ, Milken Inst, Sch Publ Hlth, Dept Epidemiol & Biostat, 950 New Hampshire Ave,NW,5th Floor, Washington, DC 20052 USA. [Greenberg, Alan E.] Dist Columbia Ctr AIDS Res, Washington, DC USA. [Gordon, Christopher M.] NIMH, Div AIDS Res, Bethesda, MD 20892 USA. [Purcell, David W.] Ctr Dis Control & Prevent, Div HIV AIDS, Atlanta, GA USA. RP Greenberg, AE (reprint author), George Washington Univ, Milken Inst, Sch Publ Hlth, Dept Epidemiol & Biostat, 950 New Hampshire Ave,NW,5th Floor, Washington, DC 20052 USA. EM aeg1@gwu.edu FU National Institutes of Health [P30AI117970] FX Supported by funds from the National Institutes of Health to the District of Columbia Center for AIDS Research (P30AI117970). NR 51 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2017 VL 74 SU 2 BP S75 EP S80 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EN5BZ UT WOS:000396021900001 PM 28079716 ER PT J AU Johns, M AF Johns, Michelle TI DIFFERENCES IN EXPERIENCES OF HARASSMENT AND MENTAL DISTRESS AMONG ADOLESCENT GIRLS BY SEXUAL MINORITY AND ACTUAL/PERCEIVED WEIGHT STATUS: FINDINGS FROM A NATIONALLY REPRESENTATIVE SAMPLE OF HIGH SCHOOL STUDENTS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Johns, Michelle] Ctr Dis Control, Atlanta, GA 30333 USA. FU Arcus Foundation FX MMJ is supported by a grant from the Arcus Foundation awarded to the CDC Foundation. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 43 BP S24 EP S25 PG 3 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700044 ER PT J AU Liddon, N Steiner, R Martinez, GM AF Liddon, Nicole Steiner, Riley Martinez, Gladys M. TI SEXUALLY ACTIVE ADOLESCENT AND YOUNG FEMALES' RECEIPT OF PREVENTIVE COUNSELING DURING SEXUAL AND REPRODUCTIVE HEALTH VISITS: FINDINGS FROM THE 2011-2013 NATIONAL SURVEY OF FAMILY GROWTH SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Liddon, Nicole] Ctr Dis Control & Prevent, Atlanta, GA USA. [Steiner, Riley; Martinez, Gladys M.] Natl Ctr Hlth Stat, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 61 BP S34 EP S35 PG 3 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700062 ER PT J AU Lowry, R Johns, M Robin, L Kann, L AF Lowry, Richard Johns, Michelle Robin, Leah Kann, Laura TI THE EFFECT OF MINORITY STRESS ON SUBSTANCE USE DISPARITIES AMONG SEXUAL MINORITY US HIGH SCHOOL STUDENTS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Lowry, Richard; Johns, Michelle; Robin, Leah; Kann, Laura] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 54 BP S30 EP S31 PG 3 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700055 ER PT J AU Marcell, AV Pilgrim, N Jennings, JM Sanders, R Page, KR Loosier, PS Dittus, PJ AF Marcell, Arik V. Pilgrim, Nanlesta Jennings, Jacky M. Sanders, Renata Page, Kathleen R. Loosier, Penny S. Dittus, Patricia J. TI YOUNG MEN'S OVERALL PERCEIVED QUALITY OF CARE: ROLE OF SEXUAL AND REPRODUCTIVE HEALTH AND PATIENT-CENTERED CARE SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Marcell, Arik V.; Jennings, Jacky M.; Sanders, Renata; Page, Kathleen R.] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Pilgrim, Nanlesta] Populat Council, New York, NY USA. Hopkins SPH, Baltimore, MD USA. [Loosier, Penny S.; Dittus, Patricia J.] CDC, Atlanta, GA 30333 USA. FU CDC [1H25PS003796]; Secretary's Minority AIDS Initiative Fund FX CDC 1H25PS003796 and Secretary's Minority AIDS Initiative Fund. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 66 BP S37 EP S37 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700067 ER PT J AU Neilan, A Dunville, R Ocfemia, MCB Salomon, J Francke, J Wang, LY Bulteel, A Hsu, K DiNenno, E Parker, R Walensky, R Freedberg, K Ciaranello, A AF Neilan, Anne Dunville, Richard Ocfemia, M. Cheryl Banez Salomon, Joshua Francke, Jordan Wang, Li Yan Bulteel, Alex Hsu, Kathy DiNenno, Elizabeth Parker, Robert Walensky, Rochelle Freedberg, Kenneth Ciaranello, Andrea TI SCREENING ADOLESCENTS AND YOUNG ADULTS FOR HIV IN THE UNITED STATES: A COST-EFFECTIVENESS ANALYSIS SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Neilan, Anne; Francke, Jordan; Bulteel, Alex; Parker, Robert; Walensky, Rochelle; Freedberg, Kenneth; Ciaranello, Andrea] Massachusetts Gen Hosp, Boston, MA USA. [Dunville, Richard; Ocfemia, M. Cheryl Banez; Wang, Li Yan; DiNenno, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Salomon, Joshua] Harvard Sch Publ Hlth, Boston, MA USA. [Hsu, Kathy] Boston Med Ctr, Massachusetts Dept Publ Hlth, Boston, MA USA. FU US Centers for Disease Control and Prevention National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement [6NU38PS004644]; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute for Child Health and Human Development [NIAID T32 AI007433, R01 HD079214, R01 AI042006, R01 AI112340] FX This research was funded by US Centers for Disease Control and Prevention National Center for HIV, Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement 6NU38PS004644 as well as the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NIAID T32 AI007433, R01 HD079214, R01 AI042006, R01 AI112340). NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 32 BP S18 EP S18 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700033 ER PT J AU Steiner, RJ Liddon, N Dittus, P AF Steiner, Riley J. Liddon, Nicole Dittus, Patricia TI ASSOCIATIONS BETWEEN PARENT-ADOLESCENT COMMUNICATION ABOUT SEX AND PROVIDER COUNSELING ABOUT HIV AMONG ADOLESCENTS: FINDINGS FROM THE 2011-2013 NATIONAL SURVEY OF FAMILY GROWTH SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Steiner, Riley J.; Liddon, Nicole; Dittus, Patricia] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2017 VL 60 IS 2 MA 4 BP S2 EP S3 PG 3 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA EP3GL UT WOS:000397270700005 ER PT J AU Esona, MD Roy, S Rungsrisuriyachai, K Sanchez, J Vasquez, L Gomez, V Rios, LA Bowen, MD Vazquez, M AF Esona, Mathew D. Roy, Sunando Rungsrisuriyachai, Kunchala Sanchez, Jacqueline Vasquez, Lina Gomez, Virgen Rios, Lourdes Aviles Bowen, Michael D. Vazquez, Marietta TI Characterization of a triple-recombinant, reassortant rotavirus strain from the Dominican Republic SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID SEQUENCE-INDEPENDENT AMPLIFICATION; GROUP-A ROTAVIRUS; INTRAGENIC RECOMBINATION; RNA RECOMBINATION; GENOMIC CHARACTERIZATION; GENETIC-HETEROGENEITY; PHYLOGENETIC ANALYSIS; GENOTYPE; VIRUSES; MECHANISMS AB We report the genome of a novel human triple-recombinant G4P[ 6-8_ R] mono-reassortant strain identified in a stool sample from the Dominican Republic during routine facility-based rotavirus strain surveillance. The strain was designated as RVA/Human-wt/DOM/2013840364/2013/G4P[6-8_R], with a genomic constellation of G4-P[6-8_R]-I1-R1-C1-M1-(A1-A8_R)-N1(T1-T7_R)-E1-H1. Recombinant gene segments NSP1 and NSP3 were generated as a result of recombination between genogroup 1 rotavirus A1 human strain and a genotype A8 porcine strain and between genogroup 1 rotavirus T1 human strain and a genotype T7 bovine strain, respectively. Analyses of the RNA secondary structures of gene segment VP4, NSP1 and NSP3 showed that all the recombinant regions appear to start in a loop (single-stranded) region and terminate in a stem (double-stranded) structure. Also, the VP7 gene occupied lineage VII within the G4 genotypes consisting of mostly porcine or porcine-like G4 strains, suggesting the occurrence of reassortment. The remaining gene segments clustered phylogenetically with genogroup 1 strains. This exchange of whole or partial genetic materials between rotaviruses by recombination and reassortment contributes directly to their diversification, adaptation and evolution. C1 [Esona, Mathew D.; Roy, Sunando; Rungsrisuriyachai, Kunchala; Bowen, Michael D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sanchez, Jacqueline; Vasquez, Lina; Gomez, Virgen] Hosp Infantil Dr Robert Reid Cabral, Santo Domingo, Dominican Rep. [Rios, Lourdes Aviles; Vazquez, Marietta] Yale Sch Med, New Haven, CT USA. RP Esona, MD (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM mdi4@cdc.gov FU Centers for Disease Control and Prevention FX Funding for this study was provided by the Centers for Disease Control and Prevention. NR 45 TC 0 Z9 0 U1 0 U2 0 PU MICROBIOLOGY SOC PI LONDON PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD FEB PY 2017 VL 98 IS 2 BP 134 EP 142 DI 10.1099/jgv.0.000688 PG 9 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA EN6LQ UT WOS:000396115900003 PM 27983480 ER PT J AU Fleming, E Gaines, J O'Connor, K Ogutu, J Atieno, N Atieno, S Kamb, ML Quick, R AF Fleming, Eleanor Gaines, Joanna O'Connor, Katherine Ogutu, Judith Atieno, Nancy Atieno, Salimah Kamb, Mary L. Quick, Robert TI Can incentives reduce the barriers to use of antenatal care and delivery services in Kenya? Results of a qualitative inquiry SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Kenya; prenatal care; women's health; maternal health services; social determinants of health ID HEALTH BELIEF MODEL; WATER-TREATMENT; HYGIENE PRACTICES; INTEGRATION; MALAWI; WOMEN; IMPACT; INTERVENTION; ACCESS AB A qualitative inquiry was used to assess if incentives consisting of a hygiene kit, protein-fortified flour, and delivery kit reduced barriers to antenatal care and delivery services in Nyanza Province, Kenya. We conducted 40 interviews (baseline: five nurses, six mothers, one focus group of five mothers; follow-up: nine nurses, 19 mothers) to assess perceptions of these services. Mothers and nurses identified poor quality of care, fear of HIV diagnosis and stigma, inadequate transport, and cost of care as barriers. Nurses believed incentives encouraged women to use services; mothers described wanting good birth outcomes as their motivation. While barriers to care did not change during the study, incentives may have increased service use. These findings suggest that structural improvements upgraded infrastructure, adequate staffing, improved treatment of women by nurses, low or no-cost services, and provision of transport could increase satisfaction with and use of services, improving maternal and infant health. C1 [Fleming, Eleanor] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, Div Appl Sci,Epidem Intelligence Serv,Sci Educ &, Atlanta, GA USA. [Gaines, Joanna; O'Connor, Katherine] Ctr Dis Control & Prevent, Div Appl Sci, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off,Natl Ctr Emerg, Atlanta, GA USA. [Ogutu, Judith; Atieno, Nancy; Atieno, Salimah] Safe Water & AIDS Project, Kisumu, Kenya. [Kamb, Mary L.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Director, Atlanta, GA USA. [Quick, Robert] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Fleming, E (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd Mailstop E07, Atlanta, GA 30333 USA. EM efleming@cdc.gov NR 31 TC 0 Z9 0 U1 0 U2 0 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2017 VL 28 IS 1 BP 153 EP 174 PG 22 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EL6JU UT WOS:000394729200016 PM 28238994 ER PT J AU Murray, A Toledo, L Brown, E Sutton, MY AF Murray, Ashley Toledo, Lauren Brown, Emma (EJ) Sutton, Madeline Y. TI "We as Black Men Have to Encourage Each other:" Facilitators and Barriers Associated with HIV Testing among Black/African American Men in Rural Florida SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE HIV; testing; rural; African American; men ID SOUTHERN UNITED-STATES; HEALTH-CARE; PREVENTION RESEARCH; TRANSMISSION; STRATEGIES; PARTICIPATION; ADOLESCENTS; INFECTION; SETTINGS; SERVICES AB HIV testing for some African American men remains a challenge, and effective interventions are lacking. We explored facilitators and barriers associated with HIV testing among heterosexual African American men in rural Florida. We conducted focus group interviews with 67 African American men who were low-income, and HIV-uninfected based on prior testing or had unknown HIV status. Using computer-assisted thematic analyses, we examined transcribed focus group responses for main themes. Thematic analyses revealed three main themes regarding facilitators of HIV testing: 1) using preferred HIV testing community locations (park, library, gym); 2) receiving incentives (food or money); and 3) the importance of peer-led messaging for free, rapid HIV testing. Barriers included HIV testing at the local health department, and perceived social and emotional consequences to testing and the possibility of receiving a positive result. Effective HIV testing interventions for heterosexual African American men in rural Florida may need to incorporate suggested facilitators and reduce perceived barriers in order to improve HIV testing strategies. C1 [Murray, Ashley; Toledo, Lauren; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Murray, Ashley; Brown, Emma (EJ)] CHARM, Lake Butler, FL USA. RP Murray, A (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA.; Murray, A (reprint author), CDC, DHAP, NCHHSTP, 1600 Clifton Rd NE MS E-45, Atlanta, GA 30329 USA. EM hfx8@cdc.gov FU CDC's Minority HIV/AIDS Research Initiative award [U01PS000677] FX This study was supported with CDC's Minority HIV/AIDS Research Initiative award # U01PS000677. NR 35 TC 0 Z9 0 U1 0 U2 0 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2017 VL 28 IS 1 BP 487 EP 498 PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EL6JU UT WOS:000394729200036 PM 28239014 ER PT J AU Fekedulegn, D Burchfiel, CM Ma, CC Andrew, ME Hartley, TA Charles, LE Gu, JK Violanti, JM AF Fekedulegn, Desta Burchfiel, Cecil M. Ma, Claudia C. Andrew, Michael E. Hartley, Tara A. Charles, Luenda E. Gu, Ja K. Violanti, John M. TI Fatigue and on-duty injury among police officers: The BCOPS study SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 6th National Occupational Injury Research Symposium (NOIRS) CY MAY 19-21, 2015 CL Kingwood, WV DE Non-fatal injuries; Chronic tiredness; Law enforcement; Work history ID NONFATAL OCCUPATIONAL INJURIES; SLEEP QUALITY; RISK-FACTORS; SHIFT WORK; PSYCHOLOGICAL DISTRESS; MAASTRICHT COHORT; PHYSICAL-ACTIVITY; UNITED-STATES; SAFETY; PERFORMANCE AB Introduction: Policing involves inherent physical and psychological dangers as well as occupational stressors that could lead to chronic fatigue. Although accounts of adverse events associated with police fatigue are not scarce, literature on the association between chronic fatigue and on-duty injury are limited. Methods: Participants were officers from the Buffalo Cardio-Metabolic Occupational Police Stress (BCOPS) Study. A 10-item questionnaire was administered to assess how tired or energetic the officers generally felt irrespective of sleep hours or workload. The questionnaire consisted of five positively worded and five negatively phrased items that measured feelings of vigor/energy and tiredness, respectively. Total as well as separate scores for positive and negative items were computed by summing scores of individual items. Payroll records documenting each officer's work history were used to assess occurrence of injury. Poisson regression was used to estimate prevalence ratios (PR) of injury. Results: Nearly 40% of officers reported feeling drained. Overall prevalence of on-duty injury during the past year was 23.9%. Injury prevalence showed a significant increasing trend across tertiles of total fatigue score: 19.6, 21.7, and 30.8% for lowest, middle and highest tertiles, respectively (trend p-value = 0.037). After controlling for potential confounders, a 5-unit increase in total fatigue score Was associated with a 12% increase in prevalence of injury which was marginally significant (p = 0.075). A 5-tinit increase in fatigue score of the positively worded items was associated with a 33% increase in prevalence of injury (PR = 1.33, 95% CI: 1.04-1.70, p = 0.022). Conclusion: Officers who do not feel active, full of vigor, alert, or lively had a significantly higher prevalence of non-fatal work place injury compared to their counter parts. Practical applications: With additional prospective evidence, workplace interventions designed to enhance level of energy may reduce feelings of tiredness and hence may prevent workplace injury. Published by Elsevier Ltd. on behalf of National Safety Council. C1 [Fekedulegn, Desta; Burchfiel, Cecil M.; Ma, Claudia C.; Andrew, Michael E.; Hartley, Tara A.; Charles, Luenda E.; Gu, Ja K.] Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, Hlth Effects Lab Div, Biostat & Epidemiol Branch, Morgantown, WV USA. [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. RP Fekedulegn, D (reprint author), Natl Inst Occupat Safety & Hlth, HELD BEB, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM djf7@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), contract no. 200-2003-01580. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. In addition, citations to websites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these websites. All web addresses referenced in this document were accessible as of the publication date. This project was made possible through a partnership with the CDC Foundation. NR 48 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2017 VL 60 SI SI BP 43 EP 51 DI 10.1016/j.jsr.2016.11.006 PG 9 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA EL5BF UT WOS:000394635900009 PM 28160813 ER PT J AU Bunting, J Branche, C Trahan, C Goldenhar, L AF Bunting, Jessica Branche, Christine Trahan, Chris Goldenhar, Linda TI A national safety stand-down to reduce construction worker falls SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 6th National Occupational Injury Research Symposium (NOIRS) CY MAY 19-21, 2015 CL Kingwood, WV DE Safety stand-down; Construction falls; Fall prevention; Construction safety; Social marketing campaign AB Introduction: Falls are the leading cause of death and third leading cause of non-fatal injuries in construction. In an effort to combat these numbers, The National Campaign to Prevent Falls in Construction began in April 2012. As the campaign gained momentum, a week called the National Safety Stand-Down to Prevent Falls was launched to draw attention to the campaign and its goals. The purpose of this paper is to examine the reach of the Stand Down and lessons learned from its implementation. Methods: The Occupational Safety & Health Administration offered a certificate of participation during the Stand-DOwn. To print the certificate, respondents provided information about their company and stand-down event. CPWR - The Center for Construction Research and Training conducted analyses on the data collected to assess reach and extent of participation. Results: In 2014, 4,882 stand downs were reported. The total number reported in 2015 was 3,759. The number of participants, however, increased from 770,193 in 2014 to 1,041,307 in 2015. DiScussion: The Stand-Down successfully reached the construction industry and beyond. Respondents were enthusiastic and participated nationally and internationally in variety of activities. They also provided significant feedback that will be influential in future campaign planning. Conclusion: Numbers of Stand-Downs and participants for both years are estimated to be substantially higher than the data recorded from the certificate database. While we cannot determine impact, the reach of the Stand-Down has surpassed expectations. Practical applications: The data gathered provide support for the continuation of the Stand-Down. Campaign planners incorporated findings into future Stand-Down planning, materials creation, and promotion. This analysis also prdvides insight on how organizations can partner to create targeted national campaigns that include activities stakeholders in the construction industry respond to, and can be used to replicate our efforts for other safety and health initiatives in construction and other industries. (C) 2016 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Bunting, Jessica; Trahan, Chris; Goldenhar, Linda] Ctr Construct Res & Training, CPWR, 8484 Georgia Ave,Suite 1000, Silver Spring, MD 20910 USA. [Branche, Christine] Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, Off Construct Safety & Hlth, 395 E St,NW,Suite 9200, Washington, DC 20201 USA. RP Bunting, J (reprint author), Ctr Construct Res & Training, CPWR, 8484 Georgia Ave,Suite 1000, Silver Spring, MD 20910 USA. EM jbunting@cpwr.com FU Centers for Disease Control and Prevention (CDC/NIOSH) [U60-OH009762]; Occupational Health and Safety Administration (OSHA) FX This journal article and the research therein were funded by Cooperative Agreement U60-OH009762 from the Centers for Disease Control and Prevention (CDC/NIOSH). Research was also supported in-kind by the provision of data from the Occupational Health and Safety Administration (OSHA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC/NIOSH, the Department of Health and Human Services, or OSHA NR 6 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2017 VL 60 SI SI BP 103 EP 111 DI 10.1016/j.jsr.2016.12.005 PG 9 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA EL5BF UT WOS:000394635900015 PM 28160804 ER PT J AU Lincoln, JM Woodward, CC King, GW Case, SL Lucas, DL Teske, TD AF Lincoln, Jennifer M. Woodward, Chelsea C. King, Grant W. Case, Samantha L. Lucas, Devin L. Teske, Theodore D. TI Preventing fatal winch entanglements in the US southern shrimp fleet: A research to practice approach SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 6th National Occupational Injury Research Symposium (NOIRS) CY MAY 19-21, 2015 CL Kingwood, WV DE Commercial fishing; Injury prevention; Entanglement hazards; Engineering solution; Entanglements AB Introduction: During 2000-2011, 35 injuries (8 fatal) involving winches were reported to the Coast Guard in the Southern shrimp fleet. Injuries involving the main winch drums had a higher risk for fatal outcomes compared to injuries involving the winch cathead (RR = 7.5; 1.1-53.7). The objective of this study was to design effective solutions to protect deckhands from entanglement hazards posed by winches found on the vessels in the Southern shrimp fleet. Methods: Based on injury characteristics, site visit observations, and input from vessel owners, NIOSH determined that the design and implementation of effective main-winch guarding was a feasible first step in mitigating the entanglement hazard. Design considerations for stationary guards favor systems that are simple, affordable, durable, unobtrusive, and will not interfere with normal fishing operations. In addition, an auxiliary-stop method was tested to prevent entanglements in try-net winches. Results: Standardized passive guards were designed for three commonly found main winch models. Initial prototype guards have been sea tested. The design of six additional guards is underway, for a total of three iterations for each winch model identified. These will incorporate features found to be valued by fishermen, will be more efficient, and will reduce the overall cost of fabrication and maintenance. Sea testing of these iterations continues. The auxiliary-stop circuit control prototype system was designed to prevent entanglements in the try-net winch and is currently being sea tested. Discussion: NIOSH has completed initial designs for stationary-winch guards. Through collaborations with shrimper associations and safety groups, the successfully tested winch guard and auxiliary stop designs will be made available to qualified welders and craftsmen to use. This approach has proven effective in preventing other types of winch injuries. Practical applications: Injury epidemiologic methods and industry input are an effective way to identify workplace hazards and to design effective safety interventions to control hazards. Published by Elsevier Ltd. on behalf of National Safety Council. C1 [Lincoln, Jennifer M.; Woodward, Chelsea C.; King, Grant W.; Case, Samantha L.; Lucas, Devin L.; Teske, Theodore D.] NIOSH, Western States Div, Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Lincoln, JM (reprint author), 4230 Univ Dr,Grace Hall Suite 310, Anchorage, AK 99508 USA. EM Jxw7@cdc.gov NR 10 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2017 VL 60 SI SI BP 119 EP 123 DI 10.1016/j.jsr.2016.12.007 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA EL5BF UT WOS:000394635900017 PM 28160806 ER PT J AU Bell, JL Taylor, MA Chen, GX Kirk, RD Leatherman, ER AF Bell, Jennifer L. Taylor, Matthew A. Chen, Guang-Xiang Kirk, Rachel D. Leatherman, Erin R. TI Evaluation of an in-vehicle monitoring system (IVMS) to reduce risky driving behaviors in commercial drivers: Comparison of in-cab warning lights and supervisory coaching with videos of driving behavior SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 6th National Occupational Injury Research Symposium (NOIRS) CY MAY 19-21, 2015 CL Kingwood, WV DE In-vehicle monitoring system; Occupational safety; Driving; Motor vehicle; Injury ID SEAT-BELT USE; LEADERSHIP-BASED INTERVENTION; HAUL TRUCK DRIVERS; UNITED-STATES; SAFETY; PERFORMANCE; FEEDBACK; FATALITIES; DISTRACTION; SIMULATION AB Problem: Roadway incidents are the leading cause of work-related death in the United States. Methods: The objective of this research was to evaluate whether two types of feedback from a commercially available in-vehicle monitoring system (IVMS) would reduce the incidence of risky driving behaviors in drivers from two companies. IVMS were installed in 315 vehicles representing the industries Of local truck transportation and oil and gas support operations, and data were collected over an approximate two-year period in intervention and control groups. In one period, intervention group drivers were given feedback from in-cab warning lights from an IVMS that indicated occurrence of harsh vehicle maneuvers. In another period, intervention group drivers viewed video recordings of their risky driving behaviors with supervisors, and were coached by supervisors on safe driving practices. Results: Risky driving behaviors declined significantly more during the period with coaching plus instant feedback with lights in comparison to the period with lights-only feedback (ORadj = 0.61 95% CI 0.43-0.86; Holm-adjusted p = 0.035) and the control group (ORadj = 0.52 95% CI 0.33-0.82; Holm-adjusted p = 0.032). Lights-only feedback was not found to be significantly different than the control group's decline from baseline (ORadj = 0.86 95% CI 0.51-1.43; Holm-adjusted p > 0.05). Conclusions: The largest decline in the rate of risky driving behaviors occurred when feedback included both supervisory coaching and lights. Practical applications: Supervisory coaching is an effective form of feedback to improve driving habits in the workplace. The potential advantages and limitations of this IVMS-based intervention program are discussed. Published by Elsevier Ltd. on behalf of National Safety Council. C1 [Bell, Jennifer L.; Chen, Guang-Xiang] Natl Inst Occupat Safety & Hlth Div Safety Res, Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Taylor, Matthew A.] Natl Inst Occupat Safety, Ctr Dis Control & Prevent, Atlanta, GA USA. [Taylor, Matthew A.] Hlth Effects Lab Div, Atlanta, GA USA. [Kirk, Rachel D.] JAB Innovat Solut LLC, Bristow, VA USA. [Leatherman, Erin R.] West Virginia Univ, Dept Stat, Morgantown, WV 26506 USA. RP Bell, JL (reprint author), Natl Inst Occupat Safety & Hlth Div Safety Res, Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM JBell@cdc.gov NR 63 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2017 VL 60 SI SI BP 125 EP 136 DI 10.1016/j.jsr.2016.12.008 PG 12 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA EL5BF UT WOS:000394635900018 PM 28160807 ER PT J AU Leroy, ZC Wallin, R Lee, S AF Leroy, Zanie C. Wallin, Robin Lee, Sarah TI The Role of School Health Services in Addressing the Needs of Students With Chronic Health Conditions: A Systematic Review SO JOURNAL OF SCHOOL NURSING LA English DT Review DE academic achievement; attendance; chronic diseases; school health; services; student health outcomes ID ASTHMA MANAGEMENT PROGRAM; NURSE CASE-MANAGEMENT; INNER-CITY CHILDREN; PREVENTIVE ASTHMA; CARE; INTERVENTION; OUTCOMES; CENTERS; IMPACT; TRIAL AB Children and adolescents in the United States spend many hours in school. Students with chronic health conditions (CHCs) may face lower academic achievement, increased disability, fewer job opportunities, and limited community interactions as they enter adulthood. School health services provide safe and effective management of CHCs, often for students with limited access to health care. A systematic review to assess the role of school health services in addressing CHCs among students in Grades K-12 was completed using primary, peer-reviewed literature published from 2000 to 2015, on selected conditions: asthma, food allergies, diabetes, seizure disorders, and poor oral health. Thirty-nine articles met the inclusion criteria and results were synthesized; however, 38 were on asthma. Direct access to school nursing and other health services, as well as disease-specific education, improved health and academic outcomes among students with CHCs. Future research needs to include standardized definitions and data collection methods for students with CHCs. C1 [Leroy, Zanie C.; Lee, Sarah] Ctr Dis Control & Prevent, Sch Hlth Branch, Div Populat Hlth, 4770 Buford Highway,MS F78, Atlanta, GA 30329 USA. [Wallin, Robin] Pkwy Sch Dist, St Louis, MO USA. RP Leroy, ZC (reprint author), Ctr Dis Control & Prevent, Sch Hlth Branch, Div Populat Hlth, 4770 Buford Highway,MS F78, Atlanta, GA 30329 USA. EM ezv6@cdc.gov NR 48 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1059-8405 EI 1546-8364 J9 J SCH NURS JI J. Sch. Nurs. PD FEB PY 2017 VL 33 IS 1 BP 64 EP 72 DI 10.1177/1059840516678909 PG 9 WC Nursing SC Nursing GA EL5NY UT WOS:000394669000007 PM 27872391 ER PT J AU Heidari, L Younger, M Chandler, G Gooch, J Schramm, P AF Heidari, Leila Younger, Margalit Chandler, George Gooch, James Schramm, Paul TI Integrating Health Into Buildings of the Future SO JOURNAL OF SOLAR ENERGY ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Review ID INDOOR ENVIRONMENTAL-QUALITY; PROMOTE STAIR USE; PHYSICAL-ACTIVITY; BUILT ENVIRONMENT; GREEN RENOVATION; TOBACCO-SMOKE; UNITED-STATES; CO-BENEFITS; ASTHMA; CHILDREN AB The health and wellbeing of building occupants should be a key priority in the design, building, and operation of new and existing buildings. Buildings can be designed, renovated, and constructed to promote healthy environments and behaviors and mitigate adverse health outcomes. This paper highlights health in terms of the relationship between occupants and buildings, as well as the relationship of buildings to the community. In the context of larger systems, smart buildings and green infrastructure strategies serve to support public health goals. At the level of the individual building, interventions that promote health can also enhance indoor environmental quality (IEQ) and provide opportunities for physical activity. Navigating the various programs that use metrics to measure a building's health impacts reveals that there are multiple co-benefits of a "healthy building," including those related to the economy, environment, society, transportation, planning, and energy efficiency. C1 [Heidari, Leila; Younger, Margalit; Chandler, George; Gooch, James; Schramm, Paul] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Heidari, L (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. NR 105 TC 0 Z9 0 U1 0 U2 0 PU ASME PI NEW YORK PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA SN 0199-6231 EI 1528-8986 J9 J SOL ENERG-T ASME JI J. Sol. Energy Eng. Trans.-ASME PD FEB PY 2017 VL 139 IS 1 SI SI AR 010802 DI 10.1115/1.4035061 PG 8 WC Energy & Fuels; Engineering, Mechanical SC Energy & Fuels; Engineering GA EK8DQ UT WOS:000394154500003 ER PT J AU Broyles, G Butler, CR Kardous, CA AF Broyles, George Butler, Corey R. Kardous, Chucri A. TI Noise exposure among federal wildland fire fighters SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID HEARING-LOSS; FIREFIGHTERS; WORKERS AB Wildland fire fighters use many tools and equipment that produce noise levels that may be considered hazardous to hearing. This study evaluated 174 personal dosimetry measurements on 156 wildland fire fighters conducting various training and fire suppression tasks. Noise exposures often exceeded occupational exposure limits and suggest that wildland fire fighters may be at risk of developing noise-induced hearing loss, particularly those operating chainsaws, chippers, and masticators. The authors recommend a comprehensive approach to protecting these fire fighters that includes purchasing quieter equipment, noise and administrative controls, and enrolling these fire fighters into hearing conservation program. C1 [Broyles, George] US Forest Serv, Technol & Dev Program, USDA, Boise, ID 83705 USA. [Butler, Corey R.] NIOSH, Western States Div, Denver, CO 80225 USA. [Kardous, Chucri A.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Broyles, G (reprint author), US Forest Serv, Technol & Dev Program, USDA, Boise, ID 83705 USA. EM gbroyles@fs.fed.us; crbutler@cdc.gov; ckardous@cdc.gov NR 15 TC 0 Z9 0 U1 0 U2 0 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD FEB PY 2017 VL 141 IS 2 BP EL177 EP EL183 DI 10.1121/1.4976041 PG 7 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA EM4VD UT WOS:000395310100016 PM 28253638 ER PT J AU Morales-Aleman, MM Opoku, J Murray, A Lanier, Y Kharfen, M Sutton, MY AF Morales-Aleman, Mercedes M. Opoku, Jenevieve Murray, Ashley Lanier, Yzette Kharfen, Michael Sutton, Madeline Y. TI Disparities in Retention in HIV Care Among HIV-Infected Young Men Who Have Sex with Men in the District of Columbia, 2013 SO LGBT HEALTH LA English DT Article DE District of Columbia; health disparities; HIV/AIDS; YMSM; retention in care ID UNITED-STATES; AFRICAN-AMERICAN; DIAGNOSED HIV; POSITIVE MEN; ENGAGEMENT; ADOLESCENTS; CONTINUUM; LINKAGE; SUPPRESSION; OUTREACH AB Purpose: Among young men who have sex with men (YMSM), aged 13-24 years, Blacks/African Americans and Hispanics/Latinos are disproportionately affected by HIV, accounting for 58% and 21%, respectively, of diagnoses of HIV infection in the United States. In the District of Columbia (DC), YMSM of color are also disproportionately affected by HIV. National goals are that 80% of HIV-infected persons be retained in HIV care. We analyzed DC surveillance data to examine retention among YMSM living with HIV infection in DC. Methods: We characterized correlates of retention in HIV care (2 clinical visits, 3 months apart, within 12 months of diagnosis) among YMSM in DC to inform and strengthen local HIV care efforts. We analyzed data from DC HIV surveillance system for YMSM aged 13-29 years diagnosed between 2005 and 2012 and alive in 2013. We also combined demographic and clinical variables with sociodemographic data from the U.S. American Community Survey (ACS) by census tracts. Results: From 2005 to 2012, 1034 YMSM were diagnosed and living with HIV infection in DC; 83% were Black or Latino. Of the 1034 YMSM, 910 (88%) had census tract data available and were included in analyses (72% Black, 10% Latino, and 17% White); among the 854 (94%) linked to care, 376 (44%) were retained in care. In multivariate analyses, retention in care was less likely among 19-24 year YMSM compared with 13-18-year-old YMSM (adjusted prevalence ratios [aPR] = 0.89, 95% confidence intervals [CI] 0.80-0.99). Conclusion: Retention in HIV care was suboptimal for YMSM. Increased retention efforts are warranted to improve outcomes and reduce age and racial/ethnic disparities. C1 [Morales-Aleman, Mercedes M.] Univ Alabama, Coll Community Hlth Sci, Inst Rural Hlth Res, Dept Community & Rural Med, Tuscaloosa, AL USA. [Morales-Aleman, Mercedes M.; Murray, Ashley; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Opoku, Jenevieve; Kharfen, Michael] Dist Columbia Dept Hlth, HIV AIDS Hepatitis STD & TB Adm, Washington, DC USA. [Lanier, Yzette] NYU, Coll Nursing, New York, NY USA. RP Sutton, MY (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, 1600 Clifton Rd,NE MS E-45, Atlanta, GA 30333 USA. EM zxa3@cdc.gov FU None [HS013852] NR 43 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2325-8292 EI 2325-8306 J9 LGBT HEALTH JI LGBT Health PD FEB PY 2017 VL 4 IS 1 BP 34 EP 41 DI 10.1089/lgbt.2016.0126 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3GC UT WOS:000394506600006 PM 28045573 ER PT J AU Nakhleh, RE Stuart, LN Volmar, KE Nowak, JA Fatheree, LA Souers, RJ Fitzgibbons, PL Goldsmith, JD Astles, JR AF Nakhleh, Raouf E. Stuart, Lauren N. Volmar, Keith E. Nowak, Jan A. Fatheree, Lisa A. Souers, Rhona J. Fitzgibbons, Patrick L. Goldsmith, Jeffrey D. Astles, J. R. TI New Benchmark Data from College of American Pathologists for Immunohistochemical Assay Validation SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. Emory Univ, Atlanta, GA 30322 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Coll Amer Pathologists, Northfield, IL USA. St Jude Med Ctr, Fullerton, CA USA. Childrens Hosp Boston, Boston, MA USA. Harvard Med Sch, Boston, MA USA. Ctr Dis Control & Prevent, Atlanta, GA USA. UNC REX Healthcare, Raleigh, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2069 BP 514A EP 514A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302640 ER PT J AU Nakhleh, RE Goldsmith, JD Souers, RJ Fatheree, LA Volmar, KE Stuart, LN Nowak, JA Astles, JR Fitzgibbons, PL AF Nakhleh, Raouf E. Goldsmith, Jeffrey D. Souers, Rhona J. Fatheree, Lisa A. Volmar, Keith E. Stuart, Lauren N. Nowak, Jan A. Astles, J. R. Fitzgibbons, Patrick L. TI Impact of College of American Pathologists Evidence-Based Guideline on Immunohistochemistry Assay Validation Practices SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 106th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) CY MAR 04-10, 2017 CL San Antonio, TX SP US & Canadian Acad Pathol C1 Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA. Childrens Hosp Boston, Boston, MA USA. Harvard Med Sch, Boston, MA USA. Coll Amer Pathologists, Northfield, IL USA. UNC Rex Healthcare, Raleigh, NC USA. Emory Univ, Atlanta, GA 30322 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. St Jude Med Ctr, Fullerton, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2017 VL 30 SU 2 MA 2068 BP 514A EP 514A PG 1 WC Pathology SC Pathology GA EL2RO UT WOS:000394467302639 ER PT J AU Yong, LC Li, J Calvert, GM AF Yong, Lee C. Li, Jia Calvert, Geoffrey M. TI Sleep-related problems in the US working population: prevalence and association with shiftwork status SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID HEALTH INTERVIEW SURVEY; NATIONAL-HEALTH; DAY WORKERS; DURATION; CONSEQUENCES; DISORDERS; INSOMNIA; RISK; PERFORMANCE; MORTALITY AB Objective To estimate the prevalence of a comprehensive set of self-reported sleep problems by job characteristics, including shiftwork status, among a representative sample of US workers. Methods Data for 6338 workers aged >= 18 years were obtained from the National Health and Nutrition Examination Survey. Short sleep duration was defined as <7 hours per weekday/workday. Sleep quality was categorised as good, moderate and poor based on the frequency of 6 sleep-related symptoms. A sleep-related activities of daily living (ADL) score >= 2 was defined as impaired. Insomnia was defined as having poor sleep quality and impaired ADL. Shiftwork status was categorised as daytime, night, evening, rotating or another schedule. Prevalence rates were calculated and multivariate logistic regression analyses were used. Results The prevalence of short sleep duration (37.6% overall) was highest among night shift workers (61.8%; p<0.001). The prevalence of poor sleep quality was 19.2% among all workers, with the highest prevalence among night shift workers (30.7%, p=0.004). The prevalence of impaired ADL score (24.8% overall) and insomnia (8.8% overall) was also highest for night shift workers (36.2%, p=0.001 and 18.5%, p=0.013, respectively). In multivariate analysis, night shift workers had the highest likelihood of these sleep problems. Conclusions Self-reported short sleep duration, poor sleep quality, impaired ADL score and insomnia are common among US workers especially among night shift workers. Although these findings should be confirmed with objective sleep measures, they support the need for intervention programmes to improve sleep quantity and quality among night shift workers. C1 [Yong, Lee C.; Li, Jia; Calvert, Geoffrey M.] Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, NIOSH, Cincinnati, OH USA. RP Calvert, GM (reprint author), NIOSH, 1090 Tusculum Ave,R-17, Cincinnati, OH 45226 USA. EM jac6@cdc.gov NR 40 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 EI 1470-7926 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD FEB PY 2017 VL 74 IS 2 BP 93 EP 104 DI 10.1136/oemed-2016-103638 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EL3KB UT WOS:000394516900004 PM 27609325 ER PT J AU O'Ryan, M Riera-Montes, M Lopman, B AF O'Ryan, Miguel Riera-Montes, Margarita Lopman, Benjamin TI Norovirus in Latin America Systematic Review and Meta-analysis SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Review DE norovirus; human caliciviruses; acute gastroenteritis; Latin America; diarrheal disease ID GASTROENTERITIS; CHILDREN; PREVALENCE; INFECTION; COMMUNITY; ENGLAND; FINLAND; DISEASE AB Background: Noroviruses are increasingly recognized as a major cause of sporadic and epidemic acute gastroenteritis (AGE). Although there have been multiple studies published on norovirus epidemiology in Latin America, no comprehensive assessment of the role of norovirus has been conducted in the region. We aim to estimate the role of norovirus in the Latin American region through a systematic review and meta-analysis of the existing literature. Methods: We carried out a literature search in MEDLINE, SciELO and LILACS. We included papers that provided information on the prevalence or incidence of norovirus (including seroprevalence studies and outbreaks), with a recruitment and/or follow-up period of at least 12 months and where the diagnosis of norovirus was confirmed by reverse transcription polymerase chain reaction. The data were pooled for meta-analysis to estimate the prevalence of norovirus AGE and norovirus asymptomatic infection with 95% confidence intervals (CIs). Results: Thirty-eight studies were included in the review. Overall, the prevalence of norovirus among AGE cases was 15% (95% CI: 13-18). By location, it was 15% in the community (95% CI: 11%-21%), 14% in outpatient settings (95% CI: 10%-19%) and 16% in hospital locations (95% CI: 12%21%). The prevalence of norovirus among asymptomatic subjects was 8% (95% CI: 4-13). Norovirus GII. 4 strains were associated with 37%-100% of norovirus AGE cases, but only 7% of norovirus asymptomatic detections. Conclusions: Noroviruses are associated with almost 1 out of every 6 hospitalizations because of acute diarrhea in children younger than 5 years of age in Latin America. C1 [O'Ryan, Miguel] Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Microbiol & Micol, Santiago, Chile. [Riera-Montes, Margarita] P95 Epidemiol & Pharmacovigilance Consulting & Se, Infect Dis Epidemiol Ctr, Leuven, Belgium. [Lopman, Benjamin] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Lopman, Benjamin] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA. RP O'Ryan, M (reprint author), Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Microbiol & Micol, Santiago, Chile. EM moryan@med.uchile.cl FU Takeda FX M.O. has received funding from Takeda for ongoing norovirus epidemiologic studies in Chile, not included in this review, and has been a consultant for norovirus vaccine development. M.R.M. has received consulting fees from Takeda, not related to this review. The authors have no conflicts of interest to disclose. NR 25 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2017 VL 36 IS 2 BP 127 EP 134 DI 10.1097/INF.0000000000001369 PG 8 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EL1AI UT WOS:000394352500004 PM 27755462 ER PT J AU Satter, SM Gastanaduy, PA Islam, K Rahman, M Rahman, M Luby, SP Heffelfinger, JD Parashar, UD Gurley, ES AF Satter, Syed M. Gastanaduy, Paul A. Islam, Khaleda Rahman, Mahmudur Rahman, Mustafizur Luby, Stephen P. Heffelfinger, James D. Parashar, Umesh D. Gurley, Emily S. TI Hospital-based Surveillance for Rotavirus Gastroenteritis Among Young Children in Bangladesh Defining the Potential Impact of a Rotavirus Vaccine Program SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE Bangladesh; acute gastroenteritis; rotavirus; hospital-based surveillance; rotavirus vaccination ID DIAGNOSING ROTAVIRUS; DIARRHEA; INFANTS; DISEASE; EFFICACY; BURDEN; STRAIN; SAFETY; METAANALYSIS; G2 AB Background: In anticipation of introduction of a rotavirus vaccine into the national immunization program of Bangladesh, active hospital-based surveillance was initiated to provide prevaccine baseline data on rotavirus disease. Methods: Children 5 years of age and younger admitted with acute gastroenteritis (AGE) (>= 3 watery or looser-than-normal stools or >= 1 episode of forceful vomiting) at 7 hospitals throughout Bangladesh were identified. Clinical information and stool specimens were collected from every 4th patient. Specimens were tested for rotavirus antigen by enzyme immunoassays; 25% of detected rotaviruses were genotyped. Results: From July 2012 to June 2015, rotavirus was detected in 2432 (64%) of 3783 children hospitalized for AGE. Eight enrolled children died, including 4 (50%) who were rotavirus positive. Rotavirus was detected year-round in Bangladesh with peak detection rates of > 80% during November-February. Most (86%) rotavirus AGE cases were 6-23 months of age. Sixty-nine percent of children with rotavirus had severe disease (Vesikari score, >= 11). Among 543 strains genotyped, G1P[8] (31%) and G12P[ 8] (29%) were the most common. Conclusions: Rotavirus is a major cause of morbidity in Bangladeshi children, accounting for nearly two-thirds of AGE hospitalizations. These data highlight the potential value of rotavirus vaccination in Bangladesh, and will be the key for future measurement of vaccine impact. C1 [Satter, Syed M.; Rahman, Mustafizur; Gurley, Emily S.] Int Ctr Diarrheal Dis Res Icddr b, Programme Emerging Infect, Div Infect Dis, Dhaka 1212, Bangladesh. [Gastanaduy, Paul A.; Parashar, Umesh D.] Ctr Dis Control & Prevent CDC, Div Viral Dis, Atlanta, GA USA. [Islam, Khaleda; Rahman, Mahmudur] Inst Epidemiol Dis Control & Res, Dept Epidemiol, Dhaka, Bangladesh. [Luby, Stephen P.] Stanford Univ, Ctr Innovat Global Hlth, Stanford, CA 94305 USA. [Heffelfinger, James D.] WHO, Western Pacific Reg Off, Manila, Philippines. [Heffelfinger, James D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Satter, SM (reprint author), Int Ctr Diarrheal Dis Res Icddr b, Programme Emerging Infect, Div Infect Dis, Dhaka 1212, Bangladesh. EM dr.satter@icddrb.org RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 FU USAID-Bangladesh, US Agency for International Development; US Centers for Disease Control and Prevention (CDC) [1U51GH001209-01] FX This work was supported by USAID-Bangladesh, US Agency for International Development, under the terms of an Interagency Agreement with US Centers for Disease Control and Prevention (CDC); agreement no. 1U51GH001209-01. NR 28 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2017 VL 36 IS 2 BP 168 EP 172 DI 10.1097/INF.0000000000001381 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EL1AI UT WOS:000394352500011 PM 27798545 ER PT J AU Kobayashi, M Misegades, L Fleming-Dutra, KE Ahmed, S Gierke, R Nanduri, S Healy, JM Nguyen, DT Carvalho, MD Pimenta, F Waterman, SH Moore, MR Kim, C Whitney, CG AF Kobayashi, Miwako Misegades, Lara Fleming-Dutra, Katherine E. Ahmed, Sana Gierke, Ryan Nanduri, Srinivas Healy, Jessica M. Nguyen, Duong T. Carvalho, Maria da Gloria Pimenta, Fabiana Waterman, Stephen H. Moore, Matthew R. Kim, Curi Whitney, Cynthia G. TI PNEUMOCOCCAL SEROTYPE 5 COLONIZATION PREVALENCE AMONG NEWLY ARRIVED UNACCOMPANIED CHILDREN 1 YEAR AFTER AN OUTBREAK-TEXAS, 2015 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE unaccompanied children; Streptococcus pneumoniae; colonization; outbreak; 13-valent pneumococcal conjugate vaccine ID STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; DISEASE; POPULATION AB In 2014, an acute respiratory illness outbreak affected unaccompanied children from Central America entering the United States; 9% of 774 surveyed children were colonized with Streptococcus pneumoniae serotype 5. In our 2015 follow-up survey of 475 children, serotype 5 was not detected, and an interim recommendation to administer 13-valent pneumococcal conjugate vaccine to all unaccompanied children was discontinued. C1 [Kobayashi, Miwako; Ahmed, Sana; Nanduri, Srinivas; Healy, Jessica M.; Nguyen, Duong T.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Kobayashi, Miwako; Fleming-Dutra, Katherine E.; Ahmed, Sana; Gierke, Ryan; Nanduri, Srinivas; Carvalho, Maria da Gloria; Pimenta, Fabiana; Moore, Matthew R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Div Bacterial Dis, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30329 USA. [Kim, Curi] Adm Children & Families, Off Refugee Resettlement, Washington, DC USA. [Healy, Jessica M.] Ctr Dis Control & Prevent, US Mexico Unit, Div Global Migrat & Quarantine, San Diego, CA USA. [Healy, Jessica M.] Cty San Diego Hlth & Human Serv Agcy, Epidemiol & Immunizat Serv Branch, San Diego, CA USA. [Nguyen, Duong T.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Waterman, Stephen H.] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, San Diego, CA USA. RP Kobayashi, M (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30329 USA. EM mkobayashi@cdc.gov FU Texas Department of State Health Services FX The authors thank the children who participated in the colonization survey. They acknowledge the generous support from the Texas Department of State Health Services, regional and county medical directors, ORR intakes team and project officers, as well as staff members at the programs. NR 8 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2017 VL 36 IS 2 BP 236 EP 238 DI 10.1097/INF.0000000000001398 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA EL1AI UT WOS:000394352500026 PM 27832022 ER PT J AU Omura, JD Carlson, SA Paul, P Sliwa, S Onufrak, SJ Fulton, JE AF Omura, John D. Carlson, Susan A. Paul, Prabasaj Sliwa, Sarah Onufrak, Stephen J. Fulton, Janet E. TI Shared use agreements between municipalities and public schools in the United States, 2014 SO PREVENTIVE MEDICINE LA English DT Article DE School; Community; Policy; Shared use ID PHYSICAL-ACTIVITY; RECREATIONAL FACILITIES; AVAILABILITY; SPACES; DISPARITIES; ADOLESCENTS; CHILDREN; PARTICIPATION; ASSOCIATION; ENVIRONMENT AB Shared use agreements allow public use of school facilities during non-school hours. Such agreements can cover outdoor facilities alone or may be more comprehensive by also including indoor facilities. Our aim was to: 1) estimate the prevalence of shared use agreements and facility types coveredamong U. S. municipalities and 2) identify differences in prevalence by municipality characteristics. The 2014 National Survey of Community-based Policy and Environmental Supports for Healthy Eating and Active Living is a representative survey of US municipalities (n=2029). Data were analyzed using surveyweights to create national estimates. Logistic and multinomial regression models determined odds ratios adjusting for municipality characteristics. Among 1930 municipalities with a school, 41.6% had a shared use agreement as reported by a local official, 45.6% did not, and 12.8% did not know. Significant differences in prevalence existed by population size, rural/ urban status, poverty prevalence, median education level, and census region; however, after adjustment for other municipality characteristics significant differences remained only by population size, median education level, and census region. Among municipalities with a shared use agreement, 59.6% covered both outdoor and indoor facilities, 5.5% covered indoor facilities only, and 34.9% covered outdoor facilities only. Opportunities exist to expand the use of shared use agreements particularly in municipalities with small populations, lower education levels, and in the South, and to promote more comprehensive shared use agreements that include both indoor and outdoor facilities. Published by Elsevier Inc. C1 [Omura, John D.; Carlson, Susan A.; Paul, Prabasaj; Onufrak, Stephen J.; Fulton, Janet E.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Bufford Highway NE,MS F-77, Atlanta, GA 30341 USA. [Sliwa, Sarah] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, 4770 Bufford Highway NE,MS F-77, Atlanta, GA 30341 USA. RP Omura, JD (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Phys Act & Hlth Branch, 4770 Bufford Highway NE,MS F-77, Atlanta, GA 30341 USA. EM ydk8@cdc.gov; clo3@cdc.gov; vig5@cdc.gov; xxh8@cdc.gov; seo5@cdc.gov; jkf2@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD FEB PY 2017 VL 95 SU S BP S53 EP S59 DI 10.1016/j.ypmed.2016.09.026 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EP3SQ UT WOS:000397302400007 PM 27658899 ER PT J AU Ochoa, C Lunsford, NB Smith, JL AF Ochoa, Carol Lunsford, Natasha Buchanan Smith, Judith Lee TI The quality of life of informal cancer caregivers in the United States: A systematic literature review SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Ochoa, Carol] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lunsford, Natasha Buchanan; Smith, Judith Lee] CDC, NCCDPHP, DCPC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA T5 BP 48 EP 49 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700106 ER PT J AU Ragan, K Lunsford, NB Smith, JL Saraiya, M Aketch, M AF Ragan, Kathleen Lunsford, Natasha Buchanan Smith, Judith Lee Saraiya, Mona Aketch, Millicent TI Environmental and psychosocial benefits of and barriers to cervical cancer treatment in Kenya SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Ragan, Kathleen; Lunsford, Natasha Buchanan; Smith, Judith Lee; Saraiya, Mona] CDC, NCCDPHP, DCPC, Atlanta, GA 30333 USA. [Aketch, Millicent] KEMRI, Atlanta, GA USA. FU CDC through KEMRI/CDC/CGH/OD [1U01GH000048-03] FX Report findings and conclusions are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC), Kenya Medical Research Institute (KEMRI), or Oak Ridge Institute for Science and Education (ORISE). This manuscript utilizes data whose collection was funded by the CDC through the KEMRI/CDC/CGH/OD Cooperative agreement 1U01GH000048-03. Ms Ragan's role as a coauthor of this manuscript was also supported, in part, by her appointment to the Research Participation Program at the CDC administered by ORISE through an inter-agency agreement between the US Department of Energy and CDC. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD FEB PY 2017 VL 26 SU 1 SI SI MA T40 BP 63 EP 64 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA EL9UX UT WOS:000394966700141 ER PT J AU Fujishiro, K Heaney, CA AF Fujishiro, Kaori Heaney, Catherine A. TI "Doing what I do best": The association between skill utilization and employee health with healthy behavior as a mediator SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Self-determination theory; Self-rated health; Work organization; Mediation analysis; Self-efficacy ID SELF-RATED HEALTH; JOB CHARACTERISTICS; DISEASE INCIDENCE; METAANALYSIS; MORTALITY; UNDEREMPLOYMENT; SATISFACTION; PREVALENCE; MECHANISMS; CANCER AB Objective: Skill utilization, defined as having the opportunity to do one's best at work, has been examined as a contributor to productivity, organizational efficiency, job satisfaction, and mental health. Drawing from self-determination theory, we postulate that high levels of skill utilization are positively associated with physical health and that some of the effect is mediated by health behavior. Methods: Using the 2014 Gallup Daily Tracking Survey data (n = 87,316), a nationally representative sample of working adults in the United States, we examine the associations between perceived skill utilization and five health outcomes (self-rated health, hypertension, high cholesterol, cancer, asthma) with healthy behavior (regular exercising, fruits and vegetable consumption) as a mediator of the associations. Results: The regression results showed that a one-point increase in skill utilization (on a three-point scale) was associated with 20% lower odds of reporting poor or fair health, 3% and 8% lower odds of reporting hypertension and high cholesterol, but had no significant association with cancer or asthma. Health behavior mediated 10% of the association between skill utilization and self-rated health, 46% for hypertension, and 18% for high cholesterol. Conclusion: The findings suggest that providing employees the opportunities to use their skills well at work improves health in general, and the effect is partly through enhancing the likelihood of engaging in healthy behaviors. Implications for organizational practice as well as future research directions are discussed. C1 [Fujishiro, Kaori] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, M-S R-15,1090 Tusculum Ave, Cincinnati, OH 45226 USA. [Heaney, Catherine A.] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94305 USA. RP Fujishiro, K (reprint author), NIOSH, M-S R-15,1090 Tusculum Ave, Cincinnati, OH 45226 USA. EM kfujishiro@cdc.gov NR 53 TC 0 Z9 0 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD FEB PY 2017 VL 175 BP 235 EP 243 DI 10.1016/j.socscimed.2016.12.048 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA EM5OG UT WOS:000395360500028 PM 28111118 ER PT J AU Smithson, C Tang, N Sammons, S Frace, M Batra, D Li, Y Emerson, GL Carroll, DS Upton, C AF Smithson, Chad Tang, Nick Sammons, Scott Frace, Mike Batra, Dhwani Li, Yu Emerson, Ginny L. Carroll, Darin S. Upton, Chris TI The genomes of three North American orthopoxviruses SO VIRUS GENES LA English DT Article DE Poxvirus; Skunkpox; Volepox; Raccoonpox; Orthopox; Evolution; Phylogeny ID MEMBRANE-PROTEIN TOPOLOGY; TAIL-ANCHORED PROTEINS; RACCOON POXVIRUS; MYXOMA VIRUS; VIRAL GENOMES; WEB SERVER; NUCLEOPROTEIN; GLYCOPROTEIN; RECOMBINANT; ALIGNMENTS AB The complete genomes of a skunkpox, volepox, and raccoonpox virus were sequenced and annotated. Phylogenetic analysis of these genomes indicates that although these viruses are all orthopoxviruses, they form a distinct clade to the other known species. This supports the ancient divergence of the North American orthopoxviruses from other members of the orthopoxviruses. Only two open reading frames appear to be unique to this group of viruses, but a relatively small number of insertions/deletions contribute to the varied gene content of this clade. The availability of these genomes will help determine whether skunkpox and volepox viruses share the characteristics that make raccoonpox a useful vaccine vector. C1 [Smithson, Chad; Tang, Nick; Upton, Chris] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada. [Sammons, Scott; Frace, Mike; Batra, Dhwani; Li, Yu; Emerson, Ginny L.; Carroll, Darin S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Upton, C (reprint author), Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada. EM cupton@uvic.ca FU Natural Sciences and Engineering Research Council FX The authors thank the many University of Victoria undergraduate Co-op students who have helped develop the virology.uvic.ca bioinformatics tools. CU was funded by a Natural Sciences and Engineering Research Council Discovery Grant. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, USA. NR 39 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-8569 EI 1572-994X J9 VIRUS GENES JI Virus Genes PD FEB PY 2017 VL 53 IS 1 BP 21 EP 34 DI 10.1007/s11262-016-1388-9 PG 14 WC Genetics & Heredity; Virology SC Genetics & Heredity; Virology GA EL2IZ UT WOS:000394444600003 PM 27613417 ER PT J AU Lu, P Amburgey, JE Hill, VR Murphy, JL Schneeberger, C Arrowood, MJ AF Lu, Ping Amburgey, James E. Hill, Vincent R. Murphy, Jennifer L. Schneeberger, Chandra Arrowood, Michael J. TI A full-scale study of Cryptosporidium parvum oocyst and Cryptosporidium-sized microsphere removals from swimming pools via sand filtration SO WATER QUALITY RESEARCH JOURNAL OF CANADA LA English DT Article DE coagulation; Cryptosporidium parvum; filtration; full-scale swimming pool ID FILTER; SURROGATES; WATER AB Removal of Cryptosporidium parvum oocysts and Cryptosporidium-sized microspheres was evaluated in full-scale swimming pools via high-rate sand filtration (31-34 m/h) with coagulation. Results showed that at least 90% of C. parvum oocysts and microspheres were removed by filtration with an initial dosage of coagulant B (1.56 mg/L), D (1.9 mg/L or 305 g/m(2)), or F (1.56 mg/L) from each swimming pool. Filtration with an initial dosage of coagulant E (0.1 mg.Al/L) achieved 82% C. parvum oocyst removal and 97% microsphere removal. Coagulants B and F had a tendency to overdose over time with continuous feeding (based on corresponding pilot-scale experiments) and did not consistently achieve removals greater than 90% in the full-scale trials. As high as 99% of C. parvum oocysts and 98% of microspheres were removed with a continuous dosage of coagulant D. Up to 98% (1.7 log) of C. parvum oocysts and 93% (1.1 log) of microspheres were removed by continuous dosing of coagulant E at 27 m/h. Consistent oocyst and microsphere removal by aluminum-based coagulants (D and E) was achieved under the tested swimming pool conditions. C1 [Lu, Ping] China Univ Min & Technol, Dept Environm Sci & Spatial Informat, Xuzhou 221116, Peoples R China. [Lu, Ping; Amburgey, James E.] Univ North Carolina Charlotte, Civil & Environm Engn, Charlotte, NC 28223 USA. [Hill, Vincent R.; Murphy, Jennifer L.; Arrowood, Michael J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Waterborne Dis Prevent Branch, Atlanta, GA 30329 USA. [Schneeberger, Chandra] Anyar Inc, Ft Walton Beach, FL 32547 USA. RP Lu, P (reprint author), China Univ Min & Technol, Dept Environm Sci & Spatial Informat, Xuzhou 221116, Peoples R China. EM luping_cumt@126.com FU National Swimming Pool Foundation (NSPF); Arch Chemicals, Inc.; National Natural Science Foundation of China [41403090] FX The authors wish to thank financial supporting by the National Swimming Pool Foundation (NSPF), Arch Chemicals, Inc. (now LonzaGroup Ltd) and other companies whose products were tested, the National Natural Science Foundation of China (41403090), and Amber Khanzada for her assistance with pool maintenance in the full-scale studies. The use of trade names and names of commercial sources is for identification only and does not imply endorsement by the CDC or the US Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the CDC. NR 24 TC 0 Z9 0 U1 0 U2 0 PU IWA PUBLISHING PI LONDON PA ALLIANCE HOUSE, 12 CAXTON ST, LONDON SW1H0QS, ENGLAND SN 1201-3080 J9 WATER QUAL RES J CAN JI Water Qual. Res. J. Canada PD FEB PY 2017 VL 52 IS 1 BP 18 EP 25 DI 10.2166/wqrjc.2016.015 PG 8 WC Water Resources SC Water Resources GA EN2FR UT WOS:000395825800004 ER PT J AU Gokhale, RH Galang, RR Pitman, JP Brooks, JT AF Gokhale, Runa H. Galang, Romeo R. Pitman, John P. Brooks, John T. TI A tale of 2 HIV outbreaks caused by unsafe injections in Cambodia and the United States, 2014-2015 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material ID INFECTIONS; DRUG C1 [Gokhale, Runa H.; Galang, Romeo R.; Brooks, John T.] Ctr Dis Control, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA. [Gokhale, Runa H.; Galang, Romeo R.] Ctr Dis Control, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Pitman, John P.] Ctr Dis Control, Div Global HIV AIDS & TB, Atlanta, GA 30329 USA. RP Gokhale, RH (reprint author), Ctr Dis Control, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E46, Atlanta, GA 30329 USA. EM yet7@cdc.gov NR 19 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB 1 PY 2017 VL 45 IS 2 BP 106 EP 107 DI 10.1016/j.ajic.2016.10.014 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EO8IW UT WOS:000396933700004 PM 27889274 ER PT J AU Calles, DL Collier, MG Khudyakov, Y Mixson-Hayden, T VanderBusch, L Weninger, S Miller, TK AF Calles, Dinorah L. Collier, Melissa G. Khudyakov, Yury Mixson-Hayden, Tonya VanderBusch, Lindsey Weninger, Sarah Miller, Tracy K. CA North Dakota Hepatitis C Virus Inv TI Hepatitis C virus transmission in a skilled nursing facility, North Dakota, 2013 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Hepatitis C virus; Skilled nursing facility; Infection control ID UNSAFE INJECTION PRACTICES; UNITED-STATES; VIRAL-HEPATITIS; CARE; INFECTIONS; HEALTH; RESIDENTS; OUTBREAKS; VIRGINIA AB Background: From March-May 2013, 3 cases of acute hepatitis C virus (HCV) infection were diagnosed among elderly patients residing at the same skilled nursing facility (facility A) and who received health care at hospital X during their likely exposure period. Methods: We performed HCV testing of at-risk populations; quasispecies analysis was performed to determine relatedness of HCV in persons with current infection. Infection control practice assessments were conducted at facility A and hospital X. Persons residing in facility A on September 9, 2013, were enrolled in a case-control study to identify risk factors for HCV infection. Results: Forty-five outbreak-associated infections were identified. Thirty cases and 62 controls were enrolled in the case-control study. Only podiatry (odds ratio, 11.6; 95% confidence interval, 2.4-57.2) and international normalized ratio monitoring by phlebotomy (odds ratio, 6.7; 95% confidence interval, 1.7-26.6) at facility A were significantly associated with case status. Infection control lapses during podiatry and point-of-care testing procedures at facility A were identified. Conclusions: HCV transmission was confirmed among residents of facility A. The exact mode of transmission was not able to be identified, but infection control lapses were likely responsible. This outbreak highlights the importance of prompt reporting and investigation of incident HCV infection and the need for adherence to basic infection control procedures by health care personnel. Published by(C) Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Calles, Dinorah L.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Mailstop E22,1600 Clifton Rd NE, Atlanta, GA 30329 USA. [Collier, Melissa G.; Khudyakov, Yury; Mixson-Hayden, Tonya] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [VanderBusch, Lindsey; Weninger, Sarah; Miller, Tracy K.] North Dakota Dept Hlth, Bismarck, ND USA. RP Calles, DL (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Mailstop E22,1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM vge2@cdc.gov NR 24 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB 1 PY 2017 VL 45 IS 2 BP 126 EP 132 DI 10.1016/j.ajic.2016.08.013 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EO8IW UT WOS:000396933700008 PM 27816216 ER PT J AU Brantley, MD Davis, NL Goodman, DA Callaghan, WM Barfield, WD AF Brantley, Mary D. Davis, Nicole L. Goodman, David A. Callaghan, William M. Barfield, Wanda D. TI Perinatal regionalization: a geospatial view of perinatal critical care, United States, 2010-2013 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE critical care; geospatial; neonatal; obstetric; perinatal ID LOW-BIRTH-WEIGHT; MATERNAL-FETAL MEDICINE; NEONATAL-MORTALITY; INFANTS; POPULATION; LEVEL AB BACKGROUND: Perinatal services exist today as a dyad of maternal and neonatal care. When perinatal care is fragmented or unavailable, excess morbidity and mortality may occur in pregnant women and newborns. OBJECTIVE: The objective of the study was to describe spatial relationships between women of reproductive age, individual perinatal subspecialists (maternal-fetal medicine and neonatology), and obstetric and neonatal critical care facilities in the United States to identify gaps in health care access. STUDY DESIGN: We used geographic visualization and conducted surface interpolation, nearest neighbor, and proximity analyses. Source data included 2010 US Census, October 2013 National Provider Index, 2012 American Hospital Association, 2012 National Center for Health Statistics Natality File, and the 2011 American Academy of Pediatrics directory. RESULTS: In October 2013, there were 2.5 neonatologists for every maternal-fetal medicine specialist in the United States. In 2012 there were 1.4 level III or higher neonatal intensive care units for every level III obstetric unit (hereafter, obstetric critical care unit). Nationally, 87% of women of reproductive age live within 50 miles of both an obstetric critical care unit and a neonatal intensive care unit. However, 18% of obstetric critical care units had no neonatal intensive care unit, and 20% of neonatal intensive care units had no obstetric critical care unit within a 10 mile radius. Additionally, 26% of obstetric critical care units had no maternalfetal medicine specialist practicing within 10 miles of the facility, and 4% of neonatal intensive care units had no neonatologist practicing within 10 miles. CONCLUSION: Gaps in access and discordance between the availability of level III or higher obstetric and neonatal care may affect the delivery of risk-appropriate care for high-risk maternal fetal dyads. Further study is needed to understand the importance of these gaps and discordance on maternal and neonatal outcomes. C1 [Brantley, Mary D.; Davis, Nicole L.; Goodman, David A.; Callaghan, William M.; Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Goodman, DA (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM igc4@cdc.gov NR 32 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2017 VL 216 IS 2 DI 10.1016/j.ajog.2016.10.011 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EO9YJ UT WOS:000397043700032 ER PT J AU Wade, R Becker, BD Bevans, KB Ford, DC Forrest, CB AF Wade, Roy, Jr. Becker, Brandon D. Bevans, Katherine B. Ford, Derek C. Forrest, Christopher B. TI Development and Evaluation of a Short Adverse Childhood Experiences Measure SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; HOUSEHOLD DYSFUNCTION; PRIMARY-CARE; ALCOHOL-USE; ABUSE; HEALTH; RISK; VALIDITY; DEPRESSION; DISEASE AB Introduction: Clinicians require tools to rapidly identify individuals with significant childhood adversity as part of routine primary care. The goal of this study was to shorten the 11-item Behavioral Risk Factor Surveillance System Adverse Childhood Experiences (ACEs) measure and evaluate the feasibility and validity of this shortened measure as a screener to identify adults who have experienced significant childhood adversity. Methods: Statistical analysis was conducted in 2015. ACE item responses obtained from 2011-2012 Behavioral Risk Factor Surveillance System data were combined to form a sample of 71,413 adults aged Z18 years. The 11-item Behavioral Risk Factor Surveillance System ACE measure was subsequently reduced to a two-item screener by maintaining the two dimensions of abuse and household stressors and selecting the most prevalent item within each dimension. Results: The screener included household alcohol and childhood emotional abuse items. Overall, 42% of respondents and at least 75% of the individuals with four or more ACEs endorsed one or both of these experiences. Using the 11-item ACE measure as the standard, a cut off of one or more ACEs yielded a sensitivity of 99%, but specificity was low (66%). Specificity improved to 94% when using a cut off of two ACEs, but sensitivity diminished (70%). There was no substantive difference between the 11-and two-item ACE measures in their strength of association with an array of health outcomes. Conclusions: A two-item ACE screener appropriate for rapid identification of adults who have experienced significant childhood adversity was developed. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. C1 [Wade, Roy, Jr.; Becker, Brandon D.; Bevans, Katherine B.; Forrest, Christopher B.] Childrens Hosp Philadelphia, Dept Pediat, 3535 Market St,Room 1627, Philadelphia, PA 19104 USA. [Wade, Roy, Jr.; Bevans, Katherine B.; Forrest, Christopher B.] Univ Penn, Perelman Sch Med, Pediat, Philadelphia, PA 19104 USA. [Ford, Derek C.] US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA USA. RP Wade, R (reprint author), Childrens Hosp Philadelphia, Dept Pediat, 3535 Market St,Room 1627, Philadelphia, PA 19104 USA. EM wader2@email.chop.edu NR 57 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2017 VL 52 IS 2 BP 163 EP 172 DI 10.1016/j.amepre.2016.09.033 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EO9DP UT WOS:000396989700005 PM 27865652 ER PT J AU Kempe, A Hurley, LP Cardemil, CV Allison, MA Crane, LA Brtnikova, M Beaty, BL Pabst, LJ Lindley, MC AF Kempe, Allison Hurley, Laura P. Cardemil, Cristina V. Allison, Mandy A. Crane, Lori A. Brtnikova, Michaela Beaty, Brenda L. Pabst, Laura J. Lindley, Megan C. TI Use of Immunization Information Systems in Primary Care SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID COMPARATIVE EFFECTIVENESS TRIAL; RECALL; MODELS; POLICY; RATES; RISK AB Introduction: Immunization information systems (IISs) are highly effective for increasing vaccination rates but information about how primary care physicians use them is limited. Methods: Pediatricians, family physicians (FPs), and general internists (GIMs) were surveyed by email and mail from January 2015 to April 2015 from all states with an existing IIS. Providers were recruited to be representative of national provider organization memberships. Multivariable log binomial regression examined factors associated with IIS use (October 2015-April 2016). Results: Response rates among pediatricians, FPs, and GIMs, respectively, were 75% (325/435), 68% (310/459), and 63% (272/431). A proportion of pediatricians (5%), FPs (14%), and GIMs (48%) did not know there was a state/local IIS; 81%, 72%, and 27% reported using an IIS (p<0.0001). Among those who used IISs, 64% of pediatricians, 61% of FPs, and 22% of GIMs thought the IIS could tell them a patient's immunization needs; 22%, 29%, and 51% did not know. The most frequently reported major barriers to use included the IIS not updating the electronic medical record (29%, 28%, 35%) and lack of ability to submit data electronically (22%, 27%, 31%). Factors associated with lower IIS use included FP (adjusted risk ratio = 0.85; 95% CI = 0.75, 0.97) or GIM (adjusted risk ratio = 0.33; 95% CI = 0.25, 0.42) versus pediatric specialty and older versus younger provider age (adjusted risk ratio = 0.96; 95 CI% = 0.94, 0.98). Conclusions: There are substantial gaps in knowledge of IIS capabilities, especially among GIMs; barriers to interoperability between IISs and electronic medical records affect all specialties. Closing these gaps may increase use of proven IIS functions including decision support and reminder/recall. (C) 2016 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Kempe, Allison; Hurley, Laura P.; Allison, Mandy A.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.] Univ Colorado, Sch Med, Adult & Child Consortium Hlth Outcomes Res & Deli, 13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. [Kempe, Allison; Hurley, Laura P.; Allison, Mandy A.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.] Childrens Hosp Colorado, 13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. [Kempe, Allison; Allison, Mandy A.; Brtnikova, Michaela] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO USA. [Cardemil, Cristina V.; Pabst, Laura J.; Lindley, Megan C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Crane, Lori A.] Colorado Sch Publ Hlth, Community & Behav Hlth, Denver, CO USA. RP Kempe, A (reprint author), Univ Colorado, Sch Med, Adult & Child Consortium Hlth Outcomes Res & Deli, 13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA.; Kempe, A (reprint author), Childrens Hosp Colorado, 13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM allison.kempe@childrenscolorado.org FU Centers for Disease Control and Prevention [1U01IP000849-01] FX Funding for this study is from Centers for Disease Control and Prevention, grant 1U01IP000849-01. NR 31 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2017 VL 52 IS 2 BP 173 EP 182 DI 10.1016/j.amepre.2016.07.029 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EO9DP UT WOS:000396989700006 PM 27639786 ER PT J AU Clayton, HB Demissie, Z Lowry, R Lundeen, EA Sharma, AJ Bohm, MK AF Clayton, Heather B. Demissie, Zewditu Lowry, Richard Lundeen, Elizabeth A. Sharma, Andrea J. Bohm, Michele K. TI Unhealthy Weight Management Practices and Non-medical Use of Prescription Drugs SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEALTH-COMPROMISING BEHAVIORS; EATING-DISORDERED BEHAVIORS; HIGH-SCHOOL-STUDENTS; SUBSTANCE USE; ADOLESCENT GIRLS; STIMULANT USE; BODY-IMAGE; RISK; PREVALENCE; PATTERNS AB Introduction: Non-medical use of prescription drugs (NMUPD) has reached epidemic proportions in the U.S. With approximately one in five high school students engaging in NMUPD, it is important to understand behavioral correlates. Methods: Data were combined from the 2011 and 2013 cycles of the Youth Risk Behavior Survey, a nationally representative, cross-sectional survey. After restricting the analytic sample to students who reported a weight loss goal of either staying the same weight or losing weight, logistic regression models were used to estimate adjusted prevalence ratios and 95% CIs for associations between unhealthy weight management practices (UWMPs) and lifetime NMUPD. Individual UWMPsfasting; taking diet pills, powders, or liquids without a doctor's advice; and vomiting or taking laxatives-and total number of UWMPs were examined. Data were analyzed in 2016. Results: UWMPs were more prevalent among female students (21.1% vs 10.7% for fasting; 7.5% vs 5.2% for taking diet pills, powders, or liquids; and 7.6% vs 3.2% for vomiting or taking laxatives). Significant associations between individual UWMPs and NMUPD and between the number of UWMPs and NMUPD were observed. Discussion: UWMPs were associated with NMUPD. Health educators in the school setting, as well as other health professionals who provide services to an adolescent population, can focus on healthy weight management strategies, and other substance-specific messages. Conclusions: The association between UWMPs and NMUPD may reflect a constellation of problem behaviors exhibited among some adolescents. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine. C1 [Clayton, Heather B.; Demissie, Zewditu; Lowry, Richard] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent & Sch Hlth, 1600 Clifton Rd NE,Mailstop E-75, Atlanta, GA 30329 USA. [Demissie, Zewditu; Sharma, Andrea J.] US Publ Hlth Serv Commissioned Corps, Rockville, MD USA. [Lundeen, Elizabeth A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Lundeen, Elizabeth A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Sharma, Andrea J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Bohm, Michele K.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA. RP Clayton, HB (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Adolescent & Sch Hlth, 1600 Clifton Rd NE,Mailstop E-75, Atlanta, GA 30329 USA. EM hhc9@cdc.gov NR 30 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2017 VL 52 IS 2 BP 215 EP 219 DI 10.1016/j.amepre.2016.09.015 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EO9DP UT WOS:000396989700011 PM 27863921 ER PT J AU Appiah, GD Chaves, SS Kirley, PD Miller, L Meek, J Anderson, E Oni, O Ryan, P Eckel, S Lynfield, R Bargsten, M Zansky, SM Bennett, N Lung, K McDonald-Hamm, C Thomas, A Brady, D Lindegren, ML Schaffner, W Hill, M Garg, S Fry, AM Campbell, AP AF Appiah, Grace D. Chaves, Sandra S. Kirley, Pam D. Miller, Lisa Meek, James Anderson, Evan Oni, Oluwakemi Ryan, Patricia Eckel, Seth Lynfield, Ruth Bargsten, Marisa Zansky, Shelley M. Bennett, Nancy Lung, Krista McDonald-Hamm, Christie Thomas, Ann Brady, Diane Lindegren, Mary L. Schaffner, William Hill, Mary Garg, Shikha Fry, Alicia M. Campbell, Angela P. TI Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015 SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material DE influenza; antiviral; oseltamivir ID NEURAMINIDASE INHIBITORS; CHEMOPROPHYLAXIS; METAANALYSIS; INFECTION AB Using population-based surveillance data, we analyzed antiviral treatment among hospitalized patients with laboratory- confirmed influenza. Treatment increased after the influenza A(H1N1) 2009 pandemic from 72% in 2010-2011 to 89% in 2014-2015 (P < .001). Overall, treatment was higher in adults (86%) than in children (72%); only 56% of cases received antivirals on the day of admission. C1 [Appiah, Grace D.] Epidem Intelligence Serv, Atlanta, GA USA. [Appiah, Grace D.; Chaves, Sandra S.; Garg, Shikha; Campbell, Angela P.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Kirley, Pam D.] California Emerging Infect Program, Oakland, CA USA. [Miller, Lisa] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Meek, James] Yale Sch Publ Hlth, Connecticut Emerging Infect Program, New Haven, CT USA. [Anderson, Evan] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Oni, Oluwakemi] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Ryan, Patricia] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Eckel, Seth] Iowa Dept Hlth, Des Moines, IA USA. [Lynfield, Ruth] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Bargsten, Marisa] Michigan Dept Hlth & Human Serv, Lansing, MI USA. [Zansky, Shelley M.] Minnesota Dept Hlth, St Paul, MN USA. [Bennett, Nancy] New Mexico Dept Hlth, Santa Fe, NM USA. [Lung, Krista] New York State Dept Hlth, Albany, NY USA. [McDonald-Hamm, Christie] Univ Rochester, Sch Med & Dent, Rochester, NY USA. [Thomas, Ann] Ohio Dept Hlth, Columbus, OH 43266 USA. [Brady, Diane] Oklahoma Dept Hlth, Oklahoma City, OK USA. [Lindegren, Mary L.] Oregon Dept Publ Hlth, Portland, OR USA. [Brady, Diane] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Hill, Mary] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Hill, Mary] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Appiah, Grace D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd,NE,Mailstop C 09, Atlanta, GA 30329 USA. RP Campbell, AP (reprint author), Influenza Div, Epidemiol & Prevent Branch, 1600 Clifton Rd NE,MS A 32, Atlanta, GA 30329 USA. EM ydg3@cdc.gov; app4@cdc.gov FU Centers for Disease Control and Prevention [CDC-RFA-CK12-1202, 5U38HM000414] FX FluSurv-NET is a collaboration of state health departments, academic institutions, and local partners and is supported by the Centers for Disease Control and Prevention (cooperative agreements CDC-RFA-CK12-1202 and 5U38HM000414). NR 12 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2017 VL 64 IS 3 BP 364 EP 367 DI 10.1093/cid/ciw745 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3RQ UT WOS:000397299800027 PM 28013261 ER PT J AU Moehring, RW Anderson, DJ Cochran, RL Hicks, LA Srinivasan, A Ashley, ESD AF Moehring, Rebekah W. Anderson, Deverick J. Cochran, Ronda L. Hicks, Lauri A. Srinivasan, Arjun Ashley, Elizabeth S. Dodds CA Structured Taskforce Experts Work TI Expert Consensus on Metrics to Assess the Impact of Patient-Level Antimicrobial Stewardship Interventions in Acute-Care Settings SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE antimicrobial stewardship; patient safety; process measure; outcome measure; quality metrics ID DE-ESCALATION AB Antimicrobial stewardship programs (ASPs) positively impact patient care, but metrics to assess ASP impact are poorly defined. We used a modified Delphi approach to select relevant metrics for assessing patient-level interventions in acute-care settings for the purposes of internal program decision making. An expert panel rated 90 candidate metrics on a 9-point Likert scale for association with 4 criteria: improved antimicrobial prescribing, improved patient care, utility in targeting stewardship efforts, and feasibility in hospitals with electronic health records. Experts further refined, added, or removed metrics during structured teleconferences and re-rated the retained metrics. Six metrics were rated > 6 in all criteria: 2 measures of Clostridium difficile incidence, incidence of drug-resistant pathogens, days of therapy over admissions, days of therapy over patient days, and redundant therapy events. Fourteen metrics rated > 6 in all criteria except feasibility were identified as targets for future development. C1 [Moehring, Rebekah W.; Anderson, Deverick J.; Ashley, Elizabeth S. Dodds] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA. [Moehring, Rebekah W.; Anderson, Deverick J.; Ashley, Elizabeth S. Dodds] Duke Antimicrobial Stewardship Outreach Network, Durham, NC USA. [Cochran, Ronda L.; Hicks, Lauri A.; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Moehring, RW (reprint author), Duke Univ, Med Ctr, POB 102359, Durham, NC 27710 USA. EM rebekah.moehring@duke.edu FU CDC Foundation; Agency for Healthcare Research and Quality [K08 HS023866]; National Institutes of Health [K23 AI095357]; CDC FX This work was supported by the CDC Foundation; the Agency for Healthcare Research and Quality (grant number K08 HS023866 to R. W. M.); and the National Institutes of Health (grant number K23 AI095357 to D. J. A.). The source of this information is the Patient Tools for Antibiotic Stewardship Programs, a joint project made possible by a partnership between the CDC Foundation and Merck and Co., Inc.; Multiple STEWARDS panel members were supported by the CDC Epicenters Program grants to Duke University (Durham, North Carolina), Washington University (St Louis, Missouri), Rush University Medical Center (Chicago, Illinois), University of Pennsylvania (Philadelphia, Pennsylvania), and Harvard University (Boston, Massachusetts). NR 18 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2017 VL 64 IS 3 BP 377 EP 383 DI 10.1093/cid/ciw787 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP3RQ UT WOS:000397299800030 PM 27927866 ER PT J AU Bartenfeld, M Griese, S Uyeki, T Gerber, SI Peacock, G AF Bartenfeld, Michael Griese, Stephanie Uyeki, Timothy Gerber, Susan I. Peacock, Georgina TI Middle East Respiratory Syndrome Coronavirus and Children: What Pediatric Health Care Professionals Need to Know SO CLINICAL PEDIATRICS LA English DT Article ID MERS-COV INFECTION; UNITED-STATES C1 [Bartenfeld, Michael] Ctr Dis Control & Prevent, Ctr Global Hlth, CDC, Atlanta, GA USA. [Griese, Stephanie] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Uyeki, Timothy; Gerber, Susan I.] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Peacock, Georgina] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Bartenfeld, M (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, 1600 Clifton Rd NE,MS-D69, Atlanta, GA 30329 USA. EM vdv4@cdc.gov FU Intramural CDC HHS [CC999999] NR 15 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 EI 1938-2707 J9 CLIN PEDIATR JI Clin. Pediatr. PD FEB PY 2017 VL 56 IS 2 BP 187 EP 189 DI 10.1177/0009922816678820 PG 3 WC Pediatrics SC Pediatrics GA EP2MV UT WOS:000397218300015 PM 27872356 ER PT J AU Haegerich, TM David-Ferdon, C Noonan, RK Manns, BJ Billie, HC AF Haegerich, Tamara M. David-Ferdon, Corinne Noonan, Rita K. Manns, Brian J. Billie, Holly C. TI Technical Packages in Injury and Violence Prevention to Move Evidence Into Practice: Systematic Reviews and Beyond SO EVALUATION REVIEW LA English DT Review DE systematic review; injury; violence; implementation ID PUBLIC-HEALTH; REDUCING DRINKING; IMPLEMENTATION; INTERVENTIONS; PROGRAMS; POLICY; TRANSLATION; INCREASE; IMPACT; COLLABORATION AB Injury and violence prevention strategies have greater potential for impact when they are based on scientific evidence. Systematic reviews of the scientific evidence can contribute key information about which policies and programs might have the greatest impact when implemented. However, systematic reviews have limitations, such as lack of implementation guidance and contextual information, that can limit the application of knowledge. "Technical packages,'' developed by knowledge brokers such as the federal government, nonprofit agencies, and academic institutions, have the potential to be an efficient mechanism for making information from systematic reviews actionable. Technical packages provide information about specific evidence-based prevention strategies, along with the estimated costs and impacts, and include accompanying implementation and evaluation guidance to facilitate adoption, implementation, and performance measurement. We describe how systematic reviews can inform the development of technical packages for practitioners, provide examples of technical packages in injury and violence prevention, and explain how enhancing review methods and reporting could facilitate the use and applicability of scientific evidence. C1 [Haegerich, Tamara M.; Noonan, Rita K.; Billie, Holly C.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F62, Atlanta, GA 30341 USA. [David-Ferdon, Corinne] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Manns, Brian J.] Ctr Dis Control & Prevent, Off Associate Director Policy, Atlanta, GA USA. RP Haegerich, TM (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F62, Atlanta, GA 30341 USA. EM thaegerich@cdc.gov NR 78 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0193-841X EI 1552-3926 J9 EVALUATION REV JI Eval. Rev. PD FEB PY 2017 VL 41 IS 1 SI SI BP 78 EP 108 DI 10.1177/0193841X16667214 PN 1 PG 31 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA EP2HG UT WOS:000397203400004 ER PT J AU Johnson, SR Grad, Y Abrams, AJ Pettus, K Trees, DL AF Johnson, Steven R. Grad, Yonatan Abrams, A. Jeanine Pettus, Kevin Trees, David L. TI Use of whole-genome sequencing data to analyze 23S rRNA-mediated azithromycin resistance SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Article DE Azithromycin; Resistance; Neisseria gonorrhoeae; 23S rRNA ID NEISSERIA-GONORRHOEAE; MULTIDRUG-RESISTANT; HIGH-LEVEL; SUSCEPTIBILITY; MUTATION; STRAIN AB The whole-genome sequences of 24 isolates of Neisseria gonorrhoeae with elevated minimum inhibitory concentrations (MICs) to azithromycin (>= 2.0 mu g/mL) were analyzed against a modified sequence derived from the whole-genome sequence of N. gonorrhoeae FA1090 to determine, by signal ratio, the number of mutant copies of the 23S rRNA gene and the copy number effect on 50S ribosome-mediated azithromycin resistance. Isolates that were predicted to contain four mutated copies were accurately identified compared with the results of direct sequencing. Fewer than four mutated copies gave less accurate results but were consistent with elevated MICs. Published by Elsevier B.V. C1 [Johnson, Steven R.; Abrams, A. Jeanine; Pettus, Kevin; Trees, David L.] US Ctr Dis Control & Prevent, NCHHSTP, Div STD Prevent, Atlanta, GA 30333 USA. [Grad, Yonatan] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA. [Grad, Yonatan] Harvard Med Sch, Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA. RP Johnson, SR (reprint author), US Ctr Dis Control & Prevent CDC, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM sbj1@cdc.gov FU National Institute of Allergy and Infectious Diseases [1-K08-AL104767] FX YG was supported by the National Institute of Allergy and Infectious Diseases [1-K08-AL104767]. NR 13 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 EI 1872-7913 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD FEB PY 2017 VL 49 IS 2 BP 252 EP 254 DI 10.1016/j.ijantimicag.2016.10.023 PG 3 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA EP1KR UT WOS:000397144300018 PM 28038960 ER PT J AU Ukwah, BN Ezeonu, IM Ezeonu, CT Roellig, D Xiao, L AF Ukwah, Boniface Nwofoke Ezeonu, Ifeoma Maureen Ezeonu, Chinonyelum Thecla Roellig, Dawn Xiao, Lihua TI Cryptosporidium species and subtypes in diarrheal children and HIV-infected persons in Ebonyi and Nsukka, Nigeria SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES LA English DT Article DE Cryptosporidium; genetic diversity; HAART; HIV-infected persons; diarrheal children ID ENTEROCYTOZOON-BIENEUSI GENOTYPES; HOMINIS SUBTYPES; IDENTIFICATION; DIVERSITY; HUMANS; CATTLE AB Introduction: Cryptosporidiosis is a common disease of children and immune-compromised persons. This study evaluated the diversity and distribution of Cryptosporidium species in diarrheal children and HIV-infected persons on highly active antiretroviral therapy (HAART) and those not on HAART. Methodology: A total of 394 fecal specimens were collected from patients attending clinics in Nsukka and Ebonyi, Nigeria. Detection and identification of Cryptosporidium species were conducted by PCR-RFLP of the small subunit (SSU) rRNA gene, whereas subtyping was done by sequence analysis of the 60 kDa glycoprotein (gp60) gene. Results: Twenty-five (6.3%) specimens yielded four Cryptosporidium species, including C. hominis, C. parvum, C. felis, and C. viatorum. C. hominis was the most dominant species with 48.0% occurrence and three identified subtype families: Ia (six specimens), Ib (three specimens), Ie (two specimens), and one un-subtyped species. C. parvum had 44.0% occurrence and two subtype families: IIc (eight specimens) and IIe (three specimens), while C. felis and C. viatorum each had 4.0% occurrence. There were significant differences in Cryptosporidium species distribution between age groups in children and HIV-infected persons, between suburban and urban areas, and between low and high CD4(+) cell counts in HIV-infected patients. There were no significant differences in infection rate and species distribution between HIV-infected patients on HAART and those not on HAART. Conclusions: The results from this study show that there is a high diversity of Cryptosporidium spp. in humans in Ebonyi and Nsukka, Nigeria, and that all the C. parvum subtypes identified are most likely anthroponotic in origin. C1 [Ukwah, Boniface Nwofoke] Ebonyi State Univ, Fac Hlth Sci, Dept Med Lab Sci, Abakaliki, Nigeria. [Ukwah, Boniface Nwofoke; Roellig, Dawn; Xiao, Lihua] Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Div Food Borne Waterborne & Environm Dis, Atlanta, GA USA. [Ezeonu, Ifeoma Maureen] Univ Nigeria, Fac Biol Sci, Dept Microbiol, Nsukka, Nigeria. [Ezeonu, Chinonyelum Thecla] Ebonyi State Univ, Fac Clin Med, Dept Pediat, Abakaliki, Nigeria. RP Ukwah, BN (reprint author), Ebonyi State Univ, Fac Hlth Sci, Dept Med Lab Sci, Abakaliki, Nigeria.; Ukwah, BN (reprint author), Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Div Food Borne Waterborne & Environm Dis, Atlanta, GA USA.; Ukwah, BN (reprint author), Ebonyi State Univ, Dept Med Lab Sci, 1 Enugu Abakaliki Expressway, Abakaliki 480214, Nigeria. EM bnukwah@gmail.com FU TETFund; Nigeria/Ebonyi State University, Abakaliki FX We thank the TETFund, Nigeria/Ebonyi State University, Abakaliki for financial support, members of the CDC laboratory for technical assistance, and participating hospitals and patients for specimen collection. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 23 TC 0 Z9 0 U1 0 U2 0 PU J INFECTION DEVELOPING COUNTRIES PI TRAMANIGLIO PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY SN 1972-2680 J9 J INFECT DEV COUNTR JI J. Infect. Dev. Ctries. PD FEB PY 2017 VL 11 IS 2 BP 173 EP 179 DI 10.3855/j.idc.8034 PG 7 WC Infectious Diseases SC Infectious Diseases GA EP2FG UT WOS:000397198000010 PM 28248679 ER PT J AU Collett, MS Hincks, JR Benschop, K Duizer, E van der Avoort, H Rhoden, E Liu, HM Oberste, MS McKinlay, MA Hartford, M AF Collett, Marc S. Hincks, Jeffrey R. Benschop, Kimberley Duizer, Erwin van der Avoort, Harrie Rhoden, Eric Liu, Hongmei Oberste, M. Steven McKinlay, Mark A. Hartford, Marianne TI Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Polio; antiviral; pocapavir; poliovirus; clinical efficacy; drug resistance; virus challenge; transmission; clinical trial design; virus eradication ID ERADICATION; V-073; RESISTANCE; COMPOUND AB Background. Immunodeficient individuals who excrete vaccine-derived polioviruses threaten polio eradication. Antivirals address this threat. Methods. In a randomized, blinded, placebo-controlled study, adults were challenged with monovalent oral poliovirus type 1 vaccine (mOPV1) and subsequently treated with capsid inhibitor pocapavir or placebo. The time to virus negativity in stool was determined. Results. A total of 144 participants were enrolled; 98% became infected upon OPV challenge. Pocapavir-treated subjects (n = 93) cleared virus a median duration of 10 days after challenge, compared with 13 days for placebo recipients (n = 48; P = .0019). Fifty-two of 93 pocapavir-treated subjects (56%) cleared virus in 2-18 days with no evidence of drug resistance, while 41 of 93 (44%) treated subjects experienced infection with resistant virus while in the isolation facility, 3 (3%) of whom were infected at baseline, before treatment initiation. Resistant virus was also observed in 5 placebo recipients (10%). Excluding those with resistant virus, the median time to virus negativity was 5.5 days in pocapavir recipients, compared with 13 days in placebo recipients (P <.0001). There were no serious adverse events and no withdrawals from the study. Conclusions. Treatment with pocapavir was safe and significantly accelerated virus clearance. Emergence of resistant virus and transmission of virus were seen in the context of a clinical isolation facility. C1 [Collett, Marc S.; Hincks, Jeffrey R.] ViroDef Inc, 5425 Wisconsin Ave,Ste 600, Chevy Chase, MD 20815 USA. [Rhoden, Eric; Liu, Hongmei; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [McKinlay, Mark A.] Task Force Global Hlth, Decatur, GA USA. [Benschop, Kimberley; Duizer, Erwin; van der Avoort, Harrie] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands. [Hartford, Marianne] Sahlgrens Univ Hosp, Clin Trial Ctr, Gothenburg, Sweden. RP Collett, MS (reprint author), ViroDef Inc, 5425 Wisconsin Ave,Ste 600, Chevy Chase, MD 20815 USA. EM mscollett@aol.com FU Task Force for Global Health FX M.S.C. and J.R.H. are employees of the drug-developer ViroDefense, sponsor of pocapavir, and report grants from the Task Force for Global Health during the conduct of this study. K. B., E. D., and H. A. report grants to the Dutch National Institute for Public Health and the Environment from the Task Force for Global Health during this study. M. A. M. is an employee of the Task Force for Global Health, the funder of this study, and reports grants from the Bill and Melinda Gates Foundation during the conduct of this study. All other authors report no potential conflicts. NR 19 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2017 VL 215 IS 3 BP 335 EP 343 DI 10.1093/infdis/jiw542 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP2HT UT WOS:000397204700002 PM 27932608 ER PT J AU George, Z Omosun, Y Azenabor, AA Partin, J Joseph, K Ellerson, D He, Q Eko, F Bandea, C Svoboda, P Pohl, J Black, CM Igietseme, JU AF George, Zenas Omosun, Yusuf Azenabor, Anthony A. Partin, James Joseph, Kahaliah Ellerson, Debra He, Qing Eko, Francis Bandea, Claudiu Svoboda, Pavel Pohl, Jan Black, Carolyn M. Igietseme, Joseph U. TI The Roles of Unfolded Protein Response Pathways in Chlamydia Pathogenesis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Chlamydia; pathogenesis; unfolded protein response ID ENDOPLASMIC-RETICULUM STRESS; INHIBITS ER-STRESS; CARTILAGE DEVELOPMENT; MAMMALIAN-CELLS; GENE-EXPRESSION; MESSENGER-RNAS; TRACHOMATIS; INFECTION; ACTIVATION; ATF6 AB Chlamydia is an obligate intracellular bacterium that relies on host cells for essential nutrients and adenosine triphosphate (ATP) for a productive infection. Although the unfolded protein response (UPR) plays a major role in certain microbial infectivity, its role in chlamydial pathogenesis is unknown. We hypothesized that Chlamydia induces UPR and exploits it to upregulate host cell uptake and metabolism of glucose, production of ATP, phospholipids, and other molecules required for its replicative development and host survival. Using a combination of biochemical and pathway inhibition assays, we showed that the 3 UPR pathway transducers-protein kinase RNA-activated (PKR)-like ER kinase (PERK), inositol-requiring enzyme-1 alpha (IRE1 alpha), and activating transcription factor-6 alpha (ATF6 alpha)-were activated during Chlamydia infection. The kinase activity of PERK and ribonuclease (RNase) of IRE1 alpha mediated the upregulation of hexokinase II and production of ATP via substrate-level phosphorylation. In addition, the activation of PERK and IRE1a promoted autophagy formation and apoptosis resistance for host survival. Moreover, the activation of IRE1a resulted in the generation of spliced X-box binding protein 1 (sXBP1) and upregulation of lipid production. The vital role of UPR pathways in Chlamydia development and pathogenesis could lead to the identification of potential molecular targets for therapeutics against Chlamydia. C1 [George, Zenas; Omosun, Yusuf; Partin, James; Joseph, Kahaliah; Ellerson, Debra; He, Qing; Bandea, Claudiu; Svoboda, Pavel; Pohl, Jan; Black, Carolyn M.; Igietseme, Joseph U.] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. [Omosun, Yusuf; He, Qing; Eko, Francis] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA USA. [Azenabor, Anthony A.] Univ Wisconsin, Dept Biomed Sci, Milwaukee, WI USA. RP Igietseme, JU (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM jigietseme@cdc.gov FU Centers for Disease Control and Prevention and Public Health Service from the National Institutes of Health [AI41231, GM 08248, RR03034, 1SC1GM098197] FX This work was supported by the Centers for Disease Control and Prevention and Public Health Service grants (AI41231, GM 08248, RR03034, and 1SC1GM098197) from the National Institutes of Health. NR 49 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2017 VL 215 IS 3 BP 456 EP 465 DI 10.1093/infdis/jiw569 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA EP2HT UT WOS:000397204700016 PM 27932618 ER PT J AU Cramer, R Hexem, S LaPollo, A Cuffe, KM Chesson, HW Leichliter, JS AF Cramer, Ryan Hexem, Sarah LaPollo, Archana Cuffe, Kendra M. Chesson, Harrell W. Leichliter, Jami S. TI State and local policies related to sexual orientation in the United States SO JOURNAL OF PUBLIC HEALTH POLICY LA English DT Article DE law; policy; same-sex marriage; discrimination; sexual orientation; sexual minority health ID MENTAL-HEALTH; NORTH-AMERICA AB Poorer health suffered by lesbian, gay, and bisexual (LGB) populations may be associated with public policies. We collected the laws that in 2013 prohibited discrimination based on sexual orientation from 50 United States (US) states, the District of Columbia (Washington, DC or DC), and the 30 most populous US metropolitan areas. To facilitate future research, we coded certain aspects of these laws to create a dataset. We generated descriptive statistics by jurisdiction type and tested for regional differences in state law using Chi-square tests. Sixteen (31.4 per cent) states prohibited discrimination by all employers based on sexual orientation, 25 states (49.0 per cent) in public employment, 18 states (35.3 per cent) in government contracting, and 21 states (41.2 per cent) in private employment. Twenty-one states prohibited discrimination (41.2 per cent) in housing practices (selling and renting), and 17 (33.3 per cent) in public accommodations. Local (county/city) laws prohibiting discrimination were less common. State laws differed significantly by US census region - West, Midwest, Northeast, and South. Future analyses of these data could examine the impact of these laws on various outcomes, including health among LGB populations. C1 [Cramer, Ryan; Cuffe, Kendra M.; Chesson, Harrell W.; Leichliter, Jami S.] Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd MS E-02, Atlanta, GA 30329 USA. [Hexem, Sarah] Public Hlth Management Corp, Philadelphia, PA USA. [LaPollo, Archana] Public Hlth Management Corp, Res & Evaluat Grp, Philadelphia, PA USA. RP Cramer, R (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd MS E-02, Atlanta, GA 30329 USA. EM rcramer@cdc.gov; shexem@nncc.us; archana@phmc.org; kcuffe@cdc.gov; hchesson@cdc.gov; jleichliter@cdc.gov NR 29 TC 1 Z9 1 U1 0 U2 0 PU PALGRAVE MACMILLAN LTD PI BASINGSTOKE PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND SN 0197-5897 EI 1745-655X J9 J PUBLIC HEALTH POL JI J. Public Health Policy PD FEB PY 2017 VL 38 IS 1 BP 58 EP 79 DI 10.1057/s41271-016-0037-9 PG 22 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EO6YO UT WOS:000396838600006 PM 28275249 ER PT J AU Royce, RA Colson, PW Woodsong, C Swinson-Evans, T Walton, W Maiuri, A DeLuca, N AF Royce, Rachel A. Colson, Paul W. Woodsong, Cynthia Swinson-Evans, Tammeka Walton, Wanda Maiuri, Allison DeLuca, Nickolas CA TBESC TI Tuberculosis Knowledge, Awareness, and Stigma Among African-Americans in Three Southeastern Counties in the USA: a Qualitative Study of Community Perspectives SO JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES LA English DT Article DE African-American; Tuberculosis; Health disparities; Stigma; Qualitative research; Health knowledge, attitudes, and practices (KAP) ID PERCEIVED RISK; MYCOBACTERIUM-TUBERCULOSIS; HOMELESS ADULTS; UNITED-STATES; HEALTH-CARE; DRUG-USERS; ATTITUDES; COMMUNICATION; DISPARITIES; INFECTION AB To inform strategies to address the tuberculosis (TB) excess among US-born African-Americans, we sought to understand the TB experience in the most highly affected southeastern communities. We conducted semi-structured interviews and focus groups in three communities with a TB excess-urban (Georgia and Tennessee) and rural (North Carolina). Participants from five groups provided diverse perspectives-African-Americans: patients with TB disease or latent TB infection (LTBI), or at high risk of contracting TB; and local community leaders and TB program staff. Few differences emerged between sites. Many participants demonstrated low levels of knowledge and awareness and held many misconceptions about TB. Patients expressed a preference for verbal communication of medical information. Patients reported fear of stigmatization and shunning, but few experienced discrimination. Patient trust for TB program staff was high, though community leaders often assumed the opposite. The findings will help guide interventions to improve knowledge and awareness regarding TB, including specific attention to the role of public and private health care providers in dispelling persistent misinformation about TB. The insight from these communities will help build the scientific foundation required to effectively eliminate health inequities. C1 [Royce, Rachel A.; Woodsong, Cynthia; Swinson-Evans, Tammeka] RTI Int, Durham, NC USA. [Colson, Paul W.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA. [Woodsong, Cynthia] Int Partnership Microbicides, Silver Spring, MD USA. [Walton, Wanda; Maiuri, Allison; DeLuca, Nickolas] Ctr Dis Control & Prevent, NCHHSTP Div TB Eliminat, Atlanta, GA USA. [DeLuca, Nickolas] Ctr Dis Control & Prevent, NCHHSTP Div HIV AIDS Prevent, Atlanta, GA USA. RP Colson, PW (reprint author), Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA. EM rroyce@rti.org; pwc2@columbia.edu; cwoodsong@ipmglobal.org; tsevans@rti.org; wxw2@cdc.gov; fpg3@cdc.gov; ncd4@cdc.gov FU Centers for Disease Control and Prevention [200-2001-00125/0011]; North Carolina site of the Tuberculosis Epidemiologic Studies Consortium (TBESC) of the Centers for Disease Control and Prevention FX The study was supported through a Centers for Disease Control and Prevention contract (Contract #200-2001-00125/0011) to RTI International, the North Carolina site of the Tuberculosis Epidemiologic Studies Consortium (TBESC) of the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 40 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2197-3792 EI 2196-8837 J9 J RACIAL ETHN HEALTH JI J. Racial Ethn. Health Disparities PD FEB PY 2017 VL 4 IS 1 BP 47 EP 58 DI 10.1007/s40615-015-0200-1 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EO9GV UT WOS:000396998100006 PM 26715219 ER PT J AU Guy, GP Zhang, YH Ekwueme, DU Rim, SH Watson, M AF Guy, Gery P., Jr. Zhang, Yuanhui Ekwueme, Donatus U. Rim, Sun Hee Watson, Meg TI The potential impact of reducing indoor tanning on melanoma prevention and treatment costs in the United States: An economic analysis SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE indoor tanning; melanoma; prevention; skin cancer ID SURVEILLANCE; METAANALYSIS; PREVALENCE; YOUTH; CARE; US C1 [Guy, Gery P., Jr.; Zhang, Yuanhui; Ekwueme, Donatus U.; Rim, Sun Hee; Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop F-76, Atlanta, GA 30341 USA. EM irm2@cdc.gov NR 29 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD FEB PY 2017 VL 76 IS 2 BP 226 EP 233 DI 10.1016/j.jaad.2016.09.029 PG 8 WC Dermatology SC Dermatology GA EO7YC UT WOS:000396905000021 PM 27939556 ER PT J AU Watson, M Guy, GP AF Watson, Meg Guy, Gery P., Jr. TI Indoor tanning among New Jersey high school students before and after the enactment of youth access restrictions SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Letter ID PREVALENCE C1 [Watson, Meg; Guy, Gery P., Jr.] Ctr Dis Prevent & Control, Canc Prevent Div, Atlanta, GA USA. RP Watson, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,Mailstop F76, Atlanta, GA 30341 USA. EM eze5@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD FEB PY 2017 VL 76 IS 2 BP E67 EP E68 DI 10.1016/j.jaad.2016.08.072 PG 2 WC Dermatology SC Dermatology GA EO7YC UT WOS:000396905000012 PM 28089019 ER PT J AU Taylor, JR Thompson, PJ Genzen, JR Hickner, J Marques, MB AF Taylor, Julie R. Thompson, Pamela J. Genzen, Jonathan R. Hickner, John Marques, Marisa B. TI Opportunities to Enhance Laboratory Professionals(') Role On the Diagnostic Team SO LABORATORY MEDICINE LA English DT Article DE laboratory test ordering; laboratory test interpretation; diagnostic team; laboratory medicine practices; medical laboratory practices; physician practice patterns; diagnostic tests; laboratory utilization; diagnosis AB Background: The 2015 Institue of Medicine report Improving Diagnosis in Health Care highlighted that diagnostic errors cause patient harm and that improvement in the diagnostic process requires better collaboration among physicians and laboratory professionals. The purpose of this study is to understand why physicians do not contact laboratory professionals when facing diagnostic challenges and identify opportunities for laboratory professionals to become more recognized members of the clinical care team. Methods: A random sample of 31,689 physicians from the American Medical Association Masterfile were surveyed about diagnostic challenges in laboratory test ordering and results interpretation, solutions to these challenges, and interactions with laboratory professionals. Results: We received responses from 1768 physicians (5.6%). When faced with diagnostic challenges, they reported using electronic resources because they find it difficult and time-consuming to contact the laboratory. Only 20% had an effective way to access laboratory professionals, mostly seeking help for logistical but less for clinical issues. Continuing medical education, professional articles, and updates from the laboratory were helpful. Conclusions: Laboratory professionals have an opportunity to play a greater role in the diagnostic process by becoming active members of the clinical care team, beyond providing results. This study provides strategies to increase laboratory professionals' role in the diagnostic process. C1 [Taylor, Julie R.] Ctr Dis Control & Prevent, Div Lab Syst, 83 Lorelei Loop, Lakemont, GA 30552 USA. [Thompson, Pamela J.] Ctr Dis Control & Prevent, Div Lab Syst, Atlanta, GA USA. [Genzen, Jonathan R.] Univ Utah, Dept Pathol, ARUP Labs, Salt Lake City, UT USA. [Hickner, John] Univ Illinois, Dept Family Med, Coll Med, Chicago, IL USA. [Marques, Marisa B.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA. EM Julie.taylor5@icloud.com FU Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry [GS-10F0261K] FX This report was supported in part from a contract (GS-10F0261K) funded by the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry. OMB Control number 0920-0893 NR 6 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0007-5027 EI 1943-7730 J9 LAB MED JI Lab. Med. PD FEB PY 2017 VL 48 IS 1 BP 97 EP 103 DI 10.1093/labmed/lmw048 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA EP0NF UT WOS:000397083300016 PM 27744341 ER PT J AU Hogben, M Behel, S AF Hogben, Matthew Behel, Stephanie TI Assisted partner services for HIV case-finding SO LANCET HIV LA English DT Editorial Material C1 [Hogben, Matthew] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. [Behel, Stephanie] Ctr Dis Control & Prevent, Div Global HIV & TB, Atlanta, GA 30333 USA. RP Hogben, M (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. EM mhogben@cdc.gov FU Intramural CDC HHS [CC999999] NR 12 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD FEB PY 2017 VL 4 IS 2 BP E55 EP E56 DI 10.1016/S2352-3018(16)30211-9 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EP3EV UT WOS:000397266500005 PM 27913226 ER PT J AU Justman, J Reed, JB Bicego, G Donnell, D Li, K Bock, N Koler, A Philip, NM Mlambo, CK Parekh, BS Duong, YT Ellenberger, DL El-Sadr, WM Nkambule, R AF Justman, Jessica Reed, Jason B. Bicego, George Donnell, Deborah Li, Keala Bock, Naomi Koler, Alison Philip, Neena M. Mlambo, Charmaine K. Parekh, Bharat S. Duong, Yen T. Ellenberger, Dennis L. El-Sadr, Wafaa M. Nkambule, Rejoice TI Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study SO LANCET HIV LA English DT Article ID ACUTE INFECTIONS; PREVENTION; WOMEN AB Background Swaziland has the highest national HIV prevalence worldwide. The Swaziland HIV Incidence Measurement Survey (SHIMS) provides the first national HIV incidence estimate based on prospectively observed HIV seroconversions. Methods A two-stage survey sampling design was used to select a nationally representative sample of men and women aged 18-49 years from 14 891 households in 575 enumeration areas in Swaziland, who underwent household-based counselling and rapid HIV testing during 2011. All individuals aged 18-49 years who resided or had slept in the household the night before and were willing to undergo home-based HIV testing, answer demographic and behavioural questions in English or siSwati, and provide written informed consent were eligible for the study. We performed rapid HIV testing and assessed sociodemographic and behavioural characteristics with use of a questionnaire at baseline and, for HIV-seronegative individuals, 6 months later. We calculated HIV incidence with Poisson regression modelling as events per person-years x 100, and we assessed covariables as predictors with Cox proportional hazards modelling. Survey weighting was applied and all models used survey sampling methods. Findings Between Dec 10, 2010, and June 25, 2011, 11 897 HIV-seronegative adults were enrolled in SHIMS and 11 232 (94%) were re-tested. Of these, 145 HIV seroconversions were observed, resulting in a weighted HIV incidence of 2.4% (95% CI 2.1-2.8). Incidence was nearly twice as high in women (3.1%; 95% CI 2.6-3.7) as in men (1.7%; 1.3-2.1, p<0.0001). Among men, partner's HIV-positive status (adjusted hazard ratio [aHR] 2.67, 1.06-6.82, p=0.040) or unknown serostatus (aHR 4.64, 2.32-9.27, p<0.0001) in the past 6 months predicted HIV seroconversion. Among women, significant predictors included not being married (aHR 2.90, 1.44-5.84, p=0.0030), having a spouse who lives elsewhere (aHR 2.66, 1.29-5.45, p=0.0078), and having a partner in the past 6 months with unknown HIV status (aHR 2u 87, 1.44-5.84, p=0.0030). Interpretation Swaziland has the highest national HIV incidence in the world. In high-prevalence countries, population-based incidence measures and programmes that further expand HIV testing and support disclosure of HIV status are needed. C1 [Justman, Jessica; Philip, Neena M.; Duong, Yen T.; El-Sadr, Wafaa M.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA. [Reed, Jason B.] Jhpiego, Washington, DC USA. [Bicego, George; Bock, Naomi; Parekh, Bharat S.; Ellenberger, Dennis L.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Donnell, Deborah; Li, Keala] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Koler, Alison] Pact, Dar Es Salaam, Tanzania. [Mlambo, Charmaine K.] Clinton Hlth Access Initiat, Mbabane, Swaziland. [Nkambule, Rejoice] Minist Health Swaziland, Mbabane, Swaziland. RP Justman, J (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.; Justman, J (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Med, New York, NY 10032 USA. EM jj2158@columbia.edu FU President's Emergency Plan for AIDS Relief (PEPFAR) by the Centers for Disease Control and Prevention FX President's Emergency Plan for AIDS Relief (PEPFAR) by the Centers for Disease Control and Prevention. NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD FEB PY 2017 VL 4 IS 2 BP E83 EP E92 DI 10.1016/S2352-3018(16)30190-4 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EP3EV UT WOS:000397266500010 PM 27863998 ER PT J AU Martin, M Vanichseni, S Suntharasamai, P Sangkum, U Mock, PA Chaipung, B Worrajittanon, D Leethochawalit, M Chiamwongpaet, S Kittimunkong, S Gvetadze, RJ McNicholl, JM Paxton, LA Curlin, ME Holtz, TH Samandari, T Choopanya, K AF Martin, Michael Vanichseni, Suphak Suntharasamai, Pravan Sangkum, Udomsak Mock, Philip A. Chaipung, Benjamaporn Worrajittanon, Dararat Leethochawalit, Manoj Chiamwongpaet, Sithisat Kittimunkong, Somyot Gvetadze, Roman J. McNicholl, Janet M. Paxton, Lynn A. Curlin, Marcel E. Holtz, Timothy H. Samandari, Taraz Choopanya, Kachit CA Bangkok Tenofovir Study Grp TI Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study SO LANCET HIV LA English DT Article ID ANTIRETROVIRAL PROPHYLAXIS; INFECTION; THAILAND; PREVENTION; TRIAL; USERS; WOMEN; PREP; MEN AB Background Results of the randomised, double-blind, placebo-controlled Bangkok Tenofovir Study (BTS) showed that taking tenofovir daily as pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection by 49% in people who inject drugs. In an extension to the trial, participants were offered 1 year of open-label tenofovir. We aimed to examine the demographic characteristics, drug use, and risk behaviours associated with participants' uptake of and adherence to PrEP. Methods In this observational, open-label extension of the BTS (NCT00119106), non-pregnant, non-breastfeeding, HIV-negative BTS participants, all of whom were current or previous injecting drug users at the time of enrolment in the BTS, were offered daily oral tenofovir (300 mg) for 1 year at 17 Bangkok Metropolitan Administration drug-treatment clinics. Participant demographics, drug use, and risk behaviours were assessed at baseline and every 3 months using an audio computer-assisted self-interview. HIV testing was done monthly and serum creatinine was assessed every 3 months. We used logistic regression to examine factors associated with the decision to take daily tenofovir as PrEP, the decision to return for at least one PrEP follow-up visit, and greater than 90% adherence to PrEP. Findings Between Aug 1, 2013, and Aug 31, 2014, 1348 (58%) of the 2306 surviving BTS participants returned to the clinics, 33 of whom were excluded because they had HIV (n=27) or grade 2-4 creatinine results (n=6). 798 (61%) of the 1315 eligible participants chose to start open-label PrEP and were followed up for a median of 335 days (IQR 0-364). 339 (42%) participants completed 12 months of follow-up; 220 (28%) did not return for any follow-up visits. Participants who were 30 years or older (odds ratio [OR] 1.8, 95% CI 1.4-2,2; p< 0.0001), injected heroin (OR 1.5, 1.1-2.1; p=0.007), or had been in prison (OR 1.7, 1.3-2.1; p< 0.0001) during the randomised trial were more likely to choose PrEP than were those without these characteristics. Participants who reported injecting heroin or being in prison during the 3 months before open-label enrolment were more likely to return for at least one open-label follow-up visit than those who did not report injecting heroin (OR 3.0, 95 % CI 1.3-7.3; p=0.01) or being in prison (OR 2.3, 1.4-3.7; p=0.0007). Participants who injected midazolam or were in prison during open-label follow-up were more likely to be greater than 90% adherent than were those who did not inject midazolam (OR 2.2, 95% CI 1.2-4.3; p=0.02) or were not in prison (OR 4.7,3.1-7.2; p< 0.0001). One participant tested positive for HIV, yielding an HIV incidence of 2.1 (95% CI 0.05-11.7) per 1000 person-years. No serious adverse events related to tenofovir use were reported. Interpretation More than 60% of returning, eligible BTS participants started PrEP, which indicates that a substantial proportion of PWID who are knowledgeable about PrEP might be interested in taking it. Participants who had injected heroin or been in prison were more likely to choose to take PrEP, suggesting that participants based their decision to take PrEP, at least in part, on their perceived risk of incident HIV infection. C1 [Martin, Michael; Mock, Philip A.; Chaipung, Benjamaporn; Worrajittanon, Dararat; Curlin, Marcel E.; Holtz, Timothy H.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [Martin, Michael; Gvetadze, Roman J.; McNicholl, Janet M.; Paxton, Lynn A.; Curlin, Marcel E.; Holtz, Timothy H.; Samandari, Taraz] Ctr Dis Control & Prevent, Atlanta, GA USA. [Vanichseni, Suphak; Suntharasamai, Pravan; Sangkum, Udomsak; Choopanya, Kachit] Taksin Hosp, Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Leethochawalit, Manoj; Chiamwongpaet, Sithisat] Bangkok Metropolitan Adm, Bangkok, Thailand. [Kittimunkong, Somyot] Thailand Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Curlin, Marcel E.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. RP Martin, M (reprint author), Minist Publ Hlth, Nonthaburi 11000, Thailand. EM znd9@cdc.gov FU US Centers for Disease Control and Prevention; Bangkok Metropolitan Administration FX US Centers for Disease Control and Prevention and the Bangkok Metropolitan Administration. NR 27 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 2352-3018 J9 LANCET HIV JI Lancet HIV PD FEB PY 2017 VL 4 IS 2 BP E59 EP E66 DI 10.1016/S2352-3018(16)30207-7 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EP3EV UT WOS:000397266500007 PM 27866873 ER PT J AU Ades, PA Keteyian, SJ Wright, JS Hamm, LF Lui, K Newlin, K Shepard, DS Thomas, RJ AF Ades, Philip A. Keteyian, Steven J. Wright, Janet S. Hamm, Larry F. Lui, Karen Newlin, Kimberly Shepard, Donald S. Thomas, Randal J. TI Increasing Cardiac Rehabilitation Participation From 20% to 70%: A Road Map From the Million Hearts Cardiac Rehabilitation Collaborative SO MAYO CLINIC PROCEEDINGS LA English DT Article ID CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; ASSOCIATION TASK-FORCE; SECONDARY PREVENTION; HOSPITAL DISCHARGE; BYPASS SURGERY; EXERCISE; ATTENDANCE; FAILURE; UPDATE AB The primary aim of the Million Hearts initiative is to prevent 1 million cardiovascular events over 5 years. Concordant with the Million Hearts' focus on achieving more than 70% performance in the "ABCS" of aspirin for those at risk, blood pressure control, cholesterol management, and smoking cessation, we outline the cardiovascular events that would be prevented and a road map to achieve more than 70% participation in cardiac rehabilitation ( CR)/secondary prevention programs by the year 2022. Cardiac rehabilitation is a class Ia recommendation of the American Heart Association and the American College of Cardiology after myocardial infarction or coronary revascularization, promotes the ABCS along with lifestyle counseling and exercise, and is associated with decreased total mortality, cardiac mortality, and rehospitalizations. However, current participation rates for CR in the United States generally range from only 20% to 30%. This road map focuses on interventions, such as electronic medical record-based prompts and staffing liaisons that increase referrals of appropriate patients to CR, increase enrollment of appropriate individuals into CR, and increase adherence to longer- term CR. We also calculate that increasing CR participation from 20% to 70% would save 25,000 lives and prevent 180,000 hospitalizations annually in the United States. (C) 2016 Mayo Foundation for Medical Education and Research C1 [Ades, Philip A.; Keteyian, Steven J.; Wright, Janet S.; Hamm, Larry F.; Lui, Karen; Newlin, Kimberly; Shepard, Donald S.; Thomas, Randal J.] Univ Vermont, Vermont Med Ctr, Coll Med, Cardiac Rehabil & Prevent Program, 62 Tilley Dr, Burlington, VT 05403 USA. [Ades, Philip A.; Keteyian, Steven J.; Wright, Janet S.; Hamm, Larry F.; Lui, Karen; Newlin, Kimberly; Shepard, Donald S.; Thomas, Randal J.] Henry Ford Hosp, Prevent Cardiol, Detroit, MI 48202 USA. [Ades, Philip A.; Keteyian, Steven J.; Wright, Janet S.; Hamm, Larry F.; Lui, Karen; Newlin, Kimberly; Shepard, Donald S.; Thomas, Randal J.] Ctr Dis Control & Prevent, Mill Hearts, Atlanta, GA USA. [Ades, Philip A.; Keteyian, Steven J.; Wright, Janet S.; Hamm, Larry F.; Lui, Karen; Newlin, Kimberly; Shepard, Donald S.; Thomas, Randal J.] George Washington Univ, Dept Exercise & Nutr Sci, Clin Exercise Physiol Program, Washington, DC USA. [Ades, Philip A.; Keteyian, Steven J.; Wright, Janet S.; Hamm, Larry F.; Lui, Karen; Newlin, Kimberly; Shepard, Donald S.; Thomas, Randal J.] GRQ LLC, Vienna, VA USA. [Ades, Philip A.; Keteyian, Steven J.; Wright, Janet S.; Hamm, Larry F.; Lui, Karen; Newlin, Kimberly; Shepard, Donald S.; Thomas, Randal J.] Sutter Roseville Med Ctr, Cardiac & Pulmonary Rehabil, Roseville, CA USA. RP Ades, PA (reprint author), Univ Vermont, Vermont Med Ctr, Coll Med, Cardiac Rehabil & Prevent Program, 62 Tilley Dr, Burlington, VT 05403 USA. EM Philip.ades@uvmhealth.org FU National Institutes of Health Center of Biomedical Research Excellence [P20GM103644]; National Institute of General Medical Sciences FX This work was supported in part by National Institutes of Health Center of Biomedical Research Excellence award P20GM103644 from the National Institute of General Medical Sciences (P.A.A., D.S.S.). NR 57 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2017 VL 92 IS 2 BP 234 EP 242 DI 10.1016/j.mayocp.2016.10.014 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA EO7WY UT WOS:000396902000014 PM 27855953 ER PT J AU Moura, A Criscuolo, A Pouseele, H Maury, MM Leclercq, A Tarr, C Bjorkman, JT Dallman, T Reimer, A Enouf, V Larsonneur, E Carleton, H Bracq-Dieye, H Katz, LS Jones, L Touchon, M Tourdjman, M Walker, M Stroika, S Cantinelli, T Chenal-Francisque, V Kucerova, Z Rocha, EPC Nadon, C Grant, K Nielsen, EM Pot, B Gerner-Smidt, P Lecuit, M Brisse, S AF Moura, Alexandra Criscuolo, Alexis Pouseele, Hannes Maury, Mylene M. Leclercq, Alexandre Tarr, Cheryl Bjorkman, Jonas T. Dallman, Timothy Reimer, Aleisha Enouf, Vincent Larsonneur, Elise Carleton, Heather Bracq-Dieye, Helene Katz, Lee S. Jones, Louis Touchon, Marie Tourdjman, Mathieu Walker, Matthew Stroika, Steven Cantinelli, Thomas Chenal-Francisque, Viviane Kucerova, Zuzana Rocha, Eduardo P. C. Nadon, Celine Grant, Kathie Nielsen, Eva M. Pot, Bruno Gerner-Smidt, Peter Lecuit, Marc Brisse, Sylvain TI Whole genome-based population biology and epidemiological surveillance of Listeria monocytogenes SO NATURE MICROBIOLOGY LA English DT Article ID FOOD-ASSOCIATED ENVIRONMENTS; PROCESSING PLANTS; MAJOR CLONES; STRAINS; IDENTIFICATION; TRANSMISSION; PERSISTENCE; EVOLUTION; VIRULENCE; OUTBREAK AB Listeria monocytogenes (Lm) is a major human foodborne pathogen. Numerous Lm outbreaks have been reported worldwide and associated with a high case fatality rate, reinforcing the need for strongly coordinated surveillance and outbreak control. We developed a universally applicable genome-wide strain genotyping approach and investigated the population diversity of Lm using 1,696 isolates from diverse sources and geographical locations. We define, with unprecedented precision, the population structure of Lm, demonstrate the occurrence of international circulation of strains and reveal the extent of heterogeneity in virulence and stress resistance genomic features among clinical and food isolates. Using historical isolates, we show that the evolutionary rate of Lm from lineage I and lineage II is low (similar to 2.5 x 10(-7) substitutions per site per year, as inferred from the core genome) and that major sublineages (corresponding to so-called 'epidemic clones') are estimated to be at least 50-150 years old. This work demonstrates the urgent need to monitor Lm strains at the global level and provides the unified approach needed for global harmonization of Lm genome-based typing and population biology. C1 [Moura, Alexandra; Maury, Mylene M.; Leclercq, Alexandre; Bracq-Dieye, Helene; Cantinelli, Thomas; Chenal-Francisque, Viviane; Lecuit, Marc] Inst Pasteur, Natl Reference Ctr & World Hlth Org Collaborating, F-75724 Paris, France. [Moura, Alexandra; Maury, Mylene M.; Leclercq, Alexandre; Bracq-Dieye, Helene; Lecuit, Marc] Inst Pasteur, Biol Infect Unit, F-75724 Paris, France. [Moura, Alexandra; Maury, Mylene M.; Lecuit, Marc] INSERM, U1117, F-75015 Paris, France. [Moura, Alexandra; Maury, Mylene M.; Larsonneur, Elise; Touchon, Marie; Rocha, Eduardo P. C.; Brisse, Sylvain] Inst Pasteur, Microbial Evolutionary Genom Unit, F-75724 Paris, France. [Moura, Alexandra; Maury, Mylene M.; Touchon, Marie; Rocha, Eduardo P. C.; Brisse, Sylvain] CNRS, UMR 3525, F-75015 Paris, France. [Criscuolo, Alexis; Larsonneur, Elise] USR 3756 IP CNRS, Inst Pasteur Hub Bioinformat & Biostat, F-75724 Paris, France. [Pouseele, Hannes; Pot, Bruno] Appl Maths, B-9830 Sint Martens Latem, Belgium. [Maury, Mylene M.] Paris Diderot Univ, Sorbonne Paris Cite, Cellule Pasteur, F-75013 Paris, France. [Tarr, Cheryl; Carleton, Heather; Katz, Lee S.; Stroika, Steven; Kucerova, Zuzana; Gerner-Smidt, Peter] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Bjorkman, Jonas T.; Nielsen, Eva M.] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Dallman, Timothy; Grant, Kathie] Publ Hlth England, London NW9 5EQ, England. [Reimer, Aleisha; Walker, Matthew; Nadon, Celine] Publ Hlth Agcy Canada, Winnipeg, MB R3E 3R2, Canada. [Enouf, Vincent] Inst Pasteur, Mutualized Microbiol Platform P2M, Pasteur Int Bioresources Network PIBnet, F-75724 Paris, France. [Larsonneur, Elise] CNRS, UMS IFB Core 3601, F-91198 Gif Sur Yvette, France. [Tourdjman, Mathieu] Publ Hlth France, F-94415 St Maurice, France. [Lecuit, Marc] Sorbonne Paris Cite, Inst Imagine, F-75006 Paris, France. [Lecuit, Marc] Paris Descartes Univ, Necker Enfants Malad Univ Hosp, AP HP, Div Infect Dis & Trop Med, F-75015 Paris, France. RP Lecuit, M (reprint author), Inst Pasteur, Natl Reference Ctr & World Hlth Org Collaborating, F-75724 Paris, France.; Lecuit, M (reprint author), Inst Pasteur, Biol Infect Unit, F-75724 Paris, France.; Lecuit, M (reprint author), INSERM, U1117, F-75015 Paris, France.; Brisse, S (reprint author), Inst Pasteur, Microbial Evolutionary Genom Unit, F-75724 Paris, France.; Brisse, S (reprint author), CNRS, UMR 3525, F-75015 Paris, France.; Lecuit, M (reprint author), Sorbonne Paris Cite, Inst Imagine, F-75006 Paris, France.; Lecuit, M (reprint author), Paris Descartes Univ, Necker Enfants Malad Univ Hosp, AP HP, Div Infect Dis & Trop Med, F-75015 Paris, France. EM marc.lecuit@pasteur.fr; sylvain.brisse@pasteur.fr OI Leclercq, Alexandre/0000-0003-3778-7313 FU Institut Pasteur; INSERM; Public Health France; French government's Investissement d'Avenir program Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" [ANR-10-LABX-62-IBEID]; European Research Council; Swiss National Fund for Research; Advanced Molecular Detection (AMD) initiative at CDC FX The authors thank K. Jolley (Oxford University) for assistance with BIGSdb implementation, PulseNet International Network members for continuous surveillance and data sharing, the Genomics platform (PF1, Institut Pasteur) for assistance with sequencing, D. Mornico (Institut Pasteur) for assistance with the submission of raw data, J. Haase and M. Achtman (Environmental Research Institute, Ireland) for providing cultures of historical isolates of SL1. The authors also thank N. Tessaud-Rita, G. Vales and P. Thouvenot (National Reference Centre for Listeria, Institut Pasteur) for recovering and extracting DNA from historical isolates of SL9. This work was supported by Institut Pasteur, INSERM, Public Health France, French government's Investissement d'Avenir program Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant ANR-10-LABX-62-IBEID), European Research Council, Swiss National Fund for Research and the Advanced Molecular Detection (AMD) initiative at CDC. NR 45 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2058-5276 J9 NAT MICROBIOL JI NAT. MICROBIOL PD FEB PY 2017 VL 2 IS 2 AR 16185 DI 10.1038/nmicrobiol.2016.185 PG 10 WC Microbiology SC Microbiology GA EP0VN UT WOS:000397104900003 ER PT J AU Jack, L AF Jack, Leonard, Jr. TI Preventing Chronic Disease: Celebrating Contributions and Defining Future Directions SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material C1 [Jack, Leonard, Jr.] Ctr Dis Control & Prevent, Off Med & Sci, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-80, Atlanta, GA 30341 USA. RP Jack, L (reprint author), Ctr Dis Control & Prevent, Off Med & Sci, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F-80, Atlanta, GA 30341 USA. EM ljack@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2017 VL 14 AR 170013 DI 10.5888/pcd14.170013 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP1KW UT WOS:000397144800004 ER PT J AU Kamali, A Hameed, H Shih, M Simon, P AF Kamali, Amanda Hameed, Heena Shih, Margaret Simon, Paul TI Turning the Curve on Obesity Prevalence Among Fifth Graders in the Los Angeles Unified School District, 2001-2013 SO PREVENTING CHRONIC DISEASE LA English DT Article ID HIGH BMI; TRENDS; ADOLESCENTS; OVERWEIGHT; DISPARITIES; CHILDREN; MASSACHUSETTS; FOOD AB Introduction After multiple decades of increasing childhood obesity prevalence in the United States, findings from recent studies suggest that prevalence has leveled or is decreasing in some populations. However, demographic and socioeconomic disparities in prevalence remain and may be increasing. Methods To assess recent trends and disparities in childhood obesity prevalence in Los Angeles County, we analyzed data from 2001 through 2013 in fifth graders in the Los Angeles Unified School District (LAUSD). Obesity was defined as a body mass index at or above the 95th percentile for children of the same age and sex as compared with Centers for Disease Control and Prevention growth charts, on the basis of measured height and weight. Trends were examined by sex, race/ethnicity, and socioeconomic status (SES). SES was determined by using school-level data on the percentage of students participating in a free and reduced-price meal program. Results Obesity prevalence increased from 27.5% in 2001 to 31.6% in 2005, was stable from 2005 through 2010, and decreased from 31.6% in 2010 to 28.5% in 2013. Similar trajectories in prevalence were observed for all demographic and SES subgroups, although the decline in prevalence began earlier among whites and students attending schools in the highest SES group. Disparities in prevalence by race/ethnicity and SES were observed during the entire study period but narrowed slightly from 2010 through 2013. Conclusion Although obesity prevalence among fifth graders in LAUSD declined from 2010 through 2013, prevalence remains higher than in 2001, and demographic and socioeconomic disparities in prevalence persist. Future interventions in the county should prioritize Latinos and students attending low SES schools. C1 [Kamali, Amanda] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Los Angeles Cty Dept Publ Hlth, Acute Communicable Dis Control, Los Angeles, CA USA. [Hameed, Heena; Shih, Margaret] Los Angeles Cty Dept Publ Hlth, Off Hlth Assessment & Epidemiol, Los Angeles, CA USA. [Simon, Paul] Los Angeles Cty Dept Publ Hlth, Div Chron Dis & Injury Prevent, Los Angeles, CA USA. RP Kamali, A (reprint author), Roche Mol Solut Inc, Infect Dis, 4300 Hacienda Dr, Pleasanton, CA 94803 USA. EM ydh3@cdc.gov NR 27 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2017 VL 14 AR 160377 DI 10.5888/pcd14.160377 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP1KW UT WOS:000397144800007 ER PT J AU Lich, KH Cornejo, DA Mayorga, ME Pignone, M Tangka, FKL Richardson, LC Kuo, TM Meyer, AM Hall, IJ Smith, JL Durham, TA Chall, SA Crutchfield, TM Wheeler, SB AF Lich, Kristen Hassmiller Cornejo, David A. Mayorga, Maria E. Pignone, Michael Tangka, Florence K. L. Richardson, Lisa C. Kuo, Tzy-Mey Meyer, Anne-Marie Hall, Ingrid J. Smith, Judith Lee Durham, Todd A. Chall, Steven A. Crutchfield, Trisha M. Wheeler, Stephanie B. TI Cost-Effectiveness Analysis of Four Simulated Colorectal Cancer Screening Interventions, North Carolina SO PREVENTING CHRONIC DISEASE LA English DT Article ID SERVICES TASK-FORCE; UNITED-STATES; COLON-CANCER; STRATEGIES; PROGRAM; COMMUNICATION; METAANALYSIS; TRIAL AB Introduction Colorectal cancer (CRC) screening rates are suboptimal, particularly among the uninsured and the under-insured and among rural and African American populations. Little guidance is available for state-level decision makers to use to prioritize investment in evidence-based interventions to improve their population's health. The objective of this study was to demonstrate use of a simulation model that incorporates synthetic census data and claims-based statistical models to project screening behavior in North Carolina. Methods We used individual-based modeling to simulate and compare intervention costs and results under 4 evidence-based and stakeholder- informed intervention scenarios for a 10-year intervention window, from January 1, 2014, through December 31, 2023. We compared the proportion of people living in North Carolina who were aged 50 to 75 years at some point during the window (that is, age-eligible for screening) who were up to date with CRC screening recommendations across intervention scenarios, both overall and among groups with documented disparities in receipt of screening. Results We estimated that the costs of the 4 intervention scenarios considered would range from $1.6 million to $3.75 million. Our model showed that mailed reminders for Medicaid enrollees, mass media campaigns targeting African Americans, and colonoscopy vouchers for the uninsured reduced disparities in receipt of screening by 2023, but produced only small increases in overall screening rates ( 0.2-0.5 percentage-point increases in the percentage of age-eligible adults who were up to date with CRC screening recommendations). Increased screenings ranged from 41,709 additional life-years up to date with screening for the voucher intervention to 145,821 for the mass media intervention. Reminders mailed to Medicaid enrollees and the mass media campaign for African Americans were the most cost-effective interventions, with costs per additional life-year up to date with screening of $ 25 or less. The intervention expanding the number of endoscopy facilities cost more than the other 3 interventions and was less effective in increasing CRC screening. Conclusion Cost-effective CRC screening interventions targeting observed disparities are available, but substantial investment (more than $3.75 million) and additional approaches beyond those considered here are required to realize greater increases population-wide. C1 [Lich, Kristen Hassmiller; Durham, Todd A.; Wheeler, Stephanie B.] Univ North Carolina Chapel Hill, Dept Hlth Policy & Management, 1105E McGavran Greenberg,Campus Box 7411, Chapel Hill, NC 27599 USA. [Cornejo, David A.; Mayorga, Maria E.] North Carolina State Univ, Dept Ind & Syst Engn, Raleigh, NC USA. [Pignone, Michael; Kuo, Tzy-Mey; Meyer, Anne-Marie; Wheeler, Stephanie B.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Pignone, Michael; Crutchfield, Trisha M.; Wheeler, Stephanie B.] Univ North Carolina Chapel Hill, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA. [Pignone, Michael] Univ North Carolina Chapel Hill, Div Gen Med & Clin Epidemiol, Chapel Hill, NC USA. [Pignone, Michael; Crutchfield, Trisha M.] Univ North Carolina Chapel Hill, Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. [Tangka, Florence K. L.; Richardson, Lisa C.; Hall, Ingrid J.; Smith, Judith Lee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Meyer, Anne-Marie] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA. [Chall, Steven A.] Univ North Carolina Chapel Hill, Renaissance Comp Inst, Chapel Hill, NC USA. RP Lich, KH (reprint author), Univ North Carolina Chapel Hill, Dept Hlth Policy & Management, 1105E McGavran Greenberg,Campus Box 7411, Chapel Hill, NC 27599 USA. EM klich@unc.edu FU CDC Special Interest Project "Behavioral Economics of Colorectal Cancer Screening in Underserved Populations" [CDC-SIP-11-041]; National Science Foundation [1433602] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). This publication is a product of a Prevention Research Center and was funded by the CDC Special Interest Project "Behavioral Economics of Colorectal Cancer Screening in Underserved Populations" (CDC-SIP-11-041, co-principal investigators, Michael Pignone and Stephanie B. Wheeler). Maria E. Mayorga and David A. Cornejo were supported by National Science Foundation Grant 1433602, "CAREER: Incorporating Patient Heterogeneity and Choice into Predictive Models of Health and Economic Outcomes" (principal investigator, Maria E. Mayorga). NR 30 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD FEB PY 2017 VL 14 AR 160158 DI 10.5888/pcd14.160158 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EP1KW UT WOS:000397144800009 ER PT J AU Mulumba-Mfumu, LK Achenbach, JE Mauldin, MR Dixon, LK Tshilenge, CG Thiry, E Moreno, N Blanco, E Saegerman, C Lamien, CE Diallo, A AF Mulumba-Mfumu, Leopold K. Achenbach, Jenna E. Mauldin, Matthew R. Dixon, Linda K. Tshilenge, Cure Georges Thiry, Etienne Moreno, Noelia Blanco, Esther Saegerman, Claude Lamien, Charles E. Diallo, Adama TI Genetic Assessment of African Swine Fever Isolates Involved in Outbreaks in the Democratic Republic of Congo between 2005 and 2012 Reveals Co-Circulation of p72 Genotypes I, IX and XIV, Including 19 Variants SO VIRUSES-BASEL LA English DT Article DE African swine fever virus; outbreaks; Democratic Republic of Congo; swine; genotypes; molecular epidemiology; p72 gene; p54 gene; CVR ID CENTRAL VARIABLE REGION; MOLECULAR EPIDEMIOLOGY; VIRUS; TANZANIA; STRAINS; PIGS; DNA AB African swine fever (ASF) is a devastating disease of domestic pigs. It is a socioeconomically important disease, initially described from Kenya, but subsequently reported in most Sub-Saharan countries. ASF spread to Europe, South America and the Caribbean through multiple introductions which were initially eradicated-except for Sardinia-followed by re-introduction into Europe in 2007. In this study of ASF within the Democratic Republic of the Congo, 62 domestic pig samples, collected between 2005-2012, were examined for viral DNA and sequencing at multiple loci: C-terminus of the B646L gene (p72 protein), central hypervariable region (CVR) of the B602L gene, and the E183L gene (p54 protein). Phylogenetic analyses identified three circulating genotypes: I (64.5% of samples), IX (32.3%), and XIV (3.2%). This is the first evidence of genotypes IX and XIV within this country. Examination of the CVR revealed high levels of intra-genotypic variation, with 19 identified variants. C1 [Mulumba-Mfumu, Leopold K.; Tshilenge, Cure Georges] Cent Vet Lab, Ave Wangata,POB 8842, Kinshasa I, DEM REP CONGO. [Mulumba-Mfumu, Leopold K.; Thiry, Etienne; Saegerman, Claude] Univ Liege, Fac Vet Med, Res Unit Epidemiol & Risk Anal Appl Vet UREAR Ulg, Fundamental & Appl Res Animals & Hlth, B-4000 Liege, Belgium. [Achenbach, Jenna E.; Lamien, Charles E.; Diallo, Adama] IAEA, Anim Prod & Hlth Lab, Wagramer Str 5,POB 100, A-1400 Vienna, Austria. [Mauldin, Matthew R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Dixon, Linda K.] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England. [Moreno, Noelia; Blanco, Esther] CISA, INIA, Madrid 28130, Spain. [Mauldin, Matthew R.] Oak Ridge Inst Sci & Educ, CDC Fellowship Program, Oak Ridge, TN 37830 USA. RP Achenbach, JE (reprint author), IAEA, Anim Prod & Hlth Lab, Wagramer Str 5,POB 100, A-1400 Vienna, Austria. EM labovetkin@yahoo.fr; achenbach@battelle.org; MMauldin@cdc.gov; linda.dixon@pirbright.ac.uk; george.tshilenge@sacids.org; etienne.thiry@ulg.ac.be; moreno.noelia@inia.es; blanco@inia.es; claude.saegerman@ulg.ac.be; c.lamien@iaea.org; adama.diallo@cirad.fr RI Institute, Pirbright/K-4476-2014 FU International Atomic Energy Agency (IAEA) project "Improvement of Veterinary Laboratory Capacities in Sub-Saharan African Countries"; Wellcome Trust (WT) [WT075813/C/04/Z, WT087546MA] FX This work was supported by the International Atomic Energy Agency (IAEA) project "Improvement of Veterinary Laboratory Capacities in Sub-Saharan African Countries". We pay gratitude to the Wellcome Trust (WT) for its support of this research through two grants, WT075813/C/04/Z and, WT087546MAthat allowed advanced field investigations. NR 44 TC 0 Z9 0 U1 0 U2 0 PU MDPI AG PI BASEL PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD FEB PY 2017 VL 9 IS 2 AR 31 DI 10.3390/v9020031 PG 15 WC Virology SC Virology GA EP2ZA UT WOS:000397251000002 ER PT J AU Chen, MJ Kim, CR Whitehouse, KC Berry-Bibee, E Gaffield, ME AF Chen, Melissa J. Kim, Caron R. Whitehouse, Katherine C. Berry-Bibee, Erin Gaffield, Mary E. TI Development, updates, and future directions of the World Health Organization Selected Practice Recommendations for Contraceptive Use SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS LA English DT Editorial Material ID MEDICAL ELIGIBILITY CRITERIA; RESEARCH GAPS; GUIDANCE C1 [Chen, Melissa J.] Univ Calif Davis, Dept Obstet & Gynecol, Sacramento, CA 95817 USA. [Kim, Caron R.; Whitehouse, Katherine C.; Gaffield, Mary E.] WHO, Dept Reprod Hlth & Res, Geneva, Switzerland. [Berry-Bibee, Erin] Ctr Dis Control & Prevent, Div Reprod Hlth, Chamblee, GA USA. RP Chen, MJ (reprint author), Univ Calif Davis, Dept Obstet & Gynecol, Sacramento, CA 95817 USA. EM mejchen@ucdavis.edu NR 17 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7292 EI 1879-3479 J9 INT J GYNECOL OBSTET JI Int. J. Gynecol. Obstet. PD FEB PY 2017 VL 136 IS 2 BP 113 EP 119 DI 10.1002/ijgo.12064 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EP0TC UT WOS:000397098600001 PM 28099730 ER PT J AU Moro, P Baumblatt, J Lewis, P Cragan, J Tepper, N Cano, M AF Moro, Pedro Baumblatt, Jane Lewis, Paige Cragan, Janet Tepper, Naomi Cano, Maria TI Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010-May 2016 SO DRUG SAFETY LA English DT Article ID NEONATAL OUTCOMES; SAFETY; IMMUNIZATION; STILLBIRTH; IMPACT; BIRTH; VAERS AB Introduction Routine immunization of pregnant women with seasonal inactivated influenza vaccines (IIVs) is recommended in all trimesters of pregnancy. A review of the Vaccine Adverse Event Reporting System (VAERS) during 1990-2009 did not find any unexpected patterns of pregnancy complications or fetal outcomes after administration of IIV or live attenuated influenza vaccines (LAIVs). During the 2009-2010 pandemic influenza A (H1N1) vaccination campaign, a study noted that the number of VAERS reports from pregnant women who received the H1N1 2009 inactivated monovalent vaccine (n = 288) increased compared with 1990-2009 seasonal IIV pregnancy reports (n = 148). Objectives The objective of this study was to assess the safety of seasonal influenza vaccines in pregnant women and their infants whose reports were submitted to VAERS during 2010-2016. Methods We searched VAERS for US reports of adverse events (AEs) in pregnant women who received IIV or LAIV from 1 July 2010 through 6 May 2016. Clinicians reviewed reports and available medical records and assigned a primary clinical category for each report. Reports were coded as serious based on the Code of Federal Regulations. Results We identified 671 reports after seasonal influenza vaccines administered to pregnant women: 544 after IIV and 127 after LAIV. Serious events occurred among 61 (11.2%) reports following IIV and one (0.8%) report following LAIV. No deaths were reported. Among reports with trimester information (n = 296), IIV was administered during the first trimester in 116 (39.2%). Among IIV reports, the most frequent pregnancy-specific AE was spontaneous abortion in 62 (11.4%) reports, followed by stillbirth in ten (1.8%) and preterm delivery in six (1.1%). The most common non-pregnancy-specific AEs were injection-site reactions (55 [10.1%]). Neonatal or infant outcomes were reported in 22 (4.0%) reports, seven of which had major birth defects of different types and no neonatal deaths. Conclusion As in 2009-2010, no new or unexpected patterns in maternal or fetal outcomes were observed during 2010-2016. C1 [Moro, Pedro; Lewis, Paige; Cano, Maria] Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Div Healthcare Qual Promot, NCEZID, 1600 Clifton Rd,MS D26, Atlanta, GA 30329 USA. [Baumblatt, Jane] US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA. [Cragan, Janet] CDC, Birth Defects Branch, Div Congenital & Dev Disabil, NCBDDD, Atlanta, GA 30333 USA. [Tepper, Naomi] CDC, Womens Hlth & Fertil Branch, Div Reprod Hlth, NCCDPHP, Atlanta, GA 30333 USA. RP Moro, P (reprint author), Ctr Dis Control & Prevent CDC, Immunizat Safety Off, Div Healthcare Qual Promot, NCEZID, 1600 Clifton Rd,MS D26, Atlanta, GA 30329 USA. EM pmoro@cdc.gov NR 25 TC 0 Z9 0 U1 0 U2 0 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 0114-5916 EI 1179-1942 J9 DRUG SAFETY JI Drug Saf. PD FEB PY 2017 VL 40 IS 2 BP 145 EP 152 DI 10.1007/s40264-016-0482-1 PG 8 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology GA EL1ZB UT WOS:000394418800007 PM 27988883 ER PT J AU Iwamoto, M Reynolds, J Karp, BE Tate, H Fedorka-Cray, PJ Plumblee, JR Hoekstra, RM Whichard, JM Mahon, BE AF Iwamoto, Martha Reynolds, Jared Karp, Beth E. Tate, Heather Fedorka-Cray, Paula J. Plumblee, Jodie R. Hoekstra, Robert M. Whichard, Jean M. Mahon, Barbara E. TI Ceftriaxone-Resistant Nontyphoidal Salmonella from Humans, Retail Meats, and Food Animals in the United States, 1996-2013 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article DE Salmonella; antimicrobial resistance; foodborne disease; cephalosporin ID ENTERICA SEROVAR HEIDELBERG; AMPC BETA-LACTAMASE; MULTIDRUG-RESISTANT; NEWPORT INFECTIONS; OUTBREAK; TYPHIMURIUM; EMERGENCE; PLASMIDS AB Background: Ceftriaxone resistance in Salmonella is a serious public health threat. Ceftriaxone is commonly used to treat severe Salmonella infections, especially in children. Identifying the sources and drivers of ceftriaxone resistance among nontyphoidal Salmonella is crucial. Materials and Methods: The National Antimicrobial Resistance Monitoring System (NARMS) tracks antimicrobial resistance in foodborne and other enteric bacteria from humans, retail meats, and food animals. We examined NARMS data reported during 1996-2013 to characterize ceftriaxone-resistant Salmonella infections in humans. We used Spearman rank correlation to examine the relationships between the annual percentage of ceftriaxone resistance among Salmonella isolates from humans with isolates from retail meats and food animals. Results: A total of 978 (2.9%) of 34,100 nontyphoidal Salmonella isolates from humans were resistant to ceftriaxone. Many (40%) ceftriaxone-resistant isolates were from children younger than 18 years. Most ceftriaxone-resistant isolates were one of three serotypes: Newport (40%), Typhimurium (26%), or Heidelberg (12%). All were resistant to other antimicrobials, and resistance varied by serotype. We found statistically significant correlations in ceftriaxone resistance between human and ground beef Newport isolates (r = 0.83), between human and cattle Typhimurium isolates (r = 0.57), between human and chicken Heidelberg isolates (r = 0.65), and between human and turkey Heidelberg isolates (r = 0.67). Conclusions: Ceftriaxone resistance among Salmonella Newport, Typhimurium, and Heidelberg isolates from humans strongly correlates with ceftriaxone resistance in isolates from ground beef, cattle, and poultry, respectively. These findings support other lines of evidence that food animals are important reservoirs of ceftriaxone-resistant Salmonella that cause human illness in the United States. C1 [Iwamoto, Martha; Reynolds, Jared; Karp, Beth E.; Hoekstra, Robert M.; Whichard, Jean M.; Mahon, Barbara E.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,Mailstop C-09, Atlanta, GA 30333 USA. [Tate, Heather] US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, Laurel, MD USA. [Fedorka-Cray, Paula J.; Plumblee, Jodie R.] ARS, Bacterial Epidemiol & Antimicrobial Resistance Re, USDA, Athens, GA USA. [Fedorka-Cray, Paula J.] North Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA. RP Iwamoto, M; Reynolds, J (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,Mailstop C-09, Atlanta, GA 30333 USA. EM miwamoto@cdc.gov; jreynolds3@cdc.gov NR 44 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD FEB PY 2017 VL 14 IS 2 BP 74 EP 83 DI 10.1089/fpd.2016.2180 PG 10 WC Food Science & Technology SC Food Science & Technology GA EL0ST UT WOS:000394332800002 PM 27860517 ER PT J AU Mazurek, JM Syamlal, G AF Mazurek, Jacek M. Syamlal, Girija TI Current Asthma Prevalence in Working Adults-United States, 2009-2014 SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 03-16, 2017 CL Atlanta, GA SP Amer Acad Allergy, Asthma & Immunol C1 [Mazurek, Jacek M.; Syamlal, Girija] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2017 VL 139 IS 2 SU S MA 77 BP AB23 EP AB23 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA EO8NM UT WOS:000396946000078 ER PT J AU Soke, GN Rosenberg, SA Hamman, RF Fingerlin, T Rosenberg, CR Carpenter, L Lee, LC Giarelli, E Wiggins, LD Durkin, MS Reynolds, A DiGuiseppi, C AF Soke, G. N. Rosenberg, S. A. Hamman, R. F. Fingerlin, T. Rosenberg, C. R. Carpenter, L. Lee, L. C. Giarelli, E. Wiggins, L. D. Durkin, M. S. Reynolds, A. DiGuiseppi, C. TI Factors Associated with Self-Injurious Behaviors in Children with Autism Spectrum Disorder: Findings from Two Large National Samples SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism spectrum disorder; Autism; Selfinjurious behaviors; Challenging behaviors; Maladaptive behaviors; Children ID DISABILITIES MONITORING NETWORK; FULLY CONDITIONAL SPECIFICATION; DIAGNOSTIC OBSERVATION SCHEDULE; DEVELOPMENTAL-DISABILITIES; YOUNG-CHILDREN; RISK-FACTORS; CHALLENGING BEHAVIORS; MALADAPTIVE BEHAVIORS; MULTIPLE IMPUTATION; SURVEILLANCE SYSTEM AB In this study, we explored potential associations among self-injurious behaviors (SIB) and a diverse group of protective and risk factors in children with autism spectrum disorder from two databases: Autism and Developmental Disabilities Monitoring (ADDM) Network and the Autism Speaks-Autism Treatment Network (AS-ATN). The presence of SIB was determined from children's records in ADDM and a parent questionnaire in AS-ATN. We used multiple imputation to account for missing data and a non-linear mixed model with site as a random effect to test for associations. Despite differences between the two databases, similar associations were found; SIB were associated with developmental, behavioral, and somatic factors. Implications of these findings are discussed in relation to possible etiology, future longitudinal studies, and clinical practice. C1 [Soke, G. N.; Hamman, R. F.; Fingerlin, T.; DiGuiseppi, C.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Soke, G. N.; Wiggins, L. D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Hwy,MS E-86, Atlanta, GA 30341 USA. [Rosenberg, S. A.; Rosenberg, C. R.] Univ Colorado Anschutz Med Campus, Sch Med, Dept Psychiat, Aurora, CO 80045 USA. [Rosenberg, C. R.] Univ Colorado Anschutz Med Campus, Sch Med, Dept Pediat, Aurora, CO 80045 USA. [Carpenter, L.] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA. [Lee, L. C.] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19102 USA. [Giarelli, E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Durkin, M. S.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53726 USA. [Reynolds, A.] Childrens Hosp Colorado, Child Dev Unit, Aurora, CO 80045 USA. RP Soke, GN (reprint author), Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA.; Soke, GN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Hwy,MS E-86, Atlanta, GA 30341 USA. EM Yxo2@cdc.gov FU U.S. Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program [UA3 MC11054] FX We acknowledge CDC ADDM project personnel, ADDM projects coordinators, clinician reviewers, abstractors, data managers, and ADDM investigators at each site who contributed to the ADDM surveillance project and data collection. We acknowledge AS-ATN project coordinators and all families who provided data into the AS-ATN registry. This Network activity was supported by Autism Speaks and cooperative agreement UA3 MC11054 through the U.S. Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program to the Massachusetts General Hospital. This work was conducted through the Autism Speaks-Autism Treatment Network. NR 81 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 EI 1573-3432 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD FEB PY 2017 VL 47 IS 2 BP 285 EP 296 DI 10.1007/s10803-016-2951-x PG 12 WC Psychology, Developmental SC Psychology GA EL1DL UT WOS:000394360600005 PM 27830427 ER PT J AU Flores, AL Isenburg, J Hillard, CL deRosset, L Colen, L Bush, T Mai, CT AF Flores, Alina L. Isenburg, Jennifer Hillard, Christina L. deRosset, Leslie Colen, Lisa Bush, Troy Mai, Cara T. TI Folic Acid Education for Hispanic Women: The Promotora de Salud Model SO JOURNAL OF WOMENS HEALTH LA English DT Article DE folic acid; neural tube defects; Promotora de Salud model; Hispanics ID NEURAL-TUBE DEFECTS; UNITED-STATES; HEALTH; FORTIFICATION; PREVENTION; CARE AB Background: Although rates of neural tube defects (NTDs) have declined in the United States since fortification, disparities still exist with Hispanic women having the highest risk of giving birth to a baby with a NTD. The Promotora de Salud model using community lay health workers has been shown to be an effective tool for reaching Hispanics for a variety of health topics; however, literature on its effectiveness in folic acid interventions is limited. Materials and Methods: An intervention using the Promotora de Salud model was implemented in four U.S. counties with large populations of Hispanic women. The study comprised the following: (1) a written pretest survey to establish baseline levels of folic acid awareness, knowledge, and consumption; (2) a small group education intervention along with a 90-day supply of multivitamins; and (3) a postintervention (posttest) assessment conducted 4 months following the intervention. Results: Statistically significant differences in pre- and posttests were observed for general awareness about folic acid and vitamins and specific knowledge about the benefits of folic acid. Statistically significant changes were also seen in vitamin consumption and multivitamin consumption. Folic acid supplement consumption increased dramatically by the end of the study. Conclusions: The Promotora de Salud model relies on interpersonal connections forged between promotoras and the communities they serve to help drive positive health behaviors. The findings underscore the positive impact that these interpersonal connections can have on increasing awareness, knowledge, and consumption of folic acid. Utilizing the Promotora de Salud model to reach targeted populations might help organizations successfully implement their programs in a culturally appropriate manner. C1 [Flores, Alina L.; Isenburg, Jennifer; Hillard, Christina L.; Mai, Cara T.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 4770 Buford Highway NE,MS E-86, Atlanta, GA 30341 USA. [Isenburg, Jennifer; Hillard, Christina L.] Car